[{"protocol_id":36043,"protocol_no":"OCOG-2014-ALMERA","submission_no":"174284","status_id":1,"start_date":"2015-02-03","end_date":null,"nol_date":"2014-05-21","protocol_title":"A PHASE II STUDY TO INVESTIGATE A COMBINATION OF METFORMIN WITH CHEMO-RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER.","medConditionList":[{"med_condition_id":505,"med_condition":"LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER"},{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28991,"protocol_no":"AC-055E202","submission_no":"170477","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-20","protocol_title":"MERIT-2: MACITENTAN IN THE TREATMENT OF INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (OPEN-LABEL) LONG TERM, MULTICENTER, SINGLE-ARM, OPEN-LABEL EXTENSION STUDY OF THE MERIT-1 STUDY, TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF MACITENTAN IN SUBJECTS WITH INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)","medConditionList":[{"med_condition_id":326,"med_condition":"CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41618,"protocol_no":"COG AOST1421","submission_no":"192063","status_id":1,"start_date":"2016-09-26","end_date":null,"nol_date":"2016-03-23","protocol_title":"A PHASE II STUDY OF HUMAN-MOUSE CHIMERIC ANTI-DISIALOGANGLIOSIDE MONOCLONAL ANTIBODY CH14.18 (DINUTUXIMAB, NSC#764038, IND#4308) IN COMBINATION WITH SARGRAMOSTIM (GM-CSF) IN PATIENTS WITH RECURRENT OSTEOSARCOMA","medConditionList":[{"med_condition_id":586,"med_condition":"OSTEOSARCOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43462,"protocol_no":"CFAZ053X2101","submission_no":"198163","status_id":1,"start_date":"2017-09-05","end_date":null,"nol_date":"2016-10-06","protocol_title":"A PHASE I, OPEN-LABEL, MULTI-CENTER STUDY OF SAFETY AND DOSE OF FAZ053 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":474,"med_condition":"MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35670,"protocol_no":"15396","submission_no":"173062","status_id":1,"start_date":"2015-01-13","end_date":null,"nol_date":"2014-04-30","protocol_title":"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF RADIUM-223 DICHLORIDE IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE/PREDNISOLONE IN THE TREATMENT OF ASYMPTOMATIC OR MILDLY SYMPTOMATIC CHEMOTHERAPY-NAIVE SUBJECTS WITH BONE PREDOMINANT METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43269,"protocol_no":"16-061","submission_no":"197671","status_id":1,"start_date":"2016-10-10","end_date":null,"nol_date":"2016-10-06","protocol_title":"THE SAFETY AND EFFICACY OF 18F-FLUOROMETHYLCHOLINE (18F-FCH) PET/CT IN PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46820,"protocol_no":"AAMLI421","submission_no":"208796","status_id":1,"start_date":"2017-10-04","end_date":null,"nol_date":"2017-09-26","protocol_title":"A PHASE 1/2 STUDY OF CPX-351 (NSC# 775341; IND #129443) ALONE","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40751,"protocol_no":"GS-US-367-1172","submission_no":"189007","status_id":2,"start_date":"2015-12-18","end_date":"2017-01-11","nol_date":"2015-11-27","protocol_title":"A PHASE 3, GLOBAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/GS-9857 FIXED-DOSE COMBINATION FOR 8 WEEKS COMPARED TO SOFOSBUVIR/VELPATASVIR FOR 12 WEEKS IN DIRECT-ACTING ANTIVIRAL-NA√èVE SUBJECTS WITH CHRONIC HCV INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42659,"protocol_no":"54179060LYM3003","submission_no":"195718","status_id":1,"start_date":"2017-06-19","end_date":null,"nol_date":"2016-06-27","protocol_title":"A RANDOMIZED, OPEN-LABEL, SAFETY AND EFFICACY STUDY OF IBRUTINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29408,"protocol_no":"14724B","submission_no":"171736","status_id":2,"start_date":"2014-08-07","end_date":"2015-04-02","nol_date":"2014-02-20","protocol_title":"INTERVENTIONAL, OPEN-LABEL, FLEXIBLE-DOSE EXTENSION STUDY OF ARIPIPRAZOLE ONCE-MONTHLY IN PATIENTS WITH SCHIZOPHRENIA","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40277,"protocol_no":"D419LC00001","submission_no":"187574","status_id":1,"start_date":"2017-02-06","end_date":null,"nol_date":"2015-10-06","protocol_title":"A PHASE III RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF MEDI4736 IN COMBINATION WITH TREMELIMUMAB VERSUS STANDARD OF CARE IN THE TREATMENT OF FIRST-LINE RECURRENT OR METASTATIC SQUAMOUS CELL HEAD AND NECK CANCER PATIENTS","medConditionList":[{"med_condition_id":95,"med_condition":"HEAD AND NECK CANCER"},{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42067,"protocol_no":"CAEB1102-100C","submission_no":"193795","status_id":1,"start_date":"2016-08-10","end_date":null,"nol_date":"2016-04-29","protocol_title":"A PHASE 1 DOSE-ESCALATION STUDY OF AEB1102 (CO-ARGI-PEG) IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME REFRACTORY TO HYPOMETHYLATING AGENTS","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26609,"protocol_no":"CSOM230B2412","submission_no":"163238","status_id":1,"start_date":"2013-09-23","end_date":null,"nol_date":"2013-04-10","protocol_title":"AN OPEN LABEL, MULTI-CENTER PASIREOTIDE ROLL-OVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS-SPONSORED PASIREOTIDE STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED PASIREOTIDE TREATMENT","medConditionList":[{"med_condition_id":561,"med_condition":"MELANOMA NEGATIVE FOR NRAS"},{"med_condition_id":58,"med_condition":"CUSHING'S DISEASE"},{"med_condition_id":556,"med_condition":"ECTOPIC ACTH SECRETING (EAS) TUMORS"},{"med_condition_id":214,"med_condition":"PROSTATE CANCER"},{"med_condition_id":554,"med_condition":"ACROMEGALY"},{"med_condition_id":555,"med_condition":"PITUIARY TUMOR"},{"med_condition_id":557,"med_condition":"DUMPING SYNDROME"},{"med_condition_id":154,"med_condition":"MELANOMA"},{"med_condition_id":560,"med_condition":"MELANOMA NEGATIVE FOR BRAF"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47170,"protocol_no":"MVT-601-3101","submission_no":"210034","status_id":1,"start_date":"2017-12-28","end_date":null,"nol_date":"2017-11-09","protocol_title":"SPIRIT 1: AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN","medConditionList":[{"med_condition_id":74,"med_condition":"ENDOMETRIOSIS"},{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43509,"protocol_no":"PM-MM003","submission_no":"198283","status_id":1,"start_date":"2016-12-01","end_date":null,"nol_date":"2016-11-17","protocol_title":"A PHASE II OPEN LABEL, MULTICENTER, TRIAL OF JNJ-42756493 IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF FGFR3 WILD-TYPE OR MUTATION POSITIVE RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27351,"protocol_no":"AMB116457","submission_no":"165540","status_id":1,"start_date":"2013-10-30","end_date":null,"nol_date":"2013-07-05","protocol_title":"AN OPEN-LABEL EXTENSION STUDY OF THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF AMBRISENTAN IN SUBJECTS WITH INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH).","medConditionList":[{"med_condition_id":326,"med_condition":"CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)"},{"med_condition_id":260,"med_condition":"PULMONARY DISORDERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40835,"protocol_no":"15-300","submission_no":"189400","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-30","protocol_title":"IMPLEMENTATION OF HIGH-RESOLUTION MANOMETRY (HRCM) TO IMPROVE THE CARE OF CHILDREN WITH REFRACTORY CHRONIC CONSTIPATION","medConditionList":[{"med_condition_id":468,"med_condition":"CONSTIPATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46692,"protocol_no":"ML30171","submission_no":"208370","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-20","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF PIRFENIDONE IN PATIENTS WITH RHEUMATOID ARTHRITIS INTERSTITIAL LUNG DISEASE","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"},{"med_condition_id":423,"med_condition":"INTERSTITIAL LUNG DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40972,"protocol_no":"6002-018","submission_no":"189830","status_id":2,"start_date":"2016-08-23","end_date":"2018-01-25","nol_date":"2015-12-10","protocol_title":"A PHASE 3, LONG-TERM, OPEN-LABEL STUDY OF ISTRADEFYLLINE IN SUBJECTS WITH MODERATE TO SEVERE PARKINSON¬øS DISEASE","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43565,"protocol_no":"RD.03.SPR.109696","submission_no":"198476","status_id":1,"start_date":"2017-03-15","end_date":null,"nol_date":"2016-10-14","protocol_title":"SAFETY AND EFFICACY OF CD5024 0.3% CREAM IN SUBJECTS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45675,"protocol_no":"CLCZ696D2302","submission_no":"205139","status_id":1,"start_date":"2017-10-16","end_date":null,"nol_date":"2017-05-24","protocol_title":"A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, PARALLEL GROUP, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFECT OF LCZ696 ON NT-PROBNP, SYMPTOMS, EXERCISE FUNCTION AND SAFETY COMPARED TO INDIVIDUALIZED MEDICAL MANAGEMENT OF COMORBIDITIES IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION","medConditionList":[{"med_condition_id":523,"med_condition":"HEART FAILURE WITH PRESERVED EJECTION FRACTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44685,"protocol_no":"E2007-G000-311","submission_no":"202086","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-02-10","protocol_title":"AN OPEN-LABEL, MULTICENTER STUDY WITH AN EXTENSION PHASE TO EVALUATE THE SAFETY, TOLERABILITY, AND EXPOSURE-EFFICACY RELATIONSHIP OF PERAMPANEL ORAL SUSPENSION WHEN ADMINISTERED AS AN ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS (AGE 4 TO LESS THAN 12 YEARS) WITH INADEQUATELY CONTROLLED PARTIAL-ONSET SEIZURES OR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES","medConditionList":[{"med_condition_id":229,"med_condition":"SEIZURES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46051,"protocol_no":"15-07","submission_no":"206175","status_id":1,"start_date":"2017-11-24","end_date":null,"nol_date":"2017-06-20","protocol_title":"A RANDOMIZED PHASE III TRIAL OF CISPLATIN AND TUMOR VOLUME DIRECTED IRRADIATION FOLLOWED BY CARBOPLATIN AND PACLITAXEL VS. SANDWICH THERAPY OF CARBOPLATIN AND PACLITAXEL FOLLOWED BY TUMOR VOLUME DIRECTED IRRADIATION THEN FURTHER CARBOPLATIN AND PACLITAXEL FOR OPTIMALLY DEBULKED ADVANCED ENDOMETRIAL CARCINOMA","medConditionList":[{"med_condition_id":73,"med_condition":"ENDOMETRIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46055,"protocol_no":"7163-CL-3201","submission_no":"206235","status_id":1,"start_date":"2017-12-04","end_date":null,"nol_date":"2017-06-29","protocol_title":"A PHASE 2A, RANDOMIZED, OPEN-LABEL, ACTIVE CONTROL, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BLESELUMAB IN PREVENTING THE RECURRENCE OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS","medConditionList":[{"med_condition_id":476,"med_condition":"FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35544,"protocol_no":"EFC12404","submission_no":"172728","status_id":3,"start_date":"2014-08-20","end_date":null,"nol_date":"2014-04-10","protocol_title":"A RANDOMIZED, 30 WEEK, ACTIVE-CONTROLLED, OPEN-LABEL,  3-TREATMENT ARM, PARALLEL-GROUP MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF INSULIN GLARGINE/LIXISENATIDE FIXED RATIO COMBINTATION TO INSULIN GLARGINE ALONE AND TO LIXISENATIDE ALONE ON TOP OF METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38486,"protocol_no":"COG AEWS1221","submission_no":"182190","status_id":1,"start_date":"2017-01-31","end_date":null,"nol_date":"2015-03-19","protocol_title":"RANDOMIZED PHASE II TRIAL EVALUATING THE ADDITION OF THE IGF-1R MONOCLONAL ANTIBODY GANITUMAB (AMG 479, NSC#750008, IND#120449) TO MULTIAGENT CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED METASTATIC EWING SARCOMA","medConditionList":[{"med_condition_id":334,"med_condition":"SARCOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39220,"protocol_no":"14-005","submission_no":"184530","status_id":1,"start_date":"2016-02-19","end_date":null,"nol_date":"2015-06-05","protocol_title":"A LONG-TERM, OPEN-LABEL, SAFETY AND MAINTENANCE OF EFFICACY STUDY OF JZP-110 [(R)-2-AMINO-3-PHENYLPROPYLCARBAMATE HYDROCHLORIDE] IN THE TREATMENT OF EXCESSIVE SLEEPINESS IN SUBJECTS WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA).","medConditionList":[{"med_condition_id":310,"med_condition":"SLEEP APNEA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39144,"protocol_no":"MOBILITY-002","submission_no":"184284","status_id":1,"start_date":"2016-12-21","end_date":null,"nol_date":"2015-06-04","protocol_title":"MOLECULAR BASKET TRIAL IN MULTIPLE MALIGNANCIES WITH COMMON TARGET PATHWAY ABERRANCIES: A PHASE II TRIAL OF GSK2256098 AND TRAMETINIB IN PATIENTS WITH ADVANCED PANCREATIC CANCER","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40364,"protocol_no":"M13-594","submission_no":"187822","status_id":2,"start_date":"2016-01-06","end_date":"2016-12-13","nol_date":"2015-10-07","protocol_title":"A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY TO COMPARE EFFICACY AND SAFETY OF ABT-493/ABT-530 TO SOFOSBUVIR CO-ADMINISTERED WITH DACLATASVIR IN ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 3 INFECTION (ENDURANCE-3)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"},{"med_condition_id":108,"med_condition":"HEPATITIS C VIRUS GENOTYPE 3"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41870,"protocol_no":"1000051475","submission_no":"193000","status_id":1,"start_date":"2016-06-13","end_date":null,"nol_date":"2016-04-01","protocol_title":"THE SAFETY AND FEASIBILITY OF LOSARTAN THERAPY FOR TREATMENT OF PULMONARY VEIN STENOSIS IN PEDIATRIC PATIENTS","medConditionList":[{"med_condition_id":729,"med_condition":"PULMONARY VEIN STENOSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36944,"protocol_no":"FOXY2014","submission_no":"177028","status_id":1,"start_date":"2014-11-03","end_date":null,"nol_date":"2014-09-18","protocol_title":"EFFICIENCY AND TOLERANCE OF FESOTERODIN AND OXYBUTYNIN IN CHILDREN WITH A HYPERACTIVE BLADDER: A COMPARATIVE STUDY","medConditionList":[{"med_condition_id":185,"med_condition":"OVERACTIVE BLADDER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37206,"protocol_no":"B1481045","submission_no":"177847","status_id":1,"start_date":"2014-11-20","end_date":null,"nol_date":"2014-10-10","protocol_title":"A 52 WEEK, PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS.   SPIRE-LL: STUDIES OF PCSK9 INHIBITION AND THE REDUCTION OF VASCULAR EVENTS - LIPID LOWERING","medConditionList":[{"med_condition_id":296,"med_condition":"MIXED DYSLIPIDEMIA"},{"med_condition_id":295,"med_condition":"PRIMARY HYPERLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46431,"protocol_no":"VEDOLIZUMAB-2005","submission_no":"207531","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-10","protocol_title":"A PHASE 2B, EXTENSION STUDY TO DETERMINE THE LONG-TERM SAFETY OF VEDOLIZUMAB IV IN PEDIATRIC SUBJECTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"},{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28126,"protocol_no":"CAPCR 13-6588","submission_no":"167678","status_id":3,"start_date":"2013-11-01","end_date":null,"nol_date":"2013-09-18","protocol_title":"\"18F-FCH-PET/MR STAGING OF HIGH-RISK PROSTATE CANCER: A MULTIPARAMETRIC APPROACH.\"","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38740,"protocol_no":"AC-058B301","submission_no":"183014","status_id":1,"start_date":"2015-12-11","end_date":null,"nol_date":"2015-04-10","protocol_title":"OPTIMUM: ORAL PONESIMOD VERSUS TERIFLUNOMIDE IN RELAPSING MULTIPLE SCLEROSIS MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROLLED, SUPERIORITY STUDY TO COMPARE THE EFFICACY AND SAFETY OF PONESIMOD TO TERIFLUNOMIDE IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45572,"protocol_no":"HEADSTART 4","submission_no":"204836","status_id":1,"start_date":"2018-02-21","end_date":null,"nol_date":"2017-05-02","protocol_title":"NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS:  CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO EITHER SINGLE-CYCLE OR TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE","medConditionList":[{"med_condition_id":460,"med_condition":"MEDULLOBLASTOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35424,"protocol_no":"292-00","submission_no":"172336","status_id":2,"start_date":"2014-11-07","end_date":"2016-10-13","nol_date":"2014-03-20","protocol_title":"A PHASE III MULTICENTER, DOUBLE-BLIND, RANDOMIZED, ACTIVE COMPARATOR-CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF REFORMULATED RALTEGRAVIR  1200 MG ONCE DAILY VERSUS RALTEGRAVIR  400 MG TWICE DAILY, EACH IN COMBINATION WITH TRUVADA(TM), IN TREATMENT-NA√èVE HIV-1 INFECTED SUBJECTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29170,"protocol_no":"CFZ004","submission_no":"171109","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-01-23","protocol_title":"PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY OF CARFILZOMIB, CARBOPLATIN, AND ETOPOSIDE IN SUBJECTS WITH PREVIOUSLY UNTREATED EXTENSIVE-STAGE SMALL-CELL LUNG CANCER","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41089,"protocol_no":"471101","submission_no":"190232","status_id":1,"start_date":"2016-06-28","end_date":null,"nol_date":"2016-01-05","protocol_title":"A PHASE 3/4 STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY, AND EFFECTS ON THE ALPHA1-PROTEINASE INHIBITOR (A1PI) LEVELS IN EPITHELIAL LINING FLUID FOLLOWING GLASSIA THERAPY IN A1PI-DEFICIENT SUBJECTS,","medConditionList":[{"med_condition_id":667,"med_condition":"ALPHA1-PROTEINASE INHIBITOR DEFICIENT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41658,"protocol_no":"100","submission_no":"192255","status_id":1,"start_date":"2016-05-06","end_date":null,"nol_date":"2016-03-09","protocol_title":"A PHASE II, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF PEMBROLIZUMAB MONOTHERAPY IN SUBJECTS WITH ADVANCED RECURRENT OVARIAN CANCER (KEYNOTE-100)","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38956,"protocol_no":"LPS14245","submission_no":"183721","status_id":1,"start_date":"2015-06-30","end_date":null,"nol_date":"2015-05-13","protocol_title":"\"A MULTI-COUNTRY, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO DOCUMENT THE SAFETY, TOLERABLITY AND EFFECT OF ALIROCUMAB ON ATHEROGENIC LIPOPROTEINS IN HIGH CARDIO-VASCULAR RISK PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA NOT ADEQUATELY CONTROLLED WITH CONVENTIONAL LIPID-MODIFYING THERAPIES.\"","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38733,"protocol_no":"201636","submission_no":"183003","status_id":1,"start_date":"2015-07-28","end_date":null,"nol_date":"2015-04-13","protocol_title":"A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF SWITCHING TO DOLUTEGRAVIR PLUS RILPIVIRINE FROM CURRENT INI-, NNRTI-, OR PI-BASED ANTIRETROVIRAL REGIMEN IN HIV-1-INFECTED ADULTS WHO ARE VIROLOGICALLY SUPPRESSED","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38116,"protocol_no":"X052171","submission_no":"180949","status_id":1,"start_date":"2015-02-10","end_date":null,"nol_date":"2015-01-16","protocol_title":"A 2-YEAR, OPEN-LABEL, SAFETY EXTENSION STUDY OF GEVOKIZUMAB IN SUBJECTS WITH PYODERMA GANGRENOSUM","medConditionList":[{"med_condition_id":595,"med_condition":"PYODERMA GANGRENOSUM"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29307,"protocol_no":"CAMHPET-CTA-81","submission_no":"171426","status_id":1,"start_date":"2017-09-12","end_date":null,"nol_date":"2014-02-19","protocol_title":"IMAGING ALTERATIONS IN ENDOCANNABINOID METABOLISM IN SCHIZOPHRENIA USING A NOVEL FATTY ACID AMIDE HYDROLASE TRACER [C-11]CURB","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46943,"protocol_no":"15-AVP-786-302","submission_no":"209247","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-12","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-DESIGN STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM; INN:DEUDEXTROMETHORPHAN]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER¬øS TYPE.","medConditionList":[{"med_condition_id":361,"med_condition":"DEMENTIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35413,"protocol_no":"1301.4","submission_no":"172256","status_id":3,"start_date":"2014-04-17","end_date":null,"nol_date":"2014-03-14","protocol_title":"SAFETY AND EFFICACY OF BI 695500 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: AN OPEN-LABEL EXTENSION TRIAL","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43322,"protocol_no":"16044","submission_no":"197801","status_id":1,"start_date":"2017-05-12","end_date":null,"nol_date":"2016-09-22","protocol_title":"AN OPEN-LABEL PHASE I DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, MAXIMUM TOLERATED DOSE, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ANTI-C4.4A ANTIBODY DRUG CONJUGATE BAY 1129980 IN SUBJECTS WITH ADVANCED SOLID TUMORS KNOWN TO EXPRESS C4.4A","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41007,"protocol_no":"RBXHE01","submission_no":"189945","status_id":1,"start_date":"2016-03-17","end_date":null,"nol_date":"2015-12-24","protocol_title":"A PROSPECTIVE OPEN LABEL SINGLE CENTRE TRIAL OF RBX2660 (MICROBIOTA SUSPENSION) IN THE MANAGEMENT OF HEPATIC ENCEPHALOPATHY (HE)","medConditionList":[{"med_condition_id":282,"med_condition":"HEPATIC ENCEPHALOPATHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41173,"protocol_no":"MEDI4736-MM-002","submission_no":"190545","status_id":1,"start_date":"2016-05-13","end_date":null,"nol_date":"2016-01-20","protocol_title":"A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) IN COMBINATION WITH LENALIDOMIDE (LEN) WITH AND WITHOUT DEXAMETHASONE (DEX) IN SUBJECTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28898,"protocol_no":"MGU-4HPR-13-01","submission_no":"170194","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-17","protocol_title":"AN ADAPTIVE PHASE I INTRA-PATIENT DOSE ESCALATION STUDY OF FENRETINIDE IN ADULT CYSTIC FIBROSIS PATIENTS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46893,"protocol_no":"281102","submission_no":"209030","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-29","protocol_title":"A PHASE 3, PROSPECTIVE, RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER, 2-PERIOD CROSSOVER STUDY WITH A SINGLE ARM CONTINUATION EVALUATING THE SAFETY AND EFFICACY OF BAX930 (RADAMTS13) IN PROPHYLACTIC AND ON-DEMAND TREATMENT OF SUBJECTS WITH SEVERE CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (CTTP, UPSHAW-SCHULMAN SYNDROME [USS], HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA [HTTP])","medConditionList":[{"med_condition_id":648,"med_condition":"THROMBOTIC THROMBOCYTOPENIC PURPURA"},{"med_condition_id":807,"med_condition":"UPSHAW-SCHULMAN SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39389,"protocol_no":"ANAE-273-15","submission_no":"185053","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-06-26","protocol_title":"DOES MAGNESIUM SULFATE AS A SUPPLEMENT IN ADDUCTOR CANAL BLOCKS IMPROVE PAIN CONTROL AFTER TOTAL KNEE ARTHROPLASTY?","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39032,"protocol_no":"201025-001","submission_no":"183920","status_id":1,"start_date":"2016-07-11","end_date":null,"nol_date":"2015-05-14","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, EVALUATING SAFETY AND EFFICACY OF LIRIS¬Æ 400 MG IN FEMALES WITH INTERSTITIAL CYSTITIS WITH HUNNER'S LESIONS","medConditionList":[{"med_condition_id":132,"med_condition":"INTERSTITIAL CYSTITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27897,"protocol_no":"FLUMIST250613","submission_no":"166990","status_id":3,"start_date":"2013-10-01","end_date":null,"nol_date":"2013-08-30","protocol_title":"PILOT PROJECT REGARDING CLINCIAL TOLERANCE TO THE LIVE ATTENUATED VIRUS VACCINE AGAINST INFLUENZA (FLUMIST) AS PART OF THE INFLUENZA VACCINE IN A POPULATION WITH EGG ALLERGIES.","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41721,"protocol_no":"CEC.6 / N0577","submission_no":"192458","status_id":1,"start_date":"2016-06-29","end_date":null,"nol_date":"2016-03-22","protocol_title":"PHASE III INTERGROUP STUDY OF TEMOZOLOMIDE ALONE VERSUS RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE VERSUS RADIOTHERAPY WITH ADJUVANT PCV CHEMOTHERAPY IN PATIENTS WITH 1P/19Q CO-DELETED ANAPLASTIC GLIOMA OR LOW GRADE GLIOMA","medConditionList":[{"med_condition_id":92,"med_condition":"GLIOMA MALIGNANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41754,"protocol_no":"201832","submission_no":"192584","status_id":2,"start_date":"2016-05-24","end_date":"2017-02-03","nol_date":"2016-03-22","protocol_title":"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, CROSSOVER COMPARISON OF FLUTICASONE FUROATE/VILANTEROL 100/25 MCG ONCE DAILY VERSUS FLUTICASONE PROPIONATE 250 MCG TWICE DAILY IN ADOLESCENT AND ADULT SUBJECTS WITH ASTHMA AND EXERCISE-INDUCED BRONCHOCONSTRICTION","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40885,"protocol_no":"GH29914","submission_no":"189595","status_id":1,"start_date":"2017-04-03","end_date":null,"nol_date":"2015-12-16","protocol_title":"A PHASE IB/II MULTI-ARM STUDY WITH VENETOCLAX IN COMBINATION WITH COBIMETINIB AND VENETOCLAX IN COMBINATION WITH IDASANUTLIN IN PATIENTS AGED ? 60 YEARS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WHO ARE NOT ELIGIBLE FOR CYTOTOXIC THERAPY","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27536,"protocol_no":"CL3-78989-006 / X052131","submission_no":"166047","status_id":1,"start_date":"2014-02-18","end_date":null,"nol_date":"2013-07-25","protocol_title":"A RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GEVOKIZUMAB IN THE TREATMENT OF SUBJECTS WITH NON-INFECTIOUS INTERMEDIATE, POSTERIOR, OR PAN-UVEITIS CURRENTLY CONTROLLED WITH SYSTEMIC TREATMENT. THE EYEGUARD -C STUDY","medConditionList":[{"med_condition_id":378,"med_condition":"PAN-UVEITIS"},{"med_condition_id":376,"med_condition":"INTERMEDIATE UVEITIS"},{"med_condition_id":377,"med_condition":"POSTERIOR UVEITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38094,"protocol_no":"AGL-P5-310 (AMG112)","submission_no":"180832","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-01-16","protocol_title":"A SINGLE CENTER, RANDOMIZED, 4-PERIOD STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF SINGLE OR REPEATED 3 MG DOSES OF INTRANASALLY ADMINISTERED GLUCAGON IN ADULTS WITH TYPE 1 OR TYPE 2 DIABETES","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"},{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43384,"protocol_no":"REB 16-5909","submission_no":"197946","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-10-04","protocol_title":"ASSESSING THE EFFECTS OF INTRANASAL GLUCAGON ON ENERGY BALANCE IN HUMANS","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43719,"protocol_no":"MR308-3502","submission_no":"198996","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-10-28","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF MR308 IN THE TREATMENT OF ACUTE PAIN AFTER ABDOMINAL HYSTERECTOMY SURGERY UNDER GENERAL ANAESTHESIA (STARDOM2)","medConditionList":[{"med_condition_id":569,"med_condition":"HYSTERECTOMY ASSOCIATED PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36452,"protocol_no":"MYL-GAI-3001","submission_no":"175465","status_id":1,"start_date":"2014-10-10","end_date":null,"nol_date":"2014-08-07","protocol_title":"AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN'S INSULIN GLARGINE WITH LANTUS IN TYPE 1 DIABETES MELLITUS PATIENTS","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40554,"protocol_no":"AX-CSARC-PI-0001","submission_no":"188480","status_id":1,"start_date":"2016-06-01","end_date":null,"nol_date":"2015-11-03","protocol_title":"A MULTICENTRE, OPEN-LABEL PHASE II STUDY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE + CISPLATIN AS FIRST LINE TREATMENT IN PATIENTS WITH UNRESECTABLE BILIARY TRACT CANCER","medConditionList":[{"med_condition_id":458,"med_condition":"BILIARY CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36745,"protocol_no":"FX006-2014-006","submission_no":"176455","status_id":1,"start_date":"2014-08-20","end_date":null,"nol_date":"2014-08-14","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF FX006 FOR THE TREATMENT OF PAIN IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27631,"protocol_no":"CLJM716X2103","submission_no":"166302","status_id":1,"start_date":"2014-04-28","end_date":null,"nol_date":"2013-08-07","protocol_title":"\"A PHASE IB/II, OPEN-LABEL STUDY OF LJM716 IN COMBINATION WITH BYL719 COMPARED TO TAXANE OR IRINOTECAN IN PATIENTS WITH PREVIOUSLY TREATED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC).\"","medConditionList":[{"med_condition_id":352,"med_condition":"ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39599,"protocol_no":"TOZ-CL05","submission_no":"185820","status_id":2,"start_date":"2015-08-06","end_date":"2017-12-19","nol_date":"2015-07-27","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL PHASE TO DETERMINE THE EFFICACY AND SAFETY OF TOZADENANT AS ADJUNCTIVE THERAPY IN LEVODOPA-TREATED PATIENTS WITH PARKINSON¬øS DISEASE EXPERIENCING END OF DOSE ¬øWEARING OFF¬ø","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47855,"protocol_no":"C16027","submission_no":"212173","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-04","protocol_title":"AN OPEN-LABEL, ROLLOVER PROTOCOL FOR PATIENTS PREVIOUSLY ENROLLED IN MILLENNIUM-SPONSORED IXAZOMIB STUDIES.","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"},{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47503,"protocol_no":"R668-AD-1652","submission_no":"211110","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-08","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43203,"protocol_no":"PJC-022 / NCI 9881","submission_no":"197474","status_id":1,"start_date":"2017-04-13","end_date":null,"nol_date":"2016-08-30","protocol_title":"A PHASE 2 STUDY OF CEDIRANIB IN COMBINATION WITH OLAPARIB IN ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37278,"protocol_no":"POISE3034","submission_no":"178123","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-10","protocol_title":"PERIOPERATIVE ISCHEMIC EVALUATION-3 TRIAL: A PILOT STUDY (POISE-3)","medConditionList":[{"med_condition_id":445,"med_condition":"ATHEROSCLEROTIC VASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40043,"protocol_no":"000174","submission_no":"186864","status_id":1,"start_date":"2015-12-23","end_date":null,"nol_date":"2015-09-04","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MESALAMINE 4 G EXTENDED RELEASE GRANULES (SACHET) FOR THE INDUCTION OF CLINICAL AND ENDOSCOPIC REMISSION IN ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43488,"protocol_no":"H9X-MC-GBGC(A)","submission_no":"198236","status_id":1,"start_date":"2017-03-17","end_date":null,"nol_date":"2016-10-05","protocol_title":"A RANDOMIZED, DOUBLE-BLIND STUDY WITH AN OPEN-LABEL EXTENSION COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH PLACEBO IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS (AWARD-PEDS: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-PEDIATRIC STUDY)","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35626,"protocol_no":"ING201147","submission_no":"172945","status_id":1,"start_date":"2014-05-12","end_date":null,"nol_date":"2014-04-03","protocol_title":"A PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF SWITCHING TO A FIXED-DOSE COMBINATION OF ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE FROM CURRENT ANTIRETROVIRAL REGIMEN COMPARED WITH CONTINUATION OF THE CURRENT ANTIRETROVIRAL REGIMEN IN HIV-1 INFECTED ADULTS WHO ARE VIROLOGICALLY SUPPRESSED","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40354,"protocol_no":"ALX0681-C301","submission_no":"187791","status_id":1,"start_date":"2015-11-27","end_date":null,"nol_date":"2015-10-30","protocol_title":"A PHASE III DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, MULTICENTER PLACEBO-CONTROLLED TRIAL TO STUDY THE EFFICACY AND SAFETY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA","medConditionList":[{"med_condition_id":648,"med_condition":"THROMBOTIC THROMBOCYTOPENIC PURPURA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35630,"protocol_no":"NCT02008786","submission_no":"172955","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-08","protocol_title":"THE EFFECTS OF STATIN AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR ON CORONARY FLOW RESERVE, INDEX OF MICROCIRCULATORY RESISTANCE, AND SYMPTOMS IN PATIENTS WITH SPONTANEOUS CORONARY ARTERY DISSECTION (SAFER-SCAD) STUDY","medConditionList":[{"med_condition_id":502,"med_condition":"SPONTANEOUS CORONARY ARTERY DISSECTION (SCAD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42185,"protocol_no":"224","submission_no":"194203","status_id":1,"start_date":"2016-05-30","end_date":null,"nol_date":"2016-05-12","protocol_title":"A PHASE II STUDY OF PEMBROLIZUMAB (MK-3475) AS MONOTHERAPY IN SUBJECTS WITH PREVIOUSLY SYSTEMICALLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (KEYNOTE-224)","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43047,"protocol_no":"CAIN457A2323","submission_no":"196986","status_id":1,"start_date":"2016-09-28","end_date":null,"nol_date":"2016-08-23","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK STUDY TO DEMONSTRATETHE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUS SECUKINUMAB INJECTIONS WITH 2ML PRE-FILLED SYRINGES (300 MG) IN ADULT SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS - ALLURE","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28202,"protocol_no":"1000039945A","submission_no":"167933","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-06","protocol_title":"FAST (FETAL ATRIAL FLUTTER & SUPRAVENTRICULAR TACHYCARDIA) THERAPY TRIAL - SUBSTUDY A","medConditionList":[{"med_condition_id":416,"med_condition":"ATRIAL FLUTTER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40697,"protocol_no":"GS-US-283-1062","submission_no":"188865","status_id":1,"start_date":"2016-01-07","end_date":null,"nol_date":"2015-11-20","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GS-9620 IN COMBINATION WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF SUBJECTS WITH CHRONIC HEPATITIS B AND WHO ARE CURRENTLY NOT ON TREATMENT","medConditionList":[{"med_condition_id":345,"med_condition":"CHRONIC HEPATITIS B"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35711,"protocol_no":"BBI503-205B","submission_no":"173202","status_id":1,"start_date":"2015-08-12","end_date":null,"nol_date":"2014-04-28","protocol_title":"A PHASE II CLINICAL STUDY OF BBI503 IN ADULT PATIENTS WITH ADVANCED HEPATOBILIARY CANCER","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"},{"med_condition_id":458,"med_condition":"BILIARY CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38907,"protocol_no":"061","submission_no":"183563","status_id":1,"start_date":"2017-02-21","end_date":null,"nol_date":"2015-06-18","protocol_title":"\"A PHASE III, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERUS PACLITAXEL IN SUBJECTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA WHO PROGRESSED AFTER FIRST-LINE THERAPY WITH PLATINUM AND FLUOROPYRIMIDINE.\"","medConditionList":[{"med_condition_id":320,"med_condition":"ADENOCARCINOMA"},{"med_condition_id":337,"med_condition":"GASTRIC CANCER"},{"med_condition_id":619,"med_condition":"GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35435,"protocol_no":"NN9211-4083","submission_no":"172382","status_id":1,"start_date":"2014-05-07","end_date":null,"nol_date":"2014-03-25","protocol_title":"ADJUNCT TWO, THE EFFICACY AND SAFETY OF LIRAGLUTIDE ADJUNCT TO INSULIN TREATMENT IN TYPE 1 DIABETES - A 26 WEEKS RANDOMISED, INSULIN CAPPED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP, MULTINATIONAL, MULTI-CENTRE TRIAL)","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41273,"protocol_no":"MLN0002-3023","submission_no":"191059","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-01-26","protocol_title":"A RADOMIZED GLOBAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB IV FOR THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS, WITH UNDERLYING INFLAMMATORY BOWEL DISEASE","medConditionList":[{"med_condition_id":601,"med_condition":"PRIMARY SCLEROSING CHOLANGITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28305,"protocol_no":"CL3-06790-010","submission_no":"168192","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-11","protocol_title":"THE EFFICACY AND SAFETY OF TRIMETAZIDINE IN PATIENTS WITH ANGINA PECTORIS HAVING BEEN TREATED BY PERCUTANEOUS CORONARY INTERVENTION. ATPCI STUDY.","medConditionList":[{"med_condition_id":272,"med_condition":"ANGINA PECTORIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45445,"protocol_no":"M15-891","submission_no":"203527","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-05","protocol_title":"A MULTICENTER, PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF ABBV-181, A MONOCLONAL ANTIBODY, IN SUBJECTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36338,"protocol_no":"PLAN14001","submission_no":"175100","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-02","protocol_title":"PREGABALIN AND LIDOCAINE IN BREAST CANCER SURGERY TO ALTER NEUROPATHIC PAIN (PLAN): A PILOT TRIAL","medConditionList":[{"med_condition_id":174,"med_condition":"NEUROPATHIC PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45414,"protocol_no":"ST2017-PRO00067953","submission_no":"204352","status_id":1,"start_date":"2017-05-30","end_date":null,"nol_date":"2017-04-12","protocol_title":"SONOTHROMBOLYSIS IN PATIENTS WITH AN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION","medConditionList":[{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47750,"protocol_no":"SAV005-04","submission_no":"211728","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-21","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AEROVANC FOR THE TREATMENT OF PERSISTENT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS LUNG INFECTION IN CYSTIC FIBROSIS PATIENTS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36799,"protocol_no":"AC220-007","submission_no":"176602","status_id":1,"start_date":"2016-12-02","end_date":null,"nol_date":"2014-08-22","protocol_title":"A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF QUIZARTINIB (AC220) MONOTHERAPY VERSUS SALVAGE CHEMOTHERAPY IN SUBJECTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) REFRACTORY TO OR RELAPSED AFTER FIRST-LINE TREATMENT WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) CONSOLIDATION","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27390,"protocol_no":"1241.30","submission_no":"165607","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-07-17","protocol_title":"A PHASE II RANDOMISED, DOUBLE-BLIND AND PLACEBO-CONTROLLED STUDY OF BI 207127 IN COMBINATION WITH FALDAPREVIR AND RIBAVIRIN IN PATIENTS WITH MODERATE HEPATIC IMPAIRMENT (CHILD-PUGH B) WITH GENOTYPE 1B CHRONIC HEPATITIS C INFECTION","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40232,"protocol_no":"RPC01-2201","submission_no":"187445","status_id":1,"start_date":"2015-12-30","end_date":null,"nol_date":"2015-09-30","protocol_title":"A PHASE 2, MULTI-CENTER, OPEN-LABEL INDUCTION TRIAL WITH EXTENSION PERIOD TO ASSESS ENDOSCOPIC IMPROVEMENT AND CHANGES IN INTESTINAL AND SERUM BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE RECEIVING ORAL RPC1063 AS INDUCTION THERAPY","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27156,"protocol_no":"AI452032","submission_no":"164975","status_id":1,"start_date":"2013-08-27","end_date":null,"nol_date":"2013-06-14","protocol_title":"\"A PHASE 3 OPEN LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF PEGYLATED INTERFERON LAMBDA-1A, IN COMBINATION WITH RIBAVIRIN AND DELATASVIR, FOR TREATMENT OF CHRONIC HCV INFECTION WITH TREATMENT NAIVE GENOTYPS 1,2,3 OR 4 IN SUBJECTS CO-INFECTED WITH HIV.\"","medConditionList":[{"med_condition_id":105,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1 OR 4"},{"med_condition_id":107,"med_condition":"HEPATITIS C VIRUS GENOTYPE 2 OR 3"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48392,"protocol_no":"CCTG OV.25","submission_no":"213800","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-12","protocol_title":"A RANDOMIZED PHASE II DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF ACETYLSALICYLIC ACID (ASA) IN PREVENTION OF OVARIAN CANCER IN WOMEN WITH BRCA 1/2 MUTATIONS (STICS AND STONES)","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37895,"protocol_no":"201411-2177","submission_no":"179917","status_id":1,"start_date":"2015-04-28","end_date":null,"nol_date":"2014-12-19","protocol_title":"CELLULAR IMMUNOTHERAPY FOR SEPTIC SHOCK (CISS)","medConditionList":[{"med_condition_id":583,"med_condition":"SEPTIC SHOCK"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27333,"protocol_no":"HALPCARD13-132","submission_no":"165452","status_id":1,"start_date":"2013-08-01","end_date":null,"nol_date":"2013-06-24","protocol_title":"HALOPERIDOL PROPHYLAXIS IN CARDIAC SURGERY FOR PATIENTS AT RISK FOR DELIRIUM: A RANDOMIZED PLACEBO-CONTROLLED PILOT STUDY","medConditionList":[{"med_condition_id":305,"med_condition":"DELERIUM"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39186,"protocol_no":"MM-141-07-02-02","submission_no":"184397","status_id":2,"start_date":"2016-07-13","end_date":"2017-01-24","nol_date":"2015-06-05","protocol_title":"\"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF MM-141 PLUS NAB-PACLITAXEL AND GEMCITABINE VERSUS NAB-PACLITAXEL AND GEMCITABINE IN FRONT-LINE METASTATIC PANCREATIC CANCER (CARRIE).\"","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41407,"protocol_no":"CV006004","submission_no":"191410","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-02-16","protocol_title":"CLINICAL PROTOCOL:  A PHASE 2, PLACEBO CONTROLLED, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BMS-986141 FOR THE PREVENTION OF RECURRENT BRAIN INFARCTION IN SUBJECTS RECEIVING ACETYLSALICYCLIC ACID (ASA) FOLLOWING ACUTE ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK","medConditionList":[{"med_condition_id":134,"med_condition":"ISCHEMIC ATTACK AND MINOR STROKE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27400,"protocol_no":"32793","submission_no":"165272","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-07-05","protocol_title":"THE EFFECT OF LUTEAL PHASE SUPPORT ON PREGNANCY RATE IN INTRAUTERINE INSEMINATION CYCLES FOLLOWING OVARIAN STIMULATION WITH GONADOTROPINS","medConditionList":[{"med_condition_id":301,"med_condition":"INFERTILITY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39701,"protocol_no":"109MS306","submission_no":"186046","status_id":1,"start_date":"2016-01-15","end_date":null,"nol_date":"2015-08-05","protocol_title":"OPEN-LABEL, RANDOMIZED, MULTICENTER, MULTIPLE-DOSE, ACTIVE-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF BG00012 IN CHILDREN FROM 10 TO LESS THAN 18 YEARS OF AGE WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":565,"med_condition":"RELAPSING-REMITTING MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28553,"protocol_no":"RTOG 1221","submission_no":"168951","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-31","protocol_title":"RANDOMIZED PHASE II TRIAL OF TRANSORAL ENDOSCOPIC HEAD AND NECK SURGERY FOLLOWED BY RISK-BASED IMRT AND WEEKLY CISPLATIN VERSUS IMRT AND WEEKLY CISPLATIN FOR HPV NEGATIVE OROPHARYNX CANCER","medConditionList":[{"med_condition_id":486,"med_condition":"OROPHARYNX CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36121,"protocol_no":"SCI-TA1-SEP-P2/3-001","submission_no":"174544","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-06-03","protocol_title":"MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2/3 CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF ZADAXIN (THYMALFASIN/TA1) TO PLACEBO IN SUBJECTS WITH SEVERE SEPSIS","medConditionList":[{"med_condition_id":230,"med_condition":"SEPSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42952,"protocol_no":"426","submission_no":"196741","status_id":1,"start_date":"2016-11-01","end_date":null,"nol_date":"2016-08-08","protocol_title":"A PHASE III RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH AXITINIB VERSUS SUNITINIB MONOTHERAPY AS A FIRST-LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA (MRCC) (KEYNOTE-426)","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35555,"protocol_no":"CA209-139","submission_no":"172765","status_id":1,"start_date":"2014-10-15","end_date":null,"nol_date":"2014-04-03","protocol_title":"A SINGLE-ARM, OPEN-LABEL, PHASE 2 STUDY OF NIVOLUMAB (BMS-936558) IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AFTER FAILURE OF AUTOLOGUS STEM CELL TRANSPLANT (ASCT) OR AFTER FAILURE OF AT LEAST TWO PRIOR MULTI-AGENT CHEMOTHERAPY REGIMENS IN SUBJECTS WHO ARE NOT CANDIDATES FOR ASCT","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44129,"protocol_no":"1381.1","submission_no":"200207","status_id":1,"start_date":"2017-01-25","end_date":null,"nol_date":"2016-12-13","protocol_title":"AN OPEN-LABEL, PHASE I TRIAL TO DETERMINE THE MAXIMUM-TOLERATED DOSE AND INVESTIGATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BI 754091 IN PATIENTS WITH ADVANCED SOLID TUMOURS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38411,"protocol_no":"20101228","submission_no":"181991","status_id":1,"start_date":"2015-05-01","end_date":null,"nol_date":"2015-03-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL EXTENSION TO EVALUATE THE SAFETY AND EFFICACY OF BRODALUMAB IN SUBJECTS WITH AXIAL SPONDYLOARTHRITIS","medConditionList":[{"med_condition_id":673,"med_condition":"AXIAL SPONDYLARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45392,"protocol_no":"MVT-601-3201","submission_no":"204288","status_id":1,"start_date":"2017-06-16","end_date":null,"nol_date":"2017-04-26","protocol_title":"HERO:  A MULTINATIONAL PHASE 3, RANDOMIZED, OPEN-LABEL, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELUGOLIX IN MEN WITH ADVANCED PROSTATE CANCER.","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48080,"protocol_no":"1245.167","submission_no":"212877","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-12","protocol_title":"A PHASE III RANDOMISED, DOUBLE-BLIND TRIAL TO EVALUATE THE EFFECT OF 12WEEKS TREATMENT OF ONCE DAILY EMPAGLIFLOZIN 10 MG COMPARED WITHPLACEBO ON EXERCISE ABILITY AND HEART FAILURE SYMPTOMS, IN PATIENTSWITH CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION(HFPEF) (EMPERIAL ¬ø PRESERVED).","medConditionList":[{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47997,"protocol_no":"CA209-9KD","submission_no":"212668","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-23","protocol_title":"A PHASE 2 STUDY OF NIVOLUMAB IN COMBINATION WITH EITHER RUCAPARIB, DOCETAXEL, OR ENZALUTAMIDE IN MEN WITH CASTRATION-RESISTANT METASTATIC PROSTATE CANCER (CHECKMATE 9KD: CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 9KD)","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47662,"protocol_no":"CLSZ102X2101","submission_no":"211454","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-04","protocol_title":"A PHASE, I/IB, OPEN LABEL STUDY OF LSZ102 SINGLE AGENT AND LSZ102 IN COMBINATION WITH RIBOCICLIB (LSZ102 + RIBOCICLIB) OR ALPELISIB (LSZ102 + ALPELISIB) IN PATIENTS WITH ADVANCED OR METASTATIC ER+ BREAST CANCER WHO HAVE PROGRESSED ON PRIOR ENDOCRINE THERAPY.","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45597,"protocol_no":"NN1218-4113","submission_no":"204498","status_id":1,"start_date":"2017-09-19","end_date":null,"nol_date":"2017-05-18","protocol_title":"EFFICACY AND SAFETY OF FAST-ACTING INSULIN ASPART COMPARED TO NOVORAPID¬Æ BOTH IN COMBINATION WITH INSULIN DEGLUDEC WITH OR WITHOUT METFORMIN IN ADULTS WITH TYPE 2 DIABETES (ONSET¬Æ 9)","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44732,"protocol_no":"MP-101-01","submission_no":"202230","status_id":1,"start_date":"2017-07-31","end_date":null,"nol_date":"2017-02-17","protocol_title":"TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MP-101 IN THE TREATMENT OF PSYCHOSIS IN PATIENTS WITH ALZHEIMER¬øS DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"},{"med_condition_id":312,"med_condition":"PSYCHOTIC DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40834,"protocol_no":"NCIC CTG MA.38","submission_no":"189388","status_id":1,"start_date":"2016-03-14","end_date":null,"nol_date":"2015-12-10","protocol_title":"RANDOMIZED PHASE II STUDY COMPARING TWO DIFFERENT SCHEDULES OF PALBOCICLIB PLUS SECOND LINE ENDOCRINE THERAPY IN WOMEN WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE ADVANCED/METASTATIC BREAST CANCER.","medConditionList":[{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27967,"protocol_no":"PPO116097","submission_no":"167190","status_id":1,"start_date":"2013-12-24","end_date":null,"nol_date":"2013-09-04","protocol_title":"A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND (SPONSOR OPEN) STUDY OF GSK1278863, A HIF-PROLYL HYDROXYLASE INHIBITOR, TO REDUCE ISCHEMIC EVENTS IN PATIENTS UNDERGOING THORACIC AORTIC ANEURYSM REPAIR","medConditionList":[{"med_condition_id":419,"med_condition":"AORTIC ANEURYSM"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35688,"protocol_no":"GS-US-311-1089","submission_no":"173117","status_id":1,"start_date":"2014-05-23","end_date":null,"nol_date":"2014-04-30","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, SWITCH STUDY TO EVALUATE F/TAF IN HIV 1 POSITIVE SUBJECTS WHO ARE VIROLOGICALLY SUPPRESSED ON REGIMENS CONTAINING FTC/TDF","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40487,"protocol_no":"EMR 100070-005","submission_no":"188305","status_id":1,"start_date":"2016-09-09","end_date":null,"nol_date":"2015-11-06","protocol_title":"A PHASE III, OPEN-LABEL, MULTICENTER TRIAL OF AVELUMAB (MSB0010718C) VERSUS PLATINUM-BASED DOUBLET AS A FIRST-LINE TREATMENT OF RECURRENT OR STAGE IV PD-L1 + NON-SMALL-CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27165,"protocol_no":"NP28902","submission_no":"165002","status_id":2,"start_date":"2014-06-04","end_date":"2015-06-03","nol_date":"2013-06-14","protocol_title":"A MULTICENTER, OPEN-LABEL CLINICAL PHARMACOLOGY STUDY WITH RO5503781, AN MDM2 ANTAGONIST, IN PATIENTS WITH SOLID TUMORS TO DETERMINE: PART 1 - ONE-SEQUENCE, 2-PERIOD CROSSOVER DESIGN TO INVESTIGATE THE EFFECT OF POSACONAZOLE, A STRONG CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF RO5503781 AND PART 2 - A RANDOMIZED, SINGLE-DOSE, 3 PERIOD CROSSOVER DESIGN TO INVESTIGATE THE RELATIVE BIOAVAILABILITY OF TWO NEW RO5503781 TABLET FORMULATIONS FOLLOWING ORAL ADMINISTRATION","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38066,"protocol_no":"2010 - 023988 - 17","submission_no":"180727","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-05-29","protocol_title":"MANAGEMENT OF HYPOTENSION IN THE PRETERM: A MULTI CENTRE, RANDOMISED, CONTROLLED TRIAL OF HYPOTENSION MANAGEMENT IN THE EXTREMELY LOW GESTATIONAL AGE NEW-BORN","medConditionList":[{"med_condition_id":605,"med_condition":"HYPOTENSION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37514,"protocol_no":"ISIS 396443-CS4","submission_no":"178841","status_id":2,"start_date":"2015-02-10","end_date":"2017-01-17","nol_date":"2014-11-13","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, SHAM-PROCEDURE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY AND SAFETY OF ISIS 396443 ADMINISTERED INTRATHECALLY IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY","medConditionList":[{"med_condition_id":321,"med_condition":"SPINAL MUSCULAR ATROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39927,"protocol_no":"WB29804","submission_no":"186630","status_id":1,"start_date":"2016-02-11","end_date":null,"nol_date":"2015-08-27","protocol_title":"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND A HISTORY OF EXACERBATIONS","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35907,"protocol_no":"PAC326 (PERSIST-2)","submission_no":"173682","status_id":1,"start_date":"2014-05-12","end_date":null,"nol_date":"2014-05-09","protocol_title":"A RANDOMIZED CONTROLLED PHASE 3 STUDY OF ORAL PACRITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH THROMBOCYTOPENIA AND PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS.","medConditionList":[{"med_condition_id":515,"med_condition":"THROMBOCYTOPENIA"},{"med_condition_id":249,"med_condition":"THROMBOCYTHEMIA MYELOFIBROSIS"},{"med_condition_id":514,"med_condition":"POST-POLYCYTHEMIA VERA MYELOFIBROSIS"},{"med_condition_id":513,"med_condition":"POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS"},{"med_condition_id":211,"med_condition":"PRIMARY MYELOFIBROSIS (PMF)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27084,"protocol_no":"214-2012","submission_no":"164740","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-06-07","protocol_title":"EFFECTS OF VARENICLINE ON CORTICAL NEUROPLASTICITY AND WORKING MEMORY IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY CONTROLS","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42340,"protocol_no":"REC-15-017","submission_no":"194640","status_id":1,"start_date":"2016-09-01","end_date":null,"nol_date":"2016-06-07","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EVALUATION OF THE SAFETY OF N1539 FOLLOWING MAJOR SURGERY","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36021,"protocol_no":"CIG025ECA01","submission_no":"174223","status_id":1,"start_date":"2014-07-09","end_date":null,"nol_date":"2014-05-28","protocol_title":"OPTIMA: EFFICACY OF OPTIMIZED RE-TREATMENT AND STEP-UP THERAPY WITH OMALIZUMAB IN CHRONIC SPONTANEOUS URTICARIA PATIENTS","medConditionList":[{"med_condition_id":399,"med_condition":"CHRONIC SPONTANEOUS URTICARIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46911,"protocol_no":"PJC-024 / NCI 10021","submission_no":"209124","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-05","protocol_title":"A PHASE 2 STUDY OF MEDI4736 (DURVALUMAB) AND TREMELIMUMAB ALONE OR IN COMBINATION WITH HIGH OR LOW-DOSE RADIATION IN METASTATIC COLORECTAL AND NSCLC","medConditionList":[{"med_condition_id":505,"med_condition":"LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER"},{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38209,"protocol_no":"PERSDMECYTOKINETA","submission_no":"181276","status_id":1,"start_date":"2015-01-30","end_date":null,"nol_date":"2015-02-10","protocol_title":"CYTOKINE LEVELS IN PATIENTS WITH PERSISTENT DIABETIC MACULAR EDEMA FOLLOWING RANIBIZUMAB THERAPY TREATED WITH TRIAMCINOLONE ACETONIDE: AN INTERVENTIONAL PROSPECTIVE STUDY","medConditionList":[{"med_condition_id":64,"med_condition":"DIABETIC MACULAR EDEMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28807,"protocol_no":"ECU-MG-301","submission_no":"169909","status_id":1,"start_date":"2014-03-25","end_date":null,"nol_date":"2013-12-11","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG)","medConditionList":[{"med_condition_id":88,"med_condition":"GENERALIZED MYASTHENIA GRAVIS (MG).\""}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35760,"protocol_no":"BO28984","submission_no":"173336","status_id":1,"start_date":"2014-11-20","end_date":null,"nol_date":"2014-04-30","protocol_title":"RANDOMIZED, MULTI-CENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NA√èVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":509,"med_condition":"ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28490,"protocol_no":"AC-061A302","submission_no":"168738","status_id":2,"start_date":"2014-01-15","end_date":"2017-05-02","nol_date":"2013-10-28","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO COMPARE THE EFFICACY AND SAFETY OF CADAZOLID VERSUS VANCOMYCIN IN SUBJECTS WITH CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD)","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39316,"protocol_no":"20120296","submission_no":"184813","status_id":1,"start_date":"2015-12-18","end_date":null,"nol_date":"2015-06-23","protocol_title":"\"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMG 334 IN MIGRAINE PREVENTION.\"","medConditionList":[{"med_condition_id":157,"med_condition":"MIGRAINE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48147,"protocol_no":"204686","submission_no":"213067","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-21","protocol_title":"A PHASE I, OPEN-LABEL STUDY OF GSK1795091 ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPIES IN PARTICIPANTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":293,"med_condition":"MALIGNANT SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41531,"protocol_no":"M12-817","submission_no":"191759","status_id":1,"start_date":"2017-12-07","end_date":null,"nol_date":"2016-02-23","protocol_title":"A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELAGOLIX IN COMBINATION WITH ESTRADIOL/NORETHINDRONE ACETATE FOR THE MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS IN PREMENOPAUSAL WOMEN","medConditionList":[{"med_condition_id":333,"med_condition":"UTERINE FIBROIDS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37218,"protocol_no":"BRAIN-001","submission_no":"177884","status_id":1,"start_date":"2015-09-24","end_date":null,"nol_date":"2014-10-16","protocol_title":"BLINDED RANDOMIZED TRIAL OF ANTICOAGULATION TO PREVENT ISCHEMIC STROKE AND NEUROCOGNITIVE IMPAIRMENT IN ATRIAL FIBRILLATION","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47452,"protocol_no":"ARQ-151-101","submission_no":"210989","status_id":1,"start_date":"2018-01-08","end_date":null,"nol_date":"2017-11-28","protocol_title":"A PHASE 1/2A SINGLE DOSE AND 28-DAY PARALLEL GROUP, DOUBLE BLIND, VEHICLE-CONTROLLED STUDY OF THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARQ-151 CREAM 0.5% AND 0.15% IN ADULTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40676,"protocol_no":"UAZ2015-05-02","submission_no":"188794","status_id":1,"start_date":"2016-06-15","end_date":null,"nol_date":"2015-11-17","protocol_title":"M4OC-PREVENT: METFORMIN FOR ORAL CANCER PREVENTION","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"},{"med_condition_id":34,"med_condition":"CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28820,"protocol_no":"NOH401","submission_no":"169975","status_id":1,"start_date":"2014-03-12","end_date":null,"nol_date":"2013-12-11","protocol_title":"PHOENIX: A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY","medConditionList":[{"med_condition_id":438,"med_condition":"ORTHOSTATIC HYPOTENSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47990,"protocol_no":"PHL-099 / NCI 10104","submission_no":"212625","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-05","protocol_title":"A RANDOMIZED PHASE 2 STUDY OF CABOZANTINIB IN COMBINATION WITH NIVOLUMAB IN ADVANCED, RECURRENT METASTATIC ENDOMETRIAL CANCER","medConditionList":[{"med_condition_id":366,"med_condition":"METASTATIC ENDOMETRIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37738,"protocol_no":"B5161002","submission_no":"179608","status_id":1,"start_date":"2016-11-17","end_date":null,"nol_date":"2014-12-10","protocol_title":"A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06252616 IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY.\"","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36259,"protocol_no":"CP027.2002","submission_no":"174902","status_id":2,"start_date":"2014-04-27","end_date":"2016-03-21","nol_date":"2014-06-18","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EXPLORE THE EFFICACY OF TRV027 IN PATIENTS HOSPITALIZED FOR ACUTE DECOMPENSATED HEART FAILURE","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35349,"protocol_no":"061001","submission_no":"170767","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-01-08","protocol_title":"ADVATE HEMOPHILIA A OUTCOME DATABASE","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28531,"protocol_no":"T705AUS317","submission_no":"168877","status_id":2,"start_date":"2014-01-13","end_date":"2015-10-01","nol_date":"2013-11-08","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF FAVIPIRAVIR IN ADULT SUBJECTS WITH UNCOMPLICATED INFLUENZA.","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46999,"protocol_no":"NP39051","submission_no":"209420","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-13","protocol_title":"A MULTI-CENTER, OPEN-LABEL, CLINICAL PHARMACOLOGY STUDY FOR IDASANUTLIN, AN MDM2 ANTAGONIST WITH A HYBRID RANDOMIZED/SEQUENTIAL, SINGLE-DOSE, 4-PERIOD, CROSSOVER DESIGN TO INVESTIGATE THE BIOEQUIVALENCE OR RELATIVE BIOAVAILABILITY OF THREE NEW IDASANUTLIN TABLET VARIANTS FOLLOWING ORAL ADMINISTRATION IN PATIENTS WITH SOLID TUMORS.","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43776,"protocol_no":"IM101-567","submission_no":"199117","status_id":1,"start_date":"2017-05-04","end_date":null,"nol_date":"2016-11-01","protocol_title":"A RANDOMIZED, HEAD-TO-HEAD, SINGLE-BLINDED STUDY TO ASSESS CHANGES IN THE IMMUNE PROFILE IN RESPONSE TO TREATMENT WITH SUBCUTANEOUS ABATACEPT IN COMBINATION WITH METHOTREXATE VERSUS SUBCUTANEOUS ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN ADULTS WITH EARLY RHEUMATOID ARTHRITIS WHO ARE NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26504,"protocol_no":"I1F-MC-RHBA(B)","submission_no":"162961","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-04-17","protocol_title":"\"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS\"","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44887,"protocol_no":"MEDI4736-MM-005","submission_no":"199877","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-09","protocol_title":"A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY TO DETERMINE THE EFFICACY OF THE COMBINATION OF DARATUMUMAB (DARA) PLUS DURVALUMAB (DURVA) (D2) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) WHO HAVE PROGRESSED ON DARA WHILE ON A DARA-CONTAINING REGIMEN AS THE MOST RECENT MM THERAPY.(FUSION MM-005)","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37830,"protocol_no":"GS-US-279-1503","submission_no":"179816","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-18","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL STUDY OF GS-6615 IN SUBJECTS WITH CHRONIC STABLE ANGINA AND CORONARY ARTERY DISEASE","medConditionList":[{"med_condition_id":598,"med_condition":"CORONARY ARTERY DISEASE"},{"med_condition_id":272,"med_condition":"ANGINA PECTORIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42486,"protocol_no":"407","submission_no":"195155","status_id":1,"start_date":"2016-09-23","end_date":null,"nol_date":"2016-06-10","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF CARBOPLATIN-PACLITAXEL/NAB-PACLITAXEL CHEMOTHERAPY WITH OR WITHOUT PEMBROLIZUMAB (MK-3475) IN FIRST LINE METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER SUBJECTS (KEYNOTE-407)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29423,"protocol_no":"052-00","submission_no":"171776","status_id":1,"start_date":"2014-07-10","end_date":null,"nol_date":"2014-02-26","protocol_title":"A  PHASE  II/III  RANDOMIZED  CLINICAL  TRIAL  TO  STUDY  THE  EFFICACY  AND  SAFETY  OF  THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND CHRONIC KIDNEY DISEASE","medConditionList":[{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"},{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38758,"protocol_no":"CAMHPET-CTA-85","submission_no":"183062","status_id":1,"start_date":"2015-08-17","end_date":null,"nol_date":"2015-04-17","protocol_title":"\"VALIDATION OF A NEW PET TRACER TARGETING TAU PATHOLOGY IN PARKINSONISM.\"","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35875,"protocol_no":"PM1116197","submission_no":"173674","status_id":1,"start_date":"2014-07-07","end_date":null,"nol_date":"2014-05-07","protocol_title":"A CLINICAL OUTCOMES STUDY TO COMPARE THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS PRESENTING WITH ACUTE CORONARY SYNDROME TREATED WITH LOSMAPIMOD COMPARED TO PLACEBO (PM1116197)","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36147,"protocol_no":"LUM001-305","submission_no":"174621","status_id":1,"start_date":"2018-03-28","end_date":null,"nol_date":"2014-06-05","protocol_title":"A MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH ALAGILLE SYNDROME","medConditionList":[{"med_condition_id":453,"med_condition":"ALAGILLE SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35825,"protocol_no":"GAP02-01.1","submission_no":"173597","status_id":1,"start_date":"2015-02-06","end_date":null,"nol_date":"2014-05-02","protocol_title":"PROPS: PET/MRI PRE-RADIOTHERAPY FOR POST-PROSTATECTOMY SALVAGE","medConditionList":[{"med_condition_id":485,"med_condition":"POST-PROSTATECTOMY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27941,"protocol_no":"2013PETMRIEF","submission_no":"167122","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-18","protocol_title":"ADVANCED MOLECULAR NEUROIMAGING TECHNIQUES FOR DIAGNOSIS AND PROGNOSIS IN NEURODEGENERATIVE DISEASES","medConditionList":[{"med_condition_id":385,"med_condition":"NEURODEGENERATIVE DISEASES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26734,"protocol_no":"WA28118","submission_no":"163649","status_id":1,"start_date":"2013-11-06","end_date":null,"nol_date":"2013-05-02","protocol_title":"\"A PHASE IB, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMIS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS.\"","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35909,"protocol_no":"M12-914","submission_no":"173818","status_id":1,"start_date":"2016-10-17","end_date":null,"nol_date":"2014-05-16","protocol_title":"A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CARBOPLATIN AND PACLITAXEL WITH OR WITHOUT THE PARP INHIBITOR VELIPARIB (ABT-888) IN HER2 NEGATIVE METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BRCA ASSOCIATED BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"},{"med_condition_id":516,"med_condition":"HER2 NEGATIVE METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BRCA ASSOCIATED BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41025,"protocol_no":"185","submission_no":"189998","status_id":1,"start_date":"2016-08-03","end_date":null,"nol_date":"2016-01-06","protocol_title":"A PHASE III STUDY OF LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE WITH OR WITHOUT PEMBROLIZUMAB (MK3475) IN NEWLY DIAGNOSED AND TREATMENT NA√èVE MULTIPLE MYELOMA (KEYNOTE 185)","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48083,"protocol_no":"EP0091","submission_no":"212823","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-16","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38084,"protocol_no":"20130601","submission_no":"180805","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-01-16","protocol_title":"REASSESSMENT OF ANTI-PLATELET THERAPY USING INDIVIDUALIZED STRATEGIES - MODIFYING ACUTE CORONARY SYNDROME ALGORITHMS BASED ON GENETIC AND DEMOGRAPHIC EVALUATION: THE RAPID-MANAGE STUDY RESEARCH PROPOSAL","medConditionList":[{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36994,"protocol_no":"201128","submission_no":"177174","status_id":2,"start_date":"2015-11-24","end_date":"2016-02-10","nol_date":"2014-09-11","protocol_title":"A PHASE II STUDY TO EVALUATE THE EFFECTS OF UP TO 12 WEEKS OF PAZOPANIB DOSING ON BLEEDING IN SUBJECTS WITH HEREDITARY HAEMORRHAGIC TELANGIECTASIA.","medConditionList":[{"med_condition_id":572,"med_condition":"HEREDITARY HAEMORRHAGIC TELANGIECTASIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43886,"protocol_no":"INCB 18424-206","submission_no":"199502","status_id":1,"start_date":"2017-01-19","end_date":null,"nol_date":"2016-11-18","protocol_title":"A PHASE 2, RANDOMIZED, DOSE-RANGING, VEHICLE-CONTROLLED AND TRIAMCINOLONE 0.1% CREAM¬øCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INCB018424 PHOSPHATE CREAM APPLIED TOPICALLY TO ADULTS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37932,"protocol_no":"FREE FLAP - 14-8151","submission_no":"180174","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-22","protocol_title":"MULTI-MODALITY IMAGING FOR HEAD & NECK CANCER FREE FLAP DESIGN AND ASSESSMENT","medConditionList":[{"med_condition_id":95,"med_condition":"HEAD AND NECK CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40369,"protocol_no":"GED-0301-UC-002","submission_no":"187861","status_id":2,"start_date":"2015-12-12","end_date":"2017-10-24","nol_date":"2015-10-23","protocol_title":"A PHASE 2, OPEN-LABEL, MULTICENTER STUDY TO EXPLORE THE EFFICACY AND SAFETY OF MONGERSEN (GED-0301) IN SUBJECTS WITH ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48565,"protocol_no":"R2810-ONC-1763","submission_no":"214300","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-04-05","protocol_title":"A RANDOMIZED, OPEN-LABEL STUDY OF COMBINATIONS OF STANDARD AND HIGH DOSE REGN2810 (CEMIPLIMAB, ANTI-PD-1 ANTIBODY) AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) IN SECOND-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH TUMORS EXPERESSING PD-L1 <50%","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27245,"protocol_no":"H8A-MC-LZAX","submission_no":"165214","status_id":1,"start_date":"2014-03-20","end_date":null,"nol_date":"2013-06-26","protocol_title":"EFFECT OF PASSIVE IMMUNIZATION ON THE PROGRESSION OF MILD ALZHEIMER'S DISEASE: SOLANEZUMAB (LY2062430) VERSUS PLACEBO.","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42420,"protocol_no":"IPI-145-21","submission_no":"194874","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-10","protocol_title":"A PHASE 2, RANDOMIZED STUDY OF DUVELISIB ADMINISTERED IN COMBINATION WITH RITUXIMAB VS R-CHOP IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40310,"protocol_no":"15-237","submission_no":"187650","status_id":1,"start_date":"2016-05-09","end_date":null,"nol_date":"2015-09-25","protocol_title":"SHORT-COURSE ANTIMICROBIAL THERAPY FOR PAEDIATRIC RESPIRATORY INFECTION (SAFER): A MULTICENTRE, RANDOMIZED, CONTROLLED, NON-INFERIORITY TRIAL","medConditionList":[{"med_condition_id":442,"med_condition":"PNEUMONIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37126,"protocol_no":"CACZ885G2306","submission_no":"177615","status_id":1,"start_date":"2015-05-05","end_date":null,"nol_date":"2014-10-01","protocol_title":"B-SPECIFIC 4 PATIENTS: STUDY OF PEDIATRIC EFFICACY AND SAFETY WITH FIRST-LINE USE OF CANAKINUMAB: AN OPEN-LABEL CANAKINUMAB (ACZ885) DOSE REDUCTION OR DOSE INTERVAL PROLONGATION EFFICACY AND SAFETY STUDY IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36027,"protocol_no":"D4191C00001","submission_no":"174237","status_id":1,"start_date":"2015-03-09","end_date":null,"nol_date":"2014-05-28","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTRE, INTERNATIONAL STUDY OF MEDI4736 AS SEQUENTIAL THERAPY IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE NON-SMALL CELL LUNG CANCER (STAGE III) WHO HAVE NOT PROGRESSED FOLLOWING DEFINITIVE, PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42176,"protocol_no":"OCOG-2016-PETABC","submission_no":"194153","status_id":1,"start_date":"2016-12-01","end_date":null,"nol_date":"2016-05-12","protocol_title":"IMPACT OF 18 F-FDG PET-CT VERSUS CONVENTIONAL STAGING IN THE MANAGEMENT OF PATIENTS PRESENTING WITH CLINICAL STAGE III BREAST CANCER (PETABC)","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26598,"protocol_no":"14724A","submission_no":"163217","status_id":2,"start_date":"2013-09-20","end_date":"2014-12-11","nol_date":"2013-04-11","protocol_title":"A 28-WEEK, RANDOMISED, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS OF ARIPIPRAZOLE ONCE-MONTHLY VERSUS PALIPERIDONE PALMITATE IN ADULT PATIENTS WITH SCHIZOPHRENIA","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36424,"protocol_no":"I7T-MC-RMAH","submission_no":"175374","status_id":1,"start_date":"2014-08-01","end_date":null,"nol_date":"2014-07-04","protocol_title":"A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, PARALLEL, PHASE 2A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LY2623091 IN PATIENTS WITH PRIMARY HYPERTENSION","medConditionList":[{"med_condition_id":124,"med_condition":"HYPERTENSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38578,"protocol_no":"CV185-155","submission_no":"182476","status_id":1,"start_date":"2017-03-22","end_date":null,"nol_date":"2015-03-27","protocol_title":"A PHASE III RANDOMIZED, OPEN LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF APIXABAN FOR THROMBOEMBOLISM PREVENTION VERSUS NO SYSTEMIC ANTICOAGULANT PROPHYLAXIS DURING INDUCTION CHEMOTHERAPY IN CHILDREN WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR LYMPHOMA (T OR B CELL) TREATED WITH PEGYLATED (PEG) L-ASPARAGINASE","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"},{"med_condition_id":651,"med_condition":"PROPHYLAXIS FOR THROMBOEMBOLISM PREVENTION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42938,"protocol_no":"CL2-44819-004","submission_no":"196720","status_id":1,"start_date":"2017-07-29","end_date":null,"nol_date":"2016-08-03","protocol_title":"RANDOMIZED EFFICACY AND SAFETY TRIAL WITH ORAL S 44819 AFTER RECENT ISCHEMIC CEREBRAL EVENT INTERNATIONAL, MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II STUDY","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"},{"med_condition_id":134,"med_condition":"ISCHEMIC ATTACK AND MINOR STROKE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26576,"protocol_no":"20110165","submission_no":"163146","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-04-18","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF ADD-ON AMG 747 ON SCHIZOPHRENIA NEGATIVE SYMPTOMS","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26560,"protocol_no":"116796 (ZOSTER-033)","submission_no":"163117","status_id":2,"start_date":"2013-06-05","end_date":"2014-11-24","nol_date":"2013-04-11","protocol_title":"\"A PHASE III, NON-RANDOMIZED, OPEN-LABEL, MULTICENTRE CLINICAL TRIAL TO ASSESS THE IMMUNOGENICITY AND SAFETY GSK BIOLOGICALS' HERPES ZOSTER HZ/SU CANDIDATE VACCINE WHEN ADMINISTERED INTRAMUSCULARLY ON A 0 AND 2 MONTH SCHEDULE TO ADULTS >50 YEARS OF AGE WITH A PRIOR EPISODE OF HERPES ZOSTER.\"","medConditionList":[{"med_condition_id":289,"med_condition":"HERPES ZOSTER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26543,"protocol_no":"2013-3193","submission_no":"163068","status_id":1,"start_date":"2013-04-14","end_date":null,"nol_date":"2013-04-04","protocol_title":"A MULTIPLE-DOSE, COMPARATIVE BIOAVAILABILITY STUDY OF TWO FORMULATIONS OF QUETIAPINE 400 MG PROLONGED RELEASE TABLETS UNDER FASTING CONDITIONS IN SUBJECTS WITH PRIMARY PSYCHOTIC AND/OR BIPOLAR DISORDER","medConditionList":[{"med_condition_id":25,"med_condition":"BIPOLAR DEPRESSION"},{"med_condition_id":312,"med_condition":"PSYCHOTIC DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27792,"protocol_no":"ISIS 426115-CS2","submission_no":"166661","status_id":1,"start_date":"2013-09-13","end_date":null,"nol_date":"2013-08-19","protocol_title":"A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF ISIS 426115 (AN ANTISENSE GLUCOCORTICOID RECEPTOR ANTAGONIST) ADMINISTERED SUBCUTANEOUSLY ONCE WEEKLY FOR 6 WEEKS TO PATIENTS WITH TYPE 2 DIABETES MELLITUS BEING TREATED WITH METFORMIN","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"},{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37440,"protocol_no":"CMX001-304","submission_no":"178619","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-30","protocol_title":"A PHASE 3, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY/TOLERABILITY AND EFFICACY OF BRINCIDOFOVIR (CMX001) FOR THE PREVENTION OF ADENOVIRUS (ADV) DISEASE IN SUBJECTS WITH ASYMPTOMATIC ADV INFECTION AT RISK OF PROGRESSION AND FOR THE TREATMENT OF SUBJECTS WITH LOCALIZED OR DISSEMINATED ADV DISEASE.","medConditionList":[{"med_condition_id":581,"med_condition":"ADENOVIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36933,"protocol_no":"ROPP-2008-01","submission_no":"177013","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-09-03","protocol_title":"DETERMINATION OF THE RHIGF-1/RHIGF-1BP# DOSE, ADMINISTERED AS A CONTINUOUS INFUSION, REQUIRED TO ESTABLISH AND MAINTAIN LONGITUDINAL SERUM IGF-1 LEVELS WITHIN PHYSIOLOGICAL LEVELS IN PREMATURE INFANTS TO PREVENT RETINOPATHY OF PREMATURITY. A PHASE 2, RANODMIZED CONTROLLED, ASSESSOR-BLIND, DOSE-CONFIRMING, PHARMACOKINETIC, SAFETY AND EFFICACY, MULTICENTER STUDY","medConditionList":[{"med_condition_id":564,"med_condition":"RETINOPATHY OF PREMATURITY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36940,"protocol_no":"NRG-LU001","submission_no":"177030","status_id":1,"start_date":"2015-04-01","end_date":null,"nol_date":"2014-08-20","protocol_title":"RANDOMIZED PHASE II TRIAL OF CONCURRENT CHEMORADIOTHERAPY +/- METFORMIN HCL IN LOCALLY ADVANCED NSCLC","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43933,"protocol_no":"CAIN457A2322","submission_no":"199425","status_id":1,"start_date":"2017-07-18","end_date":null,"nol_date":"2016-11-14","protocol_title":"A RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFECT OF SECUKINUMAB 300 MG S.C. ADMINISTERED DURING 52 WEEKS TO PATIENTS SUFFERING FROM NEW-ONSET MODERATE TO SEVERE PLAQUE  PSORIASIS AS EARLY INTERVENTION COMPARED TO STANDARD TREATMENT WITH NARROW-BAND UVB (STEPIN STUDY)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46223,"protocol_no":"VX16-150-102","submission_no":"206771","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-17","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 6-WEEK, PARALLEL-DESIGN STUDY OF THE EFFICACY AND SAFETY OF VX-150 IN TREATING SUBJECTS WITH PAIN CAUSED BY SMALL FIBER NEUROPATHY","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37652,"protocol_no":"D5740C00001","submission_no":"179277","status_id":1,"start_date":"2014-12-16","end_date":null,"nol_date":"2014-11-28","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF ROXADUSTAT FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS","medConditionList":[{"med_condition_id":329,"med_condition":"ANEMIA"},{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46293,"protocol_no":"ALL SCTPED 2012 FORUM","submission_no":"206761","status_id":1,"start_date":"2017-11-02","end_date":null,"nol_date":"2017-07-26","protocol_title":"ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41051,"protocol_no":"20150432","submission_no":"190078","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-16","protocol_title":"MOBILIZATION OF ENDOTHELIAL PROGENITOR CELLS FOLLOWING ALCOHOL SEPTAL ABLATION IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY: RANDOMIZED CONTROLLED TRIAL OF ASPIRIN (TROPHIC 3)","medConditionList":[{"med_condition_id":508,"med_condition":"HYPERTROPHIC CARDIOMYOPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26696,"protocol_no":"HDL100-102","submission_no":"163513","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-05-03","protocol_title":"A PHASE II, TWO-STAGE, OPEN-LABEL, SINGLE-TREATMENT, ADAPTIVE TRIAL DESIGN EXAMINING THE PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF UP TO THREE SEPARATE HLD100 MODIFIED RELEASE FORMULATIONS OF DEXTROAMPHETAMINE SULFATE IN ADOLESCENT (STAGE 1) AND PEDIATRIC (STAGE 2) PATIENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER.","medConditionList":[{"med_condition_id":9,"med_condition":"ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38129,"protocol_no":"018-00","submission_no":"180935","status_id":1,"start_date":"2015-06-01","end_date":null,"nol_date":"2015-01-29","protocol_title":"A PHASE 3 MULTICENTER, DOUBLE-BLIND, RANDOMIZED, ACTIVE COMPARATOR-CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DORAVIRINE (MK-1439) 100 MG ONCE DAILY VERSUS DARUNAVIR 800 MG ONCE DAILY PLUS RITONAVIR 100 MG ONCE DAILY, EACH IN COMBINATION WITH TRUVADA¬ô OR EPZICOM¬ô/KIVEXA¬ô, IN TREATMENT-NA√èVE HIV-1INFECTED SUBJECTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37601,"protocol_no":"RT002-CL002","submission_no":"179120","status_id":1,"start_date":"2014-12-08","end_date":null,"nol_date":"2014-11-21","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOSE RANGING, ACTIVE AND PLACEBO CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY AND DURATION OF EFFECT OF RT002, A BOTULINUM TOXIN TYPE A FOR INJECTION, TO TREAT GLABELLAR LINES","medConditionList":[{"med_condition_id":380,"med_condition":"GLABELLAR LINES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38243,"protocol_no":"14VR4","submission_no":"181382","status_id":1,"start_date":"2015-03-18","end_date":null,"nol_date":"2015-02-12","protocol_title":"COMPARISON OF VRS-317, A LONG-ACTING HUMAN GROWTH HORMONE, TO DAILY RHGH IN A PHASE 3, RANDOMIZED, ONE-YEAR, OPEN-LABEL, MULTICENTER, NON-INFERIORITY TRIAL IN PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENC","medConditionList":[{"med_condition_id":94,"med_condition":"GROWTH HORMONE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36786,"protocol_no":"1289.6","submission_no":"176563","status_id":2,"start_date":"2015-10-30","end_date":"2016-08-30","nol_date":"2014-08-15","protocol_title":"A PHASE II RANDOMISED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF FOUR ORALLY ADMINISTRATED DOSES OF BI 409306 ONCE DAILY DURING A 12-WEEK TREATMENT PERIOD IN PATIENTS WITH SCHIZOPHRENIA ON STABLE ANTIPSYCHOTIC TREATMENT","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28261,"protocol_no":"CMEK162X2116","submission_no":"168093","status_id":2,"start_date":"2016-01-21","end_date":"2016-01-25","nol_date":"2013-10-16","protocol_title":"A PHASE IB/II, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION STUDY OF MEK162 IN COMBINATION WITH PANITUMUMAB IN ADULT PATIENTS WITH MUTANT RAS OR WILD-TYPE RAS METASTATIC COLORECTAL CANCER","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38317,"protocol_no":"D6010C00004","submission_no":"181642","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-27","protocol_title":"A MULTICENTRE RANDOMISED PHASE II STUDY OF AZD1775 PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH PLATINUM-RESISTANT TP53-MUTATED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":184,"med_condition":"OVARIAN CANCER PRIMARY PERITONEAL"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36211,"protocol_no":"CXA-NP-11-04","submission_no":"174807","status_id":1,"start_date":"2014-11-13","end_date":null,"nol_date":"2014-07-04","protocol_title":"A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVENOUS CEFTOLOZANE/TAZOBACTAM COMPARED WITH MEROPENEM IN ADULT PATIENTS WITH VENTILATED NOSOCOMIAL PNEUMONIA, VERSION 4.0, 14 MARCH 2014","medConditionList":[{"med_condition_id":442,"med_condition":"PNEUMONIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36375,"protocol_no":"M12-963","submission_no":"175232","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-06-27","protocol_title":"A PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ABT-122 GIVEN WITH METHOTREXATE IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE AN INADEQUATE RESPONSE TO METHOTREXATE","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28759,"protocol_no":"6002-014","submission_no":"169689","status_id":2,"start_date":"2014-02-20","end_date":"2016-01-16","nol_date":"2013-12-04","protocol_title":"A PHASE 3, 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF ORAL ISTRADEFYLLINE 20 AND 40 MG/DAY AS TREATMENT FOR SUBJECTS WITH MODERATE TO SEVERE PARKINSON'S DISEASE","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41266,"protocol_no":"CA017-003","submission_no":"191001","status_id":1,"start_date":"2017-07-17","end_date":null,"nol_date":"2016-02-03","protocol_title":"A PHASE 1/2A STUDY OF BMS-986205 ADMINISTERED IN COMBINATION WITH NIVOLUMAB (BMS-936558, ANTI-PD-1 MONOCLONAL ANTIBODY) IN ADVANCED MALIGNANT TUMOURS","medConditionList":[{"med_condition_id":665,"med_condition":"ADVANCED MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35866,"protocol_no":"DRM04-HH02","submission_no":"173667","status_id":1,"start_date":"2014-05-09","end_date":null,"nol_date":"2014-05-01","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, COMPARATOR STUDY OF THE EFFECT OF DRM04B AND DRM04 IN SUBJECTS WITH AXILLARY HYPERHIDROSIS","medConditionList":[{"med_condition_id":511,"med_condition":"AXILLARY HYPERHIDROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37849,"protocol_no":"42160443PAI3007","submission_no":"179874","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-19","protocol_title":"RANDOMIZED, 16-WEEK, MULTI-PHASE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF FULRANUMAB AS ADJUNCTIVE THERAPY IN SUBJECTS WITH SIGN AND SYMPTOMS OF OSTEOARTHRITIS OF THE HIP OR KNEE","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45524,"protocol_no":"RA101495-01.201","submission_no":"204692","status_id":1,"start_date":"2017-09-01","end_date":null,"nol_date":"2017-05-01","protocol_title":"A PHASE 2 MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RA101495 IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA","medConditionList":[{"med_condition_id":649,"med_condition":"PAROXYSMAL NOCTURNAL HEMOGLOBINURIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26639,"protocol_no":"C16014","submission_no":"163325","status_id":1,"start_date":"2013-12-23","end_date":null,"nol_date":"2013-04-17","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37018,"protocol_no":"MSC-001","submission_no":"177258","status_id":1,"start_date":"2014-09-01","end_date":null,"nol_date":"2014-09-12","protocol_title":"HUMAN AUTOGOLOUS MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF MID TO LATE STAGE KNEE OSTEOARTHRITIS","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40769,"protocol_no":"PTC124-GD-021E-CF","submission_no":"189092","status_id":1,"start_date":"2016-03-23","end_date":null,"nol_date":"2015-11-26","protocol_title":"A PHASE 3 EXTENSION STUDY OF ATALUREN (PTC124) IN PATIENTS WITH NONSENSE MUTATION CYSTIC FIBROSIS.","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42172,"protocol_no":"BCX7353-203","submission_no":"194145","status_id":2,"start_date":"2016-09-06","end_date":"2017-09-18","nol_date":"2016-05-10","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF BCX7353 AS A PREVENTATIVE TREATMENT TO REDUCE THE FREQUENCY OF ATTACKS IN SUBJECTS WITH HEREDITARY ANGIOEDEMA","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36855,"protocol_no":"EPZ-5676-12-002","submission_no":"176771","status_id":1,"start_date":"2014-10-09","end_date":null,"nol_date":"2014-08-27","protocol_title":"A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF EPZ-5676 IN THE TREATMENT OF PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY LEUKEMIAS BEARING A REARRANGEMENT OF THE MLL GENE","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"},{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39149,"protocol_no":"CQGE031C2201","submission_no":"184299","status_id":1,"start_date":"2015-08-21","end_date":null,"nol_date":"2015-06-18","protocol_title":"\"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE-CONTROLLED PHASE 2B DOSE-FINDING STUDY OF QGE031 AS ADD-ON THERAPY TO INVESTIGATE THE EFFICACY AND SAFETY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (CSU).\"","medConditionList":[{"med_condition_id":399,"med_condition":"CHRONIC SPONTANEOUS URTICARIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44875,"protocol_no":"ALXN1210-PNH-302","submission_no":"202678","status_id":1,"start_date":"2017-05-16","end_date":null,"nol_date":"2017-03-09","protocol_title":"A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF ALXN1210 VERSUS ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) CURRENTLY TREATED WITH ECULIZUMAB","medConditionList":[{"med_condition_id":649,"med_condition":"PAROXYSMAL NOCTURNAL HEMOGLOBINURIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35936,"protocol_no":"B1481038","submission_no":"174017","status_id":1,"start_date":"2014-06-23","end_date":null,"nol_date":"2014-05-16","protocol_title":"PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS","medConditionList":[{"med_condition_id":538,"med_condition":"MAJOR CARDIOVASCULAR EVENTS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38568,"protocol_no":"GS29250","submission_no":"182445","status_id":1,"start_date":"2015-05-22","end_date":null,"nol_date":"2015-03-26","protocol_title":"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH PERSISTENT MODERATE TO SEVERE ATOPIC DERMATITIS THAT IS INADEQUATELY CONTROLLED BY TOPICAL CORTICOSTEROIDS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29343,"protocol_no":"NSABP B-52","submission_no":"171536","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-19","protocol_title":"A RANDOMIZED PHASE III TRIAL EVALUATING PATHOLOGIC COMPLETE RESPONSE RATES IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-POSITIVE, LARGE OPERABLE AND LOCALLY ADVANCED BREAST CANCER TREATED WITH NEOADJUVANT THERAPY OF DOCETAXEL, CARBOPLATIN,TRASTUZUMAB, AND PERTUZUMAB (TCHP) WITH OR WITHOUT ESTROGEN DEPRIVATION","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40079,"protocol_no":"505-2014","submission_no":"187042","status_id":1,"start_date":"2016-02-08","end_date":null,"nol_date":"2015-09-17","protocol_title":"APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2)","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46460,"protocol_no":"INCB 50465-202","submission_no":"207664","status_id":1,"start_date":"2017-10-10","end_date":null,"nol_date":"2017-08-21","protocol_title":"A PHASE 2, MULTICENTER, INTERNATIONAL, OPEN-LABEL, SAFETY AND EFFICACY STUDY OF INCB050465 IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"},{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37130,"protocol_no":"GS-US-357-1394","submission_no":"177623","status_id":2,"start_date":"2015-03-24","end_date":"2016-10-17","nol_date":"2014-10-01","protocol_title":"A PHASE 2, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF GS 4997 IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION","medConditionList":[{"med_condition_id":218,"med_condition":"PULMONARY ARTERIAL HYPERTENSION (PAH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39382,"protocol_no":"WA29767","submission_no":"185004","status_id":1,"start_date":"2017-02-07","end_date":null,"nol_date":"2015-06-30","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS","medConditionList":[{"med_condition_id":246,"med_condition":"SYSTEMIC SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40632,"protocol_no":"M13-536","submission_no":"188667","status_id":2,"start_date":null,"end_date":"2015-05-20","nol_date":"2015-11-19","protocol_title":"A PHASE 3, MULTICENTER, BLINDED, LONG-TERM EXTENSION (LTE) STUDY IN RHEUMATOID ARTHRITIS SUBJECTS WHO HAVE COMPLETED A PRECEDING PHASE 3 RANDOMIZED CONTROLLED TRIAL (RCT) WITH ABT-494","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38478,"protocol_no":"LPS14022","submission_no":"182165","status_id":1,"start_date":"2015-10-28","end_date":null,"nol_date":"2015-03-09","protocol_title":"PHASE II, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY IN CHEMOTHERAPY-NA√èVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS WHO HAVE PRIMARY RESISTANCE TO ABIRATERONE ACETATE OR ENZALUTAMIDE TREATMENT COMPARING THE ANTI-TUMOR EFFECT OF CABAZITAXEL TO ALTERNATIVE ANDROGEN RECEPTORS (AR) TARGETED THERAPY","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41268,"protocol_no":"PHL-097 / NCI 9742","submission_no":"191009","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-01-26","protocol_title":"MULTICENTER PHASE II STUDY OF NIVOLUMAB IN PREVIOUSLY TREATED PATIENTS WITH RECURRENT AND METASTATIC NASOPHARYNGEAL CARCINOMA","medConditionList":[{"med_condition_id":521,"med_condition":"NASOPHARYNGEAL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27701,"protocol_no":"LTS12593","submission_no":"166491","status_id":3,"start_date":"2014-01-25","end_date":null,"nol_date":"2013-08-02","protocol_title":"\"A MULTICENTER SINGLE-ARM OPEN LABEL EXTENSION STUDY EVALUATING THE LONG TERM SAFETY AND TOLERABILITY OF SAR339658 IN PATIENTS WITH ULCERATIVE COLITIS (UC).\"","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28211,"protocol_no":"OPH1002","submission_no":"167953","status_id":1,"start_date":"2014-01-24","end_date":null,"nol_date":"2013-10-01","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS ADMINISTRATION OF FOVISTATM (ANTI PDGF-B  PEGYLATED APTAMER) ADMINISTERED IN COMBINATION WITH LUCENTIS¬Æ COMPARED TO LUCENTIS¬Æ MONOTHERAPY IN SUBJECTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION","medConditionList":[{"med_condition_id":390,"med_condition":"SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40879,"protocol_no":"NN2211-4232","submission_no":"189578","status_id":1,"start_date":"2016-04-01","end_date":null,"nol_date":"2015-12-16","protocol_title":"LIRA-PRIME: EFFICACY IN CONTROLLING GLYCAEMIA WITH VICTOZA (LIRAGLUTIDE) AS ADD-ON TO METFORMIN VS OADS AS ADD-ON TO METFORMIN AFTER UP TO 104 WEEKS OF TREATMENT IN SUBJECTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY AND TREATED IN A PRIMARY CARE SETTING","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38661,"protocol_no":"VLZ-MD-23","submission_no":"182768","status_id":1,"start_date":"2015-11-30","end_date":null,"nol_date":"2015-03-31","protocol_title":"AN OPEN-LABEL LONG-TERM SAFETY STUDY OF VILAZODONE IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29262,"protocol_no":"1000039963","submission_no":"171340","status_id":2,"start_date":"2015-01-20","end_date":"2016-11-02","nol_date":"2014-02-06","protocol_title":"QUANTIFICATION OF DIFFUSE MYOCARDIAL FIBROSIS IN CHILDREN WITH CARDIOMYOPATHY OR CONGENITAL HEART DISEASE BY T1 MAPPING CARDIAC MAGNETIC RESONANCE","medConditionList":[{"med_condition_id":464,"med_condition":"MYOCARDIAL FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28742,"protocol_no":"MRZ60201_3072_1","submission_no":"169617","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-04","protocol_title":"PROSPECTIVE, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, DOSE-RESPONSE STUDY OF THREE DOSES XEOMIN (INCOBOTULINUMTOXIN A, NT 201) FOR THE TREATMENT OF UPPER LIMB SPASTICITY ALONE OR COMBINED UPPER AND LOWER LIMB SPASTICITY IN CHILDREN AND ADOLESCENTS (AGE 2-17 YEARS) WITH CEREBRAL PALSY","medConditionList":[{"med_condition_id":141,"med_condition":"LIMB SPASTICITY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47327,"protocol_no":"02","submission_no":"210571","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-29","protocol_title":"PILOT STUDY OF THE EFFICACY AND SAFETY OF MICROBARIC OXYGEN THERAPY FOR AUTISM SPECTRUM DISORDERS","medConditionList":[{"med_condition_id":351,"med_condition":"AUTISM SPECTRUM DISORDER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45655,"protocol_no":"CC-220-SLE-002","submission_no":"204182","status_id":1,"start_date":"2017-09-13","end_date":null,"nol_date":"2017-06-16","protocol_title":"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS","medConditionList":[{"med_condition_id":311,"med_condition":"SYSTEMIC LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47155,"protocol_no":"B9991025","submission_no":"209942","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-02","protocol_title":"A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOISE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTIC SOLID TUMORS","medConditionList":[{"med_condition_id":796,"med_condition":"METASTATIC SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27957,"protocol_no":"GUO-P3-523 (AMG 105)","submission_no":"167156","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-12","protocol_title":"A SINGLE CENTER, RANDOMIZED, PARALLEL SAFETY STUDY TO EVALUATE THE IMMUNOGENICITY OF A NOVEL GLUCAGON FORMULATION COMPARED TO COMMERCIALLY AVAILABLE GLUCAGON ADMINISTERED BY INTRAMUSCULAR INJECTION IN ADULTS WITH TYPE 1 OR TYPE 2 DIABETES","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29289,"protocol_no":"R668-AD-1225","submission_no":"171383","status_id":1,"start_date":"2014-06-12","end_date":null,"nol_date":"2014-02-13","protocol_title":"AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45382,"protocol_no":"CPDR001X2106","submission_no":"204267","status_id":1,"start_date":"2017-07-17","end_date":null,"nol_date":"2017-04-27","protocol_title":"A PHASE I/IB, MULTI-CENTER, OPEN-LABEL, STUDY OF SINGLE AGENT CJM112, AND PDR001 IN COMBINATION WITH LCL161 OR CJM112 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27280,"protocol_no":"ECU-NMO-302","submission_no":"165265","status_id":3,"start_date":"2014-06-09","end_date":null,"nol_date":"2013-06-27","protocol_title":"A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS (NMO)","medConditionList":[{"med_condition_id":324,"med_condition":"NEUROMYELITIS OPTICA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38664,"protocol_no":"WA29249","submission_no":"182779","status_id":1,"start_date":"2015-05-04","end_date":null,"nol_date":"2015-04-08","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD-TO-MODERATE ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27860,"protocol_no":"BTA51-350-201","submission_no":"166899","status_id":1,"start_date":"2014-02-27","end_date":null,"nol_date":"2013-08-28","protocol_title":"A PHASE 2 RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF INHALED LANINAMIVIR OCTANOATE TWINCAPS¬Æ DRY POWDER INHALER IN ADULTS WITH SYMPTOMATIC INFLUENZA A OR B INFECTION","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38925,"protocol_no":"OTT 14-02","submission_no":"183615","status_id":1,"start_date":"2015-07-27","end_date":null,"nol_date":"2015-05-20","protocol_title":"A PHASE 2 RANDOMIZED, DOUBLE-BLIND, WINDOW OF OPPORTUNITY TRIAL EVALUATING CLINICAL AND CORRELATIVE EFFECTS OF CHLOROQUINE AS A NOVEL THERAPEUTIC STRATEGY IN BREAST CANCER; THE CUBIC STUDY [PLACEBO CONTROLLED]","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38650,"protocol_no":"NSABP FB-11","submission_no":"182747","status_id":1,"start_date":"2015-12-17","end_date":null,"nol_date":"2015-03-23","protocol_title":"A PHASE II RANDOMIZED STUDY EVALUATING THE BIOLOGICAL AND CLINICAL EFFECTS OF THE COMBINATION OF PALBOCICLIB WITH LETROZOLE AS NEOADJUVANT THERAPY IN POST-MENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE PRIMARY BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45120,"protocol_no":"00058586","submission_no":"203358","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-11","protocol_title":"DEVELOPING PET PERFUSION IMAGING TECHNIQUES AND COMPARING THEM TO CT PERFUSION IMAGING IN STROKE PATIENTS","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41704,"protocol_no":"24NOV2015","submission_no":"192383","status_id":1,"start_date":"2016-04-01","end_date":null,"nol_date":"2016-03-17","protocol_title":"SHOULD WE USE ORAL VALACYCLOVIR IN ACUTE HERPETIC GINGIVOSTOMATITS IN CHILDREN? A RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":726,"med_condition":"ACUTE HERPETIC GINGIVOSTOMATITS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26510,"protocol_no":"H6D-MC-LVHV*","submission_no":"162975","status_id":1,"start_date":"2013-12-12","end_date":null,"nol_date":"2013-04-04","protocol_title":"A DOUBLE-BLIND EFFICACY AND SAFETY STUDY OF THE PHOSPHODIESTERASE TYPE 5 INHIBITOR TADALAFIL IN PEDIATRIC PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION.","medConditionList":[{"med_condition_id":218,"med_condition":"PULMONARY ARTERIAL HYPERTENSION (PAH)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39462,"protocol_no":"ASTX727-01","submission_no":"185366","status_id":1,"start_date":"2017-04-17","end_date":null,"nol_date":"2015-07-08","protocol_title":"A PHASE 1-2 PHARMACOKINETIC GUIDED DOSE-ESCALATION AND DOSE-CONFIRMATION STUDY OF ASTX727, A COMBINATION OF THE ORAL CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727 WITH ORAL DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS)","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28451,"protocol_no":"D5134C00001","submission_no":"168609","status_id":2,"start_date":"2014-03-06","end_date":"2016-03-02","nol_date":"2013-10-30","protocol_title":"A RANDOMISED, DOUBLE-BLIND, MULTINATIONAL STUDY TO PREVENT MAJOR VASCULAR EVENTS WITH TICAGRELOR COMPARED TO ASPIRIN (ASA) IN PATIENTS WITH ACUTE ISCHAEMIC STROKE OR TIA.","medConditionList":[{"med_condition_id":358,"med_condition":"ISCHEMIC EVENTS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46210,"protocol_no":"MET-2-101","submission_no":"206753","status_id":1,"start_date":"2017-10-20","end_date":null,"nol_date":"2017-08-01","protocol_title":"A PHASE I, OPEN-LABEL, SINGLE-CENTRE STUDY OF THE SAFETY AND EFFICACY OF MET-2 IN PATIENTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (CDI)","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39598,"protocol_no":"201928","submission_no":"185816","status_id":1,"start_date":"2017-02-13","end_date":null,"nol_date":"2015-07-23","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, EFFICACY AND CHANGES IN INDUCED SPUTUM AND BLOOD BIOMARKERS FOLLOWING DAILY REPEAT DOSES OF INHALED GSK2269557 FOR 12 WEEKS IN ADULT SUBJECTS DIAGNOSED WITH AN ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41995,"protocol_no":"CNS7056-008","submission_no":"193569","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-04-21","protocol_title":"A PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF REMIMAZOLAM (CNS 7056) COMPARED TO PLACEBO AND MIDAZOLAM IN PATIENTS UNDERGOING BRONCHOSCOPY","medConditionList":[{"med_condition_id":340,"med_condition":"SEDATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35679,"protocol_no":"SA-309JG","submission_no":"173014","status_id":1,"start_date":"2014-10-10","end_date":null,"nol_date":"2014-04-11","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY, OF SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA (NMO) AND NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)","medConditionList":[{"med_condition_id":324,"med_condition":"NEUROMYELITIS OPTICA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37001,"protocol_no":"ANZCTRN12611000791932","submission_no":"177206","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-09-18","protocol_title":"CONTROLLED TRIAL OF SLOWING OF KIDNEY DISEASE PROGRESSION FROM THE INHIBITION OF XANTHINE OXIDASE","medConditionList":[{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41481,"protocol_no":"20150925-01H","submission_no":"191624","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-02-01","protocol_title":"FEASIBILITY AND SAFETY OF IMMUNOGLOBULIN (IG) PROPHYLACTIC TREATMENT IN COPD PATIENTS WTH FREQUENT EXACERBATIONS: A PILOT STUDY 2A","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47541,"protocol_no":"669","submission_no":"211209","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-13","protocol_title":"A PHASE 3 RANDOMIZED, OPEN-LABEL CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEMBROLIZUMAB PLUS EPACADOSTATE, PEMBROLIZUMAB MONOTHERAPY, AND THE EXTREME REGIMEN AS FIRST LINE TREATMENT FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (KEYNOTE-669/ECHO-304)","medConditionList":[{"med_condition_id":724,"med_condition":"SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47968,"protocol_no":"I5T-MC-AACG(B)","submission_no":"212580","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-02","protocol_title":"ASSESSMENT OF SAFETY, TOLERABILILTY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36945,"protocol_no":"B5381002","submission_no":"177038","status_id":2,"start_date":"2015-11-09","end_date":"2016-07-11","nol_date":"2014-09-04","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42327,"protocol_no":"CLFT218-1501","submission_no":"194609","status_id":1,"start_date":"2016-11-21","end_date":null,"nol_date":"2016-05-27","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, TWO ARM MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF A ONCE NIGHTLY FORMULATION OF SODIUM OXYBATE FOR EXTENDED-RELEASE ORAL SUSPENSION (FT218) FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND CATAPLEXY IN SUBJECTS WITH NARCOLEPSY","medConditionList":[{"med_condition_id":656,"med_condition":"NARCOLEPSY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40903,"protocol_no":"CA209-498","submission_no":"189656","status_id":1,"start_date":"2016-08-12","end_date":null,"nol_date":"2015-12-15","protocol_title":"A RANDOMIZED PHASE 3 OPEN LABEL STUDY OF NIVOLUMAB VS TEMOZOLOMIDE EACH IN COMBINATION WITH RADIATION THERAPY IN NEWLY DIAGNOSED ADULT SUBJECTS WITH UNMETHYLATED MGMT (TUMOR O-6-METHYLGUANINE DNA METHYLTRANSFERASE) GLIOBLASTOMA","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35526,"protocol_no":"20120119","submission_no":"172665","status_id":1,"start_date":"2016-03-04","end_date":null,"nol_date":"2014-03-28","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF EVOLOCUMAB (AMG 145) IN COMBINATION WITH STATIN THERAPY IN DIABETIC SUBJECTS WITH HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA","medConditionList":[{"med_condition_id":348,"med_condition":"HYPERLIPIDEMIA"},{"med_condition_id":388,"med_condition":"DIABETES"},{"med_condition_id":387,"med_condition":"DYSLIPIDEAMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27062,"protocol_no":"LMS-002","submission_no":"164651","status_id":1,"start_date":"2013-07-17","end_date":null,"nol_date":"2013-05-30","protocol_title":"A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED DISCONTINUATION STUDY FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF AMIFAMPRIDINE PHOSPHATE (3,4-DIAMINOPYRIDINE PHOSPHATE) IN PATIENTS WITH LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)","medConditionList":[{"med_condition_id":270,"med_condition":"LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26730,"protocol_no":"000080","submission_no":"163639","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-04-30","protocol_title":"A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION TO DEMONSTRATE THE EFFICACY AND SAFETY OF ELOBIXIBAT 5 MG AND 10 MG FOR 12 WEEKS FOLLOWED BY A 4-WEEK WITHDRAWAL PERIOD.","medConditionList":[{"med_condition_id":322,"med_condition":"IDIOPATHIC CONSTIPATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27382,"protocol_no":"KCP-330-003","submission_no":"165595","status_id":2,"start_date":"2016-02-03","end_date":"2016-11-08","nol_date":"2013-07-05","protocol_title":"AN OPEN LABEL PHASE IB TRIAL TO EVALUATE THE EFFECTS OF FOOD AND FORMULATION ON PHARMACOKINETICS OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) KPT-330 IN PATIENTS WITH SOFT-TISSUE OR BONE SARCOMA","medConditionList":[{"med_condition_id":334,"med_condition":"SARCOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43938,"protocol_no":"108342","submission_no":"199620","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-11-22","protocol_title":"MOLECULAR IMAGING OF BRAIN INFLAMMATION IN DEPRESSIVE DISORDER (DIME)","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47529,"protocol_no":"CEMA401A2202","submission_no":"211150","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-12","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO DETERMINE THE SAFETY AND EFFICACY OF EMA401 100 MG B.I.D. IN REDUCING 24-HOUR AVERAGE PAIN INTENSITY SCORE IN PATIENTS WITH PAINFUL DIABETIC NEUROPATHY (EMPADINE)","medConditionList":[{"med_condition_id":66,"med_condition":"DIABETIC NEUROPATHIC PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47487,"protocol_no":"A3921288","submission_no":"211056","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-06","protocol_title":"A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28736,"protocol_no":"MK-8835-003-00 (B1521022)","submission_no":"169595","status_id":2,"start_date":"2014-02-14","end_date":"2016-07-28","nol_date":"2013-12-13","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26 WEEK MULTICENTER STUDY WITH A 26-WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN MONOTHERAPY IN THE TREATMENT OF SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL DESPITE DIET AND EXERCISE","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28098,"protocol_no":"TH002A","submission_no":"167600","status_id":1,"start_date":"2013-10-10","end_date":null,"nol_date":"2013-09-18","protocol_title":"\"AN OPTIONAL FOLLOW-UP STUDY TO EVALUATE THE CONTINUED EFFICACY OF TOLERMUNE HDM IN HOUSE DUST MITE ALLERGIC SUBJECTS FOLLOWING CHALLENGE WITH HOUSE DUST MITE ALLERGEN IN AN ENVIRONMENT EXPOSURE CHAMBER.\"","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38796,"protocol_no":"INCB 18424-267","submission_no":"183203","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-17","protocol_title":"A RANDOMIZED, DOUBLE-BLIND STUDY OF RUXOLITINIB OR PLACEBO IN COMBINATION WITH REGORAFENIB IN SUBJECTS WITH RELAPSED OR REFRACTORY METASTATIC COLORECTAL CANCER","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36189,"protocol_no":"AGS67E-14-1","submission_no":"174755","status_id":1,"start_date":"2015-07-16","end_date":null,"nol_date":"2014-06-13","protocol_title":"A PHASE I STUDY EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS67E GIVEN AS MONOTHERAPY IN SUBJECTS WITH REFRACTORY OR RELAPSED LYMPHOID MALIGNANCIES","medConditionList":[{"med_condition_id":440,"med_condition":"LYMPHOID MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28661,"protocol_no":"CA002-001","submission_no":"169345","status_id":2,"start_date":"2015-01-06","end_date":"2017-01-07","nol_date":"2013-11-18","protocol_title":"PHASE I ASCENDING MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF BMS-986115 IN SUBJECTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47668,"protocol_no":"CA017-063","submission_no":"211517","status_id":2,"start_date":null,"end_date":"2018-04-20","nol_date":"2017-12-19","protocol_title":"A RANDOMIZED, GLOBAL, OPEN-LABEL STUDY OF NIVOLUMAB IN COMBINATION WITH BMS-986205 VS STANDARD OF CARE EXTREME REGIMEN IN FIRST-LINE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK","medConditionList":[{"med_condition_id":724,"med_condition":"SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40400,"protocol_no":"D5160C00022","submission_no":"187979","status_id":1,"start_date":"2016-05-16","end_date":null,"nol_date":"2015-10-22","protocol_title":"OPEN LABEL, MULTINATIONAL, MULTICENTER, REAL WORLD TREATMENT STUDY OF SINGLE AGENT AZD9291 FOR PATIENTS WITH ADVANCED/METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE RECEIVED PRIOR THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR (EGFR-TKI)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44216,"protocol_no":"204959","submission_no":"199411","status_id":1,"start_date":"2017-05-04","end_date":null,"nol_date":"2016-12-20","protocol_title":"AN OPEN-LABEL, SINGLE ARM, REPEAT DOSE, MULTI-CENTRE STUDY TO EVALUATE THE USE OF AN AUTOINJECTOR FOR THE SUBCUTANEOUS ADMINISTRATION OF MEPOLIZUMAB IN SUBJECTS WITH SEVERE EOSINOPHILIC ASTHMA (STUDY 204959)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36959,"protocol_no":"CNTO148PSA3001","submission_no":"177075","status_id":1,"start_date":"2014-11-18","end_date":null,"nol_date":"2014-09-05","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF GOLIMUMAB, AND ANTI-TNFA MONOCLONAL ANTIBODY ADMINISTERED INTRAVENOUSLY, IN SUBJECTS WITH PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29141,"protocol_no":"CO-338-010","submission_no":"171030","status_id":2,"start_date":"2014-03-20","end_date":"2016-08-05","nol_date":"2014-01-22","protocol_title":"A PHASE I/II, OPEN-LABEL, SAFETY, PHARMACOKINETIC, AND PRELIMINARY EFFICACY STUDY OF ORAL RUCAPARIB IN PATIENTS WITH GBRCA OVARIAN CANCER OR OTHER SOLID TUMOR","medConditionList":[{"med_condition_id":184,"med_condition":"OVARIAN CANCER PRIMARY PERITONEAL"},{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":73,"med_condition":"ENDOMETRIAL CANCER"},{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38273,"protocol_no":"CC-4047-MM-008","submission_no":"181465","status_id":1,"start_date":"2015-09-18","end_date":null,"nol_date":"2015-02-19","protocol_title":"A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS (PK) AND SAFETY OF POMALIDOMIDE (POM) WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE (LD-DEX) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) AND IMPAIRED RENAL FUNCTION","medConditionList":[{"med_condition_id":220,"med_condition":"RENAL FAILURE"},{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27688,"protocol_no":"2013","submission_no":"166465","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-08-14","protocol_title":"THE EFFICACY OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF ALLODYNIC-TYPE NEUROPATHIC PAIN IN PEOPLE WITH SPINAL CORD INJURY","medConditionList":[{"med_condition_id":174,"med_condition":"NEUROPATHIC PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44776,"protocol_no":"204810 (RSV F-004)","submission_no":"202362","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-01","protocol_title":"A PHASE I/II, RANDOMISED, OBSERVER-BLIND, CONTROLLED MULTI-COUNTRY STUDY TO ASSESS THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF A SINGLE INTRAMUSCULAR DOSE OF GSK BIOLOGICALS' INVESTIGATIONAL RSV VACCINE (GSK3003891A), IN HEALTHY PREGNANT WOMEN AGED 18 TO 40 YEARS AND INFANTS BORN TO VACCINATED MOTHERS","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"},{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27310,"protocol_no":"CO-338-017","submission_no":"165303","status_id":1,"start_date":"2015-04-17","end_date":null,"nol_date":"2013-07-03","protocol_title":"A PHASE 2, OPEN-LABEL STUDY OF RUCAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE, RELAPSED, HIGH-GRADE EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36276,"protocol_no":"1000044983","submission_no":"174933","status_id":1,"start_date":"2016-03-30","end_date":null,"nol_date":"2014-07-04","protocol_title":"NANT 2012-01: PHASE STUDY OF DIFLUOROMETHYLORNITHINE (DFMO) AND CELECOXIB WITH CYCLOPHOSPHAMIDE/TOPOTECAN FOR PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA.","medConditionList":[{"med_condition_id":172,"med_condition":"NEUROBLASTOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28160,"protocol_no":"GSN000200","submission_no":"167823","status_id":1,"start_date":"2014-04-07","end_date":null,"nol_date":"2013-09-24","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF ORAL GKT137831 IN PATIENTS WITH TYPE 2 DIABETES AND ALBUMINURIA","medConditionList":[{"med_condition_id":414,"med_condition":"ALBUMINURIA"},{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42349,"protocol_no":"472-2015","submission_no":"194654","status_id":1,"start_date":"2016-12-08","end_date":null,"nol_date":"2016-06-20","protocol_title":"METFORMIN WITH NEOADJUVANT CHEMORADIATION (CRT) TO IMPROVE PATHOLOGIC RESPONSES IN RECTAL CANCER: AN INTERNAL PILOT STUDY.","medConditionList":[{"med_condition_id":671,"med_condition":"RECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28855,"protocol_no":"CE01-301","submission_no":"170088","status_id":2,"start_date":"2014-03-10","end_date":"2016-06-15","nol_date":"2013-12-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS TO ORAL SOLITHROMYCIN (CEM-101) COMPARED TO INTRAVENOUS TO ORAL MOXIFLOXACIN IN THE TREATMENT OF ADULT PATIENTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA.","medConditionList":[{"med_condition_id":442,"med_condition":"PNEUMONIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28547,"protocol_no":"TXA LIVER - PK","submission_no":"168928","status_id":2,"start_date":"2014-03-03","end_date":"2015-11-06","nol_date":"2013-11-07","protocol_title":"OPEN LABEL, NON-RANDOMIZED, STUDY TO EVALUATE THE PHARMACOKINETICS OF TRANEXAMIC ACID IN PATIENTS UNDERGOING MAJOR LIVER RESECTION","medConditionList":[{"med_condition_id":142,"med_condition":"LIVER DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40542,"protocol_no":"1245.100","submission_no":"188435","status_id":1,"start_date":"2016-11-30","end_date":null,"nol_date":"2015-11-04","protocol_title":"A PHASE II,  DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER RENAL MECHANISTIC TRIAL TO  ASSESS THE EFFECT OF ADDING EMPAGLIFLOZIN VERSUS PLACEBO ON RENAL HYPERFILTRATION IN PATIENTS WITH TYPE 1 DIABETES ON A BACKGROUND OF THE ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI) RAMIPRIL: BETWEEN STUDY","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28599,"protocol_no":"CLDK378A2303","submission_no":"169104","status_id":1,"start_date":"2016-03-16","end_date":null,"nol_date":"2013-11-15","protocol_title":"A PHASE III, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ALK REARRANGED (ALK-POSITIVE) ADVANCED NON-SMALL CELL LUNG CANCER WHO HAVE BEEN TREATED PREVIOUSLY WITH CHEMOTHERAPY (PLATINUM DOUBLET) AND CRIZOTINIB","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41639,"protocol_no":"E7080-G000-211","submission_no":"192179","status_id":1,"start_date":"2017-03-23","end_date":null,"nol_date":"2016-03-08","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 2 TRIAL OF LENVATINIB (E7080) IN SUBJECTS WITH 131I-REFRACTORY DIFFERENTIATED THYROID CANCER TO EVALUATE WHETHER AN ORAL STARTING DOSE OF 20 MG OR 14 MG DAILY WILL PROVIDE COMPARABLE EFFICACY TO A 24 MG STARTING DOSE, BUT HAVE A BETTER SAFETY PROFILE","medConditionList":[{"med_condition_id":250,"med_condition":"THYROID CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36411,"protocol_no":"998HB303","submission_no":"175334","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-02","protocol_title":"AN OPEN-LABEL, MULTICENTER EVALUATION OF THE LONG-TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR IX FUSION PROTEIN (RFIXFC) IN THE PREVENTION AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY TREATED SUBJECTS WITH HEMOPHILIA B","medConditionList":[{"med_condition_id":100,"med_condition":"HEMOPHILIA B"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28549,"protocol_no":"M13-958","submission_no":"168932","status_id":2,"start_date":null,"end_date":"2014-04-10","nol_date":"2013-11-04","protocol_title":"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SAFETY AND EFFICACY TRIAL OF MULTIPLE DOSING REGIMENS OF ABT-719 FOR THE PREVENTION OF ACUTE KIDNEY INJURY IN SUBJECTS UNDERGOING HIGH RISK MAJOR SURGERY","medConditionList":[{"med_condition_id":551,"med_condition":"PREVENTION OF ACUTE RENAL INJURY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43990,"protocol_no":"PB-102-F30","submission_no":"199806","status_id":1,"start_date":"2017-06-07","end_date":null,"nol_date":"2016-11-30","protocol_title":"AN OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF PRX-102 IN PATIENTS WITH FABRY DISEASE CURRENTLY TREATED WITH REPLAGAL (AGALSIDASE ALFA)","medConditionList":[{"med_condition_id":79,"med_condition":"FABRY DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39811,"protocol_no":"I4T-MC-JVCZ","submission_no":"186325","status_id":2,"start_date":"2015-11-24","end_date":"2017-11-08","nol_date":"2015-08-18","protocol_title":"RANDOMIZED PHASE 2 TRIAL EVALUATING ALTERNATIVE RAMUCIRUMAB DOSES IN COMBINATION WITH PACLITAXEL IN SECOND-LINE METASTATIC OR LOCALLY ADVANCED, UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA","medConditionList":[{"med_condition_id":619,"med_condition":"GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"},{"med_condition_id":337,"med_condition":"GASTRIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41624,"protocol_no":"AKB-6548-CI-0014","submission_no":"192081","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-29","protocol_title":"PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT ¬ø CORRECTION)","medConditionList":[{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"},{"med_condition_id":329,"med_condition":"ANEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41625,"protocol_no":"AKB-6548-CI-0015","submission_no":"192084","status_id":1,"start_date":"2016-09-19","end_date":null,"nol_date":"2016-03-29","protocol_title":"PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT - CONVERSION)","medConditionList":[{"med_condition_id":329,"med_condition":"ANEMIA"},{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43705,"protocol_no":"20110203","submission_no":"198957","status_id":1,"start_date":"2016-12-14","end_date":null,"nol_date":"2016-11-03","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF OMECAMTIV MECARBIL ON MORTALITY AND MORBIDITY IN SUBJECTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION","medConditionList":[{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36872,"protocol_no":"A3921187","submission_no":"176819","status_id":2,"start_date":"2015-03-16","end_date":"2018-03-12","nol_date":"2014-09-02","protocol_title":"A PHASE 3B/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OF TOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TO ADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS.","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28425,"protocol_no":"20130111","submission_no":"168526","status_id":1,"start_date":"2015-02-27","end_date":null,"nol_date":"2013-10-25","protocol_title":"A MULTICENTER, PHASE 2, SINGLE ARM, TWO COHORT STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF AMG 337 IN SUBJECTS WITH MET AMPLIFIED GASTRIC/GASTROESOPHAGEAL JUNCTION/ESOPHAGEAL ADENOCARCINOMA OR OTHER MET AMPLIFIED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41968,"protocol_no":"CTMT212X2106","submission_no":"193459","status_id":1,"start_date":"2017-03-28","end_date":null,"nol_date":"2016-04-15","protocol_title":"A PHASE I/II STUDY OF SAFETY AND EFFICACY OF RIBOCICLIB (LEE011) IN COMBINATION WITH TRAMETINIB (TMT212) IN PATIENTS WITH METASTATIC OR ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35571,"protocol_no":"18F-AV-45-A15-ADNI-GO","submission_no":"172811","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-04","protocol_title":"SAFETY EVALUATION OF FLORBETAPIR F 18 (18F-AV-45) IN SUBJECTS PARTICIPATING IN THE ADNI-GO PROTOCOL","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45352,"protocol_no":"54135419SUI3002","submission_no":"204172","status_id":1,"start_date":"2018-01-12","end_date":null,"nol_date":"2017-04-20","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRANASAL ESKETAMINE IN ADDITION TO COMPREHENSIVE STANDARD OF CARE FOR THE RAPID REDUCTION OF THE SYMPTOMS OF MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDAL IDEATION, IN ADULT SUBJECTS ASSESSED TO BE AT IMMINENT RISK FOR SUICIDE","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43264,"protocol_no":"ARRAY-818-302","submission_no":"197632","status_id":1,"start_date":"2017-02-07","end_date":null,"nol_date":"2016-09-12","protocol_title":"A MULTICENTER, RANDOMIZED, OPEN-LABEL, 3-ARM PHASE 3 STUDY OF ENCORAFENIB + CETUXIMAB PLUS OR MINUS BINIMETINIB VS. IRINOTECAN/CETUXIMAB OR INFUSIONAL 5-FLUOROURACIL (5-FU)/FOLINIC ACID (FA) /IRINOTECAN (FOLFIRI)/CETUXIMAB WITH A SAFETY LEAD-IN OF ENCORAFENIB + BINIMETINIB + CETUXIMAB IN PATIENTS WITH BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47267,"protocol_no":"AS0009","submission_no":"210387","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-14","protocol_title":"A MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN SUBJECTS WITH ANKYLOSING SPONDYLITIS","medConditionList":[{"med_condition_id":397,"med_condition":"ANKYLOSING SPONDYLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46321,"protocol_no":"418-2016","submission_no":"207130","status_id":1,"start_date":"2018-03-01","end_date":null,"nol_date":"2017-07-28","protocol_title":"PROPHYLACTIC USE OF TRANEXAMIC ACID FOR PREVENTING POSTPARTUM HEMORRHAGE: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PILOT TRIAL (TAPPH-1)","medConditionList":[{"med_condition_id":590,"med_condition":"HEMORRHAGE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37312,"protocol_no":"PS0002","submission_no":"178256","status_id":1,"start_date":"2015-01-21","end_date":null,"nol_date":"2014-10-23","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUTE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41473,"protocol_no":"EP-104IAR-101","submission_no":"191588","status_id":2,"start_date":"2017-01-09","end_date":"2018-01-11","nol_date":"2016-02-19","protocol_title":"STEP-UP: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE I TRIAL EVALUATING THE PK, SAFETY AND PRELIMINARY EFFICACY OF EP-104IAR (LONG-ACTING FLUTICASONE PROPIONATE) IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35467,"protocol_no":"16507","submission_no":"172469","status_id":1,"start_date":"2016-02-02","end_date":null,"nol_date":"2014-03-17","protocol_title":"A THREE ARM RANDOMIZED, OPEN-LABEL PHASE II STUDY OF RADIUM-223 DICHLORIDE 50 KBQ/KG VERSUS 80 KBQ/KG AND VERSUS 50 KBQ/KG IN AN EXTENDED DOSING SCHEDULE IN SUBJECTS WITH CASTRATION-RESISTANT PROSTATE CANCER METASTATIC TO THE BONE","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40420,"protocol_no":"B9991009","submission_no":"188041","status_id":1,"start_date":"2016-04-08","end_date":null,"nol_date":"2015-11-04","protocol_title":"A PHASE 3, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"},{"med_condition_id":197,"med_condition":"PLATINUM-RESISTANT OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41944,"protocol_no":"ELICE-BD-O1","submission_no":"193350","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-23","protocol_title":"A 6-WEEK RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF LURASIDONE ADJUNCTIVE THERAPY IN IMPROVING COGNITIVE FUNCTIONING IN EUTHYMIC BIPOLAR DISORDER PATIENTS (ELICE-BD)","medConditionList":[{"med_condition_id":501,"med_condition":"BIPOLAR DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29169,"protocol_no":"ASG-22CE-13-2","submission_no":"171102","status_id":1,"start_date":"2016-03-09","end_date":null,"nol_date":"2014-01-24","protocol_title":"A PHASE I STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF ASG-22CE GIVEN AS MONOTHERAPY IN SUBJECTS WITH METASTATIC UROTHELIAL CANCER THAT EXPRESS NECTIN-4","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36130,"protocol_no":"AP26113-13-201","submission_no":"174559","status_id":1,"start_date":"2014-10-17","end_date":null,"nol_date":"2014-05-30","protocol_title":"A RANDOMIZED PHASE 2 STUDY OF AP26113 IN PATIENTS WITH ALK-POSITIVE, NON-SMALL CELL LUNG CANCER (NSCLC) PREVIOUSLY TREATED WITH CRIZOTINIB","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36371,"protocol_no":"RIVAROXDVT3002 (17261)","submission_no":"173739","status_id":1,"start_date":"2015-06-18","end_date":null,"nol_date":"2014-06-19","protocol_title":"MEDICALLY ILL PATIENT ASSESSMENT OF RIVAROXABAN VERSUS PLACEBO IN REDUCING POST-DISCHARGE VENOUS THROMBO-EMBOLISM RISK (MARINER)","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35468,"protocol_no":"200056","submission_no":"172465","status_id":1,"start_date":"2014-11-06","end_date":null,"nol_date":"2014-03-21","protocol_title":"A PHASE IIB STUDY EVALUATING A LONG-ACTING INTRAMUSCULAR REGIMEN OF GSK1265744 PLUS TMC278 FOR THE MAINTENANCE OF VIROLOGIC SUPPRESSION FOLLOWING AN INDUCTION OF VIROLOGIC SUPPRESSION ON AN ORAL REGIMEN OF GSK1265744 PLUS ABACAVIR/LAMIVUDINE IN HIV-1 INFECTED, ANTIRETROVIRAL THERAPY-NAIVE ADULT SUBJECTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27567,"protocol_no":"EG-01-1962-02","submission_no":"166138","status_id":2,"start_date":"2014-01-16","end_date":"2016-07-01","nol_date":"2013-07-26","protocol_title":"PHASE 1/2A MULTICENTER, CONTROLLED, RANDOMIZED, OPEN-LABEL, DOSE ESCALATION, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY COMPARING EG-1962 AND NIMODIPINE IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE","medConditionList":[{"med_condition_id":336,"med_condition":"ANEURYSMAL SUBARACHNOID HEMORRHAGE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35512,"protocol_no":"CA209-142","submission_no":"172612","status_id":1,"start_date":"2017-09-04","end_date":null,"nol_date":"2014-03-24","protocol_title":"A PHASE 2 CLINICAL TRIAL OF NIVOLUMAB AND NIVOLUMAB PLUS IPILIMUMAB IN RECURRENT AND METASTATIC MICROSATELLITE HIGH (MSI-H) COLON CANCER (CHECKMATE 142: CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 142)","medConditionList":[{"med_condition_id":49,"med_condition":"COLON CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38355,"protocol_no":"AI438047","submission_no":"181787","status_id":1,"start_date":"2015-09-03","end_date":null,"nol_date":"2015-03-05","protocol_title":"A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF BMS-663068 IN HEAVILY TREATMENT EXPERIENCED SUBJECTS INFECTED WITH MULTI-DRUG RESISTANT HIV-1","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43480,"protocol_no":"17777","submission_no":"198199","status_id":1,"start_date":"2017-04-28","end_date":null,"nol_date":"2016-10-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY OF ODM-201 VERSUS PLACEBO IN ADDITION TO STANDARD ANDROGEN DEPRIVATION THERAPY AND DOCETAXEL IN PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39031,"protocol_no":"CLEE011F2301","submission_no":"183923","status_id":1,"start_date":"2015-11-19","end_date":null,"nol_date":"2015-05-21","protocol_title":"MONALEESA-3: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER WHO HAVE RECEIVED NO OR ONLY ONE LINE OF PRIOR ENDOCRINE TREATMENT","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45076,"protocol_no":"BP29541","submission_no":"203230","status_id":1,"start_date":"2018-01-22","end_date":null,"nol_date":"2017-03-24","protocol_title":"AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6958688, A NOVEL T-CELL BISPECIFIC ANTIBODY THAT TARGETS THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3 ON T CELLS, ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA (+) SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"},{"med_condition_id":780,"med_condition":"METASTATIC CEA-POSITIVE SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45746,"protocol_no":"1366.4","submission_no":"205380","status_id":1,"start_date":"2018-02-12","end_date":null,"nol_date":"2017-05-29","protocol_title":"RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF 4 MULTIPLE RISING ORAL DOSES OF BI 685509 OVER 28 DAYS IN MALE AND FEMALE PATIENTS WITH DIABETIC NEPHROPATHY.","medConditionList":[{"med_condition_id":65,"med_condition":"DIABETIC NEPHROPATHY"},{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44930,"protocol_no":"CA209-908","submission_no":"202850","status_id":1,"start_date":"2017-06-07","end_date":null,"nol_date":"2017-03-14","protocol_title":"PHASE IB/II CLINICAL TRIAL OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN PEDIATRIC SUBJECTS WITH HIGH GRADE PRIMARY CNS MALIGNANCIES","medConditionList":[{"med_condition_id":773,"med_condition":"CENTRAL NERVOUS SYSTEM MALIGNANCY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44664,"protocol_no":"16-001","submission_no":"202011","status_id":1,"start_date":"2017-10-06","end_date":null,"nol_date":"2017-02-14","protocol_title":"TREATMENT OF NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41827,"protocol_no":"NN9924-4221","submission_no":"192904","status_id":1,"start_date":"2017-01-17","end_date":null,"nol_date":"2016-04-01","protocol_title":"PIONEER 6 - CARDIOVASCULAR OUTCOMES. A TRIAL INVESTIGATING THE CARDIOVASCULAR SAFETY OF ORAL SEMAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47445,"protocol_no":"PM60184-B-002-17","submission_no":"210958","status_id":1,"start_date":"2018-03-08","end_date":null,"nol_date":"2017-12-08","protocol_title":"A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF PM060184 IN PATIENTS WITH ADVANCED COLORECTAL CANCER AFTER STANDARD TREATMENT","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40598,"protocol_no":"APD334-003","submission_no":"188591","status_id":2,"start_date":"2016-06-14","end_date":"2018-02-14","nol_date":"2015-11-12","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF APD334 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42859,"protocol_no":"16/27E","submission_no":"196439","status_id":2,"start_date":"2016-12-13","end_date":"2017-06-19","nol_date":"2016-07-21","protocol_title":"ORAL DEXAMETHASONE FOR THE TREATMENT OF ACUTE MIGRAINE RECURRENCE IN PEDIATRIC PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH MIGRAINE: A PILOT RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":157,"med_condition":"MIGRAINE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41543,"protocol_no":"MEDI4736-MDS-001","submission_no":"191804","status_id":1,"start_date":"2016-02-28","end_date":null,"nol_date":"2016-02-26","protocol_title":"A RANDOMIZED MULTICENTER, OPEN-LABEL, PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF AZACITIDINE SUBCUTANEOUS IN COMBINATION WITH DURVALUMAB (MEDI4736) IN PREVIOUSLY UNTREATED SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR IN ELDERLY (? 65 YEARS) ACUTE MYELOID LEUKEMIA (AML) SUBJECTS NOT ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"},{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41558,"protocol_no":"014-01","submission_no":"191869","status_id":1,"start_date":"2016-08-15","end_date":null,"nol_date":"2016-03-02","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY, TOLERABILITY, AND EFFICACY OF IMIPENEM/CILASTATIN/RELEBACTAM (MK-7655A, HEREAFTER REFERRED TO AS IMI/REL) VERSUS PIPERACILLIN/TAZOBACTAM (HEREAFTER REFERRED TO AS PIP/TAZ) IN SUBJECTS WITH HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA OR VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA","medConditionList":[{"med_condition_id":442,"med_condition":"PNEUMONIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39555,"protocol_no":"CA209-218","submission_no":"185711","status_id":1,"start_date":"2015-10-02","end_date":null,"nol_date":"2015-07-24","protocol_title":"EXPANDED ACCESS PROGRAM WITH NIVOLUMAB (BMS-936558) IN COMBINATION WITH IPILIMUMAB (YERVOY) IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27838,"protocol_no":"GS-US-320-0110","submission_no":"166835","status_id":1,"start_date":"2013-11-15","end_date":null,"nol_date":"2013-08-23","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TENOFOVIR ALAFENAMIDE  (TAF) 25 MG QD VERSUS TENOFOVIR DISOPROXIL FUMARATE (TDF) 300 MG QD FOR THE TREATMENT OF HBEAG POSITIVE, CHRONIC HEPATITIS B","medConditionList":[{"med_condition_id":345,"med_condition":"CHRONIC HEPATITIS B"},{"med_condition_id":103,"med_condition":"HEPATITIS B VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46955,"protocol_no":"EFC13738 (ELIKIDS)","submission_no":"209288","status_id":1,"start_date":"2018-04-05","end_date":null,"nol_date":"2017-10-02","protocol_title":"OPEN LABEL, TWO COHORT (WITH AND WITHOUT IMIGLUCERASE), MULTICENTER STUDY TO EVALUATE PHARMACOKINETICS (PK), SAFETY, AND EFFICACY OF ELIGLUSTAT IN PEDIATRIC PATIENTS WITH GAUCHER DISEASE (GD) TYPE 1 (GD1) AND TYPE 3 (GD3)","medConditionList":[{"med_condition_id":87,"med_condition":"GAUCHER DISEASE TYPE 1"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38845,"protocol_no":"EFC13579","submission_no":"183359","status_id":1,"start_date":"2015-07-23","end_date":null,"nol_date":"2015-05-08","protocol_title":"\"A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUTE THE EFFICACY AND SAFETY OF DUPILUMAB IN PATIENTS WITH PERSISTENT ASTHMA.\"","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37816,"protocol_no":"AB12010","submission_no":"179793","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-12","protocol_title":"A PROSPECTIVE, MULTICENTRE, OPEN-LABEL, RANDOMIZED, ACTIVE-CONTROLLED, 3 PARALLEL GROUPS, PHASE 2 STUDY TO COMPARE THE EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH FOLFIRI (IRINOTECAN, 5-FLUOROURACIL AND FOLINIC ACID), VERSUS MASITINIB ALONE, VERSUS BEST SUPPORTIVE CARE, IN THIRD OR FOURTH LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER.","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43670,"protocol_no":"GS-US-419-3895","submission_no":"198860","status_id":1,"start_date":"2017-08-28","end_date":null,"nol_date":"2016-10-31","protocol_title":"COMBINED PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDIES EVALUATING THE EFFICACY AND SAFETY OF FILGOTINIB IN THE INDUCTION AND MAINTENANCE OF REMISSION IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN¬øS DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43721,"protocol_no":"CO39262","submission_no":"199003","status_id":1,"start_date":"2017-06-16","end_date":null,"nol_date":"2016-11-02","protocol_title":"A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION-POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36495,"protocol_no":"20130173","submission_no":"175602","status_id":1,"start_date":"2016-07-05","end_date":null,"nol_date":"2014-07-16","protocol_title":"PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE EFFICACY, SAFETY AND PHARMACOKINETICS OF DENOSUMAB IN CHILDREN WITH OSTEOGENIS IMPERFECTA PROTOCOL","medConditionList":[{"med_condition_id":549,"med_condition":"OSTEOGENESIS IMPERFECTA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28656,"protocol_no":"20120324","submission_no":"169322","status_id":1,"start_date":"2014-07-18","end_date":null,"nol_date":"2013-11-22","protocol_title":"A PHASE 2, MULTICENTER, SINGLE-ARM TRIAL TO EVALUATE THE BIODISTRIBUTION AND SHEDDING OF TALIMOGENE LAHERPAREPVEC IN SUBJECTS WITH UNRESECTED, STAGE IIIB TO IVM1A MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46727,"protocol_no":"0891","submission_no":"208493","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-28","protocol_title":"PHASE 2 STUDY OF AN IMMUNOTHERAPEUTIC VACCINE, DPXSURVIVAC WITH LOW DOSE CYCLOPHOSPHAMIDE ADMINISTERED WITH A PEMBROLIZUMAB IN PATIENTS WITH PERSISTENT OR RECURRENT/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27206,"protocol_no":"ISIS 404173-CS2","submission_no":"165111","status_id":1,"start_date":"2013-10-22","end_date":null,"nol_date":"2013-06-21","protocol_title":"A DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF ISIS 404173 ADMINISTERED ONCE WEEKLY TO OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS BEING TREATED WITH METFORMIN OR METFORMIN PLUS SULFONYLUREA","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29171,"protocol_no":"D081CC00006","submission_no":"171119","status_id":1,"start_date":"2016-04-14","end_date":null,"nol_date":"2014-01-23","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED MULTI-CENTRE PHASE III STUDY TO ASSESS THE EFFICACY AND SAFETY OF OLAPARIB VERSUS PLACEBO AS ADJUVANT TREATMENT IN PATIENTS WITH GERMLINE BRCA1/2 MUTATIONS AND HIGH RISK HER2 NEGATIVE PRIMARY BREAST CANCER WHO HAVE COMPLETED DEFINITIVE LOCAL TREATMENT AND NEOADJUVANT OR ADJUVANT CHEMOTHERAPY","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37286,"protocol_no":"17096","submission_no":"178157","status_id":1,"start_date":"2017-02-28","end_date":null,"nol_date":"2014-10-17","protocol_title":"A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF RADIUM-223 DICHLORIDE IN COMBINATION WITH EXEMESTANE AND EVEROLIMUS VERSUS PLACEBO IN COMBINATION WITH EXEMESTANE AND EVEROLIMUS WHEN ADMINISTERED TO METASTATIC HER2 NEGATIVE HORMONE RECEPTOR POSITIVE BREAST CANCER SUBJECTS WITH BONE METASTASES","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45525,"protocol_no":"I1F-MC-RHCF","submission_no":"204693","status_id":1,"start_date":"2017-09-11","end_date":null,"nol_date":"2017-05-03","protocol_title":"A 52-WEEK MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS WHO ARE BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUG NAIVE","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41275,"protocol_no":"LA48-0215","submission_no":"191070","status_id":1,"start_date":"2017-10-06","end_date":null,"nol_date":"2016-02-01","protocol_title":"A DOSE-RANGING STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF DEFERIPRONE DELAYED RELEASE TABLETS IN PATIENTS WITH PARKINSON'S DISEASE","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39491,"protocol_no":"ACDC","submission_no":"185526","status_id":1,"start_date":"2016-09-22","end_date":null,"nol_date":"2015-06-26","protocol_title":"ANTI-ANDROGENS AND CABAZITAXEL IN DEFINING COMPLETE RESPONSE IN PROSTATECTOMY (ACDC-RP TRIAL)","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44292,"protocol_no":"IRX-2 2015A","submission_no":"200658","status_id":1,"start_date":"2017-03-20","end_date":null,"nol_date":"2016-12-28","protocol_title":"A RANDOMIZED PHASE 2 TRIAL OF NEOADJUVANT AND ADJUVANT THERAPY WITH THE IRX-2 REGIMEN IN PATIENTS WITH NEWLY DIAGNOSED STAGE II, III AND IVA SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41096,"protocol_no":"652-205","submission_no":"190260","status_id":2,"start_date":"2016-07-14","end_date":"2017-11-08","nol_date":"2016-01-05","protocol_title":"A PHASE 2 PROOF OF CONCEPT STUDY INVESTIGATING THE PRELIMINARY EFFICACY AND SAFETY OF CENICRIVIROC IN ADULT SUBJECTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC)","medConditionList":[{"med_condition_id":601,"med_condition":"PRIMARY SCLEROSING CHOLANGITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43466,"protocol_no":"RP3128-1601","submission_no":"198185","status_id":1,"start_date":"2017-04-28","end_date":null,"nol_date":"2016-10-07","protocol_title":"AN INTEGRATED PHASE I/IIA, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSE(S) OF ORAL RP3128 (CRAC CHANNEL MODULATORS) IN HEALTHY VOLUNTEERS AND TO EVALUATE THE EFFECT ON LATE PHASE ASTHMATIC RESPONSE (LAR) TO ALLERGEN CHALLENGE IN PATIENTS WITH MILD ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28352,"protocol_no":"NIDA CTN0055","submission_no":"168271","status_id":1,"start_date":"2014-06-01","end_date":null,"nol_date":"2013-10-24","protocol_title":"COMPARING TREATMENTS FOR HIV-INFECTED OPIOID AND ALCOHOL USERS IN AN INTEGRATED CARE EFFECTIVENESS STUDY (CHOICES)","medConditionList":[{"med_condition_id":68,"med_condition":"DRUG ADDICTION"},{"med_condition_id":428,"med_condition":"SUBSTANCE ABUSE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39251,"protocol_no":"086","submission_no":"184602","status_id":1,"start_date":"2016-09-28","end_date":null,"nol_date":"2015-06-11","protocol_title":"\"A PHASE II CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) AS MONOTHERAPY FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)-(KEYNOTE-086),\"","medConditionList":[{"med_condition_id":627,"med_condition":"BREAST CANCER METASTATIC TRIPLE NEGATIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38052,"protocol_no":"SGI-110-04","submission_no":"180672","status_id":1,"start_date":"2015-05-05","end_date":null,"nol_date":"2015-01-29","protocol_title":"A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF SGI-110 VERSUS TREATMENT CHOICE (TC) IN ADULTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML) WHO ARE NOT CONSIDERED CANDIDATES FOR INTENSIVE REMISSION INDUCTION CHEMOTHERAPY","medConditionList":[{"med_condition_id":46,"med_condition":"CHRONIC MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44900,"protocol_no":"RHB-104-04","submission_no":"202779","status_id":1,"start_date":"2017-04-07","end_date":null,"nol_date":"2017-03-09","protocol_title":"AN OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION RHB-104 IN SUBJECTS WITH ACTIVE CROHN'S DISEASE DESPITE 26 WEEKS OF PARTICIPATION IN THE MAP US RHB-104-01 STUDY (MAP US2)","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45062,"protocol_no":"3662-CL-0017","submission_no":"203175","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-23","protocol_title":"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF ASP3662 FOR THE TREATMENT OF AGITATION IN SUBJECTS WITH PROBABLE MILD TO MODERATE ALZHEIMER¬øS DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44145,"protocol_no":"CP-4-006","submission_no":"200238","status_id":1,"start_date":"2017-08-25","end_date":null,"nol_date":"2016-12-12","protocol_title":"A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, 12 MONTHS, EFFICACY AND SAFETY STUDY OF WEEKLY MOD-4023 COMPARED TO DAILY GENOTROPIN THERAPY IN PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENCY","medConditionList":[{"med_condition_id":94,"med_condition":"GROWTH HORMONE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36388,"protocol_no":"EFC11759","submission_no":"175253","status_id":1,"start_date":"2015-02-23","end_date":null,"nol_date":"2014-07-02","protocol_title":"A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TERIFLUNOMIDE ADMINISTERED ORALLY ONCE DAILY IN PEDIATRIC PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44345,"protocol_no":"NASPAF-ICH","submission_no":"200949","status_id":1,"start_date":"2017-06-07","end_date":null,"nol_date":"2017-01-20","protocol_title":"NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION AND PREVIOUS INTRACEREBRAL HEMORRHAGE STUDY","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"},{"med_condition_id":404,"med_condition":"INTRACEREBAL HEMORRAGE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45254,"protocol_no":"28431754OBE3001","submission_no":"203787","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP 104-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF THE CO-ADMINISTRATION OF CANAGLIFLOZIN AND PHENTERMINE COMPARED WITH PLACEBO FOR THE TREATMENT OF OVERWEIGHT AND OBESE SUBJECTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45301,"protocol_no":"E7080-G000-218","submission_no":"203990","status_id":1,"start_date":"2017-10-06","end_date":null,"nol_date":"2017-04-13","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL TO ASSESS SAFETY AND EFFICACY OF LENVATINIB AT TWO DIFFERENT STARTING DOSES (18 MG VS. 14 MG QD) IN COMBINATION WITH EVEROLIMUS (5 MG QD) IN RENAL CELL CARCINOMA FOLLOWING ONE PRIOR VEGF-TARGETED TREATMENT","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43395,"protocol_no":"ALX0681-C302","submission_no":"197980","status_id":1,"start_date":"2016-12-15","end_date":null,"nol_date":"2016-09-30","protocol_title":"PROSPECTIVE FOLLOW-UP STUDY FOR PATIENTS WHO COMPLETED STUDY ALX0681-C301 (HERCULES) TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB (POST-HERCULES)","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40128,"protocol_no":"012","submission_no":"187169","status_id":1,"start_date":"2015-10-09","end_date":null,"nol_date":"2015-09-18","protocol_title":"A PHASE III, RANDOMIZED, PLACEBO-CONTROLLED, CLINICAL TRIAL TO STUDY THE SAFETY AND IMMUNOGENICITY OF THREE CONSISTENCY LOTS AND A HIGH DOSE LOT OF RVSV-ZEBOV-GP (V920 EBOLA VACCINE) IN HEALTHY ADULTS","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40275,"protocol_no":"AP24534-14-203","submission_no":"187568","status_id":1,"start_date":"2016-11-28","end_date":null,"nol_date":"2015-10-08","protocol_title":"A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES (OPTIC)","medConditionList":[{"med_condition_id":46,"med_condition":"CHRONIC MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43885,"protocol_no":"M16-048","submission_no":"199496","status_id":1,"start_date":"2017-02-27","end_date":null,"nol_date":"2016-11-18","protocol_title":"A PHASE 2B MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND DOSE-RANGING STUDY TO EVALUATE ABT-494 IN ADULT SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46824,"protocol_no":"ARC008","submission_no":"208810","status_id":1,"start_date":"2017-10-17","end_date":null,"nol_date":"2017-09-26","protocol_title":"A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY","medConditionList":[{"med_condition_id":12,"med_condition":"ALLERGIES PEANUT"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29028,"protocol_no":"D513BC00001","submission_no":"170633","status_id":1,"start_date":"2014-02-03","end_date":null,"nol_date":"2014-01-06","protocol_title":"A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF TICAGRELOR 90 MG TWICE DAILY ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39048,"protocol_no":"14-002","submission_no":"183955","status_id":2,"start_date":"2016-01-07","end_date":"2017-02-14","nol_date":"2015-05-20","protocol_title":"A TWELVE-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP-110 [(R)-2-AMINO-3-PHENYLPROPYLCARBAMATE HYDROCHLORIDE] IN THE TREATMENT OF EXCESSIVE SLEEPINESS IN SUBJECTS WITH NARCOLEPSY","medConditionList":[{"med_condition_id":656,"med_condition":"NARCOLEPSY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47711,"protocol_no":"ID-076A201","submission_no":"211629","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-19","protocol_title":"A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE PHARMACODYNAMICS, PHARMACOKINETICS, TOLERABILITY, AND SAFETY OF A SINGLE SUBCUTANEOUS INJECTION OF ACT-246475 IN ADULTS WITH STABLE CORONARY ARTERY DISEASE","medConditionList":[{"med_condition_id":598,"med_condition":"CORONARY ARTERY DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47486,"protocol_no":"D6185C00001","submission_no":"211057","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-06","protocol_title":"AN OPEN-LABEL, MULTI-DRUG, BIOMARKER-DIRECTED, MULTI-CENTRE PHASE II UMBRELLA STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER, WHO PROGRESSED ON AN ANTI-PD-1/PD-L1 CONTAINING THERAPY (HUDSON)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41246,"protocol_no":"OZM-065","submission_no":"190834","status_id":1,"start_date":"2017-11-01","end_date":null,"nol_date":"2016-01-22","protocol_title":"A PHASE-II PROOF OF PRINCIPLE STUDY OF THE ACTIVITY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH SBRT IN PRIMARY TYROSINE KINASE INHIBITOR (TKI) REFRACTORY METASTATIC KIDNEY CANCER (MRCC) PATIENTS","medConditionList":[{"med_condition_id":669,"med_condition":"KIDNEY CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43126,"protocol_no":"ACE-CL-309","submission_no":"197257","status_id":1,"start_date":"2017-10-18","end_date":null,"nol_date":"2016-08-24","protocol_title":"A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF ACALABRUTINIB (ACP-196) VERSUS INVESTIGATOR'S CHOICE OF EITHER IDELALISIB PLUS RITUXIMAB OR BENDAMUSTINE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37283,"protocol_no":"031","submission_no":"178141","status_id":2,"start_date":"2016-06-20","end_date":"2016-09-08","nol_date":"2014-10-17","protocol_title":"A CLINICAL TRIAL TO EVALUATE THE EFFECT OF NEOADJUVANT MK-3475 (PEMBROLIZUMAB) THERAPY ON INTRATUMORAL IMMUNE INFILTRATES IN RENAL CELL CANCER (RCC) PATIENTS UNDERGOING SURGICAL RESECTION (KEYNOTE 031)","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48287,"protocol_no":"OMS-I103","submission_no":"213267","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-15","protocol_title":"THE PISCES STUDY: A MULTICENTER PHASE 2, OPEN-LABEL TRIAL OF INTRATUMORAL PIL-12 PLUS ELECTROPORATION IN COMBINATION WITH INTRAVENOUS PEMBROLIZUMAB IN PATIENTS WITH STAGE III/IV MELANOMA WHO ARE PROGRESSING ON EITHER PEMBROLIZUMAB OR NIVOLUMAB TREATMENT","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41024,"protocol_no":"183","submission_no":"189997","status_id":1,"start_date":"2017-03-16","end_date":null,"nol_date":"2015-12-24","protocol_title":"A PHASE III STUDY OF POMALIDOMIDE AND LOW DOSE DEXAMETHASONE WITH OR WITHOUT PEMBROLIZUMAB (MK3475) IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) (KEYNOTE 183)","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48041,"protocol_no":"D933IC00003","submission_no":"212794","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-07","protocol_title":"A PHASE II, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, COMPARATIVE GLOBAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DURVALUMAB IN COMBINATION WITH OLAPAIB FOR FIRST-LINE TREATMENT IN CISPLATIN-INELIGIBLE PATIENTS WITH UNRESECTABLE STAGE IV UROTHELIAL CANCER (BAYOU)","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44790,"protocol_no":"CT-PAH002","submission_no":"202459","status_id":1,"start_date":"2017-09-28","end_date":null,"nol_date":"2017-03-03","protocol_title":"THE SAPPHIRE TRIAL: STUDY OF ANGIOGENIC CELL THERAPY FOR PROGRESSIVE PULMONARY HYPERTENSION: INTERVENTION WITH REPEAT DOSING OF ENOS-ENHANCED EPC'S","medConditionList":[{"med_condition_id":483,"med_condition":"PULMONARY HYPERTENSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27428,"protocol_no":"ABI-007-PST-001","submission_no":"165725","status_id":1,"start_date":"2014-06-07","end_date":null,"nol_date":"2013-07-09","protocol_title":"A PHASE 1/2, MULTICENTER, OPEN-LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF WEEKLY NAB¬Æ-PACLITAXEL IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS.","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40191,"protocol_no":"CLS001-CO-PR-004","submission_no":"187331","status_id":1,"start_date":"2015-12-01","end_date":null,"nol_date":"2015-09-28","protocol_title":"A PHASE 3, RANDOMIZED, VEHICLE-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A ONCE-DAILY CLS001 TOPICAL GEL VERSUS VEHICLE ADMINISTERED FOR 12 WEEKS TO SUBJECTS WITH PAPULOPUSTULAR ROSACEA WITH AN OPEN-LABEL SAFETY EXTENSION","medConditionList":[{"med_condition_id":225,"med_condition":"ROSACEA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45665,"protocol_no":"204697","submission_no":"205102","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-24","protocol_title":"A PHASE IB OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF GSK525762 IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY AND OTHER AGENTS IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER (CRPC).","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46136,"protocol_no":"CTN 287","submission_no":"206480","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-29","protocol_title":"OPTIMIZING THE DELIVERY OF HIV POST-EXPOSURE PROPHYLAXIS: A RANDOMIZED CONTROLLED TRIAL OF TEXT MESSAGING SUPPORT AND PHYSICIAN TO NURSE TASK-SHIFTING","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37657,"protocol_no":"D3610C00002","submission_no":"179321","status_id":1,"start_date":"2015-07-22","end_date":null,"nol_date":"2014-11-26","protocol_title":"A PHASE I/II, MULTICENTRE, STUDY COMPRISING A SAFETY RUN-IN OF AZD5363 WHEN COMBINED WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER; FOLLOWED BY A RANDOMISED EXPANSION OF AZD5363 WHEN COMBINED WITH PACLITAXEL VS. PACLITAXEL PLUS PLACEBO IN PATIENTS WITH ERPOSITIVE ADVANCED OR METASTATIC BREAST CANCER, STRATIFIED BY PIK3CA MUTATION STATUS (BEECH)","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"},{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41105,"protocol_no":"NCT02486666","submission_no":"190308","status_id":1,"start_date":"2017-05-22","end_date":null,"nol_date":"2016-01-07","protocol_title":"A PILOT FEASIBILITY AND SAFETY MULTICENTER TRIAL OF ADMINISTERING WEIGHT ADJUSTED FIEXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES WITH THROMBOSIS (FIXET): STUDY PROTOCOL","medConditionList":[{"med_condition_id":668,"med_condition":"THROMBOSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46996,"protocol_no":"ZP4207-16137","submission_no":"209405","status_id":1,"start_date":"2017-12-01","end_date":null,"nol_date":"2017-10-11","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL TRIAL TO CONFIRM THE CLINICAL EFFICACY AND SAFETY OF DASIGLUCAGON IN THE RESCUE TREATMENT OF HYPOGLYCEMIA IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS (T1DM) COMPARED TO PLACEBO AND WITH REFERENCE TO GLUCAGEN¬Æ","medConditionList":[{"med_condition_id":761,"med_condition":"HYPOFIBRINOGENEMIA"},{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47161,"protocol_no":"MDCO-PCS-17-03","submission_no":"209973","status_id":1,"start_date":"2018-01-29","end_date":null,"nol_date":"2017-11-02","protocol_title":"A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO EVALUATE THE EFFECT OF 300 MG OF INCLISIRAN SODIUM GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) AND ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), (ORION-9)","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36111,"protocol_no":"024","submission_no":"174525","status_id":1,"start_date":"2015-03-05","end_date":null,"nol_date":"2014-06-13","protocol_title":"A RANDOMIZED OPEN-LABEL PHASE III TRIAL OF MK-3475 VERSUS PLATINUM BASED CHEMOTHERAPY IN 1L SUBJECTS WITH PD-L1 STRONG METASTATIC NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40274,"protocol_no":"MHIPS-003","submission_no":"187569","status_id":1,"start_date":"2015-11-16","end_date":null,"nol_date":"2015-10-08","protocol_title":"COLCHICINE CARDIOVASCULAR OUTCOMES TRIAL (COLCOT) [PLACEBO CONTROLLED]","medConditionList":[{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48213,"protocol_no":"SHP634-404","submission_no":"213314","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-01","protocol_title":"AN OPEN-LABEL STUDY INVESTIGATING THE SAFETY AND EFFICACY OF RHPTH (1-84) IN SUBJECTS WITH HYPOPARATHYROIDISM","medConditionList":[{"med_condition_id":816,"med_condition":"HYPOPARATHYROIDISM"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47005,"protocol_no":"SPI-QAP-306","submission_no":"209438","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-16","protocol_title":"A RANDOMIZED, MULTICENTER, TWO-ARM, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF INTRAVESICAL QAPZOLA¬ø (APAZIQUONE) AS A CHEMOTHERAPY ADJUVANT TO TRANSURETHRAL RESECTION OF BLADDER TUMORS IN PATIENTS WITH LOW- TO INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (CONQUER)","medConditionList":[{"med_condition_id":625,"med_condition":"BLADDER CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46931,"protocol_no":"2077-103","submission_no":"209207","status_id":2,"start_date":"2017-10-12","end_date":"2018-01-09","nol_date":"2017-10-03","protocol_title":"A PHASE 1 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF NK2077 TOPICAL OINTMENT IN HEALTHY VOLUNTEERS AND PATIENTS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41232,"protocol_no":"CQVM149B2302","submission_no":"190729","status_id":1,"start_date":"2016-03-16","end_date":null,"nol_date":"2016-01-14","protocol_title":"A MULTI-CENTER RANDOMIZED 52-WEEK TREATMENT, DOUBLE-BLIND, PARALLEL GROUP CONTROLLED STUDY TO COMPARE THE EFFICACY AND SAFETY OF QVM149 WITH QMF149 IN PATIENTS WITH ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46114,"protocol_no":"CV202-103","submission_no":"206409","status_id":1,"start_date":"2017-09-14","end_date":null,"nol_date":"2017-07-13","protocol_title":"A PHASE 1B/2 STUDY OF BMS-813160 IN COMBINATION WITH CHEMOTHERAPY OR NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39586,"protocol_no":"BO29159","submission_no":"185709","status_id":1,"start_date":"2015-11-25","end_date":null,"nol_date":"2015-07-20","protocol_title":"A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN SC IN COMBINATION WITH PERJETA AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY RECURRENT)","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27711,"protocol_no":"ING117172","submission_no":"166516","status_id":2,"start_date":"2013-08-29","end_date":"2015-09-20","nol_date":"2013-08-07","protocol_title":"A PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF  OLUTEGRAVIR/ABACAVIR/LAMIVUDINE ONCE DAILY COMPARED TO ATAZANAVIR AND RITONAVIR PLUS TENOFOVIR/EMTRICITABINE ONCE DAILY IN HIV-1 INFECTED ANTIRETROVIRAL THERAPY NA√èVE WOMEN","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37360,"protocol_no":"GS-US-218-1502","submission_no":"178372","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-24","protocol_title":"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-CENTER STUDY EVALUATING ANTIVIRAL EFFECTS, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF GS-5806 IN HEMATOPOIETIC CELL TRANSPLANT (HCT) RECIPIENTS WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION OF THE LOWER RESPIRATORY TRACT","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44210,"protocol_no":"205832","submission_no":"200410","status_id":2,"start_date":"2017-01-18","end_date":"2017-10-20","nol_date":"2016-12-14","protocol_title":"A PHASE IIB, 24 WEEK, RANDOMIZED, DOUBLE-BLIND, 3 ARM PARALLEL GROUP STUDY, COMPARING THE EFFICACY, SAFETY AND TOLERABILITY OF TWO DOSES OF UMECLIDINIUM BROMIDE ADMINISTERED ONCE-DAILY VIA A DRY POWDER INHALER, VERSUS PLACEBO, IN PARTICIPANTS WITH ASTHMA.","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43701,"protocol_no":"CLCZ696B2320","submission_no":"198949","status_id":1,"start_date":"2017-08-23","end_date":null,"nol_date":"2016-11-03","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF LCZ696 COMPARED TO VALSARTAN ON COGNITIVE FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE AND PRESERVED EJECTION FRACTION.","medConditionList":[{"med_condition_id":523,"med_condition":"HEART FAILURE WITH PRESERVED EJECTION FRACTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28529,"protocol_no":"RMT001","submission_no":"168874","status_id":1,"start_date":"2013-11-28","end_date":null,"nol_date":"2013-11-15","protocol_title":"A SINGLE GROUP STUDY EVALUATING REPRODUCIBILITY OF RHINITIS SYMPTOMS INDUCED BY ALLERGEN EXPOSURE IN THE RED MAPLE TRIALS ALLERGEN CHALLENGE THEATRE (ACT) IN SUBJECTS WITH GRASS POLLEN ALLERGY","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27687,"protocol_no":"D3250C00018","submission_no":"166460","status_id":1,"start_date":"2013-10-01","end_date":null,"nol_date":"2013-08-08","protocol_title":"A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF BENRALIZUMAB (MEDI-563) ADDED TO HIGH-DOSE INHALED CORTICOSTEROID PLUS LONG-ACTING B 2 AGONIST IN PATIENTS WITH UNCONTROLLED ASTHMA (CALIMA)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35576,"protocol_no":"205.446","submission_no":"172820","status_id":2,"start_date":"2014-07-08","end_date":"2015-08-14","nol_date":"2014-04-01","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO EVALUATE EFFICACY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION (2.5 ¬µG AND 5 ¬µG) DELIVERED VIA RESPIMAT¬Æ INHALER ONCE DAILY IN THE EVENING OVER 12 WEEKS AS ADD-ON CONTROLLER THERAPY ON TOP OF USUAL CARE IN CHILDREN (6 TO 11 YEARS OLD) WITH SEVERE PERSISTENT ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28055,"protocol_no":"GS-US-334-0153","submission_no":"167450","status_id":2,"start_date":"2014-01-13","end_date":"2016-07-07","nol_date":"2013-09-20","protocol_title":"A PHASE 3B RANDOMIZED, OPEN-LABEL, MULTI-CENTER TRIAL ASSESSING SOFOSBUVIR + RIBAVIRIN FOR 16 OR 24 WEEKS AND SOFOSBUVIR + PEGYLATED INTERFERON + RIBAVIRIN FOR 12 WEEKS IN SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HCV INFECTION","medConditionList":[{"med_condition_id":107,"med_condition":"HEPATITIS C VIRUS GENOTYPE 2 OR 3"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40226,"protocol_no":"M13-590","submission_no":"187416","status_id":2,"start_date":"2016-01-15","end_date":"2016-11-25","nol_date":"2015-09-29","protocol_title":"A RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABT 493/ABT-530 IN ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION (ENDURANCE-1)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43231,"protocol_no":"1160.248","submission_no":"197540","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-09-15","protocol_title":"RE-SPECT CVT: A RANDOMISED, OPEN-LABEL, EXPLORATORY TRIAL WITH BLINDED ENDPOINT ADJUDICATION(PROBE), COMPARING EFFICACY AND SAFETY OF ORAL DABIGATRAN ETEXILATE VERSUS ORAL WARFARIN IN PATIENTS WITH CEREBRAL VENOUS AND DURAL SINUS THROMBOSIS OVER A 24-¬∑WEEK PERIOD. CLINICAL PHASE: III","medConditionList":[{"med_condition_id":668,"med_condition":"THROMBOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40433,"protocol_no":"A5332","submission_no":"188076","status_id":1,"start_date":"2017-03-06","end_date":null,"nol_date":"2015-11-04","protocol_title":"RANDOMIZED TRIAL TO PREVENT VASCULAR EVENTS IN HIV - REPRIEVE","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28144,"protocol_no":"AEZS-108-050","submission_no":"167692","status_id":2,"start_date":"2014-01-27","end_date":"2017-02-02","nol_date":"2013-09-27","protocol_title":"RANDOMIZED CONTROLLED STUDY COMPARING AEZS 108 WITH DOXORUBICIN AS SECOND LINE THERAPY FOR LOCALLY ADVANCED, RECURRENT OR METASTATIC ENDOMETRIAL CANCER.","medConditionList":[{"med_condition_id":366,"med_condition":"METASTATIC ENDOMETRIAL CANCER"},{"med_condition_id":320,"med_condition":"ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42083,"protocol_no":"ALXN1101-MCD-202","submission_no":"193853","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-05-04","protocol_title":"A PHASE 2/3, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A","medConditionList":[{"med_condition_id":732,"med_condition":"MOLYBDENUM COFACTOR DEFICIENCY TYPE A"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38615,"protocol_no":"PS0005","submission_no":"182626","status_id":1,"start_date":"2015-05-14","end_date":null,"nol_date":"2015-04-01","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46494,"protocol_no":"MADDY1","submission_no":"207742","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-18","protocol_title":"MICRONUTRIENTS FOR ADHD IN YOUTH: THE ¬øMADDY¬ø STUDY","medConditionList":[{"med_condition_id":9,"med_condition":"ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38506,"protocol_no":"AB-16B5-101","submission_no":"182253","status_id":1,"start_date":"2015-05-04","end_date":null,"nol_date":"2015-03-16","protocol_title":"A PHASE I DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABLITY AND PHARMACOKINETICS OF AB-16B5 IN SUBJECTS WITH AN ADVANCED SOLID MALIGNANCY.","medConditionList":[{"med_condition_id":293,"med_condition":"MALIGNANT SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40752,"protocol_no":"GS-US-367-1173","submission_no":"189008","status_id":2,"start_date":"2016-01-21","end_date":"2017-01-02","nol_date":"2015-11-27","protocol_title":"A PHASE 3, GLOBAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/GS 9857 FIXED-DOSE COMBINATION FOR 8 WEEKS AND SOFOSBUVIR/VELPATASVIR FOR 12 WEEKS IN SUBJECTS WITH CHRONIC GENOTYPE 3 HCV INFECTION AND CIRRHOSIS","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45153,"protocol_no":"OT-15-001","submission_no":"203450","status_id":1,"start_date":"2017-11-22","end_date":null,"nol_date":"2017-03-31","protocol_title":"A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFLORNITHINE WITH LOMUSTINE COMPARED TO LOMUSTINE ALONE IN PATIENTS WITH ANAPLASTIC ASTROCYTOMA THAT PROGRESS/RECUR AFTER IRRADIATION AND ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY - STELLAR STUDY","medConditionList":[{"med_condition_id":638,"med_condition":"ANAPLASTIC ASTROCYTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38163,"protocol_no":"20101177","submission_no":"181173","status_id":1,"start_date":"2015-02-10","end_date":null,"nol_date":"2015-02-06","protocol_title":"A SINGLE-ARM STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF ETANERCEPT PRODUCED USING A MODIFIED PROCESS IN SUBJECTS WITH PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35822,"protocol_no":"00001-U","submission_no":"173593","status_id":1,"start_date":"2015-09-01","end_date":null,"nol_date":"2014-04-25","protocol_title":"PILOT CLINICAL TRIAL OF USTEKINUMAB IN PATIENTS WITH NEW-ONSET T1D","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26720,"protocol_no":"PJC-012 / NCI 9231","submission_no":"163596","status_id":1,"start_date":"2015-11-10","end_date":null,"nol_date":"2013-04-26","protocol_title":"A PHASE I TRIAL OF DINACICLIB (SCH727965) AND MK2206 IN METASTATIC PANCREATIC CANCER WITH AN EXPANSION COHORT IN ADVANCED PANCREATIC CANCER","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28222,"protocol_no":"019-00","submission_no":"167982","status_id":1,"start_date":"2014-09-29","end_date":null,"nol_date":"2013-10-04","protocol_title":"A PHASE III, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE-BLIND CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK-8931 (SCH 900931) IN SUBJECTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE (PRODROMAL AD).","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35938,"protocol_no":"B1481020","submission_no":"174019","status_id":2,"start_date":"2014-07-04","end_date":"2016-09-08","nol_date":"2014-05-16","protocol_title":"A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS","medConditionList":[{"med_condition_id":295,"med_condition":"PRIMARY HYPERLIPIDEMIA"},{"med_condition_id":296,"med_condition":"MIXED DYSLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37119,"protocol_no":"156-13-211","submission_no":"177583","status_id":1,"start_date":"2014-12-31","end_date":null,"nol_date":"2014-09-24","protocol_title":"A PHASE 3B, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY OF TITRATED IMMEDIATE-RELEASE TOLVAPTAN (OPC 41061, 30 MG TO 120 MG/DAY, SPLIT DOSE) IN SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE","medConditionList":[{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40583,"protocol_no":"M15-462","submission_no":"188531","status_id":2,"start_date":"2016-02-09","end_date":"2016-12-15","nol_date":"2015-11-12","protocol_title":"A SINGLE-ARM, OPEN-LABEL, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABT-493/ABT-530 IN RENALLY IMPAIRED ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 - 6 INFECTION (EXPEDITION-4)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27933,"protocol_no":"MELO-D","submission_no":"167104","status_id":1,"start_date":"2014-07-02","end_date":null,"nol_date":"2013-09-03","protocol_title":"ANTI-PROLIFERATIVE EFFECTS OF VITAMIN D AND MELATONIN IN BREAST CANCER (MELO-D)","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47050,"protocol_no":"ATX-MTM-002","submission_no":"209581","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-20","protocol_title":"ASPIRO: A PHASE 1/2, RANDOMIZED, OPEN-LABEL, ASCENDING-DOSE, DELAYED-TREATMENT CONCURRENT CONTROL CLINICAL STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF AT132, AN AAV8-DELIVERED GENE THERAPY IN X-LINKED MYOTUBULAR MYOPATHY (XLMTM) PATIENTS","medConditionList":[{"med_condition_id":810,"med_condition":"X-LINKED MYOTUBULAR MYOPATHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28019,"protocol_no":"1326V9235","submission_no":"167339","status_id":2,"start_date":"2014-01-09","end_date":"2016-02-25","nol_date":"2013-09-03","protocol_title":"A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP,  MULTICENTER, PHASE 3 STUDY TO EVALUATE THE LONG-TERM SAFETY OF  NALDEMEDINE FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN SUBJECTS WITH NON-MALIGNANT CHRONIC PAIN RECEIVING OPIOID THERAPY","medConditionList":[{"med_condition_id":276,"med_condition":"OPIOID-INDUCED CONSTIPATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39930,"protocol_no":"LX4211.1-312-T1DM","submission_no":"186638","status_id":2,"start_date":"2016-02-16","end_date":"2017-08-08","nol_date":"2015-08-26","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE NET CLINICAL BENEFIT OF SOTAGLIFLOZIN AS ADJUNCT TO INSULIN THERAPY IN TYPE 1 DIABETES","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36850,"protocol_no":"000070","submission_no":"176748","status_id":1,"start_date":"2014-09-29","end_date":null,"nol_date":"2014-08-28","protocol_title":"A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING TWO DOSES OF SUBCUTANEOUS PULSATILE GNRH ADMINISTERED VIA OMNIPOD PUMP FOR OVULATION INDUCTION IN FEMALE SUBJECTS WITH PRIMARY AMENORRHEA WITH HYPOGONADOTROPIC HYPOGONADISM.","medConditionList":[{"med_condition_id":570,"med_condition":"PRIMARY AMENORRHEA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41823,"protocol_no":"ISIS 304801-CS7","submission_no":"192865","status_id":1,"start_date":"2017-06-02","end_date":null,"nol_date":"2016-03-30","protocol_title":"AN OPEN-LABEL EXTENSION STUDY OF VOLANESORSEN ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA (FCS)","medConditionList":[{"med_condition_id":82,"med_condition":"FAMILIAL CHYLOMICRONEMIA SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38948,"protocol_no":"PRO00047923","submission_no":"183689","status_id":1,"start_date":"2016-03-18","end_date":null,"nol_date":"2015-05-22","protocol_title":"\"IMPROVING SINGLE DONOR SUCCESS RATE IN CLINICAL ISLET TRANSPLANTATION USING ALPHA-1 ANTITRYPSIN (ARALAST NP).\"","medConditionList":[{"med_condition_id":135,"med_condition":"ISLET TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48509,"protocol_no":"BCI-001-DT17","submission_no":"214117","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-29","protocol_title":"PHASE I TRIAL OF BC2059 (TEGAVIVINT) IN PATIENTS WITH UNRESECTABLE DESMOID","medConditionList":[{"med_condition_id":612,"med_condition":"DESMOID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27708,"protocol_no":"OLFUS-VIPES","submission_no":"166507","status_id":1,"start_date":"2014-02-05","end_date":null,"nol_date":"2013-08-07","protocol_title":"\"OPEN-LABEL FOLLOW-UP STUDY OF THE VIPES STUDY TO EVALUATE LONG-TERM EFFICACY AND SAFETY OF THE VIASKIN PEANUT.\"","medConditionList":[{"med_condition_id":12,"med_condition":"ALLERGIES PEANUT"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29175,"protocol_no":"ISRCTN15088122","submission_no":"171130","status_id":1,"start_date":"2015-05-12","end_date":null,"nol_date":"2014-02-24","protocol_title":"TRANEXAMIC ACID FOR THE TREATMENT OF SIGNIFICANT TRAUMATIC BRAIN INJURY: AN INTERNATIONAL RANDOMISED, DOUBLE BLIND PLACEBO CONTROLLED TRIAL","medConditionList":[{"med_condition_id":437,"med_condition":"TRAUMATIC BRAIN INJURY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44564,"protocol_no":"MA30143","submission_no":"201740","status_id":1,"start_date":"2017-05-04","end_date":null,"nol_date":"2017-01-26","protocol_title":"AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":565,"med_condition":"RELAPSING-REMITTING MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35952,"protocol_no":"CSLCT-HDL-12-77","submission_no":"174048","status_id":2,"start_date":"2015-05-14","end_date":"2016-03-16","nol_date":"2014-05-22","protocol_title":"A PHASE 2B, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF MULTIPLE DOSE ADMINISTRATION OF CSL112 IN SUBJECTS WITH ACUTE MYCARDIAL INFARCTION","medConditionList":[{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29010,"protocol_no":"BEAM 221-2013","submission_no":"170571","status_id":1,"start_date":"2016-02-03","end_date":null,"nol_date":"2014-01-03","protocol_title":"THE BRAIN-EYE AMYLOID MEMORY (BEAM) STUDY: VALADATION OF OCULAR MEASURES AS POTENTIAL BIOMARKERS FOR EARLY DETECTION AMYLOID AND NEURODEGENERATION","medConditionList":[{"med_condition_id":385,"med_condition":"NEURODEGENERATIVE DISEASES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46047,"protocol_no":"GX30191","submission_no":"206189","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-29","protocol_title":"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A RACHE-SPONSORED STUDY","medConditionList":[{"med_condition_id":568,"med_condition":"MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47809,"protocol_no":"PSMA 303","submission_no":"212042","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-09","protocol_title":"THE SAFETY AND EFFICACY OF 68GA-HBED-CC-PSMA (DKFZ-11) PET/CT IN PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35457,"protocol_no":"PRX302-3-01","submission_no":"172443","status_id":3,"start_date":"2014-03-17","end_date":null,"nol_date":"2014-03-20","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, MULTICENTER SAFETY AND EFFICACY STUDY OF A SINGLE INTRAPROSTATIC TREATMENT OF PRX302 FOR LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATE HYPERPLASIA (THE PLUS I TRIAL)","medConditionList":[{"med_condition_id":478,"med_condition":"PROSTATE HYPERPLASIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40031,"protocol_no":"GO29527","submission_no":"186906","status_id":1,"start_date":"2017-04-13","end_date":null,"nol_date":"2015-09-11","protocol_title":"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN BASED CHEMOTHERAPY IN PD-L1-SELECTED PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER,","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45428,"protocol_no":"SPK-8011-101","submission_no":"204393","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-03","protocol_title":"GENE-TRANSFER, OPEN-LABEL, DOSE-ESCALATION STUDY OF SPK-8011 [ADENO-ASSOCIATED VIRAL VECTOR WITH B-DOMAIN DELETED HUMAN FACTOR VIII GENE] IN INDIVIDUALS WITH HEMOPHILIA A","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27463,"protocol_no":"CFI-400945-CL-001","submission_no":"165815","status_id":1,"start_date":"2017-12-27","end_date":null,"nol_date":"2013-07-17","protocol_title":"AN OPEN-LABEL, DOSE-ESCALATION, SAFETY, AND PHARMACOKINETIC STUDY OF CFI-400945 FUMARATE ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48327,"protocol_no":"D419JC00001","submission_no":"213622","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-14","protocol_title":"A PHASE III RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF DURVALUMAB AND BACILLUS CALMETTE-GUERIN (BCG) ADMINISTERED AS COMBINATION THERAPY VERSUS BCG ALONE IN HIGH-RISK, BCG-NA√èVE NON-MUSCLE-INVASIVE-BLADDER CANCER PATIENTS (POTOMAC)","medConditionList":[{"med_condition_id":625,"med_condition":"BLADDER CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48068,"protocol_no":"NN7088-4410","submission_no":"212864","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-05","protocol_title":"SAFETY AND EFFICACY OF TUROCTOCOG ALFA PEGOL (N8-GP) IN PROPHYLAXIS AND TREATMENT OF BLEEDS IN PREVIOUSLY N8-GP TREATED PATIENTS WITH SEVERE HAEMOPHILIA A","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44049,"protocol_no":"PEOPLE","submission_no":"199982","status_id":1,"start_date":"2017-02-28","end_date":null,"nol_date":"2016-11-18","protocol_title":"OPEN-LABEL FOLLOW-UP STUDY OF THE PEPITES STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF VIASKIN PEANUT","medConditionList":[{"med_condition_id":12,"med_condition":"ALLERGIES PEANUT"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35373,"protocol_no":"28431754DNE3001","submission_no":"172143","status_id":1,"start_date":"2014-09-18","end_date":null,"nol_date":"2014-03-13","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, EVENT-DRIVEN, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFECTS OF CANAGLIFLOZIN ON RENAL AND CARDIOVASCULAR OUTCOMES IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY","medConditionList":[{"med_condition_id":65,"med_condition":"DIABETIC NEPHROPATHY"},{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38035,"protocol_no":"AT1001-042","submission_no":"180632","status_id":1,"start_date":"2016-04-15","end_date":null,"nol_date":"2015-01-15","protocol_title":"AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF MIGALASTAT HYDROCHLORIDE MONOTHERAPY IN SUBJECTS WITH FABRY DISEASE","medConditionList":[{"med_condition_id":79,"med_condition":"FABRY DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39126,"protocol_no":"221AD302","submission_no":"184233","status_id":1,"start_date":"2017-03-07","end_date":null,"nol_date":"2015-06-05","protocol_title":"A PHASE MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADUCANUMAB (BIIB037) IN SUBJECTS WITH EARLY ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38208,"protocol_no":"TTP488-301","submission_no":"181266","status_id":1,"start_date":"2016-09-22","end_date":null,"nol_date":"2015-02-10","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43189,"protocol_no":"116811 (HBV-322)","submission_no":"197447","status_id":1,"start_date":"2016-10-17","end_date":null,"nol_date":"2016-09-02","protocol_title":"A PHASE IV, OPEN-LABEL, NON-RANDOMISED, MULTICENTRE STUDY TO ASSESS THE LONG-TERM PERSISTENCE OF IMMUNITY TO HEPATITIS B IN ADULTS VACCINATED 20 TO 30 YEARS AGO WITH 3 OR 4 DOSES OF GSK BIOLOGICALS' HEPATITIS B VACCINE, ENGERIX-B","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48075,"protocol_no":"PS0009","submission_no":"212818","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-15","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (AMENDMENT 2)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42851,"protocol_no":"SPI-GCF-301","submission_no":"196398","status_id":1,"start_date":"2017-07-24","end_date":null,"nol_date":"2016-07-29","protocol_title":"RANDOMIZED TRIAL OF SPI-2012 VERSUS PEGFILGRASTIM IN THE MANAGEMENT OF CHEMOTHERAPY INDUCED NEUTROPENIA IN BREAST CANCER PATIENTS RECEIVING DOCETAXEL AND CYCLOPHOSPHAMIDE (TC) (ADVANCE)","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38984,"protocol_no":"GUILLANI-02 (FLT PET POST SBRT","submission_no":"183796","status_id":1,"start_date":"2015-12-02","end_date":null,"nol_date":"2015-05-14","protocol_title":"\"PILOTING THE FEASIBILITY OF FLT-PET/CT NON-SMALL CELL LUNG CANCER MANAGED WITH SBRT.\"","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39697,"protocol_no":"NRG-BR003","submission_no":"186087","status_id":1,"start_date":"2016-01-27","end_date":null,"nol_date":"2015-08-05","protocol_title":"A RANDOMIZED PHASE III TRIAL OF ADJUVANT THERAPY COMPARING DOXORUBICIN PLUS CYCLOPHOSPHAMIDE FOLLOWED BY WEEKLY PACLITAXEL WITH OR WITHOUT CARBOPLATIN FOR NODE-POSITIVE OR HIGH-RISK NODE-NEGATIVE TRIPLE-NEGATIVE INVASIVE BREAST CANCER","medConditionList":[{"med_condition_id":627,"med_condition":"BREAST CANCER METASTATIC TRIPLE NEGATIVE"},{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40757,"protocol_no":"56021927PCR3003","submission_no":"188987","status_id":1,"start_date":"2016-04-29","end_date":null,"nol_date":"2015-12-03","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF JNJ-56021927 IN SUBJECTS WITH HIGH RISK, LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER RECEIVING TREATMENT WITH PRIMARY RADIATION THERAPY","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40370,"protocol_no":"D4198C00001","submission_no":"187866","status_id":1,"start_date":"2015-11-23","end_date":null,"nol_date":"2015-10-21","protocol_title":"A PHASE II OPEN-LABEL, MULTI-CENTER STUDY OF MEDI4736 EVALUATED AS SINGLE AGENT OR IN COMBINATION WITH TREMELIMUMAB IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA","medConditionList":[{"med_condition_id":650,"med_condition":"METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41475,"protocol_no":"I1F-MC-RHBV","submission_no":"191596","status_id":1,"start_date":"2017-01-25","end_date":null,"nol_date":"2016-02-23","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG-TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB (LY2439821) IN BDMARD-NAIVE PATIENTS WITH  RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS,","medConditionList":[{"med_condition_id":673,"med_condition":"AXIAL SPONDYLARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39121,"protocol_no":"RPC01-3101","submission_no":"184226","status_id":1,"start_date":"2015-07-17","end_date":null,"nol_date":"2015-05-28","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ORAL RPC1063 AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATE TO SEVERE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39524,"protocol_no":"008-00","submission_no":"185618","status_id":1,"start_date":"2016-12-01","end_date":null,"nol_date":"2015-07-17","protocol_title":"A PHASE III, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK-3641, A RAGWEED (AMBROSIA ARTEMISIIFOLIA) SUBLINGUAL IMMUNOTHERAPY TABLET, IN CHILDREN WITH A HISTORY OF RAGWEED-INDUCED RHINOCONJUNCTIVITIS WITH OR WITHOUT ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45098,"protocol_no":"BERLIN-01","submission_no":"203297","status_id":1,"start_date":"2017-12-18","end_date":null,"nol_date":"2017-03-24","protocol_title":"PHASE II STUDY: [18F]DCFPYL PET/MRI FOR PERSONALIZING PROSTATE CANCER SUBCLINICAL METASTATIC ABLATIVE MR-GUIDED RADIOTHERAPY (MRGRT)","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41794,"protocol_no":"CINC424A2353","submission_no":"192709","status_id":2,"start_date":"2016-05-24","end_date":"2018-02-26","nol_date":"2016-03-24","protocol_title":"A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PHASE III STUDY INVESTIGATING THE EFFICACY AND SAFETY OF RUXOLITINIB IN EARLY MYELOFIBROSIS PATIENTS WITH HIGH MOLECULAR RISK MUTATIONS","medConditionList":[{"med_condition_id":353,"med_condition":"MYELOFIBROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38020,"protocol_no":"CC-4047-MM-007","submission_no":"180575","status_id":1,"start_date":"2015-09-09","end_date":null,"nol_date":"2015-01-12","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE (POM), BORTEZOMIB (BTZ) AND LOW-DOSE DEXAMETHASONE (LD-DEX) VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45238,"protocol_no":"NCT02844634","submission_no":"203746","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-20","protocol_title":"USE OF TENOFOVIR/EMTRICITABINE WITH IMMEDIATE OR DEFERRED DOXYCYCLINE 100MG PO DAILY FOR COMBINATION HIV AND SYPHILIS PRE-EXPOSURE PROPHYLAXIS IN HIV-NEGATIVE MEN WHO HAVE SEX WITH MEN: A PILOT STUDY OF DUAL DAILY HIV AND SYPHILIS PREP (THE DUDHS TRIAL).","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39125,"protocol_no":"221AD301","submission_no":"184230","status_id":1,"start_date":"2016-02-18","end_date":null,"nol_date":"2015-06-05","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADUCANUMAB (BIIB037) IN SUBJECTS WITH EARLY ALZHEIMER'S DISEASE.","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37712,"protocol_no":"SP-420-702","submission_no":"179512","status_id":1,"start_date":"2015-04-15","end_date":null,"nol_date":"2014-12-05","protocol_title":"MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF SP 420 IN SUBJECTS WITH TRANSFUSION-DEPENDENT   THALASSEMIA","medConditionList":[{"med_condition_id":535,"med_condition":"TRANSFUSION DEPENDENT THALASSEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44381,"protocol_no":"1000053716","submission_no":"201133","status_id":1,"start_date":"2017-07-14","end_date":null,"nol_date":"2017-01-11","protocol_title":"RANDOMIZED CONTROLLED TRIAL OF OLANZAPINE FOR THE CONTROL OF CHEMOTHERAPY-INDUCED VOMITING IN CHILDREN RECEIVING CYCLOPHOSPHAMIDE-BASED CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT.","medConditionList":[{"med_condition_id":431,"med_condition":"HEMATOPOIETIC STEM CELL TRANSPLANT"},{"med_condition_id":302,"med_condition":"NAUSEA AND VOMITING"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44170,"protocol_no":"I1F-MC-RHBY","submission_no":"200301","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-11-22","protocol_title":"A MULTICENTER, LONG-TERM EXTENSION STUDY OF 104 WEEKS, INCLUDING A DOUBLE-BLIND, PLACEBO-CONTROLLED 40-WEEK RANDOMIZED WITHDRAWAL-RETREATMENT PERIOD, TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB (LY2439821) IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS","medConditionList":[{"med_condition_id":673,"med_condition":"AXIAL SPONDYLARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38785,"protocol_no":"GS29735","submission_no":"183169","status_id":2,"start_date":"2015-08-07","end_date":"2016-10-03","nol_date":"2015-04-29","protocol_title":"\"AN OPEN-LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS.\"","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38441,"protocol_no":"DOM-RRMS-01","submission_no":"182051","status_id":1,"start_date":"2015-08-26","end_date":null,"nol_date":"2015-03-04","protocol_title":"RANDOMIZED, CONTROLLED PILOT TRIAL OF DOMPERIDONE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (MS)","medConditionList":[{"med_condition_id":565,"med_condition":"RELAPSING-REMITTING MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29270,"protocol_no":"EFC12405","submission_no":"171350","status_id":1,"start_date":"2014-02-18","end_date":null,"nol_date":"2014-02-11","protocol_title":"A RANDOMIZED, 30-WEEK, ACTIVE-CONTROLLED, OPEN LABEL, 2-TREATMENT ARM, PARALLEL-GROUP, MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF THE INSULIN GLARGINE/LIXISENATIDE FIXED RATIO COMBINATION IN INSULIN GLARGINE WITH OR WITHOUT METFORMIN IN PATIENTS WITH T2DM","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"},{"med_condition_id":388,"med_condition":"DIABETES"},{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42656,"protocol_no":"ARCAAT2001","submission_no":"195742","status_id":1,"start_date":"2016-08-18","end_date":null,"nol_date":"2016-07-05","protocol_title":"AN OPEN-LABEL, MULTI-DOSE, PHASE 2 STUDY TO DETERMINE THE SAFETY, TOLERABILITY AND EFFECT ON CIRCULATING AND INTRAHEPATIC ALPHA-1 ANTITRYPSIN LEVELS OF ARC-AAT AS EVIDENCED BY CHANGES IN LIVER BIOPSY IN PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)","medConditionList":[{"med_condition_id":828,"med_condition":"ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39270,"protocol_no":"150998-006","submission_no":"184669","status_id":1,"start_date":"2016-03-09","end_date":null,"nol_date":"2015-06-29","protocol_title":"\"SAFETY AND EFFICACY OF ABICIPAR PEGOL (AGN-150998) IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.","medConditionList":[{"med_condition_id":288,"med_condition":"NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38820,"protocol_no":"MO29518","submission_no":"183287","status_id":1,"start_date":"2016-01-21","end_date":null,"nol_date":"2015-05-07","protocol_title":"\"AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF MPDL3280A IN ADVANCED SOLID TUMORS.\"","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43228,"protocol_no":"CNTO1959PSO3006","submission_no":"197531","status_id":1,"start_date":"2017-03-06","end_date":null,"nol_date":"2016-09-09","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF CNTO1959 (GUSELKUMAB) DELIVERED VIA A SELFDOSE DEVICE IN THE TREATMENT OF SUBJECTS WITH MODERATE TO SEVERE PLAQUE-TYPE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28815,"protocol_no":"H8A-MC-LZAZ/ ADC-040-A4","submission_no":"169930","status_id":1,"start_date":"2014-11-20","end_date":null,"nol_date":"2013-12-12","protocol_title":"ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER'S DISEASE (A4 STUDY)","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42526,"protocol_no":"TTI-621-01","submission_no":"195262","status_id":1,"start_date":"2017-05-10","end_date":null,"nol_date":"2016-06-17","protocol_title":"A PHASE 1A/1B DOSE ESCALATION AND EXPANSION TRIAL OF SINGLE-AGENT TTI-621, A NOVEL BIOLOGIC TARGETING CD47, IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45915,"protocol_no":"415-2016","submission_no":"205829","status_id":1,"start_date":"2017-11-15","end_date":null,"nol_date":"2017-06-19","protocol_title":"A PILOT STUDY OF AVELUMAB IN UNRESECTABLE/METASTATIC, PROGRESSIVE, POORLY DIFFERENTIATED GRADE 3 NEUROENDOCRINE CARCINOMAS","medConditionList":[{"med_condition_id":633,"med_condition":"NEUROENDOCRINE TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41490,"protocol_no":"LA52-0215","submission_no":"191640","status_id":1,"start_date":"2016-11-28","end_date":null,"nol_date":"2016-02-23","protocol_title":"EFFICACY AND SAFETY OF DEFERIPRONE IN TREATMENT-NA√èVE AND NON-TREATMENT-NA√èVE PATIENTS WITH PARKINSON¬øS DISEASE.","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26538,"protocol_no":"COG ANBL1221","submission_no":"163060","status_id":1,"start_date":"2014-06-03","end_date":null,"nol_date":"2013-04-05","protocol_title":"\"A PHASE II RANDOMIZED TRIAL OF IRINOTECAN / TEMOZOLOMIDE WITH TEMSIROLIMUS (NSC# 683864, IND# 61010) OR CHIMERIC 14.18 ANTIBODY (CH1.18)(NSC# 623408, IND# 4308) IN CHILDREN WITH REFRACTORY, RELAPSED OR PROGRESSIVE NEURBLASTOMA.\"","medConditionList":[{"med_condition_id":172,"med_condition":"NEUROBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38721,"protocol_no":"LP0105-1032","submission_no":"182965","status_id":1,"start_date":"2015-04-01","end_date":null,"nol_date":"2015-04-09","protocol_title":"EFFICACY AND SAFETY OF INGENOL MEBUTATE GEL IN FIELD TREATMENT OF ACTINIC KERATOSIS ON FULL FACE, BALDING SCALP OR APPROXIMATELY 250 CM2 ON THE CHEST","medConditionList":[{"med_condition_id":520,"med_condition":"ACTINIC KERATOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39492,"protocol_no":"M14-483","submission_no":"181138","status_id":2,"start_date":"2016-03-29","end_date":"2017-01-19","nol_date":"2015-02-06","protocol_title":"ABT 414 ALONE OR ABT 414 PLUS TEMOZOLOMIDE VERSUS LOMUSTINE OR TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA: A RANDOMIZED PHASE II STUDY OF THE EORTC BRAIN TUMOR GROUP","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26945,"protocol_no":"D1693C00001","submission_no":"164297","status_id":1,"start_date":"2014-01-29","end_date":null,"nol_date":"2013-05-21","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN 10 MG ONCE DAILY ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37076,"protocol_no":"042","submission_no":"177432","status_id":1,"start_date":"2016-04-08","end_date":null,"nol_date":"2014-09-19","protocol_title":"A RANDOMIZED, OPEN LABEL, PHASE III STUDY OF OVERALL SURVIVAL COMPARING PEMBROLIZUMAB (MK-3475) VERSUS PLATINUM BASED CHEMOTHERAPY IN TREATMENT NAIVE SUBJECTS WITH PD-L1 POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (KEYNOTE 042)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43901,"protocol_no":"PBI-4050-CT-9-08","submission_no":"199522","status_id":1,"start_date":"2017-06-05","end_date":null,"nol_date":"2016-11-10","protocol_title":"A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PBI-4050 IN TYPE 2 DIABETES MELLITUS PATIENTS WITH METABOLIC SYNDROME (PBI-4050-CT-9-08)","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":306,"med_condition":"METABOLIC SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43117,"protocol_no":"EMR 100070-006","submission_no":"197169","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-08-26","protocol_title":"A PHASE III MULTICENTER STUDY OF AVELUMAB (MSB0010718C) VERSUS CHEMOTHERAPY IN SYSTEMIC CHEMOTHERAPY TREATMENT NAIVE PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA","medConditionList":[{"med_condition_id":721,"med_condition":"MERKEL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37840,"protocol_no":"GO29294","submission_no":"179846","status_id":1,"start_date":"2015-02-09","end_date":null,"nol_date":"2014-12-17","protocol_title":"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM CONTAINING CHEMOTHERAPY","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37912,"protocol_no":"CC-10004-UC-001","submission_no":"180066","status_id":1,"start_date":"2016-08-23","end_date":null,"nol_date":"2014-12-23","protocol_title":"A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45127,"protocol_no":"PJC-023 / NCI 10014","submission_no":"203373","status_id":1,"start_date":"2017-09-11","end_date":null,"nol_date":"2017-03-30","protocol_title":"A PILOT STUDY OF ATEZOLIZUMAB (MPDL3280A) FOLLOWING ADOPTIVE CELL TRANSFER IN ACTIVE HEMATOLOGIC OR SOLID TUMOR MALIGNANCIES","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"},{"med_condition_id":293,"med_condition":"MALIGNANT SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37157,"protocol_no":"ITN059AI","submission_no":"177470","status_id":1,"start_date":"2015-03-31","end_date":null,"nol_date":"2014-09-23","protocol_title":"EFFICACY OF USTEKINUMAB (ANTI-IL-12/23) FOLLOWED BY ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF PSORIASIS VULGARIS","medConditionList":[{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43544,"protocol_no":"MS700149_0002","submission_no":"198416","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-10-07","protocol_title":"A PROOF-OF-CONCEPT STUDY TO ASSESS THE EFFECT OF RECOMBINANT HUMAN GROWTH HORMONE ON THE SIZE OF THE REPLICATION-COMPETENT VIRAL RESERVOIR IN HIV-INFECTED INDIVIDUALS ON SUPPRESSIVE ANTIRETROVIRAL THERAPY","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36901,"protocol_no":"CO-1686-019","submission_no":"176910","status_id":2,"start_date":"2014-10-06","end_date":"2017-09-11","nol_date":"2014-08-25","protocol_title":"TIGER-2: A PHASE 2, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY OF ORAL CO-1686 AS 2ND LINE EGFR-DIRECTED TKI IN PATIENTS WITH MUTANT EGFR NON-SMALL CELL LUNG CANCER (NSCLC) WITH THE T790M RESISTANCE MUTATION.","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45155,"protocol_no":"ANAE-305-16","submission_no":"203364","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-12","protocol_title":"PAIN IMPROVEMENT WITH NOVEL COMBINATION ANALGESIC REGIMENS: THE PAIN-CARE TRIAL","medConditionList":[{"med_condition_id":174,"med_condition":"NEUROPATHIC PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41979,"protocol_no":"RD.03.SPR.109807","submission_no":"193495","status_id":2,"start_date":"2016-05-16","end_date":"2016-11-02","nol_date":"2016-04-20","protocol_title":"EFFICACY AND SAFETY OF CD5024 1% IN ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45081,"protocol_no":"TO-TAS-102-302","submission_no":"203258","status_id":1,"start_date":"2017-05-01","end_date":null,"nol_date":"2017-03-29","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC GASTRIC CANCER REFRACTORY TO STANDARD TREATMENTS","medConditionList":[{"med_condition_id":337,"med_condition":"GASTRIC CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38978,"protocol_no":"MOBILITY-001","submission_no":"183778","status_id":1,"start_date":"2015-08-24","end_date":null,"nol_date":"2015-05-15","protocol_title":"MOLECULAR BASKET TRIAL IN MULTIPLE MALIGNANCIES WITH COMMON TARGET PATHWAY ABERRANCIES","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39496,"protocol_no":"A14-11-2181","submission_no":"185540","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-06-19","protocol_title":"PHASE II PERSONALIZED RADIOACTIVE THERAPY FOR NEUROENDOCRINE TUMORS.","medConditionList":[{"med_condition_id":633,"med_condition":"NEUROENDOCRINE TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37002,"protocol_no":"GO29313","submission_no":"177207","status_id":2,"start_date":"2014-11-05","end_date":"2017-11-30","nol_date":"2014-09-11","protocol_title":"A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMAOKINETICS OF MOXR0916 ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39869,"protocol_no":"ALDNS2-203-D1 (15-MO-001)","submission_no":"186490","status_id":1,"start_date":"2015-08-28","end_date":null,"nol_date":"2015-08-24","protocol_title":"A RANDOMIZED, PARALLEL, SINGLE-CENTER, DOUBLE-MASKED, VEHICLE-CONTROLLED PHASE II STUDY TO EVALUATE THE ACTIVITY OF NS2 OPHTHALMIC SOLUTION IN SUBJECTS WITH ALLERGIC CONJUNCTIVITIS USING THE CONJUNCTIVAL ALLERGEN PROVOCATION TEST (CAPT)","medConditionList":[{"med_condition_id":631,"med_condition":"ALLERGIC CONJUNCTIVITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42518,"protocol_no":"PCS IX","submission_no":"195253","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-17","protocol_title":"THE ROLE OF STEREOTACTIC BODY RADIOTHERAPY IN THE MANAGEMENT OF CASTRATION-RESISTANT PROSTATE CANCER WITH OLIGOMETASTASES: AN ADAPTIVE PHASE II/III RANDOMIZED TRIAL","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45985,"protocol_no":"AGCT1531","submission_no":"206000","status_id":1,"start_date":"2017-08-09","end_date":null,"nol_date":"2017-06-06","protocol_title":"A PHASE 3 STUDY OF ACTIVE SURVEILLANCE FOR LOW RISK AND A RANDOMIZED TRIAL OF CARBOPLATIN VS. CISPLATIN FOR STANDARD RISK PEDIATRIC AND ADULT PATIENTS WITH GERM CELL TUMOURS","medConditionList":[{"med_condition_id":735,"med_condition":"GERM CELL TUMOUR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38327,"protocol_no":"D4711C00001","submission_no":"181672","status_id":2,"start_date":"2014-06-02","end_date":"2015-11-25","nol_date":"2015-02-25","protocol_title":"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, MULTI-CENTRE, PHASE III, SINGLE DOSE, 4-WAY CROSS-OVER PHARMACODYNAMIC STUDY EVALUATING THE EFFICACY OF BRICANYL TURBUHALER M3 COMPARED TO BRICANYL TURBUHALER M2 BY STUDYING THE PROTECTIVE EFFECT ON METHACHOLINE INDUCED BRONCHOCONSTRICTION IN PATIENTS WITH STABLE, MILD TO MODERATE ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27011,"protocol_no":"13-5845","submission_no":"164474","status_id":1,"start_date":"2013-07-29","end_date":null,"nol_date":"2013-05-27","protocol_title":"USE OF VOLATILE ANESTHETICS FOR LONG-TERM SEDATION IN CRITICALLY ILL PATIENTS","medConditionList":[{"med_condition_id":340,"med_condition":"SEDATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35972,"protocol_no":"CACZ885N2301","submission_no":"174082","status_id":1,"start_date":"2015-01-06","end_date":null,"nol_date":"2014-05-23","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF CANAKINUMAB IN PATIENTS WITH HEREDITARY PERIODIC FEVERS (TRAPS, HIDS, OR CRFMF), WITH SUBSEQUENT RANDOMIZED WITHDRAWAL/DOSING FREQUENCY REDUCTION AND OPEN-LABEL LONG TERM TREATMENT EPOCHS","medConditionList":[{"med_condition_id":539,"med_condition":"HEREDITARY PERIODIC FEVERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38204,"protocol_no":"GED-0301-CD-001","submission_no":"181251","status_id":1,"start_date":"2015-06-16","end_date":null,"nol_date":"2015-02-10","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PHARMACODYNAMIC EFFECTS OF GED-0301 FOR THE TREATMENT OF SUBJECTS WITH ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37506,"protocol_no":"LTS13840","submission_no":"178827","status_id":1,"start_date":"2015-03-03","end_date":null,"nol_date":"2014-11-13","protocol_title":"A LONG-TERM FOLLOW-UP STUDY ASSESSING THE SAFETY AND EFFICACY OF VATELIZUMAB IN MULTIPLE SCLEROSIS (MS) PATIENTS WHO COMPLETED TREATMENTS IN STUDY DRI13839","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38759,"protocol_no":"17119","submission_no":"183070","status_id":2,"start_date":"2016-04-14","end_date":"2018-02-28","nol_date":"2015-05-28","protocol_title":"AN OPEN-LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TO EVALUATE EFFICACY AND SAFETY OF TREATMENT WITH SINGLE AGENT COPANLISIB AND THE IMPACT OF BIOMARKERS THEREUPON.","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28878,"protocol_no":"023","submission_no":"170158","status_id":1,"start_date":"2017-08-14","end_date":null,"nol_date":"2013-12-19","protocol_title":"A PHASE I TRIAL OF MK-3475 IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN SUBJECTS WITH MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29301,"protocol_no":"028","submission_no":"171419","status_id":1,"start_date":"2017-10-05","end_date":null,"nol_date":"2014-02-10","protocol_title":"PHASE 1B STUDY OF MK-3475 IN SUBJECTS WITH SELECT ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28365,"protocol_no":"010-00","submission_no":"168341","status_id":1,"start_date":"2015-07-16","end_date":null,"nol_date":"2013-10-17","protocol_title":"A PHASE III CLINICAL TRIAL TO STUDY THE TOLERABILITY AND IMMUNOGENICITY OF A 2-DOSE REGIMEN OF V503, A MULTIVALENT HUMAN PAPILLOMAVIRUS (HPV) L1 VIRUS-LIKE PARTICLE (VLP) VACCINE, ADMINISTERED IN PREADOLESCENTS AND ADOLESCENTS (9 TO 14 YEAR OLDS) WITH A COMPARISON TO YOUNG WOMEN (16 TO 24 YEAR OLDS)","medConditionList":[{"med_condition_id":119,"med_condition":"HUMAN PAPILLOMA VIRUS (HPV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45918,"protocol_no":"PEMRAD","submission_no":"205834","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-21","protocol_title":"PEMBROLIZUMAB AND STEREOTACTIC RADIOTHERAPY COMBINED IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA - A PHASE II STUDY (PEMRAD)","medConditionList":[{"med_condition_id":519,"med_condition":"ADVANCED HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36089,"protocol_no":"N/A","submission_no":"174460","status_id":1,"start_date":"2014-09-26","end_date":null,"nol_date":"2014-06-02","protocol_title":"ASSESSMENT OF CRPC RESPONSE THROUGH COMPREHENSIVE CHARACTERIZATION USING NOVEL BIOMARKERS (PET CRPC)","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36200,"protocol_no":"PHL-093 / NCI 9568","submission_no":"174782","status_id":1,"start_date":"2014-09-09","end_date":null,"nol_date":"2014-06-12","protocol_title":"A RANDOMIZED PLACEBO-CONTROLLED PHASE II TRIAL COMPARING GEMCITABINE MONOTHERAPY TO GEMCITABINE IN COMBINATION WITH AZD 1775 (MK 1775) IN WOMEN WITH RECURRENT, PLATINUM RESISTANT EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCERS","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":197,"med_condition":"PLATINUM-RESISTANT OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28434,"protocol_no":"M13-674","submission_no":"168549","status_id":2,"start_date":"2014-04-17","end_date":"2016-08-02","nol_date":"2013-10-24","protocol_title":"A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ADALIMUMAB FOR TREATMENT OF NAIL PSORIASIS IN SUBJECTS WITH CHRONIC PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26646,"protocol_no":"TH-CR-413","submission_no":"163354","status_id":1,"start_date":"2013-08-09","end_date":null,"nol_date":"2013-04-19","protocol_title":"A PHASE 2 BIOMARKER-ENRICHED STUDY OF TH-302 IN SUBJECTS WITH ADVANCED MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38717,"protocol_no":"PLX108-10","submission_no":"182932","status_id":1,"start_date":"2015-11-24","end_date":null,"nol_date":"2015-04-14","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF ORALLY ADMINISTERED PLX3397 IN SUBJECTS WITH PIGMENTED VILLONODULAR SYNOVITIS OR GIANT CELL TUMOR OF THE TENDON SHEATH","medConditionList":[{"med_condition_id":672,"med_condition":"PIGMENTED VILLONODULAR SYNOVITIS OR GIANT CELL TUMOR OF THE TENDON SHEATH"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38771,"protocol_no":"ACT14205","submission_no":"183122","status_id":2,"start_date":"2015-09-11","end_date":"2015-12-02","nol_date":"2015-04-17","protocol_title":"PHASE II, OPEN LABEL, SINGLE ARM STUDY ASSESSING THE CLINICAL BENEFIT OF SAR125844, ADMINISTERED AS SINGLE AGENT BY WEEKLY INTRAVENOUS (IV) INFUSION, FOR THE TREATMENT OF PATIENTS WITH ADVANCED PRETREATED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET GENE AMPLIFICATION","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41095,"protocol_no":"UHN: 15-8723 ITA: 235748","submission_no":"190277","status_id":1,"start_date":"2016-03-07","end_date":null,"nol_date":"2016-02-02","protocol_title":"DETECTION AND LOCALIZATION OF CARCINOMA USING HIGH RESOLUTION TRANSRECTAL GAMMA IMAGING (TRGI)","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26563,"protocol_no":"ACPM-SI-1009","submission_no":"163120","status_id":1,"start_date":"2013-09-10","end_date":null,"nol_date":"2013-04-10","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AC105 IN PATIENTS WITH ACUTE SPINAL CORD INJURY","medConditionList":[{"med_condition_id":238,"med_condition":"SPINAL CORD LESION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27831,"protocol_no":"B2013:075","submission_no":"166825","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-09","protocol_title":"EFFECTS OF COLESEVELAM AS AN ADJUNCT THERAPY FOR SITOSTEROLEMIA","medConditionList":[{"med_condition_id":357,"med_condition":"SITOSTEROLEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27446,"protocol_no":"12-0257-C","submission_no":"165778","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-07-09","protocol_title":"TITLE: ACCURACY OF SENTINEL LYMPH NODE BIOPSY AND GADOFOSVESET-ENHANCED MR IN NODAL STAGING OF HIGH RISK ENDOMETRIAL CANCER: A PROSPECTIVE TRIAL","medConditionList":[{"med_condition_id":73,"med_condition":"ENDOMETRIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27418,"protocol_no":"115415 (FLU Q-PAN H7N1= AS03-0","submission_no":"165684","status_id":1,"start_date":"2013-08-13","end_date":null,"nol_date":"2013-07-11","protocol_title":"A SINGLE-BLIND STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS' INFLUENZA VACCINE(S) GSK2789869A AND GSK2789868A ADMINISTERED IN ADULTS 21 TO 64 YEARS OF AGE","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37874,"protocol_no":"063-006","submission_no":"179940","status_id":2,"start_date":"2015-03-10","end_date":"2015-04-26","nol_date":"2014-12-19","protocol_title":"A RANDOMIZED, 2-WAY CROSSOVER, PHARMACOKINETIC STUDY OF PRC-063 CAPSULES AND IMMEDIATE RELEASE TABLETS IN MALE OR FEMALE ADOLESCENTS 12 TO 17 YEARS OF AGE WITH ADHD","medConditionList":[{"med_condition_id":9,"med_condition":"ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28706,"protocol_no":"28431754DIA4003","submission_no":"169495","status_id":2,"start_date":"2014-02-18","end_date":"2017-06-05","nol_date":"2013-11-29","protocol_title":"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF CANAGLIFLOZIN ON RENAL ENDPOINTS IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40154,"protocol_no":"JU-001","submission_no":"187237","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-09-22","protocol_title":"INFLUENZA VACCINE TO EFFECTIVELY STOP CARDIO THORACIC EVENTS AND DECOMPENSATED HEART FAILURE (INVESTED)","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39856,"protocol_no":"NRG-CC001","submission_no":"186360","status_id":1,"start_date":"2016-05-02","end_date":null,"nol_date":"2015-08-07","protocol_title":"A RANDOMIZED, PHASE III TRIAL OF MEMANTINE AND WHOLE-BRAIN RADIOTHERAPY WITH OR WITHOUT HIPPOCAMPAL AVOIDANCE IN PATIENTS WITH BRAIN METASTASES","medConditionList":[{"med_condition_id":27,"med_condition":"BRAIN METASTASES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47966,"protocol_no":"AUR-VCS-2016-02","submission_no":"212577","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-01","protocol_title":"A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, CONTINUATION STUDY COMPARING THE LONG-TERM SAFETY AND EFFICACY OF ORELVO (VOCLOSPORIN) (23.7 MG TWICE DAILY) WITH PLACEBO IN SUBJECTS WITH LUPUS NEPHRITIS.","medConditionList":[{"med_condition_id":681,"med_condition":"LUPUS NEPHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35780,"protocol_no":"47055","submission_no":"173448","status_id":1,"start_date":null,"end_date":null,"nol_date":"2014-04-25","protocol_title":"A PROSPECTIVE, OPEN LABEL, SINGLE CENTER TRIAL OF FECAL MICROBIOTA TRANSPLANTATION (FMT) IN THE MANAGEMENT OF ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37201,"protocol_no":"DEC-GEN 001","submission_no":"177835","status_id":2,"start_date":"2015-02-04","end_date":"2017-10-24","nol_date":"2014-11-13","protocol_title":"A PHASE 1/IIA STUDY OF DECITABINE IN COMBINATION WITH GENISTEIN IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS AND LEUKEMIA","medConditionList":[{"med_condition_id":308,"med_condition":"LEUKEMIA"},{"med_condition_id":507,"med_condition":"RELAPSED OR REFRACTORY SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40932,"protocol_no":"20150154","submission_no":"189724","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-18","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF AMG 282 IN ADULT SUBJECTS WITH UNCONTROLLED SEVERE ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28283,"protocol_no":"GS-US-337-0124","submission_no":"168152","status_id":1,"start_date":"2014-01-24","end_date":null,"nol_date":"2013-10-09","protocol_title":"A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR/LEDIPASVIR FIXED-DOSE COMBINATION + RIBAVIRIN ADMINISTERED IN SUBJECTS INFECTED WITH CHRONIC HCV WHO HAVE ADVANCED LIVER DISEASE OR ARE POST-LIVER TRANSPLANT","medConditionList":[{"med_condition_id":105,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1 OR 4"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43351,"protocol_no":"CTX-4430-CF-201","submission_no":"197872","status_id":1,"start_date":"2016-10-12","end_date":null,"nol_date":"2016-10-06","protocol_title":"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CTX-4430 ADMINISTERED ORALLY ONCE-DAILY FOR 48 WEEKS IN ADULT PATIENTS WITH CYSTIC FIBROSIS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47933,"protocol_no":"Z7224L02","submission_no":"212474","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-31","protocol_title":"A DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER, CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF 12 MONTHS OF THERAPY WITH INHALED PROMIXIN¬Æ (COLISTIMETHATE SODIUM) IN THE TREATMENT OF SUBJECTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA (P. AERUGINOSA)","medConditionList":[{"med_condition_id":497,"med_condition":"NON-CYSTIC FIBROSIS BRONCHIECTASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28569,"protocol_no":"CAMHPET-CTA-76","submission_no":"169016","status_id":3,"start_date":"2013-12-01","end_date":null,"nol_date":"2013-11-15","protocol_title":"IMAGING NEUROINFLAMMATION IN ALZHEIMER DISEASE WITH MODERATE WHITE MATTER DISEASE: AN [18F]-FEPPA PET/MRI STUDY","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38735,"protocol_no":"AI468048","submission_no":"183008","status_id":2,"start_date":"2015-08-13","end_date":"2017-07-07","nol_date":"2015-04-15","protocol_title":"A PHASE 2B RANDOMIZED, ACTIVE-CONTROLLED, STAGED, OPEN-LABEL TRIAL TO INVESTIGATE SAFETY AND EFFICACY OF BMS-955176 IN COMBINATION WITH DOLUTEGRAVIR AND ATAZANAVIR (WITH OR WITHOUT RITONAVIR) IN TREATMENT-EXPERIENCED HIV-1 INFECTED ADULTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36501,"protocol_no":"RPC02-201","submission_no":"175618","status_id":1,"start_date":"2014-08-26","end_date":null,"nol_date":"2014-07-16","protocol_title":"A PHASE 2, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RPC4046 IN ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS","medConditionList":[{"med_condition_id":550,"med_condition":"EOSINOPHILIC ESOPHAGITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36671,"protocol_no":"I3Y-MC-JPBK","submission_no":"176211","status_id":1,"start_date":"2015-11-13","end_date":null,"nol_date":"2014-07-31","protocol_title":"A RANDOMIZED PHASE 3 STUDY OF LY2835219 PLUS BEST SUPPORTIVE CARE VERSUS ERLOTINIB PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH STAGE IV NSCLC WITH A DETECTABLE KRAS MUTATION WHO HAVE PROGRESSED AFTER PLATINUM BASED CHEMOTHERAPY","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36104,"protocol_no":"I3Y-MC-JPBL","submission_no":"174508","status_id":1,"start_date":"2014-10-06","end_date":null,"nol_date":"2014-06-11","protocol_title":"MONARCH 2: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FULVESTRANT WITH OR WITHOUT LY2835219, A CDK4/6 INHIBITOR, FOR WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER.","medConditionList":[{"med_condition_id":527,"med_condition":"BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28220,"protocol_no":"200285","submission_no":"167975","status_id":2,"start_date":"2013-10-15","end_date":"2014-02-04","nol_date":"2013-10-04","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, 3 WAY CROSS OVER STUDY IN SUBJECTS WITH ALLERGIC RHINITIS TO ASSESS THE EFFECT OF INTRANASAL REPEAT DOSES OF LEVOCABASTINE WHEN ADMINISTERED ONCE DAILY OR TWICE DAILY ON THE SYMPTOMS OF RHINITIS IN AN ALLERGEN CHALLENGE CHAMBER","medConditionList":[{"med_condition_id":475,"med_condition":"RHINITIS"},{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28723,"protocol_no":"225678-006","submission_no":"169542","status_id":2,"start_date":"2014-09-10","end_date":"2015-03-24","nol_date":"2013-11-28","protocol_title":"A SAFETY AND EFFICACY STUDY TO COMPARE DAPSONE DERMAL GEL WITH VEHICLE CONTROL IN PATIENTS WITH ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27282,"protocol_no":"200190 (FLU Q-TIV-015)","submission_no":"165284","status_id":1,"start_date":"2013-07-04","end_date":null,"nol_date":"2013-06-26","protocol_title":"IMMUNOGENICITY AND SAFETY STUDY OF GSK BIOLOGICALS' TRIVALENT SPLIT VIRION INFLUENZA VACCINE (GSK1536489A) FLUVIRAL (2013-2014 SEASON) IN ADULTS AGED 18 YEARS AND OLDER.","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39450,"protocol_no":"SB-2-004-005","submission_no":"185312","status_id":1,"start_date":"2015-12-03","end_date":null,"nol_date":"2015-07-10","protocol_title":"A PHASE 2B, PARALLEL-GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF SYN-004 COMPARED TO PLACEBO FOR THE PREVENTION OF CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA IN PATIENTS WITH A DIAGNOSIS OF LOWER RESPIRATORY TRACT INFECTION","medConditionList":[{"med_condition_id":635,"med_condition":"LOWER RESPIRATORY TRACT INFECTION"},{"med_condition_id":531,"med_condition":"CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHOEA (CDAD)"},{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44402,"protocol_no":"261203","submission_no":"201168","status_id":1,"start_date":"2017-09-18","end_date":null,"nol_date":"2017-01-12","protocol_title":"PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII (BAX 855) IN PREVIOUSLY UNTREATED PATIENTS (PUPS) <6 YEARS WITH SEVERE HEMOPHILIA A (FVIII < 1%)","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42923,"protocol_no":"2401BT-002P","submission_no":"196659","status_id":1,"start_date":"2016-12-14","end_date":null,"nol_date":"2016-08-08","protocol_title":"A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF A CONDITIONALLY REPLICATIVE ADENOVIRUS (DNX-2401) WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA OR GLIOSARCOMA (CAPTIVE)","medConditionList":[{"med_condition_id":713,"med_condition":"GLIOSARCOMA"},{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28212,"protocol_no":"1000039945C","submission_no":"167935","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-06","protocol_title":"FAST (FETAL ATRIAL FLUTTER & SUPRAVENTRICULAR TACHYCARDIA) THERAPY TRIAL - SUBSTUDY C","medConditionList":[{"med_condition_id":418,"med_condition":"SUPRAVENTRICULAR TACHYARRHYTHMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46097,"protocol_no":"CA209-914","submission_no":"206382","status_id":1,"start_date":"2017-10-17","end_date":null,"nol_date":"2017-07-07","protocol_title":"A PHASE 3 RANDOMIZED STUDY COMPARING NIVOLUMAB AND IPILIMUMAB COMBINATION VS PLACEBO IN PARTICIPANTS WITH LOCALIZED RENAL CELL CARCINOMA WHO UNDERWENT RADICAL OR PARTIAL NEPHRECTOMY AND WHO ARE AT HIGH RISK OF RELAPSE","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36973,"protocol_no":"PCS VII","submission_no":"177119","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-09-09","protocol_title":"PROPHYLACTIC VERSUS THERAPEUTIC ALPHA-BLOCKERS IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL COURSE RADIATION THERAPY ¬± HDR BOOST. A GROUQ PHASE III RANDOMIZED CLINICAL TRIAL","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47196,"protocol_no":"SHP647-304","submission_no":"209529","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-24","protocol_title":"A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE UICERATIVE COLITIS (AIDA)","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47665,"protocol_no":"I8H-MC-BDCB","submission_no":"211515","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-19","protocol_title":"SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3209590 FOLLOWING MULTIPLE WEEKLY DOSES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27218,"protocol_no":"5945-OIC-12-03","submission_no":"165167","status_id":1,"start_date":"2013-08-07","end_date":null,"nol_date":"2013-06-21","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CB-5945 FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN ADULTS TAKING OPIOID THERAPY FOR CHRONIC NON-CANCER PAIN","medConditionList":[{"med_condition_id":276,"med_condition":"OPIOID-INDUCED CONSTIPATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45591,"protocol_no":"M15-991","submission_no":"203525","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-19","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY TO ASSESS THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO FAILED PRIOR BIOLOGIC TREATMENT","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28659,"protocol_no":"1200.48","submission_no":"169336","status_id":2,"start_date":"2015-01-06","end_date":"2016-06-15","nol_date":"2013-11-21","protocol_title":"AN OPEN LABEL TRIAL OF AFATINIB IN TREATMENT-NAIVE OR CHEMOTHERAPY PRETREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EGFR MUTATION(S)","medConditionList":[{"med_condition_id":92,"med_condition":"GLIOMA MALIGNANT"},{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37762,"protocol_no":"ISIS 304801-CS16","submission_no":"179664","status_id":2,"start_date":"2016-01-23","end_date":"2017-01-11","nol_date":"2014-12-12","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ISIS 304801 ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HYPERTRIGLYCERIDEMIA","medConditionList":[{"med_condition_id":349,"med_condition":"HYPERTRIGLYCERIDEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44138,"protocol_no":"CA018-003","submission_no":"200223","status_id":1,"start_date":"2017-06-28","end_date":null,"nol_date":"2016-12-06","protocol_title":"A PHASE 2, FAST REAL-TIME ASSESSMENT OF COMBINATION THERAPIES IN IMMUNO-ONCOLOGY STUDY IN PARTICIPANTS WITH ADVANCED GASTRIC CANCER (FRACTION-GASTRIC CANCER)","medConditionList":[{"med_condition_id":337,"med_condition":"GASTRIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42446,"protocol_no":"204653","submission_no":"194989","status_id":1,"start_date":"2017-11-16","end_date":null,"nol_date":"2016-06-24","protocol_title":"A PHASE I, OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF GSK3326595 IN SUBJECTS WITH SOLID TUMORS AND NON- HODGKIN'S LYMPHOMA","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39239,"protocol_no":"EER001","submission_no":"184576","status_id":1,"start_date":"2016-11-10","end_date":null,"nol_date":"2015-05-29","protocol_title":"TWO WEEK ESTRADIOL EXPOSURE IN POSTMENOPAUSAL WOMEN WITH NEWLY DIAGNOSED ER POSITIVE BREAST CANCER - PRIOR TO SURGERY: WINDOW OF OPPORTUNITY STUDY","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28619,"protocol_no":"CCI-AMANIE-02","submission_no":"169188","status_id":3,"start_date":"2014-03-13","end_date":null,"nol_date":"2013-11-20","protocol_title":"A PROSPECTIVE SINGLE-ARM PHASE I/II STUDY USING 11C-CHOLINE PET SCANS FOR DOSE ESCALATED HYPOFRACTIONATED IMAGE GUIDED INVERSELY PLANNED INTENSITY MODULATED EXTERNAL BEAM RADIOTHERAPY WITH BOOST TO PET DEFINE DOMINANT INTRAPROSTATIC LESIONS AND AS A PREDICTIVE FACTOR FOR BIOCHEMICAL DISEASE-FREE SURVIVAL IN PATIENTS WITH LOCALIZED PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44299,"protocol_no":"CR-AIR-009","submission_no":"200672","status_id":1,"start_date":"2017-06-01","end_date":null,"nol_date":"2017-01-06","protocol_title":"A PHASE III, RANDOMIZED CONTROLLED STUDY TO COMPARE SAFETY AND EFFICACY OF A HAPLOIDENTICAL HSCT AND ADJUNCTIVE TREATMENT WITH ATIR101 VERSUS A HAPLOIDENTICAL HSCT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH HEMATOLOGIC MALIGNANCY","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44435,"protocol_no":"CARE-E-01","submission_no":"201271","status_id":1,"start_date":"2017-09-13","end_date":null,"nol_date":"2017-01-12","protocol_title":"CANNABIDIOL IN CHILDREN WITH REFRACTORY EPILEPTIC ENCEPHALOPATHY: A PHASE 1 OPEN LABEL DOSE ESCALATION STUDY","medConditionList":[{"med_condition_id":823,"med_condition":"REFRACTORY EPILEPTIC ENCEPHALOPATHY"},{"med_condition_id":825,"med_condition":"DRAVET SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47737,"protocol_no":"R1500-CL-1719","submission_no":"211689","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-29","protocol_title":"AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTERLEMIA","medConditionList":[{"med_condition_id":116,"med_condition":"HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28543,"protocol_no":"INOXT-10-2013","submission_no":"168920","status_id":1,"start_date":"2015-02-10","end_date":null,"nol_date":"2013-11-07","protocol_title":"INTRANASAL OXYTOCIN FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS (ASD) [INOXT STUDY]","medConditionList":[{"med_condition_id":351,"med_condition":"AUTISM SPECTRUM DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41157,"protocol_no":"D4190C00006","submission_no":"190503","status_id":1,"start_date":"2016-08-25","end_date":null,"nol_date":"2016-01-12","protocol_title":"PHASE 1B OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MEDI4736 IN COMBINATION WITH TREMELIMUMAB IN SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40366,"protocol_no":"16275","submission_no":"187842","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-10-19","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FINERENONE COMPARED TO EPLERENONE ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED EJECTION FRACTION AFTER RECENT HEART FAILURE DECOMPENSATION AND ADDITIONAL RISK FACTORS, EITHER TYPE 2 DIABETES MELLITUS OR CHRONIC KIDNEY DISEASE OR BOTH.","medConditionList":[{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"},{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"},{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28886,"protocol_no":"7487-CL-0209","submission_no":"170178","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-16","protocol_title":"A PHASE II OPEN-LABEL ROLLOVER STUDY FOR SUBJECTS THAT HAVE PARTICIPATED IN AN ASTELLAS SPONSORED LINSITINIB TRIAL","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48543,"protocol_no":"IFX-1-P2.4","submission_no":"214220","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-04-03","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE II STUDY TO DETERMINE EFFICACY AND SAFETY OF IFX-1 IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA","medConditionList":[{"med_condition_id":112,"med_condition":"HIDRADENITIS SUPPURATIVA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37940,"protocol_no":"CL-N03-SC","submission_no":"180193","status_id":1,"start_date":"2016-04-18","end_date":null,"nol_date":"2014-12-17","protocol_title":"LONG-TERM FOLLOW-UP STUDY OF THE PHASE I/II SAFETY AND PRELIMINARY EFFICACY INVESTIGATION OF INTRAMEDULLARY SPINAL CORD TRANSPLANTATION OF HUCNS-SC IN SUBJECTS WITH THORACIC (T2-T11) SPINAL CORD TRAUMA","medConditionList":[{"med_condition_id":238,"med_condition":"SPINAL CORD LESION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28852,"protocol_no":"191622-120","submission_no":"170079","status_id":1,"start_date":"2013-02-27","end_date":null,"nol_date":"2013-12-16","protocol_title":"BOTOX IN THE TREATMENT OF URINARY INCONTINENCE DUE TO NEUROGENIC DETRUSOR OVERACTIVITY IN PATIENTS 8 TO 17 YEARS OF AGE","medConditionList":[{"med_condition_id":405,"med_condition":"URINARY INCONTINENCE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37447,"protocol_no":"CLEE011E2301","submission_no":"178651","status_id":1,"start_date":"2015-08-24","end_date":null,"nol_date":"2014-10-31","protocol_title":"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LEE011 OR PLACEBO IN COMBINATION WITH TAMOXIFEN AND GOSERELIN OR A NON-STEROIDAL AROMATASE INHIBITOR (NSAI) AND GOSERELIN FOR THE TREATMENT OF PREMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER","medConditionList":[{"med_condition_id":527,"med_condition":"BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48495,"protocol_no":"MS700568_0022","submission_no":"214048","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-23","protocol_title":"A 2-YEAR PROSPECTIVE STUDY TO EVALUATE THE ONSET OF ACTION OF MAVENCLAD¬Æ IN SUBJECTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS.","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36159,"protocol_no":"GS-US-330-1401","submission_no":"174680","status_id":1,"start_date":"2017-03-02","end_date":null,"nol_date":"2014-06-10","protocol_title":"A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GS-4774 IN COMBINATION WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF SUBJECTS WITH CHRONIC HEPATITIS B AND WHO ARE CURRENTLY NOT ON TREATMENT","medConditionList":[{"med_condition_id":103,"med_condition":"HEPATITIS B VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48346,"protocol_no":"SPI-POZ-101","submission_no":"213683","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-15","protocol_title":"A PHASE 1B STUDY OF POZIOTINIB IN COMBINATION WITH T DM1 IN WOMEN WITH ADVANCED OR METASTATIC HER2 POSITIVE BREAST CANCER","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26967,"protocol_no":"16653","submission_no":"164366","status_id":1,"start_date":"2014-04-09","end_date":null,"nol_date":"2013-05-22","protocol_title":"A PHASE I, MULTI-CENTER, NON-RANDOMIZED, OPEN LABEL, PARALLEL-GROUP STUDY EVALUATING THE PHARMACOKINETICS AND SAFETY OF REGORAFENIB (BAY 73-4506) IN CANCER SUBJECTS WITH SEVERE RENAL IMPAIRMENT COMPARED TO A CONTROL GROUP","medConditionList":[{"med_condition_id":221,"med_condition":"RENAL INSUFFICIENCY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35734,"protocol_no":"1245.87","submission_no":"173276","status_id":2,"start_date":"2015-11-18","end_date":"2016-04-28","nol_date":"2014-04-15","protocol_title":"AN OPEN-LABEL, RANDOMISED, MULTICENTRE, SINGLE-DOSE, PARALLEL GROUP TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EMPAGLIFLOZIN IN CHILDREN AND ADOLESCENTS FROM 10 TO LESS THAN 18 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39625,"protocol_no":"16598","submission_no":"185773","status_id":1,"start_date":"2015-09-14","end_date":null,"nol_date":"2015-08-04","protocol_title":"AN OPEN-LABEL, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE-3B STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF 2 MG AFLIBERCEPT ADMINISTERED BY INTRAVITREAL INJECTIONS USING TWO DIFFERENT TREATMENT REGIMENS TO SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)","medConditionList":[{"med_condition_id":288,"med_condition":"NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37728,"protocol_no":"1000024289","submission_no":"179581","status_id":1,"start_date":"2015-11-16","end_date":null,"nol_date":"2014-12-05","protocol_title":"EFFECTS OF ANOREXIA ON PEAK BONE MASS","medConditionList":[{"med_condition_id":703,"med_condition":"ANOREXIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44824,"protocol_no":"CO-338-052","submission_no":"202560","status_id":1,"start_date":"2017-06-23","end_date":null,"nol_date":"2017-02-20","protocol_title":"TRITON2: A MULTICENTER, OPEN-LABEL PHASE 2 STUDY OF RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40739,"protocol_no":"AN-EPI3331","submission_no":"188977","status_id":1,"start_date":"2016-08-30","end_date":null,"nol_date":"2015-12-09","protocol_title":"A PHASE 3, RANDOMIZED, OPEN-LABEL, ASSESSOR-BLIND, NON-INFERIORITY, ACTIVE-COMPARATOR STUDY EVALUATING THE EFFICACY AND SAFETY OF LIPROTAMASE IN SUBJECTS WITH CYSTIC FIBROSIS-RELATED EXOCRINE PANCREATIC INSUFFICIENCY","medConditionList":[{"med_condition_id":704,"med_condition":"PANCREATIC INSUFFICIENCY EXOCRINE"},{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29184,"protocol_no":"GEMS-001","submission_no":"171163","status_id":1,"start_date":"2015-11-26","end_date":null,"nol_date":"2014-01-30","protocol_title":"GENOMIC PROFILING AND MATCHED THERAPY FOR RECURRENT OR METASTATIC SALIVARY GLAND NEOPLASMS (GEMS)","medConditionList":[{"med_condition_id":459,"med_condition":"METASTATIC SALIVARY GLAND NEOPLASM"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38445,"protocol_no":"LX4211.1-309-T1DM","submission_no":"182058","status_id":2,"start_date":"2015-10-21","end_date":"2017-08-03","nol_date":"2015-03-05","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF LX4211 AS ADJUNCT THERAPY IN ADULT PATIENTS WITH TYPE 1 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL WITH INSULIN THERAPY","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37008,"protocol_no":"N/A","submission_no":"175887","status_id":3,"start_date":"2014-08-04","end_date":null,"nol_date":"2014-07-24","protocol_title":"IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A PLANT-MADE SEASONAL QUADRIVALENT VLP INFLUENZA VACCINE IN ELDERLY PATIENTS","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35693,"protocol_no":"D589SC00001","submission_no":"173114","status_id":2,"start_date":"2014-11-05","end_date":"2017-08-02","nol_date":"2014-04-14","protocol_title":"A 52-WEEK, DOUBLE-BLIND, RANDOMISED, MULTI-CENTRE, PARALLEL-GROUP, PHASE III STUDY IN PATIENTS 12 YEARS AND OLDER WITH ASTHMA, EVALUATING THE EFFICACY AND SAFETY OF SYMBICORT  (BUDESONIDE/FORMOTEROL) TURBUHALER  160/4.5 ¬µG 'AS NEEDED' COMPARED WITH TERBUTALINE TURBUHALER  0.4 MG 'AS NEEDED' AND WITH PULMICORT  (BUDESONIDE) TURBUHALER  200 ¬µG TWICE DAILY PLUS TERBUTALINE TURBUHALER  0.4 MG 'AS NEEDED'","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27955,"protocol_no":"ALC.3 / S1203","submission_no":"167150","status_id":1,"start_date":"2015-01-16","end_date":null,"nol_date":"2013-09-04","protocol_title":"A RANDOMIZED PHASE III STUDY OF STANDARD CYTARABINE PLUS DAUNORUBICIN (7+3) THERAPY OR IDARUBICIN WITH HIGH DOSE CYTARABINE (IA) VERSUS IA WITH VORINOSTAT (IA+V) IN YOUNGER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML)","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37647,"protocol_no":"RCT-01-001-2014","submission_no":"179262","status_id":1,"start_date":"2015-10-28","end_date":null,"nol_date":"2014-11-26","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RCT-01 IN MEN AND WOMEN WITH UNILATERAL, CHRONIC ACHILLES TENDINOSIS","medConditionList":[{"med_condition_id":578,"med_condition":"ACHILLES TENDINOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37143,"protocol_no":"HPN-100-009","submission_no":"177680","status_id":2,"start_date":"2016-12-15","end_date":"2017-07-17","nol_date":"2014-10-02","protocol_title":"AN OPEN LABEL STUDY OF THE SAFETY, EFFICACY AND PHARMACOKINETICS OF GLYCEROL PHENYLBUTYRATE (GPB; RAVICTI¬Æ) IN PEDIATRIC SUBJECTS UNDER TWO YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS)","medConditionList":[{"med_condition_id":262,"med_condition":"UREA CYCLE DISORDERS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38234,"protocol_no":"CAMHPET-CTA-90","submission_no":"181349","status_id":1,"start_date":"2015-02-01","end_date":null,"nol_date":"2015-02-12","protocol_title":"D3 DOPAMINE RECEPTORS IN SUBSTANCE USE DISORDER: PET STUDIES WITH [11C]-(+)PHNO","medConditionList":[{"med_condition_id":428,"med_condition":"SUBSTANCE ABUSE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27208,"protocol_no":"20120265","submission_no":"165123","status_id":1,"start_date":"2014-06-23","end_date":null,"nol_date":"2013-06-20","protocol_title":"\"A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 215 COMPARED WITH BEVACIZUMAB IN SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER.\"","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36863,"protocol_no":"KCP-330-008","submission_no":"176789","status_id":2,"start_date":null,"end_date":"2018-01-08","nol_date":"2014-08-25","protocol_title":"A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) VERSUS SPECIFIED PHYSICIAN'S CHOICE IN PATIENTS ? 60 YEARS OLD WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY AND/OR TRANSPLANTATION [SOPRA STUDY: SELINEXOR (KPT-330) IN OLDER PATIENTS WITH RELAPSED AML]","medConditionList":[{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48131,"protocol_no":"PS0013","submission_no":"212870","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-21","protocol_title":"A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN INITIAL TREATMENT PERIOD FOLLOWED BY A RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (AMENDMENT 1)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35827,"protocol_no":"GAP02-01.1 (UHN REB 14-7308)","submission_no":"173599","status_id":1,"start_date":"2014-10-17","end_date":null,"nol_date":"2014-05-02","protocol_title":"PROPS: PET/MRI PRE-RADIOTHERAPY FOR POST-PROSTATECTOMY SALVAGE","medConditionList":[{"med_condition_id":485,"med_condition":"POST-PROSTATECTOMY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38396,"protocol_no":"SESTAMIBI 1.0","submission_no":"181959","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-03-06","protocol_title":"EVALUATION OF TECHNETIUM-99M SESTAMIBI TO DETERMINE MUSCLE ENERGY METABOLISM IN RCC (RENAL CELL CANCER) PATIENTS TREATED WITH SUNITINIB.","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35510,"protocol_no":"ROB0040","submission_no":"172452","status_id":1,"start_date":"2014-04-14","end_date":null,"nol_date":"2014-04-02","protocol_title":"FUNCTIONAL LUNG AVOIDANCE FOR INDIVIDUALIZED RADIOTHERAPY (FLAIR):  A RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38250,"protocol_no":"TMC435HPC2013","submission_no":"181412","status_id":2,"start_date":"2015-08-17","end_date":"2016-06-30","nol_date":"2015-02-04","protocol_title":"A PHASE 2, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF 6 OR 8 WEEKS OF TREATMENT WITH SIMEPREVIR, DACLATASVIR AND SOFOSBUVIR IN TREATMENT-NA√èVE SUBJECTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION.","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37863,"protocol_no":"GS-US-223-1015","submission_no":"179895","status_id":2,"start_date":"2015-05-06","end_date":"2016-08-22","nol_date":"2014-12-19","protocol_title":"A PHASE 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY EVALUATING THE EFFICACY, SAFETY,  AND TOLERABILITY OF  GS 4997 IN SUBJECTS WITH DIABETIC KIDNEY DISEASE","medConditionList":[{"med_condition_id":388,"med_condition":"DIABETES"},{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46984,"protocol_no":"BGB-3111-212","submission_no":"209369","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-13","protocol_title":"AN INTERNATIONAL, PHASE 2, OPEN-LABEL, RANDOMIZED STUDY OF BGB-3111 COMBINED WITH OBINUTUZUMAB COMPARED WITH OBINUTUZUMAB MONOTHERAPY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38565,"protocol_no":"CAMHPET-CTA-92","submission_no":"182437","status_id":1,"start_date":"2015-04-01","end_date":null,"nol_date":"2015-03-25","protocol_title":"IMPACT OF NICOTINE METABOLISM ON BRAIN DOPAMINE TRANSMISSION","medConditionList":[{"med_condition_id":420,"med_condition":"ADDICTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45863,"protocol_no":"1381.2","submission_no":"205670","status_id":1,"start_date":"2017-08-23","end_date":null,"nol_date":"2017-06-14","protocol_title":"AN OPEN LABEL, PHASE I DOSE-FINDING STUDY OF BI 754111 AS MONOTHERAPY AND IN COMBINATION WITH BL 754091 IN PATIENTS WITH ADVANCED CANCER FOLLOWED BY EXPANSION COHORTS AT THE RPIID OF THE COMBINATION IN PATIENTS WITH NSCLC AND OTHER TUMOUR TYPES","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42310,"protocol_no":"ALTE1621","submission_no":"194567","status_id":1,"start_date":"2017-12-04","end_date":null,"nol_date":"2016-05-24","protocol_title":"PHARMACOLOGIC REVERSAL OF VENTRICULAR REMODELING IN CHILDHOOD CANCER SURVIVORS AT RISK FOR HEART FAILURE (PREVENT-HF): A PHASE 2B RANDOMIZED PLACEBO-CONTROLLED (CARVEDILOL) TRIAL","medConditionList":[{"med_condition_id":662,"med_condition":"ARTICULAR CARTILAGE INJURY"},{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42365,"protocol_no":"RIM-01","submission_no":"194715","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-30","protocol_title":"RADIO-IMMUNO-MODULATION FOR ADVANCED LUNG CANCER HAVING PROGRESSED AFTER ONE LINE OF CHEMOTHERAPY: A PILOT STUDY EVALUATING TOLERANCE AND IMMUNE RESPONSE OF THE APPROACH","medConditionList":[{"med_condition_id":698,"med_condition":"ADVANCED LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43296,"protocol_no":"VBP15-002","submission_no":"197746","status_id":1,"start_date":"2017-04-18","end_date":null,"nol_date":"2016-09-16","protocol_title":"A PHASE IIA, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EXPLORATORY EFFICACY OF VAMOROLONE IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD)","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39538,"protocol_no":"NN8022-4179","submission_no":"185662","status_id":1,"start_date":"2015-11-06","end_date":null,"nol_date":"2015-07-30","protocol_title":"SCALE-EFFECT OF LIRAGLUTIDE FOR WEIGHT MANAGEMENT IN PAEDIATRIC SUBJECTS WITH PRADER-WILLI SYNDROME. A RANDOMISED, PLACEBO CONTROLLED, PARALLEL GROUP, MULTI-CENTRE, MULTINATIONAL TRIAL WITH A 16-WEEK DOUBLE-BLIND PERIOD AND 36-WEEK OPEN-LABEL PERIOD","medConditionList":[{"med_condition_id":415,"med_condition":"OVERWEIGHT/OBESITY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36558,"protocol_no":"OS320-3006","submission_no":"175793","status_id":2,"start_date":"2014-09-11","end_date":"2016-05-20","nol_date":"2014-07-22","protocol_title":"A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, 26 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMANTADINE HCL EXTENDED RELEASE TABLETS IN PARKINSON'S DISEASE SUBJECTS WITH LEVODOPA-INDUCED DYSKINESIAS","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41238,"protocol_no":"DAL-301","submission_no":"190799","status_id":1,"start_date":"2016-03-31","end_date":null,"nol_date":"2016-01-20","protocol_title":"A PHASE III, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF DALCETRAPIB ON CARDIOVASCULAR (CV) RISK IN A GENETICALLY DEFINED POPULATION WITH A RECENT ACUTE CORONARY SYNDROME (ACS): THE DAL-GENE TRIAL","medConditionList":[{"med_condition_id":499,"med_condition":"ACUTE CORONARY SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29292,"protocol_no":"CA194-103","submission_no":"171394","status_id":2,"start_date":"2014-06-06","end_date":"2017-05-18","nol_date":"2014-02-14","protocol_title":"EXTENSION PROTOCOL OF BMS-833923 IN SUBJECTS WITH BASAL CELL NEVUS SYNDROME","medConditionList":[{"med_condition_id":492,"med_condition":"BASAL CELL NEVUS SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39110,"protocol_no":"DALF-PS-1029","submission_no":"184192","status_id":1,"start_date":"2016-03-21","end_date":null,"nol_date":"2015-05-25","protocol_title":"AN EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF DALFAMPRIDINE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF CHRONIC POST-ISCHEMIC STROKE WALKING DEFICITS IN SUBJECTS WHO PARTICIPATED IN THE DALFPS-1016 STUDY (MILESTONESM)","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27833,"protocol_no":"NN5401-3816","submission_no":"166827","status_id":3,"start_date":"2014-01-14","end_date":null,"nol_date":"2013-08-23","protocol_title":"\"A TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF INSULIN DEGLUDEC/INSULIN ASPART ONCE DAILY PLUS INSULIN ASPART FOR THE REMAINING MEALS VERSUS INSULIN DETEMIR ONCE OR TWICE DAILY PLUS MEAL TIME INSULIN ASPART IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS.\"","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44889,"protocol_no":"WO39392","submission_no":"202736","status_id":1,"start_date":"2017-10-02","end_date":null,"nol_date":"2017-03-10","protocol_title":"A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY COMPARED WITH PLACEBO AND CHEMOTHERAPY IN PATIENTS WITH PRIMARY INVASIVE TRIPLE-NEGATIVE BREAST CANCER","medConditionList":[{"med_condition_id":702,"med_condition":"BREAST CANCER TRIPLE NEGATIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36545,"protocol_no":"HGT-SAN-093","submission_no":"175750","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-18","protocol_title":"RANDOMIZED, CONTROLLED, OPEN-LABEL, MULITCENTER, PHASE IIB SAFETY AND EFFICACY STUDY OF HGT-1410 (RECOMBINANT HUMAN HEPARAN N SULFATASE) ADMINISTRATION VIA AN IT DRUG DELIVERY DEVICE IN PEDIATRIC PATIENTS WITH EARLY STAGE MUCOPOLYSACCHARIDOSIS DISEASE","medConditionList":[{"med_condition_id":160,"med_condition":"MUCOPOLYSACCHARIDOSIS IVA (MORQUIO  SYNDROME)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28462,"protocol_no":"SPARC_LTD._CLR_13_10","submission_no":"168644","status_id":1,"start_date":"2013-11-15","end_date":null,"nol_date":"2013-10-28","protocol_title":"EFFICACY AND SAFETY OF INTRANASAL S0597 IN AN ENVIRONMENTAL EXPOSURE UNIT MODEL OF SEASONAL ALLERGIC RHINITIS: A PHASE 2, SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO, AND ACTIVE-CONTROLLED PARALLEL GROUP STUDY","medConditionList":[{"med_condition_id":425,"med_condition":"SEASONAL ALLERGIC RHINITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45592,"protocol_no":"M16-000","submission_no":"203526","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-19","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 52-WEEK MAINTENANCE AND AN OPEN-LABEL EXTENSION STUDY OF THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH CROHN'S DISEASE WHO RESPONDED TO INDUCTION TREATMENT IN M16-006 OR M15-991","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29467,"protocol_no":"CL2-78989-012","submission_no":"171883","status_id":1,"start_date":"2015-04-23","end_date":null,"nol_date":"2014-02-28","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY OF THE EFFICACY AND THE SAFETY OF GEVOKIZUMAB IN THE TREATMENT OF PATIENTS WITH GIANT CELL ARTERITIS","medConditionList":[{"med_condition_id":330,"med_condition":"GIANT CELL ARTERITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41607,"protocol_no":"9785-CL-0335","submission_no":"192036","status_id":1,"start_date":"2016-04-20","end_date":null,"nol_date":"2016-03-04","protocol_title":"A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VERSUS PLACEBO PLUS ADT IN PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36410,"protocol_no":"CAN-BTX-RCT","submission_no":"175330","status_id":3,"start_date":"2014-08-27","end_date":null,"nol_date":"2014-07-04","protocol_title":"RANDOMIZED CONTROL TRIAL OF THE USE OF BOTOX TO TREAT CHRONIC SCROTAL PAIN","medConditionList":[{"med_condition_id":548,"med_condition":"CHRONIC SCROTAL PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38268,"protocol_no":"I3Y-MC-JPBO","submission_no":"181445","status_id":1,"start_date":"2016-05-30","end_date":null,"nol_date":"2015-02-11","protocol_title":"A PHASE 2 STUDY OF ABEMACICLIB IN PATIENTS WITH BRAIN METASTASES SECONDARY TO HORMONE RECEPTOR POSITIVE BREAST CANCER","medConditionList":[{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28655,"protocol_no":"1000038363","submission_no":"169321","status_id":1,"start_date":"2016-12-09","end_date":null,"nol_date":"2013-12-11","protocol_title":"CTLA-4 IG (ABATACEPT) FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN RELATIVES AT-RISK FOR TYPE 1 DIABETES MELLITUS (TN-18)","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37335,"protocol_no":"I3Y-MC-JPBM","submission_no":"178319","status_id":1,"start_date":"2015-04-07","end_date":null,"nol_date":"2014-10-17","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF NONSTEROIDAL AROMATASE INHIBITORS (ANASTROZOLE OR LETROZOLE) PLUS LY2835219, A CDK4/6 INHIBITOR, OR PLACEBO IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCOREGIONALLY RECURRENT OR METASTATIC BREAST CANCER WITH NO PRIOR SYSTEMIC THERAPY IN THIS DISEASE SETTING","medConditionList":[{"med_condition_id":527,"med_condition":"BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37467,"protocol_no":"BN001","submission_no":"178715","status_id":1,"start_date":"2015-05-25","end_date":null,"nol_date":"2014-10-30","protocol_title":"RANDOMIZED PHASE II TRIAL OF HYPOFRACTIONATED DOSE-ESCALATED PHOTON IMRT OR PROTON BEAM THERAPY VERSUS CONVENTIONAL PHOTON IRRADIATION WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45160,"protocol_no":"E2609-G000-302","submission_no":"203496","status_id":1,"start_date":"2017-10-17","end_date":null,"nol_date":"2017-04-04","protocol_title":"A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 24 MONTH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF E2609 IN SUBJECTS WITH EARLY ALZHEIMER¬øS DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46028,"protocol_no":"20160928","submission_no":"206120","status_id":1,"start_date":"2017-11-01","end_date":null,"nol_date":"2017-06-28","protocol_title":"VEDOLIZUMAB TREATMENT IN ANTIRETROVIRAL DRUG TREATED CHRONIC HIV INFECTION","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28705,"protocol_no":"OTX015_104","submission_no":"169493","status_id":1,"start_date":"2014-03-28","end_date":null,"nol_date":"2013-11-27","protocol_title":"A PHASE 1, DOSE-FINDING STUDY OF THE BROMODOMAIN (BD) INHIBITOR OTX015 IN HAEMATOLOGICAL MALIGNANCIES","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38924,"protocol_no":"ERC-249","submission_no":"183616","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-05-08","protocol_title":"PLACEBO-CONTROLLED, DOUBLE-BLIND, PROSPECTIVE AND RANDOMIZED PHASE III STUDY TO EVALUATE THE EFFECT OF 12-WEEK TREATMENT WITH DHEA (PRASTERONE) + LOW DOSE ACOLBIFENE ON VASOMOTOR SYMPTOMS (HOT FLUSHES) IN POSTMENOPAUSAL WOMEN","medConditionList":[{"med_condition_id":659,"med_condition":"VASOMOTOR SYMPTOMS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37892,"protocol_no":"011-01","submission_no":"179992","status_id":2,"start_date":"2015-10-30","end_date":"2016-11-29","nol_date":"2014-12-18","protocol_title":"A PHASE II, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-3682 WITH EITHER MK-8742 OR MK-8408 IN SUBJECTS WITH CHRONIC HCV GT1, GT2, AND GT4 INFECTION","medConditionList":[{"med_condition_id":577,"med_condition":"HEPATITIS C VIRUS GENOTYPE 4"},{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"},{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46480,"protocol_no":"215MS202","submission_no":"207713","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-25","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS TO EVALUATE THE EFFICACY AND SAFETY OF BIIB033 AS AN ADD-ON THERAPY TO ANTI-INFLAMMATORY DISEASE-MODIFYING THERAPIES","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27655,"protocol_no":"D1532C00079","submission_no":"166337","status_id":1,"start_date":"2015-03-09","end_date":null,"nol_date":"2013-08-09","protocol_title":"A PHASE III, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SELUMETINIB (AZD6244; ARRY-142886) (HYD-SULFATE) IN COMBINATION WITH DOCETAXEL, IN PATIENTS RECEIVING SECOND-LINE TREATMENT FOR KRAS MUTATION-POSITIVE LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (STAGE IIIB - IV) (SELECT-1)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48437,"protocol_no":"SLC0111-17-01","submission_no":"213886","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-26","protocol_title":"AN OPEN-LABEL, MULTI-CENTER, PHASE 1B STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF SLC-0111 (WBI-5111) IN COMBINATION WITH GEMCITABINE IN METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA SUBJECTS POSITIVE FOR CARBONIC ANHYDRASE IX","medConditionList":[{"med_condition_id":650,"med_condition":"METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38141,"protocol_no":"TNX-LVO-01","submission_no":"181096","status_id":1,"start_date":"2015-08-31","end_date":null,"nol_date":"2015-02-04","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF LEVOSIMENDAN IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION UNDERGOING CARDIAC SURGERY REQUIRING CARDIOPULMONARY BYPASS; LEVO-CTS","medConditionList":[{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27542,"protocol_no":"B2151002","submission_no":"166057","status_id":1,"start_date":"2016-03-21","end_date":null,"nol_date":"2013-07-22","protocol_title":"A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212384 (PI3K/MTOR INHIBITOR) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48354,"protocol_no":"CC-92480-MM001","submission_no":"213599","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-23","protocol_title":"A PHASE 1 MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-92480 IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA.","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28660,"protocol_no":"1000038585","submission_no":"169334","status_id":1,"start_date":"2017-03-30","end_date":null,"nol_date":"2013-11-21","protocol_title":"THE USE OF METOCLOPRAMIDE VS. PLACEBO IN INFANTS WITH GASTROSCHISIS. A PILOT DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL.","medConditionList":[{"med_condition_id":488,"med_condition":"GASTROSCHISIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29392,"protocol_no":"117106","submission_no":"171696","status_id":1,"start_date":"2014-05-02","end_date":null,"nol_date":"2014-02-25","protocol_title":"MEPOLIZUMAB VS. PLACEBO AS ADD-ON TREATMENT FOR FREQUENTLY EXACERBATING COPD PATIENTS","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40888,"protocol_no":"GBR 830-201","submission_no":"189614","status_id":2,"start_date":"2016-12-06","end_date":"2017-06-05","nol_date":"2015-12-22","protocol_title":"A PHASE ILA, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, EXPLORATORY STUDY TO EVALUATE THE SAFETY, BIOLOGICAL ACTIVITY AND PHARMACOKINETICS OF GBR 830 IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38776,"protocol_no":"GS-US-395-1663","submission_no":"183141","status_id":1,"start_date":"2015-07-28","end_date":null,"nol_date":"2015-04-16","protocol_title":"\"A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF GS-5745 IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE-CROHN'S DISEASE.\"","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45272,"protocol_no":"MBPS205","submission_no":"203861","status_id":1,"start_date":"2017-10-31","end_date":null,"nol_date":"2017-04-13","protocol_title":"A PHASE 2B, MULTICENTRE, MULTINATIONAL, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE-FINDING STUDY IN ADULT PATIENTS WITH TYPE I, III OR IV OSTEOGENESIS IMPERFECTA TREATED WITH BPS804","medConditionList":[{"med_condition_id":549,"med_condition":"OSTEOGENESIS IMPERFECTA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35440,"protocol_no":"CD-IA-MEDI-551-1155","submission_no":"172401","status_id":1,"start_date":"2016-06-15","end_date":null,"nol_date":"2014-03-20","protocol_title":"A DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY WITH OPEN LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MEDI-551 IN ADULT SUBJECTS WITH NEUROMYELITIS OPTICA AND NEUROMYELITIS OPTICA SPECTRUM DISORDERS","medConditionList":[{"med_condition_id":324,"med_condition":"NEUROMYELITIS OPTICA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28068,"protocol_no":"55-1202-1","submission_no":"167494","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-13","protocol_title":"\"A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF TRANSENDOCARDIAL INJECTION OF IXMYCLOCEL-T IN SUBJECTS WITH HEART FAILURE DUE TO ISCHEMIC DILATED CARDIOMYOPATHY (IDCM).\"","medConditionList":[{"med_condition_id":372,"med_condition":"ISCHEMIC DILATED CARDIOMYOPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36839,"protocol_no":"GTI1305","submission_no":"176716","status_id":1,"start_date":"2015-10-26","end_date":null,"nol_date":"2014-08-21","protocol_title":"A MULTICENTER, PROSPECTIVE, OPEN-LABEL, NON-CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF IMMUNE GLOBULIN (HUMAN), 10% CAPRYLATE/CHROMATOGRAPHY PURIFIED (IGIV-C) IN PATIENTS WITH MYASTHENIA GRAVIS EXACERBATION","medConditionList":[{"med_condition_id":163,"med_condition":"MYASTHENIA GRAVIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37313,"protocol_no":"200862","submission_no":"178258","status_id":1,"start_date":"2015-06-16","end_date":null,"nol_date":"2014-10-23","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTRE 24-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEPOLIZUMAB ADJUNCTIVE THERAPY IN SUBJECTS WITH SEVERE EOSINOPHILIC ASTHMA ON MARKERS OF ASTHMA CONTROL","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41786,"protocol_no":"B2341002","submission_no":"192700","status_id":1,"start_date":"2017-04-19","end_date":null,"nol_date":"2016-03-30","protocol_title":"A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE MAXIMUM TOLERATED DOSE OF PF-05230907 IN SUBJECTS WITH INTRACEREBRAL HEMORRHAGE (ICH)","medConditionList":[{"med_condition_id":404,"med_condition":"INTRACEREBAL HEMORRAGE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36980,"protocol_no":"SLC0111-14-C01","submission_no":"177137","status_id":2,"start_date":"2015-09-01","end_date":"2016-07-15","nol_date":"2014-09-05","protocol_title":"A PHASE I, MULTI-CENTER, OPEN-LABEL, STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETIC (PK) OF SLC-0111 IN SUBJECTS WITH ADVANCED SOLID TUMOURS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43856,"protocol_no":"402-C-1504","submission_no":"199406","status_id":1,"start_date":"2017-02-01","end_date":null,"nol_date":"2016-11-16","protocol_title":"A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION","medConditionList":[{"med_condition_id":218,"med_condition":"PULMONARY ARTERIAL HYPERTENSION (PAH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39991,"protocol_no":"PDY14192","submission_no":"186796","status_id":1,"start_date":"2016-06-23","end_date":null,"nol_date":"2015-09-04","protocol_title":"AN EXPLORATORY, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF DUPILUMAB ON AIRWAY INFLAMMATION OF ADULTS WITH PERSISTENT ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46776,"protocol_no":"IIT-WALKER-01/MS100070_0294","submission_no":"208635","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-20","protocol_title":"A STUDY TO EVALUATE THE FEASIBILITY AND EFFICACY OF THE COMBINED USE OF AVELUMAB WITH VALPROIC ACID FOR THE TREATMENT OF VIRUS-ASSOCIATED CANCER","medConditionList":[{"med_condition_id":800,"med_condition":"VIRUS-ASSOCIATED CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43307,"protocol_no":"MDV3100-20","submission_no":"197777","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-09-21","protocol_title":"ENDEAR:  A PHASE 3, RANDOMIZED, INTERNATIONAL STUDY COMPARING THE EFFICACY AND SAFETY OF ENZALUTAMIDE IN COMBINATION WITH PACLITAXEL CHEMOTHERAPY OR AS MONOTHERAPY VERSUS PLACEBO WITH PACLITAXEL IN PATIENTS WITH ADVANCED, DIAGNOSTIC POSITIVE, TRIPLE NEGATIVE BREAST CANCER.","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39274,"protocol_no":"TV7820-CNS-20016","submission_no":"184687","status_id":1,"start_date":"2017-10-10","end_date":null,"nol_date":"2015-06-17","protocol_title":"A MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF PRIDOPIDINE IN PATIENTS WITH HUNTINGTON'S DISEASE (OPEN PRIDE-HD- OPEN PRIDOPIDINE DOSE EVALUATION IN HUNTINGTON'S DISEASE)","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41347,"protocol_no":"AV-951-15-303","submission_no":"191236","status_id":1,"start_date":"2017-01-06","end_date":null,"nol_date":"2016-02-12","protocol_title":"A PHASE 3, RANDOMIZED, CONTROLLED, MULTI-CENTER, OPEN-LABEL STUDY TO COMPARE TIVOZANIB HYDROCHLORIDE (AV-951) TO SORAFENIB IN SUBJECTS WITH REFRACTORY ADVANCED RENAL CELL CARCINOMA","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28370,"protocol_no":"WINTHER","submission_no":"168355","status_id":1,"start_date":"2013-12-13","end_date":null,"nol_date":"2013-10-11","protocol_title":"A STUDY TO SELECT RATIONAL THERAPEUTICS BASED ON THE ANALYSIS OF MATCHED TUMOR AND NORMAL BIOPSIES WITH ADVANCED MALIGNANCIES.","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36233,"protocol_no":"OCZ103-300-1401","submission_no":"174837","status_id":1,"start_date":"2014-08-08","end_date":null,"nol_date":"2014-06-13","protocol_title":"A PHASE I CLINICAL STUDY ON THE HEPATIC UPTAKE, PHARMACOKINETICS, SAFETY AND TOLERANCE OF A NEW ORAL PENTAMIDINE FORMULATION IN HEPATOCELLULAR CARCINOMA SUBJECTS UNDERGOING THERMAL ABLATION","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38885,"protocol_no":"FGCL-3019-067","submission_no":"183510","status_id":1,"start_date":"2015-08-20","end_date":null,"nol_date":"2015-05-22","protocol_title":"\"A PHASE 2, RANDOMZIED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FG-3019 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS.\"","medConditionList":[{"med_condition_id":127,"med_condition":"IDIOPATHIC PULMONARY FIBROSIS (IPF)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35355,"protocol_no":"318-2013","submission_no":"172082","status_id":1,"start_date":"2016-04-06","end_date":null,"nol_date":"2014-03-27","protocol_title":"SAFETY AND EFFICACY OF NABILONE IN INSTITUTIONALIZED PATIENTS WITH ALZHEIMER'S DISEASE: A PILOT STUDY","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42604,"protocol_no":"ALN-TTR02-006","submission_no":"195539","status_id":1,"start_date":"2017-05-25","end_date":null,"nol_date":"2016-06-24","protocol_title":"A MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PATISIRAN IN PATIENTS WITH FAMILIAL AMYLOIDOTIC POLYNEUROPATHY WHO HAVE COMPLETED A PRIOR CLINICAL STUDY WITH PATISIRAN.","medConditionList":[{"med_condition_id":742,"med_condition":"FAMILIAL AMYLOIDOTIC POLYNEUROPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40687,"protocol_no":"IND.222","submission_no":"188829","status_id":2,"start_date":"2016-12-15","end_date":"2018-04-12","nol_date":"2015-11-25","protocol_title":"A PHASE I/II STUDY OF THE MTORC1/MTORC2 KINASE INHIBITOR AZD2014 IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA MULTIFORME","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28052,"protocol_no":"GS-US-312-0115","submission_no":"167444","status_id":1,"start_date":"2016-12-20","end_date":null,"nol_date":"2013-09-12","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (GS 1101) IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41075,"protocol_no":"177","submission_no":"190196","status_id":1,"start_date":"2016-03-04","end_date":null,"nol_date":"2015-12-23","protocol_title":"A PHASE III STUDY OF PEMBROLIZUMAB (MK-3475) VS CHEMOTHERAPY IN MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) STAGE IV COLORECTAL CARCINOMA (KEYNOTE-177)","medConditionList":[{"med_condition_id":51,"med_condition":"COLORECTAL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45941,"protocol_no":"CLASS15","submission_no":"205898","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-13","protocol_title":"ALLEVIATING CARBOHYDRATE-COUNTING BURDEN IN TYPE 1 DIABETES USING ARTIFICIAL PANCREAS AND SODIUM GLUCOSE-LINKED TRANSPORTER 2 INHIBITION: A RANDOMIZED OPEN-LABEL CROSSOVER TRIAL","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44590,"protocol_no":"3152-301-002","submission_no":"201804","status_id":1,"start_date":"2017-05-29","end_date":null,"nol_date":"2017-02-08","protocol_title":"STELLARIS: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS","medConditionList":[{"med_condition_id":734,"med_condition":"NONALCOHOLIC STEATOHEPATITIS (NASH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42113,"protocol_no":"NSR-REP-01","submission_no":"193958","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-05-06","protocol_title":"A SINGLE-MASKED, RANDOMIZED, CONTROLLED, PARALLEL GROUP, PHASE 3 CLINICAL TRIAL OF RETINAL GENE THERAPY FOR CHOROIDEREMIA USING AN ADENO-ASSOCIATED VIRAL VECTOR (AAV2) ENCODING RAB ESCORT PROTEIN 1 (REP1)","medConditionList":[{"med_condition_id":382,"med_condition":"CHOROIDEREMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45055,"protocol_no":"M16-127","submission_no":"203164","status_id":1,"start_date":"2017-09-13","end_date":null,"nol_date":"2017-03-21","protocol_title":"A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF  GLECAPREVIR/PIBRENTASVIR IN RENALLY-IMPAIRED ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 ¬ø 6 INFECTION  (EXPEDITION-5)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43026,"protocol_no":"CMAK683X2101","submission_no":"196926","status_id":1,"start_date":"2018-03-02","end_date":null,"nol_date":"2016-08-19","protocol_title":"A PHASE I/II, MULTICENTER, OPEN-LABEL STUDY OF MAK683 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":665,"med_condition":"ADVANCED MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35778,"protocol_no":"47057","submission_no":"173436","status_id":1,"start_date":"2014-07-23","end_date":null,"nol_date":"2014-04-23","protocol_title":"A PROSPECTIVE, OPEN LABEL, SINGLE CENTER TRIAL OF FECAL MICROBIOTA TRANSPLANTATION (FMT) IN THE MANAGEMENT OF HEPATIC ENCEPHALOPATHY","medConditionList":[{"med_condition_id":282,"med_condition":"HEPATIC ENCEPHALOPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44505,"protocol_no":"AD-DBS-001","submission_no":"201585","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-01-13","protocol_title":"DEEP BRAIN STIMULATION OF THE FORNIX IN ALZHEIMER'S DISEASE: INVESTIGATIONS INTO CLINICAL AND IMAGING BIOMARKERS AND DOSE OPTIMIZATION","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40702,"protocol_no":"I5Q-MC-CGAG (EVOLVE-1)","submission_no":"188879","status_id":1,"start_date":"2015-01-07","end_date":null,"nol_date":"2015-11-26","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE","medConditionList":[{"med_condition_id":663,"med_condition":"EPISODIC MIGRAINE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44669,"protocol_no":"EFC14335","submission_no":"202027","status_id":1,"start_date":"2017-04-08","end_date":null,"nol_date":"2017-02-10","protocol_title":"A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE VERSUS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41364,"protocol_no":"1230.43","submission_no":"191275","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-02-08","protocol_title":"AN OPEN LABEL, PHASE I TRIAL OF INTRAVENOUS ADMINISTRATION OF VOLASERTIB AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENTS TREATMENT FAILURE","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28761,"protocol_no":"2014-1817","submission_no":"169701","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-05","protocol_title":"ESSAI RANDOMIS√â COMPARANT L¬íEFFET DE L¬íASPIRINE √Ä FAIBLE DOSE AU PLACEBO SUR LE POIDS DE NAISSANCE DES GROSSESSES G√âMELLAIRES (√âTUDE GAP)","medConditionList":[{"med_condition_id":437,"med_condition":"TRAUMATIC BRAIN INJURY"},{"med_condition_id":435,"med_condition":"PREMATURE LABOUR"},{"med_condition_id":436,"med_condition":"CRANIOCEREBRAL TRAUMA"},{"med_condition_id":434,"med_condition":"PRE-ECLAMPSIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28362,"protocol_no":"021/2013","submission_no":"168324","status_id":2,"start_date":"2013-12-13","end_date":"2016-03-01","nol_date":"2013-10-18","protocol_title":"A DIETARY SUPPLEMENT FOR EARLY CIGARETTE WITHDRAWAL","medConditionList":[{"med_condition_id":420,"med_condition":"ADDICTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39621,"protocol_no":"I4T-MC-JVCY","submission_no":"185881","status_id":1,"start_date":"2017-07-11","end_date":null,"nol_date":"2015-07-29","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RAMUCIRUMAB AND BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO AND BSC AS SECOND-LINE TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN (AFP) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27875,"protocol_no":"013","submission_no":"166939","status_id":1,"start_date":"2016-02-12","end_date":null,"nol_date":"2013-09-12","protocol_title":"\"A PHASE 1B MULTI-COHORT TRIAL OF MK-3475 IN SUBJECTS WITH HEMATOLOGIC MALIGNANCIES.\"","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35527,"protocol_no":"D3250C00020","submission_no":"172672","status_id":1,"start_date":"2014-04-24","end_date":null,"nol_date":"2014-03-24","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, PHASE 3 EFFICACY AND SAFETY STUDY OF BENRALIZUMAB (MEDI-563) TO REDUCE ORAL CORTICOSTEROID USE IN PATIENTS WITH UNCONTROLLED ASTHMA ON HIGH DOSE INHALED CORTICOSTEROID PLUS LONG-ACTING B2 AGONIST AND CHRONIC ORAL CORTICOSTEROID THERAPY (ZONDA)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37583,"protocol_no":"M14-361","submission_no":"179076","status_id":1,"start_date":"2016-10-13","end_date":null,"nol_date":"2014-11-18","protocol_title":"A PHASE 1 DOSE ESCALATION AND PHASE 2 RANDOMIZED DOUBLE-BLIND STUDY OF VELIPARIB IN COMBINATION WITH CARBOPLATIN AND ETOPOSIDE AS A THERAPY OF TREATMENT-NA√èVE EXTENSIVE STAGE DISEASE SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27263,"protocol_no":"ECU-NMO-301","submission_no":"165252","status_id":3,"start_date":"2014-06-09","end_date":null,"nol_date":"2013-06-27","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO).","medConditionList":[{"med_condition_id":324,"med_condition":"NEUROMYELITIS OPTICA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46910,"protocol_no":"1615R2132","submission_no":"209114","status_id":1,"start_date":"2018-03-21","end_date":null,"nol_date":"2017-09-28","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLELGROUP, CLINICAL STUDY OF S-649266 COMPARED WITH MEROPENEM FOR THE TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA, VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA, OR HEALTHCARE-ASSOCIATED BACTERIAL PNEUMONIA CAUSED BY GRAM-NEGATIVE PATHOGENS","medConditionList":[{"med_condition_id":442,"med_condition":"PNEUMONIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39888,"protocol_no":"17508","submission_no":"186543","status_id":1,"start_date":"2016-06-02","end_date":null,"nol_date":"2015-08-21","protocol_title":"MANAGING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OVER 2 YEARS WITH A TREAT AND EXTEND (T&E) REGIMEN OF 2 MG INTRAVITREAL (IVT) AFLIBERCEPT - A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE IV/IIIB STUDY (ARIES)","medConditionList":[{"med_condition_id":568,"med_condition":"MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27464,"protocol_no":"LA38-0411","submission_no":"165822","status_id":1,"start_date":"2013-12-01","end_date":null,"nol_date":"2013-07-19","protocol_title":"THE EFFICACY AND SAFETY OF FERRIPROX¬Æ FOR THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS","medConditionList":[{"med_condition_id":329,"med_condition":"ANEMIA"},{"med_condition_id":232,"med_condition":"SICKLE CELL DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41725,"protocol_no":"PRO00016263","submission_no":"192464","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-22","protocol_title":"THE EFFECT OF BRIMONIDINE ON THE DEVELOPMENT OF SUBCONJUNCTIVAL HEMORRHAGE FOLLOWING FEMTOSECOND LASER ASSISTED CATARACT SURGERY","medConditionList":[{"med_condition_id":727,"med_condition":"CATARACT SURGERY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38354,"protocol_no":"OZM-052 / ML28606","submission_no":"181778","status_id":1,"start_date":"2016-02-05","end_date":null,"nol_date":"2015-03-06","protocol_title":"A PILOT STUDY OF NEO-ADJUVANT USE OF VEMURAFENIB PLUS COBIMETINIB (GDC-0973) IN PATIENTS WITH BRAF MUTANT MELANOMA WITH PALPABLE LYMPH NODE METASTASES","medConditionList":[{"med_condition_id":342,"med_condition":"MELANOMA WITH BRAF MUTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28650,"protocol_no":"201072 (FLU Q-PAN H7N9=AS03-00","submission_no":"169311","status_id":3,"start_date":"2013-12-02","end_date":null,"nol_date":"2013-11-22","protocol_title":"AN OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS' INFLUENZA VACCINE(S) GSK3206641A AND GSK3206640A ADMINISTERED IN ADULTS 18 TO 64 YEARS OF AGE","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28642,"protocol_no":"DVX_MDD_COMORB","submission_no":"169296","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-11-27","protocol_title":"DESVENLAFAXINE SUCCINATE EXTENDED RELEASE IN MAJOR DEPRESSION WITH ANXIETY DISORDER COMORBIDITY","medConditionList":[{"med_condition_id":429,"med_condition":"ANXIETY DISORDER"},{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43018,"protocol_no":"16159B","submission_no":"196893","status_id":1,"start_date":"2016-11-07","end_date":null,"nol_date":"2016-08-12","protocol_title":"INTERVENTIONAL, OPEN-LABEL, FLEXIBLE-DOSE, LONG-TERM SAFETY STUDY OF LU AF35700 IN ADULT PATIENTS WITH SCHIZOPHRENIA","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28463,"protocol_no":"H13-01316","submission_no":"168646","status_id":1,"start_date":"2013-11-07","end_date":null,"nol_date":"2013-11-05","protocol_title":"ACARBOSE AND OLDER ADULTS WITH POSTPRANDIAL HYPOTENSION","medConditionList":[{"med_condition_id":412,"med_condition":"POSTPRANDIAL HYPOTENSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27723,"protocol_no":"010-02","submission_no":"166545","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-08-14","protocol_title":"A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF MK-8353 COMBINATION THERAPIES IN SUBJECTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"},{"med_condition_id":51,"med_condition":"COLORECTAL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35989,"protocol_no":"HN001","submission_no":"174070","status_id":1,"start_date":"2015-04-07","end_date":null,"nol_date":"2014-05-20","protocol_title":"RANDOMIZED PHASE II AND PHASE III STUDIES OF INDIVIDUALIZED TREATMENT FOR NASOPHARYNGEAL CARCINOMA BASED ON BIOMARKER EPSTEIN BARR VIRUS (EBV) DEOXYRIBONUCLEIC ACID","medConditionList":[{"med_condition_id":521,"med_condition":"NASOPHARYNGEAL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35694,"protocol_no":"CC-10004-AD-001","submission_no":"173143","status_id":2,"start_date":"2014-07-18","end_date":"2016-02-22","nol_date":"2014-04-17","protocol_title":"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40209,"protocol_no":"TXA-WASH-01","submission_no":"187378","status_id":1,"start_date":"2015-10-01","end_date":null,"nol_date":"2016-03-23","protocol_title":"TOPICAL TRANEXAMIC ACID (TXA) IN HIP FRACTURES, A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":607,"med_condition":"HIP FRACTURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37217,"protocol_no":"14-8122","submission_no":"177877","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-02","protocol_title":"HEPATIC ARTERIAL BLOOD FLOW MODULATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: INFLUENCE OF INTRA-ARTERIAL NOREPINEPHRINE ASSESSED WITH CT PERFUSION.","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27803,"protocol_no":"NN1218-3853","submission_no":"166742","status_id":3,"start_date":"2013-08-26","end_date":null,"nol_date":"2013-08-22","protocol_title":"\"ONSET: EFFICACY AND SAFETY OF FIASP COMPARED TO INSULIN ASPART IN COMBINATION WITH INSULIN GLARGINE AND METFORMIN IN ADULTS WITH TYPE 2 DIABETES.\"","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37277,"protocol_no":"PRVT-12724","submission_no":"178122","status_id":1,"start_date":"2016-08-22","end_date":null,"nol_date":"2014-10-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE WHETHER CHRONIC TREATMENT OF CYSTIC FIBROSIS SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE USING SITAGLIPTIN (JANUVIA TM) PREVENTS THE DEVELOPMENT OF DIABETES.","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"},{"med_condition_id":388,"med_condition":"DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39973,"protocol_no":"15-1817","submission_no":"186757","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-09-30","protocol_title":"INVESTIGATION OF MYOCARDIAL TISSUE MARKERS, VASCULAR REACTIVITY AND PRO-INFLAMMATORY STATUS IN PATIENTS WITH DECOMPENSATED VERSUS RECOMPENSATED HEART FAILURE","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46536,"protocol_no":"TRANSCON HGH CT-302","submission_no":"207867","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-24","protocol_title":"A MULTICENTER, PHASE 3, OPEN-LABEL, 26-WEEK TRIAL INVESTIGATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRANSCON HGH ADMINISTERED ONCE WEEKLY IN CHILDREN WITH GROWTH HORMONE DEFICIENCY (GHD)","medConditionList":[{"med_condition_id":94,"med_condition":"GROWTH HORMONE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40385,"protocol_no":"OZM-064","submission_no":"187918","status_id":1,"start_date":"2017-05-29","end_date":null,"nol_date":"2015-10-21","protocol_title":"PHASE 2 TRIAL OF ROSUVASTATIN (CRESTOR¬Æ) COMBINED WITH STANDARD CHEMORADIATION THERAPY IN THE TREATMENT OF HIGH-RISK LOCALLY ADVANCED RECTAL CANCER","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27448,"protocol_no":"H-030-014","submission_no":"165777","status_id":1,"start_date":"2013-07-29","end_date":null,"nol_date":"2013-07-24","protocol_title":"\"EFFICACY, IMMUNOGENICITY, AND SAFETY STUDY OF CLOSTRIDIUM DIFFICLE TOXOIS VACCINE IN SUBJECTS AT RISK FOR C. DIFFICILE INFECTION.\"","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36329,"protocol_no":"CCLR457X2101","submission_no":"175078","status_id":1,"start_date":"2015-03-03","end_date":null,"nol_date":"2014-07-02","protocol_title":"A PHASE I/II MULTICENTER, OPEN-LABEL STUDY OF CLR457, ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED SOLID MALIGNANCIES","medConditionList":[{"med_condition_id":293,"med_condition":"MALIGNANT SOLID TUMOURS"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"},{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36559,"protocol_no":"BIOS-13-006","submission_no":"175794","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-17","protocol_title":"A PROSPECTIVE RANDOMIZED, CONTROLLED CLINIC STUDY EVALUATING THE SAFETY AND EFFICACY OF EVICEL USED FOR SUTURE - LINE SEALING IN DURA-MATER CLOSURE DURING PAEDIATRIC NEUROSURGICAL CRANIAL PROCEDURES.\"","medConditionList":[{"med_condition_id":562,"med_condition":"NEUROSURGICAL CRANIAL PROCEDURES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37771,"protocol_no":"D5740C00002","submission_no":"179686","status_id":1,"start_date":"2015-02-27","end_date":null,"nol_date":"2014-12-19","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ROXADUSTAT IN THE TREATMENT OF ANEMIA IN DIALYSIS PATIENTS","medConditionList":[{"med_condition_id":329,"med_condition":"ANEMIA"},{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46764,"protocol_no":"EFC15246","submission_no":"208602","status_id":1,"start_date":"2018-02-23","end_date":null,"nol_date":"2017-09-15","protocol_title":"RANDOMIZED, OPEN LABEL, MULTICENTER STUDY ASSESSING THE CLINICAL BENEFIT OF ISATUXIMAB COMBINED WITH CARFILZOMIB (KYPROLIS) AND DEXAMETHASONE VERSUS CARFILZOMIB WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH 1 TO 3 PRIOR LINES","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46787,"protocol_no":"D419CC00002","submission_no":"208666","status_id":1,"start_date":"2018-02-21","end_date":null,"nol_date":"2017-09-20","protocol_title":"A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE III STUDY OF DURVALUMAB AND TREMELIMUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HIMALAYA)","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27889,"protocol_no":"UL1208","submission_no":"166968","status_id":1,"start_date":"2014-10-01","end_date":null,"nol_date":"2013-08-21","protocol_title":"A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ULIPRISTAL ACETATE FOR THE INTERMITTENT TREATMENT OF ABNORMAL UTERINE BLEEDING ASSOCIATED WITH LEIOMYOMAS.","medConditionList":[{"med_condition_id":355,"med_condition":"UTERINE LEIOMYOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47190,"protocol_no":"AVRO-RD-01-201","submission_no":"210143","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-01","protocol_title":"AN OPEN-LABEL, MULTINATIONAL STUDY OF THE EFFICACY AND SAFETY OF EX VIVO, LENTIVIRAL VECTOR-MEDIATED GENE THERAPY AVR-RD-01 FOR TREATMENT-NAIVE SUBJECTS WITH CLASSIC FABRY DISEASE","medConditionList":[{"med_condition_id":79,"med_condition":"FABRY DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27739,"protocol_no":"103696","submission_no":"166594","status_id":1,"start_date":"2014-01-31","end_date":null,"nol_date":"2013-08-15","protocol_title":"A RANDOMIZED CONTROLLED TRIAL ASSESSING THE EFFICACY OF ANTIMICROBIAL PROPHYLAXIS FOR EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY (SWL) ON REDUCING URINARY TRACT INFECTION.","medConditionList":[{"med_condition_id":264,"med_condition":"URINARY TRACT INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38329,"protocol_no":"D356NC00001","submission_no":"181676","status_id":1,"start_date":"2015-04-30","end_date":null,"nol_date":"2015-02-27","protocol_title":"AN OPEN-LABEL LONG-TERM EXTENSION TO THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, CROSS-OVER STUDY OF ROSUVASTATIN IN CHILDREN AND ADOLESCENTS (AGED 6 TO <18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","medConditionList":[{"med_condition_id":116,"med_condition":"HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35752,"protocol_no":"GB29260","submission_no":"173325","status_id":2,"start_date":"2016-02-03","end_date":"2017-02-13","nol_date":"2014-04-25","protocol_title":"A PHASE II, RANDOMIZED,DOUBLE-BLIND, PLACEBO-CONTROLLED BRONCHOSCOPY STUDY TO EVALUATE THE EFFECTS OF LEBRIKIZUMAB ON AIRWAY EOSINOPHILIC INFLAMMATION IN PATIENTS WITH UNCONTROLLED ASTHMA ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38620,"protocol_no":"REGORAFENIB BODY COMPOSITION 1","submission_no":"182636","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-03-25","protocol_title":"A PHASE I OPEN LABEL STUDY OF EFFECTS OF LEAN BODY MASS (LBM) AND PROTON PUMP INHIBITORS (PPIS) ON PHARMACOKINETICS AND SAFETY OF REGORAFENIB (BAY 73-4506) IN CANCER PATIENTS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37998,"protocol_no":"D5160C00019","submission_no":"180459","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-01-08","protocol_title":"A PHASE I, OPEN-LABEL, NON-RANDOMISED, MULTICENTRE STUDY TO ASSESS THE EFFECT OF AZD9291 ON THE PHARMACOKINETICS OF ROSUVASTATIN (A SENSITIVE BCRP SUBSTRATE) IN PATIENTS WITH EGFRM POSITIVE NSCLC WHOSE DISEASE HAS PROGRESSED ON AN EGFR TKI","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28270,"protocol_no":"VX12-809-105","submission_no":"168121","status_id":1,"start_date":"2014-01-28","end_date":null,"nol_date":"2013-10-01","protocol_title":"A PHASE 3, ROLLOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LONG TERM TREATMENT WITH LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS, HOMOZYGOUS OR HETEROZYGOUS FOR THE F508DEL CFTR MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47087,"protocol_no":"PRO 00076309","submission_no":"209690","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-20","protocol_title":"A PROSPECTIVE, DOUBLE BLIND, RANDOMIZED PILOT STUDY COMPARING THE EFFICACY OF LYOPHILIZED FECAL MICROBIOTA TRANSPLANTATION (FMT) TO LYOPHILIZED STERILE FECAL FILTRATE IN THE MANAGEMENT OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (CDI)","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39479,"protocol_no":"M14-726","submission_no":"185450","status_id":2,"start_date":null,"end_date":"2016-02-11","nol_date":"2015-07-10","protocol_title":"OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE COMBINATION OF OMBITASVIR, PARITAPREVIR/R ¬± DASABUVIR WITH RIBAVIRIN (RBV) IN ADULT PATIENTS WITH GT1 OR GT4 CHRONIC HCV INFECTION AND RESPONSE TO PRIOR TREATMENT OF EARLY STAGE HEPATOCELLULAR CARCINOMA","medConditionList":[{"med_condition_id":105,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1 OR 4"},{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42615,"protocol_no":"FS10214100 (CA014001)","submission_no":"195575","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-30","protocol_title":"PHASE 1, MULTIPLE ACENDING DOSE STUDY OF ANTI-HER2 FCAB FS102 IN HER2 POSITIVE SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44597,"protocol_no":"CA212-016","submission_no":"201820","status_id":1,"start_date":"2017-10-27","end_date":null,"nol_date":"2017-02-08","protocol_title":"A PHASE 1/2, OPEN-LABEL RANDOMIZED STUDY OF ULOCUPLUMAB (BMS-936564) IN COMBINATION WITH LOW DOSE CYTARABINE IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47357,"protocol_no":"PDY15079","submission_no":"210689","status_id":1,"start_date":"2018-03-14","end_date":null,"nol_date":"2017-12-01","protocol_title":"AN EXPLORATORY, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ARM TRIAL OF THE SAFETY AND PHARMACODYNAMIC ACTIVITY OF SOTAGLIFLOZIN IN HEMODYNAMICALLY STABLE PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39917,"protocol_no":"CP-MGAH22-04","submission_no":"186611","status_id":1,"start_date":"2017-04-26","end_date":null,"nol_date":"2015-09-11","protocol_title":"A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39153,"protocol_no":"WF10-C-2015/R-2-04B","submission_no":"184304","status_id":2,"start_date":"2015-06-11","end_date":"2016-02-24","nol_date":"2015-06-05","protocol_title":"A SINGLE CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF WF10 COMPARED TO PLACEBO IN SUBJECTS WITH ALLERGIC RHINITIS.","medConditionList":[{"med_condition_id":425,"med_condition":"SEASONAL ALLERGIC RHINITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28745,"protocol_no":"002","submission_no":"169633","status_id":1,"start_date":"2014-02-24","end_date":null,"nol_date":"2013-12-04","protocol_title":"PRUCALOPRIDE VERSUS PLACEBO IN DIABETIC GASTROPARESIS: RANDOMIZED PLACEBO-CONTROLLED CROSSOVER TRIAL","medConditionList":[{"med_condition_id":432,"med_condition":"DIABETIC GASTROPARESIS"},{"med_condition_id":359,"med_condition":"GASTROPARESIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47477,"protocol_no":"PUMA-NER-5201","submission_no":"211043","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-27","protocol_title":"AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION.","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36175,"protocol_no":"003","submission_no":"174726","status_id":1,"start_date":"2014-09-22","end_date":null,"nol_date":"2014-07-29","protocol_title":"\"A STUDY TO EVALUATE THE USE OF GALA, VASCULAR CONDUIT PRESERVATION SOLUTION IN PATIENTS UNDERGOING CABG. GALA SOLUTION (SOMVC001) FOR THE PRESERVATION, STORAGE AND FLUSHING OF SAPHENOUS VEIN GRAFTS.\"","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28137,"protocol_no":"RES-008","submission_no":"167700","status_id":3,"start_date":"2013-10-29","end_date":null,"nol_date":"2013-09-24","protocol_title":"\"AN OPTIONAL INVESTIGATION OF BIOMARKERS OF EFFICACY IN TH002 CLINICAL STUDY SUBJECTS.\"","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28113,"protocol_no":"NN2211-4059","submission_no":"167652","status_id":1,"start_date":"2011-11-14","end_date":null,"nol_date":"2013-09-20","protocol_title":"\"EFFICACY AND SAFETY OF SWITCHING FROM SITAGLIPTIN TO LIRAGLUTIDE IN SUBJECS WITH TYPE 2 DIABETES NOT ACHIEVING GLYCAEMIC CONTROL ON SITAGLIPTIN AND METFORMIN","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29511,"protocol_no":"ARD-3150-1201","submission_no":"172038","status_id":2,"start_date":"2014-12-11","end_date":"2017-01-17","nol_date":"2014-03-07","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PULMAQUIN¬Æ IN THE MANAGEMENT OF CHRONIC LUNG INFECTIONS WITH PSEUDOMONAS AERUGINOSA IN SUBJECTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS, INCLUDING 28 DAY OPEN-LABEL EXTENSION AND PHARMACOKINETIC SUBSTUDY (ORBIT-3)","medConditionList":[{"med_condition_id":497,"med_condition":"NON-CYSTIC FIBROSIS BRONCHIECTASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45396,"protocol_no":"200807","submission_no":"204302","status_id":1,"start_date":"2017-09-06","end_date":null,"nol_date":"2017-04-20","protocol_title":"A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER, EVENT DRIVEN STUDY IN DIALYSIS SUBJECTS WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE TO EVALUATE THE SAFETY AND EFFICACY OF DAPRODUSTAT COMPARED TO RECOMBINANT HUMAN ERYTHROPOIETIN, FOLLOWING A SWITCH FROM ERYTHROPOIETIN-STIMULATING AGENTS.¬ø","medConditionList":[{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37252,"protocol_no":"CRLX030A2208","submission_no":"177991","status_id":1,"start_date":"2015-07-14","end_date":null,"nol_date":"2014-10-15","protocol_title":"MULTICENTRE, OPEN-LABEL, DOSE ESCALATION STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RLX030 IN ADDITION TO STANDARD OF CARE IN PEDIATRIC PATIENT FROM BIRTH TO <18 YEARS OF AGE, HOSPITALIZED WITH ACUTR HEART FAILURE.","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36942,"protocol_no":"CNTO1959PSO3003","submission_no":"177034","status_id":1,"start_date":"2014-10-31","end_date":null,"nol_date":"2014-09-05","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GUSELKUMAB FOR THE TREATMENT OF SUBJECTS WITH MODERATE TO SEVERE PLAQUE-TYPE PSORIASIS AND AN INADEQUATE RESPONSE TO USTEKINUMAB","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36539,"protocol_no":"PCYC-1123-CA","submission_no":"175733","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-09","protocol_title":"A MULTICENTER OPEN-LABEL, RANDOMIZED PHASE 1B/2, STUDY OF THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB, IN COMBINATION WITH LENALIDOMIDE, WITH AND WITHOUT RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47670,"protocol_no":"TRX-237-039","submission_no":"211520","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-12","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, 6-MONTH, BRAIN IMAGING AND SAFETY STUDY OF LEUCO-METHYLTHIONINIUM BIS(HYDROMETHANESULFONATE) (LMTM) IN SUBJECTS WITH MILD ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43279,"protocol_no":"CT14B (ACHIV-EBOLA)","submission_no":"197694","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-09-15","protocol_title":"A PHASE 2 RANDOMIZED, MULTI-CENTER DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF THE V920 (RVSVG-ZEBOV-GP) EBOLA VIRUS VACCINE CANDIDATE IN HIV-INFECTED ADULTS AND ADOLESCENTS","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"},{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37672,"protocol_no":"D4190C00010","submission_no":"179359","status_id":1,"start_date":"2015-09-22","end_date":null,"nol_date":"2014-12-03","protocol_title":"A PHASE I STUDY OF MEDI4736 (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH TREMELIMUMAB (ANTI-CTLA-4 ANTIBODY) IN SUBJECTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43104,"protocol_no":"AC-058B302","submission_no":"197117","status_id":1,"start_date":"2017-08-23","end_date":null,"nol_date":"2016-10-18","protocol_title":"MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, ADD-ON, SUPERIORITY STUDY TO COMPARE THE EFFICACY AND SAFETY OF PONESIMOD TO PLACEBO IN SUBJECTS WITH ACTIVE RELAPSING MULTIPLE SCLEROSIS WHO ARE TREATED WITH DIMETHYL FUMARATE (TECFIDERA¬Æ).","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35655,"protocol_no":"PHL-092 / NCI 8875","submission_no":"173026","status_id":1,"start_date":"2014-11-14","end_date":null,"nol_date":"2014-07-04","protocol_title":"A PHASE II TRIAL IN WHICH PATIENTS WITH METASTATIC ALVEOLAR SOFT PART SARCOMA ARE RANDOMIZED TO EITHER SUNITINIB OR CEDIRANIB MONOTHERAPY, WITH CROSS-OVER AT DISEASE PROGRESSION","medConditionList":[{"med_condition_id":237,"med_condition":"SOFT TISSUE SARCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36167,"protocol_no":"C-935788-049","submission_no":"174700","status_id":1,"start_date":"2015-03-17","end_date":null,"nol_date":"2014-06-12","protocol_title":"A PHASE 3 OPEN LABEL EXTENSION STUDY OF FOSTAMATINIB DISODIUM IN THE TREATMENT OF PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA","medConditionList":[{"med_condition_id":498,"med_condition":"IDIOPATHIC THROMBOCYTOPENIC PURPURA (IPT)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28783,"protocol_no":"XL184-309","submission_no":"169839","status_id":1,"start_date":"2016-11-29","end_date":null,"nol_date":"2013-12-02","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF CABOZANTINIB (XL184) VS PLACEBO IN SUBJECTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED PRIOR SORAFENIB","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42196,"protocol_no":"FED001","submission_no":"194217","status_id":1,"start_date":"2016-06-06","end_date":null,"nol_date":"2016-05-20","protocol_title":"AN OBSERVATIONAL, OPEN-LABEL, NON-RANDOMIZED STUDY TO MONTIOR FOR ADVERSE DRUG REACTIONS AMONG PATIENTS ADMINISTERED FEDORAK-MANUFACTURED [F-18]-FDG INJECTION","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40499,"protocol_no":"WI189526","submission_no":"188327","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-05","protocol_title":"A STUDY TO COMPARE THE EFFECT OF FESOTRODINE 4MG AND 8MG AND OXYBUTYNIN 5MG TWICE DAILY AFTER STEADY STATE DOSING VERSUS PLACEBO IN SUBJECTS OVER AGE OF 75 YEARS WITH OVERACTIVE BLADDER (OAB) AND MILD COGNITIVE IMPAIRMENT (MCI) ¬ø A DOUBLE-BLIND, RANDOMIZED, CROSS OVER STUDY","medConditionList":[{"med_condition_id":185,"med_condition":"OVERACTIVE BLADDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35439,"protocol_no":"20130213","submission_no":"172386","status_id":2,"start_date":"2014-08-28","end_date":"2017-06-26","nol_date":"2014-03-26","protocol_title":"A MULTICENTER SINGLE-ARM EXTENSION STUDY TO DESCRIBE THE LONG-TERM SAFETY OF AMG 416 (VELCALCETIDE) IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN SUBJECTS WITH CHRONIC KIDNEY DISEASE ON HEMODIALYSIS","medConditionList":[{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"},{"med_condition_id":273,"med_condition":"SECONDARY HYPERPARATHYROIDISM"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28612,"protocol_no":"BRF117019","submission_no":"169167","status_id":1,"start_date":"2017-01-31","end_date":null,"nol_date":"2013-11-15","protocol_title":"A PHASE II, OPEN-LABEL, STUDY IN SUBJECTS WITH BRAF V600E-MUTATED RARE CANCERS WITH SEVERAL HISTOLOGIES TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF THE COMBINATION THERAPY OF DABRAFENIB AND TRAMETINIB","medConditionList":[{"med_condition_id":26,"med_condition":"BRAF MUTATION-POSITIVE TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47252,"protocol_no":"MS100070-0306","submission_no":"210352","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-14","protocol_title":"OPEN-LABEL, PHASE I/II STUDY TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND ANTICANCER ACTIVITY OF AVELUMAB IN PEDIATRIC SUBJECTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE WITH REFRACTORY OR RELAPSED SOLID TUMORS AND LYMPHOMA","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"},{"med_condition_id":691,"med_condition":"LYMPHOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42492,"protocol_no":"AL001","submission_no":"195168","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-17","protocol_title":"A STUDY TO EVALUATE THE SAFETY AND FEASIBILITY OF BLOOD-BRAIN BARRIER (BBB) OPENING USING TRANSCRANIAL MR-GUIDED FOCUSED ULTRASOUND WITH INTRAVENOUS ULTRASOUND CONTRAST AGENTS IN PATIENTS WITH EARLY ALZHEIMER¬øS DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39304,"protocol_no":"ESKETINTRD3001","submission_no":"184770","status_id":1,"start_date":"2016-10-21","end_date":null,"nol_date":"2015-06-19","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF FIXED DOSES OF INTRANASAL ESKETAMINE PLUS AN ORAL ANTIDEPRESSANT IN ADULT SUBJECTS WITH TREATMENT-RESISTANT DEPRESSION","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39448,"protocol_no":"ESKETINTRD3003","submission_no":"185292","status_id":1,"start_date":"2016-08-05","end_date":null,"nol_date":"2015-07-09","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED STUDY OF INTRANASAL ESKETAMINE PLUS AN ORAL ANTIDEPRESSANT FOR RELAPSE PREVENTION IN TREATMENT-RESISTANT DEPRESSION","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"},{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48452,"protocol_no":"CP-PRO-QVLP-013","submission_no":"213939","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-21","protocol_title":"A RANDOMIZED, OBSERVER-BLIND, ACTIVE COMPARATOR-CONTROLLED, SINGLE-CENTER, PHASE 2 STUDY TO COMPARE THE IMMUNE RESPONSE OF THE ELDERLY (~ 65 YEARS OLD) TO A PLANT-DERIVED QUADRIVALENT VLP INFLUENZA VACCINE VS STANDARD OR HIGH-DOSE SPLIT VIRUS VACCINE","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46699,"protocol_no":"LEAP","submission_no":"208394","status_id":1,"start_date":"2018-01-04","end_date":null,"nol_date":"2017-08-30","protocol_title":"IRREVERSIBLE ELECTROPORTATION FOR LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA (LEAP TRIAL): A PHASE I/II PROSPECTIVE TRIAL","medConditionList":[{"med_condition_id":678,"med_condition":"PANCREATIC DUCTAL ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46036,"protocol_no":"WVE-HDSNP2-001","submission_no":"206151","status_id":1,"start_date":"2017-07-13","end_date":null,"nol_date":"2017-06-21","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1B/2A STUDY OF WVE-120102 ADMINISTERED INTRATHECALLY IN PATIENTS WITH HUNTINGTON¬øS DISEASE","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42328,"protocol_no":"PULSE-PAH-004","submission_no":"194613","status_id":1,"start_date":"2018-02-19","end_date":null,"nol_date":"2016-06-15","protocol_title":"A PHASE 3, PLACEBO CONTROLLED, DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE (INO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): INOVATION-1","medConditionList":[{"med_condition_id":218,"med_condition":"PULMONARY ARTERIAL HYPERTENSION (PAH)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38970,"protocol_no":"GO29674","submission_no":"183761","status_id":1,"start_date":"2015-06-10","end_date":null,"nol_date":"2015-05-12","protocol_title":"\"A PHASE IB, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MOXR0916 AND MPDL3280A IN PATIENTS LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44164,"protocol_no":"CA209-816","submission_no":"200280","status_id":1,"start_date":"2017-07-21","end_date":null,"nol_date":"2016-12-21","protocol_title":"RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF NIVOLUMAB AND IPILIMUMAB VERSUS PLATINUM-DOUBLET CHEMOTHERAPY IN EARLY STAGE NSCLC","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43982,"protocol_no":"CO39385","submission_no":"199777","status_id":1,"start_date":"2017-07-19","end_date":null,"nol_date":"2016-11-16","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35517,"protocol_no":"GO28915","submission_no":"172635","status_id":1,"start_date":"2015-02-09","end_date":null,"nol_date":"2014-03-28","protocol_title":"A PHASE III, OPEN-LABEL, MULTICENTER RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-LI ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44547,"protocol_no":"AHIMSA-D","submission_no":"201680","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-02-14","protocol_title":"APREPITANT FOR HARMFUL, IMPULSIVE, OR SPONTANEOUS AGGRESSION IN DEMENTIA (AHIMSA-D): A PILOT STUDY","medConditionList":[{"med_condition_id":361,"med_condition":"DEMENTIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45488,"protocol_no":"CA223-001","submission_no":"204561","status_id":1,"start_date":"2017-07-18","end_date":null,"nol_date":"2017-05-05","protocol_title":"A PHASE 1/2 STUDY OF THE COMBINATION OF LIRILUMAB (ANTI-KIR) PLUS NIVOLUMAB (ANTI-PD-1) OR LIRILUMAB PLUS NIVOLUMAB AND IPILIMUMAB IN ADVANCED REFACTRORY SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44557,"protocol_no":"B7931005","submission_no":"201716","status_id":1,"start_date":"2017-10-18","end_date":null,"nol_date":"2017-02-03","protocol_title":"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE ALOPECIA AREATA","medConditionList":[{"med_condition_id":838,"med_condition":"ALOPECIA AREATA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42394,"protocol_no":"CNTO1275PSO3013","submission_no":"194807","status_id":1,"start_date":"2016-09-22","end_date":null,"nol_date":"2016-06-03","protocol_title":"A PHASE 3 OPEN-LABEL STUDY TO ASSESS THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUSLY ADMINISTERED USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVER CHRONIC PLAQUE PSORIASIS IN PEDIATRIC SUBJECTS >6 TO <12 YEARS OF AGE","medConditionList":[{"med_condition_id":689,"med_condition":"CHRONIC PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47691,"protocol_no":"233AS102","submission_no":"211577","status_id":1,"start_date":"2018-03-09","end_date":null,"nol_date":"2017-12-20","protocol_title":"AN EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECT ON DISEASE PROGRESSION OF BIIB067 ADMINISTERED TO PREVIOUSLY TREATED ADULTS WITH AMYOTROPHIC LATERAL SCLEROSIS CAUSED BY SUPEROXIDE DISMUTASE 1 MUTATION.","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45373,"protocol_no":"MO39196","submission_no":"204238","status_id":1,"start_date":"2017-09-22","end_date":null,"nol_date":"2017-04-13","protocol_title":"A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","medConditionList":[{"med_condition_id":702,"med_condition":"BREAST CANCER TRIPLE NEGATIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47429,"protocol_no":"CLSYN.1702","submission_no":"210897","status_id":1,"start_date":"2018-01-31","end_date":null,"nol_date":"2017-11-29","protocol_title":"A 2X2 FACTORIAL RANDOMIZED CONTROLLED TRIAL OF COLCHICINE AND SPIRONOLACTONE IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION/SYNERGY STENT REGISTRY ¬ø","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"},{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"},{"med_condition_id":243,"med_condition":"STROKE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41008,"protocol_no":"AAML1531","submission_no":"189924","status_id":1,"start_date":"2017-01-18","end_date":null,"nol_date":"2015-12-14","protocol_title":"RISK-STRATIFIED THERAPY FOR ACUTE MYELOID LEUKEMIA IN DOWN SYNDROME","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44263,"protocol_no":"1002-047","submission_no":"200573","status_id":1,"start_date":"2017-02-16","end_date":null,"nol_date":"2016-12-20","protocol_title":"A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF BEMPEDOIC ACID (ETC-1002) IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK NOT ADEQUATELY CONTROLLED BY THEIR LIPID-MODIFYING THERAPY","medConditionList":[{"med_condition_id":348,"med_condition":"HYPERLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42278,"protocol_no":"EZH-202","submission_no":"194473","status_id":1,"start_date":"2017-07-05","end_date":null,"nol_date":"2016-06-30","protocol_title":"A PHASE II, MULTICENTER STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN ADULT SUBJECTS WITH INI1-NEGATIVE TUMORS OR RELAPSED/REFRACTORY SYNOVIAL SARCOMA","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"},{"med_condition_id":334,"med_condition":"SARCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41720,"protocol_no":"20150195","submission_no":"192459","status_id":1,"start_date":"2016-12-14","end_date":null,"nol_date":"2016-03-23","protocol_title":"A PHASE 1B/2 STUDY ASSESSING SAFETY AND ANTI-TUMOR ACTIVITY OF AMG 820 IN COMBINATION WITH PEMBROLIZUMAB IN SELECT ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46523,"protocol_no":"GS-US-418-4279","submission_no":"207841","status_id":1,"start_date":"2017-10-27","end_date":null,"nol_date":"2017-08-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE TESTICULAR SAFETY OF FILGOTINIB IN ADULT MALES WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47060,"protocol_no":"I7S-MC-HBEH","submission_no":"209588","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-19","protocol_title":"EFFECT OF LY3154207 ON COGNITION IN MILD-TO-MODERATE PARKINSON¬øS DISEASE DEMENTIA (PDD) (THE PRESENCE STUDY)","medConditionList":[{"med_condition_id":361,"med_condition":"DEMENTIA"},{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45166,"protocol_no":"CPDR001C2101","submission_no":"203519","status_id":1,"start_date":"2017-11-28","end_date":null,"nol_date":"2017-04-06","protocol_title":"A PHASE 1B, MULTICENTER, OPEN LABEL STUDY OF PDR001 IN COMBINATION WITH PLATINUM-DOUBLET CHEMOTHERAPY IN PD-L1 UNSELECTED, METASTATIC NSCLC PATIENTS","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43390,"protocol_no":"ARST1431","submission_no":"197960","status_id":1,"start_date":"2016-12-22","end_date":null,"nol_date":"2016-09-28","protocol_title":"A RANDOMIZED PHASE 3 STUDY OF VINCRISTINE, DACTINOMYCIN, CYCLOPHOSPHAMIDE (VAC) ALTERNATING WITH VINCRISTINE AND IRINOTECAN (VI) VERSUS VAC/VI PLUS TEMSIROLIMUS (TORI, TORISEL, NSC# 683864, IND# 122782) IN PATIENTS WITH INTERMEDIATE RISK (IR) RHABDOMYOSARCOMA (RMS)","medConditionList":[{"med_condition_id":332,"med_condition":"RHABDOMYOSARCOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47488,"protocol_no":"D5134C00003","submission_no":"211063","status_id":1,"start_date":"2018-03-20","end_date":null,"nol_date":"2017-12-06","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE, PHASE III STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TICAGRELOR AND ASA COMPARED WITH ASA IN THE PREVENTION OF STROKE AND DEATH IN PATIENTS WITH ACUTE ISCHAEMIC STROKE OR TRANSIENT ISCHAEMIC ATTACK [THALES - ACUTE STROKE OR TRANSIENT ISCHAEMIC ATTACK TREATED WITH TICAGRELOR AND ASA FOR PREVENTION OF  STROKE AND DEATH","medConditionList":[{"med_condition_id":134,"med_condition":"ISCHEMIC ATTACK AND MINOR STROKE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46609,"protocol_no":"HZA107116","submission_no":"208091","status_id":1,"start_date":"2017-10-17","end_date":null,"nol_date":"2017-08-28","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, STUDY EVALUATING THE EFFICACY AND SAFETY OF ONCE DAILY FLUTICASONE FUROATE/VILANTEROL INHALATION POWDER COMPARED TO ONCE DAILY FLUTICASONE FUROATE INHALATION POWDER IN THE TREATMENT OF ASTHMA IN PARTICIPANTS AGED 5 TO 17 YEARS OLD (INCLUSIVE) CURRENTLY UNCONTROLLED ON INHALED CORTICOSTEROIDS.","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46799,"protocol_no":"20150183","submission_no":"208718","status_id":1,"start_date":"2018-04-04","end_date":null,"nol_date":"2017-09-14","protocol_title":"A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AMG 986 IN HEALTHY SUBJECTS AND HEART FAILURE PATIENTS","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39437,"protocol_no":"AB07002","submission_no":"185237","status_id":1,"start_date":"2016-01-13","end_date":null,"nol_date":"2015-07-09","protocol_title":"A 96-WEEK, PROSPECTIVE, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF MASITINIB 4.5 MG/KG/DAY VERSUS PLACEBO IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE OR RELAPSE-FREE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46788,"protocol_no":"CA021-002","submission_no":"208667","status_id":1,"start_date":"2017-12-11","end_date":null,"nol_date":"2017-09-20","protocol_title":"A PHASE 1/2 DOSE ESCALATION AND COHORT EXPANSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF BMS-986226 (ANTI-ICOS MAB) ALONE OR IN COMBINATION WITH NIVOLUMAB OR IPILIMUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43138,"protocol_no":"GS-US-417-0303","submission_no":"197284","status_id":1,"start_date":"2016-11-14","end_date":null,"nol_date":"2016-08-25","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, MULTICENTER, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF FILGOTINIB ADMINISTERED FOR 52 WEEKS ALONE AND IN COMBINATION WITH METHOTREXATE (MTX) TO SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO ARE NA√èVE TO MTX THERAPY","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47938,"protocol_no":"RGN-ADC-002","submission_no":"212528","status_id":1,"start_date":"2018-02-21","end_date":null,"nol_date":"2018-01-26","protocol_title":"A 6-MONTH, DOUBLE-BLIND, PHASE 2 STUDY AND 6-MONTH OPEN-LABEL EXTENSION EVALUATING THE SAFETY, TOLERABILITY, AND CLINICAL BENEFIT OF RPH201 IN INDIVIDUALS WITH ALZHEIMER¬øS DISEASE WITH OR WITHOUT COEXISTING CEREBROVASCULAR DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48172,"protocol_no":"EFC15294 (SOTA-BONE)","submission_no":"213149","status_id":1,"start_date":"2018-02-24","end_date":null,"nol_date":"2018-02-20","protocol_title":"A 26-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE 3 STUDY WITH A 78-WEEK EXTENSION PERIOD TO EVALUATE THE EFFICACY AND BONE SAFETY OF SOTAGLIFLOZIN IN PATIENTS 55 YEARS OR OLDER WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36660,"protocol_no":"GEMHDM2014","submission_no":"176164","status_id":1,"start_date":"2018-01-05","end_date":null,"nol_date":"2014-08-05","protocol_title":"INFUSIONAL GEMCITABINE AND HIGH-DOSE MELPHALAN CONDITIONING PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"},{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"},{"med_condition_id":481,"med_condition":"HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27054,"protocol_no":"AB11002","submission_no":"164631","status_id":1,"start_date":"2013-10-02","end_date":null,"nol_date":"2013-06-14","protocol_title":"A PROSPECTIVE, MULTICENTER, RANDOMISED, OPEN-LABEL, ACTIVE CONTROLLED, TWO-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF MASITINIB TO SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR AFTER PROGRESSION WITH IMATINIB","medConditionList":[{"med_condition_id":86,"med_condition":"GASTROINTESTINAL STROMAL TUMOR (GIST)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35702,"protocol_no":"IMM-11-0024","submission_no":"173181","status_id":1,"start_date":"2015-03-11","end_date":null,"nol_date":"2014-04-14","protocol_title":"OSTEOARTHRITIS OF THE KNEE, INFLAMMATION, AND THE EFFECT OF ADALIMUMAB (OKINADA): A RANDOMIZED PLACEBO-CONTROLLED TRIAL","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46224,"protocol_no":"MO39129","submission_no":"206779","status_id":1,"start_date":"2017-12-08","end_date":null,"nol_date":"2017-07-20","protocol_title":"A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS","medConditionList":[{"med_condition_id":98,"med_condition":"HEMOPHILIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47182,"protocol_no":"54767414SMM3001","submission_no":"210074","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-07","protocol_title":"A PHASE 3 RANDOMIZED, MULTICENTER STUDY OF SUBCUTANEOUS DARATUMUMAB VERSUS ACTIVE MONITORING IN SUBJECTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44807,"protocol_no":"PS0018","submission_no":"202508","status_id":1,"start_date":"2017-06-07","end_date":null,"nol_date":"2017-03-10","protocol_title":"A MULTICENTER, 48-WEEK, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":689,"med_condition":"CHRONIC PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41166,"protocol_no":"1311.28","submission_no":"190527","status_id":2,"start_date":"2016-07-15","end_date":"2017-12-05","nol_date":"2016-01-14","protocol_title":"BI 655066 VERSUS USTEKINUMAB AND PLACEBO COMPARATORS IN A RANDOMIZED DOUBLE BLIND TRIAL FOR MAINTENANCE USE IN MODERATE TO SEVERE PLAQUE TYPE PSORIASIS-2 (ULTIMMA-2)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48496,"protocol_no":"18-0001-A","submission_no":"214057","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-22","protocol_title":"PREVENTION OF POSTPARTUM HAEMORRHAGE - ADDRESSING CRITICAL KNOWLEDGE GAPS FOR THE USE OF TRANEXAMIC ACID  STUDY 1  DOSE-FINDING STUDY","medConditionList":[{"med_condition_id":590,"med_condition":"HEMORRHAGE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41675,"protocol_no":"2013-000266-11 (ENGOT OV-23)","submission_no":"192298","status_id":1,"start_date":"2017-11-24","end_date":null,"nol_date":"2016-03-16","protocol_title":"MULTICENTER RANDOMIZED TRIAL OF CARBOPLATIN +/- PACLITAXEL IN VULNERABLE ELDERLY PATIENTS WITH STAGE III-IV ADVANCED OVARIAN CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45418,"protocol_no":"HYDRA-1","submission_no":"204364","status_id":1,"start_date":"2018-01-08","end_date":null,"nol_date":"2017-05-05","protocol_title":"TITLE: A PHASE I/II TRIAL INVESTIGATING THE TOLERABILITY, TOXICITY AND EFFICACY OF HYDROXYCHLOROQUINE AND ITRACONAZOLE IN PATIENTS WITH ADVANCED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (EOC)","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38860,"protocol_no":"CA209-153","submission_no":"183432","status_id":1,"start_date":"2015-07-27","end_date":null,"nol_date":"2015-04-30","protocol_title":"\"A PHASE IIIB/IV SAFETY TRIAL OF NIVOLUMAB (BMS-936558) IN SUBJECTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE PROGRESSED DURING OR AFTER RECEIVING AT LEAST ONE PRIOR SYSTEMIC REGIMEN CHECKMATE 153: CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 153.\"","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40670,"protocol_no":"56021927PCR1019","submission_no":"188773","status_id":1,"start_date":"2015-12-18","end_date":null,"nol_date":"2015-11-20","protocol_title":"AN OPEN-LABEL PHASE 1B QT/QTC STUDY OF JNJ-56021927 (ARN-509) IN SUBJECTS WITH CASTRATION-RESISTANT PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47766,"protocol_no":"15-006","submission_no":"211862","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-02","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED-WITHDRAWAL, MULTICENTER STUDY OF THE","medConditionList":[{"med_condition_id":656,"med_condition":"NARCOLEPSY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40535,"protocol_no":"242-2014","submission_no":"188418","status_id":1,"start_date":"2016-03-29","end_date":null,"nol_date":"2015-11-20","protocol_title":"MULTIPARAMETRIC MRI FOR PROSTATE CANCER LOCALIZATION AND CHARACTERIZATION USING HYPERPOLARIZED PYRUVATE (13C) INJECTION","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"},{"med_condition_id":304,"med_condition":"MRI IMAGING"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39623,"protocol_no":"NN9536-4153","submission_no":"185883","status_id":1,"start_date":"2015-10-23","end_date":null,"nol_date":"2015-07-28","protocol_title":"INVESTIGATION OF SAFETY AND EFFICACY OF ONCE-DAILY SEMAGLUTIDE IN OBESE SUBJECTS WITHOUT DIABETES MELLITUS","medConditionList":[{"med_condition_id":415,"med_condition":"OVERWEIGHT/OBESITY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44906,"protocol_no":"MK-3475-091","submission_no":"202793","status_id":1,"start_date":"2017-08-25","end_date":null,"nol_date":"2017-03-15","protocol_title":"A RANDOMIZED, PHASE 3 TRIAL WITH ANTI-PDF-1 MONOCLONAL ANTIBODY PEMBROLIZUMAB (MK-3475) VERSUS PLACEBO FOR PATIENTS WITH EARLY STAGE NSCLC AFTER RESECTION AND COMPLETION OF STANDARD ADJUVANT THERAPY (PEARLS)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44014,"protocol_no":"VX15-809-115","submission_no":"199845","status_id":2,"start_date":"2017-08-18","end_date":"2017-09-01","nol_date":"2016-11-29","protocol_title":"A PHASE 3, 2-PART, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF LUMACAFTOR/IVACAFTOR COMBINATION THERAPY IN SUBJECTS AGED 2 THROUGH 5 YEARS WITH CYSTIC FIBROSIS, HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43666,"protocol_no":"B9991016","submission_no":"198851","status_id":1,"start_date":"2017-06-14","end_date":null,"nol_date":"2016-10-27","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH SOC CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VS SOC CHEMORADIOTHERAPY IN FRONT-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOS CELL CARCINOMA","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43022,"protocol_no":"EC1456-01","submission_no":"196898","status_id":2,"start_date":null,"end_date":"2018-03-16","nol_date":"2016-08-19","protocol_title":"A PHASE 1A/B STUDY OF THE FOLIC ACID-TUBULYSIN CONJUGATE EC1456 IN PATIENTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41118,"protocol_no":"1613E","submission_no":"190376","status_id":1,"start_date":"2017-11-15","end_date":null,"nol_date":"2016-01-07","protocol_title":"A SINGLE-BLINDED, RANDOMIZED, CONTROLLED, PHASE 2 PILOT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DENOSUMAB COMPARED TO ZOLEDRONIC ACID FOR THE TREATMENT OF OSTEOPOROSIS IN CHILDREN","medConditionList":[{"med_condition_id":181,"med_condition":"OSTEROPOROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42602,"protocol_no":"1237.28","submission_no":"195534","status_id":2,"start_date":"2016-09-20","end_date":"2017-12-21","nol_date":"2016-06-28","protocol_title":"A RANDOMISED, DOUBLE-BLIND, CROSS-OVER STUDY TO EVALUATE THE EFFECT OF 6 WEEKS TREATMENT OF ORALLY INHALED TIOTROPIUM + OLODATEROL FIXED DOSE COMBINATION (5/5 ¬øG) COMPARED WITH TIOTROPIUM (5 ¬øG), BOTH DELIVERED BY THE RESPIMAT¬Æ INHALER, ON BREATHLESSNESS DURING THE THREE MINUTE CONSTANT SPEED SHUTTLE TEST (3MIN CSST) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39000,"protocol_no":"14-003","submission_no":"183847","status_id":2,"start_date":"2015-10-05","end_date":"2016-12-23","nol_date":"2015-05-20","protocol_title":"A TWELVE-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP-110 [(R)-2-AMINO-3-PHENYLPROPYLCARBAMATE HYDROCHLORIDE] IN THE TREATMENT OF EXCESSIVE SLEEPINESS IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA (OSA).","medConditionList":[{"med_condition_id":310,"med_condition":"SLEEP APNEA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42891,"protocol_no":"M14-533","submission_no":"196545","status_id":1,"start_date":"2016-12-09","end_date":null,"nol_date":"2016-07-28","protocol_title":"A PHASE 3 MULTICENTER, OPEN-LABEL EXTENSION (OLE) STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF ABT-494 IN SUBJECTS WITH ULCERATIVE COLITIS (UC)","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42894,"protocol_no":"39039039CHD3001 (IMPACT 18226)","submission_no":"196553","status_id":1,"start_date":"2017-03-21","end_date":null,"nol_date":"2016-08-02","protocol_title":"A PROSPECTIVE, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND EFFICACY OF RIVAROXABAN FOR THROMBOPROPHYLAXIS IN PEDIATRIC SUBJECTS 2 TO 8 YEARS OF AGE AFTER THE FONTAN PROCEDURE.","medConditionList":[{"med_condition_id":751,"med_condition":"THROMBOPHYLAXIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42547,"protocol_no":"D3461C00009","submission_no":"195330","status_id":1,"start_date":"2017-02-22","end_date":null,"nol_date":"2016-06-23","protocol_title":"A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 EXTENSION STUDY TO CHARACTERIZE THE LONG TERM SAFETY AND TOLERABILITY OF ANIFROLUMAB IN ADULT SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS","medConditionList":[{"med_condition_id":311,"med_condition":"SYSTEMIC LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46744,"protocol_no":"ATX201-003","submission_no":"208552","status_id":1,"start_date":"2017-09-18","end_date":null,"nol_date":"2017-09-14","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, INTRAINDIVIDUAL, VEHICLE-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICALLY APPLIED ATX201 IN SUBJECTS WITH MODERATE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42655,"protocol_no":"B9991001","submission_no":"195740","status_id":1,"start_date":"2016-12-20","end_date":null,"nol_date":"2016-07-15","protocol_title":"PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM, STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS BSC ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42582,"protocol_no":"B7601003","submission_no":"195467","status_id":2,"start_date":"2017-05-23","end_date":"2018-01-17","nol_date":"2016-06-24","protocol_title":"A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40097,"protocol_no":"GS-US-311-1717","submission_no":"187085","status_id":1,"start_date":"2015-10-20","end_date":null,"nol_date":"2015-09-15","protocol_title":"A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, SWITCH STUDY TO EVALUATE F/TAF IN HIV-1 INFECTED SUBJECTS WHO ARE VIROLOGICALLY SUPPRESSED ON REGIMENS CONTAINING ABC/3TC","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40749,"protocol_no":"GS-US-367-1170","submission_no":"189005","status_id":2,"start_date":"2016-01-21","end_date":"2017-01-18","nol_date":"2015-11-27","protocol_title":"A PHASE 3, GLOBAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/GS 9857 FIXED-DOSE COMBINATION FOR 12 WEEKS AND SOFOSBUVIR/VELPATASVIR FOR 12 WEEKS IN DIRECT ACTING ANTIVIRAL-EXPERIENCED SUBJECTS WITH CHRONIC HCV INFECTION WHO HAVE NOT RECEIVED AN NS5A INHIBITOR","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47028,"protocol_no":"ARC011","submission_no":"209532","status_id":1,"start_date":"2017-11-14","end_date":null,"nol_date":"2017-10-20","protocol_title":"REAL-WORLD AR101 MARKET-SUPPORTING EXPERIENCE STUDY IN PEANUT-ALLERGIC CHILDREN, ACTIVE TREATMENT ARM OPEN-LABEL EXTENSION STUDY (RAMSES OLE)","medConditionList":[{"med_condition_id":12,"med_condition":"ALLERGIES PEANUT"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47500,"protocol_no":"CA224-022","submission_no":"211104","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-08","protocol_title":"A PHASE 1/2A DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-LAG-3 MONOCLONAL ANTIBODY (BMS-986016) ADMINISTERED ALONE AND IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY (NIVOLUMAB, BMS-936558) IN RELAPSED OR REFRACTORY B-CELL MALIGNANCIES","medConditionList":[{"med_condition_id":815,"med_condition":"B-CELL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46463,"protocol_no":"ALN-AT3SC-003","submission_no":"207659","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-14","protocol_title":"A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FITUSIRAN IN PATIENTS WITH","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"},{"med_condition_id":100,"med_condition":"HEMOPHILIA B"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37477,"protocol_no":"CL003_168","submission_no":"178744","status_id":2,"start_date":"2015-05-11","end_date":"2016-07-18","nol_date":"2014-11-13","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ASSESSMENT PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCX168 IN SUBJECTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS","medConditionList":[{"med_condition_id":444,"med_condition":"VASCULAR INFLAMMATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38485,"protocol_no":"CLDK378A2120C","submission_no":"182188","status_id":1,"start_date":"2017-04-12","end_date":null,"nol_date":"2015-03-12","protocol_title":"A MULTI-CENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF COMBINATION CERITINIB (LDK378) AND NIVOLUMAB IN ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26684,"protocol_no":"ISIS 396443-CS3A","submission_no":"163484","status_id":2,"start_date":"2015-08-06","end_date":"2017-08-21","nol_date":"2013-04-23","protocol_title":"A STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF ISIS 396443 DELIVERED INTRATHECALLY TO PATIENTS WITH INFANTILE-ONSET SPINAL MUSCULAR ATROPHY","medConditionList":[{"med_condition_id":321,"med_condition":"SPINAL MUSCULAR ATROPHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46948,"protocol_no":"MK-3475-418","submission_no":"209273","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-11","protocol_title":"A MULTI-CENTRE, SINGLE ARM, PHASE 2 TRIAL OF PEMBROLIZUMAB IN TREATMENT NAIVE PATIENTS WITH POOR PROGNOSIS CARCINOMA OF UNKNOWN PRIMARY SITE","medConditionList":[{"med_condition_id":813,"med_condition":"CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46263,"protocol_no":"NN1250-4300","submission_no":"206740","status_id":1,"start_date":"2017-11-22","end_date":null,"nol_date":"2017-07-26","protocol_title":"EXPECT: A TRIAL COMPARING THE EFFECT AND SAFETY OF INSULIN DEGLUDEC VERSUS INSULIN DETEMIR, BOTH IN COMBINATION WITH INSULIN ASPART, IN THE TREATMENT OF PREGNANT WOMEN WITH TYPE 1 DIABETES (VERSION 1.0, DATED 24 MAY 2017)","medConditionList":[{"med_condition_id":767,"med_condition":"GESTATIONAL DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39062,"protocol_no":"SJMB12","submission_no":"184007","status_id":1,"start_date":"2017-04-12","end_date":null,"nol_date":"2015-05-22","protocol_title":"A CLINICAL AND MOLECULAR RISK-DIRECTED THERAPY FOR NEWLY DIAGNOSED MEDULLOBLASTOMA","medConditionList":[{"med_condition_id":460,"med_condition":"MEDULLOBLASTOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28142,"protocol_no":"Q-CROC-06","submission_no":"167726","status_id":1,"start_date":"2014-10-28","end_date":null,"nol_date":"2013-09-24","protocol_title":"A PHASE II EXPLORATORY STUDY TO IDENTIFY BIOMARKERS PREDICTIVE OF CLINICAL RESPONSE TO REGORAFENIB IN PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE FAILED FIRST-LINE THERAPY","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39892,"protocol_no":"1311.20","submission_no":"186549","status_id":1,"start_date":"2016-02-05","end_date":null,"nol_date":"2015-08-31","protocol_title":"AN OPEN LABEL, SINGLE GROUP, LONG TERM SAFETY EXTENSION TRIAL OF BI 655066, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45871,"protocol_no":"PRO49327","submission_no":"205719","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-08","protocol_title":"EFFECT OF FECAL MICROBIOTA TRANSPLANTATION (FMT) ON FATTY LIVER AND METABOLIC PARAMETERS IN OVERWEIGHT OR OBESE SUBJECTS WITH INSULIN RESISTANCE: A RANDOMIZED PLACEBO CONTROLLED TRIAL","medConditionList":[{"med_condition_id":142,"med_condition":"LIVER DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37665,"protocol_no":"N/A","submission_no":"177782","status_id":1,"start_date":"2014-11-12","end_date":null,"nol_date":"2014-11-05","protocol_title":"PROTOCOL FOR USE OF A RECOMBINANT VESICULAR STOMATITIS VIRUS EXPRESSING THE ENVELOPE GLYCOPROTEIN OF EBOLAVIRUS ZAIRE (RVSV ZEBOV-GP) VACCINE FOR POST-EXPOSURE PROPHYLAXIS FOR EBOLA VIRUS EXPOSURE","medConditionList":[{"med_condition_id":582,"med_condition":"EBOLA VIRUS INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36401,"protocol_no":"BIL-MEK","submission_no":"175050","status_id":1,"start_date":"2016-05-25","end_date":null,"nol_date":"2014-06-27","protocol_title":"A RANDOMIZED PHASE II TRIAL OF MEK INHIBITOR SELUMETINIB (AZD6244) COMBINED CONTINUOUSLY OR SEQUENTIALLY WITH CISPLATIN/GEMCITABINE (CIS/GEM) VERSUS CIS/GEM ALONE IN PATIENTS WITH ADVANCED BILIARY CANCER","medConditionList":[{"med_condition_id":458,"med_condition":"BILIARY CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44112,"protocol_no":"AC-055-312","submission_no":"200156","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-07","protocol_title":"A MULTICENTER, OPEN-LABEL, RANDOMIZED, EVENT-DRIVEN STUDY TO ASSESS EFFICACY, SAFETY AND PHARMACOKINETICS OF MACITENTAN VERSUS STANDARD OF CARE IN CHILDREN WITH PULMONARY ARTERIAL HYPERTENSION.","medConditionList":[{"med_condition_id":218,"med_condition":"PULMONARY ARTERIAL HYPERTENSION (PAH)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47498,"protocol_no":"21-BT-0812","submission_no":"211099","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-04","protocol_title":"NEBIVOLOL FOR INSOMNIA IN MONOTHERAPY (NIM TRIAL) - PHASE II CLINICAL TRIAL TESTING THE SAFETY AND EFFICACY OF NEBIVOLOL HYDROCHLORIDE MONOTHERAPY PRODUCT IN SUBJECTS WITH INSOMNIA.","medConditionList":[{"med_condition_id":737,"med_condition":"INSOMNIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44886,"protocol_no":"CL2-42909-016","submission_no":"202731","status_id":1,"start_date":"2017-09-11","end_date":null,"nol_date":"2017-03-29","protocol_title":"DOSE-RESPONSE RELATIONSHIP STUDY OF S42909 ON LEG ULCER HEALING AFTER ORAL REPEATED ADMINISTRATION IN PATIENTS WITH ACTIVE VENOUS LEG ULCER.","medConditionList":[{"med_condition_id":594,"med_condition":"ULCERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26850,"protocol_no":"PHL-090 / NCI 9271","submission_no":"164048","status_id":1,"start_date":"2017-05-26","end_date":null,"nol_date":"2013-05-02","protocol_title":"PHASE 2 TRIAL OF SINGLE-AGENT IBRUTINIB (PCI-32765) IN RELAPSED AND REFRACTORY FOLLICULAR LYMPHOMA","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40147,"protocol_no":"D419BC00001","submission_no":"187223","status_id":1,"start_date":"2015-12-16","end_date":null,"nol_date":"2015-10-02","protocol_title":"A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER, GLOBAL STUDY OF FIRST-LINE MEDI4736 MONOTHERAPY AND MEDI4736 IN COMBINATION WITH TREMELIMUMAB VERSUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH UNRESECTABLE STAGE IV UROTHELIAL BLADDER CANCER","medConditionList":[{"med_condition_id":625,"med_condition":"BLADDER CANCER"},{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40417,"protocol_no":"IM101-550","submission_no":"188003","status_id":1,"start_date":"2017-07-14","end_date":null,"nol_date":"2015-10-23","protocol_title":"A PHASE 3B, RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT SC IN COMBINATION WITH METHOTREXATE COMPARED TO METHOTREXATE MONOTHERAPY IN ACHIEVING CLINICAL REMISSION IN ADULTS WITH EARLY RHEUMATOID ARTHRITIS WHO ARE METHOTREXATE NAIVE","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48469,"protocol_no":"TRX-237-040","submission_no":"213983","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-23","protocol_title":"LMTM FOR THE TREATMENT OF MILD-MODERATE ALZHEIMER'S DISEASE: INDIVIDUAL PATIENT USE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42766,"protocol_no":"CA001-044","submission_no":"196169","status_id":1,"start_date":"2016-12-22","end_date":null,"nol_date":"2016-07-22","protocol_title":"A PHASE 1/2 RANDOMIZED TRIAL OF BMS-986012 IN COMBINATION WITH PLATINUM AND ETOPOSIDE AS FIRST-LINE THERAPY IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47986,"protocol_no":"ESR-16-12515","submission_no":"212617","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-31","protocol_title":"THE EFFECT OF BENRALIZUMAB ON LUNG PHYSIOLOGY, EXERCISE-INDUCED BRONCHOCONSTRICTION AND GENERAL HEALTH STATUS: AN EXPLORATORY MECHANISTIC STUDY","medConditionList":[{"med_condition_id":818,"med_condition":"BRONCHOCONSTRICTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47564,"protocol_no":"DRM01B-ACN06","submission_no":"211261","status_id":2,"start_date":null,"end_date":"2018-03-13","nol_date":"2017-12-06","protocol_title":"AN OPEN-LABEL SAFETY AND PHARMACOKINETIC STUDY OF OLUMACOSTAT GLASARETIL GEL APPLIED UNDER MAXIMUM USE CONDITIONS IN PATIENTS WITH ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39786,"protocol_no":"CR-AIR-008","submission_no":"186276","status_id":1,"start_date":"2015-10-14","end_date":null,"nol_date":"2015-08-14","protocol_title":"AN EXPLORATORY, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A TWO-DOSE REGIMEN OF ATIR101 IN PATIENTS WITH HEMATOLOGIC MALIGNANCY, WHO RECEIVED A CD34-SELECTED HSCT FROM A HAPLOIDENTICAL DONOR","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43193,"protocol_no":"D419NC00001","submission_no":"197450","status_id":1,"start_date":"2017-03-29","end_date":null,"nol_date":"2016-09-07","protocol_title":"A PHASE I STUDY OF DURVALUMAB AND IPH2201 IN ADULT SUBJECTS WITH SELECT ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41422,"protocol_no":"AI444-379","submission_no":"191465","status_id":2,"start_date":"2016-04-19","end_date":"2017-07-31","nol_date":"2016-02-18","protocol_title":"A PHASE 3 EVALUATION OF DACLATASVIR AND SOFOSBUVIR WITH RIBAVIRIN IN CIRRHOTIC SUBJECTS WITH GENOTYPE 3 CHRONIC HEPATITIS C INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"},{"med_condition_id":108,"med_condition":"HEPATITIS C VIRUS GENOTYPE 3"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45533,"protocol_no":"CLIK066B2204","submission_no":"204715","status_id":1,"start_date":"2017-10-18","end_date":null,"nol_date":"2017-05-05","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP DOSE-FINDING STUDY TO ASSESS THE EFFECT OF 3 DOSES OF LIK066 COMPARED TO PLACEBO OR EMPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS PATIENTS WITH HEART FAILURE.","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44668,"protocol_no":"H16-01905","submission_no":"202018","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-02-22","protocol_title":"A SINGLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 18F-FLUORODEOXYGALACTOSE (18F-FDGAL) COMPARED TO 18F-FFLUORODEOXYGLUCOSE (18F-FDG) TO DETECT HEPATOCELLULAR CARCINOMA VIA PET/CT IN PATIENTS WITH CIRRHOSIS OR CHRONIC LIVER DISEASE","medConditionList":[{"med_condition_id":142,"med_condition":"LIVER DISEASE"},{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"},{"med_condition_id":772,"med_condition":"CIRRHOSIS OF THE LIVER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42288,"protocol_no":"54861911ALZ2003","submission_no":"194489","status_id":1,"start_date":"2017-07-12","end_date":null,"nol_date":"2016-05-24","protocol_title":"A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF JNJ-54861911 IN SUBJECTS WHO ARE ASYMPTOMATIC AT RISK FOR DEVELOPING ALZHEIMER'S DEMENTIA","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43884,"protocol_no":"GS-US-402-1852","submission_no":"199494","status_id":2,"start_date":"2017-03-03","end_date":"2018-01-09","nol_date":"2016-11-18","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF GS 9674 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)","medConditionList":[{"med_condition_id":734,"med_condition":"NONALCOHOLIC STEATOHEPATITIS (NASH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40376,"protocol_no":"GS-US-337-1746","submission_no":"187848","status_id":2,"start_date":"2015-12-09","end_date":"2017-05-29","nol_date":"2015-10-09","protocol_title":"A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LEDIPASVIR/SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN, IN HCV INFECTED SUBJECTS WHO HAVE FAILED PRIOR TREATMENT WITH SOFOSBUVIR-BASED THERAPIES; GS-US-337-1746","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45531,"protocol_no":"CO.27/IROCAS-UC-0110/1609","submission_no":"204701","status_id":1,"start_date":"2016-07-15","end_date":null,"nol_date":"2017-05-02","protocol_title":"A PHASE III, RANDOMISED, INTERNATIONAL TRIAL COMPARING MFOLFIRINOX TRIPLET CHEMOTHERAPY TO MFOLFOX FOR HIGH-RISK STAGE III COLON CANCER IN ADJUVANT SETTING","medConditionList":[{"med_condition_id":49,"med_condition":"COLON CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39179,"protocol_no":"CA008-002","submission_no":"184383","status_id":1,"start_date":"2016-03-19","end_date":null,"nol_date":"2015-06-05","protocol_title":"\"A PHASE I/IIA STUDY OF BMS 986148, A MESOTHELIN DIRECTED ANTIBODY DRUG CONJUGATE, IN SUBJECTS WITH SELECT ADVANCED SOLID TUMORS.\"","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44714,"protocol_no":"PCYC-1140-IM","submission_no":"202168","status_id":1,"start_date":"2018-04-05","end_date":null,"nol_date":"2017-02-13","protocol_title":"A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH CORTICOSTEROIDS VERSUS PLACEBO IN COMBINATION WITH CORTICOSTEROIDS IN SUBJECTS WITH NEW ONSET CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)","medConditionList":[{"med_condition_id":370,"med_condition":"GRAFT VS HOST DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35592,"protocol_no":"435-2013","submission_no":"172848","status_id":1,"start_date":"2014-06-09","end_date":null,"nol_date":"2014-04-04","protocol_title":"NITROUS OXIDE AS A PUTATIVE NOVEL DUAL-MECHANISM TREATMENT FOR BIPOLAR DISORDER","medConditionList":[{"med_condition_id":501,"med_condition":"BIPOLAR DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43332,"protocol_no":"201584","submission_no":"197808","status_id":1,"start_date":"2017-03-03","end_date":null,"nol_date":"2016-09-30","protocol_title":"A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, OPEN-LABEL STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF LONG-ACTING INTRAMUSCULAR CABOTEGRAVIR AND RILPIVIRINE FOR MAINTENANCE OF VIROLOGIC SUPPRESSION FOLLOWING SWITCH FROM AN INTEGRASE INHIBITOR SINGLE TABLET REGIMEN IN HIV-1 INFECTED ANTIRETROVIRAL THERAPY NAIVE ADULT PARTICIPANTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41615,"protocol_no":"15-9475","submission_no":"192058","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-23","protocol_title":"THE EFFECT OF INTRANASAL INSULIN ON HEPATIC AND INTESTINAL TRIGLYCERIDE-RICH LIPOPROTEIN PRODUCTION","medConditionList":[{"med_condition_id":679,"med_condition":"LIPOPROTEIN PRODUCTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41503,"protocol_no":"MUST BE ASSIGNED","submission_no":"191678","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-09","protocol_title":"INCOBOTULINUMTOXINA FOR THE AESTHETIC CONTOURING OF HYPERTROPHIC GASTROCNEMIUS MUSCLES","medConditionList":[{"med_condition_id":674,"med_condition":"HYPERTROPHIC GASTROCNEMIUS MUSCLES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37144,"protocol_no":"191622-142","submission_no":"177686","status_id":1,"start_date":"2016-02-01","end_date":null,"nol_date":"2014-10-03","protocol_title":"EVALUATION OF THE SAFETY AND EFFICACY OF TREATMENT WITH BOTOX (BOTULIUNUM TOXIN TYPE A) PURIFIED NEUROTOXIN COMPLEX FOR SUBJECTS WITH FOREHEAD AND GLABELLAR FACIAL RHYTIDES","medConditionList":[{"med_condition_id":380,"med_condition":"GLABELLAR LINES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37179,"protocol_no":"1160.189","submission_no":"177788","status_id":1,"start_date":"2015-03-30","end_date":null,"nol_date":"2014-10-06","protocol_title":"RANDOMIZED, DOUBLE-BLIND, EVALUATION IN SECONDARY STROKE PREVENTION COMPARING THE EFFICACY AND SAFETY OF THE ORAL THROMBIN INHIBITOR DABIGATRAN ETEXILATE (110 MG OR 150 MG, ORAL B.I.D.) VERSUS ACETYLSALICYLIC ACID (100 MG ORAL Q.D.) IN PATIENTS WITH EMBOLIC STROKE OF UNDETERMINED SOURCE (RESPECT ESUS)","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44474,"protocol_no":"2016-001-PS","submission_no":"201465","status_id":1,"start_date":"2017-05-03","end_date":null,"nol_date":"2017-02-09","protocol_title":"NMDA ANTAGONISTS AND STEROIDS FOR THE PREVENTION OF PERSISTING POST-SURGICAL PAIN AFTER THORACOSCOPIC SURGERIES: A RANDOMIZED CONTROLLED, FACTORIAL DESIGN, INTERNATIONAL, MULTICENTRE PILOT STUDY","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28565,"protocol_no":"FSG117283","submission_no":"168995","status_id":1,"start_date":"2014-11-11","end_date":null,"nol_date":"2013-11-13","protocol_title":"STUDY OF LOSMAPIMOD TO REDUCE PROTEINURIA IN CORTICOSTEROID OR CALCINEURIN INHIBITOR RESISTANT IDIOPATHIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)","medConditionList":[{"med_condition_id":476,"med_condition":"FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46242,"protocol_no":"021-04","submission_no":"206664","status_id":1,"start_date":"2017-09-25","end_date":null,"nol_date":"2017-07-20","protocol_title":"A PHASE II, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMENT OF MK-3682B (MK-5172 + MK-3682 + MK-8408 FIXED DOSE COMBINATION (FDC)) IN SUBJECTS WITH CHRONIC HCV GT1 OR GT3 INFECTION WHO HAVE FAILED A DIRECT ACTING ANTIVIRAL REGIMEN","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27818,"protocol_no":"FTDOXY13EF","submission_no":"166786","status_id":1,"start_date":"2013-08-27","end_date":null,"nol_date":"2013-08-26","protocol_title":"THE IMPACT OF EMOTIONAL MIMICRY AND OXYTOCIN ON FTD","medConditionList":[{"med_condition_id":346,"med_condition":"FRONTOTEMPORAL DEMENTIA"},{"med_condition_id":347,"med_condition":"PICK'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35529,"protocol_no":"C-935788-047","submission_no":"172676","status_id":2,"start_date":"2014-11-24","end_date":"2016-09-20","nol_date":"2014-04-02","protocol_title":"A PHASE 3 MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY OF 24 WEEKS OF TREATMENT WITH FOSTAMATINIB (R788) VS. PLACEBO IN ACHIEVING A STABLE PLATELET COUNT IN SUBJECTS WITH PERSISTENT/CHRONIC ITP","medConditionList":[{"med_condition_id":498,"med_condition":"IDIOPATHIC THROMBOCYTOPENIC PURPURA (IPT)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40862,"protocol_no":"030-00","submission_no":"189507","status_id":1,"start_date":"2016-12-09","end_date":null,"nol_date":"2015-12-10","protocol_title":"A PHASE IIA MULTICENTER, OPEN-LABEL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF MK-1439A IN TREATMENT-NA√èVE HIV-1 INFECTED SUBJECTS WITH SELECTED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) TRANSMITTED RESISTANCE MUTATIONS.","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47700,"protocol_no":"ECT-001.003","submission_no":"211596","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-22","protocol_title":"A PHASE I-II OPEN-LABEL STUDY OF NONMYELOABLATIVE (NMA) ALLOGENEIC TRANSPLANT OF ECT-001 (UM171/FED-BATCH CULTURE SYSTEM) EXPANDED UMBILICAL CORD BLOOD (UCB) IN PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA (MM)","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28789,"protocol_no":"BMT CTN 1204","submission_no":"169851","status_id":1,"start_date":"2014-10-27","end_date":null,"nol_date":"2013-12-12","protocol_title":"REDUCING-INTENSITY CONDITIONING FOR CHILDREN AND ADULTS WITH HEMOPHAGOCYTIC SYNDROMES OR SELECTED PRIMARY IMMUNE DEFICIENCIES (RICHI)","medConditionList":[{"med_condition_id":210,"med_condition":"PRIMARY IMMUNODEFICIENCY DISEASES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46209,"protocol_no":"D5160C00006","submission_no":"206752","status_id":1,"start_date":"2018-01-29","end_date":null,"nol_date":"2017-07-21","protocol_title":"A MULTI-ARM, PHASE IB, OPEN-LABEL, MULTICENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF AZD9291 IN COMBINATION WITH ASCENDING DOSES OF NOVEL THERAPEUTICS IN PATIENTS WITH EGFRM+ ADVANCED NSCLC WHO HAVE PROGRESSED FOLLOWING THERAPY WITH AN EGFR TKI (TATTON)","medConditionList":[{"med_condition_id":518,"med_condition":"EGFR MUTATION SOLID MALIGNANCIES"},{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37520,"protocol_no":"18445","submission_no":"178589","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-22","protocol_title":"USE OF KINEMATIC ASSESSMENT OF HAND TREMOR PRE-AND POST-TREATMENT WITH BOTULINUM TOXIN TYPE A IN ESSENTIAL TREMOR AND PARKINSON DISEASE","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38448,"protocol_no":"CINC424B2001X","submission_no":"182062","status_id":2,"start_date":"2015-06-17","end_date":"2017-04-01","nol_date":"2015-03-12","protocol_title":"AN OPEN-LABEL, MULTI-CENTER, EXPANDED TREATMENT PROTOCOL (ETP) OF RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA WHO ARE HYDROXYUREA RESISTANT OR INTOLERANT AND FOR WHOM NO TREATMENT ALTERNATIVES ARE AVAILABLE","medConditionList":[{"med_condition_id":199,"med_condition":"POLYCYTHEMIA VERA (PV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37603,"protocol_no":"AN-IGN3321","submission_no":"179123","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-11-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BLISIBIMOD ADMINISTRATION IN SUBJECTS WITH IGA NEPHROPATHY","medConditionList":[{"med_condition_id":360,"med_condition":"NEPHROPATHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40236,"protocol_no":"GO29665","submission_no":"187418","status_id":1,"start_date":"2017-07-11","end_date":null,"nol_date":"2015-10-16","protocol_title":"A PHASE I/ II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF COBIMETINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36744,"protocol_no":"CA001-030","submission_no":"176459","status_id":1,"start_date":"2016-06-02","end_date":null,"nol_date":"2014-08-14","protocol_title":"A PHASE 1/2 MULTICENTER STUDY OF BMS-986012 IN SUBJECTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29079,"protocol_no":"20130258","submission_no":"170817","status_id":1,"start_date":"2014-05-20","end_date":null,"nol_date":"2014-01-14","protocol_title":"N OPEN-LABEL, SINGLE-ARM EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF ABP 501 IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29124,"protocol_no":"E5501-G000-311","submission_no":"170968","status_id":2,"start_date":"2014-10-17","end_date":"2017-01-30","nol_date":"2014-01-16","protocol_title":"A RANDOMIZED, GLOBAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORAL AVATROMBOPAG FOR THE TREATMENT OF ADULTS WITH THROMBOCYTOPENIA ASSOCIATED WITH LIVER DISEASE PRIOR TO AN ELECTIVE PROCEDURE","medConditionList":[{"med_condition_id":142,"med_condition":"LIVER DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38934,"protocol_no":"CURC-004","submission_no":"183657","status_id":1,"start_date":"2015-06-08","end_date":null,"nol_date":"2015-05-20","protocol_title":"\"PHASE II, RANDOMIZED, OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RADIUM 223 IN PROLONGING THE OFF TREATMENT INTERVAL IN MEN WITH A RISING PSA POST-RADIATION OR POST-PROSTATECTOMY WITHOUT BONE METASTASIS RECEIVING INTERMITTENT ANDROGEN AB.\"","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26680,"protocol_no":"AGS-22M6E-11-1","submission_no":"163476","status_id":1,"start_date":"2013-06-18","end_date":null,"nol_date":"2013-04-24","protocol_title":"\"A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS-22M6E GIVEN AS MONOTHERAPY FOLLOWED BY EXPANSION COHORTS IN SUBJECTS WITH MALIGNANT SOLID TUMORS THAT EXPRESS NECTIN-4.\"","medConditionList":[{"med_condition_id":293,"med_condition":"MALIGNANT SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40977,"protocol_no":"107243","submission_no":"189833","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-24","protocol_title":"HYOSCINE BUTYLBROMIDE VERSUS ACETAMINOPHEN FOR ACUTE ABDOMINAL PAIN IN CHILDREN: A RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27399,"protocol_no":"CL2-80881-001","submission_no":"165621","status_id":2,"start_date":"2014-04-11","end_date":"2017-05-01","nol_date":"2013-07-24","protocol_title":"AN OPEN, 3-COHORT, PHASE II TRIAL TESTING ORAL ADMINISTRATION OF LUCITANIB IN PATIENTS WITH FGFR1-AMPLIFIED OR NON-AMPLIFIED OESTROGEN RECEPTOR POSITIVE METASTATIC BREAST CANCER (FINESSE)","medConditionList":[{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38262,"protocol_no":"D2213C00001","submission_no":"181441","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-17","protocol_title":"\"A PHASE 2B, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRALOKINUMAB IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.\"","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36299,"protocol_no":"MEK116540","submission_no":"173754","status_id":1,"start_date":"2017-08-11","end_date":null,"nol_date":"2014-06-23","protocol_title":"AN OPEN-LABEL, DOSE-ESCALATION, PHASE I/II STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF THE MEK INHIBITOR TRAMETINIB IN CHILDREN AND ADOLESCENTS SUBJECTS WITH CANCER OR PLEXIFORM NEUROFIBROMAS AND TRAMETINIB IN COMBINATION WITH DABRAFENIB IN CHILDREN AND ADOLESCENTS WITH CANCERS HARBORING V600 MUTATIONS","medConditionList":[{"med_condition_id":446,"med_condition":"PLEXIFORM NEUROFIBROMAS"},{"med_condition_id":26,"med_condition":"BRAF MUTATION-POSITIVE TUMORS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27420,"protocol_no":"044/2013","submission_no":"165687","status_id":2,"start_date":"2013-08-13","end_date":"2016-03-01","nol_date":"2013-07-11","protocol_title":"A RANDOMIZED COMPARISON OF OSMOTIC RELEASE ORAL SYSTEM METHYLPHENIDATE AND COGNITIVE BEHAVIOURAL THERAPY FOR THE TREATMENT OF OBESE PATIENTS WITH BINGE EATING DISORDER","medConditionList":[{"med_condition_id":341,"med_condition":"WEIGHT GAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36394,"protocol_no":"201316","submission_no":"175269","status_id":1,"start_date":"2014-09-03","end_date":null,"nol_date":"2014-07-03","protocol_title":"A RANDOMIZED, BLINDED, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UMECLIDINIUM (UMEC) 62.5 MCG COMPARED WITH TIOTROPIUM 18 MCG IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36575,"protocol_no":"OS320-3005","submission_no":"175828","status_id":2,"start_date":"2014-09-11","end_date":"2016-05-19","nol_date":"2014-07-22","protocol_title":"A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, 16 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMANTADINE HCL EXTENDED RELEASE TABLETS IN PARKINSON'S DISEASE SUBJECTS WITH LEVODOPA-INDUCED DYSKINESIAS","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42467,"protocol_no":"IDFMT-001","submission_no":"195078","status_id":1,"start_date":"2016-04-01","end_date":null,"nol_date":"2016-06-06","protocol_title":"TRANSPLANTATION OF MICROBES OF FECAL ORIGIN FOR PREVENTION AND TREATMENT OF METABOLIC SYNDROME AND NON ALCHOHOLIC FATTY LIVER DISEASE","medConditionList":[{"med_condition_id":306,"med_condition":"METABOLIC SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40618,"protocol_no":"17938","submission_no":"188639","status_id":1,"start_date":"2016-06-16","end_date":null,"nol_date":"2015-11-17","protocol_title":"GLOBAL MULTICENTER, OPEN-LABEL, RANDOMIZED, EVENT-DRIVEN, ACTIVE-CONTROLLED STUDY COMPARING A RIVAROXABAN-BASED ANTITHROMBIC STRATEGY TO AN ANTIPLATELET-BASED STRATEGY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) TO OPTIMIZE CLINICAL OUTCOMES (GALILEO).","medConditionList":[{"med_condition_id":419,"med_condition":"AORTIC ANEURYSM"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27224,"protocol_no":"15912","submission_no":"165181","status_id":1,"start_date":"2016-03-31","end_date":null,"nol_date":"2013-06-20","protocol_title":"A MULTI-CENTER, PHASE III, NON-CONTROLLED, OPEN-LABEL TRIAL TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF BAY 94-9027 FOR PROPHYLAXIS AND TREATMENTOF BLEEDING IN PREVIOUSLY TREATED CHILDREN (AGE <12 YEARS) WITH SEVERE HEMOPHILIA A.","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29454,"protocol_no":"MLN0002SC_201","submission_no":"171855","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-03-14","protocol_title":"A RANDOMIZED, OPEN LABEL PHASE 2 STUDY TO ASSESS PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY, SAFETY AND EXPLORATORY EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS COMPARED TO VEDOLIZUMAB INTRAVENOUS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OR CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"},{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36672,"protocol_no":"JF62014","submission_no":"176209","status_id":1,"start_date":"2015-05-21","end_date":null,"nol_date":"2014-08-11","protocol_title":"A MULTI-CENTRE PHASE III STUDY TO EVALUATE PRE-EMPTIVE TENOFOVIR FOR PREVENTION OF HEPATITIS B VIRUS REACTIVATION IN HBSAG NEGATIVE/ANTI-HBC POSITIVE INDIVIDUALS UNDERGOING RITUXIMAB-BASED CHEMOTHERAPY FOR NON-HODGKIN'S LYMPHOMA/SMALL LYMPHOCYTIC LEUKEMIA.","medConditionList":[{"med_condition_id":103,"med_condition":"HEPATITIS B VIRUS"},{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37168,"protocol_no":"SCGAM-01","submission_no":"177752","status_id":1,"start_date":"2015-04-09","end_date":null,"nol_date":"2014-10-02","protocol_title":"CLINICAL PHASE III STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, TOLERABILITY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM 16.5%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES","medConditionList":[{"med_condition_id":210,"med_condition":"PRIMARY IMMUNODEFICIENCY DISEASES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38880,"protocol_no":"CAMHPET-CTA-93","submission_no":"183502","status_id":2,"start_date":"2015-05-01","end_date":"2016-03-16","nol_date":"2015-05-13","protocol_title":"\"VARENICLINE AND ALCOHOL DEPENDENCE: A [11C]-(+)-PHNO STUDY.\"","medConditionList":[{"med_condition_id":470,"med_condition":"ABUSE POTENTIAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40730,"protocol_no":"CAMHPET-CTA-102","submission_no":"188960","status_id":1,"start_date":"2016-01-05","end_date":null,"nol_date":"2015-11-30","protocol_title":"EXPLORING THE EFFECTS OF PRAZOSIN ON BASAL DOPAMINE IN HEALTHY HUMANS: A [11C]-(+)-PHNO PET STUDY","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29134,"protocol_no":"MK-8835-002","submission_no":"171017","status_id":2,"start_date":"2014-02-26","end_date":"2017-07-12","nol_date":"2014-01-24","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-COMPARATOR-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF THE ADDITION OF ERTUGLIFLOZIN (MK-8835/PF-04971729) COMPARED WITH THE ADDITION OF GLIMEPIRIDE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL ON METFORMIN","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46660,"protocol_no":"16-5153.0","submission_no":"208271","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-31","protocol_title":"18F-FLUOROCHOLINE PET/MRI FOR THE LOCALIZATION OF PARATHYROID ADENOMAS","medConditionList":[{"med_condition_id":795,"med_condition":"PARATHYROID ADENOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29506,"protocol_no":"CFTY720D2311","submission_no":"172019","status_id":1,"start_date":"2017-04-24","end_date":null,"nol_date":"2014-03-14","protocol_title":"A TWO-YEAR, DOUBLE-BLIND, RANDOMIZED, MULTICENTER, ACTIVE-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FINGOLIMOD ADMINISTERED ORALLY ONCE DAILY VERSUS INTERFERON BETA-1A I.M. ONCE WEEKLY IN PEDIATRIC PATIENTS WITH MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35614,"protocol_no":"LPCN 1111-14-003","submission_no":"172902","status_id":2,"start_date":"2014-08-23","end_date":"2014-10-15","nol_date":"2014-04-08","protocol_title":"OPEN LABEL, FOUR PERIOD, DOSE ESCALATING SINGLE AND MULTIPLE DOSE STUDY TO DETERMINE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TESTOSTERONE TRIDECANOATE (LPCN 1111) IN HYPOGONADAL MALES.","medConditionList":[{"med_condition_id":125,"med_condition":"HYPOGONADAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35964,"protocol_no":"TKM-HCC-001","submission_no":"174068","status_id":2,"start_date":"2015-05-22","end_date":"2016-09-08","nol_date":"2014-05-22","protocol_title":"AN OPEN-LABEL, MULTI-CENTER, PHASE 1, DOSE ESCALATION STUDY WITH PHASE 2 EXPANSION COHORT TO DETERMINE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF INTRAVENOUS TKM-080301 IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA","medConditionList":[{"med_condition_id":519,"med_condition":"ADVANCED HEPATOCELLULAR CARCINOMA"},{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35652,"protocol_no":"NCT01930591","submission_no":"173017","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-23","protocol_title":"THE SAFETY AND EFFICACY OF TICAGRELOR FOR CORONARY STENTING POST THROMBOLYSIS, THE SETFAST TRIAL","medConditionList":[{"med_condition_id":504,"med_condition":"ACUTE MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40689,"protocol_no":"CDI.LYO.FMT.1","submission_no":"188833","status_id":1,"start_date":"2014-11-24","end_date":null,"nol_date":"2015-11-25","protocol_title":"PROSPECTIVE, OPEN-LABEL TRIAL TO EVALUATE EFFICACY OF LYOPHILIZED FECAL MICROBIOTA TRANSPLANTATION FOR TREATMENTOF RECURRENT C.DIFFICILE INFECTION","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47800,"protocol_no":"R475-OA-1688","submission_no":"211998","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-10","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP","medConditionList":[{"med_condition_id":212,"med_condition":"OSTEOARTHRITIS OF THE KNEE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45434,"protocol_no":"LPC-004","submission_no":"204411","status_id":1,"start_date":"2017-06-15","end_date":null,"nol_date":"2017-05-09","protocol_title":"A SINGLE BLIND, TWO-STAGE DOSE FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF A SINGLE LIPROCA¬Æ DEPOT INJECTION INTO THE PROSTATE IN PATIENTS WITH LOCALIZED PROSTATE CANCER, ASSIGNED TO ACTIVE SURVEILLANCE WHO ARE AT HIGH RISK FOR DISEASE PROGRESSION (FOLLOWED BY AN OPEN LABEL EXTENSION WITH A REPEAT INJECTION (OPTIONAL)).","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37193,"protocol_no":"BMS CA180-543 (OZM-056)","submission_no":"177804","status_id":1,"start_date":"2016-07-28","end_date":null,"nol_date":"2014-09-24","protocol_title":"TREATMENT-FREE REMISSION ACCOMPLISHED WITH DASATINIB IN PATIENTS WITH CML.","medConditionList":[{"med_condition_id":46,"med_condition":"CHRONIC MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41877,"protocol_no":"RSF-P4-733 (CDI-31244-P1-001)","submission_no":"193094","status_id":1,"start_date":"2016-04-20","end_date":null,"nol_date":"2016-04-06","protocol_title":"A PHASE IA/IB STUDY ASSESSING SINGLE AND MULTIPLE DOSES OF CDI-31244, A NON-NUCLEOSIDE INHIBITOR IN HEALTHY AND HEPATITIS C VIRUS-INFECTED SUBJECTS","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42214,"protocol_no":"20150629","submission_no":"194301","status_id":1,"start_date":"2017-09-25","end_date":null,"nol_date":"2016-05-17","protocol_title":"PLATELET TRANSFUSIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION - THE PATH (PILOT) STUDY","medConditionList":[{"med_condition_id":431,"med_condition":"HEMATOPOIETIC STEM CELL TRANSPLANT"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40533,"protocol_no":"BP29889","submission_no":"188422","status_id":1,"start_date":"2016-04-25","end_date":null,"nol_date":"2015-11-06","protocol_title":"AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION COHORTS TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONISTIC MONOCLONAL ANTIBODY) IN COMBINATION WITH VANUCIZUMAB (ANTI-ANG2 AND ANTI-VEGF BI-SPECIFIC MONOCLONAL ANTIBODY) IN PATIENTS WITH METASTATIC SOLID TUMORS,","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39419,"protocol_no":"CTL019A2205B","submission_no":"185185","status_id":1,"start_date":"2015-11-26","end_date":null,"nol_date":"2015-07-03","protocol_title":"LONG TERM FOLLOW-UP OF PATIENTS EXPOSED TO LENTIVIRAL-BASED CD19 DIRECTED CAR T-CELL THERAPY","medConditionList":[{"med_condition_id":148,"med_condition":"LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48508,"protocol_no":"RPC01-3204","submission_no":"214110","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-27","protocol_title":"A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY OF ORAL OZANIMOD FOR MODERATELY TO SEVERELY ACTIVE CROHN¬øS DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40795,"protocol_no":"SHP616-302","submission_no":"189190","status_id":1,"start_date":"2017-07-13","end_date":null,"nol_date":"2015-12-04","protocol_title":"A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CINRYZE (C1 ESTERASE INHIBITOR (HUMAN)) FOR THE TREATMENT OF ACUTE ANTIBODY-MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT PATIENTS","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45864,"protocol_no":"CP-MGA271-03","submission_no":"205672","status_id":1,"start_date":"2017-11-15","end_date":null,"nol_date":"2017-06-15","protocol_title":"A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF MGA271 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH MELANOMA, SQUAMOUS CELL CANCER OF THE HEAD AND NECK, NON-SMALL CELL LUNG CANCER, UROTHELIAL CANCER, AND OTHER CANCERS","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"},{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"},{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"},{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37793,"protocol_no":"GO29058","submission_no":"179738","status_id":1,"start_date":"2015-01-29","end_date":null,"nol_date":"2014-12-10","protocol_title":"A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY","medConditionList":[{"med_condition_id":516,"med_condition":"HER2 NEGATIVE METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BRCA ASSOCIATED BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42203,"protocol_no":"CTNPT 027","submission_no":"194249","status_id":1,"start_date":"2017-07-04","end_date":null,"nol_date":"2016-05-10","protocol_title":"THE EFFECT OF METFORMIN ON HIV RESERVOIR SIZE IN NON-DIABETIC ART-TREATED PATIENTS: THE LILAC STUDY","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27855,"protocol_no":"ZAS-2013-CS-1","submission_no":"166885","status_id":1,"start_date":"2015-08-25","end_date":null,"nol_date":"2013-08-22","protocol_title":"\"A PILOT TRIAL TO ASSESS THE FEASIBILITY AND EFFICACY OF SUBCUTANEOUS IMMUNOGLOBULIN IN PATIENTS WITH MYASTHENIA GRAVIS EXACERBATION.\"","medConditionList":[{"med_condition_id":163,"med_condition":"MYASTHENIA GRAVIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42522,"protocol_no":"AM-111-CL-15-01","submission_no":"195257","status_id":2,"start_date":"2016-08-24","end_date":"2018-02-15","nol_date":"2016-06-16","protocol_title":"EFFICACY AND SAFETY OF AM-111 AS ACUTE SUDDEN SENSORINEURAL HEARING LOSS TREATMENT (ASSENT)","medConditionList":[{"med_condition_id":736,"med_condition":"SUDDEN DEAFNESS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39142,"protocol_no":"I1F-MC-RHBP","submission_no":"184282","status_id":1,"start_date":"2015-06-22","end_date":null,"nol_date":"2015-06-12","protocol_title":"\"A MULITCENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB DOSING REGIMENS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS.\"","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38541,"protocol_no":"AB12004","submission_no":"182362","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-03-19","protocol_title":"A PROSPECTIVE, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-PARALLEL GROUPS, PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF MASITINIB TO PLACEBO IN PATIENTS WITH LOCALIZED, PRIMARY GASTROINTESTINAL STROMAL TUMOR (GIST) AFTER COMPLETE SURGERY AND WITH HIGH RISK OF RECURRENCE","medConditionList":[{"med_condition_id":86,"med_condition":"GASTROINTESTINAL STROMAL TUMOR (GIST)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37013,"protocol_no":"17712 (3104007)","submission_no":"177245","status_id":1,"start_date":"2015-06-22","end_date":null,"nol_date":"2014-09-12","protocol_title":"A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44639,"protocol_no":"AM0010-301","submission_no":"201930","status_id":1,"start_date":"2017-08-09","end_date":null,"nol_date":"2017-02-27","protocol_title":"A RANDOMIZED PHASE 3 STUDY OF AM 0010 IN COMBINATION WITH FOLFOX COMPARED WITH FOLFOX ALONE AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC PANCREATIC CANCER THAT HAS PROGRESSED DURING OR FOLLOWING A FIRST-LINE GEMCITABINE CONTAINING REGIMEN","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40933,"protocol_no":"TLD1433","submission_no":"189722","status_id":1,"start_date":"2016-12-08","end_date":null,"nol_date":"2015-12-16","protocol_title":"A PHASE IB TRIAL OF INTRAVESICAL PHOTODYNAMIC THERAPY IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER AT HIGH RISK OF PROGRESSION WHO ARE REFRACTORY TO THERAPY WITH BACILLUS CALMETTER-GUERIN (BCG) AND WHO ARE MEDICALLY UNFIT FOR OR REFUSE A CYSTECTOMY.","medConditionList":[{"med_condition_id":625,"med_condition":"BLADDER CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42925,"protocol_no":"MRZ-112","submission_no":"196662","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-07-29","protocol_title":"PHASE 1B, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB WITH TEMOZOLOMIDE AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA","medConditionList":[{"med_condition_id":168,"med_condition":"MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45645,"protocol_no":"NS-065/NCNP-01-201","submission_no":"205002","status_id":1,"start_date":"2017-12-11","end_date":null,"nol_date":"2017-05-18","protocol_title":"A PHASE II, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF NS-065/NCNP-01 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD)","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26581,"protocol_no":"10-02122013","submission_no":"163160","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-04-10","protocol_title":"EVALUATION OF REGIONAL LUNG VENTILATION IN PARTICIPANTS WITH LUNG DISORDERS USING INHALED INERT FLUORINATED GASES AS CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING","medConditionList":[{"med_condition_id":260,"med_condition":"PULMONARY DISORDERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42069,"protocol_no":"845-01","submission_no":"193791","status_id":1,"start_date":"2016-09-02","end_date":null,"nol_date":"2016-04-29","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE (LANTUS¬Æ) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27691,"protocol_no":"178-CL-101","submission_no":"166448","status_id":2,"start_date":"2013-12-20","end_date":"2016-03-03","nol_date":"2013-08-07","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO- AND ACTIVE- CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF COMBINATIONS OF SOLIFENACIN SUCCINATE AND MIRABEGRON COMPARED TO SOLIFENACIN SUCCINATE AND MIRABEGRON MONOTHERAPY IN THE TREATMENT OF OVERACTIVE BLADDER","medConditionList":[{"med_condition_id":185,"med_condition":"OVERACTIVE BLADDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38686,"protocol_no":"02252015","submission_no":"182848","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-16","protocol_title":"\"ESSAI CLINIQUE VISANT A DOCUMENTER L'IMMUNOGENICITE ET L'INNOCUITE DES VACCINS GARDASIL 9 ET CERVARIX ADMINISTRES DE FACON INTERCHANGEABLE AUX JEUNES DE 9-10 ANS SELON LE CALENDRIER 0, 6 MOIS.\"","medConditionList":[{"med_condition_id":119,"med_condition":"HUMAN PAPILLOMA VIRUS (HPV)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39100,"protocol_no":"ESR-14-10095","submission_no":"184145","status_id":1,"start_date":"2015-07-01","end_date":null,"nol_date":"2015-05-29","protocol_title":"A STUDY TO INVESTIGATE THE DIFFERENTIAL EFFECTS OF INHALED SYMBICORT AND ADVAIR ON LUNG MICROBIOTA","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45395,"protocol_no":"M16-298","submission_no":"201779","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-28","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ROVALPITUZUMAB TESIRINE AS MAINTENANCE THERAPY FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN SUBJECTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (MERU)","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36303,"protocol_no":"IDX-04B-004","submission_no":"175018","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-06-23","protocol_title":"A MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SAMATASVIR AND IDX21437 GIVEN IN COMBINATION WITH OR WITHOUT RIBAVIRIN IN SUBJECTS WITH CHRONIC HEPATITIS C INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37916,"protocol_no":"D3250C00032","submission_no":"180077","status_id":1,"start_date":"2015-01-16","end_date":null,"nol_date":"2014-12-22","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVLUATE THE EFFICACY ANS SAFETY OF BENRALIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE PERSISTENT ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37899,"protocol_no":"PD536-742","submission_no":"180022","status_id":1,"start_date":"2015-01-06","end_date":null,"nol_date":"2014-12-17","protocol_title":"INGENOL MEBUTATE (PICATO¬Æ) WITH METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY  FOR THE TREATMENT OF ACTINIC KERATOSIS.","medConditionList":[{"med_condition_id":520,"med_condition":"ACTINIC KERATOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36493,"protocol_no":"SUSTAIN CSX-01","submission_no":"175599","status_id":1,"start_date":"2015-01-13","end_date":null,"nol_date":"2014-07-18","protocol_title":"TO EVALUATE THE EFFECT OF THE ADMINISTRATION OF DAILY PERIOPERATIVE SELENIUM-SELENITE ON RECOVERY AND COMPLICATIONS IN CARDIAC SURGICAL PATIENTS.","medConditionList":[{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46121,"protocol_no":"997HA402","submission_no":"206437","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-07","protocol_title":"A NON-CONTROLLED, OPEN-LABEL, MULTICENTER, STUDY OF EFFICACY OF RFVIIIFC FOR IMMUNE TOLERANCE INDUCTION (ITI) IN SEVERE HEMOPHILIA A SUBJECTS WITH INHIBITORS UNDERGOING THE FIRST ITI TREATMENT","medConditionList":[{"med_condition_id":98,"med_condition":"HEMOPHILIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38164,"protocol_no":"HMR12012101","submission_no":"181174","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-06","protocol_title":"TENECTEPLASE VERSUS ALTEPLASE FOR STROKE THROMBOLYSIS EVALUATION (TASTE)","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48272,"protocol_no":"1403.1","submission_no":"213472","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-05","protocol_title":"A PHASE IA/IB, OPEN LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF BI 907828 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42868,"protocol_no":"OTT 16-05","submission_no":"196456","status_id":1,"start_date":"2018-01-25","end_date":null,"nol_date":"2016-07-22","protocol_title":"A RANDOMIZED TRIAL OF INDIVIDUALISED CARE VERSUS STANDARD CARE FOR BREAST CANCER PATIENTS AT HIGH RISK FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.","medConditionList":[{"med_condition_id":302,"med_condition":"NAUSEA AND VOMITING"},{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41014,"protocol_no":"C38072-AS-30025","submission_no":"189967","status_id":1,"start_date":"2017-02-15","end_date":null,"nol_date":"2015-12-24","protocol_title":"A 52-WEEK DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF RESLIZUMAB 110 MG FIXED, SUBCUTANEOUS DOSING IN PATIENTS WITH UNCONTROLLED ASTHMA AND ELEVATED BLOOD EOSINOPHILS","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39145,"protocol_no":"TFP-0009","submission_no":"184286","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-10-06","protocol_title":"DOPAMINE D-2 ANTAGONIST USE IN POOR RESPONDERS IN IVF:  A RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":301,"med_condition":"INFERTILITY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38297,"protocol_no":"CTA/2015/001","submission_no":"181540","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-10","protocol_title":"THE PERITONEAL AND SYSTEMIC PHARMACOKINETICS OF INTRAPERITONEAL VANCOMYCIN ADMINISTRATION: A PILOT SAFETY STUDY","medConditionList":[{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40694,"protocol_no":"20150637","submission_no":"188845","status_id":1,"start_date":"2016-02-08","end_date":null,"nol_date":"2016-02-05","protocol_title":"TICAGRELOR ANTIPLATELET THERAPY TO REDUCE GRAFT EVENTS AND THROMBOSIS (TARGET TRIAL):  DOES TICAGRELOR IMPROVE GRAFT PATENCY AFTER CORONARY BYPASS?","medConditionList":[{"med_condition_id":55,"med_condition":"CORONARY ARTERY BYPASS GRAFT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40584,"protocol_no":"STML-401-0214","submission_no":"188537","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-13","protocol_title":"A PHASE 1/2 STUDY OF SL-401 AS CONSOLIDATION THERAPY FOR ADULT PATIENTS WITH ADVERSE RISK ACUTE MYELOID LEUKEMIA IN FIRST CR, AND/OR EVIDENCE OF MINIMAL RESIDUAL DISEASE (MRD) IN FIRST CR","medConditionList":[{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37707,"protocol_no":"GENA-21B","submission_no":"179501","status_id":2,"start_date":"2016-04-29","end_date":"2017-10-05","nol_date":"2014-12-11","protocol_title":"PROSPECTIVE OPEN-LABEL, MULTICENTRE PHASE 3B STUDY TO ASSESS THE EFFICACY AND SAFETY OF PERSONALIZED PROPHYLAXIS WITH HUMAN-CL RHFVIII IN PREVIOUSLY TREATED ADULT PATIENTS WITH SEVERE HAEMOPHILIA A","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45107,"protocol_no":"PRIMED-001","submission_no":"203266","status_id":1,"start_date":"2017-10-10","end_date":null,"nol_date":"2017-03-29","protocol_title":"PRE-OPERATIVE MOCETINOSTAT (MGCD0103) AND DURVALUMAB (MEDI4736) (PRIMED) FOR SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28747,"protocol_no":"OHSN-REB 20130563-01H","submission_no":"169646","status_id":1,"start_date":"2015-12-03","end_date":null,"nol_date":"2013-12-10","protocol_title":"\"APIXABAN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN HIGH-RISK AMBULATORY CANCER PATIENTS: A RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL (AVERT TRIAL).\"","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40450,"protocol_no":"UX023-CL304","submission_no":"188161","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-13","protocol_title":"AN OPEN-LABEL, SINGLE-ARM, PHASE 3 STUDY TO EVALUATE THE EFFECTS OF KRN23 ON OTEOMALACIA IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA (XLH)","medConditionList":[{"med_condition_id":643,"med_condition":"X-LINKED HYPOPHOSPHATEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37581,"protocol_no":"CTA/2014/002","submission_no":"179071","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-11-26","protocol_title":"THE USE OF INTRANASAL FENTANYL FOR THE TREATMENT OF INCIDENT DYSPNEA IN CONGESTIVE HEART FAILURE: A PROSPECTIVE TRIAL","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38873,"protocol_no":"20140355 (CFZ014)","submission_no":"183490","status_id":1,"start_date":"2016-10-17","end_date":null,"nol_date":"2015-04-27","protocol_title":"A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA RECEIVING CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE, COMPARING ONCE-WEEKLY VERSUS TWICE-WEEKLY CARFILZOMIB DOSING","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35715,"protocol_no":"BB1503-205C","submission_no":"173212","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-28","protocol_title":"A PHASE II CLINICAL STUDY OF BBI503 IN ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS","medConditionList":[{"med_condition_id":86,"med_condition":"GASTROINTESTINAL STROMAL TUMOR (GIST)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27573,"protocol_no":"IMGN0401","submission_no":"166131","status_id":2,"start_date":"2016-01-15","end_date":"2017-12-13","nol_date":"2013-07-26","protocol_title":"A PHASE 1, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IMGN853 IN ADULTS WITH OVARIAN CANCER AND OTHER FOLR1-POSITIVE SOLID TUMORS","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37403,"protocol_no":"CNTO148JIA3003","submission_no":"178521","status_id":1,"start_date":"2016-02-09","end_date":null,"nol_date":"2014-10-30","protocol_title":"A MULTICENTER, OPEN-LABEL TRIAL OF INTRAVENOUS GOLIMUMAB A HUMAN ANTI-TNFA ANTIBODY, IN PEDIATRIC SUBJECTS WITH ACTIVE POLYARTICULAR COURSE JUVENILE IDIOPATHIS ARTHRITIS DESPITE METHOTREXATE THERAPY","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41016,"protocol_no":"CAMHPET-CTA-101","submission_no":"189970","status_id":1,"start_date":"2016-01-04","end_date":null,"nol_date":"2015-12-24","protocol_title":"IMAGING OF NEUROINFLAMMATION IN AUTISM SPECTRUM DISORDER","medConditionList":[{"med_condition_id":351,"med_condition":"AUTISM SPECTRUM DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40872,"protocol_no":"LIN-MD-62","submission_no":"189535","status_id":1,"start_date":"2017-08-03","end_date":null,"nol_date":"2015-12-08","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, SAFETY AND EFFICACY STUDY OF A RANGE OF LINACLOTIDE DOSES ADMINISTERED ORALLY TO CHILDREN, AGES 6 TO 17 YEARS, WHO FULFILL MODIFIED ROME III CRITERIA FOR CHILD/ADOLESCENT FUNCTIONAL CONSTIPATION (FC)","medConditionList":[{"med_condition_id":468,"med_condition":"CONSTIPATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40937,"protocol_no":"MLN0002SC-3027","submission_no":"189732","status_id":1,"start_date":"2016-09-08","end_date":null,"nol_date":"2015-12-18","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, WITH A VEDOLIZUMAB IV REFERENCE ARM, TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTANEOUS AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29154,"protocol_no":"LUM001-301","submission_no":"171045","status_id":2,"start_date":"2015-11-29","end_date":"2016-11-28","nol_date":"2014-02-06","protocol_title":"THE EVALUATION OF THE INTESTINAL BILE ACID TRANSPORT (IBAT) INHIBITOR LUM001 IN THE REDUCTION OF PRURITUS IN ALAGILLE SYNDROME, A CHOLESTATIC LIVER DISEASE","medConditionList":[{"med_condition_id":452,"med_condition":"CHOLESTATIC LIVER DISEASE"},{"med_condition_id":453,"med_condition":"ALAGILLE SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29037,"protocol_no":"LX1606.1-303-CS","submission_no":"170643","status_id":2,"start_date":"2015-04-17","end_date":"2017-04-21","nol_date":"2014-01-07","protocol_title":"A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TELOTRISTAT ETIPRATE (LX1606) IN PATIENTS WITH CARCINOID SYNDROME","medConditionList":[{"med_condition_id":490,"med_condition":"CARCINOID SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37270,"protocol_no":"SINNR","submission_no":"178042","status_id":1,"start_date":"2014-09-18","end_date":null,"nol_date":"2014-10-16","protocol_title":"STRIBILD IN NON-NUCLEOSIDE RESISTANT PATIENTS, AN EVALUATION OF SAFETY AND EFFICACY IN VULNERABLE POPULATIONS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40729,"protocol_no":"D5170C00002","submission_no":"188958","status_id":1,"start_date":"2016-01-19","end_date":null,"nol_date":"2015-11-27","protocol_title":"A PHASE 2B DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEDI2070 IN SUBJECTS WITH MODERATE TO SEVERE CROHN'S DISEASE WHO HAVE FAILED OR ARE INTOLERANT TO ANTI-TUMOR NECROSIS FACTOR-ALPHA THERAPY","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35965,"protocol_no":"LP0084-1013","submission_no":"174069","status_id":1,"start_date":"2014-05-28","end_date":null,"nol_date":"2014-05-22","protocol_title":"LEO SAFETY AND EFFICACY OF ESCALATING DOSES OF TWO LEO 43204 FORMULATIONS APPLIED ONCE DAILY FOR TWO CONSECUTIVE DAYS ON FULL FACE OR APPROXIMATELY 250 CM2 (40 IN2) ON THE CHEST IN SUBJECTS WITH ACTINIC KERATOSIS; PART 2: A PHASE 2, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, VEHICLE-CONTROLLED, 8-WEEK TRIAL OF LEO 43204 GEL IN SUBJECTS WITH AK (CANADA AND US)","medConditionList":[{"med_condition_id":520,"med_condition":"ACTINIC KERATOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46785,"protocol_no":"MEDIT-001OL","submission_no":"208659","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-14","protocol_title":"AN OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY CONTINUATION STUDY OF A NEW TEST DRUG (GBM-5) ADMINISTERED INTRATHECALLY TO PATIENTS WITH MODERATE-TO-SEVERE REFRACTORY CHRONIC PAIN.","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47841,"protocol_no":"PRE1701","submission_no":"212142","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-04","protocol_title":"ECONOMIC IMPACT OF DROPLESS THERAPY VERSUS USUAL CARE FOR CATARACT SURGERY: A REAL-WORLD STUDY","medConditionList":[{"med_condition_id":727,"med_condition":"CATARACT SURGERY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36311,"protocol_no":"HAIP-6192","submission_no":"175020","status_id":1,"start_date":"2014-07-22","end_date":null,"nol_date":"2014-07-04","protocol_title":"A PHASE II STUDY OF THE RATE OF CONVERSION TO COMPLETE RESECTION IN PATIENTS WITH INITIALLY INOPERABLE HEPATIC-ONLY METASTASES FROM COLORECTAL CANCER AFTER TREATMENT WITH HEPATIC ATERIAL INFUSION WITH FLOXURIDINE AND DEXMETHASONE IN COMBINATION WITH BEST SYSTEMIC CHEMOTHERAPY.","medConditionList":[{"med_condition_id":532,"med_condition":"HEPATIC-ONLY METASTASES OF  COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28492,"protocol_no":"CB-17-01/06","submission_no":"168742","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-11-01","protocol_title":"THE SAFETY AND EFFICACY OF METHYLENE BLUE MMX¬Æ MODIFIED RELEASE TABLETS ADMINISTERED TO SUBJECTS UNDERGOING SCREENING OR SURVEILLANCE COLONOSCOPY.","medConditionList":[{"med_condition_id":439,"med_condition":"GASTROINTESTINAL DISORDERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35406,"protocol_no":"M1-1188_203","submission_no":"172235","status_id":1,"start_date":"2014-04-30","end_date":null,"nol_date":"2014-03-13","protocol_title":"A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING AND PROOF OF CONCEPT STUDY, TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NAMILUMAB/MT203 AT 4 DIFFERENT SUBCUTANEOUS DOSES IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (NEPTUNE)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43769,"protocol_no":"16GI01","submission_no":"199109","status_id":1,"start_date":"2016-11-30","end_date":null,"nol_date":"2016-11-07","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF A 12 WEEK ADD-ON TREATMENT WITH LT 02 (DELAYED RELEASE PHOSPHATIDYLCHOLINE GRANULES) VS. PLACEBO IN SUBJECTS WITH ULCERATIVE COLITIS REFRACTORY TO STANDARD TREATMENT WITH MESALAMINE FOLLOWED BY AN OPTIONAL 24-WEEK OPEN-LABEL ACTIVE DRUG DOSING PERIOD","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45500,"protocol_no":"CPDR001I2102","submission_no":"204593","status_id":1,"start_date":"2017-09-20","end_date":null,"nol_date":"2017-05-09","protocol_title":"A PHASE IB STUDY OF PDR001 IN COMBINATION WITH REGORAFENIB IN ADULT PATIENTS WITH PREVIOUSLY TREATED METASTATIC MICROSATELLITE STABLE (MSS) COLORECTAL CANCER","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45287,"protocol_no":"MNK14224049","submission_no":"203919","status_id":1,"start_date":"2016-04-20","end_date":null,"nol_date":"2017-04-12","protocol_title":"TREATMENT OF PROTEINURIA DUE TO TREATMENT RESISTANT OR TREATMENT INTOLERANT IDIOPATHIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS: A 2-PART PROSPECTIVE STUDY OF H.P. ACTHAR GEL (PODOCYTE)","medConditionList":[{"med_condition_id":476,"med_condition":"FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35736,"protocol_no":"2013-1550","submission_no":"173281","status_id":1,"start_date":"2014-09-03","end_date":null,"nol_date":"2014-04-09","protocol_title":"HCMR - NOVEL PREDICTORS OF OUTCOME IN HYPERTROPHIC CARDIOMYOPATHY","medConditionList":[{"med_condition_id":508,"med_condition":"HYPERTROPHIC CARDIOMYOPATHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38737,"protocol_no":"MRZ-108","submission_no":"183011","status_id":1,"start_date":"2017-05-08","end_date":null,"nol_date":"2015-04-16","protocol_title":"A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION, COMBINATION STUDY OF MARIZOMIB AND BEVACIZUMAB IN BEVACIZUMAB-NA√èVE SUBJECTS WITH WHO GRADE IV MALIGNANT GLIOMA","medConditionList":[{"med_condition_id":92,"med_condition":"GLIOMA MALIGNANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42779,"protocol_no":"ADP-04511","submission_no":"196200","status_id":1,"start_date":"2017-03-17","end_date":null,"nol_date":"2016-07-21","protocol_title":"A PILOT STUDY OF GENETICALLY ENGINEERED NY-ESO-1 SPECIFIC (C259) T CELLS IN HLA-A2+ PATIENTS WITH SYNOVIAL SARCOMA","medConditionList":[{"med_condition_id":710,"med_condition":"SYNOVIAL SARCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46084,"protocol_no":"BIO 17-46","submission_no":"206348","status_id":1,"start_date":"2017-07-01","end_date":null,"nol_date":"2017-07-11","protocol_title":"A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF ELECTROCONVULSIVE THERAPY WITH KETAMINE","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26888,"protocol_no":"CAMHPET-CTA-77","submission_no":"164141","status_id":1,"start_date":"2013-05-16","end_date":null,"nol_date":"2013-05-15","protocol_title":"\"PARKINSON'S DISEASE IN ADULTS WITH 22Q11.2 DELETION SYNDROME.\"","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27500,"protocol_no":"GS-US-339-0102","submission_no":"165939","status_id":1,"start_date":"2016-02-17","end_date":null,"nol_date":"2013-07-17","protocol_title":"A PHASE 2, OPEN-LABEL STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF GS 9973 IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40805,"protocol_no":"15743","submission_no":"189220","status_id":1,"start_date":"2016-12-09","end_date":null,"nol_date":"2015-12-04","protocol_title":"A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, PHASE II STUDY OF INTRAVENOUS ANETUMAB RAVTANSINE (BAY 94-9343) OR VINORELBINE IN PATIENTS WITH ADVANCED OR METASTATIC MALIGNANT PLEURAL MESOTHELIOMA OVEREXPRESSING MESOTHELIN AND PROGRESSED ON FIRST LINE PLATINUM/ PEMETREXED-BASED CHEMOTHERAPY","medConditionList":[{"med_condition_id":153,"med_condition":"MALIGNANT PLEURAL MESOTHELIOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35396,"protocol_no":"SAG/0211PFC-1131","submission_no":"172199","status_id":2,"start_date":"2015-09-25","end_date":"2016-07-27","nol_date":"2014-03-12","protocol_title":"A MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLINDED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED > 6 YEARS TO < 18 YEARS WITH FUNCTIONAL CONSTIPATION","medConditionList":[{"med_condition_id":468,"med_condition":"CONSTIPATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35933,"protocol_no":"CEGF816X2101","submission_no":"174009","status_id":1,"start_date":"2017-10-12","end_date":null,"nol_date":"2014-05-20","protocol_title":"A PHASE I/II, MULTICENTER, OPEN-LABEL STUDY OF EGFRMUT-TKI EGF816, ADMINISTERED ORALLY IN ADULT PATIENTS WITH EGFRMUT SOLID MALIGNANCIES","medConditionList":[{"med_condition_id":518,"med_condition":"EGFR MUTATION SOLID MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37550,"protocol_no":"PRO1481322014","submission_no":"178963","status_id":1,"start_date":"2017-11-02","end_date":null,"nol_date":"2014-11-20","protocol_title":"A SINGLE CENTRE STUDY OF THE FEASIBILITY AND SAFETY OF USING EX-VIVO NORMOTHERMIC MACHINE PERFUSION WITH THE METRA DEVICE TO STORE HUMAN LIVERS FOR TRANSPLANTATION","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47600,"protocol_no":"2017-001-COPAF","submission_no":"211353","status_id":1,"start_date":"2018-02-12","end_date":null,"nol_date":"2017-12-13","protocol_title":"COLCHICINE FOR THE PREVENTION OF PERIOPERATIVE ATRIAL FIBRILLATION IN PATIENTS UNDERGOING THORACIC SURGERY (COP-AF)","medConditionList":[{"med_condition_id":716,"med_condition":"THORACIC SURGERY"},{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28450,"protocol_no":"COPAF131001","submission_no":"168604","status_id":1,"start_date":"2013-11-01","end_date":null,"nol_date":"2013-12-04","protocol_title":"COLCHICINE FOR PREVENTION OF PERIOPERATIVE ATRIAL FIBRILLATION IN PATIENTS UNDERGOING THORACIC SURGERY (COP-AF) PILOT STUDY","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35582,"protocol_no":"C27002","submission_no":"172837","status_id":2,"start_date":"2014-11-04","end_date":"2017-03-07","nol_date":"2014-04-10","protocol_title":"A PHASE 2, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL GNRH ANTAGONIST TAK-385, TOGETHER WITH A LEUPRORELIN OBSERVATIONAL COHORT, IN PATIENTS WITH PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42721,"protocol_no":"GED0507-UC-001","submission_no":"196028","status_id":2,"start_date":"2017-04-28","end_date":"2017-07-31","nol_date":"2016-07-13","protocol_title":"A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF GED-0507-34-LEVO (GED0507) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27472,"protocol_no":"13-0096-A","submission_no":"165835","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-17","protocol_title":"STATINS: A NEW THERAPEUTIC OPTION FOR TREATMENT OF PATIENTS WITH ENDOMETRIOSIS","medConditionList":[{"med_condition_id":74,"med_condition":"ENDOMETRIOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28591,"protocol_no":"AMG108","submission_no":"169071","status_id":1,"start_date":"2014-05-16","end_date":null,"nol_date":"2013-11-15","protocol_title":"A MULTIPLE CENTER, OPEN LABEL, PROSPECTIVE, OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS AND EASE-OF-USE OF AMG504-1 ADMINISTERED IN THE HOME OR WORK ENVIRONMENTS FOR TREATING EPISODES OF SEVERE OR MODERATE HYPOGLYCEMIA IN PATIENTS WITH TYPE 1 DIABETES.","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"},{"med_condition_id":388,"med_condition":"DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44524,"protocol_no":"B5161004","submission_no":"201633","status_id":1,"start_date":"2017-04-03","end_date":null,"nol_date":"2017-01-26","protocol_title":"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF PF 06252616 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":48483,"protocol_no":"VX17-659-105","submission_no":"214023","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-19","protocol_title":"A PHASE 3, OPEN-LABEL STUDY EVALUATING THE LONG-TERM SAFETY AND EFFICACY OF VX-659 COMBINATION THERAPY IN SUBJECTS WITH CYSTIC FIBROSIS WHO ARE HOMOZYGOUS OR HETEROZYGOUS FOR THE F508DEL MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41488,"protocol_no":"CA209-274","submission_no":"191636","status_id":1,"start_date":"2016-07-05","end_date":null,"nol_date":"2016-02-22","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER STUDY OF ADJUVANT NIVOLUMAB VERSUS PLACEBO IN SUBJECTS WITH HIGH RISK INVASIVE UROTHELIAL CARCINOMA","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38076,"protocol_no":"EBI-005-4","submission_no":"180788","status_id":1,"start_date":"2015-04-20","end_date":null,"nol_date":"2015-01-16","protocol_title":"A MULTI-CENTER, DOUBLE-MASKED, RANDOMIZED, ONE-YEAR SAFETY STUDY OF EBI-005 5 MG/ML TOPICAL OPTHALMIC SOLUTION VERSUS VEHICLE-CONTROL IN SUBJECTS WITH DRY EYE DISEASE (DED)","medConditionList":[{"med_condition_id":593,"med_condition":"DRY EYE DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48095,"protocol_no":"1245.168","submission_no":"212921","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-12","protocol_title":"A PHASE III RANDOMISED, DOUBLE-BLIND TRIAL TO EVALUATE THE EFFECT OF 12 WEEKS TREATMENT OF ONCE DAILY EMPAGLIFLOZIN 10 MG COMPARED WITH PLACEBO ON EXERCISE ABILITY AND HEART FAILURE SYMPTOMS, IN PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) (EMPERIAL-REDUCED)","medConditionList":[{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45165,"protocol_no":"CC-90001-IPF-001","submission_no":"201814","status_id":1,"start_date":"2017-11-22","end_date":null,"nol_date":"2017-04-12","protocol_title":"A PHASE 2, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY, FOLLOWED BY A 28-WEEK TREATMENT EXTENSION, TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS","medConditionList":[{"med_condition_id":127,"med_condition":"IDIOPATHIC PULMONARY FIBROSIS (IPF)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36047,"protocol_no":"ALK5461-205","submission_no":"174324","status_id":1,"start_date":"2014-08-25","end_date":null,"nol_date":"2014-05-30","protocol_title":"A PHASE 3 EFFICACY AND SAFETY STUDY OF ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (THE FORWARD-4 STUDY)","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48057,"protocol_no":"C0221002","submission_no":"212829","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-13","protocol_title":"AN ADAPTIVE, PHASE 2 TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-0670512 FOLLOWING MULTIPLE INJECTIONS IN ADULT SUBJECTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)","medConditionList":[{"med_condition_id":476,"med_condition":"FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35710,"protocol_no":"CINC424A2407","submission_no":"173201","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-17","protocol_title":"THE RETREATMENT TRIAL: A PHASE II, OPEN-LABEL, SINGLE-ARM STUDY OF RE-TREATING MYELOFIBROSIS PATIENTS WITH RUXOLITINIB/JAKAVI AFTER TREATMENT INTERRUPTION DUE TO LOSS OF RESPONSE AND/OR ADVERSE EVENT.","medConditionList":[{"med_condition_id":353,"med_condition":"MYELOFIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37238,"protocol_no":"045","submission_no":"177937","status_id":1,"start_date":"2017-05-08","end_date":null,"nol_date":"2014-10-10","protocol_title":"A PHASE III RANDOMIZED CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERUS PACLITAXEL, DOCETAXEL OR VINFLUNINE IN SUBJECTS WITH RECURRENT OR PROGRESSIVE METASTATIC UROTHELIAL CANCER (KEYNOTE 045)","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28285,"protocol_no":"INNO-6030","submission_no":"168158","status_id":3,"start_date":"2013-11-04","end_date":null,"nol_date":"2013-10-25","protocol_title":"EFFECT OF RANKL INHIBITION ON UV-INDUCED IMMUNOSUPPRESSION","medConditionList":[{"med_condition_id":396,"med_condition":"UV-INDUCED IMMUNOSUPRESSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28269,"protocol_no":"DRM02-PSO02","submission_no":"168120","status_id":2,"start_date":"2013-10-18","end_date":"2014-03-25","nol_date":"2013-10-08","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF TOPICAL DRM02 IN SUBJECTS WITH PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40438,"protocol_no":"PEPITES","submission_no":"188103","status_id":1,"start_date":"2015-12-16","end_date":null,"nol_date":"2015-10-30","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III PIVOTAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF PEANUT EPICUTANEOUS IMMUNOTHERAPY WITH VIASKIN PEANUT IN PEANUT-ALLERGIC CHILDREN","medConditionList":[{"med_condition_id":12,"med_condition":"ALLERGIES PEANUT"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27335,"protocol_no":"H9B-MC-BCDS(A)","submission_no":"165474","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-07-04","protocol_title":"\"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LY2127399 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (ILLUMINATE-1)\"","medConditionList":[{"med_condition_id":311,"med_condition":"SYSTEMIC LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28073,"protocol_no":"PHI113633","submission_no":"167488","status_id":1,"start_date":"2014-01-07","end_date":null,"nol_date":"2013-09-17","protocol_title":"A PHASE 2B, RANDOMIZED, BLINDED, DOSE-RANGING, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER STUDY TO EVALUATE THE DOSE RESPONSE RELATIONSHIP OF GSK1278863 OVER THE FIRST 4 WEEKS OF TREATMENT AND EVALUATE THE SAFETY AND EFFICACY OF GSK1278863 OVER 24 WEEKS IN HEMODIALYSIS-DEPENDENT SUBJECTS WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE WHO SWITCH  FROM RECOMBINANT HUMAN ERYTHROPOIETIN","medConditionList":[{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"},{"med_condition_id":329,"med_condition":"ANEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35464,"protocol_no":"PARITY12-009","submission_no":"172458","status_id":1,"start_date":"2014-01-12","end_date":null,"nol_date":"2014-03-27","protocol_title":"PROPHYLACTIC ANTIBIOTIC REGIMENS IN TUMOR SURGERY (PARITY): A MULTI-CENTER RANDOMIZED CONTROLLED STUDY COMPARING ALTERNATIVE ANTIBIOTIC REGIMENS IN PATIENTS UNDERGOING TUMOR RESECTIONS WITH ENDOPROSTHETIC REPLACEMENTS","medConditionList":[{"med_condition_id":552,"med_condition":"PROPHYLAXIS OF INFECTIONS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27055,"protocol_no":"1000036223","submission_no":"164638","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-06-05","protocol_title":"THROMBOLYSIS IN PEDIATRIC STROKE (TIPS)","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"},{"med_condition_id":281,"med_condition":"THROMBOLYSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47996,"protocol_no":"8374-CL-0101","submission_no":"212664","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-07","protocol_title":"A PHASE 1 STUDY OF ASP8374, AN IMMUNE CHECKPOINT INHIBITOR, AS A SINGLE AGENT IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC CARCINOMA","medConditionList":[{"med_condition_id":813,"med_condition":"CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44783,"protocol_no":"CANSTEM111P","submission_no":"202396","status_id":1,"start_date":"2017-10-18","end_date":null,"nol_date":"2017-02-17","protocol_title":"A PHASE III STUDY OF BBI-608 PLUS NAB-PACLITAXEL WITH GEMCITABINE IN ADULT PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA.","medConditionList":[{"med_condition_id":401,"med_condition":"PANCREATIC ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38466,"protocol_no":"VLZ-MD-22","submission_no":"182121","status_id":1,"start_date":"2015-09-17","end_date":null,"nol_date":"2015-03-27","protocol_title":"A MULTICENTER, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP EVALUATION OF THE SAFETY AND EFFICACY OF VILAZODONE IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37988,"protocol_no":"IND.219","submission_no":"180389","status_id":1,"start_date":"2016-05-25","end_date":null,"nol_date":"2015-01-07","protocol_title":"A RANDOMIZED PHASE II TRIAL OF SELUMETINIB IN PATIENTS RECEIVING STANDARD PEMETREXED AND CISPLATIN CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED OR METASTATIC KRAS WILDTYPE OR UNKNOWN NON-SQUAMOUS NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27322,"protocol_no":"14564","submission_no":"165398","status_id":1,"start_date":"2013-07-25","end_date":null,"nol_date":"2013-06-27","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, MULTI-CENTER STUDY TO ASSESS SAFETY AND EFFICACY OF BAY 94-8862 IN SUBJECTS WITH EMERGENCY PRESENTATION AT THE HOSPITAL BECAUSE OF WORSENING CHRONIC HEART FAILURE WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AND EITHER TYPE 2 DIABETES MELLITUS WITH OR WITHOUT CHRONIC KIDNEY DISEASE OR MODERATE CHRONIC KIDNEY DISEASE ALONE VERSUS EPLERENONE.","medConditionList":[{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45015,"protocol_no":"ALK4230-A101","submission_no":"203073","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-06","protocol_title":"A PHASE 1 STUDY OF ALKS 4230 IN SUBJECTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36729,"protocol_no":"BP29360","submission_no":"176410","status_id":2,"start_date":"2014-12-02","end_date":"2016-06-27","nol_date":"2014-08-13","protocol_title":"OPEN-LABEL PHASE IB/II, MULTICENTER STUDY OF THE COMBINATION OF RO5479599 WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HISTOLOGY WHO HAVE NO RECEIVED PRIOR CHEMOTHERAPY OR TARGETED THERAPY FOR NSCLC","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46557,"protocol_no":"MSFMT-001","submission_no":"207956","status_id":1,"start_date":"2017-09-21","end_date":null,"nol_date":"2017-08-23","protocol_title":"FECAL MICROBIAL TRANSPLANTATION IN RELAPSING MULTIPLE SCLEROSIS PATIENTS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44441,"protocol_no":"4010-01-001","submission_no":"201296","status_id":1,"start_date":"2017-06-19","end_date":null,"nol_date":"2017-01-20","protocol_title":"A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AND ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37064,"protocol_no":"GO29365","submission_no":"177394","status_id":1,"start_date":"2016-04-22","end_date":null,"nol_date":"2014-09-17","protocol_title":"A PHASE IB/II STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN (DCDS4501A) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"},{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27493,"protocol_no":"RD.06.SPR.18240","submission_no":"165917","status_id":2,"start_date":"2013-09-04","end_date":"2015-03-25","nol_date":"2013-07-18","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP VEHICLE AND ACTIVE CONTROLLED STUDY TO COMPARE THE EFFICACY AND SAFETY OF CD0271 0.3% / CD1579 2.5% TOPICAL GEL VERSUS TOPICAL GEL VEHICLE IN SUBJECTS WITH ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45765,"protocol_no":"DRM01B-ACN05","submission_no":"205419","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-25","protocol_title":"AN OPEN-LABEL STUDY ASSESSING LONG-TERM SAFETY OF OLUMACOSTAT GLASARETIL GEL IN SUBJECTS WITH ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37311,"protocol_no":"ADS-AMT-PD302","submission_no":"178254","status_id":2,"start_date":"2015-01-23","end_date":"2015-10-08","nol_date":"2014-10-14","protocol_title":"OPEN-LABEL SAFETY STUDY OF ADS-5102 (AMANTADINE HCL) EXTENDED RELEASE CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37329,"protocol_no":"183-2014","submission_no":"178298","status_id":1,"start_date":"2015-09-24","end_date":null,"nol_date":"2014-10-07","protocol_title":"ONCE DAILY AMINOGLYCOSIDE PHARMACOKINETICS AND OPTIMAL DOSING IN THE BURN POPULATION: A PROSPECTIVE STUDY","medConditionList":[{"med_condition_id":589,"med_condition":"BURN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38611,"protocol_no":"C16021","submission_no":"182602","status_id":1,"start_date":"2015-06-03","end_date":null,"nol_date":"2015-03-30","protocol_title":"A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ORAL IXAZOMIB MAINTENANCE THERAPY AFTER INITIAL THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA NOT TREATED WITH STEM CELL TRANSPLANTATION","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47587,"protocol_no":"672","submission_no":"211308","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-13","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND TRIAL OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH EPACADOSTAT (INCB024360) OR PLACEBO IN PARTICIPANTS WITH CISPLATIN INELIGIBLE UROTHELIAL CARCINOMA (KEYNOTE-672/ECHO-307)","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28526,"protocol_no":"NN9924-790","submission_no":"168865","status_id":1,"start_date":"2013-11-18","end_date":null,"nol_date":"2013-11-13","protocol_title":"MULTIPLE DOSE TRIAL EXAMINING DOSE RANGE, ESCALATION AND EFFICACY OF ORAL SEMAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35726,"protocol_no":"ALK5461-210","submission_no":"173236","status_id":1,"start_date":"2014-06-19","end_date":null,"nol_date":"2014-04-23","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TWO TITRATION SCHEDULES FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADULTS WITH AN INADEQUATE RESPONSE TO ANTIDEPRESSANT THERAPY","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35703,"protocol_no":"NCT02079090","submission_no":"173183","status_id":1,"start_date":"2014-07-08","end_date":null,"nol_date":"2014-04-24","protocol_title":"KETOFOL VERSUS FENTOFOL FOR PROCEDURAL SEDATION OF CHILDREN 3 TO 17 YEARS OLD - A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY","medConditionList":[{"med_condition_id":469,"med_condition":"BONE FRACTURES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43044,"protocol_no":"PA.7","submission_no":"196974","status_id":1,"start_date":"2016-09-08","end_date":null,"nol_date":"2016-08-18","protocol_title":"A RANDOMIZED PHASE II TRIAL OF GEMICITABINE AND NAB-PACLITAXEL VS GEMCITABINE, NAB-PACLITAXEL, DURVALUMAB AND TREMELIMUMAB AS 1ST LINE THERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA","medConditionList":[{"med_condition_id":401,"med_condition":"PANCREATIC ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27052,"protocol_no":"NN1218-3852","submission_no":"164626","status_id":1,"start_date":"2013-08-26","end_date":null,"nol_date":"2013-06-05","protocol_title":"\"ONSET: EFFICACY AND SAFETY OF FIASP COMPARED TO INSULIN ASPART BOTH IN COMBINATION WITH INSULIN DETEMIR IN ADULTS WITH TYPE 1 DIABETES.\"","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43416,"protocol_no":"MDCO-APO-14-01","submission_no":"198045","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-09-30","protocol_title":"MULTIPLE-DOSE, DOSE-FINDING PLACEBO CONTROLLED DOUBLE-BLIND RANDOMIZED TRIAL TO COMPARE THE EFFECT OF TREATMENT ON PLAQUE BURDEN DETERMINED BY IVUS; EVALUATE EFFICACY, SAFETY, TOLERABILITY OF MDCO-216 IN SUBJECTS WITH RECENT ACS EVENT","medConditionList":[{"med_condition_id":499,"med_condition":"ACUTE CORONARY SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36630,"protocol_no":"CTNPT 019","submission_no":"176047","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-08-05","protocol_title":"PREVENTING THE PROGRESSION OF LIVER FIBROSIS WITH METFORMIN IN HCV-HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS WITH INSULIN RESISTANCE.","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"},{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37636,"protocol_no":"D4190C00011","submission_no":"179219","status_id":1,"start_date":"2014-11-26","end_date":null,"nol_date":"2014-11-26","protocol_title":"A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF MEDI4736 IN COMBINATION WITH TREMELIMUMAB ALONE IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38558,"protocol_no":"BBI401-101","submission_no":"182412","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-03-25","protocol_title":"A PHASE IB CLINICAL STUDY OF BBI608 AND BBI503 ADMINISTERED IN COMBINATION TO ADULT PATIENTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40105,"protocol_no":"14-120-PED/4015","submission_no":"187108","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-10-09","protocol_title":"EVALUATION OF THE EFFECT OF INTRAPERITONEAL NEBULIZED ROPIVACAINE ON MORPHINE CONSUMPTION AFTER LAPAROSCOPIC APPENDECTOMY IN CHILDREN. A PROSPECTIVE, RANDOMIZED DOUBLE BLIND CLINICAL TRIAL.","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29512,"protocol_no":"1275.9","submission_no":"172041","status_id":2,"start_date":"2014-04-01","end_date":"2015-06-18","nol_date":"2014-03-07","protocol_title":"A PHASE III, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, 24 WEEK STUDY TO EVALUATE EFFICACY AND SAFETY OF ONCE DAILY EMPAGLIFLOZIN 10 MG AND 25 MG COMPARED TO PLACEBO, ALL ADMINISTERED AS ORAL FIXED DOSE COMBINATIONS WITH LINAGLIPTIN 5 MG, IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCAEMIC CONTROL AFTER 16 WEEKS TREATMENT WITH LINAGLIPTIN 5 MG ONCE DAILY ON METFORMIN BACKGROUND THERAPY","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42162,"protocol_no":"GID.FMT.1","submission_no":"194097","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-05-18","protocol_title":"PROSPECTIVE, OPEN-LABEL TRIAL TO EVALUATE EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION FOR TREATMENT OF CHRONIC GASTROINTESTINAL DYSBIOSIS OR CLEARANCE OF ANTIBIOTIC RESISTANT ORGANISM","medConditionList":[{"med_condition_id":693,"med_condition":"ANTIBIOTIC RESISTANCE"},{"med_condition_id":439,"med_condition":"GASTROINTESTINAL DISORDERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27260,"protocol_no":"170904","submission_no":"165245","status_id":3,"start_date":"2010-10-30","end_date":null,"nol_date":"2013-06-27","protocol_title":"A CLINICAL STUDY OF IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN) 20% SOLUTION (IGSC,20%) FOR THE EVALUATION OF EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES","medConditionList":[{"med_condition_id":210,"med_condition":"PRIMARY IMMUNODEFICIENCY DISEASES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26638,"protocol_no":"ELND005-AG251","submission_no":"163324","status_id":1,"start_date":"2014-03-03","end_date":null,"nol_date":"2013-04-10","protocol_title":"A 12-WEEK SAFETY EXTENSION STUDY OF ORAL ELND005 FOR TREATMENT OF AGITATION AND AGGRESSION IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29406,"protocol_no":"CINC424XCA03T","submission_no":"171715","status_id":1,"start_date":"2014-04-04","end_date":null,"nol_date":"2014-03-04","protocol_title":"A PHASE I/II TRIAL OF RUXOLITINIB (JAKAVI ) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHO ARE UNFIT FOR CONVENTIONAL FIRST-LINE THERAPY DUE TO AGE OR 17P DELETIONS","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39070,"protocol_no":"EEU-MERCK-001","submission_no":"184030","status_id":1,"start_date":"2015-06-08","end_date":null,"nol_date":"2015-05-28","protocol_title":"\"THE IMPACT OF GRASS SLIT TREATMENT ON BIRCH POLLEN INDUCED ALLERGIC RHINITIS - A PILOT EVALUATION. \"","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28675,"protocol_no":"SD-809-C-16","submission_no":"169394","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-11-27","protocol_title":"AN OPEN-LABEL, LONG TERM SAFETY STUDY OF SD-809 ER IN SUBJECTS WITH CHOREA ASSOCIATED WITH HUNTINGTON DISEASE","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44497,"protocol_no":"LIFT001","submission_no":"201560","status_id":1,"start_date":"2017-04-27","end_date":null,"nol_date":"2017-01-27","protocol_title":"LITHIUM FOR FRACTURE TREATMENT (LIFT): A DOUBLE BLIND RANDOMIZED CONTROL TRIAL","medConditionList":[{"med_condition_id":469,"med_condition":"BONE FRACTURES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38592,"protocol_no":"LBS-SS201","submission_no":"182517","status_id":1,"start_date":"2015-06-05","end_date":null,"nol_date":"2015-04-01","protocol_title":"TREATMENT OF SEPTIC SHOCK BY INHIBITING AUTODIGESTION AND PRESERVING GUT INTEGRITY WITH ENTERIC LB1148 (SSAIL STUDY)","medConditionList":[{"med_condition_id":583,"med_condition":"SEPTIC SHOCK"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45001,"protocol_no":"D6410C00001","submission_no":"203025","status_id":1,"start_date":"2017-08-28","end_date":null,"nol_date":"2017-03-15","protocol_title":"A PHASE I, FIRST-TIME-IN-HUMAN STUDY OF MEDI9197, A TLR 7/8 AGONIST, ADMINISTERED INTRATUMORALLY AS A SINGLE AGENT IN SUBJECTS WITH SOLID TUMORS OR CTCL AND IN COMBINATION WITH DURVALUMAB AND PALLIATIVE RADIATION IN SUBJECTS WITH SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38435,"protocol_no":"FKB327-003","submission_no":"182037","status_id":1,"start_date":"2015-06-26","end_date":null,"nol_date":"2015-03-13","protocol_title":"AN OPEN-LABEL EXTENSION STUDY TO COMPARE THE LONG-TERM EFFICACY, SAFETY, IMMUNOGENICITY AND PHARMACOKINETICS OF FKB327 AND HUMIRA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON CONCOMITANT METHOTREXATE (ARABESC-OLE)","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27716,"protocol_no":"B5","submission_no":"166535","status_id":1,"start_date":"2013-08-29","end_date":null,"nol_date":"2013-08-15","protocol_title":"NON-ISOTOPE BASED IMAGING MODALITIES VS 99MTC SPECT MYOCARDIAL PERFUSION IMAGING (MPI) TO DETECT MYOCARDIAL ISCHEMIA IN PATIENTS AT HIGH RISK FOR ISCHEMIC CARDIOVASCULAR EVENTS","medConditionList":[{"med_condition_id":304,"med_condition":"MRI IMAGING"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48096,"protocol_no":"NN9535-4374","submission_no":"212546","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-15","protocol_title":"EFFECT AND SAFETY OF SEMAGLUTIDE 2.4 MG ONCE-WEEKLY IN SUBJECTS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47540,"protocol_no":"CA224-020","submission_no":"211208","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-14","protocol_title":"A PHASE 1/2A DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-LAG-3 MONOCLONAL ANTIBODY (BMS-986016) ADMINISTERED ALONE AND IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY (NIVOLUMAB, BMS-936558) IN ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38018,"protocol_no":"CD-ON-CAT-8015-1053","submission_no":"180603","status_id":1,"start_date":"2015-07-10","end_date":null,"nol_date":"2015-01-09","protocol_title":"A PIVOTAL MULTICENTER TRIAL OF MOXETUMOMAB PASUDOTOX IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA","medConditionList":[{"med_condition_id":592,"med_condition":"HAIRY CELL LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44161,"protocol_no":"CCTG: MA-37, BIG: 14-03","submission_no":"200268","status_id":1,"start_date":"2017-02-07","end_date":null,"nol_date":"2016-12-13","protocol_title":"PALBOCICLIB COLLABORATIVE ADJUVANT STUDY: A RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HORMONE RECEPTOR POSITIVE (HR+) / HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE EARLY BREAST CANCER.","medConditionList":[{"med_condition_id":527,"med_condition":"BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42905,"protocol_no":"CAMPHET-CTA-104","submission_no":"196593","status_id":1,"start_date":"2016-08-15","end_date":null,"nol_date":"2016-08-05","protocol_title":"EXPLORING REGULATION AND FUNCTION OF DOPAMINE D3 RECEPTORS IN ALCOHOL USE DISORDERS. A [C11]-(+)-PHNO STUDY.","medConditionList":[{"med_condition_id":715,"med_condition":"ALCOHOL USE DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26800,"protocol_no":"E7080-G000-304","submission_no":"163856","status_id":1,"start_date":"2013-01-22","end_date":null,"nol_date":"2013-05-08","protocol_title":"A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL TO COMPARE THE EFFICACY AND SAFETY OF LENVATINIB (E7080) VERSUS SORAFENIB IN FIRST-LINE TREATMENT OF SUBJECTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40963,"protocol_no":"GS-US-380-1490","submission_no":"189789","status_id":1,"start_date":"2016-03-29","end_date":null,"nol_date":"2015-12-17","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GS-9883/EMTRICITABINE/TENOFOVIR ALAFENAMIDE VERSUS DOLUTEGRAVIR + EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN HIV 1 INFECTED, ANTIRETROVIRAL TREATMENT-NA√èVE ADULTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35691,"protocol_no":"NA-1-006","submission_no":"173132","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-16","protocol_title":"A PHASE 2, MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SAFETY AND EFFICACY STUDY EVALUATING A SINGLE DOSE OF INTRAVENOUS NA 1 IN PATIENTS WITH SUBARACHNOID HEMORRHAGE UNDERGOING ENDOVASCULAR REPAIR OF RUPTURED INTRACRANIAL ANEURYSMS","medConditionList":[{"med_condition_id":389,"med_condition":"SUBARACHNOID HEMORRHAGE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27571,"protocol_no":"DRM01B-ACN01","submission_no":"166170","status_id":1,"start_date":"2013-08-08","end_date":null,"nol_date":"2013-07-31","protocol_title":"A STUDY OF THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF DRM01B TOPICAL GEL IN HEALTHY VOLUNTEERS AND SUBJECTS WITH ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44179,"protocol_no":"CV185-362","submission_no":"200319","status_id":1,"start_date":"2017-06-29","end_date":null,"nol_date":"2016-12-23","protocol_title":"A PROSPECTIVE, RANDOMIZED, OPEN LABEL, MULTI CENTER STUDY OF THE SAFETY AND PHARMACOKINETICS OF APIXABAN VERSUS VITAMIN K ANTAGONIST OR LMWH IN PEDIATRIC SUBJECTS WITH CONGENITAL OR ACQUIRED HEART DISEASE REQUIRING CHRONIC ANTICOAGULATION FOR THROMBOEMBOLISM PREVENTION","medConditionList":[{"med_condition_id":651,"med_condition":"PROPHYLAXIS FOR THROMBOEMBOLISM PREVENTION"},{"med_condition_id":832,"med_condition":"HEART DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36406,"protocol_no":"PRO00045961","submission_no":"175316","status_id":3,"start_date":"2015-08-01","end_date":null,"nol_date":"2014-07-03","protocol_title":"MANGANESE PORPYRINE MNTE-2-PYP (BMX-010) PRESERVATION OF ISLET CELL MASS AND FUNCTION FOR CLINICAL ISLET TRANSPLANTATION","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39712,"protocol_no":"CLAG525X2101C","submission_no":"186127","status_id":1,"start_date":"2017-09-26","end_date":null,"nol_date":"2015-08-20","protocol_title":"A PHASE I/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF LAG525 SINGLE AGENT AND IN COMBINATION WITH PDR001 ADMINISTERED TO PATIENTS WITH ADVANCED MALIGNANCIES.","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39477,"protocol_no":"GS-US-326-1100","submission_no":"185449","status_id":1,"start_date":"2015-09-11","end_date":null,"nol_date":"2015-07-14","protocol_title":"A COMBINED PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, INDUCTION AND MAINTENANCE STUDY EVALUATING THE SAFETY AND EFFICACY OF GS-5745 IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35405,"protocol_no":"1000042423","submission_no":"172230","status_id":1,"start_date":"2017-04-07","end_date":null,"nol_date":"2014-03-28","protocol_title":"ANTI-CD3 MAB (TEPLIZUMAB) FOR PREVENTION OF DIABETES IN RELATIVES AT-RISK FOR TYPE 1 DIABETES MELLITUS","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37653,"protocol_no":"WA25615","submission_no":"179280","status_id":1,"start_date":"2016-07-07","end_date":null,"nol_date":"2014-11-27","protocol_title":"A PHASE IIA, INTERNATIONAL, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF 4X 375 MG/M2 INTRAVENOUS RITUXIMAB IN PEDIATRIC PATIENTS WITH SEVERE GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) OR MICROSCOPIC POLYANGIITIS","medConditionList":[{"med_condition_id":580,"med_condition":"MICROSCOPIC POLYANGITIS"},{"med_condition_id":579,"med_condition":"POLYANGITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36088,"protocol_no":"N/A","submission_no":"174459","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-06-13","protocol_title":"A MULITSITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 12-WEEK STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF ADJUNCTIVE INFLIXIMAB FOR THE TREATMENT OF BIPOLAR I/II DEPRESSION","medConditionList":[{"med_condition_id":25,"med_condition":"BIPOLAR DEPRESSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27762,"protocol_no":"331-12-284","submission_no":"166659","status_id":2,"start_date":"2014-03-26","end_date":"2017-03-06","nol_date":"2013-08-08","protocol_title":"A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF FLEXIBLE DOSING OF BREXPIPRAZOLE (OPC 34712) IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE","medConditionList":[{"med_condition_id":361,"med_condition":"DEMENTIA"},{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39669,"protocol_no":"TG 511-15-01","submission_no":"186007","status_id":1,"start_date":"2017-11-14","end_date":null,"nol_date":"2015-08-05","protocol_title":"PHASE 2/3 RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511, A RETROVIAL REPLICATING VECTOR, COMBINED WITH TOCA FC VERSUS STANDARD OF CARE IN SUBJECTS UNDERGOING PLANNED RESECTION FOR RECURRENT GLIOBLASTOMA OR ANAPLASTIC ASTROCYTOMA.\"","medConditionList":[{"med_condition_id":638,"med_condition":"ANAPLASTIC ASTROCYTOMA"},{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27441,"protocol_no":"CLGX818X2102","submission_no":"165652","status_id":2,"start_date":"2014-06-12","end_date":"2015-11-25","nol_date":"2013-07-12","protocol_title":"A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF SINGLE-AGENT LGX818 FOLLOWED BY A RATIONAL COMBINATION WITH TARGETED AGENTS AFTER PROGRESSION ON LGX818, TO OVERCOME RESISTANCE IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BRAF V600 MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45934,"protocol_no":"DIV-SCLC-301","submission_no":"205884","status_id":1,"start_date":"2017-10-26","end_date":null,"nol_date":"2017-06-26","protocol_title":"A TWO-PART, OPEN-LABEL, RANDOMIZED, PHASE II/III STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND LINE TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37253,"protocol_no":"244-2014","submission_no":"177992","status_id":1,"start_date":"2016-07-12","end_date":null,"nol_date":"2014-10-31","protocol_title":"THE HELIX (HEMORRHAGE DURING LIVER RESECTION: TRANEXAMIC ACID) TRIAL: TRANEXAMIC ACID (TXA) VERSUS PLACEBO TO REDUCE PERIOPERATIVE BLOOD TRANSFUSION IN PATIENTS UNDERGOING LIVER RESECTION: A PILOT RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":590,"med_condition":"HEMORRHAGE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28429,"protocol_no":"15371","submission_no":"168538","status_id":1,"start_date":"2013-11-26","end_date":null,"nol_date":"2013-10-30","protocol_title":"A RANDOMIZED PARALLEL-GROUP, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTI-CENTER DOSE FINDING PHASE II TRIAL EXPLORING THE PHARMACODYNAMIC EFFECTS, SAFETY AND TOLERABILITY, AND PHARMACOKINETICS OF FOUR DOSE REGIMENS OF THE ORAL SGC STIMULATOR BAY 1021189 OVER 12 WEEKS IN PATIENTS WITH WORSENING HEART FAILURE AND REDUCED EJECTION FRACTION (HFREF) - SOLUBLE GUANYLATE CYCLASE STIMULATOR IN HEART FAILURE PATIENTS WITH REDUCED EF (SOCRATES-REDUCED).","medConditionList":[{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35610,"protocol_no":"20130255","submission_no":"172899","status_id":1,"start_date":"2016-07-08","end_date":null,"nol_date":"2014-04-09","protocol_title":"AN OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF AMG 334","medConditionList":[{"med_condition_id":158,"med_condition":"CHRONIC MIGRAINE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35553,"protocol_no":"CA209-140","submission_no":"172757","status_id":1,"start_date":"2014-10-15","end_date":null,"nol_date":"2014-04-03","protocol_title":"A SINGLE-ARM, OPEN-LABEL PHASE 2 STUDY OF NIVOLUMAB (BMS-936558) IN SUBJECTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42689,"protocol_no":"AD/MG1-MAGEA3-001","submission_no":"195876","status_id":1,"start_date":"2017-12-22","end_date":null,"nol_date":"2016-07-21","protocol_title":"A PHASE 1/2, MULTICENTER, OPEN-LABEL TRIAL OF MG1 MARABA EXPRESSING MAGE-A3 (MG1-MAGEA3), WITH ADENOVIRUS VACCINE EXPRESSING MAGE-A3 (AD-MAGEA3), IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37392,"protocol_no":"MB102229","submission_no":"178475","status_id":1,"start_date":"2014-12-23","end_date":null,"nol_date":"2014-10-30","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPAGLIFLOZIN AS AN ADD-ON TO INSULIN THERAPY IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26749,"protocol_no":"CV181206","submission_no":"163696","status_id":2,"start_date":"2013-10-23","end_date":"2016-09-26","nol_date":"2013-05-01","protocol_title":"A 24-WEEK INTERNATIONAL, MULTI-CENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND TRIAL TO EVALUATE METFORMIN EXTENDED RELEASE MONOTHERAPY COMPARED TO METFORMIN IMMEDIATE RELEASE MONOTHERAPY IN ADULT SUBJECTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29036,"protocol_no":"LX1606.1-302-CS","submission_no":"170641","status_id":1,"start_date":"2017-01-11","end_date":null,"nol_date":"2014-01-07","protocol_title":"A MULTICENTER, LONG-TERM EXTENSION STUDY TO FURTHER EVALUATE THE SAFETY AND TOLERABILITY OF TELOTRISTAT ETIPRATE (LX1606)","medConditionList":[{"med_condition_id":490,"med_condition":"CARCINOID SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27841,"protocol_no":"54767414MMY2002","submission_no":"166857","status_id":1,"start_date":"2014-03-25","end_date":null,"nol_date":"2013-08-21","protocol_title":"\"AN OPEN-LABEL, MULTICENTER, PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF DARATUMUMAB IN SUBJECTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 3 PRIOR LINES OF THERAPY (INCLUDING A PROTEASOME INHIBITOR AND IMID) OR ARE DOUBLE REFRACTORY TO A PROTEASOME INIBITOR AND AN IMID.\"","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27624,"protocol_no":"VCD-060","submission_no":"166291","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-08-28","protocol_title":"THE IMPACT OF VITAMIN D ON DISEASE ACTIVITY IN CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41986,"protocol_no":"GEM-201","submission_no":"193512","status_id":2,"start_date":"2016-07-04","end_date":"2017-01-31","nol_date":"2016-04-18","protocol_title":"A PHASE 2 OPEN-LABEL, DOSE-FINDING STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF GEMCABENE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE, LIPID LOWERING THERAPY (COBALT-1)","medConditionList":[{"med_condition_id":83,"med_condition":"FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26656,"protocol_no":"SPD489-406","submission_no":"163389","status_id":1,"start_date":"2013-05-28","end_date":null,"nol_date":"2013-04-17","protocol_title":"A PHASE 4, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL-GROUP, ACTIVE-CONTROLLED, FORCED-DOSE TITRATION, SAFETY AND EFFICACY STUDY OF SPD489 (VYVANSE ) COMPARED WITH OROS-MPH (CONCERTA ) WITH A PLACEBO REFERENCE ARM, IN ADOLESCENTS AGED 13-17 YEARS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).","medConditionList":[{"med_condition_id":9,"med_condition":"ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36289,"protocol_no":"CINC280X2104","submission_no":"173764","status_id":1,"start_date":"2016-01-08","end_date":null,"nol_date":"2014-06-18","protocol_title":"A PHASE IB, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY, TO EVALUATE THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF INC280 IN COMBINATION WITH CETUXIMAB IN C-MET POSITIVE CRC AND HNSCC PATIENTS WHO HAVE PROGRESSED AFTER ANTI-EGFR MONOCLONAL ANTIBODY THERAPY","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46806,"protocol_no":"CO40016","submission_no":"208751","status_id":1,"start_date":"2018-02-26","end_date":null,"nol_date":"2017-09-15","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER.","medConditionList":[{"med_condition_id":527,"med_condition":"BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37096,"protocol_no":"CA209-143","submission_no":"177497","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-09-24","protocol_title":"A RANDOMIZED PHASE 3 OPEN LABEL STUDY OF NIVOLUMAB VERSUS BEVACIZUMAB AND A SAFETY STUDY OF NIVOLUMAB OR NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (GBM)","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38727,"protocol_no":"CT-13 3.4","submission_no":"182985","status_id":2,"start_date":"2015-05-28","end_date":"2016-07-21","nol_date":"2015-04-23","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PHASE 3 STUDY TO DEMONSTRATE NONINFERIORITY IN EFFICACY AND TO ASSESS SAFETY OF CT-P13 COMPARED TO REMICADE IN PATIENTS WITH ACTIVE CROHN'S DISEASE. PHASE 3","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38621,"protocol_no":"VX14-661-109","submission_no":"182644","status_id":2,"start_date":"2015-07-10","end_date":"2017-09-19","nol_date":"2015-03-24","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, IVACAFTOR-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VX-661 IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS, HETEROZYGOUS FOR THE F508DEL-CFTR MUTATION AND A SECOND CFTR ALLELE WITH A GATING DEFECT THAT IS CLINICALLY DEMONSTRATED TO BE IVACAFTOR RESPONSIVE","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37986,"protocol_no":"079-2014","submission_no":"180377","status_id":2,"start_date":"2015-03-02","end_date":"2016-04-14","nol_date":"2014-12-31","protocol_title":"EVALUATION OF PREGABALIN'S ABUSE LIABILITY AND EFFECTS ON BENZODIAZEPINE WITHDRAWAL SYMPTOMS IN INPATIENTS UNDERGOING MEDICALLY-ASSISTED BENZODIAZEPINE WITHDRAWAL","medConditionList":[{"med_condition_id":428,"med_condition":"SUBSTANCE ABUSE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45319,"protocol_no":"CAEB1102-101A","submission_no":"204071","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-19","protocol_title":"A PHASE 1/2 OPEN-LABEL STUDY IN PATIENTS WITH ARGINASE I DEFICIENCY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS AEB1102","medConditionList":[{"med_condition_id":775,"med_condition":"ARGINASE-1 DEFICIENCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41248,"protocol_no":"15-0305-A","submission_no":"190840","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-01-20","protocol_title":"NOREPINEPHRINE TO PREVENT HYPOTENSION AFTER SPINAL ANESTHESIA FOR CESAREAN DELIVERY: A DOSE FINDING STUDY","medConditionList":[{"med_condition_id":605,"med_condition":"HYPOTENSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39595,"protocol_no":"NN9535-4191","submission_no":"185808","status_id":1,"start_date":"2015-09-21","end_date":null,"nol_date":"2015-07-28","protocol_title":"EFFICACY AND SAFETY OF SEMAGLUTIDE SUBCUTANEOUS ONCE-WEEKLY VERSUS PLACEBO IN DRUG-NAIVE SUBJECTS WITH TYPE 2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28488,"protocol_no":"AC-061A301","submission_no":"168732","status_id":2,"start_date":"2014-05-30","end_date":"2017-03-24","nol_date":"2013-10-28","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO COMPARE THE EFFICACY AND SAFETY OF CADAZOLID VERSUS VANCOMYCIN IN SUBJECTS WITH CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD)","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40940,"protocol_no":"MLN0002SC-3030","submission_no":"189751","status_id":1,"start_date":"2016-09-09","end_date":null,"nol_date":"2015-12-30","protocol_title":"A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"},{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36634,"protocol_no":"MILES","submission_no":"176048","status_id":1,"start_date":"2015-11-02","end_date":null,"nol_date":"2014-08-08","protocol_title":"DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL TO STUDY THE VIASKIN MILK EFFICACY AND SAFETY FOR TREATING IGE-MEDIATED COW'S MILK ALLERGY IN CHILDREN","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46181,"protocol_no":"CSL842_3001","submission_no":"206662","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-18","protocol_title":"A DOUBLE-BLIND, RANDOMIZED-WITHDRAWAL, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HUMAN PLASMA-DERIVED C1-ESTERASE INHIBITOR AS ADD-ON TO STANDARD OF CARE FOR THE TREATMENT OF REFRACTORY ANTIBODY MEDIATED REJECTION IN ADULT RENAL TRANSPLANT RECIPIENTS","medConditionList":[{"med_condition_id":701,"med_condition":"KIDNEY TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42435,"protocol_no":"CA204-185","submission_no":"194949","status_id":1,"start_date":"2016-09-19","end_date":null,"nol_date":"2016-06-07","protocol_title":"CONTINUING TREATMENT FOR SUBJECTS WHO HAVE PARTICIPATED IN A PRIOR PROTOCOL INVESTIGATING ELOTUZUMAB (CONTINUATION PHASE 2 ROLL-OVER PROTOCOL)","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42073,"protocol_no":"107828","submission_no":"193826","status_id":1,"start_date":"2016-10-27","end_date":null,"nol_date":"2016-05-10","protocol_title":"A DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF MIXED-AMPHETAMINE SALTS, EXTENDED RELEASE (ADDERALL XR) FOR COGNITIVE IMPAIRMENT IN MS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44454,"protocol_no":"STREAM-2","submission_no":"201360","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-01-18","protocol_title":"STREAM-2 STRATEGIC REPERFUSION IN ELDERLY PATIENTS EARLY AFTER MYOCARDIAL INFARCTION","medConditionList":[{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26729,"protocol_no":"000079","submission_no":"163636","status_id":1,"start_date":"2013-04-01","end_date":null,"nol_date":"2013-04-30","protocol_title":"A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION TO DEMONSTRATE THE EFFICACY AND SAFETY OF ELOBIXIBAT 5 MG AND 10 MG FOR 26 WEEKS.","medConditionList":[{"med_condition_id":322,"med_condition":"IDIOPATHIC CONSTIPATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27461,"protocol_no":"CRAD001H2305","submission_no":"165810","status_id":2,"start_date":"2016-01-20","end_date":"2016-06-01","nol_date":"2013-08-01","protocol_title":"A 24-MONTH, MULTI-CENTER, SINGLE ARM, PROSPECTIVE STUDY TO EVALUATE RENAL FUNCTION, EFFICACY, SAFETY, AND TOLERABILITY OF EVEROLIMUS IN COMBINATION WITH REDUCED EXPOSURE CYCLOSPORINE OR TACROLIMUS IN PAEDIATRIC LIVER TRANSPLANT RECIPIENTS","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"},{"med_condition_id":129,"med_condition":"IMMUNOSUPPRESSANTS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39635,"protocol_no":"TIDE-06-2015","submission_no":"185917","status_id":1,"start_date":"2015-09-01","end_date":null,"nol_date":"2015-07-31","protocol_title":"A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF TIDEGLUSIB VS. PLACEBO IN THE TREATMENT OF ADOLESCENTS","medConditionList":[{"med_condition_id":351,"med_condition":"AUTISM SPECTRUM DISORDER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37825,"protocol_no":"42160443PAI3001","submission_no":"179811","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-23","protocol_title":"RANDOMIZED, 16-WEEK, MULTI-PHASE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF FULRANUMAB AS ADJUNCTIVE THERAPY IN SUBJECTS WITH SIGNS AND SYMPTOMS OF OSTEOARTHRITIS OF THE HIP OR KNEE","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35378,"protocol_no":"C14018","submission_no":"172148","status_id":1,"start_date":"2015-01-12","end_date":null,"nol_date":"2014-04-24","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL OF ALISERTIB (MLN8237) IN COMBINATION WITH PACLITAXEL VERSUS PLACEBO IN COMBINATION WITH PACLITAXEL AS SECOND LINE THERAPY FOR SMALL CELL LUNG CANCER (SCLC)","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47049,"protocol_no":"000278","submission_no":"209580","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-18","protocol_title":"AN OPEN-LABEL TRIAL INVESTIGATING THE ASSOCIATION BETWEEN NOCTURIA AND SLEEP DURING 12 WEEKS OF TREATMENT WITH DESMOPRESSIN ORALLY DISINTEGRATING TABLET (ODT) FOR NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS","medConditionList":[{"med_condition_id":175,"med_condition":"NOCTURIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40965,"protocol_no":"GS-US-380-1878","submission_no":"189792","status_id":1,"start_date":"2016-04-04","end_date":null,"nol_date":"2015-12-17","protocol_title":"A PHASE 3, RANDOMIZED, OPEN LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM REGIMENS CONSISTING OF BOOSTED ATAZANAVIR OR DARUNAVIR PLUS EITHER EMTRICITABINE/TENOFOVIR OR ABACAVIR/LAMIVUDINE TO GS 9883/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN VIROLOGICALLY SUPPRESSED HIV 1 INFECTED ADULTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36749,"protocol_no":"QBKPN-01","submission_no":"176463","status_id":1,"start_date":"2015-01-13","end_date":null,"nol_date":"2014-08-14","protocol_title":"AN OPEN LABEL, SINGLE ARM, EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, COMPLIANCE AND MECHANISM OF ACTION, OF QBKPN SITE SPECIFIC IMMUNOMODULATION IN SUBJECTS WITH 2 OR MORE SECOND PRIMARY PRE-INVASIVE OR INVASIVE ADENOCARCINOMA FOLLOWING SURGICAL RESECTION OF STAGE I NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38557,"protocol_no":"GTI 1306","submission_no":"182415","status_id":1,"start_date":"2015-10-22","end_date":null,"nol_date":"2015-03-12","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IMMUNE GLOBULIN (HUMAN), 10% CAPRYLATE/CHROMATOGRAPHY PURIFIED (IGIV-C) AS A CORTICOSTEROID SPARING AGENT IN CORTICOSTEROID DEPENDENT GENERALIZED MYASTHENIA GRAVIS","medConditionList":[{"med_condition_id":163,"med_condition":"MYASTHENIA GRAVIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46418,"protocol_no":"CP-PRO-QVLP-012","submission_no":"207463","status_id":1,"start_date":"2017-09-08","end_date":null,"nol_date":"2017-08-11","protocol_title":"A RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF A PLANT-DERIVED QUADRIVALENT VLP INFLUENZA VACCINE IN ADULTS 18-64 YEARS OF AGE","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41563,"protocol_no":"GC5107B_P3","submission_no":"191897","status_id":1,"start_date":"2016-08-05","end_date":null,"nol_date":"2016-03-04","protocol_title":"AN OPEN-LABEL, SINGLE-ARM, HISTORICALLY CONTROLLED, PROSPECTIVE, MULTICENTER PHASE III STUDY TO EVALUATE THE SAFETY, EFFICACY AND PHARMACOKINETICS OF IMMUNE GLOBULLIN INTRAVENOUS (HUMAN) GC5107 IN SUBJECTS WITH PRIMARY HUMORAL IMMUNODEFICIENCY","medConditionList":[{"med_condition_id":676,"med_condition":"PRIMARY HUMORAL IMMUNDEFICIENCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37819,"protocol_no":"42160443PAI3002","submission_no":"179796","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-23","protocol_title":"RANDOMIZED, 16-WEEK, MULTI-PHASE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF FULRANUMABN AS MONOTHERAPY IN SUBJECTS WITH SIGNS AND SYMPTOMS OF OSTEOARTHRITIS OF THE HIP OR KNEE","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45215,"protocol_no":"GS-US-380-4030","submission_no":"203686","status_id":1,"start_date":"2017-06-19","end_date":null,"nol_date":"2017-04-05","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM A REGIMEN OF DOLUTEGRAVIR AND EITHER EMTRICITABINE/TENOFOVIR ALAFENAMIDE OR EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE TO A FIXED DOSE COMBINATION OF BICTEGRAVIR/ EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN HIV-1 INFECTED SUBJECTS WHO ARE VIROLOGICALLY SUPPRESSED","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39380,"protocol_no":"BB-OPMD-301","submission_no":"184997","status_id":2,"start_date":"2015-07-10","end_date":"2017-10-12","nol_date":"2015-06-23","protocol_title":"A PIVOTAL, MULTICENTER, OPEN-LABEL, RANDOMIZED, NON-TREATMENT CONCURRENT CONTROL STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF CABALETTA¬ô IN OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) PATIENTS WHO PARTICIPATED IN STUDY BBCO-001","medConditionList":[{"med_condition_id":573,"med_condition":"OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43796,"protocol_no":"ALXN1210-AHUS-311","submission_no":"199184","status_id":1,"start_date":"2017-03-31","end_date":null,"nol_date":"2016-11-10","protocol_title":"SINGLE ARM STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAIVE ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)","medConditionList":[{"med_condition_id":21,"med_condition":"ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39254,"protocol_no":"IDEAL-001","submission_no":"184609","status_id":1,"start_date":"2016-10-21","end_date":null,"nol_date":"2015-06-17","protocol_title":"IDEAL PILOT STUDY - INFLIXIMAB DOSE TO LEVEL: PILOT STUDY.","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39960,"protocol_no":"CEL201501","submission_no":"186722","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-09-04","protocol_title":"A, PILOT, OPEN-LABEL, DOSE-RESPONSE STUDY INVESTIGATING THE EFFECT OF LOW-DOSE CELECOXIB ON SMN2 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY","medConditionList":[{"med_condition_id":321,"med_condition":"SPINAL MUSCULAR ATROPHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35658,"protocol_no":"PRO00043239","submission_no":"173037","status_id":1,"start_date":"2015-02-11","end_date":null,"nol_date":"2014-04-15","protocol_title":"ASSESSING THE SAFETY AND EFFICACY OF A PORTABLE EX VIVO OXYGENATED, NORMOTHERMIC LIVER PERFUSION SYSTEM (ORGANOX METRA) PRIOR TO LIVER TRANSPLANTATION","medConditionList":[{"med_condition_id":484,"med_condition":"LIVER TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38754,"protocol_no":"CRLX030A2301","submission_no":"183054","status_id":1,"start_date":"2015-07-10","end_date":null,"nol_date":"2015-04-15","protocol_title":"\"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIIB STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILTY OF SERELAXIN WHEN ADDED TO STANDARD THERAPY IN ACUTE HEART FAILURE PATIENTS.\"","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40130,"protocol_no":"METCORE2015","submission_no":"187162","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-09-22","protocol_title":"PHASE II STUDY OF SINGLE AGENT PRE-OPERATIVE METFORMIN IN PATIENTS WITH CLINICAL STAGE I ¬ø IIIA NSCLC PROCEEDING TO SURGICAL RESECTION  `LUNG METCORE STUDY¬ø","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35733,"protocol_no":"ARD-3150-1202","submission_no":"173270","status_id":2,"start_date":"2014-08-07","end_date":"2017-01-17","nol_date":"2014-04-17","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PULMAQUIN¬Æ IN THE MANAGEMENT OF CHRONIC LUNG INFECTIONS WITH PSEUDOMONAS AERUGINOSA IN SUBJECTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS, INCLUDING 28 DAY OPEN-LABEL EXTENSION (ORBIT-4)","medConditionList":[{"med_condition_id":497,"med_condition":"NON-CYSTIC FIBROSIS BRONCHIECTASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43052,"protocol_no":"TRICEPS 123","submission_no":"196995","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-08-16","protocol_title":"SUBTENONS TRIAMCINOLONE ACETONIDE INJECTIONS FOR TREATMENT OF PERSISTENT CHOROIDAL EFFUSIONS POST GLAUCOMA SURGERY","medConditionList":[{"med_condition_id":89,"med_condition":"GLAUCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28332,"protocol_no":"BRISTOW-01","submission_no":"168253","status_id":1,"start_date":"2017-07-31","end_date":null,"nol_date":"2013-10-08","protocol_title":"CHARACTERIZATION OF PRIMARY PROSTATE CANCER CULTURES EX VIVO: STUDIES OF TUMOUR INITIATING CELL (TIC) BIOLOGY AND RESPONSE TO TREATMENT","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41597,"protocol_no":"QRK306","submission_no":"192004","status_id":1,"start_date":"2017-05-24","end_date":null,"nol_date":"2016-03-04","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QPI-1002 FOR PREVENTION OF DELAYED GRAFT FUNCTION IN RECIPIENTS OF A DONATION AFTER BRAIN DEATH OLDER DONOR KIDNEY TRANSPLANT (REGIFT)","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37219,"protocol_no":"997HA306","submission_no":"177890","status_id":1,"start_date":"2016-05-12","end_date":null,"nol_date":"2014-10-10","protocol_title":"AN OPEN-LABEL, MULTICENTER EVALUATION OF THE SAFETY AND EFFICACY OF RECOMBINANT COAGULATION FACTOR VIII FC FUSION PROTEIN (RFVIIIFC; BIIB031) IN THE PREVENTION AND TREATMENT OF BLEEDING IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45037,"protocol_no":"TV48125-CNS-30057","submission_no":"203107","status_id":1,"start_date":"2017-04-12","end_date":null,"nol_date":"2017-03-23","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF 2 DOSE REGIMENS (INTRAVENOUS/SUBCUTANEOUS AND SUBCUTANEOUS) OF TEV-48125 VERSUS PLACEBO FOR THE PREVENTION OF CHRONIC CLUSTER HEADACHE","medConditionList":[{"med_condition_id":628,"med_condition":"CHRONIC CLUSTER HEADACHE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38119,"protocol_no":"PBI-4050-ATX-9-04","submission_no":"180969","status_id":2,"start_date":"2015-10-16","end_date":"2016-11-29","nol_date":"2015-01-23","protocol_title":"A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PBI-4050 IN TYPE 2 DIABETES PATIENTS WITH METABOLIC SYNDROME","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":306,"med_condition":"METABOLIC SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45979,"protocol_no":"NCT03133897","submission_no":"205975","status_id":1,"start_date":"2018-03-05","end_date":null,"nol_date":"2017-06-28","protocol_title":"DEXAMETHASONE VERSUS PREDNISONE FOR ASTHMA TREATMENT IN THE PEDIATRIC INPATIENT POPULATION; A FEASIBILITY STUDY","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27154,"protocol_no":"12AGHS","submission_no":"164972","status_id":1,"start_date":"2015-10-04","end_date":null,"nol_date":"2013-06-14","protocol_title":"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL STUDY EVALUATING THE EFFECT OF A-F BETAFOOD¬Æ ON GALLBLADDER AND LIVER FUNCTION.","medConditionList":[{"med_condition_id":277,"med_condition":"HEALTH IMPROVEMENT"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28540,"protocol_no":"D3610C00001","submission_no":"168916","status_id":1,"start_date":"2016-05-10","end_date":null,"nol_date":"2013-11-07","protocol_title":"A PHASE I, OPEN-LABEL, MULTICENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF ASCENDING DOSES OF AZD5363 UNDER ADAPTABLE DOSING SCHEDULES IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES","medConditionList":[{"med_condition_id":293,"med_condition":"MALIGNANT SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46189,"protocol_no":"POE16-01","submission_no":"206694","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-06","protocol_title":"A PHASE I/II STUDY OF NERATINIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS OR HEMATOLOGIC MALIGNANCIES","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"},{"med_condition_id":507,"med_condition":"RELAPSED OR REFRACTORY SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46215,"protocol_no":"CFI-400945-CL-002","submission_no":"206765","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-21","protocol_title":"ADMINISTERED ORALLY TO PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME","medConditionList":[{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"},{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37754,"protocol_no":"DATAS002","submission_no":"179637","status_id":1,"start_date":"2015-03-20","end_date":null,"nol_date":"2014-12-12","protocol_title":"DABIGATRAN FOLLOWING TRANSIENT ISCHEMIC ATTACK AND MINOR STROKE (DATAS) II","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47081,"protocol_no":"CY 401-11","submission_no":"209659","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-18","protocol_title":"A PHASE 1, SINGLE-DOSE, RANDOMIZED, 2-WAY CROSSOVER STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF CRUSHED TIRASEMTIV TABLETS ADMINISTERED ORALLY COMPARED TO CRUSHED TABLETS ADMINISTERED VIA A PERCUTANEOUS ENDOSCOPIC GASTROSTOMY TUBE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38054,"protocol_no":"56021927PCR3001","submission_no":"180675","status_id":1,"start_date":"2015-05-27","end_date":null,"nol_date":"2015-01-12","protocol_title":"A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF JNJ-56021927 IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE VERSUS ABIRATERONE ACETATE AND PREDNISONE IN SUBJECTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48378,"protocol_no":"VX15/2503-N-131","submission_no":"213773","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-16","protocol_title":"A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY IN SUBJECTS WITH LATE PRODROMAL AND EARLY MANIFEST HUNTINGTON DISEASE (HD) TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VX15/2503","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40096,"protocol_no":"CNTRP-1401","submission_no":"187080","status_id":1,"start_date":"2015-10-26","end_date":null,"nol_date":"2015-09-18","protocol_title":"CONTINUOUS ALLOREACTIVE T CELL DEPLETION AND REGULATORY T CELL EXPANSION FOR THE TREATMENT OF STEROID-REFRACTORY OR DEPENDENT CHRONIC GVHD - A MULTICENTER PHASE II CLINICAL TRIAL","medConditionList":[{"med_condition_id":370,"med_condition":"GRAFT VS HOST DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27718,"protocol_no":"191622-132","submission_no":"166541","status_id":1,"start_date":"2013-08-26","end_date":null,"nol_date":"2013-08-14","protocol_title":"TO EVALUATE THE SAFETY AND EFFICACY OF BOTOX RECONSTITUTED USING VR-RHA COMPARED TO BOTOX RECONSTITUTED USING SALINE, IN THE TREATMENT OF MODERATE-TO-SEVERE FOREHEAD LINES (FHL)","medConditionList":[{"med_condition_id":379,"med_condition":"FOREHEAD LINES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27722,"protocol_no":"191622-131","submission_no":"166550","status_id":3,"start_date":"2013-08-22","end_date":null,"nol_date":"2013-08-14","protocol_title":"TO EVALUATE THE SAFETY AND EFFICACY OF RECONSTITUTING/INJECTING BOTOX WITH VEHICLE FOR RECONSTITUTION (VR) WITH RECOMBINANT HUMAN ALBUMIN (RHA) (BOTOX VR-RHA) FORMULATIONS COMPARED TO RECONSTITUTING / INJECTION BOTOX WITH STANDARD SALINE (BOTOX SALINE) IN THE TREATMENT OF MODERATE-TO-SEVERE GLABELLAR LINES (GL)","medConditionList":[{"med_condition_id":380,"med_condition":"GLABELLAR LINES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45427,"protocol_no":"1000053416","submission_no":"204390","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-02","protocol_title":"NOVEL APPROACHES TO MOLECULAR AND CLINICAL SURVEILLANCE IN LI-FRAUMENI SYNDROME-PILOT STUDY","medConditionList":[{"med_condition_id":787,"med_condition":"LI-FRAUMENI SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27045,"protocol_no":"1000035483","submission_no":"164581","status_id":1,"start_date":"2014-10-14","end_date":null,"nol_date":"2013-05-29","protocol_title":"A PHASE II OPEN LABEL PILOT STUDY OF THE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, PERINDOPRIL, IN PEDIATRIC CANCER SURVIVORS WITH EVIDENCE OF EARLY CARDIAC REMODELING OR DYSFUNCTION","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26994,"protocol_no":"NN9211-3919","submission_no":"164442","status_id":1,"start_date":"2013-12-04","end_date":null,"nol_date":"2013-06-05","protocol_title":"\"THE EFFICACY AND SAFETY OF LIRAGLUTIDE AS ADJUNCT THERAPY TO INSULIN IN THE TREATMENT OF TYPE 1 DIABETES.  A 52-WEEK RANDOMIZED, TREAT-TO-TARGET, PLACEBO-CONTROLLED, DOUBLE-BLINDED, PARALLEL-GROUP, MULTINATIONAL, MULTI-CENTRE-TRIAL","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40478,"protocol_no":"203120","submission_no":"188271","status_id":2,"start_date":"2016-01-11","end_date":"2016-10-05","nol_date":"2015-10-29","protocol_title":"A RANDOMIZED, BLINDED, VEHICLE-CONTROLLED, DOSE-FINDING STUDY OF GSK2894512 CREAM FOR THE TREATMENT OF PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40479,"protocol_no":"203121","submission_no":"188272","status_id":2,"start_date":"2016-02-01","end_date":"2017-01-12","nol_date":"2015-10-29","protocol_title":"A RANDOMIZED, BLINDED, VEHICLE-CONTROLLED, DOSE-FINDING STUDY OF GSK2894512 CREAM FOR THE TREATMENT OF ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40342,"protocol_no":"PIIR-AK-TOVIAZ-AD","submission_no":"187746","status_id":1,"start_date":"2017-06-22","end_date":null,"nol_date":"2015-10-13","protocol_title":"A PHASE II, OPEN-LABEL EXPLORATORY STUDY INVESTIGATING THE EFFICACY OF TOVIAZ FOR TREATMENT OF ADULT PATIENTS WITH SPINAL CORD INJURY (SCI) WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO) FOR AMELIORATION OF AUTONOMIC DYSREFLEXIA (AD).","medConditionList":[{"med_condition_id":238,"med_condition":"SPINAL CORD LESION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28627,"protocol_no":"CIC-AIC-01","submission_no":"169227","status_id":3,"start_date":"2013-01-22","end_date":null,"nol_date":"2013-11-22","protocol_title":"INHALED ALLERGEN CHALLENGE","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37181,"protocol_no":"COR-2012-01","submission_no":"177787","status_id":1,"start_date":"2015-01-21","end_date":null,"nol_date":"2014-10-08","protocol_title":"AN OPEN LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF COR-003 (2S, 4R- KETOCONAZOLE) IN THE TREATMENT OF ENDOGENOUS CUSHING'S SYNDROME","medConditionList":[{"med_condition_id":58,"med_condition":"CUSHING'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27794,"protocol_no":"CAIN457F2306E1","submission_no":"166724","status_id":1,"start_date":"2016-01-25","end_date":null,"nol_date":"2013-08-13","protocol_title":"\"A THREE YEAR EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY, SAFETY AND TOLERABILITY OF SECUKINUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS.\"","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36149,"protocol_no":"EVE-AT-0412","submission_no":"174625","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-06-18","protocol_title":"COMPARISON OF CEREBROLYSIN AND DONEPEZIL: A RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL ON EFFICACY IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48475,"protocol_no":"VX17-659-102","submission_no":"214001","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-19","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF VX 659 COMBINATION THERAPY IN SUBJECTS WITH CYSTIC FIBROSIS WHO ARE HETEROZYGOUS FOR THE F508DEL MUTATION AND A MINIMAL FUNCTION MUTATION (F/MF)","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27014,"protocol_no":"MEK114375","submission_no":"164487","status_id":2,"start_date":"2014-08-17","end_date":"2018-01-18","nol_date":"2013-05-22","protocol_title":"A ROLLOVER STUDY TO PROVIDE CONTINUED TREATMENT WITH GSK1120212 TO SUBJECTS WITH SOLID TUMORS OR LEUKEMIA","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41818,"protocol_no":"1293.10","submission_no":"192847","status_id":1,"start_date":"2017-05-26","end_date":null,"nol_date":"2016-04-08","protocol_title":"A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFECT OF BI 655064 ADMINISTERED AS A SUB-CUTANEOUS INJECTIONS, ON RENAL RESPONSE AFTER ONE YEAR OF TREATMENT, IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS","medConditionList":[{"med_condition_id":681,"med_condition":"LUPUS NEPHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41628,"protocol_no":"MM-398-07-02-03","submission_no":"192101","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-11","protocol_title":"A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF NANOLIPOSOMAL IRINOTECAN (NAL-IRI)-CONTAINING REGIMENS VERSUS GEMCITABINE PLUS NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED, METASTATIC PANCREATIC ADENOCARCINOMA","medConditionList":[{"med_condition_id":401,"med_condition":"PANCREATIC ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40192,"protocol_no":"CLS001-CO-PR-005","submission_no":"187332","status_id":2,"start_date":"2015-12-01","end_date":"2017-10-18","nol_date":"2015-09-28","protocol_title":"A PHASE 3, RANDOMIZED, VEHICLE-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A ONCE-DAILY CLS001 TOPICAL GEL VERSUS VEHICLE ADMINISTERED FOR 12 WEEKS TO SUBJECTS WITH PAPULOPUSTULAR ROSACEA WITH A 4 WEEK FOLLOW-UP PERIOD","medConditionList":[{"med_condition_id":225,"med_condition":"ROSACEA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39001,"protocol_no":"CB8025-21427","submission_no":"183850","status_id":2,"start_date":"2015-06-30","end_date":"2016-01-21","nol_date":"2015-05-15","protocol_title":"A 12-WEEK, OPEN-LABEL, DOSE-ESCALATING, PHASE 2 STUDY TO EVALUATE THE EFFECTS OF MBX-8025 IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)","medConditionList":[{"med_condition_id":116,"med_condition":"HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38694,"protocol_no":"361-2013","submission_no":"182872","status_id":2,"start_date":"2016-01-22","end_date":"2017-04-21","nol_date":"2015-04-02","protocol_title":"A DOUBLE-BLIND PILOT TRIAL OF THE EFFECT OF KETAMINE VS. ACTIVE PLACEBO ON SUICIDAL IDEATION IN DEPRESSED INPATIENTS WITH MAJOR DEPRESSIVE DISORDER OR BIPOLAR DEPRESSION.","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"},{"med_condition_id":501,"med_condition":"BIPOLAR DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38555,"protocol_no":"CNTO1959PSA2001","submission_no":"182413","status_id":1,"start_date":"2015-04-24","end_date":null,"nol_date":"2015-03-20","protocol_title":"A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GUSELKUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38413,"protocol_no":"ADU-CL-04","submission_no":"181994","status_id":1,"start_date":"2015-09-21","end_date":null,"nol_date":"2015-03-06","protocol_title":"A PHASE 2B, RANDOMIZED, CONTROLLED, MULTICENTER, OPEN-LABEL STUDY OF THE EFFICACY AND IMMUNE RESPONSE OF GVAX PANCREAS VACCINE (WITH CYCLOPHOSPHAMIDE) AND CRS-207 COMPARED TO CHEMOTHERAPY OR TO CRS-207 ALONE IN ADULTS WITH PREVIOUSLY-TREATED METASTATIC PANCREATIC ADENOCARCINOMA","medConditionList":[{"med_condition_id":401,"med_condition":"PANCREATIC ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39710,"protocol_no":"CA204143","submission_no":"186123","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-08-06","protocol_title":"AN EXPANDED ACCESS PROGRAM FOR ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULITPLE MYELOMA.","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36051,"protocol_no":"1311.2","submission_no":"174336","status_id":2,"start_date":"2014-07-02","end_date":"2014-09-30","nol_date":"2014-05-23","protocol_title":"A PHASE III, DOUBLE-BLIND, LOT-TO-LOT CONSISTENCY CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNIGENICITY OF V212 IN HEALTHY ADULTS","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47204,"protocol_no":"651","submission_no":"210205","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-10","protocol_title":"A PHASE 1B MULTI-COHORT STUDY OF THE COMBINATION OF PEMBROLIZUMAB (MK-3475) PLUS BINIMETINIB ALONE OR THE COMBINATION OF PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BINIMETINIB IN PARTICIPANTS WITH METASTATIC COLORECTAL CANCER (KEYNOTE-651)","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35990,"protocol_no":"MRZ60201_2094_1","submission_no":"174118","status_id":1,"start_date":"2014-08-12","end_date":null,"nol_date":"2014-05-23","protocol_title":"PROPECTIVE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF NT 201 IN THE UNILATERAL TREATMENT OF ESSENTIAL TREMOR OF THE UPPER LIMB","medConditionList":[{"med_condition_id":141,"med_condition":"LIMB SPASTICITY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40817,"protocol_no":"IM136132","submission_no":"189331","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-04","protocol_title":"A DOUBLE-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF BMS-986020 VERSUS PLACEBO IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)","medConditionList":[{"med_condition_id":246,"med_condition":"SYSTEMIC SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42075,"protocol_no":"UX001-CL302","submission_no":"193829","status_id":1,"start_date":"2016-08-22","end_date":null,"nol_date":"2016-04-27","protocol_title":"A PHASE 3B OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ACENEURAMIC ACID EXTENDED-RELEASE (ACE-ER) TABLETS IN PATIENTS WITH GNE MYOPATHY (GNEM) OR HEREDITARY INCLUSION BODY MYOPATHY (HIBM)","medConditionList":[{"med_condition_id":609,"med_condition":"GNE MYOPATHY (GNEM)"},{"med_condition_id":610,"med_condition":"HEREDITARY INCLUSION BODY MYOPATHY (HIBM)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28750,"protocol_no":"16719","submission_no":"169649","status_id":2,"start_date":"2016-05-11","end_date":"2017-01-27","nol_date":"2013-12-04","protocol_title":"AN OPEN-LABEL, INTERNATIONAL, MULTICENTER, SINGLE-ARM, UNCONTROLLED, PHASE IIIB STUDY OF RIOCIGUAT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO DEMONSTRATE AN INSUFFICIENT RESPONSE TO TREATMENT WITH APPROVED DOSAGES OF PHOSPHODIESTERASE-5 INHIBITORS (PDE-5I)","medConditionList":[{"med_condition_id":218,"med_condition":"PULMONARY ARTERIAL HYPERTENSION (PAH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47561,"protocol_no":"GLY-211-2017","submission_no":"211255","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-08","protocol_title":"A FIRST-IN-PATIENT, MULTI-CENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, ASCENDING DOSE, RANDOMIZED PHASE 1B/2A STUDY, INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF THE GLP-2 RECEPTOR AGONIST FE 203799 IN ADULTS WITH LYMPHOMAS, UNDERGOING MYELOABLATIVE CONDITIONING CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION.","medConditionList":[{"med_condition_id":691,"med_condition":"LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47229,"protocol_no":"ZS-POTS-2017","submission_no":"210282","status_id":1,"start_date":"2018-01-30","end_date":null,"nol_date":"2017-11-07","protocol_title":"A DOUBLE BLIND RANDOMIZED CONTROLLED CROSSOVER STUDY TO SYSTEMATICALLY ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS ALBUMIN INFUSIONS IN SEVERE POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME","medConditionList":[{"med_condition_id":808,"med_condition":"POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37630,"protocol_no":"1289.7","submission_no":"179212","status_id":2,"start_date":"2017-05-04","end_date":"2017-09-21","nol_date":"2014-11-27","protocol_title":"A MULTI-CENTRE, DOUBLE-BLIND, PARALLEL-GROUP, RANDOMIZED CONTROLLED STUDY TO INVESTIGATE EFFICACY, SAFETY AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306 DURING A 12-WEEK TREATMENT PERIOD COMPARED TO DONEPEZIL AND PLACEBO IN PATIENTS WITH COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36958,"protocol_no":"CNTO148AKS3001","submission_no":"177072","status_id":2,"start_date":"2014-11-18","end_date":"2016-10-11","nol_date":"2014-08-29","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF GOLIMUMAB, AND ANTI-TNFA MONOCLONAL ANTIBODY, ADMINISTERED INTRAVENOUSLY IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYTITIS","medConditionList":[{"med_condition_id":397,"med_condition":"ANKYLOSING SPONDYLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40742,"protocol_no":"AGS-16C3F-15-3","submission_no":"188988","status_id":1,"start_date":"2016-08-03","end_date":null,"nol_date":"2015-11-27","protocol_title":"A MULTI-CENTER, OPEN LABEL, RANDOMIZED PHASE 2 STUDY OF AGS-16C3F VS AXITINIB IN METASTATIC RENAL CELL CARCINOMA","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28496,"protocol_no":"0113-CL-2001","submission_no":"168771","status_id":1,"start_date":"2014-06-09","end_date":null,"nol_date":"2013-11-01","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A VACCINE, ASP0113, IN CYTOMEGALOVIRUS (CMV)-SERONEGATIVE KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ORGAN FROM A CMV-SEROPOSITIVE DONOR","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38239,"protocol_no":"CDI.FIDAXOMICIN.1","submission_no":"181365","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-20","protocol_title":"PROSPECTIVE, OPEN-LABEL TRIAL TO EVALUATE EFFICACY OF 30-DAY DURATION OF FIDAXOMICIN IN PATIENTS WITH RECURRENT C. DIFFICILE INFECTION","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38292,"protocol_no":"HC2015:001","submission_no":"181527","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-20","protocol_title":"EFFECT OF DEXAMETHASONE DOSE AND ROUTE ON DURATION OF INTERSCALENE BRACHIAL PLEXUS BLOCK FOR OUTPATIENT SHOULDER SURGERY - A DOUBLE-BLINDED, FACTORIAL DESIGN, RANDOMIZED CONTROL TRIAL","medConditionList":[{"med_condition_id":525,"med_condition":"SHOULDER SURGERY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39642,"protocol_no":"PQ-010-001","submission_no":"185941","status_id":2,"start_date":"2016-05-12","end_date":"2017-10-23","nol_date":"2015-07-30","protocol_title":"PHASE 1B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF QR-010 IN SUBJECTS WITH HOMOZYGOUS ?F508 CYSTIC FIBROSIS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40033,"protocol_no":"UX023-CL303","submission_no":"186908","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-09-11","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF KRN23 IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA (XLH)","medConditionList":[{"med_condition_id":643,"med_condition":"X-LINKED HYPOPHOSPHATEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28257,"protocol_no":"CLIK066A2202","submission_no":"168074","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-09","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP DOSE-FINDING STUDY TO EVALUATE THE CHANGE IN HBA1C AFTER 12 WEEKS MONOTHERAPY WITH LIK066 DOSES RANGING FROM 2.5 MG TO 150 MG DAILY TAKEN Q.D., B.I.D. OR T.I.D. COMPARED WITH PLACEBO OR SITAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38562,"protocol_no":"FX006-2014-008","submission_no":"182424","status_id":2,"start_date":"2015-04-10","end_date":"2016-01-13","nol_date":"2015-03-24","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, SINGLE-DOSE STUDY TO ASSESS THE SAFETY AND EFFICACY OF FX006 FOR THE TREATMENT OF PAIN IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43120,"protocol_no":"2016-MPH-02-3006","submission_no":"197184","status_id":1,"start_date":"2017-01-30","end_date":null,"nol_date":"2016-08-19","protocol_title":"√âTUDE PILOTE DE PHASE II SUR L¬øEFFET DU M√âTHYLPH√âNIDATE (MP) SUR LA FONCTION COGNITIVE DES PATIENTES EN R√âMISSION D¬øUN CANCER DU SEIN.","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40764,"protocol_no":"PRO00058260","submission_no":"189043","status_id":1,"start_date":"2016-05-30","end_date":null,"nol_date":"2015-12-02","protocol_title":"ALLOGENEIC ISLET CELLS TRANSPLANTED INTO THE OMENTUM","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40706,"protocol_no":"201842","submission_no":"188906","status_id":1,"start_date":"2016-09-09","end_date":null,"nol_date":"2015-12-10","protocol_title":"A RANDOMIZED, DOUBLE BLIND (SPONSOR OPEN), COMPARATIVE, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB (GSK1550188) AND INTRAVENOUS RITUXIMAB CO-ADMINISTRATION IN SUBJECTS WITH PRIMARY SJ√ñGREN'S SYNDROME","medConditionList":[{"med_condition_id":664,"med_condition":"SJ√ñGREN'S SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29420,"protocol_no":"AM-101-CL-12-03","submission_no":"171757","status_id":2,"start_date":"2014-03-11","end_date":"2016-11-29","nol_date":"2014-02-27","protocol_title":"AM-101 IN THE POST-ACUTE TREATMENT OF PERIPHERAL TINNITUS 1 (AMPACT1) - AN OPEN-LABEL EXTENSION TO THE TACTT2 STUDY","medConditionList":[{"med_condition_id":451,"med_condition":"TINNITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26521,"protocol_no":"13-3007 ETP","submission_no":"163018","status_id":1,"start_date":"2016-01-11","end_date":null,"nol_date":"2013-04-05","protocol_title":"\"SAFETY, BLOOD BRAIN BARRIER PERMEABILITY AND POTENTIAL EFFICACY OF ETANERCEPT FOR ANEURISMAL SUBARACHNOID HAEMORRHAGE.\"","medConditionList":[{"med_condition_id":287,"med_condition":"ANUERISMAL SUBARACHNOID HAEMORRHAGE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27266,"protocol_no":"CRFB002G2302","submission_no":"165261","status_id":1,"start_date":"2014-03-10","end_date":null,"nol_date":"2013-06-27","protocol_title":"A 12-MONTH, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 0.5MG RANIBIZUMAB INTRAVITREAL INJECTIONS IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) DRIVEN MACULAR EDEMA (ME).","medConditionList":[{"med_condition_id":151,"med_condition":"MACULAR EDEMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41077,"protocol_no":"JNMP-01","submission_no":"190215","status_id":1,"start_date":"2016-04-18","end_date":null,"nol_date":"2015-12-24","protocol_title":"COMPARISON OF PSMA-BASED 18F-DCFPYL PET/CT TO CONVENTIONAL IMAGING IN THE EVALUATION OF SUBJECTS WITH CASTRATION-RESISTANT PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46516,"protocol_no":"EFC14837","submission_no":"207824","status_id":1,"start_date":"2017-12-21","end_date":null,"nol_date":"2017-08-14","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL-GROUP, 52-WEEK MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SOTAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND MODERATE RENAL IMPAIRMENT WHO HAVE INADEQUATE GLYCEMIC CONTROL","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45651,"protocol_no":"VIS410-203","submission_no":"205053","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-09","protocol_title":"PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS VIS410 IN ADDITION TO OSELTAMIVIR (TAMIFLU) COMPARED WITH OSELTAMIVIR ALONE IN HOSPITALIZED ADULTS WITH INFLUENZA A INFECTION","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45161,"protocol_no":"E2609-G000-301","submission_no":"203503","status_id":1,"start_date":"2017-08-18","end_date":null,"nol_date":"2017-04-04","protocol_title":"A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 24 MONTH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF E2609 IN SUBJECTS WITH EARLY ALZHEIMER¬øS DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41885,"protocol_no":"DX-2930-03","submission_no":"193127","status_id":1,"start_date":"2016-07-19","end_date":null,"nol_date":"2016-04-08","protocol_title":"HELP STUDY: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE DX-2930 FOR LONG-TERM PROPHYLAXIS AGAINST ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27549,"protocol_no":"CBKM120H2201","submission_no":"166077","status_id":1,"start_date":"2014-09-15","end_date":null,"nol_date":"2013-07-22","protocol_title":"DOUBLE BLIND, PLACEBO CONTROLLED STUDY ASSESSING THE EFFICACY OF BUPARLISIB (BKM120) PLUS PACLITAXEL VS. PLACEBO PLUS PACLITAXEL IN PATIENTS WITH PLATINUM PRE-TREATED RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC).","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41023,"protocol_no":"204471","submission_no":"189996","status_id":1,"start_date":"2016-06-28","end_date":null,"nol_date":"2016-01-06","protocol_title":"A MULTI-CENTRE, OPEN LABEL, SINGLE ARM, 32-WEEK TREATMENT STUDY IN SUBJECTS WTIH SEVERE EOSINOPHILIC ASTHMA NOT OPTIMALLY CONTROLLED WITH CURRENT OMALIZUMAB TREATMENT WHO ARE SWITCHED FROM OMALIZUMAB TO MEPOLIZUMAB 100MG SUBCUTANEOUS (STUDY NUMBER 204471- THE OSMO STUDY)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40044,"protocol_no":"000175","submission_no":"186862","status_id":1,"start_date":"2015-12-23","end_date":null,"nol_date":"2015-09-04","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MESALAMINE 2 G EXTENDED RELEASE GRANULES (SACHET) FOR MAINTENANCE OF CLINICAL AND ENDOSCOPIC REMISSION IN ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36019,"protocol_no":"ECU-DGF-201","submission_no":"174218","status_id":1,"start_date":"2014-09-01","end_date":null,"nol_date":"2014-05-28","protocol_title":"A RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY OF ECULIZUMAB FOR THE PREVENTION OF DELAYS GRAFT FUNCTION AFTER KIDNEY TRANSPLANTATION IN ADULT SUBJECTS AT INCREASED RISK OF DELAYED GRAFT FUNCTION","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37356,"protocol_no":"LP0084-1015","submission_no":"178365","status_id":1,"start_date":"2014-10-27","end_date":null,"nol_date":"2014-10-17","protocol_title":"SAFETY AND EFFICACY OF ESCALATING DOSES OF LEO 43204 APPLIED ONCE DAILY FOR TWO CONSECUTIVE DAYS ON APPROXIMATELY 250 CM2 ON TRUNK AND EXTREMITIES IN SUBJECTS WITH ACTINIC KERATOSIS. PART 2 (CANADA): A PHASE 2, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, VEHICLE-CONTROLLED, 8-WEEK TRIAL","medConditionList":[{"med_condition_id":520,"med_condition":"ACTINIC KERATOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46371,"protocol_no":"CPDR001I2101","submission_no":"207295","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-31","protocol_title":"A PHASE IB STUDY OF PDR001 IN COMBINATION WITH BEVACIZUMAB AND MFOLFOX6 AS FIRST LINE THERAPY IN PATIENTS WITH METASTATIC MSS COLORECTAL CANCER","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43236,"protocol_no":"241502","submission_no":"197554","status_id":1,"start_date":"2016-11-01","end_date":null,"nol_date":"2016-09-20","protocol_title":"A PHASE 3, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF B-DOMAIN DELETED RECOMBINANT PORCINE FACTOR VIII (BAX 802) IN SUBJECTS WITH CONGENITAL HEMOPHILIA A WITH FACTOR VIII INHIBITORS UNDERGOING SURGICAL OR OTHER INVASIVE PROCEDURES","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43115,"protocol_no":"CA209-714","submission_no":"197166","status_id":1,"start_date":"2017-10-06","end_date":null,"nol_date":"2016-08-22","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, TWO ARM PHASE 2 STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB IN COMBINATION WITH IPILIMUMAB PLACEBO SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)","medConditionList":[{"med_condition_id":724,"med_condition":"SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41647,"protocol_no":"PG324-CS302","submission_no":"192204","status_id":2,"start_date":"2016-06-24","end_date":"2017-03-11","nol_date":"2016-03-30","protocol_title":"A PROSPECTIVE, DOUBLE-MASKED, RANDOMIZED, MULTI-CENTER, ACTIVE CONTROLLED, PARALLEL-GROUP, 3 MONTH STUDY ASSESSING THE SAFETY AND OCULAR HYPOTENSIVE EFFICACY OF PG324 OPHTHALMIC SOLUTION COMPARED TO AR-13324 OPHTHALMIC SOLUTION 0.02% AND LATANOPROST OPHTHALMIC SOLUTION 0.005% IN SUBJECTS WITH ELEVATED INTRAOCULAR PRESSURE","medConditionList":[{"med_condition_id":89,"med_condition":"GLAUCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46713,"protocol_no":"A011502 / CCTG MAC.21","submission_no":"208448","status_id":1,"start_date":"2018-02-26","end_date":null,"nol_date":"2017-09-08","protocol_title":"A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSITIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL.","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47585,"protocol_no":"INCB 50465-203","submission_no":"211305","status_id":1,"start_date":"2018-02-09","end_date":null,"nol_date":"2017-12-13","protocol_title":"PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF INCB050465, A PI3K¬ø INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-203)","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36706,"protocol_no":"CV205005","submission_no":"176308","status_id":2,"start_date":"2014-11-25","end_date":"2016-11-16","nol_date":"2014-08-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL ARM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFECT ON ATRIAL FIBRILLATION BURDEN OF BMS-919373 IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47472,"protocol_no":"2077-1012","submission_no":"211028","status_id":2,"start_date":null,"end_date":"2018-03-08","nol_date":"2017-11-30","protocol_title":"A PHASE 1 PHARMACOKINETIC STUDY OF NK2077 TOPICAL OINTMENT IN PATIENTS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40700,"protocol_no":"I5Q-MC-CGAJ","submission_no":"188871","status_id":1,"start_date":"2015-01-18","end_date":null,"nol_date":"2015-11-26","protocol_title":"A PHASE 3, LONG-TERM, OPEN-LABEL STUDY OF LY2951742 IN PATIENTS WITH MIGRAINE","medConditionList":[{"med_condition_id":157,"med_condition":"MIGRAINE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43864,"protocol_no":"I8J-MC-JYCA","submission_no":"199455","status_id":1,"start_date":"2017-12-15","end_date":null,"nol_date":"2016-11-15","protocol_title":"A PHASE 1A/1B STUDY OF A NOVEL ANTI-PD-L1 CHECKPOINT ANTIBODY (LY3300054) ADMINISTERED ALONE OR IN COMBINATION WITH OTHER AGENTS IN ADVANCED REFRACTORY SOLID TUMORS (PHASE 1A/1B ANTI-PD-L1 COMBINATIONS IN TUMORS-PACT)","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48017,"protocol_no":"CA209-9X8","submission_no":"212740","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-30","protocol_title":"AN OPEN-LABEL EXPLORATORY PHASE 2/3 STUDY OF NIVOLUMAB WITH STANDARD OF CARE THERAPY VS STANDARD OF CARE THERAPY FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (CHECKMATE 9X8: CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 9X8)","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38946,"protocol_no":"I5Q-MC-CGAL(A)","submission_no":"183688","status_id":1,"start_date":"2015-05-26","end_date":null,"nol_date":"2015-05-08","protocol_title":"\"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC CLUSTER HEADACHE.\"","medConditionList":[{"med_condition_id":620,"med_condition":"EPISODIC CLUSTER HEADACHE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44030,"protocol_no":"EIG-UBX-002","submission_no":"199921","status_id":1,"start_date":"2017-05-08","end_date":null,"nol_date":"2016-11-25","protocol_title":"A PHASE 2, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF UBENIMEX IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1)","medConditionList":[{"med_condition_id":218,"med_condition":"PULMONARY ARTERIAL HYPERTENSION (PAH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41911,"protocol_no":"201190 (ZOSTER-049)","submission_no":"193205","status_id":1,"start_date":"2017-03-17","end_date":null,"nol_date":"2016-04-01","protocol_title":"A PHASE IIIB, OPEN-LABEL, MULTI-COUNTRY, MULTI-CENTRE, LONG-TERM FOLLOW-UP STUDY (ZOE-LTFU) OF STUDIES 110390 AND 113077 (ZOSTER-005/022) TO ASSESS THE PROPHYLACTIC EFFICACY, SAFETY, AND IMMUNOGENICITY PERSISTENCE OF GSK BIOLOGICALS' HERPES ZOSTER SUBUNIT (HZ/SU) VACCINE AND ASSESSMENT OF 1 OR 2 ADDITIONAL DOSES ON A 0 OR 1, 2-MONTH SCHEDULE IN TWO SUBGROUPS OF OLDER ADULTS","medConditionList":[{"med_condition_id":289,"med_condition":"HERPES ZOSTER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28482,"protocol_no":"CA180-373","submission_no":"168719","status_id":1,"start_date":"2015-07-13","end_date":null,"nol_date":"2013-11-01","protocol_title":"A PHASE 1B DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY FOR THE COMBINATION OF DASATINIB (BMS-354825) PLUS NIVOLUMAB (BMS-936558) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)","medConditionList":[{"med_condition_id":46,"med_condition":"CHRONIC MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41778,"protocol_no":"CMJP-1","submission_no":"192675","status_id":1,"start_date":"2018-02-28","end_date":null,"nol_date":"2016-03-24","protocol_title":"PLACEBO-CONTROLLED, TRIPLE-BLIND, CROSSOVER STUDY OF THE SAFETY AND EFFICACY OF THREE DIFFERENT POTENCIES OF VAPORIZED CANNABIS IN 42 PARTICIPANTS WITH CHRONIC, TREATMENT-RESISTANT POSTTRAUMATIC STRESS DISORDER (PTSD).","medConditionList":[{"med_condition_id":207,"med_condition":"POST-TRAUMATIC STRESS DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38216,"protocol_no":"54767414SMM2001","submission_no":"181290","status_id":1,"start_date":"2015-11-24","end_date":null,"nol_date":"2015-02-12","protocol_title":"A RANDOMIZED PHASE 2 TRIALTO EVALUATE THREE DARATUMUMAB DOSE SCHEDULES IN SMOLDERING MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40326,"protocol_no":"CA209-459","submission_no":"187716","status_id":1,"start_date":"2017-10-12","end_date":null,"nol_date":"2015-10-15","protocol_title":"A RANDOMIZED, MULTI-CENTER PHASE III STUDY OF NIVOLUMAB VERSUS SORAFENIB AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47712,"protocol_no":"NS-065/NCNP-01-202","submission_no":"211630","status_id":1,"start_date":"2018-01-30","end_date":null,"nol_date":"2017-12-19","protocol_title":"A PHASE II, OPEN-LABEL, EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF NS-065/ NCNP-01 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD)","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27765,"protocol_no":"M13-982","submission_no":"166664","status_id":1,"start_date":"2015-04-10","end_date":null,"nol_date":"2013-08-15","protocol_title":"A PHASE 2 OPEN-LABEL STUDY OF THE EFFICACY OF ABT-199 (GDC-0199) IN SUBJECTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA HARBORING THE 17P DELETION","medConditionList":[{"med_condition_id":149,"med_condition":"LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27568,"protocol_no":"GA.1 / AG0407GR-0808","submission_no":"166157","status_id":1,"start_date":"2015-01-20","end_date":null,"nol_date":"2013-07-26","protocol_title":"TOP GEAR: TRIAL OF PREOPERATIVE THERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA A RANDOMISED PHASE II/III TRIAL OF PREOPERATIVE CHEMORADIOTHERAPY VERSUS PREOPERATIVE CHEMOTHERAPY FOR RESECTABLE GASTRIC CANCER","medConditionList":[{"med_condition_id":337,"med_condition":"GASTRIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26771,"protocol_no":"I5E-MC-TSAT","submission_no":"163789","status_id":2,"start_date":"2013-11-12","end_date":"2015-04-30","nol_date":"2013-05-02","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL STUDY WITH AN OPEN-LABEL EXTENSION TO ASSESS THE IMPACT OF TESTOSTERONE SOLUTION ON TOTAL TESTOSTERONE, SEX DRIVE AND ENERGY IN HYPOGONADAL MEN","medConditionList":[{"med_condition_id":125,"med_condition":"HYPOGONADAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38853,"protocol_no":"D0816C00012","submission_no":"183399","status_id":1,"start_date":"2016-12-15","end_date":null,"nol_date":"2015-04-22","protocol_title":"AN OPEN LABEL, SINGLE ARM, MULTICENTRE STUDY TO ASSESS THE CLINICAL EFFECTIVENESS AND SAFETY OF LYNPARZA (OLAPARIB) CAPSULES MAINTENANCE MONOTHERAPY IN PLATINUM SENSITIVE RELAPSED BRCA MUTATED OVARIAN CANCER PATIENTS WHO ARE IN COMPLETE OR PARTIAL RESPONSE FOLLOWING PLATINUM BASED CHEMOTHERAPY (ORZORA)","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44703,"protocol_no":"CA209-901","submission_no":"202135","status_id":1,"start_date":"2017-10-06","end_date":null,"nol_date":"2017-02-06","protocol_title":"A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF NIVOLUMAB COMBINED WITH IPILIMUMAB VERSUS STANDARD OF CARE CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC UROTHELIAL CANCER","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43898,"protocol_no":"GS-US-419-4015","submission_no":"199521","status_id":1,"start_date":"2017-09-21","end_date":null,"nol_date":"2016-11-17","protocol_title":"A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF FILGOTINIB IN THE TREATMENT OF SMALL BOWEL CROHN¬øS DISEASE (SBCD)","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45919,"protocol_no":"20130293","submission_no":"205840","status_id":1,"start_date":"2017-08-03","end_date":null,"nol_date":"2017-06-21","protocol_title":"A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED STUDY CHARACTERIZING THE EFFECTS OF PCSK9 INHIBITION ON ARTERIAL WALL INFLAMMATION IN PATIENTS WITH ELEVATED LP(A) (ANTISCHKOW)","medConditionList":[{"med_condition_id":791,"med_condition":"ELEVATED LEVELS OF LIPOPROTEIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44757,"protocol_no":"NEC","submission_no":"202317","status_id":1,"start_date":"2017-11-03","end_date":null,"nol_date":"2017-03-02","protocol_title":"A PHASE II, OPEN LABEL STUDY OF THE POLY(ADP-RIBOSE) POLYMERASE INHIBITOR NIRAPARIB (MK 4827) IN RECURRENT ENDOMETRIAL CANCER","medConditionList":[{"med_condition_id":73,"med_condition":"ENDOMETRIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46085,"protocol_no":"GSN000300","submission_no":"206353","status_id":1,"start_date":"2018-01-16","end_date":null,"nol_date":"2017-06-27","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ORAL GKT137831 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS RECEIVING URSODEOXYCHOLIC ACID AND WITH PERSISTENTLY ELEVATED ALKALINE PHOSPHATASE","medConditionList":[{"med_condition_id":209,"med_condition":"PRIMARY BILIARY CIRRHOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45117,"protocol_no":"S1605","submission_no":"203354","status_id":1,"start_date":"2017-08-29","end_date":null,"nol_date":"2017-03-31","protocol_title":"PHASE II TRIAL OF ATEZOLIZUMAB IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER","medConditionList":[{"med_condition_id":178,"med_condition":"NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45243,"protocol_no":"CBYL719X2402","submission_no":"203758","status_id":1,"start_date":"2017-11-07","end_date":null,"nol_date":"2017-04-10","protocol_title":"A PHASE II, MULTICENTER, OPEN-LABEL, TWO-COHORT, NON-COMPARATIVE STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB PLUS FULVESTRANT OR LETROZOLE IN PATIENTS WITH PIK3CA MUTANT, HORMONE RECEPTOR (HR) POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC), WHO HAVE PROGRESSED ON OR AFTER CDK 4/6 INHIBITOR TREATMENT","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42154,"protocol_no":"CA209-384","submission_no":"194077","status_id":1,"start_date":"2016-08-22","end_date":null,"nol_date":"2016-05-12","protocol_title":"A DOSE FREQUENCY OPTIMIZATION, PHASE IIIB/IV TRIAL OF NIVOLUMAB 240 MG EVERY 2 WEEKS VS NIVOLUMAB 480 MG EVERY 4 WEEKS IN SUBJECTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO RECEIVED 4 MONTHS OF NIVOLUMAB AT 3 MG/KG OR 240 MG EVERY 2 WEEKS","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41033,"protocol_no":"AC-065A308","submission_no":"190018","status_id":1,"start_date":"2017-12-05","end_date":null,"nol_date":"2015-12-31","protocol_title":"THE EFFICACY AND SAFETY OF INITIAL TRIPLE VERSUS INITIAL DUAL ORAL COMBINATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED PULMONARY ARTERIAL HYPERTENSION: A MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3B STUDY","medConditionList":[{"med_condition_id":218,"med_condition":"PULMONARY ARTERIAL HYPERTENSION (PAH)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42964,"protocol_no":"001-01","submission_no":"196779","status_id":1,"start_date":"2016-10-06","end_date":null,"nol_date":"2016-08-08","protocol_title":"A RANDOMIZED PARALLEL-GROUP, PLACEBO-CONTROLLED, DOUBLE-BLIND, EVENT-DRIVEN, MULTI-CENTER PIVOTAL PHASE III CLINICAL OUTCOME TRIAL OF EFFICACY AND SAFETY OF THE ORAL SGC STIMULATOR VERICIGUAT IN SUBJECTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) - VERICIGUAT GLOBAL STUDY IN SUBJECTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA)","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46228,"protocol_no":"GA39688","submission_no":"206785","status_id":1,"start_date":"2018-01-19","end_date":null,"nol_date":"2017-07-19","protocol_title":"A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS","medConditionList":[{"med_condition_id":799,"med_condition":"RHINOSINUSITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45172,"protocol_no":"I8D-MC-AZFD","submission_no":"203552","status_id":1,"start_date":"2017-05-23","end_date":null,"nol_date":"2017-04-05","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 (AZD3293) IN EARLY ALZHEIMER¬øS DISEASE DEMENTIA (EXTENSION OF STUDY AZES, THE AMARANTH STUDY)","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"},{"med_condition_id":361,"med_condition":"DEMENTIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46251,"protocol_no":"20140444","submission_no":"206887","status_id":1,"start_date":"2018-01-18","end_date":null,"nol_date":"2017-07-21","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DENOSUMAB IN PEDIATRIC SUBJECTS WITH GLUCOCORTICOID-INDUCED OSTEOPOROSIS","medConditionList":[{"med_condition_id":798,"med_condition":"GLUCOCORTICOID-INDUCED OSTEOPOROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40412,"protocol_no":"I6T-MC-AMAC(A)","submission_no":"188010","status_id":1,"start_date":"2017-04-13","end_date":null,"nol_date":"2015-10-30","protocol_title":"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43483,"protocol_no":"CA209-817","submission_no":"198212","status_id":1,"start_date":"2017-12-04","end_date":null,"nol_date":"2016-09-30","protocol_title":"A PHASE IIIB/IV SAFETY TRIAL OF FLAT DOSE NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN PARTICIPANTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":474,"med_condition":"MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44002,"protocol_no":"CLEE011A2404","submission_no":"199825","status_id":1,"start_date":"2017-03-02","end_date":null,"nol_date":"2016-12-15","protocol_title":"AN OPEN-LABEL, MULTICENTER, PHASE IIIB STUDY TO ASSESS THE SAFETY AND EFFICACY OF RIBOCICLIB (LEE011) IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF MEN AND POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+) HER2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) WITH NO PRIOR HORMONAL THERAPY FOR ADVANCED DISEASE","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44285,"protocol_no":"CPDR001E2201","submission_no":"200646","status_id":1,"start_date":"2017-04-25","end_date":null,"nol_date":"2016-12-20","protocol_title":"AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PDR001 IN PATIENTS WITH ADVANCED OR METASTATIC NON-FUNCTIONAL NEUROENDOCRINE TUMORS OF PANCREATIC, GASTROINTESTIONAL (GI), OR THORACIC ORIGIN WHO HAVE PROGRESSED ON PRIOR TREATMENT","medConditionList":[{"med_condition_id":633,"med_condition":"NEUROENDOCRINE TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48208,"protocol_no":"030","submission_no":"213291","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-26","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-7264 IN ADULT PARTICIPANTS WITH CHRONIC COUGH","medConditionList":[{"med_condition_id":42,"med_condition":"CHRONIC COUGH"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44626,"protocol_no":"BR.34","submission_no":"201890","status_id":1,"start_date":"2017-02-21","end_date":null,"nol_date":"2017-02-14","protocol_title":"A RANDOMIZED TRIAL OF DURVALUMAB (MEDI4736) AND TREMELIMUMAB +/- PLATINUM BASED CHEMOTHERAPY IN PATIENTS WITH METASTATIC (STAGE IV) SQUAMOUS OR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44676,"protocol_no":"BN29553","submission_no":"202048","status_id":1,"start_date":"2017-06-15","end_date":null,"nol_date":"2017-02-07","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47167,"protocol_no":"EFC14875","submission_no":"210021","status_id":1,"start_date":"2018-01-27","end_date":null,"nol_date":"2017-11-02","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO DEMONSTRATE THE EFFECTS OF SOTAGLIFLOZIN ON CARDIOVASCULAR AND RENAL EVENTS IN PATIENTS WITH TYPE 2 DIABETES, CARDIOVASCULAR RISK FACTORS AND MODERATELY IMPAIRED RENAL FUNCTION","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45583,"protocol_no":"R2810-ONC-1620","submission_no":"204887","status_id":1,"start_date":"2017-09-27","end_date":null,"nol_date":"2017-05-19","protocol_title":"A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITOR THERAPY, OR WERE INTOLERANT OF PRIOR HEDGEHOG PATHWAY INHIBITOR THERAPY","medConditionList":[{"med_condition_id":24,"med_condition":"BASAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47359,"protocol_no":"ARQ 087-301","submission_no":"210701","status_id":1,"start_date":"2018-04-08","end_date":null,"nol_date":"2017-11-21","protocol_title":"A PIVOTAL TRIAL OF ARQ 087 IN SUBJECTS WITH FGFR2 GENE FUSION POSITIVE INOPERABLE OR ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA","medConditionList":[{"med_condition_id":753,"med_condition":"INTRAHEPATIC CHOLANGIOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47574,"protocol_no":"CA017055","submission_no":"211268","status_id":1,"start_date":"2018-03-29","end_date":null,"nol_date":"2017-12-08","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF BMS-986205 COMBINED WITH NIVOLUMAB VERSUS NIVOLUMAB IN PARTICIPANTS WITH METASTATIC OR UNRESECTABLE MELANOMA THAT IS PREVIOUSLY UNTREATED","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48317,"protocol_no":"I4V-MC-JAIW","submission_no":"213598","status_id":1,"start_date":"2018-04-18","end_date":null,"nol_date":"2018-03-09","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47663,"protocol_no":"D3252C00001","submission_no":"211514","status_id":1,"start_date":"2018-01-02","end_date":null,"nol_date":"2017-12-27","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED PHASE 3 EFFICACY AND SAFETY STUDY OF BENRALIZUMAB IN PATIENTS WITH SEVERE NASAL POLYPOSIS (OSTRO)","medConditionList":[{"med_condition_id":759,"med_condition":"NASAL POLYPOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26705,"protocol_no":"20120138","submission_no":"163531","status_id":1,"start_date":"2014-02-27","end_date":null,"nol_date":"2013-04-24","protocol_title":"\"A MULTICENTER, CONTROLLED, OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF AMG 145.\"","medConditionList":[{"med_condition_id":295,"med_condition":"PRIMARY HYPERLIPIDEMIA"},{"med_condition_id":296,"med_condition":"MIXED DYSLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37741,"protocol_no":"ITN061AD","submission_no":"179612","status_id":1,"start_date":"2016-01-15","end_date":null,"nol_date":"2014-12-10","protocol_title":"A PILOT STUDY TO COMPARE RESPONSES TO CAT ALLERGEN EXPOSURE USING THE ENVIRONMENTAL EXPOSURE CHAMBER (EEC) AND NASAL ALLERGEN CHALLENGE (NAC)","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44885,"protocol_no":"ARC004","submission_no":"202726","status_id":1,"start_date":"2017-04-04","end_date":null,"nol_date":"2017-03-10","protocol_title":"PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW ON STUDY","medConditionList":[{"med_condition_id":12,"med_condition":"ALLERGIES PEANUT"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44436,"protocol_no":"1000053825","submission_no":"201282","status_id":1,"start_date":"2017-07-17","end_date":null,"nol_date":"2017-01-11","protocol_title":"RANDOMIZED CONTROLLED TRIAL OF PREDNISONE IN CYSTIC FIBROSIS (CF) PULMONARY EXACERBATIONS (PIPE STUDY)","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47780,"protocol_no":"63623872FLZ3002","submission_no":"211908","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-02","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PIMODIVIR IN COMBINATION WITH THE STANDARD-OF-CARE TREATMENT IN ADOLESCENT, ADULT, AND ELDERLY NON-HOSPITALIZED SUBJECTS WITH INFLUENZA A INFECTION WHO ARE AT RISK OF DEVELOPING COMPLICATIONS","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46586,"protocol_no":"207597","submission_no":"208044","status_id":1,"start_date":"2017-10-27","end_date":null,"nol_date":"2017-08-29","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED STUDY EVALUATING THE EFFICACY AND SAFETY OF REPEAT DOSES OF GSK3772847 COMPARED WITH PLACEBO IN PARTICIPANTS WITH MODERATELY SEVERE ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47567,"protocol_no":"SHP634-101","submission_no":"211271","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-22","protocol_title":"OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO ASSESS THE PK AND PD PROFILES OF ONCE-DAILY AND TWICE-DAILY DOSE REGIMENS OF RECOMBINANT HUMAN PARATHYROID HORMONE (RHPTH[1-83]) ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH HYPOPARATHYROIDISM","medConditionList":[{"med_condition_id":816,"med_condition":"HYPOPARATHYROIDISM"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39400,"protocol_no":"CPDR001X2101","submission_no":"185107","status_id":1,"start_date":"2017-10-05","end_date":null,"nol_date":"2015-07-03","protocol_title":"A MULTICENTER, RANDOMZIED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIIB STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SERELAXIN WHEN ADDED TO STANDARD THERAPY IN ACUTE HEART FAILURE PATIENTS","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44758,"protocol_no":"B3461045","submission_no":"202318","status_id":1,"start_date":"2018-01-04","end_date":null,"nol_date":"2017-02-28","protocol_title":"A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)","medConditionList":[{"med_condition_id":542,"med_condition":"TRANSTHYRETIN AMYLOID CARDIOMYOPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40851,"protocol_no":"233AS101","submission_no":"189458","status_id":1,"start_date":"2016-03-31","end_date":null,"nol_date":"2015-12-11","protocol_title":"A PHASE 1, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF BIIB067 ADMINISTERED TO ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44228,"protocol_no":"V56502","submission_no":"200472","status_id":1,"start_date":"2017-05-03","end_date":null,"nol_date":"2016-12-21","protocol_title":"A PHASE 2 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SIX WEEKS TREATMENT WITH V565 IN SUBJECTS WITH ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47725,"protocol_no":"LHSC112017","submission_no":"211667","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-21","protocol_title":"THE USE OF GASTROGRAFIN TO HELP ALLEVIATE BOWEL OBSTRUCTION RELATED TO POOR BOWEL MOTILITY IN GASTROSCHISIS PATIENTS.","medConditionList":[{"med_condition_id":488,"med_condition":"GASTROSCHISIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40016,"protocol_no":"17750","submission_no":"186850","status_id":2,"start_date":"2016-11-10","end_date":"2017-06-30","nol_date":"2015-09-01","protocol_title":"A PHASE II TRIAL OF THE EFFECT OF PERINDOPRIL ON HFSR INCIDENCE AND SEVERITY IN PATIENTS RECEIVING REGORAFENIB WITH REFRACTORY METASTATIC COLORECTAL CARCINOMA (MCRC)","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43532,"protocol_no":"I6T-MC-AMAG","submission_no":"198362","status_id":1,"start_date":"2017-02-24","end_date":null,"nol_date":"2016-10-05","protocol_title":"A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43515,"protocol_no":"DU176B-D-U312","submission_no":"198297","status_id":1,"start_date":"2017-05-02","end_date":null,"nol_date":"2016-10-12","protocol_title":"A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTI-CENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF CARE ANTICOAGULANT THERAPY IN PEDIATRIC SUBJECTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE WITH CONFIRMED VENOUS THROMBOEMBOLISM (VTE)","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41630,"protocol_no":"D-FR-52120-222","submission_no":"192109","status_id":1,"start_date":"2016-06-29","end_date":null,"nol_date":"2016-03-11","protocol_title":"A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT FOR THE TREATMENT OF URINARY INCONTINENCE IN SUBJECTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY OR MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"},{"med_condition_id":77,"med_condition":"NEUROGENIC DETRUSOR OVERACTIVITY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27164,"protocol_no":"D0816C00002","submission_no":"164991","status_id":1,"start_date":"2014-05-21","end_date":null,"nol_date":"2013-06-19","protocol_title":"A PHASE III RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE STUDY OF OLAPARIB MAINTENANCE MONOTHERAPY IN PLATINUM SENSITIVE RELAPSED BRCA MUTATED OVARIAN CANCER PATIENTS WHO ARE IN COMPLETE OR PARTIAL RESPONSE FOLLOWING PLATINUM BASED CHEMOTHERAPY","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36117,"protocol_no":"CA209-141","submission_no":"174538","status_id":1,"start_date":"2015-05-14","end_date":null,"nol_date":"2014-06-06","protocol_title":"AN OPEN LABEL, RANDOMIZED, PHASE 3 CLINICAL TRIAL OF NIVOLUMAB VS INVESTIGATORS CHOICE IN RECURRENT OR METASTATIC PLATINUM-REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45253,"protocol_no":"28431754OBE3002","submission_no":"203789","status_id":2,"start_date":null,"end_date":"2017-08-04","nol_date":"2017-04-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP 104-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF THE CO-ADMINISTRATION OF CANAGLIFLOZIN AND PHENTERMINE COMPARED WITH PLACEBO FOR THE TREATMENT OF NONDIABETIC OVERWEIGHT AND OBESE SUBJECTS","medConditionList":[{"med_condition_id":415,"med_condition":"OVERWEIGHT/OBESITY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40994,"protocol_no":"019-07","submission_no":"189901","status_id":1,"start_date":"2016-07-25","end_date":null,"nol_date":"2015-12-23","protocol_title":"A PARALLEL-GROUP, DOUBLE-BLIND, LONG TERM SAFETY AND EFFICACY TRIAL OF MK-8931 (SCH 900931) IN SUBJECTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE (PRODROMAL AD).","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44131,"protocol_no":"DRI13940","submission_no":"200208","status_id":1,"start_date":"2017-03-28","end_date":null,"nol_date":"2016-12-09","protocol_title":"A 26-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF SAR425899 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36069,"protocol_no":"AT13387-05","submission_no":"174419","status_id":2,"start_date":"2014-10-14","end_date":"2018-01-30","nol_date":"2014-06-03","protocol_title":"A STUDY OF HSP90 INHIBITOR AT13387 ALONE AND IN COMBINATION WITH CRIZOTINIB IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39634,"protocol_no":"NEOD001-CL002","submission_no":"185920","status_id":1,"start_date":"2016-12-08","end_date":null,"nol_date":"2015-07-31","protocol_title":"A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, EFFICACY AND SAFETY STUDY OF NEOD001 PLUS STANDARD OF CARE VS PLACEBO PLUS STANDARD OF CARE IN SUBJECTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS","medConditionList":[{"med_condition_id":574,"med_condition":"AMYLOIDOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36554,"protocol_no":"DU176B-A-U157","submission_no":"175789","status_id":1,"start_date":"2016-05-05","end_date":null,"nol_date":"2014-07-21","protocol_title":"A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NON-RANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35951,"protocol_no":"CMX-2043-2AK","submission_no":"174045","status_id":1,"start_date":"2014-09-08","end_date":null,"nol_date":"2014-05-21","protocol_title":"A PROSPECTIVE, COMPARATIVE, RANDOMIZED, MULTI-CENTER, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2A STUDY OF THE SAFETY AND EFFICACY OF CMX-2043 FOR PERIPROCEDURAL INJURY PROTECTION IN SUBJECTS UNDERGOING CORONARY ANGIOGRAPHY AT RISK OF RADIO-CONTRAST INDUCED NEPHROPATHY (CARIN)","medConditionList":[{"med_condition_id":360,"med_condition":"NEPHROPATHY"},{"med_condition_id":56,"med_condition":"CORONARY HEART DISEASE OR HIGH RISK OF CORONONARY HEART DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35898,"protocol_no":"W14-406","submission_no":"173838","status_id":1,"start_date":"2014-08-20","end_date":null,"nol_date":"2014-05-21","protocol_title":"CONCOMITANT LONGITUDINAL EVALUATION OF ADALIMUMAB WITH METHOTREXATE IN THE REAL WORLD: THE CLEAR STUDY","medConditionList":[{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35885,"protocol_no":"1-27032014","submission_no":"173681","status_id":1,"start_date":"2017-02-06","end_date":null,"nol_date":"2014-05-15","protocol_title":"A PHASE I/IB STUDY OF MEK162, A MEK INHIBITOR, IN COMBINATION WITH CARBOPLATIN AND PEMETREXED IN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG","medConditionList":[{"med_condition_id":512,"med_condition":"NON-SQUAMOUS CARCINOMA OF THE LUNG"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28456,"protocol_no":"M11-290","submission_no":"168631","status_id":1,"start_date":"2018-01-15","end_date":null,"nol_date":"2013-10-25","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE HUMAN ANTI-TNF MONOCLONAL ANTIBODY ADALIMUMAB IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47194,"protocol_no":"SHP647-303","submission_no":"209528","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-24","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (FIGARO UC 303)","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38616,"protocol_no":"DRI11772","submission_no":"182628","status_id":2,"start_date":"2015-11-05","end_date":"2017-10-31","nol_date":"2015-04-01","protocol_title":"EFFICACY AND SAFETY OF SAR156597 IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF): A RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, 52-WEEK DOSE-RANGING STUDY","medConditionList":[{"med_condition_id":127,"med_condition":"IDIOPATHIC PULMONARY FIBROSIS (IPF)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29213,"protocol_no":"GS-US-352-0101","submission_no":"171236","status_id":1,"start_date":"2015-05-05","end_date":null,"nol_date":"2014-02-06","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY EVALUATING MOMELOTINIB VS. RUXOLITINIB IN SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF) OR POST-POLYCYTHEMIA VERA OR POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-PV/ET MF)","medConditionList":[{"med_condition_id":200,"med_condition":"ESSENTIAL THROMBOCYTHEMIA"},{"med_condition_id":211,"med_condition":"PRIMARY MYELOFIBROSIS (PMF)"},{"med_condition_id":199,"med_condition":"POLYCYTHEMIA VERA (PV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28517,"protocol_no":"CO-338-014","submission_no":"168840","status_id":1,"start_date":"2016-10-13","end_date":null,"nol_date":"2013-11-08","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF RUCAPARIB AS SWITCH MAINTENANCE FOLLOWING PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE, HIGH-GRADE SEROUS OR ENDOMETRIOID EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCER","medConditionList":[{"med_condition_id":184,"med_condition":"OVARIAN CANCER PRIMARY PERITONEAL"},{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38933,"protocol_no":"201330 [DTPA(BOOSTRIX)-048 PRI","submission_no":"183647","status_id":1,"start_date":"2016-05-18","end_date":null,"nol_date":"2015-05-06","protocol_title":"A PHASE IV, OPEN-LABEL, NON-RANDOMISED, MULTI-CENTRE STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF INFANRIX HEXA ADMINISTERED AS PRIMARY VACCINATION IN HEALTHY INFANTS BORN TO MOTHERS GIVEN BOOSTRIX DURING PREGNANCY OR POST-DELIVERY IN 116945 [DTPA(BOOSTRIX)-047].","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45670,"protocol_no":"CODIM-MBM-17-040","submission_no":"205128","status_id":1,"start_date":"2017-07-03","end_date":null,"nol_date":"2017-05-10","protocol_title":"A STUDY OF PREOPERATIVE FOLFIRINOX FOR POTENTIALLY CURABLE (RESECTABLE AND BORDERLINE RESECTABLE) PANCREATIC CANCER.","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45822,"protocol_no":"BIDVSTID001","submission_no":"205560","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-07","protocol_title":"TREATMENT OF NON-SEVERE COMMUNITY ACQUIRED PNEUMONIA WITH TWICE DAILY COMPARED TO THRICE DAILY AMOXICILLIN REGIMEN ¬ø A NON-INFERIORITY PRAGMATIC RANDOMIZED-CONTROLLED TRIAL.","medConditionList":[{"med_condition_id":442,"med_condition":"PNEUMONIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":48039,"protocol_no":"228PD201","submission_no":"212784","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-14","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, WITH AN ACTIVE-TREATMENT DOSE-BLINDED PERIOD, TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BIIB054 IN SUBJECTS WITH PARKINSON'S DISEASE","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42540,"protocol_no":"205543","submission_no":"195299","status_id":1,"start_date":"2016-08-11","end_date":null,"nol_date":"2016-06-16","protocol_title":"A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NON-INFERIORITY STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF DOLUTEGRAVIR PLUS LAMIVUDINE COMPARED TO DOLUTEGRAVIR PLUS TENOFOVIR/EMTRICITABINE IN HIV-1-INFECTED TREATMENT-NA√èVE ADULTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27097,"protocol_no":"16243","submission_no":"164793","status_id":1,"start_date":"2013-08-15","end_date":null,"nol_date":"2013-06-07","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF DIFFERENT ORAL DOSES OF BAY 94-8862 IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND THE CLINICAL DIAGNOSIS OF DIABETIC NEPHROPATHY.","medConditionList":[{"med_condition_id":66,"med_condition":"DIABETIC NEUROPATHIC PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45624,"protocol_no":"EMR 100070-003","submission_no":"204964","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-24","protocol_title":"A PHASE II, OPEN-LABEL, MULTICENTER TRIAL TO INVESTIGATE THE CLINICAL ACTIVIITY AND SAFETY OF AVELUMAB (MSB0010718C) IN SUBJECTS WITH MERKEL CELL CARCINOMA","medConditionList":[{"med_condition_id":721,"med_condition":"MERKEL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36618,"protocol_no":"CA209-205","submission_no":"176009","status_id":1,"start_date":"2017-01-05","end_date":null,"nol_date":"2014-07-25","protocol_title":"NON-COMPARATIVE, TWO-COHORT, SINGLE ARM, OPEN-LABEL, PHASE 2 STUDY OF NIVOLUMAB (BMS-936558) IN CLASSICAL HODGKIN LYMPHOMA (CHL) SUBJECTS AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)","medConditionList":[{"med_condition_id":481,"med_condition":"HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40415,"protocol_no":"THR 1442-C-476","submission_no":"188025","status_id":1,"start_date":"2015-11-25","end_date":null,"nol_date":"2015-10-22","protocol_title":"A DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF BEXAGLIFLOZIN ON HEMOGLOBIN A1C IN PATIENTS WITH TYPE 2 DIABETES AND INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28552,"protocol_no":"ABI-007-PANC-003","submission_no":"168950","status_id":1,"start_date":"2014-07-31","end_date":null,"nol_date":"2013-11-08","protocol_title":"A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF NAB-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE AS ADJUVANT THERAPY IN SUBJECTS WITH SURGICALLY RESECTED PANCREATIC ADENOCARCINOMA","medConditionList":[{"med_condition_id":401,"med_condition":"PANCREATIC ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43598,"protocol_no":"EFC14280","submission_no":"198578","status_id":1,"start_date":"2016-11-25","end_date":null,"nol_date":"2016-10-11","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, 52-WEEK, PLACEBO CONTROLLED EFFICACY AND SAFETY STUDY OF DUPILUMAB, IN PATIENTS WITH BILATERAL NASAL POLYPOSIS ON A BACKGROUND THERAPY WITH INTRANASAL CORTICOSTEROIDS","medConditionList":[{"med_condition_id":759,"med_condition":"NASAL POLYPOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45236,"protocol_no":"D5970C00002","submission_no":"203413","status_id":1,"start_date":"2017-05-18","end_date":null,"nol_date":"2017-04-12","protocol_title":"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTRE, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF GLYCOPYRRONIUM/FORMOTEROL FUMARATE FIXED-DOSE COMBINATION RELATIVE TO UMECLIDINIUM/VILANTEROL FIXED-DOSE COMBINATION OVER 24 WEEKS IN PATIENTS WITH MODERATE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (AERISTO)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37980,"protocol_no":"IND.216","submission_no":"180374","status_id":1,"start_date":"2015-03-17","end_date":null,"nol_date":"2015-01-05","protocol_title":"A PHASE II STUDY OF BUPARLISIB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43904,"protocol_no":"TTP488-303","submission_no":"199529","status_id":1,"start_date":"2017-10-16","end_date":null,"nol_date":"2016-11-18","protocol_title":"OPEN LABEL EXTENSION STUDY FOR CONTINUED SAFETY AND EFFICACY EVALUATION OF AZELIRAGON IN PATIENTS WITH MILD ALZHEIMER¬øS DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26660,"protocol_no":"116886","submission_no":"163411","status_id":1,"start_date":"2014-11-03","end_date":null,"nol_date":"2013-04-24","protocol_title":"\"A PHASE III, RANDOMISED, OBSERVER-BLIND, PLACEBO CONTROLLED, MULTICENTRE CLINICAL STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF GASK BIOLOGICALS HZ/SU CANDIDATE VACCINE WHEN ADMINISTERED INTRAMUSCULARLY ON A 0- AND 1- AND 2-MONTHS SCHEDULE TO ADULTS >18 YEARS OF AGE WITH RENAL TRANSPLANT.\"","medConditionList":[{"med_condition_id":289,"med_condition":"HERPES ZOSTER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39732,"protocol_no":"J13161","submission_no":"186171","status_id":1,"start_date":"2017-07-07","end_date":null,"nol_date":"2015-08-06","protocol_title":"A PEDIATRIC BLOOD AND MARROW TRANSPLANT CONSORTIUM (PBMTC) MULTI-CENTER PHASE II PILOT TRIAL OF MYELOABLATIVE CONDITIONING AND TRANSPLANTATION OF PARTIALLY HLA-MISMATCHED T CELL REPLETE BONE MARROW WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR CHILDREN AND YOUNG ADULTS WITH HEMATOLOGIC MALIGNANCIES","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36835,"protocol_no":"2819-CL-0202","submission_no":"176707","status_id":1,"start_date":"2015-03-18","end_date":null,"nol_date":"2014-08-22","protocol_title":"A PHASE 3, MULTICENTER, INVESTIGATOR-BLIND, RANDOMIZED, PARALLEL GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF FIDAXOMICIN ORAL SUSPENSION OR TABLETS TAKEN Q12H, AND VANCOMYCIN ORAL LIQUID OR CAPSULES TAKEN Q6H, FOR 10 DAYS IN PEDIATRIC SUBJECTS WITH CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA. THE SUNSHINE STUDY  (VERSION 1.1, 05-JUNE 2014)","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40907,"protocol_no":"158","submission_no":"189667","status_id":1,"start_date":"2017-07-24","end_date":null,"nol_date":"2015-12-18","protocol_title":"A CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) EVALUATING PREDICTIVE BIOMARKERS IN SUBJECTS WITH ADVANCED SOLID TUMORS (KEYNOTE 158)","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29257,"protocol_no":"AB12006","submission_no":"171331","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-14","protocol_title":"A PROSPECTIVE, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH FOLFIRI (IRINOTECAN, 5-FLUOROURACIL AND FOLINIC ACID) TO PLACEBO IN COMBINATION WITH FOLFIRI IN SECOND LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39539,"protocol_no":"CBYL719C2301","submission_no":"185663","status_id":1,"start_date":"2017-03-28","end_date":null,"nol_date":"2015-07-23","protocol_title":"A PHASE III RANDOMIZED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF ALPELISIB IN COMBINATION WITH FULVESTRANT FOR MEN AND POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHICH PROGRESSED ON OR AFTER AROMATASE INHIBITOR (AI) TREATMENT","medConditionList":[{"med_condition_id":527,"med_condition":"BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47566,"protocol_no":"GO39942","submission_no":"211267","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-15","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R_CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29459,"protocol_no":"TAPIR","submission_no":"171872","status_id":1,"start_date":"2017-07-12","end_date":null,"nol_date":"2014-02-28","protocol_title":"THE ASSESSMENT OF PREDNISONE IN REMISSION TRIAL","medConditionList":[{"med_condition_id":265,"med_condition":"VASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41343,"protocol_no":"BN29552","submission_no":"191232","status_id":1,"start_date":"2017-01-30","end_date":null,"nol_date":"2016-02-11","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44054,"protocol_no":"CLCZ696G2301","submission_no":"199988","status_id":1,"start_date":"2017-04-12","end_date":null,"nol_date":"2016-12-08","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ696 COMPARED TO RAMIPRIL ON MORBIDITY AND MORTALITY IN HIGH RISK PATIENTS FOLLOWING AN ACUTE MYOCARDIAL INFARCTION","medConditionList":[{"med_condition_id":504,"med_condition":"ACUTE MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44471,"protocol_no":"MB 2017-1569","submission_no":"198593","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-16","protocol_title":"√âTUDE RANDOMIS√âE CONTR√îL√âE √Ä SIMPLE INSU COMPARANT LE TRAITEMENT PAR CORTICOST√âRO√èDES INTRANASAUX EN VAPORISATEUR OU EN IRRIGATION CHEZ LES PATIENTS AVEC RHINOSINUSITE CHRONIQUE ET POLYPOSE NASALE","medConditionList":[{"med_condition_id":759,"med_condition":"NASAL POLYPOSIS"},{"med_condition_id":799,"med_condition":"RHINOSINUSITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28839,"protocol_no":"15983","submission_no":"170046","status_id":2,"start_date":"2014-03-13","end_date":"2017-07-07","nol_date":"2013-12-10","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE-III STUDY OF ADJUVANT REGORAFENIB VERSUS PLACEBO FOR PATIENTS WITH STAGE IV COLORECTAL CANCER AFTER CURATIVE TREATMENT OF LIVER METASTASES","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"},{"med_condition_id":441,"med_condition":"LIVER METASTASES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42053,"protocol_no":"104601","submission_no":"193766","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-04-22","protocol_title":"NITRIC OXIDE IN RIGHT VENTRICULAR DYSFUNCTION: IMPROVEMENTS IN CLINICAL AND HEMODYNAMIC PARAMETERS ON VA ECMO","medConditionList":[{"med_condition_id":637,"med_condition":"ISCHEMIC LEFT VENTRICULAR DYSFUNCTION"},{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41428,"protocol_no":"CA209-568","submission_no":"191480","status_id":1,"start_date":"2016-12-14","end_date":null,"nol_date":"2016-02-19","protocol_title":"AN OPEN-LABEL, SINGLE ARM PHASE II STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB AS FIRST LINE-THERAPY IN STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35569,"protocol_no":"AC-055G201","submission_no":"172809","status_id":1,"start_date":"2014-06-24","end_date":null,"nol_date":"2014-04-08","protocol_title":"MELODY-1 A PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 12-WEEK STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MACITENTAN IN SUBJECTS WITH COMBINED PRE- AND POST-CAPILLARY PULMONARY HYPERTENSION (CPCPH) DUE TO LEFT VENTRICULAR DYSFUNCTION.","medConditionList":[{"med_condition_id":483,"med_condition":"PULMONARY HYPERTENSION"},{"med_condition_id":500,"med_condition":"PRE- AND POST-CAPILLARY PULMONARY HYPERTENSION (CPCPH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35356,"protocol_no":"CAIN457F2318","submission_no":"172083","status_id":1,"start_date":"2015-02-17","end_date":null,"nol_date":"2014-03-06","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB IN AUTOINJECTORS, TO DEMONSTRATE EFFICACY AT 24 WEEKS AND TO ASSESS THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY UP TO 3 YEARS IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38106,"protocol_no":"ALS-8176-503","submission_no":"180876","status_id":2,"start_date":"2016-03-16","end_date":"2018-01-31","nol_date":"2015-01-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY OF ORALLY ADMINISTERED ALS-008176 TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSING AND MULTIPLE ASCENDING DOSING IN INFANTS HOSPITALIZED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28331,"protocol_no":"CSL830_3001","submission_no":"168252","status_id":2,"start_date":"2014-08-12","end_date":"2015-05-07","nol_date":"2013-10-16","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF HUMAN PLASMA-DERIVED C1-ESTERASE INHIBITOR IN THE PROPHYLACTIC TREATMENT OF HEREDITARY AGIOEDEMA","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29023,"protocol_no":"UL1309","submission_no":"170613","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-19","protocol_title":"A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ULIPRISTAL ACETATE FOR THE TREATMENT OF ABNORMAL UTERINE BLEEDING ASSOCIATED WITH LEIOMYOMAS.","medConditionList":[{"med_condition_id":355,"med_condition":"UTERINE LEIOMYOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36308,"protocol_no":"PCYC-1127-CA","submission_no":"175026","status_id":1,"start_date":"2015-12-18","end_date":null,"nol_date":"2014-07-03","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF IBRUTINIB OR PLACEBO IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH PREVIOUSLY TREATED WALDENSTROM'S MACROGLOBULINEMIA","medConditionList":[{"med_condition_id":533,"med_condition":"WALDENSTR√ñM'S MACROGLOBULINEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36099,"protocol_no":"064-2014","submission_no":"174493","status_id":1,"start_date":"2014-07-07","end_date":null,"nol_date":"2014-05-29","protocol_title":"FIBRINOGEN IN INITIAL RESUSCITATION OF SEVERE TRAUMA: A RANDOMIZED FEASIBILITY TRIAL (FIIRST)","medConditionList":[{"med_condition_id":543,"med_condition":"TRAUMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45375,"protocol_no":"FTDOXY17EF","submission_no":"204233","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-28","protocol_title":"A PHASE 2 CLINICAL TRIAL OF INTRANASAL OXYTOCIN FOR FRONTOTEMPORAL DEMENTIA","medConditionList":[{"med_condition_id":346,"med_condition":"FRONTOTEMPORAL DEMENTIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26594,"protocol_no":"TX-LUT-001","submission_no":"163209","status_id":1,"start_date":"2017-04-03","end_date":null,"nol_date":"2013-04-24","protocol_title":"\"AN OPEN-LABEL PHASE II, REGISTRY STUDY OF LUTETIUM-177 [DOTA0, TYR3] OCTREOTATE (LU-DOTA-TATE) TREATMENT IN SUBJECTS WITH SOMATOSTATIN RECEPTOR POSITIVE TUMOURS.\"","medConditionList":[{"med_condition_id":291,"med_condition":"SOMATOSTATIN RECEPTOR POSITIVE TUMOURS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45378,"protocol_no":"564","submission_no":"204256","status_id":1,"start_date":"2017-09-06","end_date":null,"nol_date":"2017-04-27","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) AS MONOTHERAPY IN THE ADJUVANT TREATMENT OF RENAL CELL CARCINOMA POST NEPHRECTOMY (KEYNOTE-564)","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28813,"protocol_no":"20120295","submission_no":"169923","status_id":2,"start_date":"2016-02-09","end_date":"2016-11-07","nol_date":"2013-11-29","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMG 334 IN CHRONIC MIGRAINE PREVENTION","medConditionList":[{"med_condition_id":158,"med_condition":"CHRONIC MIGRAINE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41880,"protocol_no":"ICT-107-301","submission_no":"193092","status_id":1,"start_date":"2016-06-10","end_date":null,"nol_date":"2016-04-07","protocol_title":"STING (STUDY OF IMMUNOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA): A PHASE III RANDOMIZED DOUBLE-BLIND, CONTROLLED STUDY OF ICT-107 WITH MAINTENANCE TEMOZOLOMIDE (TMZ) IN NEWLY DIAGNOSED GLIOBLASTOMA FOLLOWING RESECTION AND CONCOMITANT TMZ CHEMORADIOTHERAPY","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37553,"protocol_no":"FLUMIST250713","submission_no":"178986","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-11-14","protocol_title":"PILOT PROJECT ON CLINICAL TOLERANCE TO A LIVE ATTENUATED VACCINE AGAINST INFLUENZA (FLUMIST) IN THE CONTEXT OF THE INFLUENZA VACCINATION IN A POPULATION ALLERGIC TO EGGS","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40193,"protocol_no":"CLS001-CO-PR-006","submission_no":"187333","status_id":1,"start_date":"2015-12-01","end_date":null,"nol_date":"2015-09-28","protocol_title":"A PHASE 3 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF OMIGANAN TOPICAL GEL IN SUBJECTS WITH ROSACEA","medConditionList":[{"med_condition_id":225,"med_condition":"ROSACEA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42513,"protocol_no":"PROTOCOL W","submission_no":"195247","status_id":1,"start_date":"2016-08-15","end_date":null,"nol_date":"2016-06-15","protocol_title":"INTRAVITRAOUS ANTI-VEGF TREATMENT FOR PREVENTION OF VISION THREATENING DIABETIC RETINOPATHY IN EYES AT HIGH RISK  (PROTOCOL W) VERSION 1.0","medConditionList":[{"med_condition_id":64,"med_condition":"DIABETIC MACULAR EDEMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38365,"protocol_no":"COG ADVL1412","submission_no":"181839","status_id":1,"start_date":"2017-12-15","end_date":null,"nol_date":"2015-03-06","protocol_title":"A PHASE 1/2 STUDY OF NIVOLUMAB (IND#124729) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH IPILIMUMAB","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48059,"protocol_no":"NP40126","submission_no":"212832","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-14","protocol_title":"A PHASE IB STUDY EVALUATING RO7082859 IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN PARTICIPANTS WITH RELAPSED REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) OR IN PARTICIPANTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38609,"protocol_no":"12-0306-A","submission_no":"181659","status_id":1,"start_date":"2016-11-10","end_date":null,"nol_date":"2015-04-02","protocol_title":"THE USE OF VAGINAL PROGESTERONE VERSUS PLACEBO FOR THE TREATMENT OF VULVOVAGINAL ATROPHY-A DOUBLE BLIND RANDOMIZED CONTROL TRIAL.","medConditionList":[{"med_condition_id":443,"med_condition":"VULVOVAGINAL ATROPHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39114,"protocol_no":"1311.14","submission_no":"184201","status_id":1,"start_date":"2016-03-11","end_date":null,"nol_date":"2015-06-05","protocol_title":"A PHASE IIA, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF SUBCUTANEOUSLY ADMINISTERED BI 655066 AS ADD-ON THERAPY OVER 24 WEEKS IN PATIENTS WITH SEVERE PERSISTENT ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41487,"protocol_no":"CA209-548","submission_no":"191634","status_id":1,"start_date":"2017-01-27","end_date":null,"nol_date":"2016-02-24","protocol_title":"A RANDOMIZED PHASE 2 SINGLE BLIND STUDY OF TEMOZOLOMIDE PLUS RADIATION THERAPY COMBINED WITH NIVOLUMAB OR PLACEBO IN NEWLY DIAGNOSED ADULT SUBJECTS WITH MGMT-METHYLATED (TUMOR O6-METHYLGUANINE DNA METHYLTRANSFERASE) GLIOBLASTOMA","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39903,"protocol_no":"CT11","submission_no":"186595","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-09-16","protocol_title":"PREPAREDNESS FOR AND RESPONSE TO MENINGOCOCCAL OUTBREAKS: A PILOT STUDY OF THE IMMUNOGENICITY, REACTOGENICITY AND TOLERABILITY OF TWO SCHEDULES OF A 4CMENB VACCINE IN ADOLESCENTS AND YOUNG ADULTS","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"},{"med_condition_id":641,"med_condition":"MENINGITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28342,"protocol_no":"LTS13463","submission_no":"168267","status_id":1,"start_date":"2015-10-08","end_date":null,"nol_date":"2013-10-17","protocol_title":"OPEN-LABEL EXTENSION STUDY OF EFC12492, R727-CL-1112, EFC12732, & LTS11717 STUDIES TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF ALIROCUMAB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","medConditionList":[{"med_condition_id":111,"med_condition":"HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48355,"protocol_no":"NMTRC014","submission_no":"213678","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-09","protocol_title":"NMTT- NEUROBLASTOMA MAINTENANCE THERAPY TRIAL USING DIFLUOROMETHYLORNITHINE (DFMO)","medConditionList":[{"med_condition_id":172,"med_condition":"NEUROBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36293,"protocol_no":"GS-US-283-1059","submission_no":"175004","status_id":2,"start_date":"2014-08-07","end_date":"2016-10-19","nol_date":"2014-06-23","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GS 9620 FOR THE TREATMENT OF VIRALLY SUPPRESSED SUBJECTS WITH CHRONIC HEPATITIS B","medConditionList":[{"med_condition_id":345,"med_condition":"CHRONIC HEPATITIS B"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28367,"protocol_no":"CBYL719A2201","submission_no":"168346","status_id":2,"start_date":"2016-06-08","end_date":"2017-07-08","nol_date":"2013-10-16","protocol_title":"A PHASE II RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED, STUDY OF LETROZOLE WITH OR WITHOUT BYL719 OR BUPARLISIB, FOR THE NEOADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38104,"protocol_no":"X052173","submission_no":"180870","status_id":1,"start_date":"2015-02-10","end_date":null,"nol_date":"2015-01-16","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF GEVOKIZUMAB IN TREATING ACTIVE ULCERS OF PYODERMA GANGRENOSUM","medConditionList":[{"med_condition_id":594,"med_condition":"ULCERS"},{"med_condition_id":595,"med_condition":"PYODERMA GANGRENOSUM"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38920,"protocol_no":"IN-CA-174-1708","submission_no":"183609","status_id":1,"start_date":"2015-09-23","end_date":null,"nol_date":"2015-05-11","protocol_title":"THE USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN THE MANAGEMENT OF PATIENTS WITH INACTIVE CHRONIC HEPATITIS B (CHB) INFECTION","medConditionList":[{"med_condition_id":103,"med_condition":"HEPATITIS B VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39801,"protocol_no":"4712","submission_no":"186313","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-08-14","protocol_title":"ASSESSMENT OF THE EFFICACY OF FORTEO (TERIPARATIDE) IN PATIENTS UNDERGOING POSTEROLATERAL LUMBAR SPINAL FUSION.","medConditionList":[{"med_condition_id":639,"med_condition":"POSTEROLATERAL LUMBAR SPINAL FUSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46540,"protocol_no":"2010-023035-42 (UC-0120/1004)","submission_no":"207898","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-15","protocol_title":"A PHASE III, RANDOMIZED STUDY TO EVALUATE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY IN TREATING REOCCURRING OVARIAN CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38993,"protocol_no":"PJC-016/NCI 9676","submission_no":"183821","status_id":1,"start_date":"2017-05-05","end_date":null,"nol_date":"2015-05-15","protocol_title":"A PHASE I TRIAL OF MK-3475 PLUS ZIV-AFLIBERCEPT IN PATIENTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45072,"protocol_no":"NCT03020303","submission_no":"203215","status_id":1,"start_date":"2017-05-29","end_date":null,"nol_date":"2017-04-10","protocol_title":"ALDOSTERONE BLOCKADE FOR HEALTH IMPROVEMENT EVALUATION IN END-STAGE RENAL DISEASE (ACHIEVE)","medConditionList":[{"med_condition_id":457,"med_condition":"END STAGE RENAL DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48444,"protocol_no":"00078715","submission_no":"213907","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-02","protocol_title":"THE EFFECT OF INHALED NITRIC OXIDE ON DYSPNEA AND EXERCISE TOLERANCE IN MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37848,"protocol_no":"EFC13799","submission_no":"179870","status_id":2,"start_date":"2015-02-17","end_date":"2016-11-11","nol_date":"2014-12-23","protocol_title":"A RANDOMIZED, OPEN-LABEL, 2-ARM PARALLEL-GROUP, MULTICENTER, 26-WEEK STUDY ASSESSING THE SAFETY AND EFFICACY OF HOE901-U300 VERSUS LANTUS IN OLDER PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ANTIDIABETIC REGIMENS EITHER INCLUDING NO INSULIN, OR WITH BASAL INSULIN AS THEIR ONLY INSULIN","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27157,"protocol_no":"H6D-MC-LVJJ","submission_no":"164977","status_id":1,"start_date":"2014-06-17","end_date":null,"nol_date":"2013-06-10","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF TADALAFIL FOR DUCHENNE MUSCULAR DYSTROPHY.","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46395,"protocol_no":"MS100070-0073","submission_no":"207399","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-01","protocol_title":"PHASE II TRIAL OF PERIOPERATIVE PD-L1 INHIBITION WITH AVELUMAB AND DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL FOR RESECTABLE LOCALLY ADVANCED ESOPHAGO-GASTRIC ADENOCARINOMA","medConditionList":[{"med_condition_id":320,"med_condition":"ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38550,"protocol_no":"M18-006","submission_no":"182401","status_id":2,"start_date":"2015-09-29","end_date":"2017-07-21","nol_date":"2015-03-26","protocol_title":"YOSEMITE:A 3-ARM PHASE 2 DOUBLE-BLIND RANDOMIZED STUDY OF GEMCITABINE, ABRAXANE PLUS PLACEBO VERSUS GEMCITABINE, ABRAXANE PLUS 1 OR 2 TRUNCATED COURSES OF DEMCIZUMAB IN SUBJECTS WITH 1ST-LINE METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA","medConditionList":[{"med_condition_id":320,"med_condition":"ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39104,"protocol_no":"I4T-MC-JVDE","submission_no":"184158","status_id":1,"start_date":"2016-11-18","end_date":null,"nol_date":"2015-05-29","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RAMUCIRUMAB AND BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO AND BSC AS SECOND-LINE TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN (AFP) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40804,"protocol_no":"104373","submission_no":"189211","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-25","protocol_title":"ULTRASOUND GUIDED MOTOR SPARING KNEE BLOCKS WITH OR WITHOUT DEXMEDETOMIDINE FOR POSTOPERATIVE ANALGESIA FOLLOWING TOTAL KNEE ARTHROPLASTY: A RANDOMIZED DOUBLE BLIND STUDY","medConditionList":[{"med_condition_id":466,"med_condition":"KNEE ARTHROPLASTY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39938,"protocol_no":"JX594-HEP024","submission_no":"186672","status_id":1,"start_date":"2016-10-12","end_date":null,"nol_date":"2015-10-08","protocol_title":"A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY COMPARING PEXA-VEC (VACCINIA GM-CSF / THYMIDINE KINASE-DEACTIVATED VIRUS) FOLLOWED BY SORAFENIB VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WITHOUT PRIOR SYSTEMIC THERAPY","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28645,"protocol_no":"PLNEU SJ 01","submission_no":"169302","status_id":1,"start_date":"2014-06-23","end_date":null,"nol_date":"2013-12-31","protocol_title":"PHASE II STUDY OF IMATINIB MESYLATE (PMS) IN NEUROFIBROMATOSIS TYPE I PATIENTS AGED 2 TO 21 WITH PLEXIFORM NEUROFIBROMAS","medConditionList":[{"med_condition_id":446,"med_condition":"PLEXIFORM NEUROFIBROMAS"},{"med_condition_id":430,"med_condition":"NEUROFIBROMATOSIS TYPE I"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36658,"protocol_no":"INCB 18424-362","submission_no":"176158","status_id":2,"start_date":"2014-10-30","end_date":"2016-10-20","nol_date":"2014-07-28","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF THE JAK1/2 INHIBITOR, RUXOLITINIB OR PLACEBO IN COMBINATION WITH CAPECITABINE IN SUBJECTS WITH ADVANCED OR METASTATIC ADENOCARCINOMA OF THE PANCREAS WHO HAVE FAILED OR ARE INTOLERANT TO FIRST-LINE CHEMOTHERAPY","medConditionList":[{"med_condition_id":401,"med_condition":"PANCREATIC ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38051,"protocol_no":"CIDH305X2101","submission_no":"180671","status_id":2,"start_date":"2018-04-10","end_date":"2018-04-10","nol_date":"2015-01-09","protocol_title":"A PHASE I STUDY OF IDH305 IN PATIENTS WITH ADVANCED MALIGNANCIES THAT HARBOR IDH1R132 MUTATIONS","medConditionList":[{"med_condition_id":474,"med_condition":"MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39980,"protocol_no":"161403","submission_no":"186773","status_id":1,"start_date":"2016-11-07","end_date":null,"nol_date":"2015-09-04","protocol_title":"A PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/HYQVIA) AND IMMUNE GLOBULIN INFUSION (HUMAN), 10% (GAMMAGARD LIQUID/KIOVIG) FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)","medConditionList":[{"med_condition_id":44,"med_condition":"CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43761,"protocol_no":"GS-US-418-3899","submission_no":"199083","status_id":1,"start_date":"2017-06-29","end_date":null,"nol_date":"2016-11-09","protocol_title":"A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FILGOTINIB IN SUBJECTS WITH ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41900,"protocol_no":"AC220-A-U302","submission_no":"193107","status_id":1,"start_date":"2016-09-22","end_date":null,"nol_date":"2016-04-07","protocol_title":"A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA (QUANTUM-FIRST)","medConditionList":[{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39336,"protocol_no":"CTNPT 025","submission_no":"184873","status_id":1,"start_date":"2017-05-25","end_date":null,"nol_date":"2015-06-25","protocol_title":"THE PROSPAR STUDY:  PROGESTERONE SUPPLEMENTATION FOR HIV-POSITIVE PREGNANT WOMEN ON ANTI-RETROVIRALS (PROSPAR)","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36663,"protocol_no":"020221","submission_no":"176178","status_id":1,"start_date":"2015-01-15","end_date":null,"nol_date":"2014-08-06","protocol_title":"A PHASE III CLINICAL TRIAL EVALUATING DCVAX-L, AUTOLOGOUS DENDRITIC CELLS PULSED WITH TUMOR LYSATE ANTIGEN FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45690,"protocol_no":"TACT2","submission_no":"205178","status_id":1,"start_date":"2018-02-20","end_date":null,"nol_date":"2017-07-07","protocol_title":"A RANDOMIZED, DOUBLE BLIND CONTROLLED FACTORIAL CLINICAL TRIAL OF EDETATE DISODIUM-BASED CHELATION AND HIGH-DOSE ORAL VITAMINS AND MINERALS TO PREVENT RECURRENT CARDIAC EVENTS IN DIABETIC PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION","medConditionList":[{"med_condition_id":388,"med_condition":"DIABETES"},{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28119,"protocol_no":"000071 (ESTHER-2)","submission_no":"167663","status_id":1,"start_date":"2014-03-01","end_date":null,"nol_date":"2013-09-20","protocol_title":"\"A CONTROLLED, ASSESSOR-BLIND, PARALLEL GROUPS, MULTICENTRE, MULTINATIONAL TRIAL EVALUATING THE IMMUNOGENICITY OF FE 999049 IN REPEATED CYCLES OF CONTROLLED OVARIAN STIMULATION IN WOMEN UNDERGOING AN ASSISTED REPRODUCTIVE TECHNOLOGY PROGRAMME. ESTHER-2 (EVIDENCE-BASED STIMULATION TRIAL AND HUMAN RFSH IN EUROPE AND REST OF THE WORLD)","medConditionList":[{"med_condition_id":373,"med_condition":"OVARIAN STIMULATION"},{"med_condition_id":374,"med_condition":"ASSISTED REPRODUCTIVE TECHNOLOGY PROGRAMME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43008,"protocol_no":"NN9931-4296","submission_no":"196880","status_id":1,"start_date":"2017-03-06","end_date":null,"nol_date":"2016-08-25","protocol_title":"INVESTIGATION OF EFFICACY AND SAFETY OF THREE DOSE LEVELS OF SUBCUTANEOUS SEMAGLUTIDE ONCE DAILY VERSUS PLACEBO IN SUBJECT WITH NON-ALCOHLIC STEATOHEPATITIS","medConditionList":[{"med_condition_id":725,"med_condition":"STEATOHEPATITIS NON-ALCOHOLIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48307,"protocol_no":"CAMHPET-CTA-105","submission_no":"213564","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-09","protocol_title":"NATURALISTIC MONITORING OF MICROGLIAL ACTIVATION IN INFLAMMATORY BOWEL DISEASE","medConditionList":[{"med_condition_id":646,"med_condition":"INFLAMMATORY BOWEL DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42000,"protocol_no":"178-MA-1008","submission_no":"193628","status_id":1,"start_date":"2016-08-17","end_date":null,"nol_date":"2016-04-21","protocol_title":"A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN MEN WITH OVERACTIVE BLADDER (OAB) SYMPTOMS WHILE TAKING THE ALPHA-BLOCKER TAMSULOSIN HYDROCHLORIDE FOR LOWER URINARY TRACT SYMPTOMS (LUTS) DUE TO BENIGN PROSTATIC HYPERPLASIA (BPH)","medConditionList":[{"med_condition_id":478,"med_condition":"PROSTATE HYPERPLASIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42103,"protocol_no":"METADUR-001","submission_no":"193911","status_id":1,"start_date":"2018-01-17","end_date":null,"nol_date":"2016-05-03","protocol_title":"AN OPEN-LABEL, PHASE II BASKET STUDY OF A HYPOMETHYLATING AGENT ORAL AZACITIDINE AND DURVALUMAB (ANTI-PDL1) IN ADVANCED SOLID TUMORS (METADUR)","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42024,"protocol_no":"CA209-602","submission_no":"193694","status_id":1,"start_date":"2017-03-13","end_date":null,"nol_date":"2016-04-28","protocol_title":"AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF COMBINATIONS OF NIVOLUMAB, ELOTUZUMAB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (CHECKMATE 602: CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 602)","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38087,"protocol_no":"CLDK378A2112","submission_no":"180820","status_id":1,"start_date":"2017-04-26","end_date":null,"nol_date":"2015-01-15","protocol_title":"A PHASE I, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY TO ASSESS THE SYSTEMIC EXPOSURE AND SAFETY OF 450 MG CERITINIB TAKEN WITH A LOW-FAT MEAL AND 600 MG OF CERITINIB TAKEN WITH A LOW-FAT MEAL AS COMPARED WITH THAT OF 750 MG CERITINIB TAKEN IN THE FASTED STATE IN ADULT PATIENTS WITH ALK REARRANGED (ALK-POSITIVE) METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC).","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44621,"protocol_no":"SCRX001-007","submission_no":"201869","status_id":1,"start_date":"2017-05-25","end_date":null,"nol_date":"2017-02-08","protocol_title":"AN INTENSIVE QT/QTC STUDY TO INVESTIGATE THE EFFECTS OF ROVALPITUZUMAB TESIRINE ON CARDIAC VENTRICULAR REPOLARIZATION IN SUBJECTS WITH SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43439,"protocol_no":"365","submission_no":"198131","status_id":1,"start_date":"2017-03-09","end_date":null,"nol_date":"2016-10-04","protocol_title":"PHASE IB/II TRIAL OF PEMBROLIZUMAB (MK-3475) COMBINATION THERAPIES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (KEYNOTE-365)","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43340,"protocol_no":"GT-201","submission_no":"197824","status_id":1,"start_date":"2017-12-15","end_date":null,"nol_date":"2016-09-13","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, TRIAL OF THE EFFECTS OF INTRAVENOUS GC4419 ON THE INCIDENCE AND DURATION OF SEVERE ORAL MUCOSITIS (OM) IN PATIENTS RECEIVING POST-OPERATIVE OR DEFINITIVE THERAPY WITH SINGLE-AGENT CISPLATIN PLUS IMRT FOR LOCALLY ADVANCED, NON-METASTATIC SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY OR OROPHARYNX","medConditionList":[{"med_condition_id":724,"med_condition":"SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44719,"protocol_no":"412","submission_no":"202198","status_id":1,"start_date":"2017-05-08","end_date":null,"nol_date":"2017-02-23","protocol_title":"A RANDOMIZED PHASE III STUDY OF PEMBROLIZUMAB GIVEN CONCOMITANTLY WITH CHEMORADIATION AND AS MAINTENANCE THERAPY VERSUS CHEMORADIATION ALONE IN SUBJECTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (KEYNOTE-412)","medConditionList":[{"med_condition_id":724,"med_condition":"SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42192,"protocol_no":"LTS12551","submission_no":"194212","status_id":1,"start_date":"2017-02-03","end_date":null,"nol_date":"2016-05-13","protocol_title":"OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF DUPILUMAB IN PATIENTS WITH ASTHMA WHO PARTICIPATED IN A PREVIOUS DUPILUMAB ASTHMA CLINICAL STUDY","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37345,"protocol_no":"T2014-001","submission_no":"178339","status_id":1,"start_date":"2016-04-25","end_date":null,"nol_date":"2014-10-24","protocol_title":"A PHASE I TRIAL OF TEMSIROLIMUS (CCI-779, PFIZER, INC.) IN COMBINATION WITH ETOPOSIDE AND CYCLOPHOSPHAMIDE IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA AND NON-HODGKINS LYMPHOMA","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"},{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41809,"protocol_no":"IND.231","submission_no":"192830","status_id":1,"start_date":"2018-03-01","end_date":null,"nol_date":"2016-03-30","protocol_title":"A PHASE I/II STUDY OF CX5461","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37132,"protocol_no":"B5201002","submission_no":"177625","status_id":1,"start_date":"2016-05-17","end_date":null,"nol_date":"2014-09-25","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL (GMI 1070) IN THE TREATMENT OF VASO OCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE","medConditionList":[{"med_condition_id":232,"med_condition":"SICKLE CELL DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26525,"protocol_no":"LA41-0412","submission_no":"163024","status_id":2,"start_date":"2013-05-15","end_date":"2014-04-28","nol_date":"2013-04-02","protocol_title":"THE PHARMACOKINETIC PROFILE OF A SINGLE DOSE OF FERRIPROX¬Æ IN PATIENTS WITH SICKLE CELL DISEASE","medConditionList":[{"med_condition_id":233,"med_condition":"SICKLE CELL ANEMIA"},{"med_condition_id":232,"med_condition":"SICKLE CELL DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43862,"protocol_no":"201000","submission_no":"199448","status_id":1,"start_date":"2018-02-21","end_date":null,"nol_date":"2016-11-17","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF GSK2330672 ADMINISTRATION FOR THE TREATMENT OF PRURITUS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS.","medConditionList":[{"med_condition_id":830,"med_condition":"PRIMARY BILIARY CHOLANGITIS (PBC)"},{"med_condition_id":792,"med_condition":"PRURITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44094,"protocol_no":"E7080-G000-307","submission_no":"200088","status_id":1,"start_date":"2017-09-14","end_date":null,"nol_date":"2016-12-09","protocol_title":"A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 3 TRIAL TO COMPARE THE EFFICACY AND SAFETY OF LENVATINIB IN COMBINATION WITH EVEROLIMUS OR PEMBROLIZUMAB VERSUS SUNITINIB ALONE IN FIRST-LINE TREATMENT OF SUBJECTS WITH ADVANCED RENAL CELL CARCINOMA (CLEAR).","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45255,"protocol_no":"ZP4207-16136","submission_no":"203798","status_id":2,"start_date":"2017-07-10","end_date":"2018-02-13","nol_date":"2017-04-19","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP SAFETY TRIAL TO EVALUATE THE IMMUNOGENICITY OF DASIGLUCAGON COMPARED TO GLUCAGEN¬Æ ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH TYPE 1 DIABETES MELLITUS (T1DM)","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42603,"protocol_no":"SAN-CTP-01","submission_no":"195535","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-29","protocol_title":"A BLINDED PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE FUNGICIDAL ACTIVITY WITH THE TOPICAL APPLICATION OF NITRIC OXIDE RELEASING SOLUTION (NORS) IN SUBJECTS WITH MODERATE TO SEVERE TINEA PEDIS (ATHLETE¬øS FOOT)","medConditionList":[{"med_condition_id":741,"med_condition":"ATHLETE'S FOOT (TINEA PEDIS)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39906,"protocol_no":"RESLIZUMAB","submission_no":"186600","status_id":1,"start_date":"2015-11-19","end_date":null,"nol_date":"2015-08-28","protocol_title":"ROUTE OF ADMINISTRATION OF ANTI-IL5 MAB IN PREDNISONE-DEPENDENT EOSINOPHILIC ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45138,"protocol_no":"CE 16.221","submission_no":"203393","status_id":1,"start_date":"2017-11-15","end_date":null,"nol_date":"2017-03-31","protocol_title":"TOPICAL INFLIXIMAB IN PATIENTS WITH SEVERE OCULAR SURFACE INFLAMMATION AND STERILE CORNEAL MELT","medConditionList":[{"med_condition_id":778,"med_condition":"CORNEAL MELT"},{"med_condition_id":779,"med_condition":"OCULAR INFLAMMATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35696,"protocol_no":"RIBAVIRIN-005","submission_no":"173149","status_id":1,"start_date":"2017-06-09","end_date":null,"nol_date":"2014-04-23","protocol_title":"A PHASE II, MULTI-CENTER, OPEN LABEL, RANDOMIZED STUDY OF RIBAVIRIN AND VISMODEGIB WITH OR WITHOUT AZACYTIDINE IN ACUTE MYELOID LEUKEMIA (AML)","medConditionList":[{"med_condition_id":506,"med_condition":"RELAPSED OR REFRACTORY ACUTE MYELOID  LEUKEMIA (AML)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40037,"protocol_no":"PHL-096 / NCI 9706","submission_no":"186920","status_id":1,"start_date":"2017-03-28","end_date":null,"nol_date":"2015-09-04","protocol_title":"RANDOMIZED PHASE II STUDY TO ASSESS THE ROLE OF NIVOLUMAB AS SINGLE AGENT TO ELIMINATE MINIMAL RESIDUAL DISEASE AND MAINTAIN REMISSION IN ACUTE MYELOGENOUS LEUKEMIA (AML) PATIENTS AFTER CHEMOTHERAPY","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40146,"protocol_no":"AS0006","submission_no":"187222","status_id":1,"start_date":"2016-01-06","end_date":null,"nol_date":"2015-10-08","protocol_title":"PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) WITHOUT X RAY EVIDENCE OF ANKYLOSING SPONDYLITIS (AS) AND OBJECTIVE SIGNS OF INFLAMMATION","medConditionList":[{"med_condition_id":645,"med_condition":"ACTIVE AXIAL SPONDYLOARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40172,"protocol_no":"1000050694/NANT 2011-01","submission_no":"187296","status_id":1,"start_date":"2015-11-27","end_date":null,"nol_date":"2015-10-16","protocol_title":"RANDOMIZED PHASE II STUDY OF I-MIBG VS. I-MIBG WITH VINCRISTINE AND IRINOTECAN VS. I-MIBG WITH VORINOSTAT FOR RESISTANT/RELAPSED NEUROBLASTOMA","medConditionList":[{"med_condition_id":172,"med_condition":"NEUROBLASTOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47018,"protocol_no":"ISIS 484137-CS2","submission_no":"209490","status_id":1,"start_date":"2017-11-03","end_date":null,"nol_date":"2017-10-12","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF ISIS 484137 (ISIS-DGAT2RX, AN ANTISENSE INHIBITOR OF DIACYLGLYCEROL ACYLTRANSFERASE 2) ADMINISTERED ONCE-WEEKLY FOR 13 WEEKS ON HEPATIC STEATOSIS IN ADULT PATIENTS WITH TYPE 2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":806,"med_condition":"HEPATIC STEATOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28315,"protocol_no":"148-2013","submission_no":"168217","status_id":1,"start_date":"2015-12-17","end_date":null,"nol_date":"2013-10-16","protocol_title":"THE SARTAN-AD TRIAL: A RANDOMIZED, OPEN LABEL, PROOF OF CONCEPT STUDY OF TELMISARTAN VS. PERINDOPRIL IN HYPERTENSIVE MILD-MODERATE ALZHEIMER'S DISEASE PATIENTS","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38648,"protocol_no":"54767414MMY3008","submission_no":"182744","status_id":1,"start_date":"2015-11-27","end_date":null,"nol_date":"2015-05-08","protocol_title":"A PHASE 3 STUDY COMPARING DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN SUBJECTS WITH PREVIOUSLY UNTREATED MULIPLE MYELOMA WHO ARE INELIGIBLE FOR HIGH DOSE THERAPY","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48116,"protocol_no":"BN40031","submission_no":"212969","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-13","protocol_title":"\"A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION OF PHASE III STUDIES (BN29552/BN29553) OF CRENEZUMAB IN PATIENTS WITH ALZHEIMER¬øS DISEASE,\"","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39418,"protocol_no":"CB001","submission_no":"185181","status_id":1,"start_date":"2015-07-24","end_date":null,"nol_date":"2015-07-03","protocol_title":"A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, ESCALATING, MULTIPLE DOSE STUDY IN BIRCH-ALLERGIC SUBJECTS TO ASSESS THE ASFETY, TOLERABILITY AND PHARMACODYNAMIC EFFECTS OF INTRADERMAL ADMINISTRATION OF BIRCH-SPIRE","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43523,"protocol_no":"ISIS 681257-CS6","submission_no":"198290","status_id":1,"start_date":"2017-07-20","end_date":null,"nol_date":"2016-10-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING PHASE 2 STUDY OF ISIS 681257 ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HYPERLIPOPROTEINEMIA(A) AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47221,"protocol_no":"D5180C00007","submission_no":"210264","status_id":1,"start_date":"2017-11-21","end_date":null,"nol_date":"2017-11-14","protocol_title":"A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TEZEPELUMAB IN ADULTS AND ADOLESCENTS WITH SEVERE UNCONTROLLED ASTHMA (NAVIGATOR)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38720,"protocol_no":"186-2014","submission_no":"182964","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-10","protocol_title":"QUANTITATIVE BLOOD OXYGENATION LEVEL DEPENDENT (QBOLD) MR IMAGING OF GLIOBLASTOMA FOR ASSESSMENT OF TUMOR HYPOXIA AND ITS CORRELATION WITH INTRAOPERATIVE MEASUREMENTS.","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28611,"protocol_no":"1199.187","submission_no":"169162","status_id":2,"start_date":"2014-12-18","end_date":"2017-03-22","nol_date":"2013-11-20","protocol_title":"A SIX MONTH DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL FOLLOWED BY EACH ARM BEING CONVERTED TO EVALUATING THE EFFECT OF ORAL NINTEDANIB 150 MG TWICE DAILY COMPARING THE EFFECT ON HIGH RESOLUTION COMPUTERIZED TOMOGRAPHY QUANTITATIVE LUNG FIBROSIS SCORE, LUNG FUNCTION, SIX MINUTE WALK TEST DISTANCE AND ST. GEORGE¬íS RESPIRATORY QUESTIONNAIRE AFTER TWELVE SIX MONTHS OF TREATMENT IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS WITH CONTINUED EVALUATIONS OVER A PERIOD OF UP TO EIGHTEEN MONTHS","medConditionList":[{"med_condition_id":127,"med_condition":"IDIOPATHIC PULMONARY FIBROSIS (IPF)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45363,"protocol_no":"402-C-1602","submission_no":"204178","status_id":1,"start_date":"2017-06-09","end_date":null,"nol_date":"2017-04-18","protocol_title":"AN EXTENDED ACCESS PROGRAM TO ASSESS LONG TERM SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH PULMONARY HYPERTENSION.","medConditionList":[{"med_condition_id":483,"med_condition":"PULMONARY HYPERTENSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36991,"protocol_no":"FER-IIT-007","submission_no":"177164","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-09-03","protocol_title":"DOSE-RANGING, PARALLEL-GROUP, RANDOMIZED CONTROLLED TRIAL OF LONG-TERM FERUMOXYTOL DOSAGE STRATEGIES IN HEMODIALYSIS PATIENTS","medConditionList":[{"med_condition_id":96,"med_condition":"HEMODIALYSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38326,"protocol_no":"PRO00054869","submission_no":"181669","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-24","protocol_title":"RANDOMIZED CONTROLLED TRIAL OF EX VIVO OXYGENATED, NORMOTHERMIC LIVER PERFUSION (ORGANOX METRA) COMPARED TO STANDARD COLD STORAGE IN CLINICAL LIVER TRANSPLANTATION","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"},{"med_condition_id":484,"med_condition":"LIVER TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37379,"protocol_no":"CINC280X2105C","submission_no":"178385","status_id":1,"start_date":"2017-07-27","end_date":null,"nol_date":"2014-10-29","protocol_title":"A PHASE IB/II, MULTICENTER, OPEN-LABEL STUDY OF EGF816 IN COMBINATION WITH INC280 IN ADULT PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43421,"protocol_no":"MDV3800 11","submission_no":"198067","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-09-30","protocol_title":"A PHASE 2, MULTIPLE COHORT, OPEN LABEL, INTERNATIONAL STUDY OF TALAZOPARIB MONOTHERAPY AND TALAZOPARIB PLUS TEMOZOLOMIDE IN WOMEN WITH RELAPSED OVARIAN, FALLOPIAN TUBE, AND PERITONEAL CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"},{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":194,"med_condition":"PERITONEAL CARCINOMATOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37088,"protocol_no":"OTX015_108","submission_no":"177471","status_id":1,"start_date":"2014-10-27","end_date":null,"nol_date":"2014-09-29","protocol_title":"A PHASE 1B TRIAL WITH OTX015, A SMALL MOLECULE INHIBITOR OF THE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEINS, IN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35810,"protocol_no":"BMA117159","submission_no":"173560","status_id":1,"start_date":"2016-09-15","end_date":null,"nol_date":"2014-05-02","protocol_title":"A PHASE I OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY AND CLINICAL ACTIVITY OF THE ANTIBODY DRUG CONJUGATE GSK2857916 IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND OTHER ADVANCED HEMATOLOGIC MALIGNANCIES EXPRESSING BCMA","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37251,"protocol_no":"006-00","submission_no":"177990","status_id":1,"start_date":"2014-10-17","end_date":null,"nol_date":"2014-10-15","protocol_title":"A PHASE IV, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL OF MK-3641 AND MK-7243 CO-ADMINISTERED IN SUBJECTS AT LEAST 18 YEARS OF AGE WITH RAGWEED AND GRASS POLLEN INDUCED ALLERGIC RHINITIS WITH OR WITHOUT CONJUCTIVITIS","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41679,"protocol_no":"261303","submission_no":"192306","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-18","protocol_title":"PHASE 3, PROSPECTIVE, RANDOMIZED, MULTI-CENTER CLINICAL STUDY COMPARING THE SAFETY AND EFFICACY OF BAX 855 FOLLOWING PK-GUIDED PROPHYLAXIS TARGETING TWO DIFFERENT FVIII TROUGH LEVELS IN SUBJECTS WITH SEVERE HEMOPHILIA A","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29113,"protocol_no":"SPD489-346","submission_no":"170933","status_id":1,"start_date":"2014-05-08","end_date":null,"nol_date":"2014-01-17","protocol_title":"A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED-WITHDRAWAL STUDY TO EVALUATE THE MAINTENANCE OF EFFICACY OF SPD489 IN ADULTS AGED 18-55 YEARS WITH MODERATE TO SEVERE BINGE EATING DISORDER","medConditionList":[{"med_condition_id":450,"med_condition":"BINGE EATING DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42451,"protocol_no":"DFI14223","submission_no":"195021","status_id":1,"start_date":"2016-08-17","end_date":null,"nol_date":"2016-06-10","protocol_title":"AN 8-WEEK OPEN-LABEL, SEQUENTIAL, REPEATED DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AIIROCUMAB IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA FOLLOWED BY AN EXTENSION PHASE","medConditionList":[{"med_condition_id":111,"med_condition":"HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42676,"protocol_no":"STML-401-0114","submission_no":"195820","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-07-06","protocol_title":"SL-401 IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM","medConditionList":[{"med_condition_id":720,"med_condition":"BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM"},{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26741,"protocol_no":"MGH-TA-01","submission_no":"163668","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-05-02","protocol_title":"A PILOT STUDY OF NEOADJUVANT DOCETAXEL, OXALIPLATIN AND 5-FLUOROURACIL (FLOT) IN PATIENTS WITH GASTRIC OR GASTROESOPHAEGAL JUNCTION ADENOCARCINOMA","medConditionList":[{"med_condition_id":320,"med_condition":"ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29397,"protocol_no":"NN7088-3908 (PATHFINDER 6)","submission_no":"171708","status_id":3,"start_date":"2014-07-14","end_date":null,"nol_date":"2014-02-18","protocol_title":"AN OPEN-LABEL SINGLE-ARM MULTICENTRE NON-CONTROLLED PHASE 3A TRIAL INVESTIGATING SAFETY AND EFFICACY OF N8-GP IN PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY UNTREATED PAEDIATRIC PATIENTS WITH SEVERE HAEMOPHILIA A","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29198,"protocol_no":"16416","submission_no":"171192","status_id":2,"start_date":"2014-08-19","end_date":"2016-12-06","nol_date":"2014-02-04","protocol_title":"REDUCED-DOSED RIVAROXABAN AND STANDARD-DOSED RIVAROXABAN VERSUS ASA IN THE LONG-TERM PREVENTION OF RECURRENT SYMPTOMATIC VENOUS THROMBOEMBOLISM IN PATIENTS WITH SYMPTOMATIC DEEP-VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42331,"protocol_no":"840","submission_no":"194627","status_id":1,"start_date":"2016-06-15","end_date":null,"nol_date":"2016-05-24","protocol_title":"AN OPEN-LABEL, RANDOMIZED, PARALLEL DESIGN TRIAL TO COMPARE THE EFFICACY OF A SITAGLIPTIN-BASED METABOLIC INTERVENTION VERSUS STANDARD DIABETES THERAPY IN INDUCING REMISSION OF TYPE 2 DIABETES.","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28613,"protocol_no":"CMX001-301","submission_no":"169177","status_id":1,"start_date":"2014-09-18","end_date":null,"nol_date":"2013-11-29","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE 3 STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF CMX001 FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) INFECTION IN CMV-SEROPOSITIVE (R+) HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS","medConditionList":[{"med_condition_id":431,"med_condition":"HEMATOPOIETIC STEM CELL TRANSPLANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43250,"protocol_no":"HCQ_MS01","submission_no":"197618","status_id":1,"start_date":"2016-10-27","end_date":null,"nol_date":"2016-09-13","protocol_title":"OPEN-LABEL, SINGLE-CENTER, SINGLE-ARM FUTILITY TRIAL OF ORAL HYDROXYCHLOROQUINE 200MG BID FOR REDUCING PROGRESSION OF DISABILITY IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29337,"protocol_no":"TV5600-IMM-30011","submission_no":"171526","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-18","protocol_title":"A PHASE III, OPEN-LABEL INDUCTION AND MAINTENANCE STUDY IN ACTIVE MODERATE TO SEVERE CROHN'S DISEASE PATIENTS","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29339,"protocol_no":"TV5600-IMM-30010","submission_no":"171534","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-18","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED 52 WEEK MAINTENANCE OF REMISSION STUDY OF LAQUINIMOD IN CROHN'S DISEASE PATIENTS","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29189,"protocol_no":"CSL654_3003","submission_no":"171182","status_id":2,"start_date":"2015-12-12","end_date":"2016-10-24","nol_date":"2014-01-31","protocol_title":"A PHASE 3B OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY EXTENSION STUDY OF A RECOMBINANT COAGULATION FACTOR IX ALBUMIN FUSION PROTEIN (RIX-FP) IN SUBJECTS WITH HEMOPHILIA B","medConditionList":[{"med_condition_id":100,"med_condition":"HEMOPHILIA B"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35727,"protocol_no":"006-02","submission_no":"173249","status_id":1,"start_date":"2014-07-15","end_date":null,"nol_date":"2014-04-24","protocol_title":"A PHASE III RANDOMIZED, INTERNATIONAL, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL TO STUDY THE TOLERABILITY AND IMMUNOGENICITY OF V503, A MULTIVALENT HUMAN PAPILLOMAVIRUS (HPV) L1 VIRUS-LIKE PARTICLE (VLP) VACCINE, GIVEN TO FEMALES 12-26 YEARS OF AGE WHO HAVE PREVIOUSLY RECEIVED GARDASIL","medConditionList":[{"med_condition_id":119,"med_condition":"HUMAN PAPILLOMA VIRUS (HPV)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36083,"protocol_no":"OCOG-2013-RASET","submission_no":"174435","status_id":1,"start_date":"2016-12-20","end_date":null,"nol_date":"2014-06-04","protocol_title":"A PHASE III, MULTI-CENTRE, RANDOMIZED TRIAL TO COMPARE RIVAROXABAN WITH PLACEBO FOR THE TREATMENT OF SYMPTOMATIC LEG SUPERFICIAL VEIN THROMBOSIS.  (THE RASET TRIAL).","medConditionList":[{"med_condition_id":526,"med_condition":"SYMPTOMATIC LEG SUPERFICIAL VEIN THROMBOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36516,"protocol_no":"FSS-AS-301","submission_no":"175673","status_id":2,"start_date":"2015-02-10","end_date":"2015-12-24","nol_date":"2014-07-17","protocol_title":"A 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF FLUTICASONE PROPIONATE MULTIDOSE DRY POWDER INHALER COMPARED WITH FLUTICASONE/SALMETEROL MULTIDOSE DRY POWDER INHALER IN ADOLESCENT AND ADULT PATIENTS WITH PERSISTENT ASTHMA SYMPTOMATIC DESPITE LOW-DOSE INHALED CORTICOSTEROID THERAPY","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29188,"protocol_no":"ACNS1221","submission_no":"171172","status_id":1,"start_date":"2014-04-24","end_date":null,"nol_date":"2014-01-31","protocol_title":"A PHASE II STUDY FOR THE TREATMENT OF NON-METASTATIC NODULAR DESMOPLASTIC MEDULLOBLASTOMA IN CHILDREN LESS THAN 4 YEARS OF AGE","medConditionList":[{"med_condition_id":460,"med_condition":"MEDULLOBLASTOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28100,"protocol_no":"GTI1201","submission_no":"167604","status_id":1,"start_date":"2016-11-25","end_date":null,"nol_date":"2013-09-18","protocol_title":"\"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWO DOSE REGIMENS (60MG/KG AND 120MG/KG) OF WEEKLY INTRAVENOUS ALPHA1-PROTEINASE INHIBITOR(HUMAN) IN SUBJECTS WITH PULMONARY EMPHYSEMA DUE TO ALPHA1-ANTITRYPSIN DEFICIENCY.\"","medConditionList":[{"med_condition_id":72,"med_condition":"PULMONARY EMPHYSEMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28935,"protocol_no":"APD356-G000-401","submission_no":"170279","status_id":1,"start_date":"2014-05-08","end_date":null,"nol_date":"2013-12-23","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF LONG-TERM TREATMENT WITH BELVIQ (LORCASERIN HCL) ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND CONVERSION TO TYPE 2 DIABETES MELLITUS IN OBESE AND OVERWEIGHT SUBJECTS WITH CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS.","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"},{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41522,"protocol_no":"HC2016-050","submission_no":"191742","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-11","protocol_title":"HYPERVENTILATION AND ECT SEIZURE DURATION: EFFECTS ON CEREBRAL OXYGEN SATURATION, AND THERAPEUTIC OUTCOME WITH COMPARISONS BETWEEN ETOMIDATE AND KETAMINE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28769,"protocol_no":"CD-ON-MEDI4736-1161","submission_no":"169772","status_id":1,"start_date":"2016-03-22","end_date":null,"nol_date":"2013-12-06","protocol_title":"A PHASE I OPEN-LABEL STUDY OF SAFETY AND TOLERABILITY OF MEDI4736 IN SUBJECTS WITH METASTATIC OR UNRESECTABLE MELANOMA IN COMBINATION WITH DABRAFENIB AND TRAMETINIB OR WITH TRAMETINIB ALONE","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27775,"protocol_no":"OXYDEP2013","submission_no":"166668","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-02","protocol_title":"THE SOCIAL INFORMATION PROCESSING RESPONSE TO INTRANASAL OXYTOCIN AS A PROSPECTIVE MARKER OF SOCIAL VULNERABILITY AND RISK FOR DEPRESSION","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46970,"protocol_no":"1.3","submission_no":"209325","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-12","protocol_title":"THE TERRY FOX PAN-CANADIAN MULTIPLE MYELOMA MOLECULAR MONITORING COHORT STUDY (THE M4 STUDY)","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45108,"protocol_no":"2015-15","submission_no":"203334","status_id":1,"start_date":"2017-08-31","end_date":null,"nol_date":"2017-04-07","protocol_title":"AN OPEN-LABEL, RANDOMIZED, THREE-WAY, CROSS-OVER STUDY TO ASSESS THE EFFICACY OF SINGLE-HORMONE CLOSED-LOOP STRATEGY, DUAL-HORMONE CLOSED-LOOP STRATEGY AND SENSOR-AUGMENTED PUMP THERAPY IN REGULATING GLUCOSE LEVELS FOR 5 DAYS IN FREE-LIVING OUTPATIENT CONDITIONS IN PATIENTS WITH TYPE 1 DIABETES","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28907,"protocol_no":"GS-US-312-0123","submission_no":"170215","status_id":2,"start_date":"2014-07-04","end_date":"2016-05-30","nol_date":"2013-12-12","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42550,"protocol_no":"ADREL","submission_no":"195338","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-22","protocol_title":"APIXABAN DOSE REDUCTION IN PATIENTS WITH ELEVATED DRUG LEVELS","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41135,"protocol_no":"R475-PN-1524","submission_no":"190432","status_id":1,"start_date":"2016-03-22","end_date":null,"nol_date":"2016-01-08","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE TO SEVERE CHRONIC LOW BACK PAIN,","medConditionList":[{"med_condition_id":626,"med_condition":"CHRONIC LOW BACK PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36949,"protocol_no":"FKB327-002","submission_no":"177044","status_id":1,"start_date":"2014-12-17","end_date":null,"nol_date":"2014-09-11","protocol_title":"A RANDOMISED, BLINDED, ACTIVE-CONTROLLED STUDY TO COMPARE FKB327 EFFICACY AND SAFETY WITH THE COMPARATOR HUMIRA IN RHEUMATOID ARTHRITIS PATIENTS INADEQUATELY CONTROLLED ON METHOTREXATE (ARABESC)","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42202,"protocol_no":"199","submission_no":"194248","status_id":1,"start_date":"2016-09-21","end_date":null,"nol_date":"2016-05-17","protocol_title":"PHASE II TRIAL OF PEMBROLIZUMAB (MK-3475) IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH CHEMOTHERAPY (KEYNOTE-199)","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28677,"protocol_no":"1000038524","submission_no":"169403","status_id":2,"start_date":"2014-02-21","end_date":"2016-03-12","nol_date":"2013-11-22","protocol_title":"PRELIMINARY EXAMINATION OF THE IMPACT OF CYCLOPHOSPHAMIDE PHARMACOKINETIC VARIABILITY ON OUTCOMES IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45351,"protocol_no":"CA209-9GW","submission_no":"204173","status_id":1,"start_date":"2017-11-17","end_date":null,"nol_date":"2017-04-20","protocol_title":"PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF NIVOLUMAB COMBINED WITH DARATUMUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44261,"protocol_no":"PTG-100-02","submission_no":"200565","status_id":1,"start_date":"2018-02-09","end_date":null,"nol_date":"2016-12-15","protocol_title":"A PHASE 2B RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ADAPTIVE 2 STAGE, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG-100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45114,"protocol_no":"008-01","submission_no":"203255","status_id":1,"start_date":"2017-05-05","end_date":null,"nol_date":"2017-03-28","protocol_title":"A PHASE II, DOUBLE-BLIND, RANDOMIZED, MULTICENTER TRIAL TO EVALUATE THE SAFETY,TOLERABILITY, AND IMMUNOGENICITY OF V114 COMPARED TO PREVNAR 13TM IN HEALTHY INFANTS","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42357,"protocol_no":"MERCK08-001","submission_no":"194682","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-10","protocol_title":"LONG TERM IMMUNE MEMORY RESPONSES TO HUMAN PAPILLOMAVIRUS (HPV) VACCINATION FOLLOWING 2 VERSUS 3 DOSES OF QUADRIVALENT HPV VACCINE","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"},{"med_condition_id":119,"med_condition":"HUMAN PAPILLOMA VIRUS (HPV)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28373,"protocol_no":"A0081279","submission_no":"168362","status_id":1,"start_date":"2014-04-30","end_date":null,"nol_date":"2013-10-23","protocol_title":"A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN (BID) IN SUBJECTS WITH POST-TRAUMATIC PERIPHERAL NEUROPATHIC PAIN","medConditionList":[{"med_condition_id":174,"med_condition":"NEUROPATHIC PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27220,"protocol_no":"5945-SOIC-12-05","submission_no":"165171","status_id":1,"start_date":"2013-07-30","end_date":null,"nol_date":"2013-06-21","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF CB5945 FOR THE TREATMENT OF OPIOIDINDUCED CONSTIPATION IN ADULTS TAKING OPIOID THERAPY FOR CHRONIC NON-CANCER PAIN","medConditionList":[{"med_condition_id":276,"med_condition":"OPIOID-INDUCED CONSTIPATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45439,"protocol_no":"M16-043","submission_no":"204418","status_id":1,"start_date":"2018-01-18","end_date":null,"nol_date":"2017-04-26","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF VENETOCLAX CO-ADMINISTERED WITH LOW DOSE CYTARABINE VERSUS LOW DOSE CYTARABINE IN TREATMENT NA√èVE PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY","medConditionList":[{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37309,"protocol_no":"TKM-EBOV-CAN","submission_no":"178246","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-14","protocol_title":"TREATMENT PROTOCOL FOR USE OF TKM-100802 IN PATIENTS WITH CONFIRMED OR SUSPECTED EBOLA VIRUS INFECTION","medConditionList":[{"med_condition_id":582,"med_condition":"EBOLA VIRUS INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44796,"protocol_no":"CNTO1959PSO3009","submission_no":"202473","status_id":1,"start_date":"2017-05-11","end_date":null,"nol_date":"2017-03-02","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY EVALUATING THE COMPARATIVE EFFICACY OF CNTO 1959 (GUSELKUMAB) AND SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE-TYPE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48366,"protocol_no":"A4250-005","submission_no":"213742","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-21","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY TO DEMONSTRATE EFFICACY AND SAFETY OF A4250 IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPES 1 AND 2 (PEDFIC 1)","medConditionList":[{"med_condition_id":454,"med_condition":"PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38719,"protocol_no":"BARRIER-P","submission_no":"182475","status_id":1,"start_date":"2016-03-23","end_date":null,"nol_date":"2015-04-10","protocol_title":"BIOMARKERS OF ANDROGEN RESPONSE AND RESISTANCE IN EVOLUTION DURING A RISING PSA","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45883,"protocol_no":"UBR-MD-03","submission_no":"205758","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-15","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE-ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE","medConditionList":[{"med_condition_id":157,"med_condition":"MIGRAINE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39713,"protocol_no":"01-0923","submission_no":"186128","status_id":1,"start_date":"2015-12-17","end_date":null,"nol_date":"2015-08-07","protocol_title":"A STUDY OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PEDIATRIC NON-MALIGNANT DISEASE USING A REDUCED-INTENSITY PREPARATORY REGIME.","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28238,"protocol_no":"ATACAS 024","submission_no":"168013","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-05-09","protocol_title":"ASPIRIN AND TRANEXAMIC ACID FOR CORONARY ARTERY SURGERY TRIAL","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45549,"protocol_no":"AALL15P1","submission_no":"204751","status_id":1,"start_date":"2017-07-11","end_date":null,"nol_date":"2017-05-05","protocol_title":"A GROUPWIDE PILOT STUDY TO TEST THE TOLERABILITY AND BIOLOGIC ACTIVITY OF THE ADDITION OF AZACITIDINE (IND# 133688, NSC# 102816) TO CHEMOTHERAPY IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND KMT2A (MLL) GENE REARRANGEMENT","medConditionList":[{"med_condition_id":148,"med_condition":"LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46981,"protocol_no":"WAVE-001","submission_no":"209365","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-06","protocol_title":"A MULTICENTRE PROSPECTIVE OBSERVATIONAL COHORT STUDY ASSESSING THE USE OF WEIGHT-ADJUSTED LOW-MOLECULAR-WEIGH-HEPARIN IN PATIENTS OVER 90KG WITH ACUTE CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44041,"protocol_no":"IM011-011","submission_no":"199503","status_id":2,"start_date":"2017-01-17","end_date":"2018-04-03","nol_date":"2016-12-13","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF BMS-986165 IN SUBJECTS WITH MODERATE TO SEVERE PSORIASIS","medConditionList":[{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47179,"protocol_no":"MVT-601-3102","submission_no":"210053","status_id":1,"start_date":"2018-01-02","end_date":null,"nol_date":"2017-11-09","protocol_title":"SPIRIT 2: AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"},{"med_condition_id":74,"med_condition":"ENDOMETRIOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37578,"protocol_no":"NSABP-B-54-I","submission_no":"179041","status_id":1,"start_date":"2015-03-16","end_date":null,"nol_date":"2014-11-20","protocol_title":"PHASE III STUDY EVALUATING PALBOCICLIB (PD-0332991), A CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITOR IN PATIENTS WITH HORMONE-RECEPTOR-POSITIVE, HER2-NORMAL PRIMARY BREAST CANCER WITH HIGH RELAPSE RISK AFTER NEOADJUVANT CHEMOTHERAPY","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39537,"protocol_no":"CRFB002H2301","submission_no":"185660","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-06-29","protocol_title":"RAINBOW STUDY: A RANDOMIZED, CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF RANIBIZUMAB COMPARED WITH LASER THERAPY FOR THE TREATMENT OF INFANTS BORN PREMATURELY WITH RETINOPATHY OF PREMATURITY","medConditionList":[{"med_condition_id":564,"med_condition":"RETINOPATHY OF PREMATURITY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46351,"protocol_no":"PB-102-F50","submission_no":"207219","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-02","protocol_title":"A PHASE 3, OPEN LABEL, SWITCH OVER STUDY TO ASSESS THE SAFETY, EFFICACY AND PHARMACOKINETICS OF PEGUNIGALSIDASE ALFA (PRX-102) 2MG/KG ADMINISTERED BY INTRAVENOUS INFUSION EVERY 4 WEEKS FOR 52 WEEKS IN PATIENTS WITH FABRY DISEASE CURRENTLY TREATED WITH ENZYME REPLACEMENT THERAPY: FABRAZYME (AGALSIDASE BETA) OR REPLAGAL (AGALSIDASE ALFA)","medConditionList":[{"med_condition_id":79,"med_condition":"FABRY DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43617,"protocol_no":"PT009002-01","submission_no":"198666","status_id":1,"start_date":"2016-11-01","end_date":null,"nol_date":"2016-10-24","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PT009 COMPARED TO PT005, PT008, AND OPEN-LABEL SYMBICORT¬Æ TURBUHALER¬Æ, AS AN ACTIVE CONTROL, ON LUNG FUNCTION OVER A 24-WEEK TREATMENT PERIOD IN SUBJECTS WITH MODERATE TO VERY SEVERE COPD","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41494,"protocol_no":"15-128","submission_no":"191658","status_id":2,"start_date":"2016-03-21","end_date":"2016-11-21","nol_date":"2016-02-19","protocol_title":"PHARMACOKINETICS AND PHARMACODYNAMICS OF APIXABAN IN END-STAGE RENAL DISEASE PATIENTS ON HEMODIALYSIS","medConditionList":[{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"},{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"},{"med_condition_id":457,"med_condition":"END STAGE RENAL DISEASE"},{"med_condition_id":96,"med_condition":"HEMODIALYSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45683,"protocol_no":"RVX222-CS-020","submission_no":"205167","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-25","protocol_title":"AN OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFECT ON KEY BIOMARKERS OF ORAL RVX000222 IN SUBJECTS WITH FABRY DISEASE","medConditionList":[{"med_condition_id":79,"med_condition":"FABRY DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44183,"protocol_no":"CACZ885X2206","submission_no":"200330","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-11-25","protocol_title":"A MULTIPLE-DOSE, SUBJECT-AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED, PARALLEL DESIGN STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ACZ885 (CANAKINUMAB) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH SICKLE CELL ANEMIA","medConditionList":[{"med_condition_id":233,"med_condition":"SICKLE CELL ANEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28784,"protocol_no":"B2013-1001","submission_no":"169845","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-13","protocol_title":"THE ROLE OF TIMING OF DEXAMETHASONE ADMINISTRATION ON PAIN SCORES AND QUALITY OF RECOVERY IN CESAREAN SECTION.","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39663,"protocol_no":"D5164C00001","submission_no":"185995","status_id":1,"start_date":"2015-08-05","end_date":null,"nol_date":"2015-07-31","protocol_title":"A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTI-CENTRE, STUDY TO ASSESS THE  EFFICACY AND SAFETY OF AZD9291 VERSUS PLACEBO, IN PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION POSITIVE STAGE IB-IIIA NON-SMALL CELL LUNG CARCINOMA, FOLLOWING COMPLETE TUMOUR RESECTION WITH OR WITHOUT ADJUVANT CHEMOTHERAPY (ADAURA)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26845,"protocol_no":"20120222-01","submission_no":"164031","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-05-14","protocol_title":"AGGRESSIVE CHOLESTEROL THERAPY TO INHIBIT VEIN GRAFT EVENTS (ACTIVE TRIAL): DOES HIGH-DOSE POSTOPERATIVE STATIN THERAPY IMPROVE GRAFT PATENCY AFTER CORONARY BYPASS.","medConditionList":[{"med_condition_id":56,"med_condition":"CORONARY HEART DISEASE OR HIGH RISK OF CORONONARY HEART DISEASE"},{"med_condition_id":55,"med_condition":"CORONARY ARTERY BYPASS GRAFT"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35924,"protocol_no":"DOXILNAP1004","submission_no":"173962","status_id":2,"start_date":"2014-09-09","end_date":"2016-04-14","nol_date":"2014-05-16","protocol_title":"A PIVOTAL BIOEQUIVALENCE STUDY OF DOXIL¬Æ/CAELYX¬Æ MANUFACTURED AT A NEW SITE IN SUBJECTS WITH ADVANCED OR REFRACTORY SOLID MALIGNANCIES INCLUDING SUBJECTS WITH OVARIAN CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42574,"protocol_no":"PRO18MAY2016NEVKP","submission_no":"195417","status_id":1,"start_date":"2017-04-04","end_date":null,"nol_date":"2016-08-18","protocol_title":"A SINGLE CENTRE STUDY OF THE FEASIBILITY AND SAFETY OF USING NORMOTHERMIC EX VIVO MACHINE PERFUSION FOR THE PRESERVATION OF HUMAN KIDNEYS PRIOR TO TRANSPLANTATION","medConditionList":[{"med_condition_id":701,"med_condition":"KIDNEY TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38774,"protocol_no":"NOT PROVIDED","submission_no":"183138","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-16","protocol_title":"\"EXPLORING THE NEURAL SUBSTRATES OF COGNITIVE DYSFUNCTION WITH GLUCAGON-LIKE PEPTIDE-1 AGONISTS.\"","medConditionList":[{"med_condition_id":285,"med_condition":"COGNITIVE IMPAIRMENT"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43973,"protocol_no":"1199.247","submission_no":"199732","status_id":1,"start_date":"2017-03-10","end_date":null,"nol_date":"2016-11-22","protocol_title":"A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF NINTEDANIB OVER 52 WEEKS IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE (PF-ILD)","medConditionList":[{"med_condition_id":423,"med_condition":"INTERSTITIAL LUNG DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28752,"protocol_no":"NN1250-4080","submission_no":"169668","status_id":1,"start_date":"2014-01-16","end_date":null,"nol_date":"2013-12-10","protocol_title":"DEVOTE: A TRIAL COMPARING CARDIOVASCULAR SAFETY OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES AS HIGH RISK OF CARDIOVASCULAR EVENTS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42047,"protocol_no":"204691","submission_no":"193739","status_id":1,"start_date":"2017-05-08","end_date":null,"nol_date":"2016-04-29","protocol_title":"A PHASE I OPEN LABEL STUDY OF GSK3359609 ADMINISTERED ALONE AND IN COMBINATION WITH ANTICANCER AGENTS IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35537,"protocol_no":"TG004","submission_no":"172704","status_id":1,"start_date":"2014-03-28","end_date":null,"nol_date":"2014-03-28","protocol_title":"A MULTI-CENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF GRASS-SPIRE IN SUBJECTS WITH ASTHMA AND GRASS-INDUCED RHINOCONJUNCTIVITIS","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"},{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27894,"protocol_no":"PREPARATORY-5","submission_no":"166977","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-08-29","protocol_title":"PILOT STUDY OF DAILY TDF/FTC-BASED PREP AMONG HIGH-RISK TORONTO MSM","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28962,"protocol_no":"201-201303","submission_no":"170367","status_id":1,"start_date":"2014-02-27","end_date":null,"nol_date":"2013-12-24","protocol_title":"A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED, MULTICENTER, PHASE 3 STUDY OF OTO-201 GIVEN AS A SINGLE INTRATYMPANIC INJECTION FOR INTRA-OPERATIVE TREATMENT OF MIDDLE EAR EFFUSION IN PEDIATRIC SUBJECTS REQUIRING TYMPANOSTOMY TUBE PLACEMENT","medConditionList":[{"med_condition_id":455,"med_condition":"MIDDLE EAR EFFUSION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35515,"protocol_no":"CAMHPET-CTA-84","submission_no":"172628","status_id":3,"start_date":"2014-04-01","end_date":null,"nol_date":"2014-03-28","protocol_title":"CHANGES IN [11C] - DIHYDROTETRABENAZINE BINDING WITH TRANSCRANIAL DIRECT CURRENT STIMULATION IN PATIENTS WITH SCHIZOPHRENIA","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35492,"protocol_no":"ONT-380-004","submission_no":"172560","status_id":2,"start_date":"2015-04-20","end_date":"2017-10-30","nol_date":"2014-03-27","protocol_title":"A PHASE 1B, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF ONT-380 COMBINED WITH ADO-TRASTUZUMAB EMTANSINE (T-DM1)","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"},{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35889,"protocol_no":"BBI608-336","submission_no":"173676","status_id":1,"start_date":"2015-12-18","end_date":null,"nol_date":"2014-05-08","protocol_title":"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF BBI608 PLUS WEEKLY PACLITAXEL VS. PLACEBO PLUS WEEKLY PACLITAXEL IN ADULT PATIENTS WITH ADVANCED, PREVIOUSLY TREATED GASTRIC AND GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA","medConditionList":[{"med_condition_id":337,"med_condition":"GASTRIC CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37822,"protocol_no":"VC01-101 / VC01-201","submission_no":"179810","status_id":1,"start_date":"2016-04-26","end_date":null,"nol_date":"2014-12-17","protocol_title":"A PROSPECTIVE, MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN PHASE 1/2 STUDY WITH TWO COHORTS TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF VARIOUS DOSES OF VC-01 COMBINATION PRODUCT IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36955,"protocol_no":"CHS-0214-04","submission_no":"177056","status_id":1,"start_date":"2015-11-16","end_date":null,"nol_date":"2014-09-11","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP, ACTIVE CONTROL STUDY TO COMPARE THE EFFICACY AND SAFETY OF CHS-0214 VERSUS ENBREL IN SUBJECTS WITH CHRONIC PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27515,"protocol_no":"WB28183","submission_no":"165969","status_id":2,"start_date":"2013-09-13","end_date":"2017-03-23","nol_date":"2013-07-24","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY, AND TOLERABILITY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH UNCONTROLLED ASTHMA WHO ARE INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35446,"protocol_no":"CAMHPET-CTA-83 (71/2013)","submission_no":"172415","status_id":1,"start_date":"2014-03-25","end_date":null,"nol_date":"2014-03-20","protocol_title":"DETECTING CENTRAL AND PERIPHERAL BIOMARKERS IN MAJOR DEPRESSIVE DISORDER","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41101,"protocol_no":"AEGR-733-020","submission_no":"190285","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-01-06","protocol_title":"A PHASE 3, SINGLE-ARM, OPEN-LABEL, INTERNATIONAL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOMITAPIDE IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ON STABLE LIPID-LOWERING THERAPY","medConditionList":[{"med_condition_id":83,"med_condition":"FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29436,"protocol_no":"BILIARY GEMOX / MEK","submission_no":"171799","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-28","protocol_title":"A PHASE I TRIAL OF MEK INHIBITOR MEK 162 COMBINED SEQUENTIALLY WITH GEMCITABINE-OXALIPLATIN (GEMOX) IN PATIENTS WITH ADVANCED BILIARY CANCER","medConditionList":[{"med_condition_id":458,"med_condition":"BILIARY CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46701,"protocol_no":"BRB-018-001","submission_no":"208396","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-29","protocol_title":"AN ADAPTIVE DESIGN STUDY FOR THE ASSESSMENT OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RYI-018 AFTER REPEAT DOSING IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)","medConditionList":[{"med_condition_id":794,"med_condition":"NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44298,"protocol_no":"BRO-HF 1","submission_no":"200665","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-01-04","protocol_title":"BROMOCRIPTINE IN THE TREATMENT OF PERIPARTUM CARDIOMYOPATHY, A BAYESIAN RANDOMIZED REGISTRY TRIAL","medConditionList":[{"med_condition_id":834,"med_condition":"CARDIOMYOPATHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44596,"protocol_no":"CA209907","submission_no":"201818","status_id":1,"start_date":"2017-05-29","end_date":null,"nol_date":"2017-01-31","protocol_title":"AN OPEN-LABEL, SINGLE-ARM PHASE II SAFETY STUDY OF NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE PROGRESSED DURING OR AFTER RECEIVING AT LEAST ONE PRIOR SYSTEMIC REGIMEN","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38259,"protocol_no":"E3-001","submission_no":"181435","status_id":1,"start_date":"2016-11-01","end_date":null,"nol_date":"2015-04-23","protocol_title":"EVALUATING THE EFFICACY OF E-CIGARETTE USE FOR SMOKING CESSATION (E3) TRIAL","medConditionList":[{"med_condition_id":236,"med_condition":"SMOKING CESSATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37310,"protocol_no":"1000045463","submission_no":"178250","status_id":1,"start_date":"2017-05-15","end_date":null,"nol_date":"2014-10-22","protocol_title":"PREDNISOLONE VS VIGABATRIN IN THE FIRST-LINE TREATMENT OF INFANTILE SPASMS","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29205,"protocol_no":"20120187","submission_no":"171211","status_id":3,"start_date":"2014-03-13","end_date":null,"nol_date":"2014-02-05","protocol_title":"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF DENOSUMAB PRODUCED BY TWO DIFFERENT PROCESSESS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS","medConditionList":[{"med_condition_id":181,"med_condition":"OSTEROPOROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36650,"protocol_no":"R1500-CL-1331","submission_no":"176120","status_id":1,"start_date":"2016-04-26","end_date":null,"nol_date":"2014-07-30","protocol_title":"AN OPEN-LABEL, SINGLE-ARM, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE AND MULTIPLE DOSES OF REGN1500 IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","medConditionList":[{"med_condition_id":116,"med_condition":"HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47371,"protocol_no":"M15-862","submission_no":"210136","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-08","protocol_title":"A MULTICENTER, PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF ABBV-927, AN IMMUNOTHERAPY, IN SUBJECTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38636,"protocol_no":"14-505","submission_no":"182703","status_id":1,"start_date":"2017-05-25","end_date":null,"nol_date":"2015-04-02","protocol_title":"PROSPECTIVE, OPEN-LABEL STUDY OF ANDEXANET ALFA IN PATIENTS RECEIVING A FACTOR XA INHIBITOR WHO HAVE ACUTE MAJOR BLEEDING","medConditionList":[{"med_condition_id":590,"med_condition":"HEMORRHAGE"},{"med_condition_id":614,"med_condition":"ACUTE MAJOR BLEEDING"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27021,"protocol_no":"1000037185","submission_no":"164510","status_id":1,"start_date":"2017-03-20","end_date":null,"nol_date":"2013-05-31","protocol_title":"NANT 2011-04: A PHASE I STUDY OF LENALIDOMIDE AND ANTI-DG2 MAB CH14.18 +/- ISOTRETINOIN IN PATIENTS WITH REFRACTORY/RECURRENT NEUROBLASTOMA NCI PROTOCOL# NANT N2011-04.","medConditionList":[{"med_condition_id":172,"med_condition":"NEUROBLASTOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36796,"protocol_no":"1000044746","submission_no":"176598","status_id":1,"start_date":"2017-10-13","end_date":null,"nol_date":"2014-08-20","protocol_title":"THE PROTECTIVE EFFECT OF THE ALPHA2-AGONIST DEXMEDETOMIDINE ON MITOCHONDRIAL STRUCTURE AND FUNCTION FOR CHILDREN WITH NON-CYANOTIC CONGENITAL HEART DEFECTS HAVING CARDIAC SURGERY: A RANDOMIZED CONTROLLED TRIAL.","medConditionList":[{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28848,"protocol_no":"IM133-066","submission_no":"170073","status_id":1,"start_date":"2014-06-13","end_date":null,"nol_date":"2013-12-13","protocol_title":"A PHASE IIB, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CLAZAKIZUMAB IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WHO HAVE EXPERIENCED AN INADEQUATE RESPONSE TO TNF INHIBITORS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42552,"protocol_no":"JU-002","submission_no":"195348","status_id":1,"start_date":"2016-08-31","end_date":null,"nol_date":"2016-06-28","protocol_title":"INFLUENZA VACCINE TO EFFECTIVELY STOP CARDIO THORACIC EVENTS AND DECOMPENSATED HEART FAILURE (INVESTED)","medConditionList":[{"med_condition_id":538,"med_condition":"MAJOR CARDIOVASCULAR EVENTS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27616,"protocol_no":"PR-30-5011-C","submission_no":"166263","status_id":1,"start_date":"2015-02-23","end_date":null,"nol_date":"2013-08-01","protocol_title":"A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27340,"protocol_no":"CA180-406","submission_no":"165492","status_id":1,"start_date":"2018-02-06","end_date":null,"nol_date":"2013-07-04","protocol_title":"OPEN-LABEL SINGLE ARM PHASE 2 STUDY EVALUATING DASATINIB THERAPY DISCONTINUATION IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH STABLE COMPLETE MOLECULAR RESPONSE (CMR): DASFREE","medConditionList":[{"med_condition_id":46,"med_condition":"CHRONIC MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27828,"protocol_no":"PMT4979G (GO00886)","submission_no":"166813","status_id":1,"start_date":"2015-08-22","end_date":null,"nol_date":"2013-08-15","protocol_title":"AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47773,"protocol_no":"GBI1406","submission_no":"211877","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-27","protocol_title":"A MULTICENTER PHASE 2 OPEN-LABEL, SINGLE-ARM, PROSPECTIVE, INTERVENTIONAL STUDY OF PLASMA-DERIVED FACTOR VIII/VWF (ALPHANATE) IN IMMUNE TOLERANCE INDUCTION THERAPY IN SUBJECTS WITH CONGENITAL HEMOPHILIA A","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26866,"protocol_no":"SD-809-C-15","submission_no":"164078","status_id":1,"start_date":"2013-05-31","end_date":null,"nol_date":"2013-05-17","protocol_title":"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF SD-809 EXTENDED RELEASE FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON DISEASE","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38837,"protocol_no":"IM101-344","submission_no":"182899","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-02","protocol_title":"A PHASE II STUDY TO EVALUATE SUBCUTANEOUS ABATACEPT VS. PLACEBO IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":246,"med_condition":"SYSTEMIC SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40065,"protocol_no":"VX15-770-123","submission_no":"186991","status_id":2,"start_date":"2017-07-27","end_date":"2017-08-08","nol_date":"2015-09-23","protocol_title":"A PHASE 3B, 2-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER STUDY WITH A LONG TERM OPEN-LABEL PERIOD TO INVESTIGATE IVACAFTOR IN SUBJECTS WITH CYSTIC FIBROSIS AGED 3 THROUGH 5 YEARS WHO HAVE A SPECIFIED CFTR GATING MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37391,"protocol_no":"DS5565-A-E312","submission_no":"178472","status_id":2,"start_date":"2015-02-11","end_date":"2017-08-28","nol_date":"2014-10-24","protocol_title":"AN OPEN-LABEL EXTENSION STUDY OF DS-5565 FOR 52 WEEKS IN PAIN ASSOCIATED WITH FIBROMYALGIA","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45204,"protocol_no":"ARC007","submission_no":"203669","status_id":1,"start_date":"2017-06-07","end_date":null,"nol_date":"2017-04-06","protocol_title":"REAL-WORLD AR101 MARKET-SUPPORTING EXPERIENCE STUDY IN PEANUT-ALLERGIC CHILDREN AGES 4 TO 17 YEARS (RAMSES)","medConditionList":[{"med_condition_id":12,"med_condition":"ALLERGIES PEANUT"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40278,"protocol_no":"15-046-MUHC","submission_no":"187577","status_id":1,"start_date":"2017-09-19","end_date":null,"nol_date":"2015-10-29","protocol_title":"GENETIC VARIANTS ASSOCIATED WITH THE OCCURRENCE OF LOCALIZED LOW BACK PAIN OR LOW BACK PAIN WITH WIDESPREAD PAIN SYMPTOMS, AND THEIR RESPONSE TO TREATMENT WITH DULOXETINE OR PROPRANOLOL","medConditionList":[{"med_condition_id":626,"med_condition":"CHRONIC LOW BACK PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38520,"protocol_no":"GTI1408","submission_no":"182286","status_id":1,"start_date":"2015-10-22","end_date":null,"nol_date":"2015-03-05","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IMMUNE GLOBULIN (HUMAN), 10% CAPRYLATE/CHROMATOGRAPHY PURIFIED (IGIV-C) IN SYMPTOMATIC SUBJECTS WITH GENERALIZED MYASTHENIA GRAVIS.","medConditionList":[{"med_condition_id":163,"med_condition":"MYASTHENIA GRAVIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28657,"protocol_no":"PJC-015 / NCI 9591","submission_no":"169323","status_id":1,"start_date":"2017-11-07","end_date":null,"nol_date":"2013-11-22","protocol_title":"A PHASE I TRIAL OF SINGLE AGENT TRAMETINIB (GSK1120212) IN ADVANCED CANCER WITH HEPATIC DYSFUNCTION","medConditionList":[{"med_condition_id":143,"med_condition":"LIVER / HEPATIC DYSFUNCTION"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36880,"protocol_no":"CICL670ACA02T","submission_no":"176843","status_id":2,"start_date":"2015-08-31","end_date":"2016-09-30","nol_date":"2014-08-15","protocol_title":"RANDOMIZED PHASE II STUDY OF AZACITIDINE PLUS DEFERASIROX (ICL670) VERSUS AZACITIDINE ALONE IN HIGHER RISK MYELODYSPLASTIC SYNDROMES (MDS)","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48259,"protocol_no":"I8B-MC-ITSA (A)","submission_no":"213448","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-07","protocol_title":"A STUDY TO EVALUATE THE PHARMACOKINETICS AND GLUCODYNAMICS OF LY900014 COMPARED TO HUMALOG IN CHILDREN, ADOLESCENTS, AND ADULTS WITH TYPE 1 DIABETES MELLITUS","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28174,"protocol_no":"012-02","submission_no":"167867","status_id":2,"start_date":"2014-04-24","end_date":"2016-02-24","nol_date":"2013-09-27","protocol_title":"A SEAMLESS PHASE IIA/IIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MK-7622 AS AN ADJUNCTIVE THERAPY TO DONEPEZIL FOR SYMPTOMATIC TREATMENT IN SUBJECTS WITH ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46292,"protocol_no":"GS-US-320-4035","submission_no":"207037","status_id":1,"start_date":"2017-09-20","end_date":null,"nol_date":"2017-07-13","protocol_title":"A PHASE 2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRAL TREATMENT (OAV) IN VIROLOGICALLY SUPPRESSED CHRONIC HEPATITIS B SUBJECTS WITH RENAL AND/OR HEPATIC IMPAIRMENT","medConditionList":[{"med_condition_id":103,"med_condition":"HEPATITIS B VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27891,"protocol_no":"A3921125","submission_no":"166971","status_id":1,"start_date":"2014-05-21","end_date":null,"nol_date":"2013-08-29","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE TNF INHIBITOR","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27899,"protocol_no":"A3921092","submission_no":"166993","status_id":1,"start_date":"2014-08-07","end_date":null,"nol_date":"2013-08-28","protocol_title":"A LONG TERM, OPEN LABEL EXTENSION STUDY OF TOFACITINIB (CP 690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36817,"protocol_no":"TOPAZ","submission_no":"176656","status_id":1,"start_date":"2017-06-13","end_date":null,"nol_date":"2014-08-21","protocol_title":"A PHASE I AND ENRICHMENT STUDY OF LOW-DOSE METRONOMIC TOPOTECAN AND PAZOPANIB IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS INCLUDING CNS TUMOURS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27873,"protocol_no":"A3921091","submission_no":"166934","status_id":1,"start_date":"2014-05-20","end_date":null,"nol_date":"2013-08-30","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP 690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":4,"med_condition":"ACTIVE PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29399,"protocol_no":"ROB0039","submission_no":"171694","status_id":1,"start_date":"2014-04-14","end_date":null,"nol_date":"2014-04-02","protocol_title":"HYPERPOLARIZED MAGNETIC RESONANCE IMAGING IN ASTHMA PRE- AND POST-BRONCHIAL THERMOPLASTY","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35381,"protocol_no":"B2081011","submission_no":"172172","status_id":1,"start_date":"2014-07-14","end_date":null,"nol_date":"2014-03-12","protocol_title":"A RANDOMIZED 18-WEEK PLACEBO-CONTROLLED DOUBLE-BLIND PARALLEL GROUP STUDY OF THE SAFETY AND EFFICACY OF PF-05212377 (SAM-760) IN SUBJECTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE WITH EXISTING NEUROPSYCHIATRIC SYMPTOMS ON A STABLE DAILY DOSE OF DONEPEZIL","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28699,"protocol_no":"GS-US-292-0119","submission_no":"169463","status_id":1,"start_date":"2014-01-17","end_date":null,"nol_date":"2013-11-26","protocol_title":"A PHASE 3 OPEN-LABEL STUDY TO EVALUATE SWITCHING FROM OPTIMIZED STABLE ANTIRETROVIRAL REGIMENS CONTAINING DARUNAVIR TO ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (E/C/F/TAF) SINGLE TABLET REGIMEN (STR) PLUS DARUNAVIR (DRV) IN TREATMENT EXPERIENCED HIV-1 POSITIVE ADULTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47650,"protocol_no":"CP-MGA271-04","submission_no":"211462","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-20","protocol_title":"A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF MGA271 IN PEDIATRIC PATIENTS WITH B7-H3-EXPRESSING RELAPSED OR REFRACTORY SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26554,"protocol_no":"2012-005","submission_no":"163110","status_id":2,"start_date":"2014-01-02","end_date":"2016-10-31","nol_date":"2013-04-04","protocol_title":"A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY OF CARFILZOMIB, MELPHALAN, AND PREDNISONE VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"},{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44880,"protocol_no":"GS-US-417-0304","submission_no":"202710","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-02-28","protocol_title":"A MULTICENTER, DOUBLE-BLIND, LONG TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF FILGOTINIB IN SUBJECTS WITH RHEUMATOID ARTHRITIS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36659,"protocol_no":"D5136C00007","submission_no":"176156","status_id":2,"start_date":"2016-04-14","end_date":"2017-02-27","nol_date":"2014-07-30","protocol_title":"MULTICENTER, OPEN-LABEL, RANDOMISED, PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) DOSE-RANGING PHASE II STUDY OF TICAGRELOR FOLLOWED BY A DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP, PLACEBO-CONTROLLED 4 WEEKS EXTENSION PHASE IN PAEDIATRIC PATIENTS WITH SICKLE CELL DISEASE","medConditionList":[{"med_condition_id":232,"med_condition":"SICKLE CELL DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36342,"protocol_no":"497-2013","submission_no":"175116","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-09","protocol_title":"THE NPH-LENS AMYLOID STUDY: BETA-AMYLOID MEASUREMENT IN THE OCULAR LENS AS A PRESYMPTOMATIC DIAGNOSTIC TEST OF INCIPIENT ALZHEIMER'S DISEASE USING NORMAL PRESSURE HYDROCEPHALUS AS A UNIQUE TEST GROUND","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42596,"protocol_no":"EQ-LEBR-001","submission_no":"195514","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-28","protocol_title":"COMPARATIVE EFFECTIVENESS AND SAFETY OF 2 DOSING REGIMENS OF LOTEPREDNOL GEL 0.5% AND BROMFENAC 0.07% SOLUTION TO CONTROL INFLAMMATION AND PAIN AFTER CATARACT SURGERY.","medConditionList":[{"med_condition_id":727,"med_condition":"CATARACT SURGERY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26650,"protocol_no":"VX12-809-104","submission_no":"163367","status_id":1,"start_date":"2013-06-27","end_date":null,"nol_date":"2013-04-18","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS, HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37359,"protocol_no":"GS-US-218-0108","submission_no":"178370","status_id":1,"start_date":"2015-11-04","end_date":null,"nol_date":"2014-10-24","protocol_title":"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED MULTI-CENTER STUDY EVALUATING ANTIVIRAL EFFECTS, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF GS 5806 IN HEMATOPOIETIC CELL TRANSPLANT (HCT) RECIPIENTS WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION OF THE UPPER RESPIRATORY TRACT","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38357,"protocol_no":"14-357-BMD","submission_no":"181804","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-17","protocol_title":"METFORMIN AND NEO-ADJUVANT TEMOZOLOMIDE AND HYPOFRACTIONATED ACCELERATED LIMITED-MARGIN RADIOTHERAPY FOLLOWED BY ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH GLIOBLASTOMA MULTIFORME: A PHASE II STUDY (M-HARTT STUDY)","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41001,"protocol_no":"CMX001-307","submission_no":"189921","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-17","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BRINCIDOFOVIR (BCV) VERSUS VALGANCICLOVIR (VGCV) FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN CMV-SEROPOSITIVE KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED ANTILYMPHOCYTE INDUCTION THERAPY","medConditionList":[{"med_condition_id":62,"med_condition":"CYTOMEGALOVIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37005,"protocol_no":"15832","submission_no":"177218","status_id":2,"start_date":"2015-03-02","end_date":"2016-11-01","nol_date":"2014-12-19","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL- GROUP, MULTI-CENTER PHASE IIB STUDY TO ASSESS THE EFFICACY AND SAFETY OF DIFFERENT DOSE COMBINATIONS OF AN AROMATASE INHIBITOR AND A PROGESTIN IN AN INTRAVAGINAL RING VERSUS PLACEBO AND LEUPRORELIN / LEUPROLIDE ACETATE IN WOMEN WITH SYMPTOMATIC ENDOMETRIOSIS OVER A 12-WEEK TREATMENT PERIOD","medConditionList":[{"med_condition_id":74,"med_condition":"ENDOMETRIOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37470,"protocol_no":"IM128-027","submission_no":"178727","status_id":1,"start_date":"2015-12-15","end_date":null,"nol_date":"2014-11-13","protocol_title":"A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BMS-931699 VS. PLACEBO ON A BACKGROUND OF LIMITED STANDARD OF CARE IN THE TREATMENT OF SUBJECTS WIHT ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS","medConditionList":[{"med_condition_id":473,"med_condition":"LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27040,"protocol_no":"SP848","submission_no":"164567","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-06-05","protocol_title":"AN OPEN-LABEL STUDY TO DETERMINE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM ORAL LACOSAMIDE (LCM) AS ADJUNCTIVE THERAPY IN CHILDREN WITH EPILEPSY.","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26362,"protocol_no":"REB# 2012-023","submission_no":"162568","status_id":1,"start_date":"2013-01-01","end_date":null,"nol_date":"2013-04-17","protocol_title":"INVESTIGATION AND OPTIMIZATION OF THE ANTIDEPRESSANT ACTION OF KETAMINE IN TREATMENT-RESISTANT DEPRESSION","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26818,"protocol_no":"DSC 127-2012-02","submission_no":"163902","status_id":2,"start_date":"2014-06-09","end_date":"2015-11-13","nol_date":"2013-05-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, VEHICLE AND STANDARD OF CARE-CONTROLLED PHASE 3 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DSC127 IN TREATING NON-HEALING FOOT ULCERS IN SUBJECTS WITH DIABETES MELLITUS","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48500,"protocol_no":"RPC01-3201","submission_no":"214073","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-26","protocol_title":"INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN¬øS DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27985,"protocol_no":"178-CL-102","submission_no":"167252","status_id":1,"start_date":"2014-04-23","end_date":null,"nol_date":"2013-09-05","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF COMBINATION OF SOLIFENACIN SUCCINATE WITH MIRABEGRON COMPARED TO SOLIFENACIN SUCCINATE AND MIRABEGRON MONOTHERAPY IN SUBJECTS WITH OVERACTIVE BLADDER","medConditionList":[{"med_condition_id":185,"med_condition":"OVERACTIVE BLADDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27975,"protocol_no":"OXY-R07-2013","submission_no":"167206","status_id":2,"start_date":"2015-07-08","end_date":"2017-01-31","nol_date":"2013-09-03","protocol_title":"THE TRIAL TITLE IS, INTRANASAL OXYTOCIN FOR THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDERS (ASD).","medConditionList":[{"med_condition_id":354,"med_condition":"AUTISM"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38884,"protocol_no":"GLH694-P001","submission_no":"183506","status_id":2,"start_date":"2015-08-04","end_date":"2018-02-27","nol_date":"2015-05-04","protocol_title":"ADDITIVE EFFECT OF TWICE DAILY BRINZOLAMIDE 1% /BRIMONIDINE 0.2% FIXED DOSE COMBINATION AS AN ADJUNCTIVE THERAPY TO A PROSTAGLANDIN ANALOGUE","medConditionList":[{"med_condition_id":89,"med_condition":"GLAUCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36576,"protocol_no":"B7461001","submission_no":"175829","status_id":1,"start_date":"2014-12-12","end_date":null,"nol_date":"2014-07-22","protocol_title":"PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28213,"protocol_no":"V118_05","submission_no":"167961","status_id":1,"start_date":"2013-11-06","end_date":null,"nol_date":"2013-10-01","protocol_title":"A PHASE III, STRATIFIED, RANDOMIZED, OBSERVER BLIND, CONTROLLED, MULTICENTER CLINICAL STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND EFFICACY OF AN ADJUVANTED QUADRIVALENT SUBUNIT INFLUENZA VIRUS VACCINE COMPARED TO NON-ADJUVANT COMPARATOR VACCINE IN CHILDREN >6 TO >72 MONTHS OF AGE","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35394,"protocol_no":"RQHR070113","submission_no":"172197","status_id":1,"start_date":"2016-02-15","end_date":null,"nol_date":"2014-03-20","protocol_title":"THE EFFECT OF TRANEXAMIC ACID IN RUPTURED ABDOMINAL AORTIC ANEURYSMS","medConditionList":[{"med_condition_id":419,"med_condition":"AORTIC ANEURYSM"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27520,"protocol_no":"M-40464-39","submission_no":"165899","status_id":2,"start_date":"2013-10-16","end_date":"2014-09-30","nol_date":"2013-07-17","protocol_title":"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF TWICE-DAILY ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE COMPARED WITH TWICE-DAILY SALMETEROL/FLUTICASONE PROPIONATE FOR 24 WEEKS TREATMENT IN SYMPTOMATIC PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45716,"protocol_no":"ITCA 650-CLP-203","submission_no":"205290","status_id":1,"start_date":"2017-06-21","end_date":null,"nol_date":"2017-05-24","protocol_title":"A PHASE 3B, RANDOMIZED, ACTIVE COMPARATOR, OPEN-LABEL, MULTICENTER STUDY TO COMPARE THE EFFICACY, SAFETY, AND TOLERABILITY OF ITCA 650 TO EMPAGLIFLOZIN AND TO GLIMEPIRIDE AS ADD-ON","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40256,"protocol_no":"ALXN1210-PNH-201","submission_no":"187523","status_id":1,"start_date":"2016-01-20","end_date":null,"nol_date":"2015-10-07","protocol_title":"\"A PHASE 2, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY,IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ALXN1210 ADMINISTERED  INTRAVENOUSLY  TO PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA,\"","medConditionList":[{"med_condition_id":649,"med_condition":"PAROXYSMAL NOCTURNAL HEMOGLOBINURIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38044,"protocol_no":"NCT02126020","submission_no":"180648","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-01-09","protocol_title":"TOPICAL INFLIXIMAB IN AUTOIMMUNE EYES WITH KERATOPROSTHESIS","medConditionList":[{"med_condition_id":596,"med_condition":"KERATOPROSTHESIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28727,"protocol_no":"1237.26","submission_no":"169572","status_id":2,"start_date":"2014-04-29","end_date":"2015-03-10","nol_date":"2013-11-28","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY OF 12 WEEKS OF ONCE DAILY TREATMENT OF TWO DOSES OF ORALLY INHALED TIOTROPIUM + OLODATEROL FIXED DOSE COMBINATION (DELIVERED BY THE RESPIMAT¬Æ INHALER) IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42108,"protocol_no":"RP-317-07302014","submission_no":"193934","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-04-29","protocol_title":"TREATMENT OF UTERINE FIBROIDS WITH MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND","medConditionList":[{"med_condition_id":333,"med_condition":"UTERINE FIBROIDS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43724,"protocol_no":"ALXN1210-PNH-301","submission_no":"199007","status_id":1,"start_date":"2016-12-13","end_date":null,"nol_date":"2016-11-03","protocol_title":"A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF ALXN1210 VERSUS ECULIZUMAB IN COMPLEMENT INHIBITOR-NAIVE ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)","medConditionList":[{"med_condition_id":649,"med_condition":"PAROXYSMAL NOCTURNAL HEMOGLOBINURIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48758,"protocol_no":"EMBRACE 2","submission_no":"214905","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-04-24","protocol_title":"\"IMAGE GUIDED INTENSITY MODULATED EXTERNAL BEAM RADIOCHEMOTHERAPY AND MRI BASED ADAPTIVE BRACHYTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER\".","medConditionList":[{"med_condition_id":356,"med_condition":"CERVICAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37561,"protocol_no":"TS-C1","submission_no":"179028","status_id":1,"start_date":"2014-12-01","end_date":null,"nol_date":"2014-12-10","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER PILOT TRIAL OF MEDICAL CANNABIS IN ADULTS WITH TOURETTE SYNDROME.","medConditionList":[{"med_condition_id":252,"med_condition":"TOURETTE¬íS SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28440,"protocol_no":"15829","submission_no":"168564","status_id":1,"start_date":"2013-11-28","end_date":null,"nol_date":"2013-10-30","protocol_title":"A RANDOMIZED PARALLEL-GROUP, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTI-CENTER DOSE FINDING PHASE II TRIAL EXPLORING THE PHARMACODYNAMIC EFFECTS, SAFETY AND TOLERABILITY, AND PHARMACOKINETICS OF FOUR DOSE REGIMENS OF THE ORAL SGC STIMULATOR BAY 1021189 OVER 12 WEEKS IN PATIENTS WITH WORSENING HEART FAILURE AND PRESERVED EJECTION FRACTION (HFPEF) - SOLUBLE GUANYLATE CYCLASE STIMULATOR IN HEART FAILURE PATIENTS WITH PRESERVED EF (SOCRATES-PRESERVED) STUDY.","medConditionList":[{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45179,"protocol_no":"D8540C00001","submission_no":"203611","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-18","protocol_title":"A PHASE 1 MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY AND ANTITUMOR ACTIVITY OF MEDI7247 IN PATIENTS WITH SELECTED RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47330,"protocol_no":"ML-39576","submission_no":"210582","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-28","protocol_title":"A PHASE II TRIAL OF TRANSURETHRAL SURGERY FOLLOWED BY A COMBINATION OF ATEZOLIZUMAB (TECENTRIQ) AN ANTI-PDL-1 (MPDL3280A) WITH TRIMODAL THERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER","medConditionList":[{"med_condition_id":625,"med_condition":"BLADDER CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36320,"protocol_no":"1160.105","submission_no":"175058","status_id":2,"start_date":"2015-01-22","end_date":"2016-05-03","nol_date":"2014-06-25","protocol_title":"OPEN-LABEL, SINGLE DOSE, TOLERABILITY, PHARMACOKINETIC/PHARMACODYNAMICS AND SAFETY STUDY OF DABIGATRAN ETEXILATE GIVEN AT THE END OF STANDARD ANTICOAGULANT THERAPY IN CHILDREN AGED LESS THAN 1 YEAR OLD.","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36655,"protocol_no":"AR-13324-CS303","submission_no":"176144","status_id":2,"start_date":"2014-07-29","end_date":"2016-12-07","nol_date":"2014-07-21","protocol_title":"A DOUBLE-MASKED, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, PARALLEL, 12-MONTH STUDY ASSESSING THE SAFETY OF AR-13324 OPHTHALMIC SOLUTION, 0.02% Q.D. AND B.I.D. COMPARED TO TIMOLOL MALEATE OPHTHALMIC SOLUTION, 0.5% B.I.D. IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE","medConditionList":[{"med_condition_id":89,"med_condition":"GLAUCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47704,"protocol_no":"BB2121-MM-001","submission_no":"211603","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-22","protocol_title":"A PHASE 2, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF BB2121 IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA.","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27308,"protocol_no":"OZM-051","submission_no":"165338","status_id":1,"start_date":"2014-10-20","end_date":null,"nol_date":"2013-07-11","protocol_title":"A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY","medConditionList":[{"med_condition_id":148,"med_condition":"LYMPHOBLASTIC LEUKEMIA"},{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39897,"protocol_no":"EBV-TCL-01","submission_no":"186585","status_id":1,"start_date":"2015-11-17","end_date":null,"nol_date":"2015-09-03","protocol_title":"A PHASE I/II OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF EPSTEIN-BARR VIRUS SPECIFIC T-CELL LINES FOR THE TREATMENT OF EBV INFECTION OR EBV-RELATED LYMPHOPROLIFERATIVE DISEASES","medConditionList":[{"med_condition_id":640,"med_condition":"EPSTEIN-BARR VIRUS (EBV) INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38036,"protocol_no":"PTC596-ONC-001-AST","submission_no":"180635","status_id":2,"start_date":"2016-03-30","end_date":"2017-01-16","nol_date":"2015-01-08","protocol_title":"A PHASE 1 STUDY OF PTC596 IN PATIENTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26992,"protocol_no":"R668-AD-1021","submission_no":"164436","status_id":1,"start_date":"2013-09-25","end_date":null,"nol_date":"2013-05-29","protocol_title":"\"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY INVESTIGATING THE EFFICACY, SAFETY, PHARMACOKINETIC AND BIOMARKER PROFILES OF REGN668 ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.\"","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28607,"protocol_no":"SPI-GCF-12-201","submission_no":"169143","status_id":3,"start_date":"2014-03-13","end_date":null,"nol_date":"2013-11-27","protocol_title":"PHASE 2, OPEN-LABEL, DOSE-RANGING STUDY OF HM10460A OR PEGFILGRASTIM USE FOR THE MANAGEMENT OF NEUTROPENIA IN PATIENTS WITH BREAST CANCER WHO ARE CANDIDATES FOR ADJUVANT AND NEOADJUVANT CHEMOTHERAPY WITH THE DOCETAXEL+CYCLOPHOSPHAMIDE (TC) REGIMEN","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48751,"protocol_no":"D933MC00001","submission_no":"214854","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-04-23","protocol_title":"\"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF DURVALUMAB IN COMBINATION WITH EPACADOSTAT IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE NON-SMALL CELL LUNG CANCER (STAGE III) WHO HAVE NOT PROGRESSED FOLLOWING DEFINITIVE, PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC-3/ECHO-312)\".","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43549,"protocol_no":"RVT-501-2001","submission_no":"198401","status_id":2,"start_date":"2016-12-15","end_date":"2017-07-03","nol_date":"2016-10-14","protocol_title":"PHASE 2 STUDY OF RVT-501 IN ADULT AND ADOLESCENT SUBJECTS WITH ATOPIC DERMATITIS.","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36168,"protocol_no":"DRCR.NET","submission_no":"174704","status_id":1,"start_date":"2014-06-20","end_date":null,"nol_date":"2014-06-12","protocol_title":"TREATMENT FOR CENTRAL-INVOLVED DIABETIC MACULAR EDEMA IN EYES WITH VERY GOOD VISUAL ACUITY","medConditionList":[{"med_condition_id":151,"med_condition":"MACULAR EDEMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38267,"protocol_no":"CL2-78989-011","submission_no":"181444","status_id":1,"start_date":"2015-05-05","end_date":null,"nol_date":"2015-02-19","protocol_title":"DOSE-RESPONSE STUDY OF GEVKIZUMAB (S78989) 3MG, 10MG, 30MG OR 60MG IN PATIENTS WITH TYPE 2 DIABETES AND DIABETIC KIDNEY DISEASE (DKD). A 66-WEEK, INTERNATIONAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO CONTROLLED STUDY","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40628,"protocol_no":"M14-465","submission_no":"188666","status_id":1,"start_date":"2016-02-29","end_date":null,"nol_date":"2015-11-19","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING ABT-494 TO PLACEBO AND TO ADALIMUMAB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO ARE ON A STABLE BACKGROUND OF METHOTREXATE (MTX) AND WHO HAVE AN INADEQUATE RESPONSE TO MTX (MTX-IR)","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40849,"protocol_no":"ARC003","submission_no":"189441","status_id":2,"start_date":"2017-11-10","end_date":"2018-03-08","nol_date":"2015-12-10","protocol_title":"PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (THE PALISADE STUDY)","medConditionList":[{"med_condition_id":12,"med_condition":"ALLERGIES PEANUT"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41129,"protocol_no":"NCIC CTG: IND.229","submission_no":"190421","status_id":1,"start_date":"2016-04-19","end_date":null,"nol_date":"2016-01-06","protocol_title":"A PHASE 1B PHARMACODYNAMIC STUDY OF DURVALUMAB (MEDI4736) IN PATIENTS WITH HER-2 POSITIVE METATSTATIC  BREAST CANCER (MBC) RECEIVING TRASTUMUZAB","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44822,"protocol_no":"205687","submission_no":"202557","status_id":1,"start_date":"2017-07-26","end_date":null,"nol_date":"2017-03-03","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHIII STUDY TO ASSESS THE CLINICAL EFFICACY AND SAFETY OF 100 MG SC MEPOLIZUMAB AS AN ADD ON TO MAINTENANCE TREATMENT IN ADULTS WITH SEVERE BILATERAL NASAL POLYPS","medConditionList":[{"med_condition_id":759,"med_condition":"NASAL POLYPOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41281,"protocol_no":"B9991003","submission_no":"191090","status_id":1,"start_date":"2017-02-08","end_date":null,"nol_date":"2016-02-04","protocol_title":"A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA) VERSUS SUNITINIB (SUTENT) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39826,"protocol_no":"VX14-787-103","submission_no":"186365","status_id":2,"start_date":"2016-05-13","end_date":"2016-04-09","nol_date":"2015-08-18","protocol_title":"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF 2 DOSE LEVELS OF VX-787 ADMINISTERED AS MONOTHERAPY AND ONE DOSE LEVEL OF VX-787 ADMINISTERED IN COMBINATION WITH OSELTAMIVIR FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A IN ADULT SUBJECTS","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46045,"protocol_no":"R2810-ONC-1676 / GOG-3016","submission_no":"206183","status_id":1,"start_date":"2018-01-17","end_date":null,"nol_date":"2017-07-11","protocol_title":"AN OPEN-LABEL, RANDOMIZED, PHASE 3 CLINICAL TRIAL OF REGN2810 VERSUS THERAPY OF INVESTIGATOR'S CHOICE CHEMOTHERAPY IN RECURRENT OR METASTATIC PLATINUM-REFRACTORY CERVICAL CARCINOMA","medConditionList":[{"med_condition_id":356,"med_condition":"CERVICAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35939,"protocol_no":"B1481022","submission_no":"174021","status_id":1,"start_date":"2014-08-13","end_date":null,"nol_date":"2014-05-16","protocol_title":"PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS","medConditionList":[{"med_condition_id":538,"med_condition":"MAJOR CARDIOVASCULAR EVENTS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37025,"protocol_no":"BBCO-001","submission_no":"177282","status_id":1,"start_date":"2015-03-20","end_date":null,"nol_date":"2014-09-15","protocol_title":"MULTI-CENTER, DOSE-ESCALATION STUDY, TO ASSESS SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS CABALETTA¬Æ IN OPMD PATIENTS","medConditionList":[{"med_condition_id":573,"med_condition":"OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40530,"protocol_no":"181501","submission_no":"188417","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-06","protocol_title":"A PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS INFUSION WITH HUMAN SOLUBLE RECOMBINANT FC-GAMMA RECEPTOR IIB (SM101/ BAX 1810) IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN)","medConditionList":[{"med_condition_id":655,"med_condition":"IMMUNOGLOBULIN A NEPHROPATHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38368,"protocol_no":"M13-740","submission_no":"181852","status_id":2,"start_date":"2015-07-28","end_date":"2017-04-19","nol_date":"2015-03-03","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABT-494 FOR THE INDUCTION OF SYMPTOMATIC AND ENDOSCOPIC REMISSION IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE INADEQUATELY RESPONDED TO OR ARE INTOLERANT TO ANTI-TNF THERAPY","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26732,"protocol_no":"WA28117","submission_no":"163642","status_id":1,"start_date":"2013-11-06","end_date":null,"nol_date":"2013-05-02","protocol_title":"\"A PHASE IBM OPEN-LABEL, MULTI-CENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS.\"","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45431,"protocol_no":"AB / VGFT-DME-1668","submission_no":"204406","status_id":1,"start_date":"2017-05-08","end_date":null,"nol_date":"2017-05-01","protocol_title":"INTRAVITIREOUS ANTI-VEGF VS. PROMPT VITRECTOMY FOR VITREOUS HEMMORHAGE FROM PROLIFERATIVE DIABETIC RETINOPATHY","medConditionList":[{"med_condition_id":784,"med_condition":"VITREOUS HEMORRHAGE"},{"med_condition_id":783,"med_condition":"DIABETIC RETINOPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47008,"protocol_no":"CX-839-005","submission_no":"209459","status_id":2,"start_date":"2017-12-22","end_date":"2018-01-17","nol_date":"2017-10-10","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING CB-839 IN COMBINATION WITH EVEROLIMUS (CBE) VS. PLACEBO WITH EVEROLIMUS (PBOE) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA (RCC)","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46827,"protocol_no":"MOR208C204","submission_no":"208815","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-27","protocol_title":"A PHASE II/IIIL, RANDOMISED, MULTICENTRE STUDY OF MOR00208 WITH BENDAMUSTINE VERSUS RITUXIMAB WITH BENDAMUSTINE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) WHO ARE NOT ELIGIBLE FOR HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT)-B-MIND","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27168,"protocol_no":"15962","submission_no":"165012","status_id":2,"start_date":"2015-08-18","end_date":"2017-02-01","nol_date":"2013-06-21","protocol_title":"MULTICENTER OPEN-LABEL STUDY TO EVALUATE EFFICACY OF GADOBUTROL-ENHANCED CARDIAC MAGNETIC RESONANCE IMAGING (CMRI) FOR DETECTION OF SIGNIFICANT CORONARY ARTERY DISEASE (CAD) IN SUBJECTS WITH KNOWN OR SUSPECTED CAD BY A BLINDED IMAGE ANALYSIS","medConditionList":[{"med_condition_id":56,"med_condition":"CORONARY HEART DISEASE OR HIGH RISK OF CORONONARY HEART DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45530,"protocol_no":"CEMA401A2201","submission_no":"204416","status_id":1,"start_date":"2018-02-13","end_date":null,"nol_date":"2017-05-10","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED DOSE RANGING TRIAL TO DETERMINE THE SAFETY AND EFFICACY OF THREE DOSE LEVELS OF EMA401 IN REDUCING 24-HOUR AVERAGE PAIN INTENSITY SCORE IN PATIENTS WITH POST-HERPETIC NEURALGIA (EMPHENE)","medConditionList":[{"med_condition_id":202,"med_condition":"POST-HERPETIC NEURALGIA (PHN)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28236,"protocol_no":"130210","submission_no":"168005","status_id":2,"start_date":"2013-11-16","end_date":"2014-04-13","nol_date":"2013-10-04","protocol_title":"OPEN-LABEL, 4-PART, MULTIPLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETIC PROFILE, SAFETY, AND TOLERABILITY OF DIFFERENT DOSES OF TESTOSTERONE UNDECANOATE IN HYPOGONADAL SUBJECTS","medConditionList":[{"med_condition_id":125,"med_condition":"HYPOGONADAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27802,"protocol_no":"SPC-SER120-DB4-201301","submission_no":"166740","status_id":1,"start_date":"2013-08-28","end_date":null,"nol_date":"2013-08-20","protocol_title":"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SER120 NASAL SPRAY FORMULATION IN PATIENTS WITH NOCTURIA","medConditionList":[{"med_condition_id":175,"med_condition":"NOCTURIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26933,"protocol_no":"PTC124-GD-020-DMD","submission_no":"164252","status_id":2,"start_date":"2014-08-25","end_date":"2015-08-19","nol_date":"2013-05-14","protocol_title":"A PHASE 3 EFFICACY AND SAFETY STUDY OF ATALUREN (PTC124) IN PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY","medConditionList":[{"med_condition_id":318,"med_condition":"NONSENSE MUTATION DYSTROPHINOPATHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28844,"protocol_no":"CC-122-DLBCL-001","submission_no":"170058","status_id":1,"start_date":"2015-08-11","end_date":null,"nol_date":"2013-12-23","protocol_title":"A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC 292 AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36629,"protocol_no":"CDEB025A2221","submission_no":"176041","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-23","protocol_title":"A MULTICENTER, OPEN-LABEL, PARTIALLY RANDOMIZED, PARALLEL-GROUP, ADAPTIVE DESIGN, PHASE II STUDY ON EFFICACY AND SAFETY OF DEB025/ALISPORIVIR IN COMBINATION WITH RG7128/MERICITABINE PLUS RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT-NA√èVE, GENOTYPE 3 PREVIOUS TREATMENT-FAILURE, AND GENOTYPE 3 CIRRHOTIC PATIENTS","medConditionList":[{"med_condition_id":108,"med_condition":"HEPATITIS C VIRUS GENOTYPE 3"},{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28579,"protocol_no":"RM08-3002","submission_no":"169043","status_id":1,"start_date":"2013-11-27","end_date":null,"nol_date":"2013-11-13","protocol_title":"A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NITAZOXANIDE AND NITAZOXANIDE PLUS OSELTAMIVIR IN THE TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44114,"protocol_no":"1002-046","submission_no":"200163","status_id":1,"start_date":"2017-02-13","end_date":null,"nol_date":"2016-12-08","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BEMPEDOIC ACID (ETC-1002) 180 MG COMPARED TO PLACEBO ADDED TO BACKGROUND LIPID-MODIFYING THERAPY IN PATIENTS WITH ELEVATED LDL-C WHO ARE STATIN INTOLERANT","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36330,"protocol_no":"THEOPHYLLINE 1.0","submission_no":"175079","status_id":1,"start_date":"2014-09-24","end_date":null,"nol_date":"2014-07-11","protocol_title":"A PHASE I, SINGLE-CENTER, NON-RANDOMIZED, OPEN LABEL, STUDY TO DETERMINE THE LOWEST EFFECTIVE THEOPHYLLINE DOSE THAT DECREASES DIARRHEA AT THE STANDARD ERLOTINIB DOSE OF 150 MG/DAY AND TO DETERMINE THE HIGHEST ERLOTINIB DOSE IN COMBINATION WITH THEOPHYLLINE THAT CAN BE ADMINISTERED TO PATIENTS","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48066,"protocol_no":"56136379HPB2001","submission_no":"212842","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-15","protocol_title":"A PHASE 2A, RANDOMIZED, PARTIALLY-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF 24 WEEKS OF TREATMENT WITH MULTIPLE DOSES OF JNJ-56136379 AS MONOTHERAPY AND IN COMBINATION WITH A NUCLEOS(T)IDE ANALOG IN SUBJECTS WITH CHRONIC HEPATITIS B VIRUS INFECTION","medConditionList":[{"med_condition_id":103,"med_condition":"HEPATITIS B VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36797,"protocol_no":"ISIS 304801-CS6","submission_no":"176599","status_id":2,"start_date":"2015-12-31","end_date":"2017-01-10","nol_date":"2014-08-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF ISIS 304801 ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)","medConditionList":[{"med_condition_id":82,"med_condition":"FAMILIAL CHYLOMICRONEMIA SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43060,"protocol_no":"IND.228","submission_no":"197013","status_id":1,"start_date":"2016-11-20","end_date":null,"nol_date":"2016-08-18","protocol_title":"A PHASE II STUDY OF DURVALUMAB AND TREMELIMUMAB IN PATIENTS WITH ADVANCED RARE TUMOURS","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43135,"protocol_no":"361","submission_no":"197278","status_id":1,"start_date":"2016-11-04","end_date":null,"nol_date":"2016-08-25","protocol_title":"A PHASE III RANDOMIZED, CONTROLLED CLINICAL TRIAL OF PEMBROLIZUMAB WITH OR WITHOUT PLATINUM-BASED COMBINATION CHEMOTHERAPY VERSUS CHEMOTHERAPY IN SUBJECTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47253,"protocol_no":"NP30179","submission_no":"210353","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-17","protocol_title":"A MULTICENTER, OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF RO7082859, ADMINISTERED AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB (GAZYVA/GAZYVARO) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NONHODGKIN'S LYMPHOMA","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40754,"protocol_no":"CLKA651X2101A","submission_no":"189029","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-02","protocol_title":"A RANDOMIZED, SHAM CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS ACTIVITY OF INTRAVITREAL LKA651 IN PATIENTS WITH DIABETIC MACULAR EDEMA","medConditionList":[{"med_condition_id":151,"med_condition":"MACULAR EDEMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26701,"protocol_no":"225-2012","submission_no":"163520","status_id":1,"start_date":"2013-05-03","end_date":null,"nol_date":"2013-05-01","protocol_title":"EVALUATING THE EFFECTS OF VARENICLINE ON SMOKING LAPSE IN SMOKERS WITH AND WITHOUT SCHIZOPHRENIA: IMPLICATIONS FOR TREATMENT","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42074,"protocol_no":"OZM-067","submission_no":"193828","status_id":1,"start_date":"2016-12-22","end_date":null,"nol_date":"2016-05-13","protocol_title":"A PROSPECTIVE SINGLE-ARM, MULTI-CENTRE, STUDY OF THE EFFICACY AND SAFETY OF LUTETIUM-177 OCTREOTATE (LU-DOTATATE) TREATMENT WITH INDIVIDUALIZED DOSIMETRY IN PATIENTS WITH 68GA-DOTATATE IDENTIFIED SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS","medConditionList":[{"med_condition_id":633,"med_condition":"NEUROENDOCRINE TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28625,"protocol_no":"H13-147","submission_no":"169218","status_id":1,"start_date":"2015-02-19","end_date":null,"nol_date":"2013-11-22","protocol_title":"AN OBSERVATIONAL, MULTICENTER, DISEASE REGISTRY TO EVALUATE CLINICAL PRACTICE TRENDS AND OUTCOMES IN ADULT PATIENTS WITH HIDRADENTISSUPPURATIVA-UNITE","medConditionList":[{"med_condition_id":112,"med_condition":"HIDRADENITIS SUPPURATIVA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37086,"protocol_no":"ASBI 802","submission_no":"177466","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-09-24","protocol_title":"A PHASE 2, MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUN13837 ADMINISTERED 28 DOSES (27/28 DAYS) TO ADULT SUBJECTS WITH AN ACUTE ISCHEMIC STROKE","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46324,"protocol_no":"CQVJ499A2404","submission_no":"207131","status_id":1,"start_date":"2017-10-10","end_date":null,"nol_date":"2017-08-02","protocol_title":"A 6-WEEK, DOUBLE MASKED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY BRINZOLAMIDE 1% / BRIMONIDINE 0.2% FIXED DOSE COMBINATION AS AN ADJUNCTIVE THERAPY TO TRAVOPROST 0.004% IN REDUCING INTRAVOCULAR PRESSURE IN PATIENTS WITH NORMAL TENSION GLAUCOMA.","medConditionList":[{"med_condition_id":89,"med_condition":"GLAUCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29377,"protocol_no":"RHB-104-01","submission_no":"171658","status_id":1,"start_date":"2015-05-01","end_date":null,"nol_date":"2014-02-24","protocol_title":"A PHASE III RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION RHB-104 IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42640,"protocol_no":"AF219-012","submission_no":"195655","status_id":2,"start_date":null,"end_date":"2016-11-30","nol_date":"2016-07-29","protocol_title":"A 12-WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF AF-219 IN SUBJECTS WITH TREATMENT REFRACTORY CHRONIC COUGH","medConditionList":[{"med_condition_id":42,"med_condition":"CHRONIC COUGH"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36732,"protocol_no":"PIMOZIDE_ALS-001","submission_no":"176396","status_id":1,"start_date":"2015-04-08","end_date":null,"nol_date":"2014-08-22","protocol_title":"A PROOF-OF-PRINCIPLE PILOT RANDOMIZED, CONTROLLED, DOUBLE-BLINDED CLINICAL TRIAL OF PIMOZIDE IN PATIENTS WITH NEUROMUSCULAR JUNCTION TRANSMISSION DYSFUNCTION DUE TO AMYOTROPHIC LATERAL SCLEROSIS","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38063,"protocol_no":"SWI-01-14","submission_no":"180703","status_id":1,"start_date":"2015-03-02","end_date":null,"nol_date":"2015-01-19","protocol_title":"TOPICAL USE OF VANCOMYCIN IN REDUCING STERNAL WOUND INFECTION IN CARDIAC SURGERY","medConditionList":[{"med_condition_id":552,"med_condition":"PROPHYLAXIS OF INFECTIONS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37694,"protocol_no":"DOM_MS01","submission_no":"179462","status_id":1,"start_date":"2015-02-02","end_date":null,"nol_date":"2014-11-28","protocol_title":"OPEN-LABEL, SINGLE-CENTER, SINGLE-ARM FUTILITY TRIAL EVALUATING ORAL DOMPERIDONE 10MG QID FOR REDUCING PROGRESSION OF DISABILITY IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42070,"protocol_no":"EIG-UBX-001","submission_no":"193816","status_id":1,"start_date":"2016-11-20","end_date":null,"nol_date":"2016-04-29","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF UBENIMEX IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) (LIBERTY)","medConditionList":[{"med_condition_id":218,"med_condition":"PULMONARY ARTERIAL HYPERTENSION (PAH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36896,"protocol_no":"M14-490","submission_no":"176897","status_id":2,"start_date":"2015-04-28","end_date":"2015-11-26","nol_date":"2014-08-26","protocol_title":"AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OMBITASVIR/ABT-450/ RITONAVIR AND DASABUVIR IN ADULTS WITH GENOTYPE 1B CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AND CIRRHOSIS (TURQUOISE-III).","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28686,"protocol_no":"20130692-01H","submission_no":"169424","status_id":2,"start_date":"2013-12-17","end_date":"2017-04-24","nol_date":"2013-12-06","protocol_title":"OPTIMIZATION OF CARDIAC IODINE-123 META-IODOBENZYLGUANDINE (123I-MIBG) SPECT IMAGING","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46464,"protocol_no":"ALN-AT3SC-004","submission_no":"207661","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-14","protocol_title":"A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FITUSIRAN IN PATIENTS WITH HEMOPHILIA A OR B, WITHOUT INHIBITORY ANTIBODIES TO FACTOR VIII OR IX","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"},{"med_condition_id":100,"med_condition":"HEMOPHILIA B"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42081,"protocol_no":"12709A","submission_no":"193847","status_id":1,"start_date":"2016-10-25","end_date":null,"nol_date":"2016-05-05","protocol_title":"INTERVENTIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (FLUOXETINE), FIXED-DOSE STUDY OF VORTIOXETINE IN PAEDIATRIC PATIENTS AGED 7 TO 11 YEARS, WITH MAJOR DEPRESSIVE DISORDER (MDD)","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27751,"protocol_no":"CBGJ398X2102","submission_no":"166625","status_id":2,"start_date":"2015-05-21","end_date":"2016-08-23","nol_date":"2013-08-22","protocol_title":"A PHASE IB, OPEN-LABEL STUDY OF ORAL BGJ398 IN COMBINATION WITH ORAL BYL719 IN ADULT PATIENTS WITH SELECT ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37755,"protocol_no":"052","submission_no":"179645","status_id":1,"start_date":"2015-04-13","end_date":null,"nol_date":"2014-12-12","protocol_title":"A PHASE II CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) IN SUBJECTS WITH ADVANCED/UNRESECTABLE OR METASTATIC UROTHELIAL CANCER","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36768,"protocol_no":"M14-227","submission_no":"176507","status_id":2,"start_date":"2014-09-25","end_date":"2017-03-03","nol_date":"2014-08-13","protocol_title":"AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR WITH RIBAVIRIN IN ADULTS WITH GENOTYPE 1 AND OMBITASVIR/PARITAPREVIR/RITONAVIR WITH RIBAVIRIN IN ADULTS WITH GENOTYPE 4 CHRONIC HEPATITIS C VIRUS INFECTION AND DECOMPENSATED CIRRHOSIS (TURQUOISE-CPB)","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28585,"protocol_no":"NN9535-3623 (SUSTAIN 1-MONOTHE","submission_no":"169070","status_id":1,"start_date":"2014-04-25","end_date":null,"nol_date":"2013-11-14","protocol_title":"EFFICACY AND SAFETY OF SEMAGLUTIDE ONCE-WEEKLY VERSUS PLACEBO IN DRUG-NAIVE SUBJECTS WITH TYPE 2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46504,"protocol_no":"V01-123A-302","submission_no":"207582","status_id":1,"start_date":"2017-08-29","end_date":null,"nol_date":"2017-08-16","protocol_title":"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35489,"protocol_no":"OCOG-20 13-THORIDAL","submission_no":"172566","status_id":2,"start_date":"2016-05-09","end_date":"2017-02-06","nol_date":"2014-03-28","protocol_title":"A PHASE I TRIAL EVALUATING ORAL THIORIDAZINE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE IN PATIENTS S5 YEARS AND OLDER WITH ACUTE MYELOID LEUKEMIA WHO HAVE RELAPSED OR HAVE REFRACTORY DISEASE (THORIDAL)","medConditionList":[{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40352,"protocol_no":"AGS67E-15-2","submission_no":"187785","status_id":1,"start_date":"2017-05-05","end_date":null,"nol_date":"2015-10-16","protocol_title":"A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS67E GIVEN AS MONOTHERAPY IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA (AML)","medConditionList":[{"med_condition_id":506,"med_condition":"RELAPSED OR REFRACTORY ACUTE MYELOID  LEUKEMIA (AML)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45299,"protocol_no":"LAU-14-01","submission_no":"203956","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-11","protocol_title":"APPLAUD: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE II STUDY OF THE EFFICACY AND SAFETY OF LAU-7B IN THE TREATMENT OF CYSTIC FIBROSIS IN ADULTS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37411,"protocol_no":"AOST1322","submission_no":"178494","status_id":1,"start_date":"2014-11-06","end_date":null,"nol_date":"2014-10-29","protocol_title":"A PHASE II STUDY OF ERIBULIN (IND# 122686, NSC# 707389) IN RECURRENT OR REFRACTORY OSTEOSARCOMA","medConditionList":[{"med_condition_id":586,"med_condition":"OSTEOSARCOMA"},{"med_condition_id":334,"med_condition":"SARCOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35642,"protocol_no":"B2151007","submission_no":"172980","status_id":2,"start_date":"2014-08-04","end_date":"2016-03-11","nol_date":"2014-04-17","protocol_title":"AN OPEN LABEL, MULTI CENTER, RANDOMIZED PHASE 1B/2 STUDY OF PF 05212384 PLUS 5 FLUOROURACIL LEUCOVORIN IRINOTECAN (FOLFIRI) VERSUS BEVACIZUMAB PLUS FOLFIRI IN METASTATIC COLORECTAL CANCER","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40698,"protocol_no":"0452","submission_no":"188864","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-26","protocol_title":"MECHANISM OF AMANTADINE AND FUNCTIONAL IMPROVEMENT FOLLOWING ACQUIRED BRAIN INJURY AS MEASURED BY MRI TRACTOGRAPHY; A PILOT STUDY","medConditionList":[{"med_condition_id":437,"med_condition":"TRAUMATIC BRAIN INJURY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47131,"protocol_no":"XL184-401","submission_no":"209860","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-25","protocol_title":"A RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CABOZANTINIB (XLL84) AT 60 MG/DAY COMPARED TO 140 MG/DAY IN PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER PATIENTS","medConditionList":[{"med_condition_id":250,"med_condition":"THYROID CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42749,"protocol_no":"CAMHPET-CTA-103","submission_no":"196088","status_id":1,"start_date":"2016-07-18","end_date":null,"nol_date":"2016-07-14","protocol_title":"INCUBATION OF CRAVING IN HUMAN SMOKERS: A [11C]-(+)-PHNO STUDY","medConditionList":[{"med_condition_id":236,"med_condition":"SMOKING CESSATION"},{"med_condition_id":711,"med_condition":"POSITRON EMISSION TOMOGRAPHY (PET)"},{"med_condition_id":420,"med_condition":"ADDICTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28854,"protocol_no":"AM-101-CL-12-01","submission_no":"170084","status_id":2,"start_date":"2014-02-20","end_date":"2016-06-22","nol_date":"2013-12-23","protocol_title":"EFFICACY AND SAFETY OF AM-101 IN THE TREATMENT OF ACUTE PERIPHERAL TINNITUS 2 (TACTT2)","medConditionList":[{"med_condition_id":451,"med_condition":"TINNITUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44439,"protocol_no":"PRO00067564","submission_no":"201291","status_id":1,"start_date":"2017-08-14","end_date":null,"nol_date":"2017-01-17","protocol_title":"CLINICAL STUDY USING ANTIAGING GLYCOPEPTIDE (PKX-001) IN ISLET TRANSPLANTATION","medConditionList":[{"med_condition_id":135,"med_condition":"ISLET TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37513,"protocol_no":"200977","submission_no":"178839","status_id":1,"start_date":"2014-12-08","end_date":null,"nol_date":"2014-11-05","protocol_title":"ALBIGLUTIDE + INSULIN GLARGINE VERSUS INSULIN LISPRO + INSULINE GLARGINE IN THE TREATMENT OF SUBJECTS WITH TYPE 2 DIABETES MELLITUS:  THE SWITCH STUDY","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46850,"protocol_no":"D0816C00018","submission_no":"208874","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-27","protocol_title":"A PHASE IIIB, SINGLE-ARM, OPEN-LABEL MULTICENTRE STUDY OF OLAPARIB MONOTHERAPY IN THE TREATMENT OF HER2-VE METASTATIC BREAST CANCER PATIENTS WITH GERMLINE BRCA1/2 MUTATIONS","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"},{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46874,"protocol_no":"201550","submission_no":"208943","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-28","protocol_title":"A DOUBLE-BLIND SAFETY AND EFFICACY STUDY OF GSK2894512 VERSUS VEHICLE IN THE TREATMENT OF ADULT ATOPIC DERMATITIS, PROTOCOL 201550, PHASE III.","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41747,"protocol_no":"COG AOST1521","submission_no":"192529","status_id":1,"start_date":"2016-04-29","end_date":null,"nol_date":"2016-03-22","protocol_title":"A PHASE 2 STUDY OF GPNMB-TARGETED ANTIBODY-DRUG CONJUGATE, CDX-011 (GLEMBATUMUMAB VEDOTIN, CR011-VCMMAE), IN RECURRENT OR REFRACTORY OSTEOSARCOMA","medConditionList":[{"med_condition_id":586,"med_condition":"OSTEOSARCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41729,"protocol_no":"PR-30-5017-C","submission_no":"192473","status_id":1,"start_date":"2017-05-27","end_date":null,"nol_date":"2016-03-17","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43805,"protocol_no":"M15-531","submission_no":"199255","status_id":2,"start_date":"2017-03-01","end_date":"2017-11-29","nol_date":"2016-11-08","protocol_title":"A RANDOMIZED PHASE 2 STUDY EVALUATING THE SAFETY, PHARMACOKINETICS AND EFFICACY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE COMPARED WITH AZACITIDINE ALONE IN SUBJECTS WITH TREATMENT-NA√èVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44396,"protocol_no":"M15-562","submission_no":"199279","status_id":1,"start_date":"2017-05-26","end_date":null,"nol_date":"2017-01-11","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE DOSE STUDY TO ASSESS EFFICACY, SAFETY,TOLERABILITY, AND PHARMACOKINETICS OF ABBV-8E12 IN PROGRESSIVE SUPRANUCLEAR PALSY","medConditionList":[{"med_condition_id":768,"med_condition":"PROGRESSIVE SUPRANUCLEAR PALSY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42765,"protocol_no":"I5Q-MC-CGAR","submission_no":"196168","status_id":1,"start_date":"2017-09-12","end_date":null,"nol_date":"2016-08-03","protocol_title":"A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 (GALCANEZUMAB) IN OUTPATIENTS WITH EPISODIC OR CHRONIC CLUSTER HEADACHE","medConditionList":[{"med_condition_id":628,"med_condition":"CHRONIC CLUSTER HEADACHE"},{"med_condition_id":620,"med_condition":"EPISODIC CLUSTER HEADACHE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42601,"protocol_no":"GO30182","submission_no":"195519","status_id":1,"start_date":"2016-12-07","end_date":null,"nol_date":"2016-06-29","protocol_title":"A PHASE III, OPEN-LABEL, MULTICENTER, THREE-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY VS. REGORAFENIB IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC COLORECTAL ADENOCARCINOMA","medConditionList":[{"med_condition_id":740,"med_condition":"COLORECTAL ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35777,"protocol_no":"PRO 47056","submission_no":"173446","status_id":1,"start_date":null,"end_date":null,"nol_date":"2014-04-25","protocol_title":"A PROSPECTIVE, OPEN LABEL, SINGLE CENTER TRIAL OF FECAL MICROBIOTA TRANSPLANTATION (FMT) IN THE MANAGEMENT OF ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41594,"protocol_no":"122","submission_no":"191999","status_id":1,"start_date":"2017-09-15","end_date":null,"nol_date":"2016-03-08","protocol_title":"A TWO-ARM, OPEN-LABEL, RANDOMIZED PHASE II STUDY OF PEMBROLIZUMAB (MK-3475) MONOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN PLATINUM PRE-TREATED, RECURRENT OR METASTATIC NASOPHARYNGEAL CANCER (NPC) (KEYNOTE-122)","medConditionList":[{"med_condition_id":521,"med_condition":"NASOPHARYNGEAL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37418,"protocol_no":"AALL1231","submission_no":"178542","status_id":1,"start_date":"2015-01-13","end_date":null,"nol_date":"2014-10-31","protocol_title":"A PHASE III RANDOMIZED TRIAL INVESTIGATING BORTEZOMIB (NSC# 681239; IND# 58443) ON A MODIFIED AUGMENTED BFM (ABFM) BACKBONE IN NEWLY DIAGNOSED T-LYMPHOBLASTIC LEUKEMIA (T-ALL) AND T-LYMPHOBLASTIC LYMPHOMA (T-LLY)","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41085,"protocol_no":"ONC-DPX-SURVIVAC-06","submission_no":"190229","status_id":1,"start_date":"2017-06-12","end_date":null,"nol_date":"2016-01-07","protocol_title":"A PHASE 1B STUDY OF AN IMMUNOTHERAPEUTIC VACCINE, DPX-SURVIVAC WITH LOW DOSE CYCLOPHOSPHAMIDE AND EPACADOSTAT (INCB024360) IN PATIENTS WITH RECURRENT OVARIAN CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39051,"protocol_no":"LA38-EXT","submission_no":"183966","status_id":1,"start_date":"2015-10-28","end_date":null,"nol_date":"2015-05-22","protocol_title":"LONG-TERM SAFETY AND EFFICACY STUDY OF FERRIPROX¬Æ FOR THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS","medConditionList":[{"med_condition_id":253,"med_condition":"TRANSFUSIONAL IRON OVERLOAD"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39887,"protocol_no":"56021927PCR3002","submission_no":"186538","status_id":1,"start_date":"2016-01-14","end_date":null,"nol_date":"2015-08-25","protocol_title":"A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF JNJ-56021927 PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VERSUS ADT IN SUBJECTS WITH LOW-VOLUME METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41709,"protocol_no":"CDRB436G2201","submission_no":"192425","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-18","protocol_title":"PHASE II OPEN-LABEL GLOBAL STUDY TO EVALUATE THE EFFECT OF DABRAFENIB TREATMENT IN CHILDREN AND ADOLESCENT PATIENTS WITH BRAF V600 MUTATION POSITIVE RELAPSED OR REFRACTORY HIGH GRADE GLIOMA (HGG)","medConditionList":[{"med_condition_id":26,"med_condition":"BRAF MUTATION-POSITIVE TUMORS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37525,"protocol_no":"BBI608-251","submission_no":"178881","status_id":1,"start_date":"2015-05-18","end_date":null,"nol_date":"2014-11-13","protocol_title":"A PHASE IB/II CLINICAL STUDY OF BBI608 IN COMBINATION WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH RECURRENT OR PROGRESSED GLIOBLASTOMA","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28356,"protocol_no":"BBI608-246","submission_no":"168308","status_id":1,"start_date":"2016-02-29","end_date":null,"nol_date":"2013-10-18","protocol_title":"A PHASE IB CLINICAL STUDY OF BBI608 IN COMBINATION WITH STANDARD CHEMOTHERAPIES IN ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL CANCER","medConditionList":[{"med_condition_id":471,"med_condition":"GASTROINTESTINAL CANCER"},{"med_condition_id":337,"med_condition":"GASTRIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43951,"protocol_no":"KTE-C19-104","submission_no":"199643","status_id":1,"start_date":"2017-04-21","end_date":null,"nol_date":"2016-11-24","protocol_title":"A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF KTE-C19 IN PEDIATRIC AND ADOLESCENT SUBJECTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL)","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37275,"protocol_no":"ARST1321 (SRC.6)","submission_no":"178099","status_id":1,"start_date":"2015-05-19","end_date":null,"nol_date":"2014-10-31","protocol_title":"PAZOPANIB NEOADJUVANT TRIAL IN NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS (PAZNTIS): A PHASE II/III RANDOMIZED TRIAL OF PREOPERATIVE CHEMORADIATION OR PREOPERATIVE RADIATION PLUS OR MINUS PAZOPANIB","medConditionList":[{"med_condition_id":237,"med_condition":"SOFT TISSUE SARCOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47093,"protocol_no":"ISIS 703802-CS2","submission_no":"209730","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-25","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE FINDING STUDY OF ISIS 703802 (AKCEA-ANGPTL3-LRX) ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH HYPERTRIGLYCERIDEMIA, TYPE 2 DIABETES MELLITUS (T2DM), AND NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)","medConditionList":[{"med_condition_id":349,"med_condition":"HYPERTRIGLYCERIDEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36131,"protocol_no":"20130109","submission_no":"174565","status_id":1,"start_date":"2016-06-22","end_date":null,"nol_date":"2014-06-20","protocol_title":"A RANDOMIZED, DOUBLE-BLIND STUDY EVALUATING THE EFFICACY, SAFETY AND IMMUNOGENICITYJ OF ABP 798 COMPARED WITH RITUXIMAB IN SUBJECTS WITH CD20 POSITIVE B-CELL NON-HODGKIN LYMPHOMA (NHL)","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42126,"protocol_no":"PJC-021 / NCI 9930","submission_no":"193993","status_id":1,"start_date":"2016-03-24","end_date":null,"nol_date":"2016-05-24","protocol_title":"A PHASE I TRIAL OF MEDI-570 IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL) FOLLICULAR VARIANT AND ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)","medConditionList":[{"med_condition_id":694,"med_condition":"ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA"},{"med_condition_id":193,"med_condition":"PERIPHERAL T CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27529,"protocol_no":"GB28547","submission_no":"166009","status_id":1,"start_date":"2014-03-05","end_date":null,"nol_date":"2013-07-23","protocol_title":"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS","medConditionList":[{"med_condition_id":127,"med_condition":"IDIOPATHIC PULMONARY FIBROSIS (IPF)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35781,"protocol_no":"D4191C00003","submission_no":"173450","status_id":1,"start_date":"2015-06-22","end_date":null,"nol_date":"2014-05-14","protocol_title":"A PHASE II, NON-COMPARATIVE, OPEN LABEL, MULTI-CENTRE, INTERNATIONAL STUDY OF MEDI4736, IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (STAGE IIIB-IV) WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC TREATMENT REGIMENS INCLUDING ONE PLATINUM-BASED CHEMOTHERAPY REGIMEN (ATLANTIC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37177,"protocol_no":"PCYC-1130-CA","submission_no":"177778","status_id":1,"start_date":"2015-05-21","end_date":null,"nol_date":"2014-10-08","protocol_title":"A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB VERSUS CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB IN SUBJECTS WITH TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41670,"protocol_no":"D3250C00037","submission_no":"192287","status_id":1,"start_date":"2016-09-14","end_date":null,"nol_date":"2016-03-18","protocol_title":"A MULTICENTER, OPEN-LABEL, SAFETY EXTENSION STUDY WITH BENRALIZUMAB (MEDI-563) FOR ASTHMATIC ADULTS ON INHALED CORTICOSTEROID PLUS LONG-ACTING SS2 AGONIST (MELTEMI)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40889,"protocol_no":"IPI-145-22","submission_no":"189617","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-18","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF DUVELISIB ADMINISTERED IN COMBINATION WITH RITUXIMAB AND BENDAMUSTINE VS PLACEBO ADMINISTERED IN COMBINATION WITH RITUXIMAB AND BENDAMUSTINE IN SUBJECTS WITH PREVIOUSLY-TREATED INDOLENT NON-HODGKIN LYMPHOMA","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46954,"protocol_no":"VX15-661-113","submission_no":"209282","status_id":1,"start_date":"2018-02-15","end_date":null,"nol_date":"2017-10-12","protocol_title":"A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF VX 661 IN COMBINATION WITH IVACAFTOR IN SUBJECTS 6 THROUGH 11 YEARS OF AGE WITH CYSTIC FIBROSIS, HOMOZYGOUS OR HETEROZYGOUS FOR THE F508DEL-CFTR MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43438,"protocol_no":"INCB 18424-269","submission_no":"198127","status_id":1,"start_date":"2017-08-01","end_date":null,"nol_date":"2016-09-26","protocol_title":"A PHASE 2 STUDY OF THE JAK1/JAK2 INHIBITOR RUXOLITINIB WITH CHEMOTHERAPY IN CHILDREN WITH DE NOVO HIGH-RISK CRLF2-REARRANGED AND/OR JAK PATHWAY¬øMUTANT ACUTE LYMPHOBLASTIC LEUKEMIA","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42011,"protocol_no":"CAIN457F2354","submission_no":"193665","status_id":1,"start_date":"2017-10-10","end_date":null,"nol_date":"2016-04-26","protocol_title":"A 52-WEEK, MULTICENTER STUDY TO ASSESS THE TIME COURSE OF RESPONSE TO SECUKINUMAB ON JOINT INFLAMMATION USING POWER DOPPLER ULTRASONOGRAPHY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46751,"protocol_no":"I8X-MC-JECA","submission_no":"208567","status_id":1,"start_date":"2018-02-22","end_date":null,"nol_date":"2017-09-27","protocol_title":"A PHASE 1 STUDY OF LY3200882 IN PATIENTS WITH SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36105,"protocol_no":"GP28363","submission_no":"174510","status_id":1,"start_date":"2015-12-14","end_date":null,"nol_date":"2014-06-05","protocol_title":"A PHASE IB STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH COMBIMETINIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43543,"protocol_no":"CA020-002","submission_no":"198411","status_id":1,"start_date":"2017-04-07","end_date":null,"nol_date":"2016-10-14","protocol_title":"PHASE 1/2A FIRST-IN-HUMAN STUDY OF BMS-986207 MONOCLONAL ANTIBODY ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45415,"protocol_no":"CTL019B2001X","submission_no":"204356","status_id":1,"start_date":"2017-07-20","end_date":null,"nol_date":"2017-04-26","protocol_title":"EXPANDED TREATMENT PROTOCOL FOR RELAPSED/REFRACTORY PEDIATRIC/YOUNG ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TO BE TREATED WITH CTL019","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42401,"protocol_no":"CA013-004","submission_no":"194837","status_id":1,"start_date":"2017-06-28","end_date":null,"nol_date":"2016-06-02","protocol_title":"A PHASE 1/2A STUDY OF BMS-986179 ADMINISTERED IN COMBINATION WITH NIVOLUMAB (BMS-936558) IN SUBJECTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28396,"protocol_no":"PJC-014 / NCI 9426","submission_no":"168443","status_id":1,"start_date":"2013-11-18","end_date":null,"nol_date":"2013-10-22","protocol_title":"A PHASE I STUDY OF IBRUTINIB (PCI-32765) IN COMBINATION WITH LENALIDOMIDE IN RELAPSED AND REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43045,"protocol_no":"CO.26","submission_no":"196975","status_id":1,"start_date":"2016-09-08","end_date":null,"nol_date":"2016-08-09","protocol_title":"A PHASE II TRIAL OF DURVALUMAB AND TREMELIMUMAB AND BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED COLORECTAL ADENOCARCINOMA REFRACTORY TO STANDARD THERAPIES","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45066,"protocol_no":"BB-OPMD-202","submission_no":"203193","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-13","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY TRIAL OF TREHALOSE FOR THE TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY","medConditionList":[{"med_condition_id":774,"med_condition":"MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43188,"protocol_no":"8118","submission_no":"197444","status_id":1,"start_date":"2016-11-23","end_date":null,"nol_date":"2016-09-07","protocol_title":"MRI- AND PET-PREDICTIVE-ASSAY OF TREATMENT OUTCOME IN CANCER OF THE CERVIX","medConditionList":[{"med_condition_id":356,"med_condition":"CERVICAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42502,"protocol_no":"MEDI4736-MM-003","submission_no":"195034","status_id":1,"start_date":"2016-12-20","end_date":null,"nol_date":"2016-06-16","protocol_title":"A PHASE 2, MULTICENTER, OPEN-LABEL, STUDY TO DETERMINE THE SAFETY AND EFFICACY FOR THE COMBINATION OF DURVALUMAB (DURVA) AND DARATUMUMAB (DARA) (D2) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42207,"protocol_no":"ML29966","submission_no":"194268","status_id":1,"start_date":"2017-03-22","end_date":null,"nol_date":"2016-05-18","protocol_title":"AN OPEN-LABEL, MULTICENTER, BIOMARKER STUDY TO EXPLORE THE MECHANISM OF ACTION OF OCRELIZUMAB AND B-CELL BIOLOGY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45294,"protocol_no":"205724","submission_no":"203945","status_id":1,"start_date":"2018-01-11","end_date":null,"nol_date":"2017-04-21","protocol_title":"RANDOMISED, DOUBLE-BLIND (SPONSOR OPEN), PLACEBO-CONTROLLED, MULTICENTRE, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DANIRIXIN TABLETS ADMINISTERED TWICE DAILY COMPARED WITH PLACEBO FOR 24 WEEKS IN ADULT PARTICIPANTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46533,"protocol_no":"C34004","submission_no":"207853","status_id":1,"start_date":"2018-02-09","end_date":null,"nol_date":"2017-09-07","protocol_title":"PHASE 2 STUDY OF TAK-659 IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40635,"protocol_no":"M13-545","submission_no":"188669","status_id":1,"start_date":"2016-10-31","end_date":null,"nol_date":"2015-11-19","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING ABT-494 15 MG ONCE DAILY MONOTHERAPY AND ABT-494 30 MG ONCE DAILY MONOTHERAPY TO METHOTREXATE (MTX) MONOTHERAPY IN MTX-NA√èVE SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39846,"protocol_no":"170-08","submission_no":"186431","status_id":1,"start_date":"2015-08-31","end_date":null,"nol_date":"2015-08-19","protocol_title":"A 34-WEEK FOLLOW-UP TO: A PHASE III, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY MK-0431A (A FIXED-DOSE COMBINATION TABLET OF SITAGLIPTIN AND METFORMIN) IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH INADEQUATE GLYCEMIC CONTROL ON METFORMIN THERAPY (ALONE OR IN COMBINATION WITH INSULIN)","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39837,"protocol_no":"CA209-227","submission_no":"186402","status_id":1,"start_date":"2016-04-11","end_date":null,"nol_date":"2015-08-25","protocol_title":"AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF NIVOLUMAB, OR NIVOLUMAB PLUS IPILIMUMAB, VERSUS PLATINUM DOUBLET CHEMOTHERAPY IN SUBJECTS WITH CHEMOTHERAPY-NAIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38210,"protocol_no":"CAIN457F2320","submission_no":"181277","status_id":1,"start_date":"2015-09-11","end_date":null,"nol_date":"2015-02-13","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB (150 MG) WITH AND WITHOUT A SUBCUTANEOUS LOADING REGIMEN TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY UP TO 2 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS","medConditionList":[{"med_condition_id":397,"med_condition":"ANKYLOSING SPONDYLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48548,"protocol_no":"TV48125-CNS-80005","submission_no":"214231","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-21","protocol_title":"FREMANEZUMAB EXPANDED ACCESS PROGRAM - MIGRAINE","medConditionList":[{"med_condition_id":157,"med_condition":"MIGRAINE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44136,"protocol_no":"CA018-005","submission_no":"200221","status_id":1,"start_date":"2017-08-14","end_date":null,"nol_date":"2016-12-06","protocol_title":"A PHASE 2, FAST REAL-TIME ASSESSMENT OF COMBINATION THERAPIES IN IMMUNO-ONCOLOGY STUDY IN PARTICIPANTS WITH ADVANCED RENAL CELL CARCINOMA (FRACTION-RCC)","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44858,"protocol_no":"CO39303","submission_no":"202646","status_id":1,"start_date":"2017-05-15","end_date":null,"nol_date":"2017-03-08","protocol_title":"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE RESISTANT PROSTATE CANCER","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37593,"protocol_no":"CA209-214","submission_no":"179099","status_id":1,"start_date":"2015-03-30","end_date":null,"nol_date":"2014-11-20","protocol_title":"A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB COMBINED WITH IPILIMUMAB VERUS SUNITINIB MONOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMA (CHECKMATE 214, CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVLUATION 214)","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28830,"protocol_no":"GO28754","submission_no":"169989","status_id":1,"start_date":"2014-08-01","end_date":null,"nol_date":"2013-12-13","protocol_title":"A PHASE II, MULTICENTRE, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44046,"protocol_no":"DSC/14/2357/48","submission_no":"199975","status_id":1,"start_date":"2017-07-26","end_date":null,"nol_date":"2016-11-30","protocol_title":"RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GIVINOSTAT IN AMBULANT PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41825,"protocol_no":"AG-221-AML-004","submission_no":"192887","status_id":1,"start_date":"2017-05-01","end_date":null,"nol_date":"2016-03-31","protocol_title":"A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG-221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION.","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45718,"protocol_no":"DEBIO 1143-NSCLC-105","submission_no":"205298","status_id":1,"start_date":"2017-10-02","end_date":null,"nol_date":"2017-06-16","protocol_title":"A PHASE-IB DOSE-FINDING STUDY OF THE SMAC MIMETIC DEBIO 1143 WHEN GIVEN IN COMBINATION WITH THE ANTI-PD-L1 ANTIBODY AVELUMAB TO PATIENTS WITH ADVANCED SOLID MALIGNANCIES AND, IN AN EXPANSION COHORT, TO PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PLATINUM-BASED THERAPY","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44864,"protocol_no":"CA209-915","submission_no":"202654","status_id":1,"start_date":"2017-08-03","end_date":null,"nol_date":"2017-03-07","protocol_title":"A PHASE 3, RANDOMIZED STUDY OF ADJUVANT IMMUNOTHERAPY WITH NIVOLUMAB COMBINED WITH IPILIMUMAB VERSUS IPILIMUMAB OR NIVOLUMAB MONOTHERAPY AFTER COMPLETE RESECTION OF STAGE IIIB/C/D OR STAGE IV MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41338,"protocol_no":"OZM-058 (ESR-ISS22810093)","submission_no":"191215","status_id":1,"start_date":"2016-07-15","end_date":null,"nol_date":"2016-01-27","protocol_title":"A PHASE II, OPEN-LABEL, RANDOMIZED, MULTI-CENTRE STUDY, OF NEOADJUVANT OLAPARIB IN PATIENTS WITH PLATINUM SENSITIVE RECURRENT HIGH GRADE SEROUS OVARIAN/PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCER","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48128,"protocol_no":"R1500-CL-1629","submission_no":"213017","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","medConditionList":[{"med_condition_id":116,"med_condition":"HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46268,"protocol_no":"MDV3800-02 /C3441002 /TRIO028","submission_no":"206960","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-24","protocol_title":"A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT.","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"},{"med_condition_id":831,"med_condition":"HEPATIC IMPAIRMENT"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40639,"protocol_no":"M13-549","submission_no":"188670","status_id":1,"start_date":"2017-09-18","end_date":null,"nol_date":"2015-11-19","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING ABT-494 TO PLACEBO IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO ARE ON A STABLE DOSE OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) AND HAVE AN INADEQUATE RESPONSE TO CSDMARDS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41627,"protocol_no":"IM006016","submission_no":"192088","status_id":2,"start_date":"2017-08-07","end_date":"2018-04-11","nol_date":"2016-03-11","protocol_title":"PHASE 2, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, DOSE-RANGING, PLACEBO CONTROLLED, ADAPTIVE DESIGN STUDY TO EVALUATE THE EFFICACY AND SAFETY/PHARMACOKINETICS OF BMS986142 IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE WITH OR WITHOUT TNF INHIBITORS.","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46620,"protocol_no":"071102","submission_no":"208143","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-13","protocol_title":"A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OR RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE","medConditionList":[{"med_condition_id":268,"med_condition":"VON WILLEBRAND DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27439,"protocol_no":"083-01","submission_no":"165756","status_id":1,"start_date":"2016-02-03","end_date":null,"nol_date":"2013-07-12","protocol_title":"A PHASE III, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO- AND METFORMIN-CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SITAGLIPTIN IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH INADEQUATE GLYCEMIC CONTROL","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43605,"protocol_no":"CANSTEM303C","submission_no":"198607","status_id":1,"start_date":"2017-03-28","end_date":null,"nol_date":"2016-10-26","protocol_title":"A PHASE III STUDY OF BBI-608 IN COMBINATION WITH 5-FLUOROURACIL, LEUCOVORIN, IRINOTECAN (FOLFIRI) IN ADULT PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (CRC).","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47460,"protocol_no":"IMATINIB-CCI-PH1-01","submission_no":"211001","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-23","protocol_title":"A PHASE I DOSE ESCALATION TRIAL TO DETERMINE IF IMATINIB TREATMENT RESTORES SODIUM IODIDE SYMPORTER FUNCTION AND SENSITIVITY TO RADIOIODINE TREATMENT IN METASTATIC THYROID CANCER PATIENTS","medConditionList":[{"med_condition_id":250,"med_condition":"THYROID CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45656,"protocol_no":"2215-CL-0304","submission_no":"205073","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-16","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF THE FLT3 INHIBITOR GILTERITINIB ADMINISTERED AS MAINTENANCE THERAPY FOLLOWING ALLOGENEIC TRANSPLANT FOR PATIENTS WITH FLT3/ITD AML","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40599,"protocol_no":"215ON203","submission_no":"188592","status_id":1,"start_date":"2016-09-01","end_date":null,"nol_date":"2015-11-18","protocol_title":"A MULTICENTER, FOLLOW-UP STUDY TO ASSESS THE LONG-TERM ELECTROPHYSIOLOGIC AND CLINICAL OUTCOMES IN SUBJECTS PREVIOUSLY ENROLLED IN STUDY 215ON201","medConditionList":[{"med_condition_id":652,"med_condition":"ACUTE OPTIC NEURITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37542,"protocol_no":"NRG-HN002","submission_no":"178954","status_id":1,"start_date":"2015-04-16","end_date":null,"nol_date":"2014-11-18","protocol_title":"A RANDOMIZED PHASE II TRIAL FOR PATIENTS WITH P16 POSITIVE, NON-SMOKING ASSOCIATED, LOCOREGIONALLY ADVANCED OROPHARYNGEAL CANCER","medConditionList":[{"med_condition_id":486,"med_condition":"OROPHARYNX CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41110,"protocol_no":"D6015C00001","submission_no":"190337","status_id":1,"start_date":"2016-03-22","end_date":null,"nol_date":"2016-01-07","protocol_title":"A PHASE IB, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOUR ACTIVITY OF AZD1775 MONOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMOURS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46672,"protocol_no":"GN39763","submission_no":"208300","status_id":1,"start_date":"2018-01-12","end_date":null,"nol_date":"2017-09-05","protocol_title":"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36735,"protocol_no":"20130385","submission_no":"176429","status_id":1,"start_date":"2014-09-09","end_date":null,"nol_date":"2014-08-14","protocol_title":"A DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFECT OF EVOLOCUMAB ON COGNITIVE FUNCTION IN PATIENTS WITH CLINICALLY EVIDENT CARDIOVASCULAR DISEASE AND RECEIVING STATIN BACKGROUND LIPID LOWERING THERAPY: A STUDY FOR SUBJECTS ENROLLED IN THE FOURIER (STUDY 20110118) TRIAL","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44078,"protocol_no":"TN-20","submission_no":"200067","status_id":1,"start_date":"2017-01-18","end_date":null,"nol_date":"2016-12-23","protocol_title":"EXPLORING IMMUNE EFFECTS OF ORAL INSULIN IN RELATIVES AT RISK FOR TYPE 1 DIABETES MELLITUS","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41611,"protocol_no":"ADU-CL-11","submission_no":"192046","status_id":1,"start_date":"2017-05-02","end_date":null,"nol_date":"2016-03-10","protocol_title":"A PHASE 1/2, OPEN-LABEL SAFETY AND EFFICACY EVALUATION OF CRS-207 IN COMBINATION WITH EPACADOSTAT IN ADULTS WITH PLATINUM-RESISTANT OVARIAN, FALLOPIAN, OR PERITONEAL CANCER","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":197,"med_condition":"PLATINUM-RESISTANT OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39978,"protocol_no":"1245.72","submission_no":"186766","status_id":2,"start_date":"2016-12-09","end_date":"2017-09-29","nol_date":"2015-09-02","protocol_title":"A PHASE III, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, EFFICACY, SAFETY AND TOLERABILITY TRIAL OF ONCE DAILY, ORAL DOSES OF EMPAGLIFLOZIN AS ADJUNCTIVE TO INSULIN THERAPY OVER 26 WEEKS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS (EASE-3)","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42573,"protocol_no":"RET IRD 04","submission_no":"195415","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-21","protocol_title":"A STUDY OF THE EFFICACY AND SAFETY OF QLT091001 IN SUBJECTS WITH INHERITED RETINAL DISEASE (IRD) CAUSED BY MUTATION IN RETINAL PIGMENT EPITHELIUM PROTEIN 65 (RPE65) OR LECITHIN:RETINOL ACYLTRANSFERASE (LRAT)","medConditionList":[{"med_condition_id":739,"med_condition":"INHERITED RETINAL DISEASE (IRD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39864,"protocol_no":"9785-CL-3021","submission_no":"186474","status_id":1,"start_date":"2016-07-27","end_date":null,"nol_date":"2015-08-24","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ENZALUTAMIDE IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA.","medConditionList":[{"med_condition_id":519,"med_condition":"ADVANCED HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41379,"protocol_no":"CN001006","submission_no":"191326","status_id":1,"start_date":"2017-04-25","end_date":null,"nol_date":"2016-02-12","protocol_title":"A MULTI-SITE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTIPLE ASCENDING SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF BMS-986089 IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27153,"protocol_no":"MMRC#048/U (IRB#12-1088)","submission_no":"164971","status_id":1,"start_date":"2014-06-06","end_date":null,"nol_date":"2013-06-14","protocol_title":"MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE 1B/2 STUDY OF THE SAFETY AND EFFICACY OF COMBINATION TREATMENT WITH POMALIDOMIDE, DEXAMETHASONE, AND CARFILZOMIB (PDC) IN","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42294,"protocol_no":"64294178HPC2001","submission_no":"194516","status_id":2,"start_date":"2017-01-13","end_date":"2017-10-31","nol_date":"2016-05-26","protocol_title":"A PHASE 2B, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF DIFFERENT TREATMENT REGIMENS OF AL-335, ODALASVIR, AND SIMEPREVIR IN TREATMENT-NA√èVE AND TREATMENT-EXPERIENCED SUBJECTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, AND 6 INFECTION, WITH AND WITHOUT CIRRHOSIS","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36610,"protocol_no":"NCIC CTG: IND.214","submission_no":"175989","status_id":1,"start_date":"2017-10-30","end_date":null,"nol_date":"2014-07-25","protocol_title":"A PHASE I/II STUDY OF MG1 MARABA/MAGE A3 (MG1MA3), WITH AND WITHOUT ADENOVIRUS VACCINE, WITH TRANGENIC MAGE A3 INSERTION (ADMA3) IN PATIENTS WITH INCURABLE ADVANCED/METASTATIC MAGE A3-EXPRESSING SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47041,"protocol_no":"I4V-MC-JAHL","submission_no":"209554","status_id":2,"start_date":null,"end_date":"2018-02-27","nol_date":"2017-10-20","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35417,"protocol_no":"IG1104","submission_no":"172304","status_id":1,"start_date":"2015-03-27","end_date":null,"nol_date":"2014-03-18","protocol_title":"MULTICENTER, PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP CLINICAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF IMMUNE GLOBULIN INTRAVENOUS (HUMAN) FLEBOGAMMA 5% DIF IN PATIENTS WITH POST-POLIO SYNDROME","medConditionList":[{"med_condition_id":477,"med_condition":"POST-POLIO SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44092,"protocol_no":"RTOG-3504","submission_no":"200092","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-07","protocol_title":"RANDOMIZED PHASE III TRIAL OF CISPLATIN-BASED CHEMOTHERAPY (CRT) +/- NIVOLUMAB (ANTI-PD-1) IN PATIENTS WITH INTERMEDIATE AND HIGH-RISK LOCAL-REGIONALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (WITH LEAD IN COMPONENT)","medConditionList":[{"med_condition_id":724,"med_condition":"SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42889,"protocol_no":"M14-234","submission_no":"196541","status_id":1,"start_date":"2016-12-09","end_date":null,"nol_date":"2016-07-28","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABT-494 FOR INDUCTION AND MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS.","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43669,"protocol_no":"NO-CF-02E","submission_no":"198855","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-10-27","protocol_title":"PROSPECTIVE, RANDOMIZED, PLACEBO CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF INHALED NITRIC OXIDE (NO) IN CYSTIC FIBROSIS (CF) PATIENTS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28696,"protocol_no":"Q-CROC-O4","submission_no":"169464","status_id":2,"start_date":"2014-09-03","end_date":"2016-07-21","nol_date":"2013-11-29","protocol_title":"A PHASE II EXPLORATORY STUDY TO IDENTIFY BIOMARKERS PREDICTIVE OF CLINICAL RESPONSE TO AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE FAILED FIRST-LINE THERAPY","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35397,"protocol_no":"119858","submission_no":"172207","status_id":2,"start_date":"2015-06-17","end_date":"2018-01-17","nol_date":"2014-03-20","protocol_title":"PREHOSPITAL TRANEXAMIC ACID USE FOR TRAUMATIC BRAIN INJURY","medConditionList":[{"med_condition_id":437,"med_condition":"TRAUMATIC BRAIN INJURY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29451,"protocol_no":"IPI-145-06","submission_no":"171844","status_id":1,"start_date":"2015-06-18","end_date":null,"nol_date":"2014-03-07","protocol_title":"A PHASE 2 STUDY OF IPI-145 IN SUBJECTS WITH REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA.","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28329,"protocol_no":"AGS15E-13-1","submission_no":"168250","status_id":1,"start_date":"2016-10-14","end_date":null,"nol_date":"2013-10-11","protocol_title":"A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS15E GIVEN AS MONOTHERAPY IN SUBJECTS WITH METASTATIC UROTHELIAL CANCER","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40050,"protocol_no":"CB8025-21528","submission_no":"186945","status_id":1,"start_date":"2015-11-18","end_date":null,"nol_date":"2015-09-16","protocol_title":"A 12-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY, TO EVALUATE THE EFFECTS OF TWO DOSES OF MBX-8025 IN SUBJECTS WITH PRIMARY BILIARY CIRRHOSIS (PBC) AND AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID (UDCA)","medConditionList":[{"med_condition_id":209,"med_condition":"PRIMARY BILIARY CIRRHOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26673,"protocol_no":"1000036780","submission_no":"163465","status_id":2,"start_date":"2013-04-19","end_date":"2016-11-29","nol_date":"2013-04-10","protocol_title":"CO-ADMINISTRATION OF KETAMINE AND PROPOFOL FOR UPPER ENDOSCOPY IN CHILDREN: A DOSE FINDING STUDY.","medConditionList":[{"med_condition_id":553,"med_condition":"ANASTHESIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36756,"protocol_no":"TRX-237-020","submission_no":"176480","status_id":2,"start_date":"2016-01-20","end_date":"2017-05-08","nol_date":"2014-08-06","protocol_title":"AN OPEN-LABEL, EXTENSION STUDY OF THE EFFECTS OF LEUCO-METHYLTHIONINIUM BIS(HYDROMETHANESULFONATE) IN SUBJECTS WITH ALZHEIMER'S DISEASE OR BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"},{"med_condition_id":313,"med_condition":"BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA (BVFTD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36352,"protocol_no":"D5160C00003","submission_no":"175135","status_id":1,"start_date":"2015-09-30","end_date":null,"nol_date":"2014-06-27","protocol_title":"A PHASE III, OPEN LABEL, RANDOMIZED STUDY OF AZD9291 VERSUS PLATINUM-BASED DOUBLET CHEMOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS PROGRESSED WITH PREVIOUS EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR THERAPY AND WHOSE TUMOURS HARBOUR A T790M MUTATION WITHIN THE EPIDERMAL GROWTH FACTOR RECEPTOR GENE (AURA3)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36118,"protocol_no":"56021927PCR1010","submission_no":"174542","status_id":1,"start_date":"2016-03-09","end_date":null,"nol_date":"2014-06-03","protocol_title":"A DRUG-DRUG INTERACTION, SAFETY AND EFFICACY STUDY WITH JNJ-56021927 (ARN-509) AND ABIRATERONE ACETATE IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47021,"protocol_no":"EFC14867 (SOTA-EMPA)","submission_no":"209502","status_id":1,"start_date":"2017-12-07","end_date":null,"nol_date":"2017-10-17","protocol_title":"A 26-WEEK RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SOTAGLIFLOZIN COMPARED TO EMPAGLIFLOZIN, AND PLACEBO IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4(I)) WITH OR WITHOUT METFORMIN","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35646,"protocol_no":"INCB 39110-203","submission_no":"172995","status_id":1,"start_date":"2015-03-02","end_date":null,"nol_date":"2014-04-07","protocol_title":"A RANDOMIZED, PHASE 2 STUDY OF INCB039110, OR PLACEBO IN COMBINATION WITH DOCETAXEL IN SUBJECTS WITH PREVIOUSLY TREATED STAGE IIIB, IV, OR RECURRENT NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47135,"protocol_no":"PRO00071320","submission_no":"209874","status_id":1,"start_date":"2018-01-02","end_date":null,"nol_date":"2017-11-02","protocol_title":"POLYCLONAL REGULATORY T CELL (POLYTREG) IMMUNOTHERAPY IN ISLET TRANSPLANTATION","medConditionList":[{"med_condition_id":135,"med_condition":"ISLET TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46257,"protocol_no":"PT001","submission_no":"206919","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-13","protocol_title":"SPARE-HF: RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF STATINS FOR THE PRIMARY PREVENTION OF HEART FAILURE IN PATIENTS WITH CANCER RECEIVING ANTHRACYCLINE BASED CHEMOTHERAPY ¬ø PILOT STUDY","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35656,"protocol_no":"D5160C00002","submission_no":"173036","status_id":1,"start_date":"2016-12-07","end_date":null,"nol_date":"2014-05-08","protocol_title":"A PHASE II, OPEN LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF AZD9291 IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER WHOSE DISEASE HAS PROGRESSED WITH PREVIOUS EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR THERAPY AND WHOSE TUMOURS ARE EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION AND T790M MUTATION POSITIVE (AURA2)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"},{"med_condition_id":505,"med_condition":"LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42183,"protocol_no":"CC-90009-AML-001","submission_no":"194192","status_id":1,"start_date":"2016-05-06","end_date":null,"nol_date":"2016-05-13","protocol_title":"A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45820,"protocol_no":"PTC124-GD-041-DMD","submission_no":"205533","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-06","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY AND OPEN-LABEL EXTENSION","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42008,"protocol_no":"T2012-002","submission_no":"193641","status_id":2,"start_date":null,"end_date":"2018-01-29","nol_date":"2016-05-19","protocol_title":"A PILOT STUDY OF VINCRISTINE SULFATE LIPOSOME INJECTION (MARQIBO¬Æ) IN COMBINATION WITH UK ALL R3 INDUCTION CHEMOTHERAPY FOR CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA IND 128316","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29060,"protocol_no":"BP27832","submission_no":"170744","status_id":2,"start_date":"2014-11-20","end_date":"2016-07-12","nol_date":"2014-01-10","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)","medConditionList":[{"med_condition_id":449,"med_condition":"DOWN SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46877,"protocol_no":"201551","submission_no":"208944","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-28","protocol_title":"A DOUBLE-BLIND SAFETY AND EFFICACY STUDY OF GSK2894512 VERSUS VEHICLE IN THE TREATMENT OF PEDIATRIC ATOPIC DERMATITIS.","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39839,"protocol_no":"C34002","submission_no":"186404","status_id":1,"start_date":"2016-04-12","end_date":null,"nol_date":"2015-08-20","protocol_title":"AN OPEN-LABEL, PHASE 1B/2 STUDY INVESTIGATING RECOMMENDED PHASE 2 DOSE, SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF TAK-659 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27036,"protocol_no":"RCM-EFF-1","submission_no":"164561","status_id":1,"start_date":"2013-07-18","end_date":null,"nol_date":"2013-05-31","protocol_title":"A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL ON THE EFFECT OF STABLOR¬ô ON THE ABDOMINAL VISCERAL FAT MASS LOSS IN PATIENTS WITH A METABOLIC SYNDROME","medConditionList":[{"med_condition_id":306,"med_condition":"METABOLIC SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48233,"protocol_no":"KTE-C19-107","submission_no":"213363","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-28","protocol_title":"A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE THERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (ZUMA-7)","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44274,"protocol_no":"OZM-079","submission_no":"200621","status_id":1,"start_date":"2018-02-05","end_date":null,"nol_date":"2016-12-22","protocol_title":"PHASE 1 STUDY OF ALLOGENEIC DOUBLE NEGATIVE T CELLS (DNT-UHN-1) IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48119,"protocol_no":"B7451012","submission_no":"212993","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-16","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND OLDER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42510,"protocol_no":"204861","submission_no":"195239","status_id":1,"start_date":"2016-10-05","end_date":null,"nol_date":"2016-06-16","protocol_title":"A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NON-INFERIORITY STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF DOLUTEGRAVIR PLUS LAMIVUDINE COMPARED TO DOLUTEGRAVIR PLUS TENOFOVIR/EMTRICITABINE IN HIV-1-INFECTED TREATMENT-NA√èVE ADULTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42455,"protocol_no":"547-PPD-202","submission_no":"195038","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-08","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SAGE-547 INJECTION IN THE TREATMENT OF ADULT FEMALE SUBJECTS WITH SEVERE POSTPARTUM DEPRESSION AND ADULT FEMALE SUBJECTS WITH MODERATE POSTPARTUM DEPRESSION","medConditionList":[{"med_condition_id":204,"med_condition":"POSTPARTUM DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40922,"protocol_no":"LP0084-1194","submission_no":"189703","status_id":2,"start_date":"2016-04-21","end_date":"2017-08-10","nol_date":"2015-12-15","protocol_title":"EFFICACY AND SAFETY OF LEO 43204 IN FIELD TREATMENT OF ACTINIC KERATOSIS ON FACE OR CHEST INCLUDING 12-MONTH FOLLOW-UP.","medConditionList":[{"med_condition_id":520,"med_condition":"ACTINIC KERATOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28869,"protocol_no":"NP28761","submission_no":"170129","status_id":2,"start_date":"2014-03-05","end_date":"2017-08-31","nol_date":"2013-12-18","protocol_title":"A PHASE I/II STUDY OF THE ALK INHIBITOR CH5424802/ RO5424802 IN PATIENTS WITH ALK-REARRANGED NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH CHEMOTHERAPY AND CRIZOTINIB","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41509,"protocol_no":"000108","submission_no":"191668","status_id":1,"start_date":"2016-04-29","end_date":null,"nol_date":"2016-02-23","protocol_title":"A MULTI-CENTER, RANDOMIZED, ASSESSOR-BLIND, CONTROLLED TRIAL COMPARING THE OCCURRENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACES) IN PATIENTS WITH PROSTATE CANCER AND CARDIOVASCULAR DISEASE RECEIVING DEGARELIX (GNRH RECEPTOR ANTAGONIST) OR LEUPROLIDE (GNRH RECEPTOR AGONIST)","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"},{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26973,"protocol_no":"IM101-332 DATED 11-MAR-2013","submission_no":"164387","status_id":1,"start_date":"2014-05-09","end_date":null,"nol_date":"2013-05-24","protocol_title":"A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT SUBCUTANEOUS INJECTION IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46514,"protocol_no":"CCTG CO.28","submission_no":"207814","status_id":1,"start_date":"2018-01-08","end_date":null,"nol_date":"2017-08-18","protocol_title":"NEOADJUVANT CHEMOTHERAPY, EXCISION AND OBSERVATION FOR EARLY RECTAL CANCER: THE NEO TRIAL.","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45586,"protocol_no":"HC2017:001","submission_no":"204890","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-03","protocol_title":"ANALGESIC DURATION OF INTERSCALENE BLOCK AFTER OUTPATIENT ARTHROSCOPIC SHOULDER SURGERY WITH INTRAVENOUS DEXAMETHASONE, DEXMEDETOMIDINE OR THEIR COMBINATION: A RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46011,"protocol_no":"M15-566","submission_no":"205158","status_id":1,"start_date":"2017-09-15","end_date":null,"nol_date":"2017-06-29","protocol_title":"A PHASE 2 MULTIPLE DOSE, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABBV-8E12 IN SUBJECTS WITH EARLY ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42058,"protocol_no":"EFC13957","submission_no":"193774","status_id":1,"start_date":"2017-02-03","end_date":null,"nol_date":"2016-04-25","protocol_title":"6-MONTH, MULTICENTER, RANDOMIZED, OPEN-LABEL, 2-ARM, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF A NEW FORMULATION OF INSULIN GLARGINE AND LANTUS INJECTED ONCE DAILY IN CHILDREN AND ADOLESCENTS AGE 6-17 YEARS WITH TYPE 1 DIABETES MELLITUS WITH A 6-MONTH SAFETY EXTENSION PERIOD","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35453,"protocol_no":"9785-CL-1121","submission_no":"172404","status_id":1,"start_date":"2014-09-22","end_date":null,"nol_date":"2014-03-21","protocol_title":"A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ENZALUTAMIDE WITH TRASTUZUMAB IN SUBJECTS WITH HER2+ AR+ METASTATIC OR LOCALLY ADVANCED BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26991,"protocol_no":"CRAD001M2304","submission_no":"164435","status_id":2,"start_date":"2014-09-25","end_date":"2017-07-28","nol_date":"2013-05-28","protocol_title":"A THREE-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE    EFFICACY AND SAFETY OF TWO TROUGH-RANGES OF EVEROLIMUS AS ADJUNCTIVE THERAPY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE REFRACTORY PARTIAL-ONSET SEIZURES.","medConditionList":[{"med_condition_id":229,"med_condition":"SEIZURES"},{"med_condition_id":309,"med_condition":"TUBEROUS SCLEROSIS COMPLEX (TSC)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37788,"protocol_no":"CSL830_3002","submission_no":"179732","status_id":2,"start_date":"2015-03-16","end_date":"2017-05-12","nol_date":"2014-11-26","protocol_title":"AN OPEN-LABEL, RANDOMIZED, STUDY TO EVALUTE THE LONG-TERM CLINICAL SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF HUMAN PLASMA-DERIVED C1-ESTERASE INHIBITOR IN THE PROPHYLACTIC TREATMENT OF HEREDITARY ANGLOEDEMA","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37954,"protocol_no":"ALN-TTRSC-003","submission_no":"180263","status_id":2,"start_date":"2015-03-19","end_date":"2017-06-20","nol_date":"2014-12-29","protocol_title":"A PHASE 2, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, CLINICAL ACTIVITY, AND PHARMACOKINETICS OF ALN TTRSC IN PATIENTS WITH TRANSTHYRETIN (TTR) CARDIAC AMYLOIDOSIS WHO HAVE PREVIOUSLY RECEIVED ALN-TTRSC","medConditionList":[{"med_condition_id":574,"med_condition":"AMYLOIDOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38131,"protocol_no":"ASG001","submission_no":"181033","status_id":1,"start_date":"2015-01-01","end_date":null,"nol_date":"2015-02-17","protocol_title":"A PROOF OF PRINCIPLE TRIAL OF AMBROXOL AS A NOVEL DISEASE MODIFYING TREATMENT FOR DEMENTIA WITH PARKINSON'S DISEASE DEMENTIA","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27535,"protocol_no":"ENMD-2076-OCCC","submission_no":"166034","status_id":1,"start_date":"2014-07-02","end_date":null,"nol_date":"2013-07-29","protocol_title":"PHASE II STUDY OF ORAL ENMD-2076 ADMINISTERED TO PATIENTS WITH OVARIAN CLEAR CELL CARCINOMAS","medConditionList":[{"med_condition_id":331,"med_condition":"OVARIAN CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46053,"protocol_no":"20170099-01H","submission_no":"206227","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-15","protocol_title":"LOW-MOLECULAR-WEIGHT HEPARIN TO PREVENT RECURRENT VTE IN PREGNANCY: A RANDOMIZED CONTROLLED TRIAL OF TWO DOSES","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46070,"protocol_no":"MEDIT-001","submission_no":"206313","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-04","protocol_title":"A PHASE IIA, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, SINGLE DOSE STUDY OF A NEW TEST DRUG (GBM-5) ADMINISTERED INTRATHECALLY TO PATIENTS WITH MODERATE-TO-SEVERE REFRACTORY CHRONIC PAIN.","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46146,"protocol_no":"170510","submission_no":"206501","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-19","protocol_title":"MACULAR EDEMA RANIBIZUMAB V. INTRAVITREAL ANTI-INFLAMMATORY THERAPY (MERIT) TRIAL","medConditionList":[{"med_condition_id":568,"med_condition":"MACULAR DEGENERATION"},{"med_condition_id":151,"med_condition":"MACULAR EDEMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35516,"protocol_no":"CAMHPET-CTA-82","submission_no":"172633","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-04","protocol_title":"A NEW BIOMARKER-BASED APPROACH TOWARDS DEVELOPING IMPROVED TREATMENT FOR MAJOR DEPRESSIVE DISORDER (MDD) BASED UPON TARGETING MONOAMINE OXIDASE A (MAO-A)","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45176,"protocol_no":"NGAM-08","submission_no":"203579","status_id":1,"start_date":"2017-09-01","end_date":null,"nol_date":"2017-04-07","protocol_title":"PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, MULTICENTER PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF THREE DIFFERENT DOSAGES OF NEWGAM IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLY(RADICULO)NEUROPATHY (PROCID TRIAL)","medConditionList":[{"med_condition_id":44,"med_condition":"CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)"},{"med_condition_id":487,"med_condition":"RADICULOPATHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37082,"protocol_no":"CNTO1959PSO3001","submission_no":"177452","status_id":1,"start_date":"2003-12-19","end_date":null,"nol_date":"2014-09-23","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GUSELKUMAB FOR THE TREATMENT OF SUBJECTS WITH MODERATE TO SEVERE PLAQUE-TYPE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35577,"protocol_no":"001","submission_no":"172766","status_id":1,"start_date":"2015-02-23","end_date":null,"nol_date":"2014-05-30","protocol_title":"A PILOT STUDY TO EVALUATE THE FEASIBILITY AND SAFETY OF PERFORMING A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED CONTROLLED TRIAL OF THE ROUTINE USE OF SSRI'S AT THE INITIATION OF END-STAGE RENAL DISEASE TREATMENT (ROSIE)","medConditionList":[{"med_condition_id":457,"med_condition":"END STAGE RENAL DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26704,"protocol_no":"14861A","submission_no":"163530","status_id":2,"start_date":"2013-11-21","end_date":"2016-07-19","nol_date":"2013-04-23","protocol_title":"RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF LU AE58054 IN PATIENTS WITH MILD-MODERATE ALZHEIMER'S DISEASE TREATED WITH DONEPEZIL; STUDY 1","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29489,"protocol_no":"R668-AD-1224","submission_no":"171946","status_id":1,"start_date":"2014-03-25","end_date":null,"nol_date":"2014-03-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMOSTRATE THE LONG TERM EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37123,"protocol_no":"PHN-UDENAFIL-01","submission_no":"177601","status_id":2,"start_date":"2014-10-06","end_date":"2015-03-06","nol_date":"2014-09-24","protocol_title":"A PHASE I/II DOSE ESCALATION TRIAL OF UDENAFIL IN ADOLESCENTS WITH SINGLE VENTRICLE PHYSIOLOGY AFTER FONTAN PALLIATION.","medConditionList":[{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":48214,"protocol_no":"C1973-204","submission_no":"213313","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-28","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF DIFFERENT DOSES OF IW-1973 OVER 12 WEEKS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (CAPACITY HFPEF)","medConditionList":[{"med_condition_id":523,"med_condition":"HEART FAILURE WITH PRESERVED EJECTION FRACTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47760,"protocol_no":"ERADICATE-HF","submission_no":"211808","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-29","protocol_title":"ERTUGLIFLOZIN TRIAL IN DIABETES WITH PRESERVED OR REDUCED EJECTION FRACTION MECHANISTIC EVALUATION IN HEART FAILURE: \"ERADICATE-HF\"","medConditionList":[{"med_condition_id":523,"med_condition":"HEART FAILURE WITH PRESERVED EJECTION FRACTION"},{"med_condition_id":421,"med_condition":"HEART FAILURE"},{"med_condition_id":388,"med_condition":"DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47918,"protocol_no":"BT008","submission_no":"212432","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-07","protocol_title":"ASSESSMENT OF SAFETY AND FEASIBILITY OF EXABLATE BLOOD-BRAIN BARRIER DISRUPTION FOR THE TREATMENT OF HIGH GRADE GLIOMA IN PATIENTS UNDERGOING STANDARD CHEMOTHERAPY","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38722,"protocol_no":"INCB 18424-268","submission_no":"182967","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-15","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF RUXOLITINIB OR PLACEBO IN COMBINATION WITH CAPECITABINE IN SUBJECTS WITH ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER.","medConditionList":[{"med_condition_id":527,"med_condition":"BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48072,"protocol_no":"ID-069A301","submission_no":"212855","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-14","protocol_title":"A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LUCERASTAT ORAL MONOTHERAPY IN ADULT SUBJECTS WITH FABRY DISEASE.","medConditionList":[{"med_condition_id":79,"med_condition":"FABRY DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46359,"protocol_no":"20170345-01H","submission_no":"207253","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-04","protocol_title":"EVALUATING MULTIPARAMETER GENE TESTING AS A PREDICTOR OF SHORT TERM ENDOCRINE THERAPY RESPONSE IN HORMONE RECEPTOR POSITIVE BREAST CANCERS: THE EMPOWER STUDY","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38151,"protocol_no":"ONC1201/12-MOXE","submission_no":"181143","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-05","protocol_title":"A PHASE II STUDY OF THE ANTI-CD22 RECOMBINANT IMMUNOTOXIN MOXETUMOMAB PASUDOTOX (CAT8015, HA22) IN CHILDREN WITH B-LINEAGE ACTUE LYMPHOBLASTIC LEUKEMIA AND MINIMAL RESIDUAL DISEASE PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION","medConditionList":[{"med_condition_id":148,"med_condition":"LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40081,"protocol_no":"I1F-MC-RHBP(A)","submission_no":"187048","status_id":1,"start_date":"2015-09-24","end_date":null,"nol_date":"2015-09-18","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB DOSING REGIMENS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS,","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39245,"protocol_no":"D419AC00001","submission_no":"184587","status_id":1,"start_date":"2015-08-18","end_date":null,"nol_date":"2015-06-23","protocol_title":"A PHASE III RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF MEDI4736 IN COMBINATION WITH TREMELIMUMAB THERAPY OR MEDI4736 MONOTHERAPY VERSUS STANDARD OF CARE PLATINUM-BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) (MYSTIC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44458,"protocol_no":"TOZ-CL06","submission_no":"201365","status_id":2,"start_date":"2017-06-16","end_date":"2017-11-21","nol_date":"2017-01-16","protocol_title":"A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TOZADENANT AS ADJUNCTIVE THERAPY IN LEVODOPA-TREATED PATIENTS WITH PARKINSON¬øS DISEASE EXPERIENCING END OF DOSE ¬øWEARING-OFF¬ø","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42870,"protocol_no":"SPC11-01-110","submission_no":"196464","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-08-03","protocol_title":"OPEN-LABEL CLINICAL STUDY TO ASSESS THE SAFETY AND ADEQUACY OF EFFECTIVENESS OF THE SPECTRACURE P18 SYSTEM (INTERSTITIAL MULTIPLE DIODE LASERS AND IDOSE¬Æ SOFTWARE) AND VERTEPORFIN FOR INJECTION (VFI) FOR THE TREATMENT OF RECURRENT PROSTATE CANCER.","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37425,"protocol_no":"CWNT974X2102C","submission_no":"178594","status_id":2,"start_date":"2015-12-24","end_date":"2016-10-18","nol_date":"2014-11-07","protocol_title":"A PHASE IB/II MULTI-CENTER, OPEN LABEL, DOSE ESCALATION STUDY OF WNT974, LGX818 AND CETUXIMAB IN PATIENTS WITH BRAFV600 MUTANT KRAS WILD-TYPE METASTATIC COLORECTAL CANCER HARBORING WNT PATHWAY MUTATIONS.","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38645,"protocol_no":"PCI-32765CAN3001","submission_no":"182732","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-03-25","protocol_title":"A PHASE 3B, MULTICENTER, OPEN-LABEL, PCI-32765 (IBRUTINIB) LONG-TERM EXTENSION STUDY","medConditionList":[{"med_condition_id":308,"med_condition":"LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47867,"protocol_no":"ZX008-1601","submission_no":"212214","status_id":1,"start_date":"2018-03-23","end_date":null,"nol_date":"2018-01-11","protocol_title":"A TWO-PART STUDY OF ZX008 IN CHILDREN AND ADULTS WITH LENNOX-GASTAUT SYNDROME (LGS); PART 1: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TWO FIXED DOSES OF ZX008 (FENFLURAMINE HYDROCHLORIDE) ORAL SOLUTION AS ADJUNCTIVE THERAPY FOR SEIZURES IN CHILDREN AND ADULTS WITH LGS, FOLLOWED BY PART 2: AN OPEN-LABEL EXTENSION TO ASSESS LONG-TERM SAFETY OF ZX008 IN CHILDREN AND ADULTS WITH LGS","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44689,"protocol_no":"MP-37-2017-2614","submission_no":"202091","status_id":1,"start_date":"2017-02-01","end_date":null,"nol_date":"2017-02-23","protocol_title":"EFFECT OF INHALED VAPORIZED CANNABIS ON PULMONARY FUNCTION, BREATHLESSNESS AND EXERCISE TOLERANCE IN SYMPTOMATIC PATIENTS WITH ADVANCED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37812,"protocol_no":"TCZ001","submission_no":"179785","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-24","protocol_title":"A DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMISED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A SINGLE INTRAVENOUS DOSE OF TOCILIZUMAB FOR THE TREATMENT OF ALLERGEN-INDUCED ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47092,"protocol_no":"ALN-CC5-004","submission_no":"209723","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-26","protocol_title":"A PHASE 2, OPEN LABEL, MULTICENTER STUDY OF ALN-CC5 ADMINISTERED SUBCUTANEOUSLY IN ADULT","medConditionList":[{"med_condition_id":21,"med_condition":"ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47464,"protocol_no":"D5336C00001","submission_no":"211011","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-15","protocol_title":"A PHASE II, OPEN LABEL, RANDOMISED, MULTI-CENTRE STUDY TO ASSESS THE SAFETY AND EFFICACY OF AGENTS TARGETING DNA DAMAGE REPAIR IN COMBINATION WITH OLAPARIB VERSUS OLAPARIB MONOTHERAPY IN THE TREATMENT OF METASTATIC TRIPLE NEGATIVE BREAST CANCER PATIENTS STRATIFIED BY ALTERATIONS IN HOMOLOGOUS RECOMBINANT REPAIR (HRR)-RELATED GENES (INCLUDING BRCA1/2) (VIOLETTE)","medConditionList":[{"med_condition_id":627,"med_condition":"BREAST CANCER METASTATIC TRIPLE NEGATIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41554,"protocol_no":"D1683C00005","submission_no":"191827","status_id":2,"start_date":"2016-09-16","end_date":"2017-10-19","nol_date":"2016-02-26","protocol_title":"A MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL GROUP, PHASE III TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN 5MG CO-ADMINISTERED WITH DAPAGLIFLOZIN 5MG COMPARED TO SAXAGLIPTIN 5MG OR DAPAGLIFLOZIN 5MG ALL GIVEN AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCAEMIC CONTROL ON METFORMIN ALONE","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40088,"protocol_no":"CNTO1275AKS3002","submission_no":"187059","status_id":1,"start_date":"2016-01-29","end_date":null,"nol_date":"2015-09-25","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF USTEKINUMAB IN THE TREATMENT OF ANTI-TNFA REFRACTORY SUBJECTS WITH ACTIVE RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS","medConditionList":[{"med_condition_id":647,"med_condition":"ACTIVE RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38085,"protocol_no":"COG AALL1331","submission_no":"180546","status_id":1,"start_date":"2016-06-08","end_date":null,"nol_date":"2015-01-09","protocol_title":"RISK-STRATIFIED RANDOMIZED PHASE III TESTING OF BLINATUMOMAB IN FIRST RELAPSE OF CHILDHOOD B-LYMPHOBLASTIC LEUKEMIA (B-ALL)","medConditionList":[{"med_condition_id":148,"med_condition":"LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44124,"protocol_no":"RR-005","submission_no":"200189","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-05","protocol_title":"DULAGLUTIDE AND THE PRESERVATION OF BETA-CELL FUNCTION IN WOMEN WITH RECENT GESTATIONAL DIABETES MELLITUS","medConditionList":[{"med_condition_id":767,"med_condition":"GESTATIONAL DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44370,"protocol_no":"DRM01B-ACN04","submission_no":"201085","status_id":2,"start_date":"2017-01-11","end_date":"2017-11-21","nol_date":"2017-01-11","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, EFFICACY AND SAFETY STUDY OF OLUMACOSTAT GLASARETIL GEL IN SUBJECTS WITH ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47685,"protocol_no":"TV507I7-CNS-30046","submission_no":"211551","status_id":1,"start_date":"2018-02-09","end_date":null,"nol_date":"2017-12-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TEV-50717 (DEUTETRABENAZINE) FOR THE TREATMENT OF TOURETTE SYNDROME IN CHILDREN AND ADOLESCENTS","medConditionList":[{"med_condition_id":252,"med_condition":"TOURETTE¬íS SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36412,"protocol_no":"LUM001-201","submission_no":"175332","status_id":1,"start_date":"2014-10-10","end_date":null,"nol_date":"2014-07-03","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS","medConditionList":[{"med_condition_id":209,"med_condition":"PRIMARY BILIARY CIRRHOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47390,"protocol_no":"CAIN457F2366","submission_no":"210696","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-28","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AT WEEK 52 OF SUBCUTANEOUSLY ADMINISTERED SECUKINUMAB MONOTHERAPY COMPARED WITH SUBCUTANEOUSLY ADMINISTERED ADALIMUMAB MONOTHERAPY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29076,"protocol_no":"TR006","submission_no":"170810","status_id":3,"start_date":"2014-04-14","end_date":null,"nol_date":"2014-01-14","protocol_title":"A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO EVALUATE FOUR DOSE REGIMEN OF RAGWEED-SPIRE IN RAGWEEK ALLERGIC SUBJECTS FOLLOWING CHALLENGE WITH RAGWEED ALLERGEN IN AN ENVIRONMENTAL EXPOSURE CHAMBER","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48301,"protocol_no":"M16-292","submission_no":"213028","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-14","protocol_title":"OPEN-LABEL, SINGLE ARM, PHASE 3B STUDY EVALUATING THE SAFETY OF ROVALPITUZUMAB TESIRINE FOR THIRD-LINE AND LATER TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY DLL3 EXPRESSING SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39896,"protocol_no":"MDCO-APO-15-01","submission_no":"186521","status_id":1,"start_date":"2015-10-22","end_date":null,"nol_date":"2015-08-26","protocol_title":"A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO COMPARE THE EFFECT OF TREATMENT ON PLAQUE BURDEN AS DETERMINED BY IVUS AND TO EVALUATE THE EFFICACY, PK, SAFETY, AND TOLERABILITY OF MDCO-216 GIVEN AS MULTIPLE WEEKLY INFUSIONS IN SUBJECTS WITH A RECENT ACUTE CORONARY SYNDROME","medConditionList":[{"med_condition_id":499,"med_condition":"ACUTE CORONARY SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29165,"protocol_no":"LP0076-1017","submission_no":"171087","status_id":1,"start_date":"2015-10-23","end_date":null,"nol_date":"2014-02-07","protocol_title":"EFFECT OF CALCIPOTRIOL PLUS BETAMETHASONE DIPROPIONATE GEL ON THE HPA AXIS AND CALCIUM METABOLISM IN ADOLESCENT SUBJECTS (AGED 12 TO 16 YEARS, 11 MONTHS) WITH SCALP AND BODY PSORIASIS.","medConditionList":[{"med_condition_id":461,"med_condition":"SCALP AND BODY PSORIASIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28941,"protocol_no":"PRISTIQ-2013","submission_no":"170301","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-20","protocol_title":"A 12-WEEK, OPEN-LABEL, EFFICACY AND SAFETY STUDY OF DESVENLAFAXINE IN THE TREATMENT OF VASCULAR DEPRESSION","medConditionList":[{"med_condition_id":472,"med_condition":"VASCULAR DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40962,"protocol_no":"GS-US-380-1489","submission_no":"189786","status_id":1,"start_date":"2016-03-29","end_date":null,"nol_date":"2015-12-17","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GS-9883/EMTRICITABINE/TENOFOVIR ALAFENAMIDE VERSUS ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE IN HIV-1 INFECTED, ANTIRETROVIRAL TREATMENT-NA√èVE ADULTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27141,"protocol_no":"20120360","submission_no":"164916","status_id":1,"start_date":"2014-03-21","end_date":null,"nol_date":"2013-06-13","protocol_title":"A MULTICENTER, MULTIPLE-DOSE, TWO-ARM, ACTIVE-CONTROLLED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE THERAPEUTIC EFFICACY AND SAFETY OF ORAL DOSES OF CINACALCET HCL WITH INTRAVENOUS DOSES OF AMG 416 IN HEMODIALYSIS SUBJECTS WITH SECONDARY HYPERPARATHYROIDISM","medConditionList":[{"med_condition_id":273,"med_condition":"SECONDARY HYPERPARATHYROIDISM"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37400,"protocol_no":"MO25757","submission_no":"178516","status_id":1,"start_date":"2015-02-17","end_date":null,"nol_date":"2014-10-31","protocol_title":"A SINGLE ARM OPEN LABEL MULTICENTER EXTENSION STUDY OF BEVACIZUMAB IN PATIENTS WITH SOLID TUMORS ON STUDY TREATMENT WITH BEVACIZUMAB AT THE END OF A F. HOFFMANN-LA ROCHE AND/OR GENENTECH SPONSORED STUDY","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35524,"protocol_no":"FAZA-MAESTRO","submission_no":"172657","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-09","protocol_title":"AN EXPLORATORY STUDY OF HYPOXIA IMAGING USING 18F-FAZA-PET IN ADVANCED PANCREATIC CANCER PATIENTS BEING TREATED WITH GEMCITABINE + TH-302/PLACEBO","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28911,"protocol_no":"ALV003-1221","submission_no":"170229","status_id":1,"start_date":"2014-01-22","end_date":null,"nol_date":"2013-12-27","protocol_title":"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF ALV003 TREATMENT IN SYMPTOMATIC CELIAC DISEASE PATIENTS MAINTAINED ON A GLUTEN-FREE DIET","medConditionList":[{"med_condition_id":38,"med_condition":"CELIAC DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27395,"protocol_no":"STS001","submission_no":"165615","status_id":1,"start_date":"2015-01-01","end_date":null,"nol_date":"2013-07-15","protocol_title":"RANDOMIZED CONTROLLED TRIAL TO TEST THE EFFICACY OF TRANS-TYMPANIC INJECTIONS OF A SODIUM THIOSULFATE GEL TO PREVENT CISPLATIN-INDUCED OTOTOXICITY IN PATIENTS WITH HEAD AND NECK CANCER","medConditionList":[{"med_condition_id":34,"med_condition":"CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29194,"protocol_no":"EBI-005-AC-1","submission_no":"171180","status_id":1,"start_date":"2014-02-12","end_date":null,"nol_date":"2014-01-29","protocol_title":"A SINGLE CENTER, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF EBI-005 TOPICAL OPHTHALMIC SOLUTION FOR THE TREATMENT OF CHRONIC ALLERGIC CONJUNCTIVITIS USING AN ENVIRONMENTAL EXPOSURE CHAMBER","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46575,"protocol_no":"09-16-32","submission_no":"208003","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-28","protocol_title":"MINERALOCORTICOID RECEPTOR ANTAGONISM CLINICAL EVALUATION IN ATHEROSCLEROSIS","medConditionList":[{"med_condition_id":388,"med_condition":"DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28964,"protocol_no":"GPL/CT/2013/001/II","submission_no":"170358","status_id":1,"start_date":"2014-01-27","end_date":null,"nol_date":"2014-01-16","protocol_title":"A SINGLE-CENTRE, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PARALLEL-GROUP, COMPARATIVE ENVIRONMENTAL EXPOSURE CHAMBER (EEC) STUDY TO EVALUATE EFFICACY, SAFETY AND TOLERABILITY OF TWO FIXED DOSE COMBINATION (FDC) PRODUCTS OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE NASAL SPRAY AS COMPARED TO THE FDC OF AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE NASAL SPRAY, OLOPATADINE NASAL SPRAY, AND PLACEBO IN PATIENTS WITH SEASONAL ALLERGIC RHINITIS","medConditionList":[{"med_condition_id":425,"med_condition":"SEASONAL ALLERGIC RHINITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36055,"protocol_no":"CTT116855","submission_no":"174334","status_id":2,"start_date":"2014-06-26","end_date":"2017-07-17","nol_date":"2014-05-29","protocol_title":"A PHASE III, 52 WEEK, RANDOMIZED, DOUBLE-BLIND, 3-ARM PARALLEL GROUP STUDY, COMPARING THE EFFICACY, SAFETY AND TOLERABILITY OF THE FIXED DOSE TRIPLE COMBINATION FF/UMEC/VI WITH THE FIXED DOSE DUAL COMBINATIONS OF FF/VI AND UMEC/VI, ALL ADMINISTERED ONCE-DAILY IN THE MORNING VIA A DRY POWDER INHALER IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41052,"protocol_no":"NEO6860-OA-01","submission_no":"190080","status_id":2,"start_date":"2016-05-13","end_date":"2016-11-24","nol_date":"2015-12-29","protocol_title":"A PROOF-OF-CONCEPT, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE CONTROL, 3-PERIOD, CROSSOVER DESIGN STUDY ASSESSING NEO6860 IN PATIENTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36354,"protocol_no":"ACE-MM-102","submission_no":"175141","status_id":1,"start_date":"2016-11-28","end_date":null,"nol_date":"2014-07-02","protocol_title":"A PHASE 1B/2 MULTI-CENTER, OPEN LABEL, DOSE- ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, SAFETY, AND EFFICACY OF ACY-1215 IN COMBINATION WITH POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48060,"protocol_no":"1368.5","submission_no":"212833","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-13","protocol_title":"A PHASE II/ILL RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BL 655130 INDUCTION THERAPY IN PATIENTS WITH MODERATE-TO-SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE FAILED PREVIOUS BIOLOGICS THERAPY","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37609,"protocol_no":"1237.19","submission_no":"179154","status_id":2,"start_date":"2015-01-29","end_date":"2017-04-12","nol_date":"2014-11-18","protocol_title":"A RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF 52 WEEKS OF ONCE DAILY TREATMENT OF ORALLY INHALED TIOTROPIUM + OLODATEROL FIXED DOSE COMBINATION COMPARED WITH TIOTROPIUM ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) EXACERBATION IN PATIENTS WITH SEVERE TO VERY SEVERE COPD","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48250,"protocol_no":"GS-US-352-4365","submission_no":"213407","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-28","protocol_title":"EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF) OR POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-PV/ET MF)","medConditionList":[{"med_condition_id":513,"med_condition":"POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS"},{"med_condition_id":211,"med_condition":"PRIMARY MYELOFIBROSIS (PMF)"},{"med_condition_id":514,"med_condition":"POST-POLYCYTHEMIA VERA MYELOFIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48793,"protocol_no":"DENIM","submission_no":"215008","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-04-27","protocol_title":"\"A MULTICENTER RANDOMIZED DOUBLE BLIND STUDY EXAMINING THE EFFICACY AND SAFETY OF DENOSUMAB IN COMBINATION WITH FIRST LINE PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH BONE METASTASES SECONDARY TO METASTATIC UROTHELIAL CANCER (DENIM STUDY)\".","medConditionList":[{"med_condition_id":712,"med_condition":"BONE METASTASES"},{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46356,"protocol_no":"CO-170302131230-URCT","submission_no":"207227","status_id":1,"start_date":"2017-10-20","end_date":null,"nol_date":"2017-07-27","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY OF PHENYLEPHRINE HCL EXTENDED-RELEASE 30 MG AND PHENYLEPHRINE HCL IMMEDIATE-RELEASE 12 MG CAPSULES IN SUBJECTS WITH NASAL CONGESTION DUE TO THE COMMON COLD","medConditionList":[{"med_condition_id":603,"med_condition":"COMMON COLD"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29342,"protocol_no":"IGPRO20_3004","submission_no":"171499","status_id":2,"start_date":"2015-09-10","end_date":"2017-03-09","nol_date":"2014-02-06","protocol_title":"MULTICENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY AND EFFICACY OF IGPRO20 IN MAINTENANCE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IN SUBJECTS COMPLETING STUDY IGPRO20_3003","medConditionList":[{"med_condition_id":44,"med_condition":"CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40596,"protocol_no":"200719","submission_no":"188587","status_id":2,"start_date":null,"end_date":"2017-07-21","nol_date":"2015-11-13","protocol_title":"RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE III STUDY COMPARING THE EFFICACY AND SAFETY OF RETOSIBAN VERSUS PLACEBO AS ADD-ON THERAPY FOR WOMEN IN SPONTANEOUS PRETERM LABOR","medConditionList":[{"med_condition_id":435,"med_condition":"PREMATURE LABOUR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28722,"protocol_no":"225678-007","submission_no":"169540","status_id":2,"start_date":"2014-01-17","end_date":"2015-02-10","nol_date":"2013-11-28","protocol_title":"A SAFETY AND EFFICACY STUDY TO COMPARE DAPSONE DERMAL GEL WITH VEHICLE CONTROL IN PATIENTS WITH ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28207,"protocol_no":"1000039945B","submission_no":"167934","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-06","protocol_title":"FAST (FETAL ATRIAL FLUTTER & SUPRAVENTRICULAR TACHYCARDIA) THERAPY TRIAL - SUBSTUDY B","medConditionList":[{"med_condition_id":417,"med_condition":"SUPRAVENTRICULAR TACHYCARDIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27724,"protocol_no":"C16017","submission_no":"166547","status_id":1,"start_date":"2014-01-17","end_date":null,"nol_date":"2013-08-19","protocol_title":"AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF ORAL MLN9708 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27518,"protocol_no":"HGS1006-C1115","submission_no":"165970","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-07-24","protocol_title":"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLED, 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELIMUMAB (HGS1006) ADMINISTERED SUBCUTANEOUSLY (SC) TO SUBJECTS WITH SYSTEMIC LUPUS ERTHEMATOSUS (SLE)","medConditionList":[{"med_condition_id":311,"med_condition":"SYSTEMIC LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40857,"protocol_no":"VTP-38543-001","submission_no":"189478","status_id":2,"start_date":"2016-02-17","end_date":"2016-09-09","nol_date":"2015-12-10","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED ASCENDING MULTIPLE DOSE AND CLINICAL PROOF¬øOF-CONCEPT STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF VTP-38543 IN ADULT PATIENTS WITH MILD TO MODERATE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35785,"protocol_no":"14861B","submission_no":"173452","status_id":2,"start_date":"2016-08-04","end_date":"2017-06-21","nol_date":"2014-04-17","protocol_title":"AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LU AE58054 AS ADJUNCTIVE TREATMENT TO DONEPEZIL IN PATIENTS WITH MILD-MODERATE ALZHEIMER'S DISEASE.","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28233,"protocol_no":"2013-002","submission_no":"168002","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-04","protocol_title":"A PHASE 2, OPEN-LABEL CLINICAL TRIAL DEMONSTRATING THE SAFETY OF RBX2660 MICROBIOTA SUSPENSION FOR THE TREATMENT OF RECURRENT CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD)","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41707,"protocol_no":"GS-US-404-1808","submission_no":"192393","status_id":1,"start_date":"2016-12-16","end_date":null,"nol_date":"2016-03-17","protocol_title":"A PHASE 2B, DOSE-RANGING STUDY OF THE EFFECT OF GS-5745 ON FEV1 IN ADULT SUBJECTS WITH CYSTIC FIBROSIS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27680,"protocol_no":"200109","submission_no":"166434","status_id":2,"start_date":"2013-09-24","end_date":"2014-04-01","nol_date":"2013-08-09","protocol_title":"A STUDY TO COMPARE THE ADDITION OF UMECLIDINIUM BROMIDE (UMEC) TO FLUTICASONE FUROATE (FF)/VILANTEROL (VI), WITH PLACEBO PLUS FF/VI IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) -STUDY 1","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38095,"protocol_no":"104584","submission_no":"180835","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-01-15","protocol_title":"BOTULINUM TOXIN TYPE A FOR INJECTION OF BILATERAL UPPER EXTREMITY TREMOR IN PATIENTS WITH ESSENTIAL TREMOR USING KINEMATIC ASSESSMENT","medConditionList":[{"med_condition_id":597,"med_condition":"ESSENTIAL TREMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46025,"protocol_no":"6014353","submission_no":"206109","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-21","protocol_title":"SAFETY AND EFFECTIVENESS OF PHARMACOLOGICAL SEDATIVES","medConditionList":[{"med_condition_id":340,"med_condition":"SEDATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40404,"protocol_no":"1199.214","submission_no":"187989","status_id":1,"start_date":"2016-06-13","end_date":null,"nol_date":"2015-10-20","protocol_title":"A DOUBLE BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL EVALUATING EFFICACY AND SAFETY OF ORAL NINTEDANIB TREATMENT FOR AT LEAST 52 WEEKS IN PATIENTS WITH 'SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE'(SSC-ILD).","medConditionList":[{"med_condition_id":246,"med_condition":"SYSTEMIC SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41960,"protocol_no":"GLY-CD-001","submission_no":"193405","status_id":1,"start_date":"2016-07-30","end_date":null,"nol_date":"2016-04-15","protocol_title":"AN OPEN LABEL, MULTI-CENTRE TRIAL OF GLYBERA (ALIPOGENE TIPARVOVEC) FOR THE TREATMENT OF LPLD PATIENTS","medConditionList":[{"med_condition_id":687,"med_condition":"LIPOPROTEIN LIPASE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46749,"protocol_no":"PM.1","submission_no":"208564","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-20","protocol_title":"CANADIAN PROFILING AND TARGETED AGENT UTILIZATION TRIAL (CAPTUR) A PHASE II BASKET TRIAL","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48816,"protocol_no":"20170533","submission_no":"215091","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-05-02","protocol_title":"A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF AMG 562 IN SUBJECTS WITH RELAPSED / REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA, OR FOLLICULAR LYMPHOMA","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"},{"med_condition_id":424,"med_condition":"MANTLE CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40916,"protocol_no":"LP0084-1195","submission_no":"189689","status_id":2,"start_date":"2016-04-21","end_date":"2017-08-16","nol_date":"2015-12-14","protocol_title":"EFFICACY AND SAFETY OF LEO 43204 IN FIELD TREATMENT OF ACTINIC KERATOSIS ON BALDING SCALP INCLUDING 12-MONTH FOLLOW-UP.","medConditionList":[{"med_condition_id":520,"med_condition":"ACTINIC KERATOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44339,"protocol_no":"OVC.1 / NRG-GY004","submission_no":"200872","status_id":1,"start_date":"2017-03-02","end_date":null,"nol_date":"2016-12-29","protocol_title":"A PHASE III STUDY COMPARING SINGLE-AGENT OLAPARIB OR THE COMBINATION OF CEDIRANIB AND OLAPARIB TO STANDARD PLATINUM-BASED CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-SENSITIVE OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":692,"med_condition":"PRIMARY PERITONEAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44185,"protocol_no":"CA209-744","submission_no":"200338","status_id":1,"start_date":"2017-06-16","end_date":null,"nol_date":"2016-12-02","protocol_title":"RISK-BASED, RESPONSE-ADAPTED, PHASE II OPEN-LABEL TRIAL OF NIVOLUMAB + BRENTUXIMAB VEDOTIN (N + BV) FOR CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED/REFRACTORY (R/R) CD30 + CLASSIC HODGKIN LYMPHOMA (CHL) AFTER FAILURE OF FIRST-LINE THERAPY, FOLLOWED BY BRENTUXIMAB + BENDAMUSTINE (BV + B) FOR PARTICIPANTS WITH A SUBOPTIMAL RESPONSE","medConditionList":[{"med_condition_id":481,"med_condition":"HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44247,"protocol_no":"ACE-LY-308","submission_no":"200527","status_id":1,"start_date":"2017-06-19","end_date":null,"nol_date":"2016-12-12","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF BENDAMUSTINE AND RITUXIMAB (BR) ALONE VERSUS IN COMBINATION WITH ACALABRUTINIB (ACP-196) IN SUBJECTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA","medConditionList":[{"med_condition_id":424,"med_condition":"MANTLE CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41981,"protocol_no":"NN9068-4229","submission_no":"193499","status_id":1,"start_date":"2016-05-20","end_date":null,"nol_date":"2016-04-29","protocol_title":"A CLINICAL TRIAL COMPARING GLYCAEMIC CONTROL AND SAFETY OF INSULIN DEGLUDEC/LIRAGLUTIDE (IDEGLIRA) VERSUS INSULIN GLARGINE (IGLAR) AS ADD-ON THERAPY TO SGLT2I IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45413,"protocol_no":"RLY5016-206P","submission_no":"204332","status_id":1,"start_date":"2017-10-02","end_date":null,"nol_date":"2017-04-25","protocol_title":"A PHASE 2, OPEN-LABEL, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC EFFECTS, SAFETY AND TOLERABILITY OF PATIROMER FOR ORAL SUSPENSION IN CHILDREN AND ADOLESCENTS 2 TO < 18 YEARS OF AGE WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA (EMERALD)","medConditionList":[{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"},{"med_condition_id":271,"med_condition":"HYPERKALEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38887,"protocol_no":"M14-004","submission_no":"183517","status_id":2,"start_date":"2015-08-20","end_date":"2016-12-08","nol_date":"2015-05-05","protocol_title":"A MULTIPART, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OMBITASVIR /PARITAPREVIR/ RITONAVIR WITH AND WITHOUT DASABUVIR COADMINISTERED WITH AND WITHOUT RIBAVIRIN IN ADULTS WITH GENOTYPE 1 OR 4 CHRONIC HEPATITIS C VIRUS INFECTION AND HUMAN IMMUNODEFICIENCY VIRUS, TYPE 1 COINFECTION (TURQUOISE-I)","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43553,"protocol_no":"AZT-001","submission_no":"198429","status_id":1,"start_date":"2017-03-16","end_date":null,"nol_date":"2017-02-01","protocol_title":"PROTOCOL TITLE: A PHASE III SAFETY AND EFFICACY STUDY OF ALZT-OP1 IN SUBJECTS WITH EVIDENCE OF EARLY ALZHEIMER¬øS DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39594,"protocol_no":"VX14-661-110","submission_no":"185802","status_id":1,"start_date":"2016-02-24","end_date":null,"nol_date":"2015-07-10","protocol_title":"A PHASE 3, OPEN-LABEL, ROLLOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LONG TERM TREATMENT WITH VX 661 IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS, HOMOZYGOUS OR HETEROZYGOUS FOR THE F508DEL CFTR MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48461,"protocol_no":"1218.91","submission_no":"213969","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-16","protocol_title":"A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EMPAGLIFLOZIN AND LINAGLIPTIN OVER 26 WEEKS, WITH A DOUBLE-BLIND ACTIVE TREATMENT SAFETY EXTENSION PERIOD UP TO 52 WEEKS, IN CHILDREN AND ADOLESCENTS WITH TYPE 2 DIABETES MELLITUS.","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47654,"protocol_no":"17664","submission_no":"211469","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-18","protocol_title":"A RANDOMIZED, ACTIVE-COMPARATOR-CONTROLLED, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF DIFFERENT DOSES OF BAY 1213790 FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING ELECTIVE PRIMARY TOTAL KNEE ARTHROPLASTY, OPEN-LABEL TO TREATMENT AND OBSERVR-BLIONDED TO BAY 1213790 DOSES.","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27538,"protocol_no":"VO73.13","submission_no":"166050","status_id":3,"start_date":"2013-07-29","end_date":null,"nol_date":"2013-07-26","protocol_title":"INVESTIGATION OF THE SAFTEY AND TOLERABILITY OF SUBLINGUAL IMMUNOTHERAPY TABLETS OF HOUSE DUST MITE ALLERGEN EXTRACTS IN ADOLESCENTS WITH HOUSE DUST MITE-ASSOCIATED ALLERGIC RHINITIS","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43597,"protocol_no":"CA209-648","submission_no":"198575","status_id":1,"start_date":"2017-06-20","end_date":null,"nol_date":"2016-10-20","protocol_title":"A TWO-COHORT, OPEN-LABEL, RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB MONOTHERAPY AND IN COMBINATION WITH IPILIMUMAB IN SUBJECTS WITH ADVANCED OR METASTATIC, PREVIOUSLY TREATED GASTRIC GASTROESOPAGEAL JUNCTION, OR PREVIOUSLY UNTREATED ESOPHAGEAL CANCER","medConditionList":[{"med_condition_id":337,"med_condition":"GASTRIC CANCER"},{"med_condition_id":696,"med_condition":"ESOPHAGEAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28823,"protocol_no":"1311.2","submission_no":"169984","status_id":2,"start_date":"2014-06-03","end_date":"2015-10-13","nol_date":"2013-12-24","protocol_title":"A 48 WEEKS STUDY OF THREE DIFFERENT DOSE REGIMENS OF BI 655066 ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (RANDOMISED, DOSE-RANGING, ACTIVE-COMPARATOR CONTROLLED (USTEKINUMAB), DOUBLE-BLIND WITHIN DOSE GROUPS OF BI 655066)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27911,"protocol_no":"PR-0001.1","submission_no":"167043","status_id":1,"start_date":"2015-04-10","end_date":null,"nol_date":"2013-08-30","protocol_title":"AN OPEN LABEL CLINICAL TRIAL OF RETINAL GENE THERAPY FOR CHOROIDEREMIA USING AN ADENO-ASSOCIATED VIRAL VECTOR (AAV2) ENCODING RAB-ESCORT PROTEIN-1 (REP-1)","medConditionList":[{"med_condition_id":382,"med_condition":"CHOROIDEREMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43633,"protocol_no":"20160909","submission_no":"198710","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-10-18","protocol_title":"PAIN FREE LACERATION REPAIRS USING INTRA-NASAL KETAMINE: A DOSE ESCALATION CLINICAL TRIAL","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42089,"protocol_no":"460503","submission_no":"193867","status_id":1,"start_date":"2016-12-20","end_date":null,"nol_date":"2016-05-02","protocol_title":"A STAGE 1, PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ALPHA-PROTEINASE INHIBITOR (AIPI) AUGMENTATION THERAPY IN SUBJECTS WITH AIPI DEFICIENCY AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"},{"med_condition_id":667,"med_condition":"ALPHA1-PROTEINASE INHIBITOR DEFICIENT"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37537,"protocol_no":"I8D-MD-AZES / D5010C00009","submission_no":"178927","status_id":1,"start_date":"2015-01-23","end_date":null,"nol_date":"2014-12-18","protocol_title":"A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMER'S DISEASE (THE AMARANTH STUDY)","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42105,"protocol_no":"2215-CL-0201","submission_no":"193909","status_id":1,"start_date":"2017-09-22","end_date":null,"nol_date":"2016-05-03","protocol_title":"A PHASE 2/3 MULTICENTER, OPEN-LABEL, 3-ARM, 2-STAGE RANDOMIZED STUDY OF ASP2215 (GILTERITINIB), COMBINATION OF ASP2215 PLUS AZACITIDINE AND AZACITIDINE ALONE IN THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WITH FLT3 MUTATION IN PATIENTS NOT ELIGIBLE FOR INTENSIVE INDUCTION CHEMOTHERAPY","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41142,"protocol_no":"051","submission_no":"190453","status_id":1,"start_date":"2016-12-12","end_date":null,"nol_date":"2016-01-15","protocol_title":"A PHASE I/II STUDY OF PEMBROLIZUMAB (MK-3475) IN CHILDREN WITH ADVANCED MELANOMA OR A PD-L1 POSITIVE ADVANCED, RELAPSED OR REFRACTORY SOLID TUMOR OR LYMPHOMA (KEYNOTE-051)","medConditionList":[{"med_condition_id":440,"med_condition":"LYMPHOID MALIGNANCIES"},{"med_condition_id":154,"med_condition":"MELANOMA"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26653,"protocol_no":"A1452020","submission_no":"163380","status_id":1,"start_date":"2013-06-27","end_date":null,"nol_date":"2013-04-19","protocol_title":"\"A PHASE 3 BLINDED RANDOMIZED STUDY OF PEGINTERFERON LAMBDA-1A AND RIBAVIRIN COMPARED TO PEGINTERFERON ALFA-2A AND RIBAVIRIN, EACH ADMINISTERED WITH TELAPREVIR IN SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C WHO ARE TREATMENT-NAIVE OR RELAPSED ON TREATMENT WITH PEGINTERFERON ALFA AND RIBAVIRIN.\"","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27613,"protocol_no":"116892 (MENACWY-TT-104)","submission_no":"166259","status_id":1,"start_date":"2013-09-24","end_date":null,"nol_date":"2013-07-31","protocol_title":"\"IMMUNOGENICITY AND SAFETY STUDY OF 1 AND 2 DOSES OF GSK BIOLOGICALS' MENINGOCOCCAL VACCINE GSK134612 IN TODDLERS, PERSISTANCE UP TO 5 YEARS AFTER VACCINATION AND CO-ADMINISTRATION WITH PFIZER'S PNEUMOCOCCAL VACCINE PREVENAR 13.\"","medConditionList":[{"med_condition_id":156,"med_condition":"MENINGITIS B"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38999,"protocol_no":"METRO2015","submission_no":"183849","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-05-04","protocol_title":"METRONIDAZOLE EVERY 24 HOURS AS PART OF TRIPLE ANTIBIOTIC THERAPY FOR RUPTURED APPENDICITIS IN CHILDREN MANAGED OPERATIVELY (METRO): A NONINFERIORITY RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":658,"med_condition":"APPENDICITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47634,"protocol_no":"654-01/ECHO-305","submission_no":"211423","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-19","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PEMBROLIZUMAB (MK-3475) PLUS EPACADOSTAT (INCB024360) VERSUS PEMBROLIZUMAB PLUS PLACEBO AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER EXPRESSING HIGH LEVELS OF PD-L1","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47621,"protocol_no":"715-01/ECHO-306","submission_no":"211384","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-20","protocol_title":"A RANDOMIZED PHASE 3 STUDY OF THE COMBINATION OF PEMBROLIZUMAB (MK-3475) PLUS EPACADOSTAT (INCB024360) ALONE OR WITH PLATINUM-BASED CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS PLATINUM-BASED CHEMOTHERAPY PLUS PLACEBO AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46800,"protocol_no":"R1500-CL-1643","submission_no":"208721","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-20","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF VARYING DOSES AND DOSE REGIMENS OF EVINACUMAB IN PATIENTS WITH PERSISTENT  HYPERCHOLESTEROLEMIA DESPITE MAXIMALLY TOLERATED LIPID MODIFYING THERAPY","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40432,"protocol_no":"PRO00053082 / IPP15070","submission_no":"188081","status_id":1,"start_date":"2017-06-29","end_date":null,"nol_date":"2015-10-29","protocol_title":"AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBILIZATION (PLERIXAFOR) AND IMMUNOLOGIC RESET IN NEW ONSET TYPE 1 DIABETES MELLITUS","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39293,"protocol_no":"003-10","submission_no":"184733","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-06-19","protocol_title":"A 9-MONTHS EXTENSION STUDY: A STUDY TO EVALUATE THE USE OF SOMVC001 (GALA). VASCULAR CONDUIT PRESERVATION SOLUTION IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING (CABG).","medConditionList":[{"med_condition_id":55,"med_condition":"CORONARY ARTERY BYPASS GRAFT"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42515,"protocol_no":"MMTPR0114","submission_no":"195236","status_id":1,"start_date":"2017-11-04","end_date":null,"nol_date":"2016-06-17","protocol_title":"A PILOT STUDY INVESTIGATING APIXABAN AND DEXAMETHASONE INTERACTION IN MULTIPLE MYELOMA (ADAM)","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27608,"protocol_no":"065/2013","submission_no":"166252","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-08-06","protocol_title":"METFORMIN FOR ATTENUATION OF EARLY CLOZAPINE-ASSOCIATED WEIGHT GAIN IN A FIRST-EPISODE SCHIZOPHRENIA POPULATION: A RANDOMIZED, PLACEBO-CONTROLLED STUDY","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"},{"med_condition_id":341,"med_condition":"WEIGHT GAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39113,"protocol_no":"TV1106-IMM-30022","submission_no":"184200","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-05-29","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, COMPARATOR-CONTROLLED STUDY TO ASSESS SAFETY AND TOLERABLITY OF WEEKLY TV-1106 COMPARED TO DAILY RHGH (GENOTROPIN) IN ADULTS WITH GROWTH HORMONE-DEFICIENCY","medConditionList":[{"med_condition_id":94,"med_condition":"GROWTH HORMONE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47504,"protocol_no":"HPV-301","submission_no":"211109","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-08","protocol_title":"A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA 5PSP FOR THE TREATMENT OF HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) OF THE CERVIX","medConditionList":[{"med_condition_id":817,"med_condition":"HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) OF THE CERVIX"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38667,"protocol_no":"TR006A","submission_no":"182783","status_id":1,"start_date":"2015-09-14","end_date":null,"nol_date":"2015-04-08","protocol_title":"AN OBSERVATIONAL FOLLOW-ON FIELD STUDY TO EVALUATE THE CONTINUED EFFICACY AND SAFETY OF RAGWEED-SPIRE TREATMENT IN RAGWEED ALLERGIC SUBJECTS APPROXIMATELY ONE YEAR AFTER THE COMPLETION OF TREATMENT","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29407,"protocol_no":"CAT-2003-203","submission_no":"171734","status_id":1,"start_date":"2014-06-23","end_date":null,"nol_date":"2014-02-25","protocol_title":"A PHASE 2 PILOT STUDY TO ASSESS THE SAFETY AND EFFICACY OF CAT-2003 IN PATIENTS WITH CHYLOMICRONEMIA","medConditionList":[{"med_condition_id":493,"med_condition":"CHYLOMICRONEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40516,"protocol_no":"GED-0301-CD-002","submission_no":"188368","status_id":1,"start_date":"2016-02-26","end_date":null,"nol_date":"2015-11-04","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MONGERSEN (GED-0301) FOR THE TREATMENT OF SUBJECTS WITH ACTIVE CROHN¬øS DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47562,"protocol_no":"IGX-CLI-2017-001","submission_no":"211259","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-14","protocol_title":"A PARALLEL OPEN DESIGN, RANDOMIZED PHASE IIA, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, FEASIBILITY, TOLERABILITY, AND EFFICACY OF A NEW BUCCAL FILM OF MONTELUKAST IN PATIENTS WITH MILD TO MODERATE ALZHEIMER¬øS DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29503,"protocol_no":"M14-347","submission_no":"172015","status_id":1,"start_date":"2014-08-13","end_date":null,"nol_date":"2014-03-03","protocol_title":"A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG TERM EFFICACY, SAFETY, AND TOLERABILITY OF REPEATED ADMINISTRATION OF ADALIMUMAB IN SUBJECTS WITH CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37573,"protocol_no":"TG1050.02","submission_no":"179058","status_id":1,"start_date":"2016-08-31","end_date":null,"nol_date":"2014-11-20","protocol_title":"A PHASE I/IB RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED AND DOSE-FINDING STUDY TO EVALUATE THE SAFETY, AND TOLERABILITY OF SINGLE (SD) AND MULTIPLE (MD) DOSES OF AN ADENOVIRUS SEROTYPE 5 (AD5) VECTOR BASED IMMUNOTHERAPEUTIC PRODUCT, TG1050, AND AN INITIAL EVALUATION OF IMMUNOLOGIC AND ANTIVIRAL ACTIVITY OF TG1050 IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B INFECTION","medConditionList":[{"med_condition_id":103,"med_condition":"HEPATITIS B VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40961,"protocol_no":"MYL-1501D-3003","submission_no":"189815","status_id":2,"start_date":"2016-04-08","end_date":"2017-03-09","nol_date":"2015-12-17","protocol_title":"AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN'S INSULIN GLARGINE WITH LANTUS¬Æ IN TYPE 1 DIABETES MELLITUS PATIENTS: AN EXTENSION STUDY","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27592,"protocol_no":"GB28688","submission_no":"166218","status_id":1,"start_date":"2013-08-29","end_date":null,"nol_date":"2013-08-02","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA WHO ARE ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38579,"protocol_no":"TWILIGHT","submission_no":"182481","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-01","protocol_title":"TICAGRELOR WITH ASPIRIN OR ALONE IN HIGH RISK PATIENTS AFTER CORONARY INTERVENTION (ISSBRIL0345)","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27789,"protocol_no":"MDV3100-14","submission_no":"166719","status_id":1,"start_date":"2014-04-23","end_date":null,"nol_date":"2013-08-15","protocol_title":"PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"},{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28501,"protocol_no":"EVP-6124-025","submission_no":"168790","status_id":1,"start_date":"2014-06-05","end_date":null,"nol_date":"2013-11-04","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 26-WEEK, PHASE 3 STUDY OF TWO DOSES OF EVP-6124 OR PLACEBO IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE CURRENTLY OR PREVIOUSLY RECEIVING AN ACETYLCHOLINESTERASE INHIBITOR MEDICATION","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38458,"protocol_no":"QBECO-UC-01","submission_no":"182086","status_id":1,"start_date":"2016-02-02","end_date":null,"nol_date":"2015-03-13","protocol_title":"AN OPEN LABEL, DOSE RANGING, EXPLORATORY STUDY TO EVLUATE THE SAFETY, TOLERABILITY, COMPLIANCE, MECHANISM OF ACTION AND EFFICACY OF QBECO SITE SPECIFIC IMMUNOMODULATION FOR THE INDUCTION OF CLINICAL RESPONSE AND REMISSION IN SUBJECTS WIHT MODERATE TO SEVERE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35853,"protocol_no":"068-01","submission_no":"173644","status_id":1,"start_date":"2014-10-16","end_date":null,"nol_date":"2014-05-06","protocol_title":"A PHASE III RANDOMIZED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172/MK-8742 IN SUBJECTS WHO HAVE FAILED PRIOR TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN (P/R) WITH CHRONIC HCV GT1, GT4, GT5, AND GT6 INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28950,"protocol_no":"13-6795","submission_no":"170338","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-01-17","protocol_title":"THE EFFECT OF DEXMEDETOMIDINE AS A LOCAL ANESTHETIC ADJUNCT IN ANKLE BLOCKS ON THE DURATION OF ANALGESIA AND HEMODYNAMIC VARIABLES FOLLOWING FOREFOOT SURGERY. A DOSE-RANGING STUDY","medConditionList":[{"med_condition_id":467,"med_condition":"ANALGESIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38248,"protocol_no":"200984","submission_no":"181401","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-11","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PAZOPANIB MONOTHERAPY PLUS BEST SUPPORTIVE CARE (BSC) COMPARED WITH PLACEBO PLUS BSC IN SUBJECTS WITH WELL-DIFFERENTIATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PANCREATIC NEUROENDOCRINE TUMORS (PNETS), WHO HAVE PROGRESSED ON OR FOLLOWING PRIOR TREATMENT WITH EVEROLIMUS AND/OR SUNITINIB","medConditionList":[{"med_condition_id":188,"med_condition":"PANCREATIC NEUROENDOCRINE TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37642,"protocol_no":"R668-AD-1416","submission_no":"179239","status_id":2,"start_date":"2014-10-24","end_date":"2016-01-21","nol_date":"2014-11-25","protocol_title":"A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46843,"protocol_no":"54767414MMY3012","submission_no":"208854","status_id":1,"start_date":"2017-11-10","end_date":null,"nol_date":"2017-09-28","protocol_title":"A PHASE 3 RANDOMIZED, MULTICENTER STUDY OF SUBCUTANEOUS VS. INTRAVENOUS ADMINSTRATION OF DARATUMUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40020,"protocol_no":"ESR-15-10942","submission_no":"186856","status_id":1,"start_date":"2015-08-01","end_date":null,"nol_date":"2015-09-09","protocol_title":"EFFECT OF ACLIDINIUM BROMIDE/FORMOTEROL 400/12¬øG (DUAKLIR) ON NIGHTTIME LUNG FUNCTION, RESPIRATORY MECHANICS AND EARLY MORNING SYMPTOMS IN COPD","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46556,"protocol_no":"ISIS 703802-CS3","submission_no":"207950","status_id":1,"start_date":"2017-11-22","end_date":null,"nol_date":"2017-08-21","protocol_title":"A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AKCEA-ANGPTL3-LRX (ISIS 703802) ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)","medConditionList":[{"med_condition_id":82,"med_condition":"FAMILIAL CHYLOMICRONEMIA SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42050,"protocol_no":"EMR200017-014","submission_no":"193748","status_id":1,"start_date":"2017-05-30","end_date":null,"nol_date":"2016-04-29","protocol_title":"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ABITUZUMAB IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)","medConditionList":[{"med_condition_id":423,"med_condition":"INTERSTITIAL LUNG DISEASE"},{"med_condition_id":246,"med_condition":"SYSTEMIC SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41941,"protocol_no":"432-2015 (CHC-CRPC-001)","submission_no":"193343","status_id":1,"start_date":"2016-12-15","end_date":null,"nol_date":"2016-04-14","protocol_title":"HYPERPOLARIZED CARBON-13 IMAGING OF METASTATIC PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29442,"protocol_no":"NA-1-005","submission_no":"171820","status_id":1,"start_date":"2015-03-02","end_date":null,"nol_date":"2014-02-26","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF INTRAVENOUS NA-1 INITIATED BY PARAMEDICS IN THE FIELD FOR ACUTE CEREBRAL ISCHEMIA WITHIN THREE HOURS OF SYMPTOM ONSET","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44163,"protocol_no":"CA209-848","submission_no":"200270","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-02","protocol_title":"A PHASE 2, MULTICENTER, SAFETY AND EFFICACY STUDY OF NIVOLUMAB IN PARTICIPANTS WITH ADVANCED MALIGNANCIES WITH MICROSATELLITE INSTABILITY HIGH (MSI-H)/DNA MISMATCH REPAIR DEFICIENCY (DMMR)","medConditionList":[{"med_condition_id":665,"med_condition":"ADVANCED MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41884,"protocol_no":"B7451006","submission_no":"193125","status_id":2,"start_date":"2016-05-11","end_date":"2017-06-07","nol_date":"2016-04-08","protocol_title":"A PHASE 2B RANDOMIZED , DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41678,"protocol_no":"GS-US-406-1840","submission_no":"192305","status_id":2,"start_date":"2017-03-23","end_date":"2018-03-06","nol_date":"2016-03-14","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND TOLERABILITY OF ENTOSPLETINIB, A SELECTIVE SYK INHIBITOR, IN COMBINATION WITH SYSTEMIC CORTICOSTEROIDS AS FIRST-LINE THERAPY IN SUBJECTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)","medConditionList":[{"med_condition_id":370,"med_condition":"GRAFT VS HOST DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28424,"protocol_no":"GO28667","submission_no":"168520","status_id":1,"start_date":"2015-05-14","end_date":null,"nol_date":"2013-10-24","protocol_title":"A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42884,"protocol_no":"12712A","submission_no":"196531","status_id":1,"start_date":"2017-01-23","end_date":null,"nol_date":"2016-07-28","protocol_title":"LONG-TERM, OPEN-LABEL, FLEXIBLE-DOSE, EXTENSION STUDY OF VORTIOXETINE IN CHILD AND ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD) FROM 7 TO 18 YEARS OF AGE","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46029,"protocol_no":"WVE-HDSNP1-001","submission_no":"206127","status_id":1,"start_date":"2017-08-28","end_date":null,"nol_date":"2017-06-21","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PHASE 1B/2A STUDY OF WVE-120101 ADMINISTERED INTRATHECALLY IN PATIENTS WITH HUNTINGTON¬øS DISEASE","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41017,"protocol_no":"NCIC CTG: MEC.5 / S1404","submission_no":"189971","status_id":1,"start_date":"2016-04-14","end_date":null,"nol_date":"2016-01-08","protocol_title":"A PHASE III RANDOMIZED TRIAL COMPARING HIGH DOSE INTERFERON TO MK-3475 (PEMBROLIZUMAB) IN PATIENTS WITH HIGH RISK RESECTED MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27255,"protocol_no":"GO28753","submission_no":"165234","status_id":1,"start_date":"2015-02-22","end_date":null,"nol_date":"2013-06-26","protocol_title":"A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE.","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35863,"protocol_no":"GO29293","submission_no":"173660","status_id":1,"start_date":"2014-09-12","end_date":null,"nol_date":"2014-05-07","protocol_title":"A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40112,"protocol_no":"M13-813","submission_no":"187117","status_id":1,"start_date":"2016-08-19","end_date":null,"nol_date":"2015-09-23","protocol_title":"A RANDOMIZED, PLACEBO CONTROLLED PHASE 2B/3 STUDY OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28519,"protocol_no":"EFC13786","submission_no":"168849","status_id":2,"start_date":"2015-09-15","end_date":"2017-10-11","nol_date":"2013-11-07","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA NOT TREATED WITH A STATIN","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36924,"protocol_no":"DIVA","submission_no":"176971","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-08-28","protocol_title":"VITAMIN D IN THE PREVENTION OF VIRAL-INDUCED ASTHMA OF PRESCHOOLERS: A RCT","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43298,"protocol_no":"VBP15-003","submission_no":"197749","status_id":1,"start_date":"2016-10-25","end_date":null,"nol_date":"2016-09-16","protocol_title":"A PHASE II OPEN-LABEL, MULTICENTER EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF VAMOROLONE IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD)","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44198,"protocol_no":"205MS305","submission_no":"200374","status_id":1,"start_date":"2017-03-10","end_date":null,"nol_date":"2016-12-16","protocol_title":"A PHASE 3B, 12-MONTH, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB019, DACLIZUMAB, IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) SWITCHING FROM NATALIZUMAB (SUSTAIN)","medConditionList":[{"med_condition_id":565,"med_condition":"RELAPSING-REMITTING MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47422,"protocol_no":"64091742PCR2002","submission_no":"210881","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-01","protocol_title":"A PHASE 1B-2 STUDY OF NIRAPARIB COMBINATION THERAPIES FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39556,"protocol_no":"PHL-095 / NCI 9673","submission_no":"185712","status_id":2,"start_date":"2015-10-14","end_date":"2016-04-29","nol_date":"2015-07-21","protocol_title":"A MULTI-INSTITUTIONAL PHASE II STUDY OF NIVOLUMAB IN REFRACTORY METASTATIC SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39924,"protocol_no":"CAMHPET-CTA-95","submission_no":"186621","status_id":1,"start_date":"2015-09-01","end_date":null,"nol_date":"2015-08-25","protocol_title":"THE ENDOCANNABINOID SYSTEM AND RISK FOR ALCOHOL USE DISORDER: A PET STUDY WITH THE NOVEL FATTY ACID AMIDE HYDROLASE RADIOLIGAND [11C]CURB","medConditionList":[{"med_condition_id":420,"med_condition":"ADDICTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46354,"protocol_no":"001","submission_no":"207224","status_id":1,"start_date":"2017-09-20","end_date":null,"nol_date":"2017-08-03","protocol_title":"A PHASE 1 TRIAL OF MK-4280 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37725,"protocol_no":"A3921133","submission_no":"179565","status_id":1,"start_date":"2015-03-27","end_date":null,"nol_date":"2014-12-10","protocol_title":"PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS.","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38342,"protocol_no":"15-3007-KTM","submission_no":"181725","status_id":1,"start_date":"2015-11-27","end_date":null,"nol_date":"2015-05-01","protocol_title":"A PILOT STUDY OF SUB-ANESTHETIC KETAMINE INFUSION FOR NEUROPROTECTION AFTER ANEURYSMAL SUBARACHNOID HEMORRHAGE: EFFECTS ON WHITE MATTER INTEGRITY, INFLAMMATORY BIOMARKERS, AND NEUROCOGNITIVE OUTCOME","medConditionList":[{"med_condition_id":336,"med_condition":"ANEURYSMAL SUBARACHNOID HEMORRHAGE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42174,"protocol_no":"TED-C14-006","submission_no":"194151","status_id":1,"start_date":"2016-09-30","end_date":null,"nol_date":"2016-05-19","protocol_title":"A 24-WEEK DOUBLE-BLIND, SAFETY, EFFICACY, AND PHARMACODYNAMIC STUDY INVESTIGATING TWO DOSES OF TEDUGLUTIDE IN PEDIATRIC SUBJECTS THROUGH 17 YEARS OF AGE WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT","medConditionList":[{"med_condition_id":697,"med_condition":"SHORT BOWEL SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35369,"protocol_no":"CB102-21425","submission_no":"172113","status_id":1,"start_date":"2014-04-10","end_date":null,"nol_date":"2014-03-03","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ARHALOFENATE FOR PREVENTING FLARES AND REDUCING SERUM URIC ACID IN GOUT PATIENTS","medConditionList":[{"med_condition_id":93,"med_condition":"GOUT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38120,"protocol_no":"MEDOPP038","submission_no":"180972","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-01-29","protocol_title":"PHASE I MULTICENTER CLINICAL TRIAL EVALUATING THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND DOXORUBICIN IN HER2-POSITIVE METASTATIC BREAST CANCER.","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45938,"protocol_no":"130908","submission_no":"205890","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-23","protocol_title":"CERTOLIZUMAB TO PREVENT PREGNANCY COMPLICATIONS IN HIGH-RISK PATIENTS WITH APS, WITH OR WITHOUT SLE","medConditionList":[{"med_condition_id":584,"med_condition":"ANTIPHOSPHOLIPID SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28205,"protocol_no":"MDV3100-12","submission_no":"167956","status_id":1,"start_date":"2015-07-21","end_date":null,"nol_date":"2013-10-02","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF EFFICACY AND SAFETY OF ENZALUTAMIDE IN COMBINATION WITH EXEMESTANE IN PATIENTS WITH ADVANCED BREAST CANCER THAT IS ESTROGEN OR PROGESTERONE RECEPTOR-POSITIVE AND HER2-NORMAL","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45010,"protocol_no":"1002-050","submission_no":"203060","status_id":1,"start_date":"2017-09-18","end_date":null,"nol_date":"2017-03-15","protocol_title":"A MULTICENTER OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF BEMPEDOIC ACID (ETC 1002) 180 MG","medConditionList":[{"med_condition_id":348,"med_condition":"HYPERLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27401,"protocol_no":"TIPBCC002","submission_no":"165476","status_id":1,"start_date":"2014-12-04","end_date":null,"nol_date":"2013-06-26","protocol_title":"PILOT STUDY OF THE IN VITRO AND IN VIVO EFFICACY OF TOBRAMYCIN INHALATION POWDER (TIP) IN CYSTIC FIBROSIS PATIENTS INFECTED WITH BURKHOLDERIA CEPACIA COMPLEX (BCC)","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35575,"protocol_no":"205.445","submission_no":"172819","status_id":2,"start_date":"2014-07-08","end_date":"2015-11-17","nol_date":"2014-04-01","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO EVALUATE EFFICACY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION (2.5 ¬µG AND 5 ¬µG) DELIVERED VIA RESPIMAT¬Æ INHALER ONCE DAILY IN THE EVENING OVER 48 WEEKS IN CHILDREN (6 TO 11 YEARS OLD) WITH MODERATE PERSISTENT ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43287,"protocol_no":"NP39148","submission_no":"197718","status_id":2,"start_date":"2016-11-11","end_date":"2017-12-14","nol_date":"2016-09-15","protocol_title":"A MULTI-CENTER, OPEN LABEL, PHASE I, DOSE FINDING AND EXPANSION STUDY OF RO7051790 ADMINISTERED ORALLY IN PATIENTS WITH RELAPSED, EXTENSIVE-STAGE DISEASE SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28739,"protocol_no":"CDX011-04","submission_no":"169598","status_id":1,"start_date":"2014-10-02","end_date":null,"nol_date":"2013-11-29","protocol_title":"A RANDOMIZED MULTICENTER PIVOTAL STUDY OF CDX-011 (CR011-VCMMAE) IN PATIENTS WITH METASTATIC, GPNMB OVER-EXPRESSING, TRIPLE-NEGATIVE BREAST CANCER","medConditionList":[{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29250,"protocol_no":"WN28745","submission_no":"171314","status_id":1,"start_date":"2014-06-02","end_date":null,"nol_date":"2014-02-07","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35595,"protocol_no":"TMC435HPC3018","submission_no":"172857","status_id":1,"start_date":"2014-05-27","end_date":null,"nol_date":"2014-04-03","protocol_title":"A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A 12-WEEK REGIMEN OF SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR IN TREATMENT-NA√èVE OR -EXPERIENCED SUBJECTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS INFECTION AND CIRRHOSIS","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42654,"protocol_no":"H8A-MC-LZBE","submission_no":"195735","status_id":1,"start_date":"2016-09-06","end_date":null,"nol_date":"2016-07-06","protocol_title":"A 24-MONTH, PHASE 3, MULTICENTER, PLACEBO-CONTROLLED STUDY OF EFFICACY AND SAFETY OF SOLANEZUMAB VERSUS PLACEBO IN PRODROMAL ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37366,"protocol_no":"M14-567","submission_no":"178401","status_id":2,"start_date":"2015-12-08","end_date":"2017-06-22","nol_date":"2014-10-15","protocol_title":"A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE CO-ADMINISTRATION OF OMBITASVIR/ABT-450/RITONAVIR (OMBITASVIR/ABT-450/R) WITH SOFOSBUVIR (SOF) WITH OR WITHOUT RIBAVIRIN (RBV) IN SUBJECTS WITH GENOTYPE 3 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION","medConditionList":[{"med_condition_id":108,"med_condition":"HEPATITIS C VIRUS GENOTYPE 3"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45936,"protocol_no":"INCB 39110-301","submission_no":"205876","status_id":1,"start_date":"2017-12-29","end_date":null,"nol_date":"2017-06-09","protocol_title":"GRAVITAS-301: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ITACITINIB OR PLACEBO IN COMBINATION WITH CORTICOSTEROIDS FOR THE TREATMENT OF FIRST-LINE ACUTE GRAFT VERSUS-HOST DISEASE","medConditionList":[{"med_condition_id":370,"med_condition":"GRAFT VS HOST DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36510,"protocol_no":"N/A","submission_no":"175646","status_id":3,"start_date":"2014-08-26","end_date":null,"nol_date":"2014-07-18","protocol_title":"ASSESSMENT OF THE EFFICACY OF STEREOTACTIC INTRACAVITARY INSTILLATION OF YTTRIUM-90 COLLOID FOR TREATMENT OF CYSTIC LESIONS OF THE PITUITARY AND SURROUNDING AREAS (SELLAR/PARASELLAR REGION)","medConditionList":[{"med_condition_id":567,"med_condition":"CYSTIC LESIONS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27067,"protocol_no":"201209135","submission_no":"164671","status_id":1,"start_date":"2014-05-05","end_date":null,"nol_date":"2013-06-06","protocol_title":"A PHASE II STUDY OF NERATINIB IN METASTATIC HER2 NON-AMPLIFIED BUT HER2 MUTANT BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43005,"protocol_no":"254-2015 (CHC_LABC_0001)","submission_no":"196838","status_id":1,"start_date":"2017-11-13","end_date":null,"nol_date":"2016-08-23","protocol_title":"STUDY TO EVALUATE THE FEASIBILITY OF 13C PYRUVATE IMAGING IN BREAST CANCER PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46337,"protocol_no":"MV116238059","submission_no":"207168","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-05","protocol_title":"THE EFFECT OF NALOXEGOL ON POST-OPERATIVE ILEUS AFTER ELECTIVE BOWEL RESECTIONS: A SINGLE CENTRE, DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL.","medConditionList":[{"med_condition_id":407,"med_condition":"ABDOMINAL SURGERY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36895,"protocol_no":"LVAD MPC II","submission_no":"176892","status_id":1,"start_date":"2015-09-01","end_date":null,"nol_date":"2014-09-12","protocol_title":"SAFETY AND EFFICACY OF INTRAMYOCARDIAL INJECTION OF MESENCHYMAL PRESURSOR CELLS ON MYOCARDIAL FUNCTION IN LVAD RECIPIENTS","medConditionList":[{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36256,"protocol_no":"PCOS-PILOT","submission_no":"174901","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-11-05","protocol_title":"EFFECT OF BROMOCRIPTINE ON INSULIN RESISTANCE IN POLYCYSTIC OVARIAN SYNDROME - A PILOT STUDY","medConditionList":[{"med_condition_id":199,"med_condition":"POLYCYTHEMIA VERA (PV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39819,"protocol_no":"CP-Q14VLP-010","submission_no":"186342","status_id":1,"start_date":"2016-04-18","end_date":null,"nol_date":"2015-08-18","protocol_title":"A RANDOMIZED, OBSERVER-BLIND, MULTICENTER, PHASE 2B STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A PLANT-DERIVED QUADRIVALENT VLP INFLUENZA VACCINE IN ELDERLY ADULTS OF 65 YEARS OF AGE OR OLDER","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"},{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48564,"protocol_no":"EFC14828","submission_no":"214298","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-04-12","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFECT OF EFPEGLENATIDE ON CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES PATIENTS AT HIGH CARDIOVASCULAR RISK","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27587,"protocol_no":"20120262","submission_no":"166211","status_id":1,"start_date":"2013-10-15","end_date":null,"nol_date":"2013-08-01","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF ABP 501 EFFICACY AND SAFETY COMPARED WITH ADALIMUMAB IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40219,"protocol_no":"109MS309","submission_no":"187405","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-10-02","protocol_title":"A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY IN PEDIATRIC SUBJECTS AGES 10 THROUGH 17 YEARS TO EVALUATE THE EFFICACY AND SAFETY OF BG00012 FOR THE TREATMENT OF RELAPSING-REMITTING FORMS OF MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47313,"protocol_no":"689","submission_no":"210521","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-22","protocol_title":"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PEMBROLIZUMAB AS NEOADJUVANT THERAPY AND IN COMBINATION WITH STANDARD OF CARE AS ADJUVANT THERAPY FOR STAGE III-IVA RESECTABLE LOCOREGIONALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (LA HNSCC)","medConditionList":[{"med_condition_id":724,"med_condition":"SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36421,"protocol_no":"PXVX-VC-200-004","submission_no":"175370","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-11","protocol_title":"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED THREE-LOT CONSISITENCY STUDY IN HEALTHY ADULT VOLUNTEERS TO ASSESS IMMUNOGENICITY, AND CLINICAL ACCEPTABILITY OF A SINGLE-DOSE OF THE LIVE ORAL CHOLERA VACCINE CANDIDATE PXVX0200, VIBRIO CHOLERAE O1 SEROTYPE INABA VACCINE STRAIN CVD 103-HGR","medConditionList":[{"med_condition_id":630,"med_condition":"CHOLERA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38670,"protocol_no":"1000047580","submission_no":"182801","status_id":1,"start_date":"2015-06-15","end_date":null,"nol_date":"2015-04-09","protocol_title":"SALINE HYPERTONIC IN PRESCHOOLERS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39707,"protocol_no":"VHCRP1309","submission_no":"186113","status_id":1,"start_date":"2015-10-05","end_date":null,"nol_date":"2015-08-10","protocol_title":"SIMPLIFY: A PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTRE, INTERNATIONAL TRIAL OF SOFOSBUVIR AND GS-5816 FOR PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTION DRUG USE","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36298,"protocol_no":"RAIDU01","submission_no":"173750","status_id":2,"start_date":"2014-11-21","end_date":"2017-01-31","nol_date":"2014-06-20","protocol_title":"LATE SODIUM CURRENT BLOCKADE IN HIGH-RISK ICD PATIENTS RANOLAZINE ICD TRIAL (RAID);","medConditionList":[{"med_condition_id":130,"med_condition":"IMPLANTABLE CARDIOVERTER DEFIBRILLATOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38125,"protocol_no":"PBI-4050-ATX-9-03","submission_no":"180999","status_id":2,"start_date":"2015-11-18","end_date":"2017-01-10","nol_date":"2015-02-03","protocol_title":"A PHASE 2, OPEN-LABEL, SINGLE ARM, EXPLORATORY, OBSERVATIONAL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PBI-4050 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)","medConditionList":[{"med_condition_id":127,"med_condition":"IDIOPATHIC PULMONARY FIBROSIS (IPF)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45038,"protocol_no":"TV48125-CNS-30056","submission_no":"203109","status_id":1,"start_date":"2017-04-12","end_date":null,"nol_date":"2017-03-23","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF 2 DOSE REGIMENS (INTRAVENOUS/SUBCUTANEOUS AND SUBCUTANEOUS) OF TEV-48125 VERSUS PLACEBO FOR THE PREVENTION OF EPISODIC CLUSTER HEADACHE","medConditionList":[{"med_condition_id":620,"med_condition":"EPISODIC CLUSTER HEADACHE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41749,"protocol_no":"VX15-210-101","submission_no":"192539","status_id":1,"start_date":"2016-05-04","end_date":null,"nol_date":"2016-04-15","protocol_title":"A PHASE 2B/3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF VX-210 IN SUBJECTS WITH ACUTE TRAUMATIC CERVICAL SPINAL CORD INJURY","medConditionList":[{"med_condition_id":699,"med_condition":"SPINAL CORD INJURY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40443,"protocol_no":"NCIC CTG MYX.1 / MCRN003","submission_no":"188118","status_id":1,"start_date":"2018-01-12","end_date":null,"nol_date":"2015-11-03","protocol_title":"A SINGLE ARM PHASE II STUDY OF HIGH-DOSE WEEKLY CARFILZOMIB PLUS CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA 1-3 PRIOR THERAPIES.","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38207,"protocol_no":"GLP116174","submission_no":"181262","status_id":1,"start_date":"2015-07-07","end_date":null,"nol_date":"2015-02-11","protocol_title":"A LONG TERM, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFECT OF ALBIGLUTIDE, WHEN ADDED TO STANDARD BLOOD GLUCOSE LOWERING THERAPIES, ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35558,"protocol_no":"ECRI-12-001, 02EU11","submission_no":"172784","status_id":2,"start_date":null,"end_date":"2018-03-26","nol_date":"2014-04-03","protocol_title":"COMPARATIVE EFFECTIVENESS OF 1 MONTH OF TICAGRELOR PLUS ASPIRIN FOLLOWED BY TICAGRELOR MONOTHERAPY VERSUS A CURRENT-DAY INTENSIVE DUAL ANTIPLATELET THERAPY IN ALL-COMERS PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH BIVALIRUDIN AND BIOMATRIX FAMILY DRUG-ELUTING STENT USE","medConditionList":[{"med_condition_id":499,"med_condition":"ACUTE CORONARY SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38011,"protocol_no":"CFZ008","submission_no":"180554","status_id":1,"start_date":"2017-08-16","end_date":null,"nol_date":"2015-01-09","protocol_title":"PHASE 1B/2 STUDY OF CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE, MITOXANTRONE, PEG ASPARAGINASE, AND VINCRISTINE (UK R3 INDUCTION BACKBONE) IN CHILDREN WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA.","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44558,"protocol_no":"B7981005","submission_no":"201718","status_id":1,"start_date":"2017-09-01","end_date":null,"nol_date":"2017-02-03","protocol_title":"A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND CHRONIC THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS.","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29092,"protocol_no":"M14-115","submission_no":"170849","status_id":1,"start_date":"2015-08-20","end_date":null,"nol_date":"2014-01-13","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO ADALIMUMAB INDUCTION REGIMENS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE AND EVIDENCE OF MUCOSAL ULCERATION","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45899,"protocol_no":"CQAW039A2315","submission_no":"205785","status_id":1,"start_date":"2017-07-06","end_date":null,"nol_date":"2017-06-23","protocol_title":"A 2-TREATMENT PERIOD, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER PARALLEL-GROUP STUDY TO ASSESS THE SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN GINA STEPS 3, 4 AND 5 PATIENTS WITH UNCONTROLLED ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46160,"protocol_no":"D5670C00004","submission_no":"206542","status_id":1,"start_date":"2017-07-27","end_date":null,"nol_date":"2017-07-10","protocol_title":"A PHASE IIB, RANDOMISED, PARALLEL, DOUBLE-BLIND PLACEBO-CONTROLLED AND OPEN-LABEL ACTIVE COMPARATOR STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEDI0382 IN THE TREATMENT OF OVERWEIGHT AND OBESE SUBJECTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":415,"med_condition":"OVERWEIGHT/OBESITY"},{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"},{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45895,"protocol_no":"GS-US-436-4092","submission_no":"205766","status_id":1,"start_date":"2017-10-02","end_date":null,"nol_date":"2017-06-09","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF FILGOTINIB AND GS-9876 IN FEMALE SUBJECTS WITH MODERATELY-TO-SEVERELY ACTIVE CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)","medConditionList":[{"med_condition_id":473,"med_condition":"LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47158,"protocol_no":"ACNS1422","submission_no":"209970","status_id":1,"start_date":"2017-12-13","end_date":null,"nol_date":"2017-10-31","protocol_title":"A PHASE 2 STUDY OF REDUCED THERAPY FOR NEWLY DIAGNOSED AVERAGE-RISK WNT-DRIVEN MEDULLOBLASTOMA PATIENTS","medConditionList":[{"med_condition_id":460,"med_condition":"MEDULLOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46262,"protocol_no":"1VIT15043","submission_no":"206939","status_id":1,"start_date":"2017-08-17","end_date":null,"nol_date":"2017-07-17","protocol_title":"PROTOCOL TITLE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FERRIC CARBOXYMALTOSE (US TRADE NAME: INJECTAFER) AS TREATMENT FOR HEART FAILURE WITH IRON DEFICIENCY","medConditionList":[{"med_condition_id":329,"med_condition":"ANEMIA"},{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48010,"protocol_no":"VBP15-004","submission_no":"212703","status_id":1,"start_date":"2018-03-29","end_date":null,"nol_date":"2018-02-07","protocol_title":"A PHASE IIB RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO- AND ACTIVE-CONTROLLED STUDY WITH DOUBLE-BLIND EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VAMOROLONE IN AMBULANT BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD)","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42079,"protocol_no":"SPI-EOQ-13-305","submission_no":"193841","status_id":2,"start_date":"2016-07-14","end_date":"2018-04-03","nol_date":"2016-04-29","protocol_title":"A MULTICENTER, MULTI-ARM, RANDOMIZED, MULTI-DOSE, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 STUDY OF INTRAVESICAL APAZIQUONE (EOQUIN¬Æ) AS A SURGICAL ADJUVANT IN THE IMMEDIATE POSTOPERATIVE PERIOD IN PATIENTS UNDERGOING TRANSURETHRAL RESECTION FOR NON-MUSCLE INVASIVE BLADDER CANCER","medConditionList":[{"med_condition_id":625,"med_condition":"BLADDER CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42691,"protocol_no":"1000052116","submission_no":"195884","status_id":1,"start_date":"2017-02-10","end_date":null,"nol_date":"2016-07-05","protocol_title":"A PHASE II, OPEN-LABELED, MULTI-CENTER, RANDOMIZED CONTROLLED TRIAL OF VINBLASTINE +/- BEVACIZUMAB FOR THE TREATMENT OF CHEMOTHERAPY-NA√èVE CHILDREN WITH UNRESECTABLE OR PROGRESSIVE LOW GRADE GLIOMA (LGG)","medConditionList":[{"med_condition_id":92,"med_condition":"GLIOMA MALIGNANT"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40129,"protocol_no":"1199.222","submission_no":"187170","status_id":2,"start_date":"2016-04-28","end_date":"2017-05-24","nol_date":"2015-09-16","protocol_title":"A TWELVE WEEK, OPEN-LABEL, RANDOMISED, PARALLEL-GROUP STUDY EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF ORAL NINTEDANIB IN COMBINATION WITH ORAL PIRFENIDONE, COMPARED TO TREATMENT WITH NINTEDANIB ALONE, IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)","medConditionList":[{"med_condition_id":127,"med_condition":"IDIOPATHIC PULMONARY FIBROSIS (IPF)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27191,"protocol_no":"EVP-6124-017","submission_no":"165059","status_id":1,"start_date":"2013-11-26","end_date":null,"nol_date":"2013-06-21","protocol_title":"A MULTICENTER 26-WEEK EXTENSION STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFECTS OF PROLONGED EXPOSURE TO 1 AND 2 MG DOSES OF EVP 6124, AN ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST, AS AN ADJUNCTIVE PRO COGNITIVE TREATMENT IN SUBJECTS WITH SCHIZOPHRENIA ON CHRONIC STABLE ATYPICAL ANTIPSYCHOTIC THERAPY","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42542,"protocol_no":"E2006-G000-304","submission_no":"195307","status_id":2,"start_date":"2016-10-25","end_date":"2018-01-30","nol_date":"2016-06-21","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE COMPARATOR, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LEMBOREXANT IN SUBJECTS 55 YEARS AND OLDER WITH INSOMNIA DISORDER","medConditionList":[{"med_condition_id":737,"med_condition":"INSOMNIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36080,"protocol_no":"437-2013","submission_no":"174415","status_id":1,"start_date":"2015-02-18","end_date":null,"nol_date":"2014-05-30","protocol_title":"COMPARISON OF THE EFFECTS OF PERINEURAL VERSUS SYSTEMIC DEXAMETHASONE ON LOW DOSE INTERSCALENE BRACHIAL PLEXUS BLOCK: A RANDOMIZED TRIAL","medConditionList":[{"med_condition_id":525,"med_condition":"SHOULDER SURGERY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45607,"protocol_no":"CC-10004-SPSO-001","submission_no":"203615","status_id":1,"start_date":"2017-06-01","end_date":null,"nol_date":"2017-05-19","protocol_title":"A PHASE 3, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS OF THE SCALP","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27357,"protocol_no":"CRAD001H2307","submission_no":"165549","status_id":2,"start_date":"2015-03-30","end_date":"2017-10-10","nol_date":"2013-07-25","protocol_title":"A 24 MONTH, RANDOMIZED, CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CONCENTRATION-CONTROLLED EVEROLIMUS PLUS REDUCED TACROLIMUS COMPARED TO STANDARD TACROLIMUS IN RECIPIENTS OF LIVING DONOR LIVER TRANSPLANTS","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40276,"protocol_no":"109MS310","submission_no":"187573","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-10-08","protocol_title":"AN OPEN-LABEL STUDY TO ASSESS THE EFFECTS OF BG00012 ON LYMPHOCYTE SUBSETS IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":565,"med_condition":"RELAPSING-REMITTING MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36464,"protocol_no":"191622-129","submission_no":"175508","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-09","protocol_title":"LONG-TERM STUDY OF BOTOX TREATMENT IN ADULT PATIENTS WITH UPPER LIMB SPASTICITY","medConditionList":[{"med_condition_id":141,"med_condition":"LIMB SPASTICITY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38896,"protocol_no":"D4193C00003","submission_no":"183537","status_id":1,"start_date":"2015-11-02","end_date":null,"nol_date":"2015-05-04","protocol_title":"\"A PHASE II, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF MEDI4736 MONOTHERAPY, TREMELIMUMAB MONOTHERAPY, AND MEDI4736 IN COMBINATION WITH TREMELIMUMAB IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN).\"","medConditionList":[{"med_condition_id":34,"med_condition":"CARCINOMA OF THE HEAD AND NECK"},{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45965,"protocol_no":"VX15-770-126","submission_no":"205938","status_id":1,"start_date":"2017-08-22","end_date":null,"nol_date":"2017-06-12","protocol_title":"A PHASE 3, 2-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACODYNAMICS OF LONG-TERM IVACAFTOR TREATMENT IN SUBJECTS WITH CYSTIC FIBROSIS WHO ARE LESS THAN 24 MONTHS OF AGE AT TREATMENT INITIATION AND HAVE A CFTR GATING MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39217,"protocol_no":"DEXMED-QT STUDY MAR17_15","submission_no":"184517","status_id":1,"start_date":"2015-08-26","end_date":null,"nol_date":"2015-06-11","protocol_title":"THE EFFECTS OF DEXMEDETOMIDINE ON MYOCARDIAL REPOLARIZATION AND BLOOD GLUCOSE CONCENTRATION IN CHILDREN","medConditionList":[{"med_condition_id":553,"med_condition":"ANASTHESIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41579,"protocol_no":"UX001-CL203","submission_no":"191942","status_id":1,"start_date":"2017-06-30","end_date":null,"nol_date":"2016-03-01","protocol_title":"A PHASE 2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF ACENEURAMIC ACID EXTENDED RELEASE (ACE-ER) TABLETS IN GNE MYOPATHY (GNEM) (ALSO KNOWN AS HEREDITARY INCLUSION BODY MYOPATHY (HIBM)) PATIENTS WITH SEVERE AMBULATORY IMPAIRMENT","medConditionList":[{"med_condition_id":609,"med_condition":"GNE MYOPATHY (GNEM)"},{"med_condition_id":610,"med_condition":"HEREDITARY INCLUSION BODY MYOPATHY (HIBM)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26683,"protocol_no":"CLDE225X2203","submission_no":"163483","status_id":1,"start_date":"2013-05-21","end_date":null,"nol_date":"2013-04-22","protocol_title":"A PHASE II MULTI-CENTER, OPEN LABEL, RANDOMIZED STUDY TO ASSESS SAFETY AND EFFICACY OF TWO DIFFERENT SCHEDULES OF ORAL LDE225 IN ADULT PATIENTS WITH RELAPSED/REFRACTORY OR UNTREATED ELDERLY PATIENTS WITH ACUTE LEUKEMIA","medConditionList":[{"med_condition_id":308,"med_condition":"LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47178,"protocol_no":"GN29823","submission_no":"210059","status_id":1,"start_date":"2018-02-20","end_date":null,"nol_date":"2017-11-02","protocol_title":"A PHASE I, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, SINGLE-AND MULTIPLE-ASCENDING-DOSE STUDY TO DETERMINE INITIAL SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0134 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS.","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42063,"protocol_no":"CAIN457A2326","submission_no":"193784","status_id":1,"start_date":"2016-06-28","end_date":null,"nol_date":"2016-04-27","protocol_title":"A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SECUKINUMAB (300 MG) TO DEMONSTRATE EFFICACY AS ASSESSED BY PSORIASIS AREA AND SEVERITY INDEX AND INVESTIGATOR'S GLOBAL ASSESSMENT AFTER 12 WEEKS OF TREATMENT, COMPARED TO USTEKINUMAB, AND TO ASSESS LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (CLARITY)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39651,"protocol_no":"GE-122-020","submission_no":"185975","status_id":1,"start_date":"2016-06-08","end_date":null,"nol_date":"2015-07-29","protocol_title":"ADREVIEW MYOCARDIAL IMAGING FOR RISK EVALUATION - A MULTICENTRE TRIAL TO GUIDE ICD IMPLANTATION IN NYHA CLASS II & III HEART FAILURE PATIENTS WITH 30%<LVEF<35%. ADMIRE-ICD","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38015,"protocol_no":"CVT-301-004E","submission_no":"180563","status_id":2,"start_date":"2016-04-11","end_date":"2018-01-09","nol_date":"2015-01-08","protocol_title":"A 12-MONTH, DOSE-LEVEL BLINDED STUDY INVESTIGATING THE SAFETY AND EFFICACY OF CVT-301 (LEVODOPA INHALATION POWDER) IN PARKINSON'S DISEASE PATIENTS WITH MOTOR RESPONSE FLUCTUATIONS (OFF PHENOMENA)","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37159,"protocol_no":"040","submission_no":"177740","status_id":1,"start_date":"2016-12-21","end_date":null,"nol_date":"2014-09-29","protocol_title":"A PHASE II RANDOMIZED TRIAL OF MK-3475 (PEMBROLIZUMAB) VERSUS STANDARD TREATMENT IN SUBJECTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER (KEYNOTE 040)","medConditionList":[{"med_condition_id":95,"med_condition":"HEAD AND NECK CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26513,"protocol_no":"20060517","submission_no":"162979","status_id":1,"start_date":"2013-07-17","end_date":null,"nol_date":"2013-04-11","protocol_title":"\"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL OF PEGYLATE LIPOSOMAL DOXORUBIN (PLD) PLUS AMG 386 OR PLACEBO IN WOMEN IN RECURRENT PARTIALLY PLATINUM SENSITIVE OR RESISTANT EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER,\"","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":184,"med_condition":"OVARIAN CANCER PRIMARY PERITONEAL"},{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28159,"protocol_no":"CAIN457F2305E1","submission_no":"167822","status_id":1,"start_date":"2014-03-13","end_date":null,"nol_date":"2013-09-27","protocol_title":"AN EXTENSION STUDY TO EVALUATE THE SUSTAINABILITY OF CLINICAL BENEFITS, SAFETY AND TOLERABILITY OF SECUKINUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS","medConditionList":[{"med_condition_id":397,"med_condition":"ANKYLOSING SPONDYLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44355,"protocol_no":"M16-126","submission_no":"200993","status_id":1,"start_date":"2017-10-06","end_date":null,"nol_date":"2016-12-29","protocol_title":"A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GLECAPREVIR (GLE)/PIBRENTASVIR (PIB) IN ADULTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 5 OR 6 INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44535,"protocol_no":"2016-1986-GRA","submission_no":"201653","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-02-14","protocol_title":"NK1 ANTAGONISTS FOR PATHOLOGICAL AGGRESSION: A PROTOCOL FOR THE APREPITANT FOR HARMFUL, IMPULSIVE, AND SELF-/AGGRESSIVE BEHAVIOR (AHIMSA-1) TRIAL","medConditionList":[{"med_condition_id":835,"med_condition":"AGGRESSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40485,"protocol_no":"CQAW039A2314","submission_no":"188286","status_id":1,"start_date":"2017-05-25","end_date":null,"nol_date":"2015-11-03","protocol_title":"A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47784,"protocol_no":"RVT-501-2004","submission_no":"211921","status_id":1,"start_date":"2018-01-24","end_date":null,"nol_date":"2018-01-11","protocol_title":"PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVT-501 TOPICAL OINTMENT IN PEDIATRIC PATIENTS WITH MILD TO MODERATE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37216,"protocol_no":"191-078","submission_no":"177887","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-10","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP 24 WEEK PLACEBO CONTROLLED EFFICACY AND SAFETY STUDY WITH A 28 WEEK LONG TERM EXTENSION, OF NEBULIZED FLUTICASONE PROPIONATE (FP) /FORMOTEROL FUMARATE (FF) COMBINATION COMPARED WITH FP AND FF MONOTHERAPY IN PATIENTS WITH COPD","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44264,"protocol_no":"1002-048","submission_no":"200574","status_id":1,"start_date":"2017-06-02","end_date":null,"nol_date":"2016-12-20","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BEMPEDOIC ACID (ETC-1002) 180 MG/DAY AS ADD-ON TO EZETIMIBE THERAPY IN PATIENTS WITH ELEVATED LDL-C","medConditionList":[{"med_condition_id":348,"med_condition":"HYPERLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44372,"protocol_no":"DRM01B-ACN03","submission_no":"201091","status_id":2,"start_date":"2017-01-11","end_date":"2017-11-28","nol_date":"2017-01-11","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, EFFICACY AND SAFETY STUDY OF OLUMACOSTAT GLASARETIL GEL IN SUBJECTS WITH ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26853,"protocol_no":"SPN-12-001","submission_no":"164052","status_id":1,"start_date":"2013-04-01","end_date":null,"nol_date":"2013-05-15","protocol_title":"A MULTI-CENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLINDED, TRIAL OF EFFICACY AND SAFETY OF RILUZOLE IN ACUTE SPINAL CORD INJURY","medConditionList":[{"med_condition_id":238,"med_condition":"SPINAL CORD LESION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28250,"protocol_no":"2.1","submission_no":"168040","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-09","protocol_title":"ULTRA-EARLY TRANEXAMIC ACID AFTER SUBARACHNOID HEMORRHAGE","medConditionList":[{"med_condition_id":389,"med_condition":"SUBARACHNOID HEMORRHAGE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27416,"protocol_no":"49095397OPD2001","submission_no":"165680","status_id":1,"start_date":"2014-01-08","end_date":null,"nol_date":"2013-07-11","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF INHALED JNJ 49095397 (RV568) IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28634,"protocol_no":"063-010","submission_no":"169241","status_id":2,"start_date":"2014-07-08","end_date":"2015-03-12","nol_date":"2013-11-21","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADULT ADHD PATIENTS.","medConditionList":[{"med_condition_id":9,"med_condition":"ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45079,"protocol_no":"D4191C00068","submission_no":"203251","status_id":1,"start_date":"2017-05-25","end_date":null,"nol_date":"2017-03-28","protocol_title":"AN OPEN-LABEL, MULTI-CENTRE, SAFETY STUDY OF FIXED-DOSE DURVALUMAB + TREMELIMUMAB COMBINATION THERAPY OR DURVALUMAB MONOTHERAPY IN ADVANCED SOLID MALIGNANCIES (STRONG) -- CORE PROTOCOL","medConditionList":[{"med_condition_id":293,"med_condition":"MALIGNANT SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28631,"protocol_no":"063-009","submission_no":"169240","status_id":2,"start_date":"2014-06-17","end_date":"2015-01-21","nol_date":"2013-11-21","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADOLESCENT ADHD PATIENTS.","medConditionList":[{"med_condition_id":9,"med_condition":"ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40428,"protocol_no":"MK-3475-269","submission_no":"188078","status_id":1,"start_date":"2016-03-21","end_date":null,"nol_date":"2015-10-29","protocol_title":"A PHASE II STUDY OF PEMBROLIZUMAB WITH CARBOPLATIN/PACLITAXEL IN PATIENTS WITH METASTATIC MELANOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27321,"protocol_no":"PCI-32765DBL3001","submission_no":"165387","status_id":1,"start_date":"2014-05-23","end_date":null,"nol_date":"2013-06-27","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE BRUTON'S TYROSINE KINASE  (BTK) INHIBITOR, PCI-32765 (IBRUTINIB), IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN SUBJECTS WITH NEWLY DIAGNOSED NON-GERMINAL CENTER B-CELL SUBTYPE OF DIFFUSE LARGE B-CELL LYMPHOMA","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27981,"protocol_no":"117036 (ZOSTER-004)","submission_no":"167240","status_id":1,"start_date":"2014-10-30","end_date":null,"nol_date":"2013-09-06","protocol_title":"A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTRE CLINICAL TRIAL TO ASSESS THE IMMUNOGENICITY AND SAFETY OF GSK BIOLOGICAL'S HERPES ZOSTER VACCINE GSK1437173A WHEN CO-ADMINISTERED WITH GSK BIOLOGICALS' QUADRIVALENT INFLUENZA VACCINE FLU-D-QIV (GSK2321138A) VERSUS SEPARATE ADMINISTRATION OF THE TWO VACCINES IN ADULTS AGED 50 YEARS AND OLDER","medConditionList":[{"med_condition_id":289,"med_condition":"HERPES ZOSTER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27387,"protocol_no":"AXP1275-201","submission_no":"165601","status_id":1,"start_date":"2013-08-21","end_date":null,"nol_date":"2013-07-10","protocol_title":"A PHASE IIA, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-WAY CROSS-OVER TRIAL OF THE EFFECTS OF REPEATED DOSES OF 50 MG AXP1275 ONCE DAILY ON THE ASTHMATIC RESPONSE TO A PULMONARY ALLERGEN CHALLENGE IN ADULTS WITH MILD-TO-MODERATE ATOPIC ASTHMA.","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28294,"protocol_no":"PCYC-1106-CA","submission_no":"168175","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-22","protocol_title":"A MULTICENTER, OPEN-LABEL, PHASE 2, SAFETY AND EFFICACY STUDY OF THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, PCI-32765, IN SUBJECTS WITH RELAPSED OR REFRACTORY DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28293,"protocol_no":"DRM02-ROS02","submission_no":"168172","status_id":2,"start_date":"2013-10-18","end_date":"2014-03-20","nol_date":"2013-10-08","protocol_title":"A  RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF TOPICAL DRM02 IN SUBJECTS WITH ROSACEA","medConditionList":[{"med_condition_id":225,"med_condition":"ROSACEA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42600,"protocol_no":"CNTO2476MDG2002","submission_no":"195532","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-29","protocol_title":"A PHASE 2B, MULTICENTER, DOUBLE-MASKED, RANDOMIZED STUDY EVALUATING THE SAFETY AND CLINICAL RESPONSE OF SUBRETINAL ADMINISTRATION OF CNTO 2476 IN SUBJECTS WITH VISUAL ACUITY IMPAIREMENT ASSOCIATED WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE RELATED MACULAR DEGENERATION","medConditionList":[{"med_condition_id":568,"med_condition":"MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39474,"protocol_no":"VX14-661-107","submission_no":"185442","status_id":1,"start_date":"2015-12-09","end_date":null,"nol_date":"2015-07-10","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VX-661 IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS, HETEROZYGOUS FOR THE F508DEL CFTR MUTATION AND WITH A SECOND CFTR MUTATION THAT IS NOT LIKELY TO RESPOND TO VX-661 AND/OR IVACAFTOR THERAPY (F508DEL/NR)","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43041,"protocol_no":"CA012-004","submission_no":"196970","status_id":1,"start_date":"2017-04-13","end_date":null,"nol_date":"2016-08-19","protocol_title":"A PHASE1/2A STUDY OF BMS-986178 ADMINISTERED ALONE AND IN COMBINATION WITH NIVOLUMAB OR IPILIMUMAB IN ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40853,"protocol_no":"B9991004","submission_no":"189467","status_id":1,"start_date":"2016-08-31","end_date":null,"nol_date":"2015-12-23","protocol_title":"A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB00100718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":665,"med_condition":"ADVANCED MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45105,"protocol_no":"1368.15","submission_no":"203327","status_id":1,"start_date":"2017-05-12","end_date":null,"nol_date":"2017-03-28","protocol_title":"MULTI-CENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PHASE IIA STUDY TO INVESTIGATE EFFICACY, SAFETY,TOLERABILITY, PHARMACOKINETICS AND PHARMACOGENOMICS OF MULTIPLE INTRAVENOUS DOSES OF BI 655130 IN PATIENTS WITH PALMOPLANTAR PUSTULOSIS (PPP)","medConditionList":[{"med_condition_id":776,"med_condition":"PALMOPLANTAR PUSTULOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46396,"protocol_no":"200879","submission_no":"207396","status_id":1,"start_date":"2018-01-15","end_date":null,"nol_date":"2017-08-08","protocol_title":"A PHASE IIB, RANDOMIZED (STRATIFIED), DOUBLE-BLIND (SPONSOR OPEN), PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING STUDY OF NEMIRALISIB (GSK2269557) ADDED TO STANDARD OF CARE (SOC) VERSUS SOC ALONE IN PARTICIPANTS DIAGNOSED WITH AN ACUTE MODERATE OR SEVERE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38807,"protocol_no":"CXMET1","submission_no":"183256","status_id":1,"start_date":"2015-05-21","end_date":null,"nol_date":"2015-04-22","protocol_title":"THE POTENTIAL FOR METFORMIN TO IMPROVE TUMOR OXYGENATION IN LOCALLY ADVANCED CERVIX CANCER: A PHASE II RANDOMIZED TRIAL","medConditionList":[{"med_condition_id":356,"med_condition":"CERVICAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39668,"protocol_no":"AB10015","submission_no":"186002","status_id":2,"start_date":"2015-11-05","end_date":"2017-10-12","nol_date":"2015-08-05","protocol_title":"A PROSPECTIVE, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUPS, PHASE 2/3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF MASITINIB VERSUS PLACEBO IN THE TREATMENT OF PATIENTS SUFFERING FROM AMYOTROPHIC LATERAL SCLEROSIS (ALS)","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38674,"protocol_no":"CPIM447X2104C","submission_no":"182813","status_id":1,"start_date":"2017-06-05","end_date":null,"nol_date":"2015-04-08","protocol_title":"A PHASE IB, MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF PIM447 IN COMBINATION WITH RUXOLITINIB (INC424) AND LEE011 ADMINISTERED ORALLY IN PATIENTS WITH MYELOFIBROSIS","medConditionList":[{"med_condition_id":353,"med_condition":"MYELOFIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27835,"protocol_no":"GS-US-320-0108","submission_no":"166834","status_id":1,"start_date":"2014-04-28","end_date":null,"nol_date":"2013-08-23","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TENOFOVIR ALAFENAMIDE (TAF) 25 MG QD VERSUS TENOFOVIR DISOPROXIL FUMARATE (TDF) 300 MG QD FOR THE TREATMENT OF  HBEAG-NEGATIVE, CHRONIC HEPATITIS B","medConditionList":[{"med_condition_id":103,"med_condition":"HEPATITIS B VIRUS"},{"med_condition_id":345,"med_condition":"CHRONIC HEPATITIS B"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29272,"protocol_no":"CINC424B2401","submission_no":"171353","status_id":1,"start_date":"2016-08-02","end_date":null,"nol_date":"2014-02-11","protocol_title":"RANDOMIZED, OPEN LABEL, MULTICENTER PHASE IIIB STUDY EVALUATING THE EFFICACY AND SAFETY OF RUXOLITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH POLYCYTHEMIA VERA WHO ARE HYDROXYUREA RESISTANT OR INTOLERANT (RESPONSE 2)","medConditionList":[{"med_condition_id":199,"med_condition":"POLYCYTHEMIA VERA (PV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48099,"protocol_no":"671","submission_no":"212933","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-16","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND TRIAL OF PLATINUM DOUBLET CHEMOTHERAPY +/- PEMBROLIZUMAB (MK-3475) AS NEOADJUVANT/ADJUVANT THERAPY FOR PARTICIPANTS WITH RESECTABLE STAGE IIB OR IIIA NON-SMALL CELL LUNG CANCER (NSCLC) (KEYNOTE-671)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47788,"protocol_no":"HN.9","submission_no":"211947","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-05","protocol_title":"RANDOMIZED PHASE II STUDY OF CISPLATIN PLUS RADIOTHERAPY VERSUS DURVALUMAB PLUS RADIOTHERAPY FOLLOWED BY ADJUVANT DURVALUMAB VERSUS DURVALUMAB PLUS RADIOTHERAPY FOLLOWED BY ADJUVANT TREMELIMUMAB AND DURVALUMAB IN INTERMEDIATE RISK HPV-POSITIVE LOCOREGIONALLY ADVANCED OROPHARYNGEAL SQUAMOUS CELL CANCER (LA-OSCC)","medConditionList":[{"med_condition_id":486,"med_condition":"OROPHARYNX CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42803,"protocol_no":"20140111","submission_no":"196263","status_id":1,"start_date":"2017-08-14","end_date":null,"nol_date":"2016-07-22","protocol_title":"A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF ABP 710 COMPARED TO INFLIXIMAB IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29251,"protocol_no":"AB12003","submission_no":"171318","status_id":1,"start_date":"2016-11-08","end_date":null,"nol_date":"2014-02-14","protocol_title":"A PROSPECTIVE, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH DOCETAXEL TO PLACEBO IN COMBINATION WITH DOCETAXEL IN FIRST LINE METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37243,"protocol_no":"U1111-1150-8501","submission_no":"177949","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-23","protocol_title":"CLINICAL EVALUATION OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE, FOR THE TREATMENT OF PSORIATIC ARTHRISITS","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38604,"protocol_no":"42165279SAX2001","submission_no":"182550","status_id":1,"start_date":"2015-09-28","end_date":null,"nol_date":"2015-04-01","protocol_title":"A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF JNJ-42165279 IN SUBJECTS WITH SOCIAL ANXIETY DISORDER","medConditionList":[{"med_condition_id":429,"med_condition":"ANXIETY DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38672,"protocol_no":"M-40464-33","submission_no":"182804","status_id":2,"start_date":null,"end_date":"2016-07-25","nol_date":"2015-04-10","protocol_title":"A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE FIXED-DOSE COMBINATION ON LUNG HYPERINFLATION, EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28384,"protocol_no":"IMGN0007","submission_no":"168395","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-07","protocol_title":"A PHASE 1/2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF LORVOTUZUMAB MERTANSINE (IMGN901) IN COMBINATION WITH CARBOPLATIN/ETOPOSIDE IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING EXTENSIVE STAGE SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"},{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44391,"protocol_no":"A221208","submission_no":"201146","status_id":1,"start_date":"2017-04-28","end_date":null,"nol_date":"2016-12-21","protocol_title":"PHASE II STUDY OF CORTICOSTEROID + BEVACIZUMAB VS CORTICOSTEROID + PLACEBO (BEST) FOR RADIONECROSIS AFTER RADIOSURGERY FOR BRAIN METASTASES","medConditionList":[{"med_condition_id":769,"med_condition":"RADIONECROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36343,"protocol_no":"20130108","submission_no":"175118","status_id":1,"start_date":"2016-04-13","end_date":null,"nol_date":"2014-06-27","protocol_title":"A RANDOMIZED, DOUBLE-BLIND STUDY TO COMPARE PHARMACOKINETICS AND PHARMACODYNAMICS, EFFICACY AND SAFETY OF ABP 798 WITH RITUXIMAB IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS PROTOCOL","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26636,"protocol_no":"AZPO2-CLT-001","submission_no":"163313","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-05-03","protocol_title":"\"A DOSE ESCALATION PHASE I STUDY OF ASPAREC (MPEG-R-CRISANTASPASE) ADMINISTERED AS INTRA VENOUS (IV) INFUSION IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES.\"","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38567,"protocol_no":"CAMHPET-CTA-89","submission_no":"182442","status_id":1,"start_date":"2015-09-17","end_date":null,"nol_date":"2015-03-26","protocol_title":"INVESTIGATING NEUROINFLAMMATION RESPONSE IN SUBSTANCE USE DISORDER","medConditionList":[{"med_condition_id":428,"med_condition":"SUBSTANCE ABUSE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43366,"protocol_no":"20150288","submission_no":"197909","status_id":1,"start_date":"2017-06-29","end_date":null,"nol_date":"2016-09-20","protocol_title":"A PHASE 2 OPEN-LABEL STUDY INVESTIGATING THE SAFETY AND EFFICACY OF BLINATUMOMAB AFTER FRONTLINE R-CHEMOTHERAPY IN ADULT SUBJECTS WITH NEWLY DIAGNOSED HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27480,"protocol_no":"986","submission_no":"165603","status_id":3,"start_date":"2013-12-19","end_date":null,"nol_date":"2013-07-19","protocol_title":"A 24-WEEK PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TREGALIZUMAB (BT601) IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE ALONE, FOLLOWED BY A 24-WEEK EXTENSION PHASE: T CELL REGULATING ARTHRITIS TRIAL 2B (TREAT 2B)","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39817,"protocol_no":"RCT-01-002-2015","submission_no":"186340","status_id":1,"start_date":"2016-02-17","end_date":null,"nol_date":"2015-07-27","protocol_title":"A LONG-TERM FOLLOW-UP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RCT-01 IN MEN AND WOMEN WITH UNILATERAL, CHRONIC ACHILLES TENDINOSIS","medConditionList":[{"med_condition_id":578,"med_condition":"ACHILLES TENDINOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40886,"protocol_no":"EZH-102","submission_no":"189603","status_id":1,"start_date":"2018-01-30","end_date":null,"nol_date":"2015-12-14","protocol_title":"A PHASE 1 STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN PEDIATRIC SUBJECTS WITH RELAPSED/REFRACTORY INI1-NEGATIVE OR SYNOVIAL SARCOMA","medConditionList":[{"med_condition_id":334,"med_condition":"SARCOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47289,"protocol_no":"CVAY736B2201","submission_no":"209211","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-22","protocol_title":"A TWO-PART RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER DOSE RANGING AND CONFIRMATORY STUDY TO ASSESS THE SAFETY AND EFFICACY OF VAY736 IN AUTOIMMUNE HEPATITIS PATIENTS WITHINCOMPLETE RESPONSE TO OR INTOLERANCE OF STANDARD THERAPY.","medConditionList":[{"med_condition_id":809,"med_condition":"AUTOIMMUNE HEPATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36206,"protocol_no":"1208012946","submission_no":"174795","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-06-02","protocol_title":"AN OPEN-LABELED, MULTICENTER PHASE II STUDY OF CABAZITAXEL IN REFRACTORY METASTATIC GASTRIC OR GASTROESOPHAGEAL ADENOCARCINOMA","medConditionList":[{"med_condition_id":471,"med_condition":"GASTROINTESTINAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40030,"protocol_no":"PJC-017 / NCI 9874","submission_no":"186901","status_id":1,"start_date":"2016-03-24","end_date":null,"nol_date":"2015-09-09","protocol_title":"A PHASE I TRIAL OF AT13387 IN PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (LA-SCCHN) RECEIVING CONCURRENT RADIATION AND CISPLATIN","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40325,"protocol_no":"CA209-032","submission_no":"187713","status_id":1,"start_date":"2017-11-03","end_date":null,"nol_date":"2015-10-14","protocol_title":"A PHASE 1/2, OPEN-LABEL STUDY OF NIVOLUMAB MONOTHERAPY OR NIVOLUMAB COMBINED WITH IPILIMUMAB IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48376,"protocol_no":"CA224-047","submission_no":"213770","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-16","protocol_title":"A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF RELATLIMAB COMBINED WITH NIVOLUMAB VERSUS NIVOLUMAB IN PARTICIPANTS WITH PREVIOUSLY UNTREATED METASTATIC OR UNRESECTABLE MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46829,"protocol_no":"OZM-078","submission_no":"208812","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-26","protocol_title":"PHASE 1 (SAFETY ASSESSMENT) OF DURVALUMAB (MEDI4736) WITH FOCAL SENSITIZING RADIOTHERAPY IN PLATINUM RESISTANT OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE EPITHELIAL CARCINOMA","medConditionList":[{"med_condition_id":197,"med_condition":"PLATINUM-RESISTANT OVARIAN CANCER"},{"med_condition_id":692,"med_condition":"PRIMARY PERITONEAL CANCER"},{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44351,"protocol_no":"GEM-401","submission_no":"200983","status_id":1,"start_date":"2017-03-02","end_date":null,"nol_date":"2017-01-11","protocol_title":"A 12-WEEK, PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF GEMCABENE IN SUBJECTS WITH SEVERE HYPERTRIGLYCERIDEMIA (INDIGO-1)","medConditionList":[{"med_condition_id":349,"med_condition":"HYPERTRIGLYCERIDEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45016,"protocol_no":"AURA-001","submission_no":"203066","status_id":1,"start_date":"2017-08-25","end_date":null,"nol_date":"2017-03-22","protocol_title":"A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AK-01 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44475,"protocol_no":"OVC.2 / GY005","submission_no":"201470","status_id":1,"start_date":"2017-03-02","end_date":null,"nol_date":"2017-01-19","protocol_title":"A RANDOMIZED PHASE II/III STUDY OF THE COMBINATION OF CEDIRANIB AND OLAPARIB COMPARED TO CEDIRANIB OR OLAPARIB ALONE, OR STANDARD OF CARE CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-RESISTANT OR -REFRACTORY OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (COCOS)","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"},{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":692,"med_condition":"PRIMARY PERITONEAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47491,"protocol_no":"ISIS 678354-CS2","submission_no":"211061","status_id":1,"start_date":"2018-01-05","end_date":null,"nol_date":"2017-12-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING PHASE 2 STUDY OF ISIS 678354 ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41840,"protocol_no":"B9991010","submission_no":"192933","status_id":1,"start_date":"2016-11-30","end_date":null,"nol_date":"2016-04-11","protocol_title":"A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER","medConditionList":[{"med_condition_id":680,"med_condition":"EPITHELIAL OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43205,"protocol_no":"REALISE","submission_no":"197487","status_id":1,"start_date":"2017-03-03","end_date":null,"nol_date":"2016-09-07","protocol_title":"LONG-TERM ASSESSMENT OF SAFETY AND THERAPEUTIC BENEFIT OF VIASKIN PEANUT EPICUTANEOUS TREATMENT IN PEANUT-ALLERGIC CHILDREN.  A 6-MONTH RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY FOLLOWED BY AN OPEN LABEL ACTIVE TREATMENT","medConditionList":[{"med_condition_id":12,"med_condition":"ALLERGIES PEANUT"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44780,"protocol_no":"MA39189","submission_no":"202390","status_id":1,"start_date":"2017-07-04","end_date":null,"nol_date":"2017-02-21","protocol_title":"MULTICENTER, INTERNATIONAL, DOUBLE BLIND, TWO-ARM, RANDOMIZED, PLACEBO CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD.","medConditionList":[{"med_condition_id":423,"med_condition":"INTERSTITIAL LUNG DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42194,"protocol_no":"1199.36","submission_no":"194209","status_id":2,"start_date":"2016-08-15","end_date":"2018-04-13","nol_date":"2016-05-10","protocol_title":"A 24-WEEK, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL NINTEDANIB CO-ADMINISTERED WITH ORAL SILDENAFIL, COMPARED TO TREATMENT WITH  NINTEDANIB ALONE, IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND ADVANCED LUNG FUNCTION IMPAIRMENT.","medConditionList":[{"med_condition_id":127,"med_condition":"IDIOPATHIC PULMONARY FIBROSIS (IPF)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43230,"protocol_no":"GS-US-416-2124","submission_no":"197536","status_id":1,"start_date":"2017-03-07","end_date":null,"nol_date":"2016-09-08","protocol_title":"A PHASE 2, DOUBLE-BLIND, RANDOMIZED STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF GS-4997 IN COMBINATION WITH PREDNISOLONE VERSUS PREDNISOLONE ALONE IN SUBJECTS WITH SEVERE ALCOHOLIC HEPATITIS (AH)","medConditionList":[{"med_condition_id":746,"med_condition":"ALCOHOLIC HEPATITIS (AH)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47147,"protocol_no":"SCGAM-03","submission_no":"209908","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-30","protocol_title":"CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM 01 TRIAL","medConditionList":[{"med_condition_id":210,"med_condition":"PRIMARY IMMUNODEFICIENCY DISEASES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47065,"protocol_no":"TTX CINP-301","submission_no":"209613","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-23","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3, MULTICENTER, EFFICACY AND SAFETY TRIAL OF TETRODOTOXIN IN THE TREATMENT OF CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN","medConditionList":[{"med_condition_id":174,"med_condition":"NEUROPATHIC PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37113,"protocol_no":"ABI-007-NSCL-006","submission_no":"177561","status_id":1,"start_date":"2015-11-17","end_date":null,"nol_date":"2014-09-25","protocol_title":"A PHASE 2, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO ASSESS SAFETY AND EFFICACY OF NAB-PACLITAXEL (ABI-007) WITH EPIGENETIC MODIFYING THERAPY OF CC-486, AND NAB-PACLITAXEL MONOTHERAPY AS SECOND-LINE TREATMENT IN SUBJECTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44792,"protocol_no":"604","submission_no":"202467","status_id":1,"start_date":"2017-10-06","end_date":null,"nol_date":"2017-02-28","protocol_title":"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PEMBROLIZUMAB (MK-3475/SCH900475) IN COMBINATION WITH ETOPOSIDE/PLATINUM (CISPLATIN OR CARBOPLATIN) FOR THE FIRST-LINE TREATMENT OF SUBJECTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27541,"protocol_no":"ASCT1221","submission_no":"166053","status_id":1,"start_date":"2014-09-23","end_date":null,"nol_date":"2013-07-26","protocol_title":"A RANDOMIZED PHASE II STUDY COMPARING TWO DIFFERENT CONDITIONING REGIMENS PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)","medConditionList":[{"med_condition_id":166,"med_condition":"MYELOMONOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38185,"protocol_no":"20140815-01H","submission_no":"181206","status_id":1,"start_date":"2015-02-16","end_date":null,"nol_date":"2015-02-04","protocol_title":"CARDIAC MAPPING OF AUTONOMIC ATRIAL INNERVATION AND ITS RELATION TO MIBG NUCLEAR IMAGING IN PATIENTS WITH ATRIAL FIBRILLATION (MIBG-AF)","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42211,"protocol_no":"PTI-428-01","submission_no":"194282","status_id":2,"start_date":"2016-11-24","end_date":"2017-07-24","nol_date":"2016-05-13","protocol_title":"A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, ASCENDING DOSE PHASE I STUDY DESIGNED TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PTI-428 IN SUBJECTS WITH CYSTIC FIBROSIS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39352,"protocol_no":"OCOG-2013-PETMUSE","submission_no":"184908","status_id":1,"start_date":"2016-07-07","end_date":null,"nol_date":"2015-07-02","protocol_title":"MPACT OF POSITRON EMISSION TOMOGRAPHY (PET) IMAGING IN MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER STAGING (PETMUSE)","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40328,"protocol_no":"PP LNM 01","submission_no":"187717","status_id":1,"start_date":"2016-07-19","end_date":null,"nol_date":"2015-10-09","protocol_title":"A RANDOMIZED, PROSPECTIVE, OPEN LABEL, MULTICENTER STUDY ASSESSING THE SAFETY AND UTILITY OF PINPOINT¬Æ NEAR INFRARED FLUORESCENCE IMAGING IN THE IDENTIFICATION OF LYMPH NODES IN SUBJECTS WITH UTERINE AND CERVICAL MALIGNANCIES WHO ARE UNDERGOING LYMPH NODE MAPPING.","medConditionList":[{"med_condition_id":356,"med_condition":"CERVICAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37796,"protocol_no":"B1371012","submission_no":"179749","status_id":1,"start_date":"2016-01-19","end_date":null,"nol_date":"2014-12-09","protocol_title":"A RANDOMIZED, DOUBLE-BLIND PHASE 1B/2 STUDY OF PF-04449913 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED INTERMEDIATE-2 OR HIGH-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA WITH 20-30% BLASTS AND MULTI-LINEAGE DYSPLASIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"},{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38004,"protocol_no":"PR.17 (ANZUP 1304)","submission_no":"180480","status_id":1,"start_date":"2015-03-16","end_date":null,"nol_date":"2015-01-09","protocol_title":"RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN FIRST LINE ANDROGEN DEPRIVATION THERAPY FOR METASTATIC PROSTATE CANCER: ENZAMET","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36082,"protocol_no":"CLJM716X2104","submission_no":"174434","status_id":1,"start_date":"2014-06-18","end_date":null,"nol_date":"2014-06-09","protocol_title":"A PHASE IB/II, MULTICENTRE STUDY OF LJM716 IN COMBINATION WITH CETUXIMAB IN PATIENTS WITH PLATINUM-PRETREATED RECURRENT/METASTIC HEAD AND NECK SQUAMOUS CELL CARCINOMA.","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28090,"protocol_no":"TH004","submission_no":"167581","status_id":3,"start_date":"2013-10-09","end_date":null,"nol_date":"2013-09-19","protocol_title":"\"A MUTLI-CENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO ASSESS THE TOLERABILITY OF TOLERMUNE HOUSE DUST MITE IN SUBJECTS WITH CONTROLLED ASTHMA AND HOUSE DUST MITE-INDUCED RHINOCONJUNCTIVITIS.\"","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43272,"protocol_no":"RG012-03","submission_no":"197678","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-09-15","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, PHARMACODYNAMICS, PHARMACOKINETICS, DOSE SELECTION, AND PRELIMINARY EFFICACY OF WEEKLY RG-012 INJECTIONS IN PATIENTS WITH ALPORT SYNDROME.","medConditionList":[{"med_condition_id":745,"med_condition":"ALPORT SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37526,"protocol_no":"DIC2014","submission_no":"178886","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-11-14","protocol_title":"DENOSUMAB (A MONOCLONAL ANTIBODY TO RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B LIGAND (RANKL) IN CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39248,"protocol_no":"CTH-300","submission_no":"184593","status_id":2,"start_date":"2016-03-21","end_date":"2018-02-08","nol_date":"2015-06-18","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EXAMINE THE EFFICACY, SAFETY AND TOLERABILITY OF APL-130277 IN LEVODOPA RESPONSIVE PATIENTS WITH PARKINSON¬íS DISEASE COMPLICATED BY MOTOR FLUCTUATIONS (\"OFF\" EPISODES)","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44324,"protocol_no":"1601T0831","submission_no":"200817","status_id":2,"start_date":"2017-02-20","end_date":"2017-05-04","nol_date":"2016-12-21","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF A SINGLE DOSE OF S 033188 COMPARED WITH PLACEBO OR OSELTAMIVIR 75 MG TWICE DAILY FOR 5 DAYS IN OTHERWISE HEALTHY PATIENTS WITH INFLUENZA","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37006,"protocol_no":"CC-5013-DLC-002","submission_no":"177226","status_id":1,"start_date":"2015-05-29","end_date":null,"nol_date":"2014-09-15","protocol_title":"PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (CC-5013) PLUS R-CHOP CHEMOTHERAPY (R2-CHOP) VERSUS PLACEBO PLUS R-CHOP CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED ACTIVATED B-CELL TYPE DIFFUSE LARGE B-CELL LYMPHOMA","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"},{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48067,"protocol_no":"WO40242","submission_no":"212861","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-13","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK","medConditionList":[{"med_condition_id":724,"med_condition":"SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41549,"protocol_no":"PR-30-5020-C","submission_no":"191819","status_id":1,"start_date":"2016-09-02","end_date":null,"nol_date":"2016-03-02","protocol_title":"A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NIRAPARIB IN PATIENTS WITH ADVANCED, RELAPSED, HIGH-GRADE SEROUS EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO HAVE RECEIVED THREE OR FOUR PREVIOUS CHEMOTHERAPY REGIMENS","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":184,"med_condition":"OVARIAN CANCER PRIMARY PERITONEAL"},{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29193,"protocol_no":"TR701-132","submission_no":"171187","status_id":2,"start_date":"2014-07-02","end_date":"2018-02-27","nol_date":"2014-01-31","protocol_title":"A PHASE 3 RANDOMIZED DOUBLE-BLIND STUDY COMPARING TR 701 FA AND LINEZOLID IN VENTILATED GRAM-POSITIVE NOSOCOMIAL PNEUMONIA","medConditionList":[{"med_condition_id":442,"med_condition":"PNEUMONIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43759,"protocol_no":"GS-US-418-3898","submission_no":"199079","status_id":1,"start_date":"2017-06-29","end_date":null,"nol_date":"2016-11-09","protocol_title":"COMBINED PHASE 2B/3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDIES EVALUATING THE EFFICACY AND SAFETY OF FILGOTINIB IN THE INDUCTION AND MAINTENANCE OF REMISSION IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39787,"protocol_no":"A3921145","submission_no":"186280","status_id":1,"start_date":"2018-02-06","end_date":null,"nol_date":"2015-08-12","protocol_title":"A LONG TERM, OPEN LABEL FOLLOW UP STUDY OF CP 690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40678,"protocol_no":"A4091056","submission_no":"188803","status_id":1,"start_date":"2016-03-14","end_date":null,"nol_date":"2015-11-25","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECT WITH OSTEOARTHRITIS OF THE HIP OR KNEE","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43930,"protocol_no":"B7931004","submission_no":"199605","status_id":1,"start_date":"2017-05-18","end_date":null,"nol_date":"2016-11-25","protocol_title":"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42811,"protocol_no":"SPK-9001-101","submission_no":"196299","status_id":1,"start_date":"2016-12-09","end_date":null,"nol_date":"2016-07-22","protocol_title":"GENE THERAPY, OPEN-LABEL, DOSE-ESCALATION STUDY OF SPK-9001 (ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR IX GENE) IN SUBJECTS WITH HEMOPHILIA B","medConditionList":[{"med_condition_id":100,"med_condition":"HEMOPHILIA B"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45687,"protocol_no":"590","submission_no":"205176","status_id":1,"start_date":"2017-10-16","end_date":null,"nol_date":"2017-05-26","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH CISPLATIN AND 5-FLUOROURACIL VERSUS PLACEBO IN COMBINATION WITH CISPLATIN AND 5-FLUOROURACIL AS FIRST-LINE TREATMENT IN SUBJECTS WITH ADVANCED/METASTATIC ESOPHAGEAL CARCINOMA (KEYNOTE-590)","medConditionList":[{"med_condition_id":696,"med_condition":"ESOPHAGEAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37516,"protocol_no":"LPS13649","submission_no":"178846","status_id":1,"start_date":"2015-03-14","end_date":null,"nol_date":"2014-11-13","protocol_title":"A LONG-TERM FOLLOW-UP STUDY FOR MULTIPLE SCLEROSIS PATIENTS WHO HAVE COMPLETED THE ALEMTUZUMAB EXTENSION STUDY (CAMMS03409)","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40931,"protocol_no":"20110235","submission_no":"189721","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-18","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING, SINGLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AMG 282 IN HEALTHY SUBJECTS WITH MILD ATOPIC ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42778,"protocol_no":"1301-02","submission_no":"196196","status_id":1,"start_date":"2017-04-18","end_date":null,"nol_date":"2016-08-05","protocol_title":"PHASE 1B STODU OF TBI-1301 (NY-ESO-1 SPECIFIC TCR GENE TRANSDUCED AUTOLOGOUS T LYMPHOCYTES) IN PATIENTS WITH SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40866,"protocol_no":"IPI-145-18","submission_no":"189516","status_id":1,"start_date":"2016-08-10","end_date":null,"nol_date":"2015-12-22","protocol_title":"A PHASE 1B STUDY OF IPI-145 ADMINISTERED IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH CLL/SLL PREVIOUSLY TREATED WITH A BRUTON'S TYROSINE KINASE INHIBITOR (BTKI)","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"},{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41626,"protocol_no":"RADICALPC_009-001","submission_no":"192086","status_id":1,"start_date":"2016-03-14","end_date":null,"nol_date":"2016-03-09","protocol_title":"A RANDOMIZED INTERVENTION FOR CARDIOVASCULAR AND LIFESTYLE RISK FACTORS IN PROSTATE CANCER PATIENTS (RADICAL PC2)","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43118,"protocol_no":"SHP616-300","submission_no":"197172","status_id":1,"start_date":"2016-10-07","end_date":null,"nol_date":"2016-08-22","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-PERIOD, THREE-SEQUENCE, PARTIAL CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF 2000 IU OF C1 ESTERASE INHIBITOR [HUMAN] LIQUID FOR INJECTION FOR THE PREVENTION OF ANGIOEDEMA ATTACKS IN ADOLESCENTS AND ADULTS WITH HEREDITARY ANGIOEDEMA","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36148,"protocol_no":"LAL-CL06","submission_no":"174623","status_id":1,"start_date":"2016-06-17","end_date":null,"nol_date":"2014-06-05","protocol_title":"A MULTICENTER, OPEN-LABEL STUDY OF SEBELIPASE ALFA IN PATIENTS WITH LYSOSOMAL ACID LIPAS DEFICIENCY","medConditionList":[{"med_condition_id":547,"med_condition":"LYSOSOMAL ACID LIPAS DEFICIENCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35712,"protocol_no":"SGN-35-015","submission_no":"173203","status_id":1,"start_date":"2014-10-02","end_date":null,"nol_date":"2014-04-30","protocol_title":"A PHASE 2 OPEN-LABEL STUDY OF BRENTUXIMAB VEDOTIN IN FRONT-LINE THERAPY OF HODGKIN LYMPHOMA (HL) IN ADULTS AGE 60 AND ABOVE","medConditionList":[{"med_condition_id":481,"med_condition":"HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47011,"protocol_no":"CA034-001","submission_no":"209470","status_id":1,"start_date":"2017-11-24","end_date":null,"nol_date":"2017-10-27","protocol_title":"PHASE 1/2A FIRST IN HUMAN STUDY OF BMS-986277 CD80/ACD3 ONCOLYTIC VIRUS ADMINISTERED ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADVANCED EPITHELIAL TUMORS","medConditionList":[{"med_condition_id":812,"med_condition":"EPITHELIAL TUMOURS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26600,"protocol_no":"ACCL1131","submission_no":"163222","status_id":1,"start_date":"2014-10-30","end_date":null,"nol_date":"2013-04-12","protocol_title":"A PHASE III OPEN-LABEL TRIAL OF CASPOFUNGIN VS. AZOLE PROPHYLAXIS FOR PATIENTS AT HIGH-RISK FOR INVASIVE FUNGAL INFECTIONS (IFI) FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47661,"protocol_no":"RVT-502-1001(DER-P7-797)","submission_no":"211507","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-20","protocol_title":"SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TOPICAL RVT-502 HCL SALT (CERDULATINIB HYDROCHLORIDE) IN HEALTHY VOLUNTEERS AND ADULTS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27534,"protocol_no":"RTOG 1201","submission_no":"166035","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-07-25","protocol_title":"A PHASE II RANDOMIZED TRIAL OF HIGH VERSUS STANDARD INTENSITY LOCAL OR SYSTEMIC THERAPY FOR UNRESECTABLE PANCREATIC CANCER","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28062,"protocol_no":"I6T-MC-AMAA","submission_no":"167473","status_id":1,"start_date":"2013-10-03","end_date":null,"nol_date":"2013-09-13","protocol_title":"\"A PHASE I, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF LY3074828, AN ANTI-IL-23 HUMANIZED ANTIBODY, IN SUBJECTS WITH PSORIASIS.\"","medConditionList":[{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27071,"protocol_no":"M12-813","submission_no":"164681","status_id":2,"start_date":"2013-08-15","end_date":"2016-01-21","nol_date":"2013-07-05","protocol_title":"A PHASE 2B STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ELAGOLIX IN PREMENOPAUSAL WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS","medConditionList":[{"med_condition_id":333,"med_condition":"UTERINE FIBROIDS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44744,"protocol_no":"17833","submission_no":"202267","status_id":1,"start_date":"2017-08-24","end_date":null,"nol_date":"2017-03-14","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS PI3K INHIBITOR COPANLISIB IN COMBINATION WITH STANDARD IMMUNOCHEMOTHERAPY VERSUS STANDARD IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN¬øS LYMPHOMA (INHL) - CHRONOS-4.","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39545,"protocol_no":"D5240C00001","submission_no":"185677","status_id":1,"start_date":"2015-08-31","end_date":null,"nol_date":"2015-07-23","protocol_title":"A PHASE 2A, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEDI9929 IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46140,"protocol_no":"BO29554","submission_no":"206490","status_id":1,"start_date":"2017-10-03","end_date":null,"nol_date":"2017-07-04","protocol_title":"A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCIC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (B FAST: BLOOD-FIRST ASSAY SCREENING TRIAL)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41061,"protocol_no":"ISIS 396443-CS11","submission_no":"190109","status_id":1,"start_date":"2016-07-26","end_date":null,"nol_date":"2015-12-18","protocol_title":"AN OPEN-LABEL EXTENSION STUDY FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY WHO PREVIOUSLY PARTICIPATED IN INVESTIGATIONAL STUDIES OF ISIS 396443","medConditionList":[{"med_condition_id":321,"med_condition":"SPINAL MUSCULAR ATROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37566,"protocol_no":"ALFIE2","submission_no":"179037","status_id":1,"start_date":"2017-06-07","end_date":null,"nol_date":"2014-11-06","protocol_title":"ANTICOAGULANTS FOR LIVING FETUSES IN WOMEN WITH RECURRENT MISCARRIAGE AND INHERITED THROMBOPHILIA","medConditionList":[{"med_condition_id":705,"med_condition":"INHERITED THROMBOPHILIA"},{"med_condition_id":706,"med_condition":"RECURRENT MISCARRIAGE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45274,"protocol_no":"CO-338-063","submission_no":"203851","status_id":1,"start_date":"2017-08-23","end_date":null,"nol_date":"2017-04-20","protocol_title":"TRITON3: A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE 3 STUDY OF RUCAPARIB VERSUS PHYSICIAN¬øS CHOICE OF THERAPY FOR PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42397,"protocol_no":"54135419TRD3008","submission_no":"194831","status_id":1,"start_date":"2017-04-12","end_date":null,"nol_date":"2016-06-01","protocol_title":"AN OPEN-LABEL LONG-TERM EXTENSION SAFETY STUDY OF INTRANASAL ESKETAMINE IN TREATMENT-RESISTANT DEPRESSION","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44516,"protocol_no":"GS-US-342-4062","submission_no":"201612","status_id":1,"start_date":"2017-03-16","end_date":null,"nol_date":"2017-01-24","protocol_title":"A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR FOR 12 WEEKS IN SUBJECTS WITH CHRONIC HCV INFECTION WHO ARE ON DIALYSIS FOR END STAGE RENAL DISEASE","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42037,"protocol_no":"CA209-577","submission_no":"193721","status_id":1,"start_date":"2016-12-01","end_date":null,"nol_date":"2016-04-19","protocol_title":"A RANDOMIZED, MULTICENTER, DOUBLE BLIND, PHASE III STUDY OF NIVOLUMAB OR PLACEBO IN SUBJECTS WITH RESECTED LOWER ESOPHAGEAL, OR GASTROESOPHAGEAL JUNCTION CANCER","medConditionList":[{"med_condition_id":696,"med_condition":"ESOPHAGEAL CANCER"},{"med_condition_id":337,"med_condition":"GASTRIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36948,"protocol_no":"M14-500","submission_no":"177043","status_id":1,"start_date":"2015-04-22","end_date":null,"nol_date":"2014-09-04","protocol_title":"A PHASE 4 TRIAL ASSESSING THE IMPACT OF RESIDUAL INFLAMMATION DETECTED VIA IMAGING TECHNIQUES DRUG LEVELS AND PATIENT CHARACTERISTICS ON THE OUTCOME OF DOSE TAPERING OF ADALIMUMAB IN CLINICAL REMISSION RHEUMATOID ARTHRITIS (RA) SUBJECT (PREDICTRA)","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42158,"protocol_no":"203167","submission_no":"194092","status_id":2,"start_date":"2016-08-04","end_date":"2018-01-04","nol_date":"2016-05-11","protocol_title":"A MULTICENTRE, RANDOMISED, DOUBLE-BLIND (SPONSOR-UNBLINDED), PLACEBO-CONTROLLED, REPEAT DOSE STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF GSK2982772 IN SUBJECTS WITH ACTIVE PLAQUE-TYPE PSORIASIS.","medConditionList":[{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41168,"protocol_no":"1311.4","submission_no":"190533","status_id":1,"start_date":"2016-05-02","end_date":null,"nol_date":"2016-01-14","protocol_title":"BI 655066 VERSUS PLACEBO IN A MULTICENTER RANDOMIZED DOUBLE-BLIND STUDY IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS EVALUATING THE EFFICACY AND SAFETY WITH RANDOMIZED WITHDRAWAL AND RE-TREATMENT (IMMHANCE),","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43226,"protocol_no":"WO30085","submission_no":"197528","status_id":1,"start_date":"2016-11-14","end_date":null,"nol_date":"2016-09-07","protocol_title":"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42424,"protocol_no":"GO30103","submission_no":"194887","status_id":1,"start_date":"2016-08-02","end_date":null,"nol_date":"2016-06-08","protocol_title":"A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"},{"med_condition_id":314,"med_condition":"METASTATIC MALIGNANCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39285,"protocol_no":"GO29781","submission_no":"184722","status_id":1,"start_date":"2017-10-18","end_date":null,"nol_date":"2015-06-25","protocol_title":"\"AN OPEN-LABEL, MULTICENTER, PHASE I TRIAL EVALUATING THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA.\"","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"},{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41642,"protocol_no":"204486 (ZOSTER-056)","submission_no":"192182","status_id":1,"start_date":"2016-04-15","end_date":null,"nol_date":"2016-03-11","protocol_title":"A PHASE IIIB, NON-RANDOMIZED, OPEN-LABEL, MULTI-COUNTRY, MULTI-CENTRIC CROSS-VACCINATION STUDY TO EVALUATE THE SAFETY OF GSK BIOLOGICALS' HERPES ZOSTER SUBUNIT (HZ/SU) VACCINE WHEN ADMINISTERED INTRAMUSCULARLY ON A TWO-DOSE SCHEDULE TO SUBJECTS WHO PREVIOUSLY RECEIVED PLACEBO IN ZOSTER-006 AND ZOSTER-022 STUDIES","medConditionList":[{"med_condition_id":289,"med_condition":"HERPES ZOSTER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37814,"protocol_no":"NBI-98854-1304","submission_no":"179790","status_id":1,"start_date":"2015-04-08","end_date":null,"nol_date":"2014-12-18","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, FIXED-DOSE STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF NBI-98854 FOR THE TREATMENT OF TARDIVE DYSKINESIA","medConditionList":[{"med_condition_id":604,"med_condition":"TARDIVE DYSKINESIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28066,"protocol_no":"PHI113747","submission_no":"167483","status_id":1,"start_date":"2014-06-26","end_date":null,"nol_date":"2013-09-17","protocol_title":"A 24-WEEK, PHASE 2B, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GSK1278863 IN SUBJECTS WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE WHO ARE NOT ON DIALYSIS","medConditionList":[{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"},{"med_condition_id":329,"med_condition":"ANEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47739,"protocol_no":"AB-423-002","submission_no":"211687","status_id":2,"start_date":null,"end_date":"2018-03-28","nol_date":"2018-01-08","protocol_title":"A PHASE 1B/2A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY EVALUATING THE SAFETY, ANTI-VIRAL ACTIVITY, AND PHARMACOKINETICS OF AB-423, A HBV CORE INHIBITOR, IN NON-CIRRHOTIC, HBV-DNA POSITIVE SUBJECTS WITH CHRONIC HBV INFECTION","medConditionList":[{"med_condition_id":103,"med_condition":"HEPATITIS B VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47510,"protocol_no":"M15-654","submission_no":"211145","status_id":1,"start_date":"2018-02-26","end_date":null,"nol_date":"2017-12-13","protocol_title":"A PHASE 1/2, MULTICENTER, DOSE-ESCALATION AND EXPANSION STUDY OF COMBINATION THERAPY WITH VENETOCLAX, DARATUMUMAB AND DEXAMETHASONE (WITH AND WITHOUT BORTEZOMIB) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":506,"med_condition":"RELAPSED OR REFRACTORY ACUTE MYELOID  LEUKEMIA (AML)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35895,"protocol_no":"15788","submission_no":"173833","status_id":2,"start_date":"2014-12-05","end_date":"2016-05-24","nol_date":"2014-05-13","protocol_title":"A RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF DIFFERENT DOSES OF BAY 1002670 IN SUBJECTS WITH UTERINE FIBROIDS OVER 3 MONTHS.","medConditionList":[{"med_condition_id":333,"med_condition":"UTERINE FIBROIDS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42159,"protocol_no":"CRFB002H2301E1","submission_no":"194094","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-05-12","protocol_title":"RAINBOW EXTENSION STUDY: AN EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF RANIBIZUMAB COMPARED WITH LASER THERAPY FOR THE TREATMENT OF INFANTS BORN PREMATURELY WITH RETINOPATHY OF PREMATURITY","medConditionList":[{"med_condition_id":564,"med_condition":"RETINOPATHY OF PREMATURITY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36005,"protocol_no":"IN-CA-236-1313","submission_no":"174163","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-06-03","protocol_title":"ELVITEGRAVIR/COBICISTAT/TENOFOVIR DF/EMTRICITABINE WITH DARUNAVIR IN TREATMENT-EXPERIENCED PATIENTS: QUALITY CONTROL MONITORING OF A TREATMENT SIMPLIFICATION STRATEGY","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36098,"protocol_no":"D4191C00004","submission_no":"174492","status_id":1,"start_date":"2016-02-15","end_date":null,"nol_date":"2014-06-05","protocol_title":"A PHASE III, OPEN LABEL, RANDOMISED, MULTI-CENTRE, INTERNATIONAL STUDY OF MEDI4736, VERSUS STANDARD OF CARE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (STAGE IIIB-IV) WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC TREATMENT REGIMENS INCLUDING ONE PLATINUM BASED CHEMOTHERAPY REGIMEN AND DO NOT HAVE KNOWN EGFR TK ACTIVATING MUTATIONS OR ALK REARRANGEMENTS (ARCTIC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45489,"protocol_no":"B5091007","submission_no":"204567","status_id":1,"start_date":"2017-07-17","end_date":null,"nol_date":"2017-05-05","protocol_title":"A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36808,"protocol_no":"RECD3125","submission_no":"176621","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-08-20","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, MULTIREGIONAL, ONE YEAR STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ORAL RIFAXIMIN DELAYED RELEASE TABLETS FOR INDUCTION OF CLINICAL REMISSION WITH ENDOSCOPIC RESPONSE AT 16 WEEKS FOLLOWED BY CLINICAL AND ENDOSCOPIC REMISSION AT 52 WEEKS IN SUBJECTS WITH ACTIVE MODERATE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38681,"protocol_no":"A8241022","submission_no":"182834","status_id":2,"start_date":"2015-04-15","end_date":"2017-04-19","nol_date":"2015-04-08","protocol_title":"AN OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON'S DISEASE WHO PREVIOUSLY COMPLETED STUDY A8241021","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45843,"protocol_no":"SCI-B-VAC-001","submission_no":"205635","status_id":1,"start_date":"2017-12-08","end_date":null,"nol_date":"2017-06-14","protocol_title":"A PHASE 3 DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL TO COMPARE THE IMMUNOGENICITY AND SAFETY OF A THREE-DOSE REGIMEN OF SCI-B-VAC TO A THREE-DOSE REGIMEN OF ENGERIX-B IN ADULTS","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46305,"protocol_no":"D1680C00019","submission_no":"207049","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-25","protocol_title":"A 26 WEEK, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP, PHASE 3 TRIAL WITH A 26 WEEK SAFETY EXTENSION PERIOD EVALUATING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 5 AND 10 MG, AND SAXAGLIPTIN 2.5 AND 5 MG IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE BETWEEN 10 AND BELOW 18 YEARS OF AGE","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39790,"protocol_no":"CY 4031","submission_no":"186286","status_id":2,"start_date":"2016-06-21","end_date":"2017-09-27","nol_date":"2015-08-13","protocol_title":"A PHASE 3, MULTI-NATIONAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, STRATIFIED, PARALLEL GROUP, STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF TIRASEMTIV IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45479,"protocol_no":"HAND IN INSULIN-001","submission_no":"204512","status_id":1,"start_date":"2018-01-01","end_date":null,"nol_date":"2017-05-01","protocol_title":"INTRANASAL TREATMENT OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"},{"med_condition_id":788,"med_condition":"NEUROCOGNITIVE DISORDERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40939,"protocol_no":"MLN0002SC-3031","submission_no":"189748","status_id":1,"start_date":"2016-09-09","end_date":null,"nol_date":"2015-12-30","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTANEOUS AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47145,"protocol_no":"207966","submission_no":"209904","status_id":1,"start_date":"2017-12-19","end_date":null,"nol_date":"2017-10-26","protocol_title":"A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY, OPEN-LABEL STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF LONG-ACTING CABOTEGRAVIR PLUS LONG-ACTING RILPIVIRINE ADMINISTERED EVERY 8 WEEKS OR EVERY 4 WEEKS IN HIV-1-INFECTED ADULTS WHO ARE VIROLOGICALLY SUPPRESSED","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39151,"protocol_no":"CNTO1275UCO3001","submission_no":"184303","status_id":1,"start_date":"2016-04-06","end_date":null,"nol_date":"2015-06-04","protocol_title":"\"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER PROTOCOL TO EVALUATE THE SAFETY AND EFFICACY OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS.\"","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45739,"protocol_no":"15789","submission_no":"204961","status_id":1,"start_date":"2017-09-29","end_date":null,"nol_date":"2017-06-07","protocol_title":"A RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF VILAPRISAN IN SUBJECTS WITH UTERINE FIBROIDS","medConditionList":[{"med_condition_id":333,"med_condition":"UTERINE FIBROIDS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43903,"protocol_no":"RVT-101-2002","submission_no":"199528","status_id":1,"start_date":"2017-02-10","end_date":null,"nol_date":"2016-11-23","protocol_title":"A LONG-TERM EXTENSION STUDY OF THE SAFETY AND TOLERABILITY OF RVT-101 IN SUBJECTS WITH DEMENTIA WITH LEWY BODIES (DLB)","medConditionList":[{"med_condition_id":361,"med_condition":"DEMENTIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37538,"protocol_no":"16277","submission_no":"178939","status_id":1,"start_date":"2015-06-23","end_date":null,"nol_date":"2014-11-14","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)","medConditionList":[{"med_condition_id":246,"med_condition":"SYSTEMIC SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40629,"protocol_no":"MDCO-PCS-15-01","submission_no":"188675","status_id":2,"start_date":"2016-08-18","end_date":"2017-05-24","nol_date":"2015-11-18","protocol_title":"A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO COMPARE THE EFFECT OF DIFFERENT DOSES OF ALN-PCSSC GIVEN AS SINGLE OR MULTIPLE SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"},{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38726,"protocol_no":"ISIS 443139-CS1","submission_no":"182969","status_id":2,"start_date":"2017-10-23","end_date":"2017-08-31","nol_date":"2015-04-15","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ASCENDING DOSES OF INTRATHECALLY ADMINISTERED ISIS 443139 IN PATIENTS WITH EARLY MANIFEST HUNTINGTON'S DISEASE","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41097,"protocol_no":"OZM-068","submission_no":"190280","status_id":1,"start_date":"2016-03-24","end_date":null,"nol_date":"2016-01-07","protocol_title":"PHASE I STUDY OF AUTOLOGOUS ACUTE MYELOGENOUS LEUKEMIA (AML) CELLS CONTAINING LENTIVIRUS ENGINEERING EXPRESSION OF IL-12","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46226,"protocol_no":"ASTX660-01","submission_no":"206781","status_id":1,"start_date":"2017-10-17","end_date":null,"nol_date":"2017-07-13","protocol_title":"PHASE 1-2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF ASTX660 IN SUBJECTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS.","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"},{"med_condition_id":691,"med_condition":"LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37926,"protocol_no":"CHDM201X2103C","submission_no":"180126","status_id":1,"start_date":"2017-02-08","end_date":null,"nol_date":"2014-12-22","protocol_title":"A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF ORAL HDM201 IN COMBINATION WITH ORAL LEE011 IN ADULT PATIENTS WITH LIPOSARCOMA","medConditionList":[{"med_condition_id":600,"med_condition":"LIPOSARCOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38194,"protocol_no":"LUM001-202","submission_no":"181237","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-10","protocol_title":"AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS","medConditionList":[{"med_condition_id":209,"med_condition":"PRIMARY BILIARY CIRRHOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45728,"protocol_no":"ENDOLORA","submission_no":"205327","status_id":1,"start_date":"2017-06-19","end_date":null,"nol_date":"2017-05-29","protocol_title":"UN ESSAI CLINIQUE RANDOMIS√âE √Ä DOUBLE INSU SUR L'EFFET D'UNE DOSE UNIQUE DE LORAZEPAM SUR LES TAUX DE CORTISOL SALIVAIRE CHEZ LES ENFANTS QUI AURONT UNE ENDOSCOPIE DIGESTIVE.","medConditionList":[{"med_condition_id":242,"med_condition":"STRESS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42396,"protocol_no":"16-5357","submission_no":"194830","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-01","protocol_title":"BRAIN INSULIN SENSITIVITY IN MOOD, HEDONIC AND COGNITIVE PROCESSING AREAS IN BIPOLAR DISORDER","medConditionList":[{"med_condition_id":501,"med_condition":"BIPOLAR DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43478,"protocol_no":"AKB-6548-CI-0017","submission_no":"198208","status_id":1,"start_date":"2017-02-13","end_date":null,"nol_date":"2016-09-29","protocol_title":"PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE ¬ø CONVERSION)","medConditionList":[{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"},{"med_condition_id":329,"med_condition":"ANEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27602,"protocol_no":"CTNPT021","submission_no":"166241","status_id":1,"start_date":"2014-02-26","end_date":null,"nol_date":"2013-08-01","protocol_title":"BONE ANTIRESORPTIVE THERAPY WITH ANTIRETROVIRAL INITIATION (BATARI) PILOT TRIAL","medConditionList":[{"med_condition_id":145,"med_condition":"LOW BONE MINERAL DENSITY"},{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40806,"protocol_no":"EMR200588-002","submission_no":"189226","status_id":1,"start_date":"2016-12-12","end_date":null,"nol_date":"2015-12-04","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, CONFIRMATORY TRIAL TO EVALUATE THE EFFICACY, SAFETY AND IMMUNOGENICITY OF MSB11022 COMPARED WITH EUROPEAN UNION-APPROVED HUMIRA¬Æ IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47483,"protocol_no":"C3291002","submission_no":"211050","status_id":1,"start_date":"2018-01-15","end_date":null,"nol_date":"2017-12-07","protocol_title":"A PHASE 4, MULTICENTER, OPEN LABEL SAFETY STUDY OF CRISABOROLE OINTMENT 2% IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS.","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26648,"protocol_no":"VX12-809-103","submission_no":"163357","status_id":1,"start_date":"2013-10-03","end_date":null,"nol_date":"2013-04-18","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS, HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38337,"protocol_no":"HAN-01 (HPV DNA-15-005)","submission_no":"181707","status_id":1,"start_date":"2015-06-01","end_date":null,"nol_date":"2015-02-27","protocol_title":"FDG-PET AND CIRCULATING HPV IN PATIENTS WITH CERVICAL CANCER TREATED WITH DEFINITIVE CHEMORADIATION","medConditionList":[{"med_condition_id":356,"med_condition":"CERVICAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26733,"protocol_no":"000081","submission_no":"163643","status_id":1,"start_date":"2014-03-03","end_date":null,"nol_date":"2013-04-30","protocol_title":"A MULTICENTER, OPEN-LABEL, SAFETY AND TOLERABILITY EXTENSION TRIAL OF 5 MG AND 10 MG ELOBIXIBAT DAILY IN THE TREATMENT OF CHRONIC IDIOPATHIC CONSTIPATION.","medConditionList":[{"med_condition_id":322,"med_condition":"IDIOPATHIC CONSTIPATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29386,"protocol_no":"GIULIANI-01 [EORTC 1219]","submission_no":"171685","status_id":1,"start_date":"2017-01-19","end_date":null,"nol_date":"2014-02-27","protocol_title":"A BLIND RANDOMIZED MULTICENTER STUDY OF ACCELERATED FRACTIONATED CHEMO-RADIOTHERAPY WITH OR WITHOUT THE HYPOXIC RADIOSENSITIZER NIMORAZOLE (NIMORAL), USING A 15 GENE SIGNATURE FOR HYPOXIA IN THE TREATMENT OF HPV/P16 NEGATIVE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27956,"protocol_no":"200613 (FLU Q-PAN H7N1=AS03-00","submission_no":"167155","status_id":1,"start_date":"2013-09-23","end_date":null,"nol_date":"2013-09-06","protocol_title":"AN OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS' INFLUENZA VACCINE(S) GSK2789869A AND GSK2789868A) ADMINISTERED IN ADULTS 65 YEARS OF AGE AND OLDER","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27005,"protocol_no":"CP-H5VLP-005","submission_no":"164460","status_id":3,"start_date":"2013-06-11","end_date":null,"nol_date":"2013-06-07","protocol_title":"IMMUNOGENICITY, SAFETY, TOLERABILITY OF A PLANT-MADE H5 VLP INFLUENZA VACCINE","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36165,"protocol_no":"PRMT15","submission_no":"174438","status_id":1,"start_date":"2015-04-20","end_date":null,"nol_date":"2014-06-05","protocol_title":"PROGESTERONE FOR THE PREVENTION OF MISCARRIAGE AND PRETERM BIRTH IN WOMEN WITH FIRST TRIMESTER BLEEDING: PREEMPT TRIAL","medConditionList":[{"med_condition_id":435,"med_condition":"PREMATURE LABOUR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45398,"protocol_no":"200808","submission_no":"204314","status_id":1,"start_date":"2017-06-20","end_date":null,"nol_date":"2017-04-20","protocol_title":"A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER, EVENT DRIVEN STUDY IN NON-DIALYSIS SUBJECTS WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE TO EVALUATE THE SAFETY AND EFFICACY OF DAPRODUSTAT COMPARED TO DARBEPOETIN ALFA.","medConditionList":[{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28351,"protocol_no":"HZC102972","submission_no":"168293","status_id":2,"start_date":"2014-01-30","end_date":"2018-03-26","nol_date":"2013-10-11","protocol_title":"MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY EVALUATING THE EFFECT OF FLUTICASONE FUROATE/ VILANTEROL (FF/VI) INHALATION POWDER ONCE DAILY COMPARED WITH VILANTEROL (VI) INHALATION POWDER ONCE DAILY ON BONE MINERAL DENSITY (BMD) IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43163,"protocol_no":"2215-CL-0302","submission_no":"197356","status_id":1,"start_date":"2017-03-21","end_date":null,"nol_date":"2016-09-02","protocol_title":"A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE FLT3 INHIBITOR GILTERITINIB (ASP2215) ADMINISTERED AS MAINTENANCE THERAPY FOLLOWING INDUCTION/CONSOLIDATION THERAPY FOR SUBJECTS WITH FLT3/ITD AML IN FIRST COMPLETE REMISSION","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42313,"protocol_no":"204","submission_no":"194583","status_id":1,"start_date":"2017-01-16","end_date":null,"nol_date":"2016-05-20","protocol_title":"A PHASE III RANDOMIZED OPEN-LABEL CLINICAL TRIAL TO COMPARE PEMBROLIZUMAB WITH BRENTUXIMAB VEDOTIN IN SUBJECTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA","medConditionList":[{"med_condition_id":481,"med_condition":"HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43081,"protocol_no":"COMB157G2302","submission_no":"197062","status_id":1,"start_date":"2017-04-24","end_date":null,"nol_date":"2016-08-31","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB VERSUS TERIFLUNOMIDE IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44849,"protocol_no":"LYC-30937-2002","submission_no":"202628","status_id":1,"start_date":"2017-12-30","end_date":null,"nol_date":"2017-02-17","protocol_title":"A MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF LYC-30937-EC IN SUBJECTS WITH ACTIVE ULCERATIVE COLITIS (VERSION: AMENDMENT 2.1; 30 NOVEMBER 2016)","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46208,"protocol_no":"TBI-001-IGIV","submission_no":"206749","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-18","protocol_title":"A PROSPECTIVE, OPEN-LABEL, MULTICENTER STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF THERAPURE PLASMACAP IG IN ADULTS AND CHILDREN WITH PRIMARY IMMUNE DEFICIENCY DISEASES","medConditionList":[{"med_condition_id":797,"med_condition":"PRIMARY IMMUNE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47106,"protocol_no":"CA209-9LA","submission_no":"209780","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-26","protocol_title":"A PHASE 3, RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB IN COMBINATION WITH CHEMOTHERAPY VS CHEMOTHERAPY ALONE AS FIRST LINE THERAPY IN STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42903,"protocol_no":"1346.9","submission_no":"196590","status_id":1,"start_date":"2018-03-07","end_date":null,"nol_date":"2016-07-27","protocol_title":"A PHASE II RANDOMISED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PARALLEL GROUP TRIAL TO EXAMINE THE EFFICACY AND SAFETY OF 4 ORAL DOSES OF BI 425809 ONCE DAILY OVER 12 WEEK TREATMENT PERIOD IN PATIENTS WITH SCHIZOPHRENIA.","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44549,"protocol_no":"WO30070","submission_no":"201682","status_id":1,"start_date":"2017-05-31","end_date":null,"nol_date":"2017-01-31","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS MONOTHERAPY AND IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44743,"protocol_no":"CV013011","submission_no":"202265","status_id":1,"start_date":"2018-01-12","end_date":null,"nol_date":"2017-03-01","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2B STUDY OF THE SAFETY AND EFFICACY OF CONTINUOUS 48-HOUR INTRAVENOUS INFUSIONS OF BMS-986231 IN HOSPITALIZED PATIENTS WITH HEART FAILURE AND IMPAIRED SYSTOLIC FUNCTION","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42813,"protocol_no":"I6T-MC-AMAF","submission_no":"196301","status_id":1,"start_date":"2016-09-30","end_date":null,"nol_date":"2016-07-22","protocol_title":"A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42790,"protocol_no":"2017-1491","submission_no":"196248","status_id":1,"start_date":"2017-01-27","end_date":null,"nol_date":"2016-07-20","protocol_title":"CAMOUFLAGE OF THE WAR BETWEEN CSII CATHETER AND SUBCUTANEOUS ADIPOSE TISSUE.","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38612,"protocol_no":"UX001-CL301","submission_no":"182601","status_id":2,"start_date":"2016-06-06","end_date":"2017-06-09","nol_date":"2015-04-01","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIALIC ACID EXTENDED-RELEASE TABLETS IN PATIENTS WITH GNE MYOPATHY (GNEM) OR HEREDITARY INCLUSION BODY MYOPATHY (HIBM)","medConditionList":[{"med_condition_id":609,"med_condition":"GNE MYOPATHY (GNEM)"},{"med_condition_id":610,"med_condition":"HEREDITARY INCLUSION BODY MYOPATHY (HIBM)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38799,"protocol_no":"PRPL-006","submission_no":"183228","status_id":1,"start_date":"2015-08-01","end_date":null,"nol_date":"2015-05-15","protocol_title":"RECONSOLIDATION IMPAIRMENT USING PROPRANOLOL TO TREAT THE TRAUMA OF ATTACHMENT INJURIES WITHIN ROMANTIC RELATIONSHIPS: AN OPEN-LABEL TRIAL","medConditionList":[{"med_condition_id":543,"med_condition":"TRAUMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35916,"protocol_no":"AV001","submission_no":"173923","status_id":1,"start_date":"2015-03-18","end_date":null,"nol_date":"2014-05-13","protocol_title":"A MULTICENTER PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA","medConditionList":[{"med_condition_id":308,"med_condition":"LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36520,"protocol_no":"FSS-AS-30017","submission_no":"175690","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-17","protocol_title":"A 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF FLUTICASONE PROPIONATE MULTIDOSE DRY POWDER INHALER COMPARED WITH FLUTICASONE/SALMETEROL MULTIDOSE DRY POWDER INHALER IN ADOLESCENT AND ADULT PATIENTS WITH PERSISTENT ASTHMA SYMPTOMATIC DESPITE INHALED CORTICOSTEROID THERAPY","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27028,"protocol_no":"TAK-875_309","submission_no":"164539","status_id":1,"start_date":"2013-06-14","end_date":null,"nol_date":"2013-05-28","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 24-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAILY ORAL TAK-875 50 MG COMPARED WITH PLACEBO AS AN ADD-ON TO GLIMEPIRIDE IN SUBJECTS WITH TYPE 2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37789,"protocol_no":"IND#15927","submission_no":"179411","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-11","protocol_title":"OPEN LABEL STUDY OF SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) IN MYASTHENIA GRAVIS","medConditionList":[{"med_condition_id":163,"med_condition":"MYASTHENIA GRAVIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36972,"protocol_no":"16270","submission_no":"177115","status_id":1,"start_date":"2015-02-19","end_date":null,"nol_date":"2014-09-05","protocol_title":"AN OPEN-LABEL, NON-RANDOMIZED, PHASE I STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF A SINGLE INTRAVENOUS DOSE OF COPANLISIB IN PATIENTS WITH ADVANCED SOLID TUMORS.","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"},{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36197,"protocol_no":"SMT19969/C002","submission_no":"174745","status_id":2,"start_date":"2015-01-30","end_date":"2015-10-12","nol_date":"2014-06-19","protocol_title":"A PHASE II, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SMT19969 (200 MG BID) FOR 10 DAYS COMPARED WITH VANCOMYCIN (125 MG QID) FOR 10 DAYS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHOEA (CDAD)","medConditionList":[{"med_condition_id":531,"med_condition":"CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHOEA (CDAD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47715,"protocol_no":"EPL29","submission_no":"211638","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-22","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF CANNABIDIOL PLUS TETRAHYDROCANNABINOL (CBD+THC) GIVEN AS ADJUNCTIVE THERAPY IN PATIENTS WITH REFRACTORY SEIZURES","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27895,"protocol_no":"1000037763","submission_no":"166979","status_id":1,"start_date":"2013-11-26","end_date":null,"nol_date":"2013-08-23","protocol_title":"HYPOTHERMIA'S IMPACT ON PHARMACOLOGY","medConditionList":[{"med_condition_id":368,"med_condition":"CARDIAC ARREST"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26980,"protocol_no":"11002X-002","submission_no":"164412","status_id":1,"start_date":"2013-08-15","end_date":null,"nol_date":"2013-05-22","protocol_title":"A MULTICENTER, DOUBLE-MASKED, RANDOMIZED STUDY TO COMPARE THE SAFETY AND EFFICACY OF AN INVESTIGATIONAL EYE DROP FORMULATION WITH REFRESH PLUS¬Æ UNIT-DOSE (REFRESH) LUBRICANT EYE","medConditionList":[{"med_condition_id":307,"med_condition":"EYE SURGERY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46707,"protocol_no":"4045-301","submission_no":"208439","status_id":1,"start_date":"2018-03-01","end_date":null,"nol_date":"2017-09-13","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF SRP-4045 AND SRP-4053 IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36079,"protocol_no":"ECU-MG-302","submission_no":"174432","status_id":1,"start_date":"2015-05-08","end_date":null,"nol_date":"2014-05-30","protocol_title":"A PHASE III, OPEN-LABEL EXTENSION OF ECU-MG-301 TO EVALUATE THE SAFETY AAND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG)","medConditionList":[{"med_condition_id":88,"med_condition":"GENERALIZED MYASTHENIA GRAVIS (MG).\""}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29223,"protocol_no":"PRO 43981","submission_no":"171256","status_id":3,"start_date":"2014-03-01","end_date":null,"nol_date":"2014-01-28","protocol_title":"A PROSPECTIVE RANDOMIZED SINGLE CENTER TRIAL OF FECAL MICROBIOTA TRANSPLANTATION (FNT) VS SHAM FMT IN THE MANAGEMENT OF ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28770,"protocol_no":"116689 (ZOSTER-035)","submission_no":"169774","status_id":3,"start_date":"2014-03-12","end_date":null,"nol_date":"2013-12-10","protocol_title":"A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL TRIAL TO ASSESS THE IMMUNOGENICITY AND SAFETY OF GSK BIOLOGICALS' HERPES ZOSTER VACCINE GSK1437173A WHEN CO-ADMINISTERED WITH PNEUMOVAX 23 IN ADULTS AGED 50 YEARS AND OLDER","medConditionList":[{"med_condition_id":289,"med_condition":"HERPES ZOSTER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37042,"protocol_no":"NN304-4093","submission_no":"177324","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-09-16","protocol_title":"A 26-WEEK OPEN LABEL, RANDOMISED, 2-ARMED, PARALLEL GROUP, MULTI-CENTRE TRIAL INVESTIGATING EFFICACY AND SAFETY OF INSULIN DETEMIR VERSUS INSULIN NEUTRAL PROTAMINE HAGEDORN IN COMBINATION WITH METFORMIN AND DIET/EXERCISE ON GLYCAEMIC CONTROL IN CHILDREN AND ADOLESCENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONTROLLED ON METFORMIN, OTHER ORAL ANTIDIABETIC DRUG(S), BASAL INSULIN","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27317,"protocol_no":"ONC-DPX-SURVIVAC-03","submission_no":"165367","status_id":1,"start_date":"2015-06-12","end_date":null,"nol_date":"2013-07-05","protocol_title":"PHASE 1B STUDY OF EXTENDED DOSING OF AN IMMUNOTHERAPEUTIC VACCINE, DPX-SURVIVAC WITH LOW DOSE CYCLOPHOSPHAMIDE IN PATIENTS WITH SURGICALLY OPERABLE OR ADVANCED STAGE OVARIAN FALLOPIAN TUBE OR PERITONEAL CANCER","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":183,"med_condition":"OVARIAN CANCER"},{"med_condition_id":194,"med_condition":"PERITONEAL CARCINOMATOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38768,"protocol_no":"GO29437","submission_no":"183115","status_id":1,"start_date":"2016-08-02","end_date":null,"nol_date":"2015-04-24","protocol_title":"\"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+PACLITAXEL OR MPDL3280A IN COMBINATION WITH CARBOPLATIN+NAB-PACLITAXEL VERSUS CARBOPLATIN+NAB-PACLITAXEL IN CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER.\"","medConditionList":[{"med_condition_id":512,"med_condition":"NON-SQUAMOUS CARCINOMA OF THE LUNG"},{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27242,"protocol_no":"WN28137","submission_no":"165207","status_id":2,"start_date":"2013-09-20","end_date":"2015-08-17","nol_date":"2013-06-26","protocol_title":"A PHASE II, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF RO4917838 IN COMBINATION WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PATIENTS WITH OBSESSIVE COMPULSIVE DISORDER.","medConditionList":[{"med_condition_id":316,"med_condition":"OBSESSIVE COMPULSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27034,"protocol_no":"AQX-1125-201","submission_no":"164551","status_id":1,"start_date":"2014-02-18","end_date":null,"nol_date":"2013-05-30","protocol_title":"THE LEADERSHIP STUDY: A PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AQX-1125 IN SUBJECTS WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME MEDIATED BY THE SHIP1 PATHWAY","medConditionList":[{"med_condition_id":132,"med_condition":"INTERSTITIAL CYSTITIS"},{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39106,"protocol_no":"CA209-169","submission_no":"184161","status_id":1,"start_date":"2015-12-30","end_date":null,"nol_date":"2015-05-29","protocol_title":"EXPANDED ACCESS PROGRAM WITH NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL (SQ) NON-SMALL CELL LUNG CANCER WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC REGIMENS FOR THE TREATMENT OF STAGE IIIB/IV SQNSCLC","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"},{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43454,"protocol_no":"OZM-073","submission_no":"198148","status_id":1,"start_date":"2016-11-16","end_date":null,"nol_date":"2016-10-19","protocol_title":"PILOT STUDY OF OBINUTUZUMAB IN COMBINATION WITH GDP CHEMO THERAPY FOR THE TREATMENT OF RELAPSED OR REFRACTORY CD20+ AGGRESSIVE NON-HODGKIN LYMPHOMA","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44663,"protocol_no":"201212","submission_no":"202009","status_id":1,"start_date":"2017-05-02","end_date":null,"nol_date":"2017-02-13","protocol_title":"A PHASE I, OPEN-LABEL STUDY OF GSK3174998 ADMINISTERED ALONE AND IN COMBINATION WITH ANTICANCER AGENTS INCLUDING PEMBROLIZUMAB IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38874,"protocol_no":"TOK-200-15","submission_no":"183488","status_id":2,"start_date":"2015-06-26","end_date":"2016-07-27","nol_date":"2015-05-07","protocol_title":"ARMOR3-SV: A PHASE 3, RANDOMIZED, OPEN LABEL, MULTICENTER, CONTROLLED STUDY OF GALETERONE COMPARED TO ENZALUTAMIDE IN MEN EXPRESSING ANDROGEN RECEPTOR SPLICE VARIANT-7 MRNA (AR-V7) METASTATIC (M1) CASTRATE RESISTANT PROSTATE CANCER (CRPC)","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47068,"protocol_no":"D0816C00020","submission_no":"209623","status_id":1,"start_date":"2018-04-05","end_date":null,"nol_date":"2017-10-13","protocol_title":"A PHASE IIIB, SINGLE-ARM, OPEN-LABEL MULTICENTRE STUDY OF OLAPARIB MAINTENANCE MONOTHERAPY IN PLATINUM SENSITIVE RELAPSED NON-GERMLINE BRCA MUTATED OVARIAN CANCER PATIENTS WHO ARE IN COMPLETE OR PARTIAL RESPONSE FOLLOWING PLATINUM BASED CHEMOTHERAPY ¬ø OPINION","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39860,"protocol_no":"DP10018","submission_no":"186458","status_id":2,"start_date":"2015-11-10","end_date":"2016-07-18","nol_date":"2015-08-18","protocol_title":"RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF APD421 (AMISULPRIDE FOR IV INJECTION) AS TREATMENT OF ESTABLISHED POSTOPERATIVE NAUSEA AND VOMITING, IN PATIENTS WHO HAVE HAD NO PRIOR PROPHYLAXIS.","medConditionList":[{"med_condition_id":302,"med_condition":"NAUSEA AND VOMITING"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41923,"protocol_no":"CAIN457ACA03","submission_no":"193241","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-04-06","protocol_title":"BEYOND: A PILOT, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFECT OF TREATMENT WITH SECUKINUMAB VERSUS PLACEBO ON SYSTEMIC INFLAMMATION AFTER 16 WEEKS AND AFTER 52 WEEKS OF TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE-TYPE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36511,"protocol_no":"B3461028","submission_no":"175652","status_id":2,"start_date":"2015-06-23","end_date":"2018-04-17","nol_date":"2014-07-18","protocol_title":"A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)","medConditionList":[{"med_condition_id":542,"med_condition":"TRANSTHYRETIN AMYLOID CARDIOMYOPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35920,"protocol_no":"HC2014:004","submission_no":"173927","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-06-13","protocol_title":"THE USE OF ORAL DEXAMETHASONE TO IMPROVE QUALITY OF RECOVERY AFTER ANESTHESIA","medConditionList":[{"med_condition_id":517,"med_condition":"RECOVERY AFTER ANESTHESIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35784,"protocol_no":"104-13-302","submission_no":"173453","status_id":1,"start_date":"2015-09-25","end_date":null,"nol_date":"2014-04-25","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE BLIND, DUMMY-CONTROLLED STUDY OF THERMODOX¬Æ (LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN-LTLD) IN HEPATOCELLULAR CARCINOMA (HCC) USING STANDARDIZED RADIOFREQUENCY ABLATION (RFA) TREATMENT TIME 45 MINUTES FOR SOLITARY LESIONS  3 CM TO 7 CM, VERSION 2.0, 14-MARCH-2014","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27460,"protocol_no":"0113-CL-1004","submission_no":"165809","status_id":1,"start_date":"2014-09-23","end_date":null,"nol_date":"2013-07-18","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL TO EVALUATE THE PROECTIVE EFFICACY AND SAFETY OF A THERAPUTIC VACCINE, ASPO113, IN CYTOMEGALOVIRUS (CMV)- SEROPOSTIVIVE RECIPIENTS UNDERGOING ALLOGENIC, HEMATOPOIETIC CELL TRANSPLANT (HCT).","medConditionList":[{"med_condition_id":62,"med_condition":"CYTOMEGALOVIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28685,"protocol_no":"AI443-113","submission_no":"169418","status_id":1,"start_date":"2013-12-19","end_date":null,"nol_date":"2013-11-28","protocol_title":"A PHASE 3 EVALUATION OF A DACLATASVIR/ASUNAPREVIR/BMS-791325 FIXED DOSE COMBINATION IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C AND ADVANCED FIBROSIS OR COMPENSATED CIRRHOSIS","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28689,"protocol_no":"AI443-102","submission_no":"169428","status_id":1,"start_date":"2014-08-20","end_date":null,"nol_date":"2013-11-28","protocol_title":"A PHASE 3 EVALUATION OF A DACLATASVIR/ASUNAPREVIR/BMS-791325 FIXED DOSE COMBINATION (FDC) IN NON-CIRRHOTIC SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44865,"protocol_no":"C38072-AS-30066","submission_no":"202655","status_id":1,"start_date":"2017-04-24","end_date":null,"nol_date":"2017-03-07","protocol_title":"AN OPEN-LABEL EXTENSION STUDY OF RESLIZUMAB 110-MG FIXED, SUBCUTANEOUS DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER WITH SEVERE EOSINOPHILIC ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46389,"protocol_no":"CLEE011G2301","submission_no":"207359","status_id":2,"start_date":null,"end_date":"2018-02-12","nol_date":"2017-09-15","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF RIBOCICLIB WITH ENDOCRINE THERAPY AS AN ADJUVANT TREATMENT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE, HIGH RISK EARLY BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39333,"protocol_no":"CQGE031B2204","submission_no":"184871","status_id":1,"start_date":"2015-09-29","end_date":null,"nol_date":"2015-06-16","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF 52 WEEKS TREATMENT WITH SUBCUTANEOUS QGE031 S.C. IN ASTHMA PATIENTS NOT ADEQUATELY CONTROLLED BY MEDIUM-OR HIGH-DOSE ICS PLUS LABA WITH OR WITHOUT OCS","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35774,"protocol_no":"CPD1028-01","submission_no":"173022","status_id":3,"start_date":"2014-05-28","end_date":null,"nol_date":"2014-04-16","protocol_title":"A PHASE 1A, MULTI-CENTER, OPEN-LABEL, NON-RANDOMIZED STUDY TO ASSESS THE SAFETY, BIODISTRIBUTION AND TUMOUR UPTAKE OF [I-124]-CPD-1028 INJECTION","medConditionList":[{"med_condition_id":293,"med_condition":"MALIGNANT SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37713,"protocol_no":"GS-US-342-1446","submission_no":"179517","status_id":2,"start_date":"2015-04-30","end_date":"2016-06-15","nol_date":"2014-12-03","protocol_title":"AN OPEN LABEL STUDY OF SOFOSBUVIR/GS-5816 FIXED-DOSE COMBINATION IN SUBJECTS WITH CHRONIC HCV INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37327,"protocol_no":"PCS VI","submission_no":"178292","status_id":1,"start_date":"2016-01-08","end_date":null,"nol_date":"2014-10-23","protocol_title":"PHASE III STUDY OF HYPOFRACTIONATED, DOSE ESCALATION RADIOTHERAPY VS. STANDARD PELVIC RADIATION THERAPY FOLLOWED BY HDR BRACHY BOOST FOR HIGH RISK ADENOCARCINOMA OF THE PROSTATE.","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"},{"med_condition_id":213,"med_condition":"PROSTATE ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29018,"protocol_no":"12-5454-B","submission_no":"170602","status_id":1,"start_date":"2013-12-12","end_date":null,"nol_date":"2013-12-20","protocol_title":"FEASIBILITY OF A NOVEL MINIMALLY INVASIVE TECHNIQUE FOR LOCALIZATION OF PULMONARY NODULES USING THE SPY THORACOSCOPE SYSTEM","medConditionList":[{"med_condition_id":447,"med_condition":"PULMONARY NODULES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28045,"protocol_no":"MK-3222-012","submission_no":"167430","status_id":1,"start_date":"2013-05-21","end_date":null,"nol_date":"2013-09-13","protocol_title":"\"A 28-WEEK, PHASE 3, RANDOMIZED, ACTIVE COMPARATOR AND PLACEBO-CONTROLLED, PARALLEL DESIGN STUDY TO EVALUATE THE EFFICACY AND SAFETY/TOLERABILITY OF SUBCUTANEOUS SCH 900222/MK-3222, FOLLOWED BY AN OPTIONAL LONG-TERM SAFETY EXTENSION STUDY, IN SUBJECTS WITH MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS.\"","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41495,"protocol_no":"CQGE031C2201E1","submission_no":"191663","status_id":1,"start_date":"2016-04-25","end_date":null,"nol_date":"2016-02-26","protocol_title":"AN OPEN LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF QGE031 240 MG S.C. GIVEN EVERY 4 WEEKS FOR 52 WEEKS IN CHRONIC SPONTANEOUS URTICARIA PATIENTS WHO COMPLETED STUDY CQGE031C2201","medConditionList":[{"med_condition_id":399,"med_condition":"CHRONIC SPONTANEOUS URTICARIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47707,"protocol_no":"53718678RSV2004","submission_no":"211617","status_id":1,"start_date":"2018-03-09","end_date":null,"nol_date":"2017-12-21","protocol_title":"A PILOT PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EXPLORE THE ANTIVIRAL ACTIVITY, CLINICAL OUTCOMES, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF JNJ-53718678 AT TWO DOSE LEVELS IN NON-HOSPITALIZED ADULT SUBJECTS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45271,"protocol_no":"R668-AD-1526","submission_no":"203860","status_id":1,"start_date":"2017-05-31","end_date":null,"nol_date":"2017-04-13","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >/= 12 TO < 18 YEARS OF AGE, WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45411,"protocol_no":"NN7415-4310 (EXPLORER 4)","submission_no":"204018","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-02","protocol_title":"A MULTI-CENTRE, RANDOMISED, OPEN-LABEL, CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF PROPHYLACTIC ADMINISTRATION OF CONCIZUMAB IN HAEMOPHILIA A AND B PATIENTS WITH INHIBITORS","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"},{"med_condition_id":100,"med_condition":"HEMOPHILIA B"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39673,"protocol_no":"17530","submission_no":"186019","status_id":1,"start_date":"2015-09-28","end_date":null,"nol_date":"2015-07-31","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EVENT-DRIVEN PHASE III STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FINERENONE ON THE REDUCTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND THE CLINICAL DIAGNOSIS OF DIABETIC KIDNEY DISEASE IN ADDITION TO STANDARD OF CARE","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42155,"protocol_no":"252","submission_no":"194085","status_id":1,"start_date":"2017-02-02","end_date":null,"nol_date":"2016-05-03","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH EPACADOSTAT OR PLACEBO IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA (KEYNOTE-252 / ECHO-301","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41602,"protocol_no":"CPI-444-001","submission_no":"192010","status_id":1,"start_date":"2017-01-31","end_date":null,"nol_date":"2016-03-09","protocol_title":"A PHASE 1/1B, OPEN-LABEL, MULTICENTER, REPEAT-DOSE, DOSE-SELECTION STUDY OF CPI-444 AS SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH SELECTED INCURABLE CANCERS","medConditionList":[{"med_condition_id":51,"med_condition":"COLORECTAL CARCINOMA"},{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"},{"med_condition_id":95,"med_condition":"HEAD AND NECK CANCER"},{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"},{"med_condition_id":154,"med_condition":"MELANOMA"},{"med_condition_id":627,"med_condition":"BREAST CANCER METASTATIC TRIPLE NEGATIVE"},{"med_condition_id":662,"med_condition":"ARTICULAR CARTILAGE INJURY"},{"med_condition_id":625,"med_condition":"BLADDER CANCER"},{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47934,"protocol_no":"DCC-2618-03-001","submission_no":"212506","status_id":1,"start_date":"2018-03-05","end_date":null,"nol_date":"2018-02-07","protocol_title":"A PHASE 3, INTERVENTIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES","medConditionList":[{"med_condition_id":86,"med_condition":"GASTROINTESTINAL STROMAL TUMOR (GIST)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48780,"protocol_no":"SYM022-01","submission_no":"214977","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-05-04","protocol_title":"\"A PHASE 1, OPEN-LABEL, MULTICENTER TRIAL INVESTIGATING THE SAFETY, TOLERABILITY, AND PRELIMINARY ANTINEOPLASTIC ACTIVITY OF SYM022 (ANTI-LAG-3) IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES OR LYMPHOMAS\".","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46493,"protocol_no":"AG120-C-009","submission_no":"207749","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-09","protocol_title":"A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF AG-120 IN COMBINATION WITH AZACITIDINE IN SUBJECTS ¬ø18 YEARS OF AGE WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA WITH AN IDH1 MUTATION.","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45537,"protocol_no":"M15-572","submission_no":"204728","status_id":1,"start_date":"2017-10-06","end_date":null,"nol_date":"2017-05-24","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING ABT-494 TO PLACEBO AND TO ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE A HISTORY OF INADEQUATE RESPONSE TO AT LEAST ONE NON-BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUG (DMARD) ¬ø SELECT ¬ø PSA 1","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44511,"protocol_no":"GBT440-031","submission_no":"201595","status_id":1,"start_date":"2018-02-12","end_date":null,"nol_date":"2017-01-20","protocol_title":"A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY OF GBT440 ADMINISTERED ORALLY TO PATIENTS WITH SICKLE CELL DISEASE","medConditionList":[{"med_condition_id":232,"med_condition":"SICKLE CELL DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41063,"protocol_no":"D6010C00005","submission_no":"190120","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-01-06","protocol_title":"A PHASE IB STUDY OF AZD1775 AND OLAPARIB IN PATIENTS WITH REFRACTORY SOLID TUMOURS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39805,"protocol_no":"EFC13691","submission_no":"186318","status_id":1,"start_date":"2016-01-16","end_date":null,"nol_date":"2015-08-19","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PATIENTS WITH SEVERE STEROID DEPENDENT ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36132,"protocol_no":"GA29103","submission_no":"174573","status_id":1,"start_date":"2014-11-20","end_date":null,"nol_date":"2014-05-29","protocol_title":"PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36420,"protocol_no":"CLCI699C2301","submission_no":"175362","status_id":1,"start_date":"2017-10-19","end_date":null,"nol_date":"2014-07-03","protocol_title":"A PHASE III, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL STUDY OF LCI699 FOLLOWING A 24 WEEK, SINGLE-ARM, OPEN-LABEL DOSE TITRATION AND TREATMENT PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF LCI699 FOR THE TREATMENT OF PATIENTS WITH CUSHING'S DISEASE","medConditionList":[{"med_condition_id":58,"med_condition":"CUSHING'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27745,"protocol_no":"1000","submission_no":"166596","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-08-16","protocol_title":"VITAMIN D AS A REMISSION AGENT IN CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47873,"protocol_no":"BCX7353-302","submission_no":"212226","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-16","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE LEVELS OF BCX7353 AS AN ORAL TREATMENT FOR THE PREVENTION OF ATTACKS IN SUBJECTS WITH HEREDITARY ANGIOEDEMA","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36349,"protocol_no":"ERC-250","submission_no":"175128","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-06-27","protocol_title":"DHEA + LOW DOSE ACOLBIFENE AGAINST VASOMOTOR SYMPTOMS (HOT FLUSHES) AND FOR OSTEOPOROSIS PREVENTION IN POSTMENOPAUSAL WOMEN (PLACEBO CONTROLLED, DOUBLE BLIND AND RANDOMIZED PHASE III STUDY TO EVALUATE THE EFFECTS OF 12-WEEK TREATMENT WITH DHEA (PRASTERONE) + LOW DOSE ACOLBIFENE ON VASOMOTOR SYMPTOMS (HOT FLUSHES) AND 52 WEEK TREATMENT FOR OSTEOPOROSIS PREVENTION IN POSTMENOPAUSAL WOMEN)","medConditionList":[{"med_condition_id":203,"med_condition":"POSTMENOPAUSAL"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29040,"protocol_no":"1000040306","submission_no":"170658","status_id":2,"start_date":"2015-03-03","end_date":"2016-01-05","nol_date":"2014-01-09","protocol_title":"OLANZAPINE FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN CHILDREN: A MULTICENTRE FEASIBILITY STUDY","medConditionList":[{"med_condition_id":302,"med_condition":"NAUSEA AND VOMITING"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37690,"protocol_no":"LUM001-401","submission_no":"179450","status_id":2,"start_date":"2015-04-07","end_date":"2016-02-12","nol_date":"2014-11-28","protocol_title":"A PILOT, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS","medConditionList":[{"med_condition_id":601,"med_condition":"PRIMARY SCLEROSING CHOLANGITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28990,"protocol_no":"AC-055E201","submission_no":"170476","status_id":2,"start_date":"2014-06-18","end_date":"2016-09-28","nol_date":"2013-12-20","protocol_title":"MERIT-1: MACITENTAN IN THE TREATMENT OF INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP, 24-WEEK STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF MACITENTAN IN SUBJECTS WITH INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION.","medConditionList":[{"med_condition_id":326,"med_condition":"CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46940,"protocol_no":"B7661001","submission_no":"209250","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-11","protocol_title":"A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647020 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43560,"protocol_no":"D3250C00031","submission_no":"198455","status_id":1,"start_date":"2016-10-27","end_date":null,"nol_date":"2016-10-19","protocol_title":"A MULTICENTER, OPEN-LABEL, FUNCTIONALITY, RELIABILITY AND PERFORMANCE STUDY OF A SINGLE-USE AUTO-INJECTOR WITH HOME-ADMINISTERED SUBCUTANEOUS BENRALIZUMAB IN ADULT PATIENTS WITH SEVERE ASTHMA (GRECO)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37787,"protocol_no":"CI1204","submission_no":"179726","status_id":1,"start_date":"2017-01-24","end_date":null,"nol_date":"2015-01-14","protocol_title":"A RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE SAFETY AND REACTOGENICITY OF DPX-RSV(A), A RESPIRATORY SYNCYTIAL VIRUS VACCINE, CONTAINING OF RESPIRATORY SYNCYTIAL VIRUS (RSV)(A) SHE ANTIGEN AND A NOVEL ADJUVANT DEPOVAXTM, IN HEALTH ADULTS","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42082,"protocol_no":"AMAG-FER-IDA-304","submission_no":"193849","status_id":2,"start_date":"2016-07-04","end_date":"2017-01-09","nol_date":"2016-04-29","protocol_title":"A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, SAFETY STUDY OF FERUMOXYTOL COMPARED TO FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA (IDA)","medConditionList":[{"med_condition_id":329,"med_condition":"ANEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26514,"protocol_no":"ACT12688","submission_no":"162984","status_id":3,"start_date":"2013-10-01","end_date":null,"nol_date":"2013-04-04","protocol_title":"\"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF SAR 339658 IN PATIENTS WITH ACTIVE MODERATE TO SEVERE ULCERATIVE COLITIS (UC).\"","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45632,"protocol_no":"IVA_01_337_HNAS_16_002","submission_no":"204982","status_id":1,"start_date":"2017-08-08","end_date":null,"nol_date":"2017-05-18","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGE, PROOF-OF-CONCEPT, 24-WEEK TREATMENT STUDY OF IVA337 IN ADULT SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)","medConditionList":[{"med_condition_id":734,"med_condition":"NONALCOHOLIC STEATOHEPATITIS (NASH)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36964,"protocol_no":"CNTO1959PSO3002","submission_no":"177102","status_id":1,"start_date":"2015-08-21","end_date":null,"nol_date":"2014-09-10","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GUSELKUMAB FOR THE TREATMENT OF SUBJECTS WITH MODERATE TO SEVERE PLAQUE-TYPE PSORIASIS WITH RANDOMIZED WITHDRAWAL AND RETREATMENT","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"},{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39983,"protocol_no":"265-109","submission_no":"186776","status_id":1,"start_date":"2017-04-25","end_date":null,"nol_date":"2015-09-02","protocol_title":"PHASE 2, PARALLEL-ARM STUDY OF MGCD265 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH ACTIVATING GENETIC ALTERATIONS IN MESENCHYMAL-EPITHELIAL TRANSITION FACTOR","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45447,"protocol_no":"BO39633","submission_no":"204439","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-25","protocol_title":"AN OPEN-LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMAN-LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40197,"protocol_no":"164","submission_no":"187350","status_id":1,"start_date":"2017-05-01","end_date":null,"nol_date":"2015-09-30","protocol_title":"A PHASE II STUDY OF PEMBROLIZUMAB (MK-3475) AS MONOTHERAPY IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC (STAGE IV) MISMATCHED REPAIR DEFICIENT OR MICROSATELLITE INSTABILITY-HIGH COLORECTAL CARCINOMA (KEYNOTE-164)","medConditionList":[{"med_condition_id":51,"med_condition":"COLORECTAL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43394,"protocol_no":"CA209-647","submission_no":"197976","status_id":1,"start_date":"2017-05-31","end_date":null,"nol_date":"2016-09-26","protocol_title":"A PHASE 2, OPEN-LABEL, SINGLE-ARM, TWO-COHORT STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA (PTL)","medConditionList":[{"med_condition_id":757,"med_condition":"CENTRAL NERVOUS SYSTEM LYMPHOMA"},{"med_condition_id":756,"med_condition":"TESTICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28485,"protocol_no":"A3921214","submission_no":"168724","status_id":2,"start_date":"2013-12-03","end_date":"2015-07-15","nol_date":"2013-11-05","protocol_title":"A PHASE 2A, MULTI-SITE, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP STUDY OF THE PILOT EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF  2%  TOFACITINIB OINTMENT IN SUBJECTS WITH MILD TO MODERATE ATOPIC DERMATITIS.","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27244,"protocol_no":"20090176","submission_no":"165211","status_id":1,"start_date":"2013-07-17","end_date":null,"nol_date":"2013-06-26","protocol_title":"AN OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO ASSESS THE PREFERENCE FOR AUTOINJECTOR A VERSUS AUTOINJECTOR B IN RHEUMATOID ARTHRITIS AND PLAQUE PSORIASIS SUBJECTS TREATED WITH ETANERCEPT","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45173,"protocol_no":"GS-US-367-4181","submission_no":"203557","status_id":1,"start_date":"2017-06-26","end_date":null,"nol_date":"2017-03-29","protocol_title":"AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR FIXED-DOSE COMBINATION FOR 12 WEEKS IN SUBJECTS WHO PARTICIPATED IN A PRIOR GILEAD-SPONSORED HCV TREATMENT STUDY","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40572,"protocol_no":"CA209-436","submission_no":"188515","status_id":1,"start_date":"2016-12-08","end_date":null,"nol_date":"2015-11-13","protocol_title":"A PHASE I/II STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF NIVOLUMAB IN COMBINATION WITH BRENTUXIMAB VEDOTIN IN SUBJECTS WITH RELAPSED REFRACTORY NON HODGKIN LYMPHOMAS WITH CD30 EXPRESSION CHECKMATE 436: CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41950,"protocol_no":"SBP-9200-HBV-201","submission_no":"193377","status_id":1,"start_date":"2016-06-29","end_date":null,"nol_date":"2016-04-07","protocol_title":"A PHASE 2, OPEN-LABEL, RANDOMIZED, TWO PART, MULTIPLE DOSE STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ANTIVIRAL EFFICACY OF SB 9200 IN SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS","medConditionList":[{"med_condition_id":103,"med_condition":"HEPATITIS B VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43234,"protocol_no":"GB39242","submission_no":"197547","status_id":1,"start_date":"2016-11-10","end_date":null,"nol_date":"2016-09-09","protocol_title":"A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40207,"protocol_no":"CC-10004-PPSO-001","submission_no":"187367","status_id":1,"start_date":"2016-07-20","end_date":null,"nol_date":"2015-09-23","protocol_title":"A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF APREMILAST (CC-10004) IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45776,"protocol_no":"SPX-101-CF-201","submission_no":"205468","status_id":1,"start_date":"2018-01-09","end_date":null,"nol_date":"2017-06-02","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SPX-101 INHALATION SOLUTION IN SUBJECTS WITH CYSTIC FIBROSIS (HOPE-1 STUDY: HYDRATION FOR OPTIMAL PULMONARY EFFECTIVENESS)","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44428,"protocol_no":"SMRI-WCH-2016","submission_no":"201262","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-01-13","protocol_title":"A RANDOMIZED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION IN A POPULATION WITH BIPOLAR DISORDER","medConditionList":[{"med_condition_id":501,"med_condition":"BIPOLAR DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36203,"protocol_no":"ME.11, 18081","submission_no":"174791","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-02","protocol_title":"ADJUVANT PEGYLATED-INTERFERON-ALPHA2B (SYLATRONTM) FOR TWO YEARS VS OBSERVATION IN PATIENTS WITH AN ULCERATED PRIMARY CUTANEOUS MELANOMA T (2-4)BN0M0: A RANDOMIZED PHASE III TRIAL OF THE EORTC MELANOMA GROUP","medConditionList":[{"med_condition_id":59,"med_condition":"CUTANEOUS MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42363,"protocol_no":"RVT-101-3002","submission_no":"194709","status_id":1,"start_date":"2015-11-08","end_date":null,"nol_date":"2016-05-25","protocol_title":"A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND TOLERABILITY OF RVT-101 IN SUBJECTS WITH ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28580,"protocol_no":"INCB 47986-103","submission_no":"169037","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-11-18","protocol_title":"A PHASE 1 OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF INCB047986 IN SUBJECTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":474,"med_condition":"MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41990,"protocol_no":"PRO00060638","submission_no":"193530","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-04-20","protocol_title":"AN HISTORICALLY CONTROLLED STUDY OF A NEW PROTOCOL FOR PERI-OPERATIVE ANALGESIA IN THE HIGHLY OPIOID TOLERANT PATIENT","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26755,"protocol_no":"11F-MC-RHAO","submission_no":"163730","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-05-03","protocol_title":"\"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG-TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB (LY2349821) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS.\"","medConditionList":[{"med_condition_id":3,"med_condition":"ACTIVE ANKYLOSING SPONDYLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43054,"protocol_no":"20150292","submission_no":"196998","status_id":1,"start_date":"2017-08-31","end_date":null,"nol_date":"2016-08-19","protocol_title":"A PHASE 2/3 MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLINATUMOMAB IN SUBJECTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA","medConditionList":[{"med_condition_id":723,"med_condition":"B-CELL NON-HODGKIN'S LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44084,"protocol_no":"NN9535-4270 / SUSTAIN 8","submission_no":"199335","status_id":1,"start_date":"2017-03-15","end_date":null,"nol_date":"2016-12-16","protocol_title":"EFFICACY AND SAFETY OF SEMAGLUTIDE VERSUS CANAGLIFLOZIN AS ADD-ON TO METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40090,"protocol_no":"WO29806","submission_no":"187066","status_id":2,"start_date":"2016-09-09","end_date":"2018-04-11","nol_date":"2015-09-16","protocol_title":"A PHASE IB/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VISMODEGIB IN COMBINATION WITH RUXOLITINIB VERSUS PLACEBO AND RUXOLITINIB IN PATIENTS WITH INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS","medConditionList":[{"med_condition_id":353,"med_condition":"MYELOFIBROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26706,"protocol_no":"CCI-PATEL-01","submission_no":"163543","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-04-17","protocol_title":"A RANDOMIZED PHASE III STUDY OF RE-IRRADIATION IN RECURRENT GLIOBLASTOMA","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36395,"protocol_no":"1311.6","submission_no":"175280","status_id":3,"start_date":"2014-05-28","end_date":null,"nol_date":"2014-07-03","protocol_title":"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF BI 655066, AN IL-23 P19 ANTAGONIST MONOCLONAL ANTIBODY, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE, WHO ARE NAIVE TO, OR WERE PREVIOUSLY TREATED WITH ANTI-TNF THERAPY","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40246,"protocol_no":"C0168IBD4020","submission_no":"187487","status_id":1,"start_date":"2016-03-10","end_date":null,"nol_date":"2015-10-01","protocol_title":"A PHASE 4, MULTICENTER, OPEN-LABEL STUDY OF SERUM INFLIXIMAB CONCENTRATIONS AND EFFICACY AND SAFETY OF DOSE ESCALATION IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE","medConditionList":[{"med_condition_id":646,"med_condition":"INFLAMMATORY BOWEL DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37407,"protocol_no":"20110186","submission_no":"178535","status_id":1,"start_date":"2015-09-28","end_date":null,"nol_date":"2014-10-29","protocol_title":"A RANDOMIZED WITHDRAWAL DOUBLE-BLIND STUDY OF ETANERCEPT MONOTHERAPY COMPARED TO METHOTREXATE MONOTHERAPY FOR MAINTENANCE OF REMISSION IN SUBJECTS WITH RHEUMATOID ARTHRITIS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37587,"protocol_no":"DMD115501","submission_no":"179075","status_id":1,"start_date":"2014-12-17","end_date":null,"nol_date":"2014-11-28","protocol_title":"AN OPEN-LABEL EXTENSION STUDY OF THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF DRISAPERSEN IN US AND CANADIAN SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY.","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47185,"protocol_no":"CF101-301RA","submission_no":"210088","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-17","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE- AND PLACEBO CONTROLLED, PARALLEL-GROUP TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CF101 COMPARED TO METHOTREXATE IN THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38480,"protocol_no":"1200.120","submission_no":"182170","status_id":1,"start_date":"2017-11-10","end_date":null,"nol_date":"2015-03-19","protocol_title":"PHASE I OPEN LABEL, DOSE ESCALATION TRIAL TO DETERMINE THE MTD, SAFETY, PK AND EFFICACY OF AFATINIB MONOTHERAPY IN CHILDREN AGED 2 YEARS TO <18 YEARS WITH RECURRENT/REFRACTORY NEUROECTODERMAL TUMOURS, RHABDOMYOSARCOMA AND/OR OTHER SOLID TUMOURS WITH KNOWN ERBB PATHWAY DEREGULATION REGARDLESS OF TUMOUR HISTOLOGY","medConditionList":[{"med_condition_id":293,"med_condition":"MALIGNANT SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47070,"protocol_no":"LOXO-TRK-15003","submission_no":"209622","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-26","protocol_title":"A PHASE 1/2 STUDY OF THE ORAL TRK INHIBITOR LOXO-101 IN PEDIATRIC PATIENTS WITH ADVANCED","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39756,"protocol_no":"CAIN457F2342","submission_no":"186221","status_id":1,"start_date":"2016-09-02","end_date":null,"nol_date":"2015-08-18","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED MULTI-CENTER STUDY OF SUBCUTANEOUS SECUKINUMAB (150 MG AND 300 MG) IN PREFILLED SYRINGE TO DEMONSTRATE EFFICACY (INCLUDING INHIBITION OF STRUCTURAL DAMAGE), SAFETY, AND TOLERABILITY UP TO 2 YEARS IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS (FUTURE 5)","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37546,"protocol_no":"GLP111892","submission_no":"178966","status_id":1,"start_date":"2015-09-11","end_date":null,"nol_date":"2014-11-07","protocol_title":"ALBIGLUTIDE VERSUS PLACEBO AS ADD-ON TO INTENSIFIED BASAL-BOLUS INSULIN THERAPY IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46386,"protocol_no":"64179375THR2001","submission_no":"207357","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-08","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, ADAPTIVE DESIGN, DOSE-ESCALATION (PART 1) AND DOSE-RESPONSE (PART 2) STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS JNJ-64179375 VERSUS ORAL APIXABAN IN SUBJECTS UNDERGOING ELECTIVE TOTAL KNEE REPLACEMENT SURGERY","medConditionList":[{"med_condition_id":466,"med_condition":"KNEE ARTHROPLASTY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43015,"protocol_no":"SGI-110-07","submission_no":"196889","status_id":1,"start_date":"2017-01-26","end_date":null,"nol_date":"2016-08-18","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF GUADECITABINE (SGI-110) VERSUS TREATMENT CHOICE IN ADULTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PREVIOUSLY TREATED WITH HYPOMETHYLATING AGENTS.","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"},{"med_condition_id":747,"med_condition":"CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29120,"protocol_no":"E5501-G000-310","submission_no":"170972","status_id":2,"start_date":"2015-10-07","end_date":"2016-03-07","nol_date":"2014-01-16","protocol_title":"A RANDOMIZED, GLOBAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORAL AVATROMBOPAG FOR THE TREATMENT OF ADULTS WITH THROMBOCYTOPENIA ASSOCIATED WITH LIVER DISEASE PRIOR TO AN ELECTIVE PROCEDURE","medConditionList":[{"med_condition_id":142,"med_condition":"LIVER DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38864,"protocol_no":"BAY 59-7939/16573","submission_no":"183447","status_id":2,"start_date":"2016-01-21","end_date":"2018-01-25","nol_date":"2015-04-28","protocol_title":"MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-COMPARATOR, EVENT-DRIVEN, SUPERIORITY PHASE III STUDY OF SECONDARY PREVENTION OF STROKE AND PREVENTION OF SYSTEMIC EMBOLISM IN PATIENTS WITH A RECENT EMBOLIC STROKE OF UNDETERMINED SOURCE (ESUS), COMPARING RIVAROXABAN 15 MG ONCE DAILY WITH ASPIRIN 100 MG (NAVIGATE ESUS)","medConditionList":[{"med_condition_id":661,"med_condition":"SYSTEMIC EMBOLISM"},{"med_condition_id":660,"med_condition":"EMBOLIC STROKE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43773,"protocol_no":"PS0011","submission_no":"199115","status_id":1,"start_date":"2017-01-12","end_date":null,"nol_date":"2016-11-08","protocol_title":"A MULTICENTER, 48-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: PHASE 2B","medConditionList":[{"med_condition_id":689,"med_condition":"CHRONIC PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45018,"protocol_no":"VEDOLIZUMAB-4014","submission_no":"203077","status_id":1,"start_date":"2017-09-28","end_date":null,"nol_date":"2017-03-13","protocol_title":"A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET)","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47993,"protocol_no":"PPP001-PH3-01","submission_no":"212649","status_id":1,"start_date":"2018-03-29","end_date":null,"nol_date":"2018-02-01","protocol_title":"SAFETY AND EFFICACY OF PPP001-KIT FOR IMPROVING HEALTH RELATED QUALITY OF LIFE IN ADVANCED CANCER PATIENTS WITH UNCONTROLLED PAIN:  A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY.","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"},{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43679,"protocol_no":"FORMA-06","submission_no":"198881","status_id":1,"start_date":"2017-01-30","end_date":null,"nol_date":"2016-11-03","protocol_title":"PROSPECTIVE, MULTI-CENTER, RANDOMIZED, ACTIVE-CONTROL, NON-INFERIORITY STUDY COMPARING FIBRINOGEN CONCENTRATE WITH CRYOPRECIPITATE FOR THE TREATMENT OF ACQUIRED HYPOFIBRINOGENEMIA IN BLEEDING ADULT CARDIAC SURGICAL PATIENTS","medConditionList":[{"med_condition_id":761,"med_condition":"HYPOFIBRINOGENEMIA"},{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42084,"protocol_no":"12710A","submission_no":"193848","status_id":1,"start_date":"2016-10-25","end_date":null,"nol_date":"2016-05-05","protocol_title":"INTERVENTIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (FLUOXETINE), FIXED-DOSE STUDY OF VORTIOXETINE IN PAEDIATRIC PATIENTS AGED 12 TO 17 YEARS, WITH MAJOR DEPRESSIVE DISORDER (MDD)","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42873,"protocol_no":"REG-UQ-GLYB-001","submission_no":"196483","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-08-09","protocol_title":"LPLD REGISTRY, OBSERVATIONAL LONGITUDINAL PHARMACO-EPIDEMIOLOGIC STUDY IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) PATIENTS, EITHER TREATED OR NOT TREATED WITH ALIPOGENE TIPARVOVEC (GLYBERA)","medConditionList":[{"med_condition_id":687,"med_condition":"LIPOPROTEIN LIPASE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37336,"protocol_no":"OZM-054","submission_no":"178320","status_id":1,"start_date":"2016-05-31","end_date":null,"nol_date":"2014-10-23","protocol_title":"A PHASE II, RANDOMIZED, MULTI-CENTER STUDY OF CABAZITAXEL VERSUS ABIRATERONE OR ENZALUTAMIDE IN POOR PROGNOSIS-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28162,"protocol_no":"CAIN457F2302E1","submission_no":"167840","status_id":1,"start_date":"2014-08-25","end_date":null,"nol_date":"2013-09-26","protocol_title":"A THREE YEAR EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY, SAFETY AND TOLERABILITY OF SECUKINUMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46947,"protocol_no":"64041575RSV2004","submission_no":"209267","status_id":1,"start_date":"2018-01-19","end_date":null,"nol_date":"2017-10-05","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE ANTIVIRAL ACTIVITY, CLINICAL OUTCOMES, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORALLY ADMINISTERED LUMICITABINE (JNJ-64041575) REGIMENS IN HOSPITALIZED INFANTS AND CHILDREN AGED 28 DAYS TO 36 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS.","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46853,"protocol_no":"160517448","submission_no":"208892","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-26","protocol_title":"DOXYCYCLINE CROSSOVER TRIAL FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)","medConditionList":[{"med_condition_id":572,"med_condition":"HEREDITARY HAEMORRHAGIC TELANGIECTASIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37996,"protocol_no":"D5160C00009","submission_no":"180453","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-01-08","protocol_title":"AN OPEN-LABEL, RANDOMISED, PHASE I STUDY TO DETERMINE THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF AZD9291 IN PATIENTS WITH EGFRM POSITIVE NSCLC WHOSE DISEASE HAS PROGRESSED ON AN EGFR TKI","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29308,"protocol_no":"CNTO148UCO2001","submission_no":"171428","status_id":2,"start_date":"2014-05-01","end_date":"2016-01-19","nol_date":"2014-02-07","protocol_title":"A PHASE 2A OPEN-LABEL STUDY TO EVALUATE PREDICTION OF RESPONSE TO GOLIMUMAB USING A TRANSCRIPTOMIC PROFILE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46643,"protocol_no":"A3921165","submission_no":"208217","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-30","protocol_title":"EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACRIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39648,"protocol_no":"VX15-809-110","submission_no":"185966","status_id":1,"start_date":"2016-01-06","end_date":null,"nol_date":"2015-07-14","protocol_title":"A PHASE 3, ROLLOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LONG TERM TREATMENT WITH LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 6 YEARS AND OLDER WITH CYSTIC FIBROSIS, HOMOZYGOUS FOR THE F508DEL CFTR MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39498,"protocol_no":"PDMDC 012014","submission_no":"185545","status_id":1,"start_date":"2016-07-18","end_date":null,"nol_date":"2015-07-07","protocol_title":"A RANDOMIZED, PLACEBO-CONTROLLED, 2-ARM PARALLEL-GROUP SUPERIORITY PHASE II STUDY OF GLYCOPYRROLATE FOR MODERATE-TO-SEVERE SIALORRHEA IN PARKINSON¬øS DISEASE","medConditionList":[{"med_condition_id":762,"med_condition":"SIALORRHEA"},{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40142,"protocol_no":"CINC280A2201","submission_no":"187204","status_id":1,"start_date":"2017-04-20","end_date":null,"nol_date":"2015-09-25","protocol_title":"A PHASE II, MULTICENTER, THREE-COHORT STUDY OF ORAL CMET INHIBITOR INC280 IN ADULT PATIENTS WITH EGFR WILD-TYPE (WT), ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE RECEIVED ONE OR TWO PRIOR LINES OF SYSTEMIC THERAPY FOR ADVANCED/METASTATIC DISEASE","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45491,"protocol_no":"17-5295","submission_no":"204572","status_id":1,"start_date":"2017-06-08","end_date":null,"nol_date":"2017-05-05","protocol_title":"DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER WITH 18F-DCFPYL PET/MR","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37625,"protocol_no":"MM-302-02-02-03","submission_no":"179192","status_id":1,"start_date":"2015-03-27","end_date":null,"nol_date":"2014-12-10","protocol_title":"A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY OF MM-302 PLUS TRASTUZUMAB VS. CHEMOTHERAPY OF PHYSICIAN'S CHOICE PLUS TRASTUZUMAB IN ANTHRACYCLINE NAIVE PATIENTS WITH LOCALLY ADVANCED/METASTATIC HER2-POSITIVE BREAST CANCER","medConditionList":[{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"},{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41153,"protocol_no":"DAR-INT-14-01","submission_no":"190470","status_id":1,"start_date":"2016-05-04","end_date":null,"nol_date":"2016-01-11","protocol_title":"AN INTERNATIONAL, MULTICENTRE, DOUBLE-BLIND, RANDOMISED STUDY OF THE EFFECT OF DIACEREIN VS. CELECOXIB ON SYMPTOMS AND STRUCTURAL CHANGES IN SYMPTOMATIC KNEE OSTEOARTHRITIS AS ASSESSED BY MAGNETIC RESONANCE IMAGING.","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36038,"protocol_no":"105056","submission_no":"174245","status_id":1,"start_date":"2015-04-30","end_date":null,"nol_date":"2014-05-23","protocol_title":"URODYNAMIC AND CLINICAL EFFICACY OF MIRABEGRON AMONG NEUROGENIC BLADDER PATIENTS","medConditionList":[{"med_condition_id":524,"med_condition":"NEUROGENIC BLADDER DYSFUNCTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37408,"protocol_no":"ARRAY-520-311","submission_no":"178523","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-28","protocol_title":"A MULTICENTER PHASE 2 STUDY OF SINGLE-AGENT FILANESIB (ARRY-520) IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42570,"protocol_no":"16-5475","submission_no":"195410","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-21","protocol_title":"FECAL MICROBIOTA TRANSPLANT FROM HEALTHY LEAN DONORS TO MORBIDLY OBESE INDIVIDUALS: EFFECTS ON INSULIN RESISTANCE AND OTHER OBESITY-RELATED PARAMETERS. A RANDOMIZED CONTROLLED TRIAL.","medConditionList":[{"med_condition_id":415,"med_condition":"OVERWEIGHT/OBESITY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44944,"protocol_no":"GS-US-384-1944","submission_no":"202917","status_id":1,"start_date":"2017-04-28","end_date":null,"nol_date":"2017-03-09","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF SELONSERTIB IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)","medConditionList":[{"med_condition_id":734,"med_condition":"NONALCOHOLIC STEATOHEPATITIS (NASH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44932,"protocol_no":"GS-US-384-1943","submission_no":"202881","status_id":1,"start_date":"2017-04-28","end_date":null,"nol_date":"2017-03-09","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF SELONSERTIB IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND BRIDGING (F3) FIBROSIS.","medConditionList":[{"med_condition_id":734,"med_condition":"NONALCOHOLIC STEATOHEPATITIS (NASH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41341,"protocol_no":"I7O-MC-JOBA(A)","submission_no":"191230","status_id":1,"start_date":"2017-10-04","end_date":null,"nol_date":"2016-02-11","protocol_title":"A PHASE I STUDY OF LY3076226, A FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH ADVANCED OR METASTATIC CANCER","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29159,"protocol_no":"LUM001-303","submission_no":"171047","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-06","protocol_title":"A MULTICENTRE EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH ALAGILLE SYNDROME","medConditionList":[{"med_condition_id":452,"med_condition":"CHOLESTATIC LIVER DISEASE"},{"med_condition_id":453,"med_condition":"ALAGILLE SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41999,"protocol_no":"DECOL.FMT","submission_no":"193621","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-05-26","protocol_title":"A PROSPECTIVE, CASE-SERIES STUDY OF FECAL MICROBIOTA TRANSPLANTATION FOR THE SELECTIVE INTESTINAL DECOLONIZATION OF MULTIDRUG-RESISTANT, PATHOGENIC ENTEROBACTERIACEAE","medConditionList":[{"med_condition_id":688,"med_condition":"ENTEROBACTERIACEAE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26536,"protocol_no":"PUMA-NER-1301","submission_no":"163051","status_id":1,"start_date":"2016-05-05","end_date":null,"nol_date":"2013-04-04","protocol_title":"A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2 DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26851,"protocol_no":"TAFF","submission_no":"164050","status_id":1,"start_date":"2013-09-23","end_date":null,"nol_date":"2013-05-16","protocol_title":"\"EFFECT OF TERIPARATIDE ON FRACTURE HEALING IN PATIENTS WITH INCOMPLETE ATYPICAL FEMUR FRACTURES: A RANDOMIZED CONTROLLED TRIAL.\"","medConditionList":[{"med_condition_id":298,"med_condition":"INCOMPLETE ATYPICAL FEMUR FRACTURES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37565,"protocol_no":"ABI-007-PANC-007","submission_no":"179013","status_id":1,"start_date":"2015-05-11","end_date":null,"nol_date":"2014-11-25","protocol_title":"NAB¬Æ-PACLITAXEL (ABRAXANE¬Æ) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE 2 STUDY (LAPACT).","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36833,"protocol_no":"AN008T","submission_no":"176692","status_id":1,"start_date":"2014-09-19","end_date":null,"nol_date":"2014-08-21","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO COMPARE THE EFFICACY AND TOLERABILITY OF THREE DOSE REGIMENS OF ALLERT, A COMBINATION OF CONTIGUOUS OVERLAPPING PEPTIDES DERIVED FROM BET V 1, IN ADULT SUBJECTS WITH ALLERGIC RHINO-CONJUNCTIVITIS TO BIRCH POLLEN STUDIED IN AN ENVIRONMENTAL EXPOSURE CHAMBER","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37509,"protocol_no":"192024-092","submission_no":"178833","status_id":1,"start_date":"2014-12-01","end_date":null,"nol_date":"2014-11-13","protocol_title":"THE EFFICACY AND SAFETY OF BIMATOPROST SR IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION","medConditionList":[{"med_condition_id":89,"med_condition":"GLAUCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40581,"protocol_no":"M14-172","submission_no":"188530","status_id":2,"start_date":"2015-11-30","end_date":"2017-01-25","nol_date":"2015-11-12","protocol_title":"A SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABT 493/ABT 530 IN ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 4, 5 OR 6 INFECTION AND COMPENSATED CIRRHOSIS (EXPEDITION-1)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39814,"protocol_no":"ISIS 416858-CS4","submission_no":"186334","status_id":2,"start_date":"2015-10-16","end_date":"2016-11-15","nol_date":"2015-08-11","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE DOSES OF ISIS 416858 (ISIS-FXIRX AN ANTISENSE INHIBITOR OF FACTOR XI), ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS","medConditionList":[{"med_condition_id":457,"med_condition":"END STAGE RENAL DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37997,"protocol_no":"D5160C00014","submission_no":"180456","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-01-08","protocol_title":"A PHASE I, OPEN-LABEL, NON-RANDOMISED, MULTICENTRE STUDY TO ASSESS THE EFFECT OF AZD9291 ON THE PHARMACOKINETICS OF SIMVASTATIN (A SENSITIVE CYP3A4 SUBSTRATE) IN PATIENTS WITH EGFRM POSITIVE NSCLC WHOSE DISEASE HAS PROGRESSED ON AN EGFR TKI","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38171,"protocol_no":"1000046583","submission_no":"181181","status_id":1,"start_date":"2015-06-10","end_date":null,"nol_date":"2015-02-05","protocol_title":"MANIPULATING THE MICROBIOME IN INFLAMMATORY BOWEL DISEASE (IBD) BY ANTIBIOTICS: A MULTICENTRE RANDOMIZED CONTROLLED TRIAL.","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"},{"med_condition_id":576,"med_condition":"IRRITABLE BOWEL SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38312,"protocol_no":"NCIC CTG: SRC.7/A091105","submission_no":"181601","status_id":1,"start_date":"2015-10-06","end_date":null,"nol_date":"2015-02-11","protocol_title":"A PHASE III, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF SORAFENIB IN DESMOID TUMORS OR AGGRESSIVE FIBROMATOSIS (DT/DF)","medConditionList":[{"med_condition_id":611,"med_condition":"AGGRESSIVE FIBROMATOSIS"},{"med_condition_id":612,"med_condition":"DESMOID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36346,"protocol_no":"N/A","submission_no":"175123","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-06-27","protocol_title":"A STUDY FOR THE UTILITY OF BOTULINUM TOXIN TYPE A FOR PAIN IN ADVANCED PARKINSON'S DISEASE","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39184,"protocol_no":"EFC13781","submission_no":"184394","status_id":1,"start_date":"2016-03-16","end_date":null,"nol_date":"2015-06-09","protocol_title":"OPEN LABEL INTERVENTIONAL MULTICENTER PHASE 3B STUDY TO EVALUATE SKELETAL RESPONSE TO ELIGLUSTAT IN ADULT PATIENTS WHO SUCCESSFULLY COMPLETED THE PHASE 2 OR PHASE 3 STUDIES.","medConditionList":[{"med_condition_id":87,"med_condition":"GAUCHER DISEASE TYPE 1"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28247,"protocol_no":"NCT01849068","submission_no":"166667","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-02","protocol_title":"EFFECTS OF SELECTIVE INHIBITION OF CHOLESTEROL ABSORPTION WITH EZETIMIBE ON INTESTINAL CHOLESTEROL HOMEOSTASIS IN DYSLIPIDEMIC MEN WITH INSULIN-RESISTANCE - A PILOT STUDY","medConditionList":[{"med_condition_id":388,"med_condition":"DIABETES"},{"med_condition_id":387,"med_condition":"DYSLIPIDEAMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46447,"protocol_no":"V01-123A-301","submission_no":"207580","status_id":1,"start_date":"2017-08-23","end_date":null,"nol_date":"2017-08-16","protocol_title":"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44740,"protocol_no":"CPDR001G2101","submission_no":"202250","status_id":1,"start_date":"2017-08-29","end_date":null,"nol_date":"2017-02-22","protocol_title":"A PHASE IB STUDY OF PDR001 IN COMBINATION WITH SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)","medConditionList":[{"med_condition_id":519,"med_condition":"ADVANCED HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41224,"protocol_no":"8273-CL-0302","submission_no":"190705","status_id":2,"start_date":"2016-03-07","end_date":"2017-09-27","nol_date":"2016-01-11","protocol_title":"AN OPEN-LABEL, RANDOMIZED PHASE 3 EFFICACY STUDY OF ASP8273 VS. ERLOTINIB OR GEFITINIB IN FIRST-LINE TREATMENT OF PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER TUMORS WITH EGFR ACTIVATING MUTATIONS","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43373,"protocol_no":"H16-00554","submission_no":"197922","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-11-10","protocol_title":"PREHOSPITAL ANALGESIA WITH INTRANASAL KETAMINE (PAIN-K).","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46748,"protocol_no":"SPD489-347","submission_no":"208559","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-15","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL-GROUP, PLACEBO-CONTROLLED, FIXED-DOSE SAFETY AND EFFICACY STUDY OF SPD489 COMPARED WITH PLACEBO IN PRESCHOOL CHILDREN AGED 4-5 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER","medConditionList":[{"med_condition_id":9,"med_condition":"ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41167,"protocol_no":"1311.3","submission_no":"190530","status_id":2,"start_date":"2016-07-12","end_date":"2018-01-09","nol_date":"2016-01-14","protocol_title":"BI 655066 VERSUS USTEKINUMAB AND PLACEBO COMPARATORS IN A RANDOMIZED DOUBLE BLIND TRIAL FOR MAINTENANCE USE IN MODERATE TO SEVERE PLAQUE TYPE PSORIASIS (ULTIMMA-1)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37930,"protocol_no":"REB 14-8171-A","submission_no":"180170","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-31","protocol_title":"THE EFFECT OF INTRANASAL GLUCAGON ON HEPATIC GLUCOSE AND TRIGLYCERIDE RICH LIPOPROTEIN PRODUCTION","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37643,"protocol_no":"CC-486-NPC-001","submission_no":"179241","status_id":2,"start_date":"2015-02-27","end_date":"2017-04-20","nol_date":"2014-11-26","protocol_title":"A PHASE 2, MULTICENTER, INTERNATIONAL, SINGLE ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF SINGLE AGENT CC-486 (ORAL AZACITIDINE) IN PREVIOUSLY TREATED SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC NASOPHARYNGEAL CARCINOMA","medConditionList":[{"med_condition_id":521,"med_condition":"NASOPHARYNGEAL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37387,"protocol_no":"SAMI-02-1-01","submission_no":"178469","status_id":2,"start_date":"2014-12-16","end_date":"2015-11-25","nol_date":"2014-10-23","protocol_title":"PHASE IIA, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND, CROSSOVER SINGLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF S-1226 (8%) ADMINISTERED BY NEBULIZATION IN SUBJECTS WITH MILD ATOPIC ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41477,"protocol_no":"I1F-MC-RHBW","submission_no":"191602","status_id":1,"start_date":"2016-11-11","end_date":null,"nol_date":"2016-03-10","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG-TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB (LY2439821) IN TNFI-EXPERIENCED PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS","medConditionList":[{"med_condition_id":673,"med_condition":"AXIAL SPONDYLARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41744,"protocol_no":"M14-467","submission_no":"192523","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-24","protocol_title":"A MULTICENTER, PHASE 1/1B, OPEN-LABEL, DOSE-ESCALATION STUDY OF ABBV-838, AN ANTIBODY DRUG CONJUGATE, IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39063,"protocol_no":"D0816C00009","submission_no":"184015","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-05-22","protocol_title":"A PHASE III, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE STUDY OF OLAPARIB MAINTENANCE MONOTHERAPY IN PATIENTS WITH PLATINUM SENSITIVE RELAPSED OVARIAN CANCER WHO ARE IN COMPLETE OR PARTIAL RESPONSE FOLLOWING PLATINUM BASED CHEMOTHERAPY AND WHOSE TUMOURS CARRY LOSS OF FUNCTION SOMATIC BRCA MUTATION(S) OR LOSS OF FUNCTION MUTATION(S) IN TUMOUR HOMOLOGOUS RECOMBINATION REPAIR -ASSOCIATED GENES","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35957,"protocol_no":"WO29217","submission_no":"174059","status_id":1,"start_date":"2014-11-26","end_date":null,"nol_date":"2014-05-21","protocol_title":"A MULTICENTER, MULTINATIONAL, PHASE II STUDY TO EVALUATE PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND STANDARD NEOADJUVANT ANTHRACYCLINE-BASED CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE. LOCALLY ADVANCED, INFLAMMATORY, OR EARLY-STAGE BREAST CANCER","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45070,"protocol_no":"WP29945","submission_no":"203224","status_id":1,"start_date":"2017-06-21","end_date":null,"nol_date":"2017-03-24","protocol_title":"AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION PHASE 1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF R06958688 IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA-POSITIVE SOLID TUMORS","medConditionList":[{"med_condition_id":780,"med_condition":"METASTATIC CEA-POSITIVE SOLID TUMORS"},{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44310,"protocol_no":"REMIT IGLARLIXI","submission_no":"200733","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-19","protocol_title":"REMISSION EVALUATION OF A METABOLIC INTERVENTION FOR TYPE 2 DIABETES WITH IGLARLIXI (REMIT IGLARLIXI)","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47961,"protocol_no":"PRA2051N","submission_no":"212564","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-02","protocol_title":"OPEN LABEL 8-WEEK STUDY OF PRAZOSIN USE IN ADULTS WITH ANXIETY DISORDERS","medConditionList":[{"med_condition_id":429,"med_condition":"ANXIETY DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43763,"protocol_no":"NN8022-4272","submission_no":"199089","status_id":1,"start_date":"2017-04-10","end_date":null,"nol_date":"2016-11-03","protocol_title":"EFFECT AND SAFETY OF LIRAGLUTIDE 3.0 MG IN SUBJECTS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES MELLITUS TREATED WITH BASAL INSULIN","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":415,"med_condition":"OVERWEIGHT/OBESITY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29421,"protocol_no":"NEC.3","submission_no":"171768","status_id":2,"start_date":"2015-01-23","end_date":"2016-10-07","nol_date":"2014-02-27","protocol_title":"PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB (NSC # 737754, IND 75648) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45518,"protocol_no":"LP0162-1326","submission_no":"204668","status_id":1,"start_date":"2017-09-05","end_date":null,"nol_date":"2017-05-11","protocol_title":"TRALOKINUMAB MONOTHERAPY FOR MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45544,"protocol_no":"RD.03.SPR.113322","submission_no":"204748","status_id":2,"start_date":"2017-06-08","end_date":"2018-01-19","nol_date":"2017-05-03","protocol_title":"EFFICACY COMPARISON OF IVERMECTIN 1% TOPICAL CREAM ASSOCIATED WITH DOXYCYCLINE 40 MG MODIFIED RELEASE (MR) CAPSULES VERSUS IVERMECTIN 1% TOPICAL CREAM ASSOCIATED WITH PLACEBO IN THE TREATMENT OF SEVERE ROSACEA.","medConditionList":[{"med_condition_id":225,"med_condition":"ROSACEA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45621,"protocol_no":"20150308","submission_no":"204952","status_id":1,"start_date":"2017-08-28","end_date":null,"nol_date":"2017-05-24","protocol_title":"A PHASE 2A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMG 301 IN MIGRAINE PREVENTION","medConditionList":[{"med_condition_id":157,"med_condition":"MIGRAINE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40648,"protocol_no":"D5660C00004","submission_no":"188702","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-18","protocol_title":"A PHASE 1B/2, OPEN-LABEL, MULTICENTRE STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF MEDI4736 IN COMBINATION WITH AZD9150 OR AZD5069 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES AND SUBSEQUENTLY COMPARING AZD9150 AND AZD5069 BOTH AS MONOTHERAPY AND IN COMBINATION WITH MEDI4736 AS SECOND LINE TREATMENT IN PATIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"},{"med_condition_id":34,"med_condition":"CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40999,"protocol_no":"CMX001-303","submission_no":"189917","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-17","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF 28 WEEKS OF BRINCIDOFOVIR (BCV) VERSUS VALGANCICLOVIR (VGCV) FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN HIGH-RISK KIDNEY ALLOGRAFT RECIPIENTS","medConditionList":[{"med_condition_id":62,"med_condition":"CYTOMEGALOVIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46868,"protocol_no":"200852","submission_no":"208942","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-28","protocol_title":"A DOUBLE-BLIND SAFETY AND EFFICACY STUDY OF GSK2894512 CREAM VERSUS VEHICLE IN THE TREATMENT OF ADULT PLAQUE PSORIASIS.","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35761,"protocol_no":"LUM001-304","submission_no":"173360","status_id":2,"start_date":"2015-07-28","end_date":"2015-09-01","nol_date":"2014-04-23","protocol_title":"ICONIC STUDY LONG-TERM, OPEN-LABEL STUDY WITH A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED DRUG WITHDRAWAL PERIOD OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN PATIENTS WITH ALAGILLE SYNDROME","medConditionList":[{"med_condition_id":453,"med_condition":"ALAGILLE SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43646,"protocol_no":"EFC14834","submission_no":"198754","status_id":1,"start_date":"2017-01-20","end_date":null,"nol_date":"2016-10-25","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SOTAGLIFLOZIN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL ON METFORMIN","medConditionList":[{"med_condition_id":388,"med_condition":"DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45647,"protocol_no":"VBP15-LTE","submission_no":"205032","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-15","protocol_title":"A 24-MONTH PHASE II OPEN-LABEL, MULTICENTER LONG-TERM EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF VAMOROLONE IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD).","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26839,"protocol_no":"DMHUI-100","submission_no":"164002","status_id":2,"start_date":"2013-09-01","end_date":"2016-06-09","nol_date":"2013-05-17","protocol_title":"PILOT DOSE-FINDING TRIAL TO EVALUATE FEASIBILITY OF SUBSEQUENT RANDOMIZED CLINICAL TRIAL OF ECOPIPAM FOR THE TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26555,"protocol_no":"CLDE225C2301","submission_no":"163111","status_id":2,"start_date":"2013-08-06","end_date":"2016-10-05","nol_date":"2013-04-05","protocol_title":"A PHASE III, MULTI-CENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL LDE225 VERSUS TEMOZOLOMIDE IN PATIENTS WITH HH-PATHWAY ACTIVATED RELAPSED MEDULLOBLASTOMA.","medConditionList":[{"med_condition_id":27,"med_condition":"BRAIN METASTASES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42333,"protocol_no":"ACE-536-MDS-001","submission_no":"194629","status_id":1,"start_date":"2016-10-28","end_date":null,"nol_date":"2016-05-26","protocol_title":"A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS WHO REQUIRE RED BLOOD CELL TRANFUSIONS","medConditionList":[{"med_condition_id":329,"med_condition":"ANEMIA"},{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37481,"protocol_no":"PRO00049850","submission_no":"178763","status_id":1,"start_date":"2015-06-01","end_date":null,"nol_date":"2014-11-07","protocol_title":"ASSESSING THE SAFETY AND EFFICACY OF THE GASTRIC SUBMUCOSAL SPACE IN ISLET TRANSPLANTATION","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40929,"protocol_no":"CA204-125","submission_no":"189716","status_id":1,"start_date":"2016-06-16","end_date":null,"nol_date":"2015-12-18","protocol_title":"AN OPEN LABEL, RANDOMIZED PHASE 2 TRIAL OF POMALIDOMIDE/ DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28728,"protocol_no":"MEA115921","submission_no":"169574","status_id":1,"start_date":"2014-10-23","end_date":null,"nol_date":"2013-12-13","protocol_title":"A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MEPOLIZUMAB IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS IN SUBJECTS RECEIVING STANDARD OF CARE THERAPY","medConditionList":[{"med_condition_id":402,"med_condition":"EOSINOPHILIC GRANULOMATOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40360,"protocol_no":"PJC-019 / NCI 9571","submission_no":"187811","status_id":1,"start_date":"2015-12-22","end_date":null,"nol_date":"2015-10-23","protocol_title":"A PHASE IB STUDY OF THE COMBINATION OF AZD6244 HYDROGEN SULFATE (SELUMETINIB) AND CYCLOSPORIN A (CSA) IN PATIENTS WITH ADVANCED SOLID TUMORS WITH AN EXPANSION COHORT IN METASTATIC COLORECTAL CANCER","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29298,"protocol_no":"B2013:089","submission_no":"170364","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-14","protocol_title":"ROLE OF LOW DOSE INTRA-ARTICULAR TRANEXAMIC ACID IN THE REDUCTION OF BLOOD LOSS IN PRIMARY TOTAL HIP AND TOTAL KNEE ARTHROPLASTY: A RANDOMIZED PLACEBO CONTROLLED STUDY","medConditionList":[{"med_condition_id":466,"med_condition":"KNEE ARTHROPLASTY"},{"med_condition_id":465,"med_condition":"HIP ARTHROPLASTY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29156,"protocol_no":"M13-741","submission_no":"170944","status_id":2,"start_date":"2014-12-10","end_date":"2017-02-28","nol_date":"2014-01-17","protocol_title":"A PHASE 2A STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACODYNAMIC EFFECTS OF ABT-981 IN PATIENTS WITH KNEE OSTEOARTHRITIS","medConditionList":[{"med_condition_id":212,"med_condition":"OSTEOARTHRITIS OF THE KNEE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28902,"protocol_no":"GS-US-312-0118","submission_no":"170203","status_id":1,"start_date":"2015-07-28","end_date":null,"nol_date":"2013-12-12","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB IN COMBINATION WITH EITHER RITUXIMAB OR CHLORAMBUCIL FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28924,"protocol_no":"PTG2013","submission_no":"170252","status_id":3,"start_date":"2014-02-28","end_date":null,"nol_date":"2014-01-16","protocol_title":"PREEMPTIVE THERAPY OF GRAFT-VS-HOST DISEASE","medConditionList":[{"med_condition_id":370,"med_condition":"GRAFT VS HOST DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45777,"protocol_no":"SPK-9001-LTFU-101","submission_no":"205470","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-09","protocol_title":"GENE THERAPY, OPEN-LABEL, DOSE-ESCALATION STUDY OF SPK-9001 [ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR IX GENE] IN SUBJECTS WITH HEMOPHILIA B","medConditionList":[{"med_condition_id":100,"med_condition":"HEMOPHILIA B"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46862,"protocol_no":"V01-126A-201","submission_no":"208916","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-28","protocol_title":"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43281,"protocol_no":"CY 4033","submission_no":"197702","status_id":1,"start_date":"2016-10-17","end_date":null,"nol_date":"2016-09-08","protocol_title":"A PHASE 3, OPEN-LABEL EXTENSION STUDY OF TIRASEMTIV FOR PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) WHO COMPLETED VITALITY-ALS (CY 4031)","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46439,"protocol_no":"200911","submission_no":"207576","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-08","protocol_title":"A PHASE 2A, MULTICENTER, RANDOMIZED, ADAPTIVE, OPEN-LABEL,  DOSE RANGING STUDY TO EVALUATE THE ANTIVIRAL EFFECT, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF COBICISTAT-BOOSTED GSK2838232 MONOTHERAPY OVER 10 DAYS IN HIV-1 INFECTED TREATMENT-NAIVE ADULTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41131,"protocol_no":"BCX4161-303","submission_no":"190422","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-01-08","protocol_title":"OPUS-4: AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF AVORALSTAT IN SUBJECTS WITH HEREDITARY ANGIOEDEMA","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38529,"protocol_no":"VX14-661-106","submission_no":"182320","status_id":2,"start_date":"2016-07-20","end_date":"2016-12-21","nol_date":"2015-03-19","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VX-661 IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS, HOMOZYGOUS FOR THE F508DEL CFTR MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40189,"protocol_no":"MM-121-01-02-09","submission_no":"187334","status_id":1,"start_date":"2017-07-17","end_date":null,"nol_date":"2015-10-23","protocol_title":"A PHASE 2 STUDY OF MM-121 IN COMBINATION WITH DOCETAXEL OR PEMETREXED VERSUS DOCETAXEL OR PEMETREXED ALONE IN PATIENTS WITH HEREGULIN POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36674,"protocol_no":"1311.13","submission_no":"176218","status_id":1,"start_date":"2014-11-10","end_date":null,"nol_date":"2014-08-06","protocol_title":"AN OPEN LABEL EXTENSION TRIAL ASSESSING THE SAFETY AND EFFICACY OF BI 655066 ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41623,"protocol_no":"ZX008-1501","submission_no":"192078","status_id":1,"start_date":"2017-02-23","end_date":null,"nol_date":"2016-03-11","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED TRIAL OF TWO FIXED DOSES OF ZX008 (FENFLURAMINE HYDROCHLORIDE) ORAL SOLUTION AS AN ADJUNCTIVE THERAPY IN CHILDREN AND YOUNG ADULTS WITH DRAVET SYNDROME","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35709,"protocol_no":"EVP-6124-026","submission_no":"173200","status_id":1,"start_date":"2014-11-26","end_date":null,"nol_date":"2014-04-15","protocol_title":"A 26-WEEK EXTENSION STUDY OF THE SAFETY AND CLINICAL EFFECTS OF EVP-6124 IN SUBJECTS WITH ALZHEIMER'S DISEASE CURRENTLY OR PREVIOUSLY RECEIVING AN ACETYLCHOLINESTERASE INHIBITOR MEDICATION","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44533,"protocol_no":"CAPI015A2201J","submission_no":"201649","status_id":1,"start_date":"2017-09-12","end_date":null,"nol_date":"2017-02-15","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-COHORT PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY OF CAD106 AND CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35970,"protocol_no":"MK-8835-005","submission_no":"174080","status_id":2,"start_date":"2014-06-03","end_date":"2016-10-20","nol_date":"2014-05-21","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF ERTUGLIFLOZIN (MK-8835/PF-04971729) WITH SITAGLIPTIN COMPARED WITH ERTUGLIFLOZIN ALONE AND SITAGLIPTIN ALONE, IN THE TREATMENT OF SUBJECTS WITH T2DM WITH INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41790,"protocol_no":"TG-MV-015","submission_no":"192717","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-30","protocol_title":"A PHASE 2, RANDOMISED, DOUBLE-MASKED, SHAM-CONTROLLED, MULTI-CENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRIPLASMIN IN INDUCING TOTAL POSTERIOR VITREOUS DETACHMENT (PVD) IN SUBJECTS WITH NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) (CIRCLE)","medConditionList":[{"med_condition_id":683,"med_condition":"NON-PROLIFERATIVE DIABETIC RETINOPATHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46942,"protocol_no":"SOBI.ANAKIN-301","submission_no":"200300","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-04","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF 2 DOSE LEVELS OF SUBCUTANEOUS ANAKINRA (KINERET) IN PATIENTS WITH STILL'S DISEASE (SJIA AND AOSD)","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"},{"med_condition_id":814,"med_condition":"ADULT ONSET STILL'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42665,"protocol_no":"NB-001-CD","submission_no":"195793","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-07-08","protocol_title":"MET-1 TREATMENT OF RECURRENT CDI","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36928,"protocol_no":"16298","submission_no":"177004","status_id":2,"start_date":"2015-10-19","end_date":"2017-11-30","nol_date":"2014-09-05","protocol_title":"A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF RADIUM-223 DICHLORIDE VERSUS PLACEBO WHEN ADMINISTERED TO METASTATIC HER2 NEGATIVE HORMONE RECEPTOR POSITIVE BREAST CANCER SUBJECTS WITH BONE METASTATSES TREATED WITH HORMONAL TREATMENT BACKGROUND THERAPY","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42442,"protocol_no":"1000047417","submission_no":"194984","status_id":1,"start_date":"2017-05-25","end_date":null,"nol_date":"2016-06-27","protocol_title":"CANNABINOID THERAPY IN MEDICALLY REFRACTORY PEDIATRIC EPILEPSY - PHASE 1: DOSING AND TOLERABILITY STUDY OF A CANNABIDIOL-RICH WHOLE CANNABIS PLANT EXTRACT","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35902,"protocol_no":"U31287-A-U301","submission_no":"173857","status_id":1,"start_date":"2015-02-27","end_date":null,"nol_date":"2014-05-09","protocol_title":"PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER, TWO-PART STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH ERLOTINIB IN EGFR WILD-TYPE SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON AT LEAST ONE PRIOR SYSTEMIC THERAPY","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42935,"protocol_no":"16-012-MUHC","submission_no":"196708","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-08-24","protocol_title":"EFFECT OF INTRANASAL INSULIN ADMINISTRATION ON GLYCAEMIA AND INSULIN CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID DURING SURGERY","medConditionList":[{"med_condition_id":717,"med_condition":"GLYCEMIA"},{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"},{"med_condition_id":716,"med_condition":"THORACIC SURGERY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27916,"protocol_no":"ADVL1217","submission_no":"167057","status_id":2,"start_date":"2014-03-19","end_date":"2017-02-06","nol_date":"2013-08-29","protocol_title":"ADVL1217, A PHASE 1 STUDY OF MK-1775 (IND#116459) CONCURRENT WITH LOCAL RADIATION THERAPY FOR THE TREATMENT OF NEWLY DIAGNOSED CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMAS","medConditionList":[{"med_condition_id":350,"med_condition":"DIFFUSE INTRINSIC PONTINE GLIOMAS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29181,"protocol_no":"GS-US-337-0115","submission_no":"171143","status_id":1,"start_date":"2014-04-03","end_date":null,"nol_date":"2014-02-14","protocol_title":"A PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SOFOSBUVIR/LEDIPASVIR FIXED-DOSE COMBINATION FOR 12 WEEKS IN SUBJECTS WITH CHRONIC GENOTYPE 1 OR 4 HEPATITIS C VIRUS (HCV) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 CO-INFECTION","medConditionList":[{"med_condition_id":105,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1 OR 4"},{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27239,"protocol_no":"D0818C00001","submission_no":"165198","status_id":1,"start_date":"2014-09-16","end_date":null,"nol_date":"2013-06-19","protocol_title":"A PHASE III, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE STUDY OF OLAPARIB MAINTENANCE MONOTHERAPY IN PATIENTS WITH BRCA MUTATED ADVANCED (FIGO STAGE III-IV) OVARIAN CANCER FOLLOWING FIRST LINE PLATINUM BASED CHEMOTHERAPY","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35928,"protocol_no":"1321.3","submission_no":"173990","status_id":2,"start_date":"2015-01-14","end_date":"2016-10-28","nol_date":"2014-05-16","protocol_title":"A PHASE III, CASE SERIES CLINICAL STUDY OF THE REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN BY INTRAVENOUS ADMINISTRATION OF 5.0G IDARUCIZUMAB IN PATIENTS TREATED WITH DABIGATRAN ETEXILATE WHO HAVE UNCONTROLLED BLEEDING OR REQUIRE EMERGENCY SUGERY OR PROCEDURES","medConditionList":[{"med_condition_id":537,"med_condition":"UNCONTROLLED BLEEDING"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42323,"protocol_no":"HIV-002","submission_no":"194604","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-05-27","protocol_title":"A PILOT RANDOMIZED, OPEN LABEL STUDY TO EVALUATE THE EFFECT OF AN HIV IMMUNOTHERAPY OF PENNVAX-GP AND INO-9012 DELIVERED VIA EP ON REDUCING HIV VIRAL RESERVOIRS IN INFECTED INDIVIDUALS WHO INITIATED THERAPY DURING THE ACUTE/EARLY PHASE OF INFECTION","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27919,"protocol_no":"MO28543","submission_no":"167068","status_id":1,"start_date":"2014-06-26","end_date":null,"nol_date":"2013-09-05","protocol_title":"A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE IIIB, INTERNATIONAL STUDY EVALUATING THE SAFETY OF OBINUTUZUMAB ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED OR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA","medConditionList":[{"med_condition_id":149,"med_condition":"LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48130,"protocol_no":"17403","submission_no":"212936","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-21","protocol_title":"RANDOMIZED, OPEN LABEL, MULTICENTER PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROGARATINIB (BAY 1163877) COMPARED TO CHEMOTHERAPY IN PATIENTS WITH FGFR-POSITIVE LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO HAVE RECEIVED PRIOR PLATINUM-CONTAINING CHEMOTHERAPY.","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46422,"protocol_no":"MLN0002-2003","submission_no":"207511","status_id":1,"start_date":"2017-11-15","end_date":null,"nol_date":"2017-08-11","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF VEDOLIZUMAB IV IN PEDIATRIC SUBJECTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"},{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36841,"protocol_no":"TOPMATEPY4067","submission_no":"176727","status_id":1,"start_date":"2018-02-06","end_date":null,"nol_date":"2014-08-21","protocol_title":"A RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, FLEXIBLE-DOSE STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF TOPIRAMATE AS MONOTHERAPY COMPARED WITH LEVETIRACETAM AS MONOTHERAPY IN PEDIATRIC SUBJECTS WITH NEW OR RECENT-ONSET EPILEPSY","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47154,"protocol_no":"CAIN457K2340","submission_no":"209940","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-10","protocol_title":"A RANDOMIZED, PARTIALLY-BLINDED, ACTIVE-CONTROLLED MULTICENTER STUDY OF SECUKINUMAB TO DEMONSTRATE REDUCTION OF RADIOGRAPHIC PROGRESSION VERSUS GP2017 (ADALIMUMAB BIOSIMILAR) AT 104 WEEKS AND TO ASSESS THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY UP TO 2 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS","medConditionList":[{"med_condition_id":397,"med_condition":"ANKYLOSING SPONDYLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44624,"protocol_no":"GO39590","submission_no":"201886","status_id":2,"start_date":"2017-06-06","end_date":"2017-09-11","nol_date":"2017-02-06","protocol_title":"A PHASE II MULTICENTER, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXRO9I6 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36605,"protocol_no":"C41750/3100","submission_no":"175986","status_id":1,"start_date":"2014-10-14","end_date":null,"nol_date":"2014-07-25","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL GROUP EFFICACY AND SAFETY STUDY OF ALLOGENIC MESENCHYMAL PRECUSOR CELLS (CEP-41750) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY","medConditionList":[{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26776,"protocol_no":"20120178","submission_no":"163800","status_id":1,"start_date":"2013-11-01","end_date":null,"nol_date":"2013-05-08","protocol_title":"\"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMG 334 IN MIGRAINE PREVENTION.\"","medConditionList":[{"med_condition_id":157,"med_condition":"MIGRAINE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47356,"protocol_no":"CLIK066X2204","submission_no":"210678","status_id":1,"start_date":"2018-02-06","end_date":null,"nol_date":"2017-11-22","protocol_title":"A 12-WEEK RANDOMIZED, PATIENT AND INVESTIGATOR BLINDED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY OF LIK066 IN OBESE PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)","medConditionList":[{"med_condition_id":734,"med_condition":"NONALCOHOLIC STEATOHEPATITIS (NASH)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38767,"protocol_no":"GO29436","submission_no":"183113","status_id":1,"start_date":"2017-01-20","end_date":null,"nol_date":"2015-04-24","protocol_title":"\"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1) IN COMBINATION WITH CARBOPLATIN+PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN+PACLITAXEL+BEVACIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.\"","medConditionList":[{"med_condition_id":512,"med_condition":"NON-SQUAMOUS CARCINOMA OF THE LUNG"},{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44227,"protocol_no":"BP39365","submission_no":"200470","status_id":1,"start_date":"2017-10-04","end_date":null,"nol_date":"2016-12-21","protocol_title":"AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED, DOSE-ESCALATION, PHASE IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6874281, IN COMBINATION WITH ATEZOLIZUMAB + BEVACIZUMAB, FOLLOWING OBINUTUZUMAB PRE-TREATMENT, IN PATIENTS WITH UNRESECTABLE ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38678,"protocol_no":"WO29637","submission_no":"182827","status_id":1,"start_date":"2016-03-16","end_date":null,"nol_date":"2015-04-09","protocol_title":"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47436,"protocol_no":"GO39775","submission_no":"210945","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-01","protocol_title":"AN OPEN-LABEL, MULTICENTER, PHASE I TRIAL EVALUATING THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF BFCR4350A IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40263,"protocol_no":"B4801010","submission_no":"187535","status_id":2,"start_date":"2015-12-04","end_date":"2017-07-04","nol_date":"2015-10-07","protocol_title":"A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF-06291874 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN.","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29285,"protocol_no":"M14-033","submission_no":"171381","status_id":1,"start_date":"2014-10-06","end_date":null,"nol_date":"2014-02-05","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, MULTICENTER STUDY OF HIGHER VERSUS STANDARD ADALIMUMAB DOSING REGIMENS FOR INDUCTION AND MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43925,"protocol_no":"205050","submission_no":"199576","status_id":1,"start_date":"2017-03-24","end_date":null,"nol_date":"2016-11-23","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MEPOLIZUMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46542,"protocol_no":"161505","submission_no":"207911","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-17","protocol_title":"LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/HYQVIA) FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)","medConditionList":[{"med_condition_id":44,"med_condition":"CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37731,"protocol_no":"M12-965","submission_no":"179588","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-05","protocol_title":"PHASE 2, MULTICENTER, OPEN-LABEL EXTENSION (OLE) STUDY WITH ABT-122 IN RHEUMATOID ARTHRITIS SUBJECTS WHO HAVE COMPLETED THE PRECEDING M12-963 PHASE 2 RANDOMIZED CONTROLLED TRIAL (RCT).","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39523,"protocol_no":"024-02","submission_no":"185613","status_id":1,"start_date":"2015-12-18","end_date":null,"nol_date":"2015-07-31","protocol_title":"A PHASE III MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE A SWITCH TO MK-1439A IN HIV-1-INFECTED SUBJECTS VIROLOGICALLY SUPPRESSED ON A REGIMEN OF A RITONAVIR-BOOSTED PROTEASE INHIBITOR AND TWO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40290,"protocol_no":"CAMHPET-CTA-97","submission_no":"187600","status_id":1,"start_date":"2015-10-16","end_date":null,"nol_date":"2015-10-09","protocol_title":"COMPARISON OF MAO-A VT BETWEEN HEALTHY MEN AND WOMEN MEASURED WITH [11C]-HARMINE PET","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37747,"protocol_no":"AQX-1125-204","submission_no":"179630","status_id":2,"start_date":"2015-02-20","end_date":"2015-08-25","nol_date":"2014-12-04","protocol_title":"THE KINSHIP TRIAL: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AQX-1125 IN SUBJECTS WITH ATOPIC DERMATITIS BY TARGETING THE SHIP1 PATHWAY","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26709,"protocol_no":"38518168ASH2001","submission_no":"163551","status_id":2,"start_date":"2013-09-11","end_date":"2015-12-11","nol_date":"2013-04-23","protocol_title":"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP STUDY OF JNJ-38518168 IN SYMPTOMATIC ADULT SUBJECTS WITH UNCONTROLLED, PERSISTENT ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28824,"protocol_no":"12-1341","submission_no":"169987","status_id":1,"start_date":"2014-01-07","end_date":null,"nol_date":"2013-12-13","protocol_title":"EVALUATION OF EARLY AND DELAYED ENHANCEMENT AREAS WITH CARDIAC MAGNETIC RESONANCE CONTRAST-ENHANCED TI MAPPING","medConditionList":[{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46762,"protocol_no":"CP-PRO-QVLP-011","submission_no":"208598","status_id":1,"start_date":"2017-09-27","end_date":null,"nol_date":"2017-09-15","protocol_title":"A RANDOMIZED, OBSERVER-BLIND, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE LOT CONSISTENCY, IMMUNOGENICITY, AND SAFETY OF A PLANT-DERIVED QUADRIVALENT VLP INFLUENZA VACCINE IN HEALTHY ADULTS 18-49 YEARS OF AGE","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45602,"protocol_no":"SHP620-302","submission_no":"199729","status_id":1,"start_date":"2018-02-16","end_date":null,"nol_date":"2017-06-06","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF MARIBAVIR COMPARED TO VALGANCICLOVIR FOR THE TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS","medConditionList":[{"med_condition_id":62,"med_condition":"CYTOMEGALOVIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38070,"protocol_no":"RTH258-C001","submission_no":"180762","status_id":1,"start_date":"2015-04-29","end_date":null,"nol_date":"2015-01-15","protocol_title":"A TWO-YEAR, RANDOMIZED, DOUBLE-MASKED, MULTICENTER, THREE-ARM STUDY COMPARING THE EFFICACY AND SAFETY OF RTH258 VERSUS AFLIBERCEPT IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION","medConditionList":[{"med_condition_id":288,"med_condition":"NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39966,"protocol_no":"2016-6083","submission_no":"186742","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-13","protocol_title":"INDOCYANINE GREEN VERSUS BLUE DYE FOR SENTINEL LYMPH NODE DETECTION IN ENDOMETRIAL CANCER","medConditionList":[{"med_condition_id":73,"med_condition":"ENDOMETRIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36208,"protocol_no":"D3251C00003","submission_no":"174806","status_id":1,"start_date":"2014-06-20","end_date":null,"nol_date":"2014-06-20","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, CHRONIC DOSING (56 WEEK) PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 2 DOSES OF BENRALIZUMAB (MEDI-563) IN PATIENTS WITH MODERATE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) WITH A HISTORY OF COPD EXACERBATIONS (GALATHEA)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26880,"protocol_no":"035-00","submission_no":"164116","status_id":1,"start_date":"2014-01-08","end_date":null,"nol_date":"2013-05-17","protocol_title":"A PHASE II RANDOMIZED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 +/-RIBAVIRIN (RBV) IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39937,"protocol_no":"D4420C00005","submission_no":"186667","status_id":1,"start_date":"2015-09-30","end_date":null,"nol_date":"2015-09-11","protocol_title":"A PHASE 2B RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF MEDI7510 FOR THE PREVENTION OF ACUTE RESPIRATORY SYNCYTIAL VIRUS-ASSOCIATED RESPIRATORY ILLNESS IN OLDER ADULTS","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48506,"protocol_no":"RPC01-3202","submission_no":"214101","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-26","protocol_title":"INDUCTION STUDY #2 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN¬øS DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29429,"protocol_no":"SP304203-00","submission_no":"171788","status_id":2,"start_date":"2014-05-20","end_date":"2015-07-10","nol_date":"2014-03-07","protocol_title":"A RANDOMIZED, 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF PLECANATIDE (3.0 AND 6.0 MG) IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION (THE CIC3 STUDY)","medConditionList":[{"med_condition_id":322,"med_condition":"IDIOPATHIC CONSTIPATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42583,"protocol_no":"061","submission_no":"195466","status_id":1,"start_date":"2016-09-16","end_date":null,"nol_date":"2016-06-24","protocol_title":"A PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUVOREXANT (MK-4305) FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMER¬øS DISEASE","medConditionList":[{"med_condition_id":737,"med_condition":"INSOMNIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48277,"protocol_no":"54179060CLL3011","submission_no":"213479","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-01","protocol_title":"A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB FOR THE FIRST-LINE TREATMENT OF SUBJECTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47863,"protocol_no":"BT006","submission_no":"212206","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-15","protocol_title":"A STUDY TO EVALUATE THE SAFETY AND FEASIBILITY OF THE BLOOD-BRAIN BARRIER DISRUPTION USING MRI-GUIDED FOCUSED ULTRASOUND IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28821,"protocol_no":"1311.6","submission_no":"169982","status_id":1,"start_date":"2015-01-27","end_date":null,"nol_date":"2013-12-11","protocol_title":"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF BI 655066, AN IL-23 P19 ANTAGONIST MONOCLONAL ANTIBODY, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE, WHO ARE NATIVE TO, OR WERE PREVIOUSLY TREATED WITH ANTI-TNF THERAPY","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35798,"protocol_no":"191622-127","submission_no":"173512","status_id":2,"start_date":"2014-11-27","end_date":"2016-03-15","nol_date":"2014-05-01","protocol_title":"BOTOX TREATMENT IN ADULT PATIENTS WITH UPPER LIMB SPASTICITY","medConditionList":[{"med_condition_id":141,"med_condition":"LIMB SPASTICITY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41065,"protocol_no":"CTN 289","submission_no":"190128","status_id":1,"start_date":"2016-08-16","end_date":null,"nol_date":"2016-01-07","protocol_title":"EVALUATION OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (ECF/TAF) SWITCH FOLLOWED BY LEDIPASVIR-SOFOSBUVIR ANTIVIRAL HCV THERAPY IN HIV-HCV CO-INFECTION: A CIHR CANADIAN HIV TRIALS NETWORK-GILEAD PILOT TRIAL PROPOSAL","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"},{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27834,"protocol_no":"RIL-07-2013","submission_no":"166828","status_id":2,"start_date":"2014-09-17","end_date":"2016-12-07","nol_date":"2013-08-22","protocol_title":"A PILOT STUDY OF RILUZOLE VS. PLACEBO IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH ASD (RILISE)","medConditionList":[{"med_condition_id":354,"med_condition":"AUTISM"},{"med_condition_id":351,"med_condition":"AUTISM SPECTRUM DISORDER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29135,"protocol_no":"01","submission_no":"171023","status_id":1,"start_date":"2014-03-31","end_date":null,"nol_date":"2014-01-29","protocol_title":"THE SHIFT-2 STUDY: USE OF INTRAVITREAL AFLIBERCEPT IN WET AGE RELATED MACULAR DEGENERATION (AMD) PATIENTS WITH AN INCOMPLETE RESPONSE TO MONTHLY RANIBIZUMAB INJECTIONS","medConditionList":[{"med_condition_id":568,"med_condition":"MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37648,"protocol_no":"CAMHPET-CTA-86","submission_no":"179263","status_id":1,"start_date":"2016-03-01","end_date":null,"nol_date":"2014-11-27","protocol_title":"BIOMARKERS OF NEUROINFLAMMATION AND ANTI-INFLAMMATORY TREATMENTS IN MAJOR DEPRESSIVE DISORDER","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29195,"protocol_no":"PRO 43981","submission_no":"171188","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-01-30","protocol_title":"A PROSPECTIVE RANDOMIZED SINGLE CENTER TRIAL OF FECAL MICROBIOTA TRANSPLANTATION (FMT) VS SHAM FMT IN THE MANAGEMENT OF ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40551,"protocol_no":"LJ501-CRH01","submission_no":"188455","status_id":1,"start_date":"2015-12-15","end_date":null,"nol_date":"2015-11-10","protocol_title":"A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND, MULTI- CENTER STUDY OF LJPC-501 IN PATIENTS WITH CATECHOLAMINE-RESISTANT HYPOTENSION (CRH)","medConditionList":[{"med_condition_id":605,"med_condition":"HYPOTENSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41541,"protocol_no":"STEP-CAT-01","submission_no":"191805","status_id":1,"start_date":"2016-07-22","end_date":null,"nol_date":"2016-02-18","protocol_title":"THE STEP-CAT COHORT MANAGEMENT STUDY: STEP-DOWN TO PROPHYLACTIC DOSES OF ENOXAPARIN AFTER A MINIMUM OF 3-6 MONTHS OF ANTICOAGULATION FOR THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS","medConditionList":[{"med_condition_id":668,"med_condition":"THROMBOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37813,"protocol_no":"42160443PAI3003","submission_no":"179789","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-24","protocol_title":"RANDOMIZED, 16-WEEK, MULTI-PHASE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF FULRANUMAB AS MONOTHERAPY IN SUBJECTS WITH SIGNS AND SYMPTOMS OF OSTEOARTHRITIS OF THE HIP OR KNEE","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29148,"protocol_no":"PR-30-5010-C","submission_no":"171044","status_id":1,"start_date":"2016-09-12","end_date":null,"nol_date":"2014-01-17","protocol_title":"A PHASE III, RANDOMIZED, OPEN LABEL, MULTICENTER, CONTROLLED TRIAL OF NIRAPARIB VERSUS PHYSICIAN'S CHOICE IN PREVIOUSLY-TREATED, HER2 NEGATIVE, GERMLINE BRCA MUTATION-POSITIVE BREAST CANCER PATIENTS","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26772,"protocol_no":"M13-093","submission_no":"163793","status_id":2,"start_date":null,"end_date":"2014-01-07","nol_date":"2013-04-30","protocol_title":"ASSESSMENT OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ABT-199 AFTER SINGLE AND MULTIPLE ASCENDING DOSES IN FEMALE SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).","medConditionList":[{"med_condition_id":311,"med_condition":"SYSTEMIC LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38929,"protocol_no":"DU176B-D-U311","submission_no":"183638","status_id":2,"start_date":"2016-04-19","end_date":"2017-09-14","nol_date":"2015-05-13","protocol_title":"A PHASE 3B, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40488,"protocol_no":"NCT02487238","submission_no":"188306","status_id":1,"start_date":"2014-12-01","end_date":null,"nol_date":"2015-11-04","protocol_title":"PEDIATRIC FECAL MICROBIAL TRANSPLANTATION FOR ULCERATIVE COLITIS (PEDI PETCH)","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39019,"protocol_no":"CHS-0214-05","submission_no":"183894","status_id":1,"start_date":"2015-10-16","end_date":null,"nol_date":"2015-05-21","protocol_title":"AN OPEN-LABEL SAFETY EXTENSION STUDY (OLSES) EVALUATING LONG-TERM SAFETY AND DURABILITY OF RESPONSE OF CHS-0214 (CHS-0214-05)","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"},{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36614,"protocol_no":"CV185-267","submission_no":"176006","status_id":2,"start_date":"2015-06-29","end_date":"2017-09-18","nol_date":"2014-07-21","protocol_title":"A PHASE IV TRIAL TO ASSESS THE EFFECTIVENESS OF APIXABAN COMPARED WITH USUAL CARE ANTICOAGULATION IN SUBJECTS WITH NON-VALVULAR ATRIAL FIBRILLATION UNDERGOING CARDIOVERSION","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43453,"protocol_no":"13VR3","submission_no":"198146","status_id":2,"start_date":"2017-05-19","end_date":"2017-11-23","nol_date":"2016-10-04","protocol_title":"AN OPEN-LABEL, LONG-TERM EXTENSION STUDY OF THE SAFETY AND EFFICACY OF A LONG-ACTING HUMAN GROWTH HORMONE SOMAVARATAN (VRS-317) IN CHILDREN WITH GROWTH HORMONE DEFICIENCY","medConditionList":[{"med_condition_id":94,"med_condition":"GROWTH HORMONE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42489,"protocol_no":"1370.2","submission_no":"195162","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-27","protocol_title":"ELUXA 2: AN INTERNATIONAL, RANDOMIZED, MULTI-CENTRE, ACTIVE CONTROLLED, OPEN-LABEL, PHASE III STUDY EVALUATING THE EFFICACY OF BI 1482694 VERSUS STANDARD PLATINUM DOUBLET CHEMOTHERAPY IN PATIENTS WITH T790M MUTATION POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE PROGRESSED ON ONE PRIOR EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI) TREATMENT","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28725,"protocol_no":"1237.25","submission_no":"169549","status_id":1,"start_date":"2013-12-06","end_date":null,"nol_date":"2013-11-28","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY OF 12 WEEKS OF ONCE DAILY TREATMENT OF TWO DOSES OF ORALLY INHALED TIOTROPIUM + OLODATEROL FIXED DOSE COMBINATION (DELIVERED BY THE RESPIMAT¬Æ INHALER) IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45527,"protocol_no":"RA101495-01.202","submission_no":"204697","status_id":1,"start_date":"2017-09-01","end_date":null,"nol_date":"2017-05-01","protocol_title":"A MULTICENTER, OPEN-LABEL, UNCONTROLLED, EXTENSION STUDY OF RA101495 IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO HAVE COMPLETED A RA101495 CLINICAL STUDY","medConditionList":[{"med_condition_id":649,"med_condition":"PAROXYSMAL NOCTURNAL HEMOGLOBINURIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36160,"protocol_no":"GA28951","submission_no":"174681","status_id":1,"start_date":"2014-12-31","end_date":null,"nol_date":"2014-06-11","protocol_title":"AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48467,"protocol_no":"1002-043","submission_no":"213979","status_id":1,"start_date":"2018-04-26","end_date":null,"nol_date":"2018-03-22","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28169,"protocol_no":"AI424-979","submission_no":"167852","status_id":1,"start_date":"2014-01-08","end_date":null,"nol_date":"2013-09-27","protocol_title":"MICROBOOSTING OF ATAZANAVIR 300 MG WITH 50 MG VERSUS 100MG RITONAVIR DAILY IN HIV-INFECTED PATIENTS; A PHARMACOKINETIC STUDY","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39789,"protocol_no":"GO29664","submission_no":"186284","status_id":2,"start_date":"2016-02-09","end_date":"2017-12-14","nol_date":"2015-08-13","protocol_title":"AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI-PD-11 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38765,"protocol_no":"GO29537","submission_no":"183110","status_id":1,"start_date":"2017-05-11","end_date":null,"nol_date":"2015-04-24","protocol_title":"\"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1) IN COMBINATION WITH CARBOPLATIN+NAB-PACLITAXEL FOR CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.\"","medConditionList":[{"med_condition_id":512,"med_condition":"NON-SQUAMOUS CARCINOMA OF THE LUNG"},{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42413,"protocol_no":"CIMS-2016-01","submission_no":"194863","status_id":1,"start_date":"2016-06-16","end_date":null,"nol_date":"2016-06-08","protocol_title":"PHASE II STUDY TO MEASURE THE SAFETY OF 68GA-DOTA-TATE PET/CT IN THE DIAGNOSIS OF TUMORS EXPRESSING SOMATOSTATIN RECEPTORS","medConditionList":[{"med_condition_id":291,"med_condition":"SOMATOSTATIN RECEPTOR POSITIVE TUMOURS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27649,"protocol_no":"062-010","submission_no":"166342","status_id":1,"start_date":"2013-12-05","end_date":null,"nol_date":"2013-08-01","protocol_title":"PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL ARM STUDY OF PRC-062 IN PATIENTS WITH CHRONIC NON-CANCER PAIN","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27348,"protocol_no":"AMB115811","submission_no":"165537","status_id":2,"start_date":"2013-10-30","end_date":"2015-03-30","nol_date":"2013-07-05","protocol_title":"A RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AMBRISENTAN IN SUBJECTS WITH INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)","medConditionList":[{"med_condition_id":326,"med_condition":"CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)"},{"med_condition_id":260,"med_condition":"PULMONARY DISORDERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39630,"protocol_no":"747-302","submission_no":"185909","status_id":1,"start_date":"2016-02-24","end_date":null,"nol_date":"2015-07-21","protocol_title":"A PHASE 3B, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFECT OF OBETICHOLIC ACID ON CLINICAL OUTCOMES IN SUBJECTS WITH PRIMARY BILIARY CIRRHOSIS","medConditionList":[{"med_condition_id":209,"med_condition":"PRIMARY BILIARY CIRRHOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39735,"protocol_no":"BN29739","submission_no":"186181","status_id":1,"start_date":"2016-02-22","end_date":null,"nol_date":"2015-08-12","protocol_title":"A PHASE IIIB, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL STUDY TO EVALUATE THE EFFECTS OF OCRELIZUMAB ON IMMUNE RESPONSES IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS.\"","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37164,"protocol_no":"065-01","submission_no":"177745","status_id":2,"start_date":"2016-04-29","end_date":"2016-04-19","nol_date":"2014-09-25","protocol_title":"A PHASE III DOUBLE BLIND CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 IN SUBJECTS WITH CHRONIC HCV GT1, GT4 AND GT6 INFECTION WITH INHERITED BLOOD DISORDERS WITH AND WITHOUT HIV CO-INFECTION","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"},{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38296,"protocol_no":"SB-1-004-003","submission_no":"181543","status_id":1,"start_date":"2015-06-08","end_date":null,"nol_date":"2015-02-20","protocol_title":"A PHASE 1B/2A, RANDOMIZED, MULTI-CENTER, OPEN-LABEL, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF ORAL SYN-004 ON THE PHARMACOKINETICS OF INTRAVENOUS CEFTRIAXONE IN HEALTHY ADULT SUBJECTS WITH A FUNCTIONING ILCOSTOMY","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45368,"protocol_no":"M16-289","submission_no":"202660","status_id":1,"start_date":"2017-07-27","end_date":null,"nol_date":"2017-04-28","protocol_title":"A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY OF ROVALPITUZUMAB TESIRINE COMPARED WITH TOPOTECAN FOR SUBJECTS WITH ADVANCED OR METASTATIC DLL3HIGH SMALL CELL LUNG CANCER (SCLC) WHO HAVE FIRST DISEASE PROGRESSION DURING OR FOLLOWING FRONT-LINE PLATINUM-BASED CHEMOTHERAPY (TAHOE)","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36825,"protocol_no":"E7389-A001-113","submission_no":"176675","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-08-13","protocol_title":"A PHASE 1 STUDY OF ERIBULIN MESYLATE (E7389, IND #116,292), A NOVEL MICROTUBULE TARGETING CHEMOTHERAPEUTIC AGENT IN CHILDREN WITH REFRACTORY OR RECURRENT SOLID TUMORS (EXCLUDING CNS), INCLUDING LYMPHOMAS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43032,"protocol_no":"CP-MGAH22-05","submission_no":"196946","status_id":1,"start_date":"2017-02-28","end_date":null,"nol_date":"2016-08-16","protocol_title":"A PHASE 1B/2, OPEN LABEL, DOSE ESCALATION STUDY OF MARGETUXIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED HER2+ GASTROESOPHAGEAL JUNCTION OR GASTRIC CANCER","medConditionList":[{"med_condition_id":337,"med_condition":"GASTRIC CANCER"},{"med_condition_id":619,"med_condition":"GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42088,"protocol_no":"GS-US-339-1562","submission_no":"193878","status_id":2,"start_date":null,"end_date":"2017-06-22","nol_date":"2016-05-03","protocol_title":"A PHASE 1B-2, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND EFFICACY OF ENTOSPLETINIB (ENTO [GS 9973]) COMBINED WITH VINCRISTINE (VCR) IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (NHL)","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43259,"protocol_no":"CR-MIHA-001","submission_no":"197630","status_id":1,"start_date":"2017-09-20","end_date":null,"nol_date":"2016-12-09","protocol_title":"A SINGLE ARM PHASE I/II OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF ANTI-MIHA T CELL LINES FOR THE TREATMENT OF PATIENTS WITH AML AND MDS WHO HAVE RELAPSED AFTER HLA-MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"},{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"},{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"},{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37388,"protocol_no":"DS5565-A-E309","submission_no":"178465","status_id":2,"start_date":"2015-01-28","end_date":"2016-07-14","nol_date":"2014-10-24","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED STUDY OF DS-5565 IN SUBJECTS WITH PAIN ASSOCIATED WITH FIBROMYALGIA","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44314,"protocol_no":"E2006-G000-303","submission_no":"200749","status_id":1,"start_date":"2017-04-05","end_date":null,"nol_date":"2016-12-23","protocol_title":"A LONG-TERM MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PARALLEL-GROUP STUDY OF THE SAFETY AND EFFICACY OF LEMBOREXANT IN SUBJECTS WITH INSOMNIA DISORDER","medConditionList":[{"med_condition_id":737,"med_condition":"INSOMNIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40640,"protocol_no":"M15-556","submission_no":"188671","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-19","protocol_title":"A PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION (OLE) STUDY IN RHEUMATOID ARTHRITIS SUBJECTS WHO HAVE COMPLETED A PRECEDING PHASE 3 RANDOMIZED CONTROLLED TRIAL (RCT) WITH ABT-494","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36705,"protocol_no":"NCIC CTG PRC.4 / ALLIANCE 0312","submission_no":"176310","status_id":1,"start_date":"2015-03-04","end_date":null,"nol_date":"2014-08-06","protocol_title":"PHASE III TRIAL OF ENZULUTAMIDE (NSC#766085) VERSUS ENZALUTAMIDE, ABIRATERONE AND PREDNISONE FOR CASTRATION RESISTANT METASTATIC PROSTATE CANCER","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40917,"protocol_no":"BIBF-SCLC-001","submission_no":"189686","status_id":2,"start_date":"2016-06-15","end_date":"2016-07-05","nol_date":"2015-12-16","protocol_title":"A PHASE II STUDY OF BIBF 1120 IN RECURRENT AND PLATINUM-SENSITIVE SMALL-CELL LUNG CANCER (SCLC)","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46003,"protocol_no":"DS9231-A-U201","submission_no":"206049","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-21","protocol_title":"EVALUATION OF SAFETY AND THROMBOLYTIC EFFECT OF ASCENDING DOSES OF DS9231(TS23) IN SUBJECTS WITH INTERMEDIATE-RISK (SUB-MASSIVE) ACUTE PULMONARY EMBOLISM (PE)","medConditionList":[{"med_condition_id":335,"med_condition":"BRONCHOPULMONARY DYSPLASIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45443,"protocol_no":"MM-CODIM-MBM-16-293","submission_no":"204430","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-16","protocol_title":"THE SAFETY AND EFFICACY OF 68GA-HBED-CC-PSMA (DKFZ-11) PET/CT IN PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38436,"protocol_no":"TA14-12-22-1","submission_no":"182035","status_id":1,"start_date":"2017-02-27","end_date":null,"nol_date":"2015-03-09","protocol_title":"TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":606,"med_condition":"CHRONIC SUBDURAL HEMATOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27453,"protocol_no":"CLDK378X2103","submission_no":"165785","status_id":1,"start_date":"2017-04-13","end_date":null,"nol_date":"2013-07-19","protocol_title":"A PHASE I, OPEN-LABEL, DOSE ESCALATION STUDY OF LDK378 IN PEDIATRIC PATIENTS WITH MALIGNANCIES THAT HAVE A GENETIC ALTERATION IN ANAPLASTIC LYMPHOMA KINASE (ALK)","medConditionList":[{"med_condition_id":172,"med_condition":"NEUROBLASTOMA"},{"med_condition_id":327,"med_condition":"ANAPLASTIC LARGE-CELL LYMPHOMA"},{"med_condition_id":328,"med_condition":"INFLAMMATORY MYOFIBROBLASTIC TUMOR"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37856,"protocol_no":"AI444-257","submission_no":"179884","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-16","protocol_title":"A MULTICENTER TREATMENT PROTOCOL FOR DACLATASVIR (BMS-790052) IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF POST-LIVER TRANSPLANT SUBJECTS WITH CHRONIC HEPATITIS C","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"},{"med_condition_id":484,"med_condition":"LIVER TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44056,"protocol_no":"SHP620-303","submission_no":"199531","status_id":1,"start_date":"2017-12-18","end_date":null,"nol_date":"2016-12-06","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF MARIBAVIR TREATMENT COMPARED TO INVESTIGATOR-ASSIGNED TREATMENT IN TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS (CMV) INFECTIONS THAT ARE REFRACTORY OR RESISTANT TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, FOSCARNET, OR CIDOFOVIR","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"},{"med_condition_id":62,"med_condition":"CYTOMEGALOVIRUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36587,"protocol_no":"PTC124-GD-020E-DMD","submission_no":"175873","status_id":1,"start_date":"2016-01-29","end_date":null,"nol_date":"2014-07-22","protocol_title":"A PHASE 3 EXTENSION STUDY OF ATALUREN (PTC124) IN PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY.","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"},{"med_condition_id":318,"med_condition":"NONSENSE MUTATION DYSTROPHINOPATHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27914,"protocol_no":"CNTO148ART3003","submission_no":"167051","status_id":1,"start_date":"2014-03-13","end_date":null,"nol_date":"2013-08-29","protocol_title":"A GOLIMUMAB PHASE 3B, MULTICENTER, ASSESSMENT OF INTRAVENOUS EFFICACY IN RHEUMATOID ARTHRITIS SUBJECTS WHO HAVE DIMINISHED DISEASE CONTROL DESPITE TREATMENT WITH INFLIXIMAB (REMICADE)","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48319,"protocol_no":"SHP647-307","submission_no":"209531","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-13","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROHN'S DISEASE (CARMEN CD 307)","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29248,"protocol_no":"CQGE031B2201E1","submission_no":"171309","status_id":1,"start_date":"2015-07-08","end_date":null,"nol_date":"2014-02-19","protocol_title":"AN OPEN-LABEL, MULTI-CENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF SUBCUTANEOUS 240MG QGE031 GIVEN EVERY 4 WEEKS FOR 52 WEEKS IN ALLERGIC ASTHMA PATIENTS WHO COMPLETED STUDY CQGE031B2201","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38431,"protocol_no":"GLARGL07496","submission_no":"182026","status_id":1,"start_date":"2015-03-26","end_date":null,"nol_date":"2015-03-17","protocol_title":"A PILOT DESCRIPTIVE CANADIAN, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF TWO TITRATION ALGORITHMS WITH INSULIN GLARGINE 300 UNITS/ML IN TYPE 2 DIABETES MELLITUS PATIENTS (TITRATION)","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37927,"protocol_no":"CEGF816X2201C","submission_no":"180131","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-22","protocol_title":"A PHASE II, MULTICENTER, OPEN-LABEL STUDY OF EGF816 IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER AND OF INC280 IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH CMET POSITIVE NON-SMALL CELL LUNG CANCER.","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35940,"protocol_no":"B1481019","submission_no":"174023","status_id":1,"start_date":"2014-07-07","end_date":null,"nol_date":"2014-05-16","protocol_title":"A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR DYSLIPDEMIA AT RISK OF CARDIOVASCULAR EVENTS","medConditionList":[{"med_condition_id":387,"med_condition":"DYSLIPIDEAMIA"},{"med_condition_id":295,"med_condition":"PRIMARY HYPERLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45850,"protocol_no":"RD.03.SPR114322","submission_no":"205644","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-05","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, PARALLEL-GROUP, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF NEMOLIZUMAB (CD14152) IN MODERATE-TO-SEVERE ATOPIC DERMATITIS SUBJECTS WITH SEVERE PRURITUS RECEIVING TOPICAL CORTICOSTEROIDS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48149,"protocol_no":"1293.0013","submission_no":"213077","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-23","protocol_title":"AN EXPLORATORY MAINTENANCE TRIAL EVALUATING THE EFFECT OF BL 655064 IN LUPUS NEPHRITIS PATIENTS WHO HAVE ACHIEVED A MEANINGFUL RESPONSE EITHER AT THE END OF 1293.10 OR AFTER AN INDUCTION TREATMENT OUTSIDE OF 1293.IO","medConditionList":[{"med_condition_id":681,"med_condition":"LUPUS NEPHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45248,"protocol_no":"ACTIVATE","submission_no":"203769","status_id":1,"start_date":"2017-07-06","end_date":null,"nol_date":"2017-04-13","protocol_title":"PHASE IB TRIAL OF PEMBROLIZUMAB ADMINISTERED IN COMBINATION WITH OR FOLLOWING ADOPTIVE CELL THERAPY - A MULTIPLE COHORT STUDY: THE ACTIVATE (ADOPTIVE CELL THERAPY INVIGORATED TO AUGMENT TUMOR ERADICATION) TRIAL","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"},{"med_condition_id":680,"med_condition":"EPITHELIAL OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27378,"protocol_no":"901001","submission_no":"165586","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-07-19","protocol_title":"A PROSPECTIVE, RANDOMIZED, DOUBLE-BLINDED, ACTIVE-CONTROL AND UNBLINDED STANDARD OF CARE (SOC) CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF TARGETED INTRAMYOCARDIAL DELIVERY OF AUTOLOGOUS CD34+CELLS (AUTO-CD34+CELLS) FOR INCREASING EXERCISE CAPACITY DURING STANDARDIZED EXERCISE TESTING IN SUBJECTS WITH REFRACTORY ANGINA PECTORIS AND CHRONIC MYOCARDIAL ISCHEMIA (CMI).","medConditionList":[{"med_condition_id":272,"med_condition":"ANGINA PECTORIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38442,"protocol_no":"DRM01B-ACN02","submission_no":"182050","status_id":1,"start_date":"2015-04-11","end_date":null,"nol_date":"2015-03-12","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, DOSE-RANGING STUDY OF DRM01B TOPICAL GEL IN SUBJECTS WITH ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42575,"protocol_no":"201-201609","submission_no":"195419","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-24","protocol_title":"A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED, MULTICENTER, PHASE 3 STUDY OF OTO-201 GIVEN AS A SINGLE ADMINISTRATION FOR TREATMENT OF ACUTE OTITIS EXTERNA","medConditionList":[{"med_condition_id":60,"med_condition":"ACUTE OTITIS EXTERNA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42740,"protocol_no":"N/A","submission_no":"196065","status_id":1,"start_date":"2017-11-20","end_date":null,"nol_date":"2016-07-14","protocol_title":"ADVANCED PROSTATE IMAGING OF RECURRENT CANCER AFTER RADIOTHERAPY (PICS)","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37645,"protocol_no":"CLCZ696B2317","submission_no":"179248","status_id":2,"start_date":"2015-02-11","end_date":"2016-12-22","nol_date":"2014-11-27","protocol_title":"A MULTICENTER STUDY TO EVALUATE SAFETY AND TOLERABILITY IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED EJECTION FRACTION FROM PARADIGM-HF RECEIVING OPEN LABEL LCZ696","medConditionList":[{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35698,"protocol_no":"CV205006","submission_no":"173150","status_id":2,"start_date":"2015-10-29","end_date":"2017-02-21","nol_date":"2014-04-16","protocol_title":"A STUDY OF THE EFFECTS OF BMS-919373 ON ATRIAL EFFECTIVE REFRACTORY PERIOD IN SUBJECTS WITH A DUAL-CHAMBER PACEMAKER","medConditionList":[{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"},{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36543,"protocol_no":"B5371002","submission_no":"175748","status_id":1,"start_date":"2014-11-11","end_date":null,"nol_date":"2014-08-01","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41656,"protocol_no":"M13-596","submission_no":"192252","status_id":2,"start_date":"2016-09-07","end_date":"2017-06-20","nol_date":"2016-03-17","protocol_title":"A SINGLE-ARM, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABT 493/ABT 530 IN ADULT POST-LIVER OR POST-RENAL TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 - 6 INFECTION (MAGELLAN-2)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36568,"protocol_no":"ARRAY-520-215","submission_no":"175808","status_id":2,"start_date":"2015-05-27","end_date":"2016-11-16","nol_date":"2014-07-22","protocol_title":"A MULTICENTER PHASE 2 STUDY OF SINGLE-AGENT FILANESIB (ARRY-520) IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28291,"protocol_no":"M12-667","submission_no":"168168","status_id":2,"start_date":"2015-06-09","end_date":"2016-08-23","nol_date":"2013-10-10","protocol_title":"EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF ELAGOLIX IN SUBJECTS WITH MODERATE TO SEVERE ENDOMETRIOSIS-ASSOCIATED PAIN","medConditionList":[{"med_condition_id":74,"med_condition":"ENDOMETRIOSIS"},{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38524,"protocol_no":"VX14-661-108","submission_no":"182304","status_id":2,"start_date":"2015-11-05","end_date":"2017-02-13","nol_date":"2015-03-19","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IVACAFTOR AND VX-661 IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS, HETEROZYGOUS FOR THE F508DEL-CFTR MUTATION, AND A SECOND ALLELE WITH A FTR MUTATION PREDICTED TO HAVE RESIDUAL FUNCTION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41582,"protocol_no":"1311.30","submission_no":"191952","status_id":2,"start_date":"2016-08-17","end_date":"2017-11-22","nol_date":"2016-03-03","protocol_title":"BI 655066 VERSUS ADALIMUMAB IN A RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP TRIAL IN MODERATE TO SEVERE PLAQUE PSORIASIS TO ASSESS SAFETY AND EFFICACY AFTER 16 WEEKS OF TREATMENT AND AFTER INADEQUATE ADALIMUMAB TREATMENT RESPONSE (IMMVENT)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45736,"protocol_no":"402-C-1603","submission_no":"205345","status_id":1,"start_date":"2017-09-15","end_date":null,"nol_date":"2017-05-31","protocol_title":"A PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME","medConditionList":[{"med_condition_id":745,"med_condition":"ALPORT SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44888,"protocol_no":"PRIME","submission_no":"202734","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-07","protocol_title":"A RANDOMIZED PHASE 3 TRIAL OF METFORMIN IN PATIENTS INITIATING ANDROGEN DEPRIVATION THERAPY AS PREVENTION AND INTERVENTION OF METABOLIC SYNDROME: THE PRIME STUDY","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"},{"med_condition_id":306,"med_condition":"METABOLIC SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40780,"protocol_no":"VEDOLIZUMAB-4003","submission_no":"189135","status_id":1,"start_date":"2016-08-18","end_date":null,"nol_date":"2015-11-25","protocol_title":"A RANDOMIZED DOUBLE-BLIND PHASE 4 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 DOSE REGIMENS OF ENTYVIO (VEDOLIZUMAB IV) IN THE TREATMENT OF FISTULIZING CROHN'S DISEASE (ENTERPRISE)","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42332,"protocol_no":"IND.232","submission_no":"194628","status_id":1,"start_date":"2016-08-16","end_date":null,"nol_date":"2016-05-26","protocol_title":"A PHASE II STUDY OF DURVALUMAB (MEDI4736) WITH OR WITHOUT TREMELIMUMAB IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41491,"protocol_no":"D4190C00021","submission_no":"191639","status_id":1,"start_date":"2017-06-15","end_date":null,"nol_date":"2016-02-19","protocol_title":"A PHASE IB/2 STUDY OF MEDI4736 IN COMBINATION WITH TREMELIMUMAB, MEDI4736 MONOTHERAPY, AND TREMELIMUMAB MONOTHERAPY IN SUBJECTS WITH METASTATIC OR RECURRENT GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA","medConditionList":[{"med_condition_id":337,"med_condition":"GASTRIC CANCER"},{"med_condition_id":619,"med_condition":"GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38311,"protocol_no":"GS-US-366-1216","submission_no":"181600","status_id":2,"start_date":"2016-07-11","end_date":"2017-11-24","nol_date":"2015-02-10","protocol_title":"A PHASE 3B, RANDOMIZED, DOUBLE-BLIND SWITCH STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EMTRICITABINE/RILPIVIRINE/TENOFOVIR ALAFENAMIDE (FTC/RPV/TAF) FIXED DOSE COMBINATION (FDC) IN HIV-1 POSITIVE SUBJECTS WHO ARE VIROLOGICALLY SUPPRESSED ON EMTRICITABINE/RILPIVIRINE/TENOFOVIR DISOPROXIL FUMARATE (FTC/RPV/TDF)","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38060,"protocol_no":"R668-AD-1415","submission_no":"180704","status_id":1,"start_date":"2014-09-30","end_date":null,"nol_date":"2015-01-12","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE IN PATIENTS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42258,"protocol_no":"848-00","submission_no":"194426","status_id":2,"start_date":"2016-07-04","end_date":"2018-01-23","nol_date":"2016-05-18","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF THE ADDITION OF SITAGLIPTIN DURING METFORMIN UP-TITRATION COMPARED WITH METFORMIN UP-TITRATION ALONE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47753,"protocol_no":"54767414AMY3001","submission_no":"211772","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-28","protocol_title":"A RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CYBORD) COMPARED WITH CYBORD ALONE IN NEWLY DIAGNOSED SYSTEMIC AL AMYLOIDOSIS","medConditionList":[{"med_condition_id":574,"med_condition":"AMYLOIDOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38825,"protocol_no":"GS-US-339-1560","submission_no":"183313","status_id":2,"start_date":"2017-07-10","end_date":"2018-02-08","nol_date":"2015-04-15","protocol_title":"A PHASE 1B, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND EFFICACY OF ENTOSPLETINIB (GS-9973) WITH VINCRISTINE AND DEXAMETHASONE IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOID LEUKEMIA (ALL)","medConditionList":[{"med_condition_id":308,"med_condition":"LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44539,"protocol_no":"E2007-G000-338","submission_no":"201655","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-02-03","protocol_title":"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH AN OPEN-LABEL EXTENSION PHASE OF PERAMPANEL AS ADJUNCTIVE TREATMENT IN SUBJECTS AT LEAST 2 YEARS OF AGE WITH INADEQUATELY CONTROLLED SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME","medConditionList":[{"med_condition_id":836,"med_condition":"LENNOX-GASTAUT SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45628,"protocol_no":"HAL-MPE1/0049","submission_no":"204969","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-24","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND IMMUNOLOGIC EFFECTS OF HAL-MPE1 SUBCUTANEOUS IMMUNOTHERAPY IN ADULT AND PAEDIATRIC SUBJECTS WITH PEANUT ALLERGY","medConditionList":[{"med_condition_id":12,"med_condition":"ALLERGIES PEANUT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38889,"protocol_no":"8632","submission_no":"183514","status_id":1,"start_date":"2015-07-01","end_date":null,"nol_date":"2015-05-28","protocol_title":"INTRANASAL KETAMINE VERSUS INTRAVENOUS KETAMINE FOR PROCEDURAL CONSCIOUS SEDATION IN CHILDREN WITH ORTHOPEDIC INJURIES: A RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL","medConditionList":[{"med_condition_id":340,"med_condition":"SEDATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45764,"protocol_no":"MCRN 004","submission_no":"205431","status_id":1,"start_date":"2017-11-03","end_date":null,"nol_date":"2017-05-26","protocol_title":"A RANDOMIZED PHASE II, OPEN LABEL STUDY OF DARATUMUMAB, WEEKLY LOW-DOSE ORAL DEXAMETHASONE AND CYCLOPHOSPHAMIDE WITH OR WITHOUT POMALIDOMIDE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":168,"med_condition":"MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46366,"protocol_no":"NP39761","submission_no":"207269","status_id":1,"start_date":"2018-01-16","end_date":null,"nol_date":"2017-08-03","protocol_title":"PROTOCOL NP39761:  A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACODYNAMICS OF IDASANUTLIN MONOTHERAPY IN PATIENTS WITH HYDROXYUREA-RESISTANT/INTOLERANT POLYCYTHEMIA VERA.","medConditionList":[{"med_condition_id":199,"med_condition":"POLYCYTHEMIA VERA (PV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28382,"protocol_no":"CLCZ696D2301","submission_no":"168392","status_id":1,"start_date":"2014-10-08","end_date":null,"nol_date":"2013-10-24","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ696 COMPARED TO VALSARTAN, ON MORBIDITY AND MORTALITY IN HEART FAILURE PATIENTS (NYHA CLASS II-IV) WITH PRESERVED EJECTION FRACTION.","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39737,"protocol_no":"A3921104","submission_no":"186183","status_id":1,"start_date":"2016-10-04","end_date":null,"nol_date":"2015-08-12","protocol_title":"EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39041,"protocol_no":"EVB-003","submission_no":"183934","status_id":2,"start_date":"2015-06-26","end_date":"2016-07-28","nol_date":"2015-05-22","protocol_title":"\"A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, ACTIVE AND PLACEBO CONTROL SINGLE DOSE TRIAL TO DEMONSTRATE THE EFFICACY AND SAFETY OF DWP-450 IN ADULT SUBJECTS FOR TREATMENT OF MODERATE TO SEVERE GLABELLAR LINES.\"","medConditionList":[{"med_condition_id":380,"med_condition":"GLABELLAR LINES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29249,"protocol_no":"CNTO136ARA3004","submission_no":"171310","status_id":1,"start_date":"2015-02-23","end_date":null,"nol_date":"2014-02-20","protocol_title":"A MULTICENTER, PARALLEL-GROUP STUDY OF LONG-TERM SAFETY AND EFFICACY OF CNTO 136 (SIRUKUMAB) FOR RHEUMATOID ARTHRITIS IN SUBJECTS COMPLETING TREATMENT IN STUDIES CNTO136ARA3002 (SIRROUND-D) AND CNTO136ARA3003 (SIRROUND-T)","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42398,"protocol_no":"A031102","submission_no":"194829","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-01","protocol_title":"A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED BY HIGH-DOSE CARBOPLATIN AND ETOPOSIDE (TI-CE) AS FIRST SALVAGE TREATMENT IN RELAPSED OR REFRACTORY GERM CELL TUMORS","medConditionList":[{"med_condition_id":735,"med_condition":"GERM CELL TUMOUR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42887,"protocol_no":"MOB015B-IV","submission_no":"196536","status_id":1,"start_date":"2016-09-16","end_date":null,"nol_date":"2016-07-27","protocol_title":"A MULTI-CENTRE, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED STUDY OF EFFICACY AND SAFETY OF TOPICAL MOB015B IN THE TREATMENT OF MILD TO MODERATE DISTAL SUBUNGUAL ONYCHOMYCOSIS (DSO)","medConditionList":[{"med_condition_id":752,"med_condition":"SUBUNGUAL ONYCHOMYCOSIS (DSO)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36844,"protocol_no":"1289.5","submission_no":"176739","status_id":2,"start_date":"2015-02-20","end_date":"2017-10-05","nol_date":"2014-08-21","protocol_title":"A MULTI-CENTRE, DOUBLE-BLIND, PARALLEL-GROUP, RANDOMIZED CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306 DURING A 12-WEEK TREATMENT PERIOD COMPARED TO PLACEBO IN PATIENTS WITH ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41596,"protocol_no":"16159A","submission_no":"192001","status_id":1,"start_date":"2016-05-24","end_date":null,"nol_date":"2016-03-09","protocol_title":"INTERVENTIONAL, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, FIXED-DOSE STUDY OF LU AF35700 IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46304,"protocol_no":"802NP206","submission_no":"207084","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-25","protocol_title":"A PHASE 2 PLACEBO CONTROLLED, DOUBLE-BLIND, ENRICHED ENROLLMENT RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB074 IN TREATING PAIN EXPERIENCED BY SUBJECTS WITH CONFIRMED SMALL FIBRE NEUROPATHY THAT IS IDIOPATHIC OR ASSOCIATED WITH DIABETES MELLITUS","medConditionList":[{"med_condition_id":174,"med_condition":"NEUROPATHIC PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43786,"protocol_no":"ADP-0022-004","submission_no":"199137","status_id":1,"start_date":"2017-05-11","end_date":null,"nol_date":"2016-11-02","protocol_title":"PHASE 1 CELL DOSE ESCALATION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF GENETICALLY ENGINEERED MAGE-A10C796T IN HLA-A2+ SUBJECTS WITH MAGE-A10 POSITIVE UROTHELIAL, MELANOMA OR HEAD AND NECK TUMORS","medConditionList":[{"med_condition_id":95,"med_condition":"HEAD AND NECK CANCER"},{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"},{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47255,"protocol_no":"THB-P8-662","submission_no":"210271","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-16","protocol_title":"A PHASE 1B/2A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSES OF HIP-002 IN PATIENTS WITH KNEE OSTEOARTHRITIS","medConditionList":[{"med_condition_id":212,"med_condition":"OSTEOARTHRITIS OF THE KNEE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48385,"protocol_no":"18594","submission_no":"212935","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-26","protocol_title":"AN OPEN-LABEL, FIRST-IN-HUMAN, DOSE-ESCALTION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND MAXIMUM TOLERATED DOSE AND / OR RECOMMENDED PHASE II DOSE OF THE ATR INHIBIOTR BAY 1895344 IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS","medConditionList":[{"med_condition_id":691,"med_condition":"LYMPHOMA"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40701,"protocol_no":"I5Q-MC-CGAI (REGAIN)","submission_no":"188877","status_id":1,"start_date":"2016-01-22","end_date":null,"nol_date":"2015-11-26","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WTIH CHRONIC MIGRAINE","medConditionList":[{"med_condition_id":158,"med_condition":"CHRONIC MIGRAINE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39323,"protocol_no":"I5Q-MC-CGAM","submission_no":"184845","status_id":1,"start_date":"2016-03-03","end_date":null,"nol_date":"2015-06-25","protocol_title":"\"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 WITH A LONG-TERM OPEN-LABEL EXTENSION IN PATIENTS WITH CHRONIC CLUSTER HEADACHE.\"","medConditionList":[{"med_condition_id":628,"med_condition":"CHRONIC CLUSTER HEADACHE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29231,"protocol_no":"PRO00041158","submission_no":"171269","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-01-22","protocol_title":"TIMING OF INDOMETHACIN ADMINISTRATION FOR THE PREVENTION OF POST-ERCP PANCREATITIS","medConditionList":[{"med_condition_id":462,"med_condition":"PANCREATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42216,"protocol_no":"PBI-4050-CT-9-07","submission_no":"194296","status_id":1,"start_date":"2017-08-01","end_date":null,"nol_date":"2016-05-17","protocol_title":"A PHASE 2, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY & TOLERABILITY OF PBI-4050 AND ITS EFFECTS ON PANCREATIC AND PULMONARY FUNCTION IN CYSTIC FIBROSIS PATIENTS WITH ABNORMAL GLUCOSE TOLERANCE","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38750,"protocol_no":"SB-1-004-004","submission_no":"183036","status_id":1,"start_date":"2015-09-16","end_date":null,"nol_date":"2015-04-14","protocol_title":"A PHASE 1B/2A, MULTI-CENTER, OPEN-LABEL, 2-PERIOD, FIXED-SEQUENCE STUDY EVALUTATING THE EFFECT OF ESOMEPRAZOLE ON SYN-004 DEGRADATION OF CEFTRIAXONE IN HEALTHY ADULT SUBJECTS WITH A FUNCTIONING ILEOSTOMY","medConditionList":[{"med_condition_id":709,"med_condition":"ILEOSTOMY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40337,"protocol_no":"14374","submission_no":"187733","status_id":1,"start_date":"2016-02-22","end_date":null,"nol_date":"2015-10-02","protocol_title":"30-DAY, OPEN-LABEL, ACTIVE-CONTROLLED, RANDOMIZED STUDY OF THE SAFETY, EFFICACY AND THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF ORAL RIVAROXABAN IN YOUNG CHILDREN WITH VARIOUS MANIFESTATIONS OF VENOUS THROMBOSIS.  THE INTEGRATED PROTOCOL INCLUDES GLOBAL AMENDMENTS 1 AND 4 AND LOCAL CANADIAN AMENDMENTS 3 AND 5.","medConditionList":[{"med_condition_id":530,"med_condition":"VENOUS THROMBOSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38618,"protocol_no":"CL-CA-P01","submission_no":"182634","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-02","protocol_title":"PHASE III, RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL OF AUTOLOGOUS DEADRITIC CELLS LOADED WITH IRRADIATED AUTOLOGOUS TUMOR CELLS IN GM-CSF (DC-TC) VS. PERIPHERAL BLOOD MONONUCLEAR CELLS IN GM-CSF (MC) FOR THE TREATMENT OF PATIENTS WITH METASTATIC MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27160,"protocol_no":"0001","submission_no":"164984","status_id":1,"start_date":"2013-10-01","end_date":null,"nol_date":"2013-06-10","protocol_title":"ADJUNCTIVE VITAMIN D IN THE TREATMENT OF NON-REMITTED DEPRESSION","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40059,"protocol_no":"HELICOPTER1","submission_no":"186975","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-09-16","protocol_title":"HELIOX CARDIOPLEGIA TRIAL DURING CARDIAC SURGERY:  HELICOPTER 1","medConditionList":[{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46988,"protocol_no":"598","submission_no":"209385","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-06","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PEMBROLIZUMAB PLUS IPILIMUMAB VS PEMBROLILZUMAB PLUS PLACEBO IN PREVIOUSLY UNTREATED, STAGE IV, METASTATIC NON-SMALL CELL LUNG CANCER SUBJECTS WHOSE TUMORS ARE PD-L1 POSITIVE (TPS IS GREATER THAN OR EQUAL TO 50%)","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35497,"protocol_no":"PPS001","submission_no":"172565","status_id":1,"start_date":"2015-06-16","end_date":null,"nol_date":"2014-03-27","protocol_title":"A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED, PROOF-OF-CONCEPT, CROSSOVER CLINICAL TRIAL (RCT) OF VAPOURIZED CANNABIS IN ADULTS WITH PAINFUL OSTEOARTHRITIS OF THE KNEE","medConditionList":[{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28420,"protocol_no":"WIN-STOPCA_001","submission_no":"168505","status_id":1,"start_date":"2014-02-12","end_date":null,"nol_date":"2013-10-22","protocol_title":"NOVEL WINDOW OF OPPORTUNITY TRIAL TO EVALUATE THE IMPACT OF STATINS TO OPPOSE PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39244,"protocol_no":"LIGAND","submission_no":"184588","status_id":1,"start_date":"2016-04-11","end_date":null,"nol_date":"2015-06-17","protocol_title":"BARRIER-P TRIAL: BIOMARKERS OF ANDROGEN RESPONSE AND RESISTANCE IN EVOLUTION DURING A RISING PSA","medConditionList":[{"med_condition_id":213,"med_condition":"PROSTATE ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36665,"protocol_no":"PIN-PHO1201","submission_no":"176181","status_id":1,"start_date":"2015-06-11","end_date":null,"nol_date":"2014-07-24","protocol_title":"MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE III CLINICAL STUDY OF THE EFFICACY AND SAFETY OF PHOTODYNAMIC THERAPY USING PORFIMER SODIUM FOR INJECTION AS TREATMENT FOR UNRESECTABLE ADVANCED PERIHILAR CHOLANGIOCARCINOMA","medConditionList":[{"med_condition_id":545,"med_condition":"UNRESECTABLE ADVANCED PERIHILAR CHOLANGIOCARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40085,"protocol_no":"45446","submission_no":"187052","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-09-09","protocol_title":"THE USE OF FIBRIN SEALANT TO REDUCE POST-OPERATIVE PAIN IN CLEFT PALATE SURGERY","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44267,"protocol_no":"ZPL389/103","submission_no":"200570","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-19","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP DOSE RANGING STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ZPL-3893787-18 (3 MG, 10 MG AND 30  MG) CAPSULES ADMINISTERED FOR 12 WEEKS IN ADULT SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29375,"protocol_no":"NCT02033434","submission_no":"171656","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-19","protocol_title":"PRE-HOSPITAL CARE WITH INTRANASAL KETAMINE FOR TRANSPORT (PRECINKT): A PILOT STUDY FOR ANALGESIA IN THE ALPINE SKI-PATROL SETTING","medConditionList":[{"med_condition_id":467,"med_condition":"ANALGESIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36439,"protocol_no":"TP-434-010","submission_no":"175418","status_id":1,"start_date":"2015-03-10","end_date":null,"nol_date":"2014-07-17","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, PROSPECTIVE STUDY TO ASSESS THE EFFICACY AND SAFETY OF ERAVACYCLINE COMPARED WITH LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTIONS","medConditionList":[{"med_condition_id":264,"med_condition":"URINARY TRACT INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38515,"protocol_no":"HREBA.CC-14-0122","submission_no":"182269","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-03-03","protocol_title":"A PHASE 2 STUDY OF PALLIATIVE CHEMO-RADIOTHERAPY WITH CARBO-TAXOL IN NON-CURATIVE CANCER OF THE ESOPHAGUS","medConditionList":[{"med_condition_id":23,"med_condition":"BARRETT'S ESOPHAGUS (BE)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27346,"protocol_no":"GO28852","submission_no":"165510","status_id":2,"start_date":"2013-11-21","end_date":"2015-04-01","nol_date":"2013-07-05","protocol_title":"A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS).","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"},{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38309,"protocol_no":"GS-US-366-1160","submission_no":"181598","status_id":2,"start_date":"2015-07-15","end_date":"2017-11-23","nol_date":"2015-02-10","protocol_title":"A PHASE 3B, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE SWITCHING FROM A REGIMEN CONSISTING OF EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (EFV/FTC/TDF) FIXED DOSE COMBINATION (FDC) TO EMTRICITABINE/RILPIVIRINE/TENOFOVIR ALAFENAMIDE (FTC/RPV/TAF) FDC IN VIROLOGICALLY-SUPPRESSED, HIV-1 INFECTED SUBJECTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43616,"protocol_no":"KTE-C19-103","submission_no":"198663","status_id":1,"start_date":"2017-08-16","end_date":null,"nol_date":"2016-10-25","protocol_title":"A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF KTE C19 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL)","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35718,"protocol_no":"BBI503-205A","submission_no":"173217","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-28","protocol_title":"A PHASE II CLINICAL STUDY OF BBI503 IN ADULT PATIENTS WITH ADVANCED UROLOGIC MALIGNANCIES","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42421,"protocol_no":"TV48125-CNS-30050","submission_no":"194883","status_id":1,"start_date":"2016-06-08","end_date":null,"nol_date":"2016-06-23","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF 2 DOSE REGIMENS OF SUBCUTANEOUS ADMINISTRATION OF TEV-48125 VERSUS PLACEBO FOR THE PREVENTATIVE TREATMENT OF EPISODIC MIGRAINE","medConditionList":[{"med_condition_id":157,"med_condition":"MIGRAINE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44077,"protocol_no":"KTE-C19-102","submission_no":"200065","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-19","protocol_title":"A PHASE 2 MULTI-CENTER STUDY EVALUATING THE EFFICACY OF KTE-C19 IN SUBJECTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL)","medConditionList":[{"med_condition_id":424,"med_condition":"MANTLE CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27858,"protocol_no":"CMEK162B2301","submission_no":"166896","status_id":1,"start_date":"2015-03-16","end_date":null,"nol_date":"2013-08-23","protocol_title":"A PHASE III RANDOMIZED, 3-ARM, OPEN LABEL, MULTICENTER STUDY OF LGX818 PLUS MEK162 AND LGX818 MONOTHERAPY COMPARED WITH VEMURAFENIB IN PATIENTS WITH UNRESECTABLE OR METASTATIC BRAF V600 MUTANT MELANOMA","medConditionList":[{"med_condition_id":342,"med_condition":"MELANOMA WITH BRAF MUTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26936,"protocol_no":"AGAL19110 (MSC12711)","submission_no":"164266","status_id":2,"start_date":"2014-07-31","end_date":"2017-02-27","nol_date":"2013-05-27","protocol_title":"A CROSS-SECTIONAL STUDY OF RENAL FUNCTION IN TREATMENT-NAIVE, YOUNG MALE PATIENTS WITH FABRY DISEASE.","medConditionList":[{"med_condition_id":79,"med_condition":"FABRY DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48305,"protocol_no":"WA40169","submission_no":"213561","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-07","protocol_title":"OPEN-LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS","medConditionList":[{"med_condition_id":759,"med_condition":"NASAL POLYPOSIS"},{"med_condition_id":799,"med_condition":"RHINOSINUSITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44246,"protocol_no":"253-2015","submission_no":"200526","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-03","protocol_title":"DEFINING A PERSONALIZED HYPOXIC RADIATION TARGET THROUGH CORRELATION OF FUNCTIONAL F18-FAZA PET IMAGING TO PIMONIDAZOLE-STAINED 3D WHOLE-MOUNTED HISTOLOGICAL SPECIMEN","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41604,"protocol_no":"HALO-109-301","submission_no":"192020","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-03","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PEGYLATED RECOMBINANT HUMAN HYALURONIDASE (PEGPH20) IN COMBINATION WITH NAB-PACLITAXEL PLUS GEMCITABINE COMPARED WITH PLACEBO PLUS NAB-PACLITAXEL AND GEMCITABINE IN SUBJECTS WITH HYALURONAN-HIGH STAGE IV PREVIOUSLY UNTREATED PANCREATIC DUCTAL ADENOCARCINOMA","medConditionList":[{"med_condition_id":678,"med_condition":"PANCREATIC DUCTAL ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43578,"protocol_no":"IM101-603","submission_no":"198508","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-10-19","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS ABATACEPT IN ADULTS WITH ACTIVE PRIMARY SJOGRENS SYNDROME","medConditionList":[{"med_condition_id":664,"med_condition":"SJ√ñGREN'S SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44405,"protocol_no":"15-102-14","submission_no":"201173","status_id":1,"start_date":"2017-07-28","end_date":null,"nol_date":"2017-01-12","protocol_title":"A PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIAN¬øS CHOICE (TPC) IN PATIENTS WITH METASTATIC BREAST CANCER WHO HAVE STABLE BRAIN METASTASES AND HAVE BEEN PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A TAXANE, AND CAPECITABINE","medConditionList":[{"med_condition_id":27,"med_condition":"BRAIN METASTASES"},{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39054,"protocol_no":"MLN0002-3028","submission_no":"183974","status_id":1,"start_date":"2016-05-30","end_date":null,"nol_date":"2015-05-22","protocol_title":"\"AN OPEN-LABEL PHASE 3B STUDY TO ASSESS MUCOSAL HEALING IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE TREATED WITH VEDOLIZUMAB IV.\"","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39863,"protocol_no":"FOXY2015","submission_no":"186469","status_id":1,"start_date":"2015-10-05","end_date":null,"nol_date":"2015-08-18","protocol_title":"EFFICACIT√â ET TOL√âRABILIT√â DE LA F√âSOT√âRODINE CHEZ LES ENFANTS ATTEINTS DE VESSIE HYPERACTIVE: PHASE D¬øEXTENSION.","medConditionList":[{"med_condition_id":185,"med_condition":"OVERACTIVE BLADDER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39299,"protocol_no":"SL75.14","submission_no":"184751","status_id":1,"start_date":"2016-10-13","end_date":null,"nol_date":"2015-06-18","protocol_title":"\"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF STG320 SUBLINGUAL TABLETS OF HOUSE DUST MITE (HDM) ALLERGEN EXTRACTS IN ADULTS AND ADOLESCENTS WITH HDM-ASSOCIATED ALLERGIC RHINITIS.\"","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"},{"med_condition_id":475,"med_condition":"RHINITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27072,"protocol_no":"D4620C00001","submission_no":"164691","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-06-06","protocol_title":"A PHASE I, OPEN-LABEL, MULTICENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF ASCENDING DOSES OF AZD8186 IN PATIENTS WITH ADVANCED CASTRATE-RESISTANT PROSTATE CANCER (CRPC), SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNSCLC), TRIPLE NEGATIVE BREAST CANCER (TNBC) AND PATIENTS WITH KNOWN PTEN-DEFICIENT ADVANCED SOLID MALIGNANCIES, WITH EXPANSION TO ASSESS THE PHARMACODYNAMIC ACTIVITY OF AZD8186 WITHIN PROSPECTIVELY-VALIDATED PTEN DEFICIENT TUMOURS.","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"},{"med_condition_id":214,"med_condition":"PROSTATE CANCER"},{"med_condition_id":293,"med_condition":"MALIGNANT SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42205,"protocol_no":"0402","submission_no":"194266","status_id":1,"start_date":"2016-08-22","end_date":null,"nol_date":"2016-05-18","protocol_title":"A PHASE 1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MIRVETUXIMAB SORAVTANSINE (IMGN853) IN COMBINATION WITH BEVACIZUMAB, CARBOPLATIN OR PEGYLATED LIPOSOMAL DOXORUBICIN IN ADULTS WITH FOLATE RECEPTOR ALPHA POSITIVE ADVANCED EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CANCER, FALLOPIAN TUBE CANCER, OR ENDOMETRIAL CANCER","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":183,"med_condition":"OVARIAN CANCER"},{"med_condition_id":73,"med_condition":"ENDOMETRIAL CANCER"},{"med_condition_id":692,"med_condition":"PRIMARY PERITONEAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37638,"protocol_no":"CER21118","submission_no":"179221","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-11-27","protocol_title":"USE OF CANAKINUMAB FOR THE TREATMENT OF EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: PROTECTIVE EFFECT ON LOCOMOTOR MUSCLES","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41621,"protocol_no":"BIO 15-253","submission_no":"192070","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-08","protocol_title":"EFFICACY OF OPIOID-FREE ANESTHESIA IN REDUCING POSTOPERATIVE PAIN IN CHRONIC PAIN PATIENTS UNDERGOING SPINAL SURGERY: A PILOT STUDY.","medConditionList":[{"med_condition_id":88,"med_condition":"GENERALIZED MYASTHENIA GRAVIS (MG).\""}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43513,"protocol_no":"160822","submission_no":"198293","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-10-21","protocol_title":"A RANDOMIZED CONTROLLED TRIAL OF ADJUVANTED VACCINE VERSUS INACTIVATED INFLUENZA VACCINE IN HUTTERITE CHILDREN","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"},{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39849,"protocol_no":"PT010005","submission_no":"186427","status_id":1,"start_date":"2015-10-06","end_date":null,"nol_date":"2015-08-27","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF PT010 RELATIVE TO PT003 AND PT009 ON COPD EXACERBATIONS OVER A 52-WEEK TREATMENT PERIOD IN SUBJECTS WITH MODERATE TO VERY SEVERE COPD","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41959,"protocol_no":"THR-1442-C-450","submission_no":"193409","status_id":2,"start_date":"2016-05-04","end_date":"2017-04-26","nol_date":"2016-04-14","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF BEXAGLIFLOZIN TO PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27934,"protocol_no":"VD0001","submission_no":"167096","status_id":2,"start_date":"2013-11-22","end_date":"2016-01-01","nol_date":"2013-09-06","protocol_title":"VITAMIN D VS PLACEBO IN THE PREVENTION OF VIRAL-INDUCED EXACERBATIONS IN PRESCHOOL AGED CHILDREN WITH ASTHMA - A PILOT RCT.","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28036,"protocol_no":"R727-CL-1308","submission_no":"167403","status_id":2,"start_date":"2013-01-14","end_date":"2015-09-04","nol_date":"2013-09-13","protocol_title":"\"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN EVERY FOUR WEEKS TREATMENT REGIMEN OF ALIROCUMAB IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA.\"","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41863,"protocol_no":"1000052256","submission_no":"192986","status_id":1,"start_date":"2016-01-10","end_date":null,"nol_date":"2016-04-05","protocol_title":"A PILOT STUDY OF THE EFFECTIVENESS AND SAFETY OF LIDOCAINE INFUSIONS FOR THE MANAGEMENT OF CHRONIC PAIN IN CHILDREN.","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46024,"protocol_no":"CNTO1959PSA3001","submission_no":"204911","status_id":1,"start_date":"2017-08-25","end_date":null,"nol_date":"2017-06-27","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GUSELKUMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS INCLUDING THOSE PREVIOUSLY TREATED WITH BIOLOGIC ANTI-TNFA AGENT(S)","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38039,"protocol_no":"D5160C00008","submission_no":"180639","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-01-09","protocol_title":"AN OPEN-LABEL, NON-RANDOMISED, MULTICENTRE, COMPARATIVE, PHASE I STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZD9291 FOLLOWING A SINGLE ORAL DOSE TO PATIENTS WITH ADVANCED SOLID TUMOURS AND NORMAL HEPATIC FUNCTION OR MILD OR MODERATE HEPATIC IMPAIRMENT","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42858,"protocol_no":"1000049533","submission_no":"196435","status_id":1,"start_date":"2017-12-01","end_date":null,"nol_date":"2016-08-11","protocol_title":"MOLECULAR-FUNCTIONAL IMAGING OF HYPOXIA IN CHILDHOOD SARCOMAS: FEASABILITY STEPS TOWARD PERSONALIZED MEDICINE","medConditionList":[{"med_condition_id":686,"med_condition":"CHILDHOOD SARCOMAS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46278,"protocol_no":"IMCGP100-201","submission_no":"206988","status_id":1,"start_date":"2017-12-08","end_date":null,"nol_date":"2017-07-24","protocol_title":"A PHASE IB/II OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 IN COMBINATION WITH DURVALUMAB (MEDI4736) OR TREMELIMUMAB OR THE COMBINATION OF DURVALUMAB AND TREMELIMUMAB COMPARED TO IMCGP100 ALONE IN PATIENTS WITH ADVANCED MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42282,"protocol_no":"I8D-MC-AZET","submission_no":"194478","status_id":1,"start_date":"2016-07-21","end_date":null,"nol_date":"2016-05-26","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMER¬øS DISEASE DEMENTIA (THE DAYBREAK STUDY)","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41516,"protocol_no":"CLJN452X2201","submission_no":"191719","status_id":1,"start_date":"2016-11-25","end_date":null,"nol_date":"2016-02-25","protocol_title":"A MULTI-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS","medConditionList":[{"med_condition_id":209,"med_condition":"PRIMARY BILIARY CIRRHOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45676,"protocol_no":"M13-833","submission_no":"205141","status_id":1,"start_date":"2017-11-07","end_date":null,"nol_date":"2017-05-24","protocol_title":"A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF VENETOCLAX IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY MALIGNANCIES","medConditionList":[{"med_condition_id":474,"med_condition":"MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42717,"protocol_no":"ISS-P8-532 (16CDN-PRG02)","submission_no":"195932","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-07-07","protocol_title":"EFFECT OF PROGESTERONE 5, 10 AND 20 MG TABLETS (IBSA INSTITUT BIOCHIMIQUE SA) COMPARED TO PROGESTERONE 100 MG CAPSULES (PROMETRIUM) ON THE ENDOMETRIAL THICKNESS OF POST MENOPAUSAL WOMEN UNDER HORMONE THERAPY - A PROSPECTIVE, OPEN-LABEL, RANDOMIZED, FOUR ARM, PARALLEL-GROUP, PHASE II CLINICAL TRIAL","medConditionList":[{"med_condition_id":203,"med_condition":"POSTMENOPAUSAL"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47134,"protocol_no":"IMMU-132-05","submission_no":"209875","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-02","protocol_title":"AN INTERNATIONAL, MULTI-CENTER, OPEN-LABEL, RANDOMIZED, PHASE III TRIAL OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN CHOICE IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHO RECEIVED AT LEAST TWO PRIOR TREATMENTS","medConditionList":[{"med_condition_id":627,"med_condition":"BREAST CANCER METASTATIC TRIPLE NEGATIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41392,"protocol_no":"181-00","submission_no":"191383","status_id":1,"start_date":"2017-06-16","end_date":null,"nol_date":"2016-02-23","protocol_title":"A PHASE III RANDOMIZED OPEN-LABEL STUDY OF SINGLE AGENT PEMBROLIZUMAB VS PHYSICIANS' CHOICE OF SINGLE AGENT DOCETAXEL, PACLITAXEL, OR IRINOTECAN IN SUBJECTS WITH ADVANCED/METASTATIC ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS THAT HAVE PROGRESSED AFTER FIRST-LINE STANDARD THERAPY (KEYNOTE-181","medConditionList":[{"med_condition_id":352,"med_condition":"ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)"},{"med_condition_id":320,"med_condition":"ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45177,"protocol_no":"AUR-VCS-2016-01","submission_no":"203561","status_id":1,"start_date":"2017-08-25","end_date":null,"nol_date":"2017-04-06","protocol_title":"A RANDOMIZED, CONTROLLED DOUBLE BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF ORELVO (VOCLOSPORIN) (23.7 MG TWICE DAILY) WITH PLACEBO IN ACHIEVING RENAL RESPONSE IN SUBJECTS WITH ACTIVE LUPUS NEPHRITIS. PROTOCOL V1.0-01 DECEMBER 2016","medConditionList":[{"med_condition_id":681,"med_condition":"LUPUS NEPHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47761,"protocol_no":"2018-1211","submission_no":"211813","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-19","protocol_title":"IMPACT DE LA DEXM√âD√âTOMIDINE, DE LA K√âTAMINE ET DE LEUR COMBINAISON SUR LA CONSOMMATION POSTOP√âRATOIRE D'OPIAC√âS EN CHIRURGIE PULMONAIRE THORACOSCOPIQUE","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45048,"protocol_no":"TRU-17-001","submission_no":"203147","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-22","protocol_title":"A PHASE II PILOT STUDY OF NON-MYELOABLATIVE CONDITIONING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SICKLE CELL DISEASE WHO HAVE A MATCHED RELATED MAJOR ABO-INCOMPATIBLE DONOR (SICLE_MAID)","medConditionList":[{"med_condition_id":232,"med_condition":"SICKLE CELL DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37363,"protocol_no":"TV5600-CNS-20006","submission_no":"178380","status_id":2,"start_date":"2015-04-28","end_date":"2017-10-01","nol_date":"2014-10-24","protocol_title":"A MULTINATIONAL, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ONCE DAILY ORAL ADMINISTRATION OF LAQUINIMOD (0.6 OR 1.5 MG) IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37431,"protocol_no":"20130207","submission_no":"178611","status_id":1,"start_date":"2015-04-16","end_date":null,"nol_date":"2014-10-31","protocol_title":"A MULTICENTER DOUBLE-BLIND, RANDOMIZED CONTROLLED STUDY OF ETANERCEPT AND METHOXTREXATE IN COMBINATION OR AS MONOTHERAPY IN SUBJECTS WITH PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27413,"protocol_no":"001-2013","submission_no":"165648","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-07-05","protocol_title":"THE EVALUATION OF THE EFFECTIVENESS OF INHALED BUDESONIDE FOR NON-VENTILATED INFANTS AT HIGH RISK OF BRONCHOPULMONARY DYSPLASIA: THE I-BUD PILOT STUDY","medConditionList":[{"med_condition_id":335,"med_condition":"BRONCHOPULMONARY DYSPLASIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42142,"protocol_no":"2012-PT023","submission_no":"194035","status_id":1,"start_date":"2016-05-06","end_date":null,"nol_date":"2016-05-06","protocol_title":"A PHASE III DOUBLE-BLINDED, PLACEBO CONTROLLED STUDY OF XILONIX(TM) FOR IMPROVING SURVIVAL IN METASTATIC COLORECTAL CANCER","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40964,"protocol_no":"GS-US-380-1844","submission_no":"189791","status_id":1,"start_date":"2016-04-04","end_date":null,"nol_date":"2015-12-17","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM A REGIMEN OF DOLUTEGRAVIR AND ABC/3TC, OR A FIXED DOSE COMBINATION (FDC) OF ABC/DTG/3TC TO A FDC OF GS 9883/F/TAF IN HIV 1 INFECTED SUBJECTS WHO ARE VIROLOGICALLY SUPPRESSED","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43626,"protocol_no":"PT009003-01","submission_no":"198683","status_id":2,"start_date":"2017-04-05","end_date":"2018-04-04","nol_date":"2016-10-24","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PT009 COMPARED TO PT005 ON COPD EXACERBATIONS OVER A 52-WEEK TREATMENT PERIOD IN SUBJECTS WITH MODERATE TO VERY SEVERE COPD","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37727,"protocol_no":"1000047212","submission_no":"179572","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-05","protocol_title":"A PHASE I STUDY OF SORAFENIB AND CYCLOPHOSPHAMIDE/TOPOTECAN IN PATIENTS WITH RELAPSED AND REFRACTORY NEUROBLASTOMA. (NANT 2013-02 VERSION  9-16-2014)","medConditionList":[{"med_condition_id":172,"med_condition":"NEUROBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28746,"protocol_no":"GENA-15","submission_no":"169645","status_id":1,"start_date":"2014-05-29","end_date":null,"nol_date":"2013-11-27","protocol_title":"EXTENSION STUDY FOR PATIENTS WHO COMPLETED GENA-05 (NUPROTECT) -  TO INVESTIGATE IMMUNOGENICITY, EFFICACY AND SAFETY OF TREATMENT WITH HUMAN-CL RHFVIII","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38001,"protocol_no":"14-8509","submission_no":"180472","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-03","protocol_title":"DIRECT-APPLICATION OF TRANEXAMIC ACID  FOR HIP FRACTURE: A RANDOMIZED  CONTROLLED TRIAL","medConditionList":[{"med_condition_id":607,"med_condition":"HIP FRACTURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43136,"protocol_no":"V920-013","submission_no":"197279","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-08-30","protocol_title":"A MULTICENTER STUDY OF THE IMMUNOGENICITY OF RECOMBINANT VESICULAR STOMATITIS VACCINE FOR EBOLA-ZAIRE (RVSVAG-ZEBOV-GP) FOR PRE-EXPOSURE PROPHYLAXIS (PREP) IN INDIVIDUALS AT POTENTIAL OCCUPATIONAL RISK FOR EBOLA VIRUS EXPOSURE","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28251,"protocol_no":"TRC112765","submission_no":"168043","status_id":1,"start_date":"2014-03-10","end_date":null,"nol_date":"2013-10-02","protocol_title":"A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED, TWO-PHASE, SEQUENTIAL COHORT, DOSE FINDING STUDY TO ASSESS THE SAFETY AND EFFICACY OF AN ORAL THROMBOPOIETIN RECEPTOR AGONIST, ELTROMBOPAG (SB-497115-GR), ADMINISTERED TO PATIENTS WITH SOLID TUMORS RECEIVING GEMCITABINE MONOTHERAPY OR THE COMBINATION OF GEMCITABINE PLUS CARBOPLATIN OR CISPLATIN","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42911,"protocol_no":"UHNTID004","submission_no":"196609","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-08-05","protocol_title":"A RANDOMIZED CONTROLLED TRIAL COMPARING HIGH-DOSE VS. STANDARD INFLUENZA VACCINE IN ADULT SOLID ORGAN TRANSPLANT RECIPIENTS","medConditionList":[{"med_condition_id":714,"med_condition":"ORGAN TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44957,"protocol_no":"B7461006","submission_no":"202379","status_id":1,"start_date":"2017-07-18","end_date":null,"nol_date":"2017-03-22","protocol_title":"A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36919,"protocol_no":"D2210C00008","submission_no":"176962","status_id":1,"start_date":"2015-09-15","end_date":null,"nol_date":"2014-09-04","protocol_title":"A 52-WEEK, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRALOKINUMAB IN ADULTS AND ADOLESCENTS WITH ASTHMA INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROID AND LONG-ACTING B2-AGENT","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47611,"protocol_no":"LP0162-1339","submission_no":"211374","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-12","protocol_title":"TRALOKINUMAB IN COMBINATION WITH TOPICAL CORTICOSTEROIDS FOR MODERATE TO SEVERE ATOPIC DERMATITIS (ECZTRA 3)","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44315,"protocol_no":"MUHC 15-312","submission_no":"200750","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-23","protocol_title":"OPIOID-FREE ANALGESIA FOR LAPAROSCOPIC COLORECTAL SURGERY WITHIN AN ENHANCED RECOVERY PROGRAM: A RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":553,"med_condition":"ANASTHESIA"},{"med_condition_id":827,"med_condition":"SURGERY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43184,"protocol_no":"16804","submission_no":"197436","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-08-26","protocol_title":"AN OPEN-LABEL PHASE I DOSE-ESCALATION STUDY TO CHARACTERIZE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND MAXIMUM TOLERATED DOSE OF ORAL BAY 1161909 IN COMBINATION WITH WEEKLY INTRAVENOUS PACLITAXEL GIVEN IN AN INTERMITTENT DOSING SCHEDULE IN SUBJECTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":665,"med_condition":"ADVANCED MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38457,"protocol_no":"CW13-0251","submission_no":"182085","status_id":1,"start_date":"2013-11-26","end_date":null,"nol_date":"2015-03-04","protocol_title":"5-HT3 ANTAGONISTS (ANTIEMETICS) AND CARDIAC SAFETY","medConditionList":[{"med_condition_id":302,"med_condition":"NAUSEA AND VOMITING"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45249,"protocol_no":"ASN002AD-101","submission_no":"203783","status_id":2,"start_date":"2017-09-20","end_date":"2017-11-21","nol_date":"2017-04-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL, MULTIPLE-DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF ASN002 IN SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43839,"protocol_no":"TPI-ALV-201","submission_no":"199350","status_id":1,"start_date":"2017-05-30","end_date":null,"nol_date":"2016-11-21","protocol_title":"A PHASE 2, RANDOMIZED, BIOMARKER-DRIVEN, CLINICAL STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41060,"protocol_no":"201810","submission_no":"190117","status_id":1,"start_date":"2016-08-25","end_date":null,"nol_date":"2016-01-06","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO COMPARE CESSATION VERSUS CONTINUATION OF LONG-TERM MEPOLIZUMAB TREATMENT IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA (201810)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43487,"protocol_no":"TINI","submission_no":"198230","status_id":1,"start_date":"2017-09-22","end_date":null,"nol_date":"2016-10-20","protocol_title":"TOTAL THERAPY FOR INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)","medConditionList":[{"med_condition_id":148,"med_condition":"LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40662,"protocol_no":"CLXH254X2101","submission_no":"188756","status_id":1,"start_date":"2016-11-08","end_date":null,"nol_date":"2015-11-19","protocol_title":"A PHASE I DOSE FINDING STUDY OF ORAL LXH254 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS HARBORING MAPK PATHWAY ALTERATIONS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44215,"protocol_no":"TRANSCON HGH CT-301","submission_no":"200420","status_id":1,"start_date":"2017-06-14","end_date":null,"nol_date":"2016-12-20","protocol_title":"A MULTICENTER, PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, PARALLEL-GROUP TRIAL INVESTIGATING THE SAFETY, TOLERABILITY, AND EFFICACY OF TRANSCON HGH ADMINISTERED ONCE A WEEK VERSUS STANDARD DAILY HGH REPLACEMENT THERAPY OVER 52 WEEKS","medConditionList":[{"med_condition_id":94,"med_condition":"GROWTH HORMONE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46368,"protocol_no":"RVT-501-2003","submission_no":"207274","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-02","protocol_title":"OPEN LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RVT-501 IN PEDIATRIC PATIENTS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40567,"protocol_no":"ONT-380-206","submission_no":"188499","status_id":1,"start_date":"2017-03-08","end_date":null,"nol_date":"2015-11-09","protocol_title":"PHASE 2 RANDOMIZED, DOUBLE-BLINDED, CONTROLLED STUDY OF ONT-380 VS. PLACEBO IN COMBINATION WITH CAPECITABINE AND TRASTUZUMAB IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CARCINOMA","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40467,"protocol_no":"ISIS 703802-CS1","submission_no":"188229","status_id":1,"start_date":"2015-11-24","end_date":null,"nol_date":"2015-10-29","protocol_title":"A PLACEBO-CONTROLLED, DOSE-ESCALATION STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE DOSES OF ISIS 703802, TARGETING ANGPTL3, ADMINISTERED SUBCUTANEOUSLY TO HEALTHY VOLUNTEERS WITH ELEVATED TRIGLYCERIDES AND SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA","medConditionList":[{"med_condition_id":83,"med_condition":"FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44641,"protocol_no":"PRO 66218","submission_no":"201939","status_id":1,"start_date":"2017-03-28","end_date":null,"nol_date":"2017-02-10","protocol_title":"A PROSPECTIVE, MULTI-CENTER, RANDOMIZED CONTROLLED TRIAL COMPARING FECAL MICROBIOTA TRANSPLANTATION (FMT) TO PLACEBO IN THE TREATMENT OF MILD TO MODERATE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39427,"protocol_no":"201956","submission_no":"185211","status_id":1,"start_date":"2015-10-13","end_date":null,"nol_date":"2015-07-09","protocol_title":"A LONG-TERM ACCESS PROGRAMME FOR SUBJECTS WITH SEVERE ASTHMA WHO PARTICIPATED IN A GSK-SPONSORED MEPOLIZUMAB CLINICAL STUDY","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45457,"protocol_no":"IOMAB-01","submission_no":"204460","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-05","protocol_title":"A MULTICENTER, PIVOTAL PHASE 3 STUDY OF IOMAB-B PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION VERSUS CONVENTIONAL CARE IN OLDER SUBJECTS WITH ACTIVE, RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43790,"protocol_no":"ZX008-1503","submission_no":"199155","status_id":1,"start_date":"2017-05-10","end_date":null,"nol_date":"2016-11-08","protocol_title":"AN OPEN-LABEL EXTENSION TRIAL TO ASSESS THE LONG-TERM SAFETY OF ZX008 (FENFLURAMINE HYDROCHLORIDE) ORAL SOLUTION AS AN ADJUNCTIVE THERAPY IN CHILDREN AND YOUNG ADULTS WITH DRAVET SYNDROME","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44667,"protocol_no":"H16-01551","submission_no":"202016","status_id":1,"start_date":"2017-03-16","end_date":null,"nol_date":"2017-02-14","protocol_title":"18F-DCFPYL POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET/CT) FOR ASSESSMENT OF RECURRENT PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46951,"protocol_no":"MM-121-02-02-10","submission_no":"209285","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-12","protocol_title":"SHERBOC: A DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF SERIBANTUMAB PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HEREGULIN POSITIVE (HRG+), HER2 NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR SYSTEMIC THERAPY","medConditionList":[{"med_condition_id":527,"med_condition":"BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48232,"protocol_no":"SHULTZ-01","submission_no":"213362","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-16","protocol_title":"A PROSPECTIVE STUDY OF HYPOXIA IMAGING IN PATIENTS WITH SOFT TISSUE SARCOMA USING POSITRON EMISSION TOMOGRAPHY (PET) WITH 18F-FLUOROAZOMYCIN ARABINOSIDE (18F-FAZA) IN COMBINATION WITH MRI","medConditionList":[{"med_condition_id":237,"med_condition":"SOFT TISSUE SARCOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35862,"protocol_no":"191622-137","submission_no":"173656","status_id":1,"start_date":"2014-11-13","end_date":null,"nol_date":"2014-05-07","protocol_title":"BOTOX IN THE TREATMENT OF URINARY INCONTINENCE DUE TO OVERACTIVE BLADDER IN PATIENTS 12 TO 17 YEARS OF AGE","medConditionList":[{"med_condition_id":405,"med_condition":"URINARY INCONTINENCE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47015,"protocol_no":"ISIS 416858-CS5","submission_no":"209473","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-16","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE DOSES OF ISIS 416858 (IONIS-FXIRX AN ANTISENSE INHIBITOR OF FACTOR XI), ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS.","medConditionList":[{"med_condition_id":220,"med_condition":"RENAL FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46297,"protocol_no":"TPU-TAS-120-101","submission_no":"207048","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-18","protocol_title":"A DOSE-FINDING PHASE 1 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH OR WITHOUT FIBROBLAST GROWTH FACTOR/RECEPTOR (FGF/FGFR)-RELATED ABNORMALITIES FOLLOWED BY A PHASE 2 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS WITH FGF/FGFR-RELATED ABNORMALITIES","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38911,"protocol_no":"RIVAROXACS2002 (IMPACT 17896)","submission_no":"183558","status_id":2,"start_date":"2015-08-27","end_date":"2017-01-06","nol_date":"2015-05-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO COMPARE THE SAFETY OF RIVAROXABAN VERSUS ACETYLSALICYLIC ACID IN ADDITION TO EITHER CLOPIDOGREL OR TICAGRELOR THERAPY IN SUBJECTS WITH ACUTE CORONARY SYNDROME","medConditionList":[{"med_condition_id":499,"med_condition":"ACUTE CORONARY SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28153,"protocol_no":"H12-03120","submission_no":"167776","status_id":1,"start_date":"2015-01-30","end_date":null,"nol_date":"2013-09-26","protocol_title":"\"18F-SODIUM FLUORIDE PET IMAGING AS A REPLACEMENT FOR BONE SCINTIGRAPHY.\"","medConditionList":[{"med_condition_id":375,"med_condition":"BONE SCINTIGRAPHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41327,"protocol_no":"MN30035","submission_no":"191195","status_id":1,"start_date":"2017-02-17","end_date":null,"nol_date":"2016-02-10","protocol_title":"AN OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE HAD A SUBOPTIMAL RESPONSE TO AN ADEQUATE COURSE OF DISEASE-MODIFYING TREATMENT","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27478,"protocol_no":"PRM-151G-101","submission_no":"165855","status_id":3,"start_date":"2013-10-08","end_date":null,"nol_date":"2013-07-19","protocol_title":"A PHASE 2, OPEN-LABEL, PROSPECTIVE STUDY OF PRM-151 IN SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (POST-PV MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MF (POST-ET MF)","medConditionList":[{"med_condition_id":249,"med_condition":"THROMBOCYTHEMIA MYELOFIBROSIS"},{"med_condition_id":211,"med_condition":"PRIMARY MYELOFIBROSIS (PMF)"},{"med_condition_id":199,"med_condition":"POLYCYTHEMIA VERA (PV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35367,"protocol_no":"GS-US-354-0101","submission_no":"172109","status_id":1,"start_date":"2014-07-10","end_date":null,"nol_date":"2014-03-10","protocol_title":"A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MOMELOTINIB IN SUBJECTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA","medConditionList":[{"med_condition_id":199,"med_condition":"POLYCYTHEMIA VERA (PV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37733,"protocol_no":"M14-868","submission_no":"179591","status_id":2,"start_date":"2015-12-07","end_date":"2016-12-22","nol_date":"2014-12-04","protocol_title":"A RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CO-ADMINISTRATION OF ABT-493 AND ABT-530 WITH AND WITHOUT RBV IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR GENOTYPE 3 INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"},{"med_condition_id":107,"med_condition":"HEPATITIS C VIRUS GENOTYPE 2 OR 3"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46567,"protocol_no":"PIMOZIDE2_ALS-002","submission_no":"207985","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-25","protocol_title":"A PHASE II RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, MULTI-CENTRE CLINICAL TRIAL OF PIMOZIDE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40750,"protocol_no":"GS-US-367-1171","submission_no":"189006","status_id":2,"start_date":"2015-12-18","end_date":"2017-05-24","nol_date":"2015-11-27","protocol_title":"A PHASE 3, GLOBAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/GS-9857 FIXED-DOSE COMBINATION FOR 12 WEEKS IN DIRECT-ACTING ANTIVIRAL-EXPERIENCED SUBJECTS WITH CHRONIC HCV INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26816,"protocol_no":"TRX-237-007","submission_no":"163900","status_id":2,"start_date":"2013-05-30","end_date":"2016-02-10","nol_date":"2013-05-10","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP, 12-MONTH SAFETY AND EFFICACY TRIAL OF LEUCO-METHYLTHIONINIUM BIS(HYDROMETHANESULFONATE) IN SUBJECTS WITH BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA (BVFTD)","medConditionList":[{"med_condition_id":313,"med_condition":"BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA (BVFTD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38755,"protocol_no":"COG AHOD1331","submission_no":"183057","status_id":1,"start_date":"2015-06-29","end_date":null,"nol_date":"2015-04-17","protocol_title":"\"A RANDOMIZED PHASE III STUDY OF BRENTUXIMAB VEDOTIN (SGN-35, IND#117117) FOR NEWLY DIAGNOSED HIGH-RISK CLASSICAL HODGKIN LYMPHOMA (CHL) IN CHILDREN AND ADOLESCENTS.\"","medConditionList":[{"med_condition_id":481,"med_condition":"HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42950,"protocol_no":"D3250C00040","submission_no":"196739","status_id":1,"start_date":"2017-05-02","end_date":null,"nol_date":"2016-08-09","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, PLACEBO-CONTROLLED MULTI-CENTRE STUDY TO EVALUATE THE EFFECT OF BENRALIZUMAB ON ALLERGEN-INDUCED INFLAMMATION IN MILD, ATOPIC ASTHMATICS","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36579,"protocol_no":"12.001","submission_no":"175816","status_id":1,"start_date":"2016-05-01","end_date":null,"nol_date":"2014-08-18","protocol_title":"CANNABIDIOL AND COCAINE DEPENDENCE","medConditionList":[{"med_condition_id":68,"med_condition":"DRUG ADDICTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44466,"protocol_no":"BBI-DSP7888-101","submission_no":"201409","status_id":1,"start_date":"2017-10-03","end_date":null,"nol_date":"2017-01-20","protocol_title":"A PHASE 1 CLINICAL STUDY OF DSP-7888 DOSING EMULSION IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":665,"med_condition":"ADVANCED MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47032,"protocol_no":"OLE-NLRC4/XIAP.2016.001","submission_no":"209539","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-27","protocol_title":"OPEN-LABEL EXTENSION STUDY WITH TADEKINIG ALFA (R-HIL-18BP) TO MONITOR SAFETY AND TOLERABILITY IN PATIENTS WITH IL-18 DRIVEN MONOGENIC AUTOINFLAMMATORY CONDITIONS: NLRC4 MUTATION AND XIAP DEFICIENCY","medConditionList":[{"med_condition_id":811,"med_condition":"IL-18 DRIVEN MONOGENIC AUTOINFLAMMATORY CONDITIONS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45132,"protocol_no":"PESCO","submission_no":"203378","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-30","protocol_title":"A PHASE 2 STUDY OF PEMBROLIZUMAB (MK-3475), DPX-SURVIVAC VACCINE AND LOW DOSE OF CYCLOPHOSPHAMIDE COMBINATION IN PATIENTS WITH ADVANCED OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCER","medConditionList":[{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"},{"med_condition_id":183,"med_condition":"OVARIAN CANCER"},{"med_condition_id":692,"med_condition":"PRIMARY PERITONEAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36325,"protocol_no":"CA209-168","submission_no":"175072","status_id":1,"start_date":"2015-04-13","end_date":null,"nol_date":"2014-06-27","protocol_title":"EXPANDED ACCESS PROGRAM WITH NIVOLUMAB FOR SUBJECTS WITH HISTOLOGICALLY CONFIRMED STAGE III (UNRESECTABLE) OR STAGE IV MELANOMA PROGRESSING POST PRIOR SYSTEMIC TREATMENT CONTAINING AN ANTI-CTLA-4 MONOCLONAL ANTIBODY","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46042,"protocol_no":"B7601017","submission_no":"206170","status_id":2,"start_date":null,"end_date":"2018-03-12","nol_date":"2017-06-20","protocol_title":"A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON¬øS DISEASE","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43624,"protocol_no":"M16-244","submission_no":"198680","status_id":1,"start_date":"2017-04-17","end_date":null,"nol_date":"2016-11-10","protocol_title":"A PHASE 2, SINGLE-ARM, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE SAFETY WITH RISANKIZUMAB IN PSORIATIC ARTHRITIS SUBJECTS WHO HAVE COMPLETED WEEK 24 VISIT OF STUDY 1311.5","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46637,"protocol_no":"NP39487","submission_no":"208205","status_id":1,"start_date":"2018-04-03","end_date":null,"nol_date":"2017-09-07","protocol_title":"OPEN-LABEL, DOSE-FINDING PHASE LB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF R06870810 AND ATEZOLIZUMAB (PD-L1 ANTIBODY) IN PATIENTS WITH ADVANCED OVARIAN CANCER OR TRIPLE NEGATIVE BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"},{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47693,"protocol_no":"3030-202-002","submission_no":"211584","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-19","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ELUXADOLINE IN PEDIATRIC PATIENTS (AGE 12 TO 17 YEARS) WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D).","medConditionList":[{"med_condition_id":576,"med_condition":"IRRITABLE BOWEL SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42934,"protocol_no":"BET115521","submission_no":"196705","status_id":1,"start_date":"2017-08-15","end_date":null,"nol_date":"2016-08-10","protocol_title":"A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF GSK525762 IN SUBJECTS WITH NUT MIDLINE CARCINOMA (NMC) AND OTHER CANCERS.","medConditionList":[{"med_condition_id":749,"med_condition":"NUT MIDLINE CARCINOMA (NMC)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46544,"protocol_no":"PROSTEP_001","submission_no":"207913","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-16","protocol_title":"IMAGING AND GENOTYPING METASTATIC PROSTATE CANCER INTERPATIENT HETEROGENEITY AND POLYCLONALITY USING DUAL-TRACER PET/CT","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27411,"protocol_no":"WA28119","submission_no":"165656","status_id":1,"start_date":"2013-07-26","end_date":null,"nol_date":"2013-07-10","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS","medConditionList":[{"med_condition_id":330,"med_condition":"GIANT CELL ARTERITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36696,"protocol_no":"SPL7013-017","submission_no":"176276","status_id":2,"start_date":"2014-09-26","end_date":"2017-01-18","nol_date":"2014-08-06","protocol_title":"A PHASE 3, DOUBLE-BLIND, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF SPL7013 GEL (VIVAGEL¬Æ) TO PREVENT THE RECURRENCE OF BACTERIAL VAGINOSIS","medConditionList":[{"med_condition_id":546,"med_condition":"BACTERIAL VAGINOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41632,"protocol_no":"ACE-536-B-THAL-001","submission_no":"192113","status_id":1,"start_date":"2016-06-29","end_date":null,"nol_date":"2016-03-11","protocol_title":"A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN ADULTS WHO REQUIRE REGULAR RED BLOOD CELL TRANSFUSIONS DUE TO BETA ()-THALASSEMIA","medConditionList":[{"med_condition_id":534,"med_condition":"THALASSEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41862,"protocol_no":"M14-031","submission_no":"192982","status_id":1,"start_date":"2017-11-30","end_date":null,"nol_date":"2016-03-30","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, STUDY OF BORTEZOMIB AND DEXAMETHASONE IN COMBINATION WITH EITHER ABT-199 OR PLACEBO IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO ARE SENSITIVE OR NA√èVE TO PROTEASOME INHIBITORS","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48493,"protocol_no":"RPI-T-087-001","submission_no":"214046","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-29","protocol_title":"\"A PHASE 1, OPEN-LABEL, NON-RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF [TC-99M]-RPI-T-087 INJECTION  AS AN IMAGING MARKER FOR COX-2 IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE COMPARED TO HEALTHY VOLUNTEERS.\"","medConditionList":[{"med_condition_id":212,"med_condition":"OSTEOARTHRITIS OF THE KNEE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47916,"protocol_no":"PPP005-PH2-01","submission_no":"212416","status_id":1,"start_date":"2018-02-04","end_date":null,"nol_date":"2018-01-26","protocol_title":"SAFETY AND EFFICACY OF MEDICAL CANNABIS OIL IN THE TREATMENT OF PATIENTS WITH CHRONIC PAIN:  A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY, FOLLOWED BY AN OPEN-LABEL EXTENSION PHASE","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43257,"protocol_no":"MDV3800-01 / TRIO031","submission_no":"197627","status_id":1,"start_date":"2017-01-06","end_date":null,"nol_date":"2016-09-14","protocol_title":"A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF RENAL IMPAIRMENT","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37381,"protocol_no":"BP29392","submission_no":"178438","status_id":1,"start_date":"2015-07-30","end_date":null,"nol_date":"2014-10-29","protocol_title":"AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST) IN COMBINATION WITH MPDL3280A (ANTI-PD-L1) IN PATIENTS WITH LOCALLY ADVANCED AND/OR SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28654,"protocol_no":"20120332","submission_no":"169319","status_id":1,"start_date":"2014-02-14","end_date":null,"nol_date":"2013-11-22","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AMG 145, COMPARED WITH EZETIMIBE, IN HYPERCHOLESTEROLEMIC SUBJECTS UNABLE TO TOLERATE AN EFFECTIVE DOSE OF A HMG-COA REDUCTASE INHIBITOR DUE TO MUSCLE RELATED SIDE EFFECTS","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43900,"protocol_no":"GS-US-419-4016","submission_no":"199524","status_id":1,"start_date":"2017-09-26","end_date":null,"nol_date":"2016-11-17","protocol_title":"A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF FILGOTINIB IN THE TREATMENT OF PERIANAL FISTULIZING CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37942,"protocol_no":"2014-01","submission_no":"180200","status_id":1,"start_date":"2015-04-01","end_date":null,"nol_date":"2014-12-22","protocol_title":"A PHASE 2B PROSPECTIVE. RANDOMIZED. DOUBLE-BLINDED. PLACEBO-CONTROLLED CLINICAL STUDY DEMONSTRATING THE EFFICACY AND SAFETY OF REBIOTIX RBX2660 (MICROBIOTA SUSPENSION) FOR THE TREATMENT OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42238,"protocol_no":"I7X-MC-LLCF","submission_no":"194383","status_id":1,"start_date":"2016-07-08","end_date":null,"nol_date":"2016-05-19","protocol_title":"EFFECT OF LY3202626 ON ALZHEIMER'S DISEASE PROGRESSION AS MEASURED BY CEREBRAL 18F-AV-1451 TAU-PET IN MILD ALZHEIMER'S DISEASE DEMENTIA","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44431,"protocol_no":"CPDR001F2301","submission_no":"201273","status_id":1,"start_date":"2017-09-13","end_date":null,"nol_date":"2017-01-13","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY COMPARING THE COMBINATION OF PDR001, DABRAFENIB AND TRAMETINIB VERSUS PLACEBO, DABRAFENIB AND TRAMETINIB IN PREVIOUSLY UNTREATED PATIENTS WITH UNRESECTABLE OR METASTATIC BRAF V600 MUTANT MELANOMA","medConditionList":[{"med_condition_id":342,"med_condition":"MELANOMA WITH BRAF MUTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42849,"protocol_no":"20160047-01H","submission_no":"196394","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-07-27","protocol_title":"THE SAVER PILOT RANDOMIZED TRIAL: STATINS FOR VENOUS EVENT REDUCTION IN PATIENTS WITH VENOUS THROMBOEMBOLISM: A PILOT STUDY ASSESSING FEASIBILITY OF A RANDOMIZED TRIAL DESIGNED TO EVALUATE IF GENERIC ROSUVASTATIN REDUCES THE RISK OF RECURRENT VTE IN PATIENTS WITH SYMPTOMATIC MAJOR VTE.","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40860,"protocol_no":"20130232","submission_no":"189503","status_id":1,"start_date":"2016-06-29","end_date":null,"nol_date":"2015-12-11","protocol_title":"A PHASE 1B/3 MULTICENTER, RANDOMIZED, OPEN-LABEL TRIAL OF TALIMOGENE LAHERPARAPVEC IN COMBINATION WITH PEMBROLIZUMAB FOR THE TREATMENT OF SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK","medConditionList":[{"med_condition_id":95,"med_condition":"HEAD AND NECK CANCER"},{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28121,"protocol_no":"A5481023","submission_no":"167662","status_id":1,"start_date":"2015-04-27","end_date":null,"nol_date":"2013-09-16","protocol_title":"MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX ) WITH OR WITHOUT PD 0332991 (PALBOCICLIB)   GOSERELIN IN WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY.","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39661,"protocol_no":"SP0047 / 14-ID-003","submission_no":"185988","status_id":1,"start_date":"2015-09-01","end_date":null,"nol_date":"2015-07-31","protocol_title":"A SINGLE-CENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE THE RELATIVE EFFICACY AND SAFETY OF IMMUNOTHERAPY WITH SUBLIVAC FIX PHLEUM PROTENSE COMPARED TO PLACEBO IN GRASS POLLEN-ALLERGIC-PATIENTS WITH IGE-MEDIATED SEASONAL ALLERGIC RHINOCONJUNCTIVITIS.\"","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44568,"protocol_no":"CRAD001M2X02B","submission_no":"201749","status_id":1,"start_date":"2017-06-21","end_date":null,"nol_date":"2017-02-02","protocol_title":"AN OPEN-LABEL, MULTI-CENTER LONG-TERM SAFETY ROLL-OVER STUDY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) AND REFRACTORY SEIZURES WHO ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH EVEROLIMUS AFTER COMPLETION OF STUDY CRAD001M2304 (EXIST-3)","medConditionList":[{"med_condition_id":229,"med_condition":"SEIZURES"},{"med_condition_id":309,"med_condition":"TUBEROUS SCLEROSIS COMPLEX (TSC)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37188,"protocol_no":"NRG-GI001","submission_no":"177797","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-09-19","protocol_title":"RANDOMIZED PHASE III STUDY OF FOCAL RADIATION THERAPY FOR UNRESECTABLE, LOCALIZED INTRAHEPATIC CHOLANGIOCARCINOMA","medConditionList":[{"med_condition_id":587,"med_condition":"CHOLANGIOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37936,"protocol_no":"MDV3100-13","submission_no":"180184","status_id":1,"start_date":"2015-05-07","end_date":null,"nol_date":"2014-12-23","protocol_title":"A PHASE 3, RANDOMIZED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE, ENZALUTAMIDE MONOTHERAPY, AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGH-RISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39424,"protocol_no":"CCFZ533X2204","submission_no":"185196","status_id":1,"start_date":"2016-08-02","end_date":null,"nol_date":"2015-07-08","protocol_title":"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO PRELIMININARY EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF CFZ533 IN PATIENTS WITH MODERATE TO SEVERE MYASTHENIA GRAVIS","medConditionList":[{"med_condition_id":163,"med_condition":"MYASTHENIA GRAVIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39256,"protocol_no":"201025-002","submission_no":"184620","status_id":2,"start_date":"2016-07-11","end_date":"2017-06-06","nol_date":"2015-06-18","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, EVALUATING SAFETY AND EFFICACY OF LIRIS¬Æ 400 MG IN FEMALES WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME","medConditionList":[{"med_condition_id":132,"med_condition":"INTERSTITIAL CYSTITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37289,"protocol_no":"CIAFS-1","submission_no":"178165","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-24","protocol_title":"COLCHICINE IN ATRIAL FIBRILLATION TO PREVENT STROKE FEASIBILITY","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27593,"protocol_no":"GB28689","submission_no":"166219","status_id":3,"start_date":"2013-09-23","end_date":null,"nol_date":"2013-08-02","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA WHO ARE ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36398,"protocol_no":"ALK5461-208","submission_no":"175303","status_id":2,"start_date":"2015-07-23","end_date":"2017-11-20","nol_date":"2014-07-02","protocol_title":"A PHASE 3 MULTICENTER STUDY OF THE LONG-TERM SAFETY AND TOLERABILITY OF ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADULTS WHO HAVE AN INADEQUATE RESPONSE TO ANTIDEPRESSANT THERAPY (THE FORWARD-2 STUDY)","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28403,"protocol_no":"PSSC-001","submission_no":"168457","status_id":2,"start_date":"2014-03-18","end_date":"2014-12-15","nol_date":"2013-10-24","protocol_title":"AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE WHEN ADMINISTERED TO PATIENTS WITH SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE","medConditionList":[{"med_condition_id":246,"med_condition":"SYSTEMIC SCLEROSIS"},{"med_condition_id":423,"med_condition":"INTERSTITIAL LUNG DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48132,"protocol_no":"PS0008","submission_no":"212868","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-21","protocol_title":"CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A DOSE-BLIND MAINTENANCE TREATMENT PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (AMENDMENT 1)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45520,"protocol_no":"354-2016","submission_no":"204678","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-11","protocol_title":"PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN SEVERE TRAUMATIC BRAIN INJURY, A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"},{"med_condition_id":437,"med_condition":"TRAUMATIC BRAIN INJURY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37495,"protocol_no":"R668-AD-1334","submission_no":"178796","status_id":1,"start_date":"2015-01-29","end_date":null,"nol_date":"2014-11-07","protocol_title":"A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35430,"protocol_no":"AB06006","submission_no":"172333","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-28","protocol_title":"A 24-WEEK WITH POSSIBLE EXTENSION, PROSPECTIVE, MULTICENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, 2-PARALLEL GROUP WITH A RANDOMIZATION 1:1, PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF MASITINIB AT 6 MG/KG/DAY TO PLACEBO IN TREATMENT OF PATIENTS WITH SMOULDERING SYSTEMIC, INDOLENT SYSTEMIC OR CUTANEOUS MASTOCYTOSIS WITH HANDICAP","medConditionList":[{"med_condition_id":494,"med_condition":"SMOLDERING SYSTEMIC MASTOCYTOSIS"},{"med_condition_id":496,"med_condition":"CUTANEOUS MASTOCYTOSIS WITH HANDICAP"},{"med_condition_id":495,"med_condition":"INDOLENT SYSTEMIC MASTOCYTOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29372,"protocol_no":"AB12005","submission_no":"171624","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-20","protocol_title":"A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37375,"protocol_no":"KCP-330-009","submission_no":"178429","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-17","protocol_title":"A PHASE 2B OPEN-LABEL, RANDOMIZED, TWO-ARM STUDY OF SELINEXOR (KPT-330) WITH LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38833,"protocol_no":"SHP-609-302","submission_no":"183324","status_id":1,"start_date":"2016-06-14","end_date":null,"nol_date":"2015-04-24","protocol_title":"\"AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFASE ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PATIENTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT.\"","medConditionList":[{"med_condition_id":479,"med_condition":"HUNTER SYNDROME"},{"med_condition_id":285,"med_condition":"COGNITIVE IMPAIRMENT"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36202,"protocol_no":"BO29337","submission_no":"174790","status_id":1,"start_date":"2015-01-16","end_date":null,"nol_date":"2014-06-11","protocol_title":"A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT-199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED AND REFRACTORY FOLLICULAR NON-HODGKIN'S LYMPHOMA","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40861,"protocol_no":"INSPIRE-001","submission_no":"189506","status_id":1,"start_date":"2016-11-03","end_date":null,"nol_date":"2015-12-11","protocol_title":"INVESTIGATOR-INITIATED PHASE II STUDY OF PEMBROLIZUMAB IMMUNOLOGICAL RESPONSE EVALUATION (INSPIRE)","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29268,"protocol_no":"400-12-006","submission_no":"171348","status_id":1,"start_date":"2015-06-05","end_date":null,"nol_date":"2014-02-11","protocol_title":"A PROSPECTIVE, RANDOMIZED, CONTROLLED, STUDY EVALUATING EVICEL FIBRIN SEALANT AS AN ADJUNCT TO HAEMOSTASIS DURING ABDOMINAL, RETROPERITONEAL OR PELVIC SURGERY IN PAEDIATRIC PATIENTS","medConditionList":[{"med_condition_id":407,"med_condition":"ABDOMINAL SURGERY"},{"med_condition_id":409,"med_condition":"PELVIC SURGERY"},{"med_condition_id":408,"med_condition":"RETROPERITONEAL SURGERY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44500,"protocol_no":"1245.110","submission_no":"201575","status_id":1,"start_date":"2017-06-29","end_date":null,"nol_date":"2017-01-18","protocol_title":"A PHASE III RANDOMISED, DOUBLE-BLIND TRIAL TO EVALUATE EFFICACY AND SAFETY OF ONCE DAILY EMPAGLIFLOZIN 10 MG COMPARED TO PLACEBO, IN PATIENTS WITH CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47914,"protocol_no":"XSGP-303","submission_no":"212383","status_id":1,"start_date":"2018-03-05","end_date":null,"nol_date":"2018-01-16","protocol_title":"G-PEN TM(GLUCAGON INJECTION) COMPARED TO LILLY GLUCAGON (GLUCAGON FOR INJECTION [RDNA ORIGIN]) FOR INDUCED HYPOGLYCEMIA RESCUE IN ADULT PATIENTS WITH T1D: A PHASE 3B MULTI-CENTERED, RANDOMIZED, CONTROLLED, SINGLE BLIND, 2-WAY CROSSOVER STUDY TO EVALUATE EFFICACY AND SAFETY","medConditionList":[{"med_condition_id":771,"med_condition":"HYPOGLYCEMIA UNAWARENESS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48454,"protocol_no":"OZM-088","submission_no":"213941","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-22","protocol_title":"PHASE I/II OF DURVALUMAB (MEDI7436) + TREMELIMUMAB + STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC HEAD AND NECK CARCINOMA","medConditionList":[{"med_condition_id":95,"med_condition":"HEAD AND NECK CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40311,"protocol_no":"CCTL019C2201","submission_no":"187651","status_id":1,"start_date":"2017-01-04","end_date":null,"nol_date":"2015-10-14","protocol_title":"A PHASE II, SINGLE ARM, MULTICENTER TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40391,"protocol_no":"CA209-451","submission_no":"187944","status_id":1,"start_date":"2016-11-15","end_date":null,"nol_date":"2015-10-23","protocol_title":"\"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY OF NIVOLUMAB, NIVOLUMAB IN COMBINATION WITH IPILIMUMAB, OR PLACEBO AS MAINTENANCE THERAPY IN SUBJECTS WITH EXTENSIVE-STAGE DISEASE SMALL CELL LUNG CANCER (ED-SCLC) AFTER COMPLETION OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY,\"","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28044,"protocol_no":"GVH 1201","submission_no":"167426","status_id":1,"start_date":"2016-09-02","end_date":null,"nol_date":"2013-09-13","protocol_title":"\"ABATACEPT COMBINED WITH A CALCINEURIN INHIBITOR AND METHOTREXATE FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS: A RANDOMIZED CONTROLLED TRIAL.\"","medConditionList":[{"med_condition_id":370,"med_condition":"GRAFT VS HOST DISEASE"},{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41021,"protocol_no":"057","submission_no":"189992","status_id":1,"start_date":"2016-10-21","end_date":null,"nol_date":"2015-12-24","protocol_title":"A PHASE II CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN SUBJECTS WITH HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG) THERAPY","medConditionList":[{"med_condition_id":178,"med_condition":"NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35687,"protocol_no":"C16019","submission_no":"173116","status_id":2,"start_date":"2015-08-28","end_date":"2016-03-23","nol_date":"2014-03-31","protocol_title":"A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ORAL IXAZOMIB CITRATE (MLN9708) MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41890,"protocol_no":"107561","submission_no":"193137","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-05-26","protocol_title":"MOLECULAR NEUROIMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DEMENTIAS","medConditionList":[{"med_condition_id":685,"med_condition":"NEURODEGENERATIVE DEMENTIAS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41296,"protocol_no":"RP-307-08312015","submission_no":"191122","status_id":1,"start_date":"2016-05-01","end_date":null,"nol_date":"2016-01-27","protocol_title":"HYPERPOLARIZED XENON-129 FUNCTIONAL MAGNETIC RESONANCE IMAGING OF HEALTHY VOLUNTEERS AND PARTICIPANTS WITH ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46132,"protocol_no":"EFC14153","submission_no":"206460","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-07","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN 6 TO <12 YEARS OF AGE WITH UNCONTROLLED PERSISTENT ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37668,"protocol_no":"D4193C00001","submission_no":"179355","status_id":1,"start_date":"2016-03-23","end_date":null,"nol_date":"2014-11-28","protocol_title":"A PHASE II, MULTI-CENTER, SINGLE-ARM, GLOBAL STUDY OF MEDI4736 MONOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36593,"protocol_no":"IPI-145-08","submission_no":"175888","status_id":1,"start_date":"2015-01-16","end_date":null,"nol_date":"2014-07-31","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF IPI-145 IN COMBINATION WITH RITUXIMAB VS RITUXIMAB IN SUBJECTS WITH PREVIOUSLY-TREATED FOLLICULAR LYMPHOMA","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26562,"protocol_no":"B2012-097","submission_no":"163119","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-05-03","protocol_title":"THE DURATION OF ACTION OF INHALED MILRINONE","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47940,"protocol_no":"JBT101-SSC-002","submission_no":"212530","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-25","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL TO EVALUATE EFFICACY AND SAFETY OF LENABASUM IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS","medConditionList":[{"med_condition_id":246,"med_condition":"SYSTEMIC SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37264,"protocol_no":"HMR-MM-001","submission_no":"178040","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-03","protocol_title":"A PHASE II, OPEN-LABEL STUDY OF BORTEZOMIB FOLLOWING NONMYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANT IN PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47984,"protocol_no":"FIRH_XE0001","submission_no":"212608","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-14","protocol_title":"SINGLE-CENTRE STUDY EXPLORING THE UTILITY OF HYPERPOLARIZED 129XE MAGNETIC RESONANCE IMAGING IN HEALTHY VOLUNTEERS AND PATIENTS WITH LUNG DISEASE","medConditionList":[{"med_condition_id":146,"med_condition":"LUNG DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37459,"protocol_no":"20101221","submission_no":"178690","status_id":1,"start_date":"2015-06-22","end_date":null,"nol_date":"2014-11-04","protocol_title":"A SINGLE ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY STUDY OF ROMIPLOSTIM IN THROMBOCYTOPENIC PEDIATRIC SUBJECTS WITH IMMUNE THROMBOCYTOPENIA (ITP)","medConditionList":[{"med_condition_id":128,"med_condition":"IMMUNE THROMBOCYTOPENIA (ITP)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37894,"protocol_no":"012-01","submission_no":"179998","status_id":2,"start_date":"2016-05-12","end_date":"2016-12-13","nol_date":"2014-12-18","protocol_title":"A PHASE II, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-3682 WITH EITHER MK-8742 OR MK-8408 IN SUBJECTS WITH CHRONIC HCV GT3 INFECTION.","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"},{"med_condition_id":108,"med_condition":"HEPATITIS C VIRUS GENOTYPE 3"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40818,"protocol_no":"R2222-RSV-1332","submission_no":"189342","status_id":1,"start_date":"2016-11-18","end_date":null,"nol_date":"2015-12-04","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF A HUMAN MONOCLONAL ANTIBODY, REGN2222, FOR THE PREVENTION OF MEDICALLY ATTENDED RSV INFECTION IN PRETERM INFANTS","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38247,"protocol_no":"GS-US-337-1701","submission_no":"181387","status_id":2,"start_date":"2015-04-07","end_date":"2015-12-03","nol_date":"2015-02-06","protocol_title":"A PHASE 2 OPEN- LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) FIXED DOSE COMBINATION TABLET WITH RIBAVIRIN FOR 12 WEEKS IN TREATMENT-NA√èVE PATIENTS WITH CHRONIC HCV GENOTYPE 3 INFECTION","medConditionList":[{"med_condition_id":108,"med_condition":"HEPATITIS C VIRUS GENOTYPE 3"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26516,"protocol_no":"311-09","submission_no":"162994","status_id":1,"start_date":"2013-04-15","end_date":null,"nol_date":"2013-04-09","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, PARALLEL ASSIGNMENT, MULTI-CENTRE, THERAPEUTIC EQUIVALENCE STUDY OF TWO TACROLIMUS 0.1% TOPICAL OINTMENT FORMULATIONS IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43609,"protocol_no":"MP-37-2017-2510","submission_no":"198634","status_id":1,"start_date":"2016-10-01","end_date":null,"nol_date":"2016-11-28","protocol_title":"A DOUBLE-BLINDED, RANDOMIZED, TWO-WAY, CROSSOVER STUDY TO ASSESS THE EFFICACY OF INSULIN-PLUS-PLACEBO CLOSED-LOOP DELIVERY AND INSULIN-PLUS-PRAMLINTIDE CLOSED-LOOP DELIVERY IN REGULATING GLUCOSE LEVELS OVER A 24-HOUR PERIOD IN ADULTS WITH TYPE 1 DIABETES IN INPATIENT SETTINGS.","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43671,"protocol_no":"GS-US-419-3896","submission_no":"198862","status_id":1,"start_date":"2017-08-28","end_date":null,"nol_date":"2016-10-31","protocol_title":"A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FILGOTINIB IN SUBJECTS WITH CROHN¬øS DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44242,"protocol_no":"D1699C00001","submission_no":"200515","status_id":1,"start_date":"2017-01-20","end_date":null,"nol_date":"2016-12-23","protocol_title":"STUDY TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN ON THE INCIDENCE OF WORSENING HEART FAILURE OR CARDIOVASCULAR DEATH IN PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION.","medConditionList":[{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42372,"protocol_no":"20130286","submission_no":"194743","status_id":1,"start_date":"2017-06-05","end_date":null,"nol_date":"2016-06-01","protocol_title":"A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY ON LDL-C OF EVOLOCUMAB (AMG 145) IN SUBJECTS WITH HIV AND WITH HYPERLIPIDEMIA AND/OR MIXED DYSLIPIDEMIN","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"},{"med_condition_id":296,"med_condition":"MIXED DYSLIPIDEMIA"},{"med_condition_id":348,"med_condition":"HYPERLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46404,"protocol_no":"CPZP034A2410","submission_no":"207411","status_id":1,"start_date":"2018-04-10","end_date":null,"nol_date":"2017-08-14","protocol_title":"A PROSPECTIVE INTERNATIONAL MULTICENTER PHASE II STUDY TO EVALUATE THE EFFICACY, SAFETY AND QUALITY OF LIFE OF ORAL DAILY PAZOPANIB IN PATIENTS WITH ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA AFTER PREVIOUS THERAPY WITH CHECKPOINT INHIBITOR TREATMENT","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47358,"protocol_no":"ISIS 703802-CS4","submission_no":"210691","status_id":1,"start_date":"2018-03-29","end_date":null,"nol_date":"2017-11-16","protocol_title":"A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF ISIS 703802 (AKCEA-ANGPTL3LRX) ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)","medConditionList":[{"med_condition_id":116,"med_condition":"HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48892,"protocol_no":"CLAG525B2101","submission_no":"215385","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-05-03","protocol_title":"\"A PHASE IB OPEN-LABEL, RANDOMIZED, THREE-ARM, MULTICENTER STUDY OF LAG525 GIVEN IN COMBINATION WITH SPARTALIZUMAB (PDR001), OR WITH SPARTALIZUMAB AND CARBOPLATIN, OR WITH CARBOPLATIN, AS FIRST OR SECOND LINE THERAPY IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER.\"","medConditionList":[{"med_condition_id":702,"med_condition":"BREAST CANCER TRIPLE NEGATIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45348,"protocol_no":"20160275","submission_no":"204167","status_id":1,"start_date":"2017-09-11","end_date":null,"nol_date":"2017-05-01","protocol_title":"A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40819,"protocol_no":"UM0128171-001","submission_no":"189343","status_id":1,"start_date":"2015-12-16","end_date":null,"nol_date":"2015-12-04","protocol_title":"A PHASE I-II OPEN-LABEL STUDY OF UM171-EXPANDED CORD BLOOD IN A FED-BATCH CULTURE SYSTEM (UFCB-001) IN PATIENTS WHO NEED AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT BUT LACK A SUITABLE DONOR","medConditionList":[{"med_condition_id":431,"med_condition":"HEMATOPOIETIC STEM CELL TRANSPLANT"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40947,"protocol_no":"189","submission_no":"189777","status_id":1,"start_date":"2016-10-13","end_date":null,"nol_date":"2015-12-23","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF PLATINUM+ PEMETREXED CHEMOTHERAPY WITH OR WITHOUT PEMBROLIZUMAB (MK-3475) IN FIRST LINE METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER SUBJECTS (KEYNOTE-189)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38782,"protocol_no":"ECT-FG-2015","submission_no":"183146","status_id":1,"start_date":"2015-10-01","end_date":null,"nol_date":"2015-04-22","protocol_title":"EFFECTS OF LOW-DOSE KETAMINE AS AN ADJUNCT TO PROPOFOL-BASED ANESTHESIA FOR ELECTROCONVULSIVE THERAPY","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"},{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39229,"protocol_no":"63935937MYF2001","submission_no":"184555","status_id":2,"start_date":"2016-02-12","end_date":"2018-05-04","nol_date":"2015-06-11","protocol_title":"A RANDOMIZED, SINGLE-BLIND, MULTICENTER PHASE 2 STUDY TO EVALUATE THE ACTIVITY OF 2 DOSE LEVELS OF IMETELSTAT IN SUBJECTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS (MF) RELAPSED/REFRACTORY TO JANUS KINASE (JAK) INHIBITOR","medConditionList":[{"med_condition_id":353,"med_condition":"MYELOFIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38972,"protocol_no":"CA011-001","submission_no":"183768","status_id":1,"start_date":"2016-08-19","end_date":null,"nol_date":"2015-05-15","protocol_title":"A PHASE I/IIA TRIAL WITH BMS-986158, A SMALL MOLECULE INHIBITOR OF THE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEINS, IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46511,"protocol_no":"M16-098","submission_no":"207811","status_id":1,"start_date":"2017-11-15","end_date":null,"nol_date":"2017-08-14","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF UPADACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS","medConditionList":[{"med_condition_id":397,"med_condition":"ANKYLOSING SPONDYLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43806,"protocol_no":"GAM10-08","submission_no":"199258","status_id":1,"start_date":"2017-08-30","end_date":null,"nol_date":"2016-11-04","protocol_title":"PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS (\"PRODERM STUDY\")","medConditionList":[{"med_condition_id":427,"med_condition":"DERMATOMYOSITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38941,"protocol_no":"CFOR258D2416","submission_no":"183673","status_id":1,"start_date":"2015-07-08","end_date":null,"nol_date":"2015-04-27","protocol_title":"A 26 WEEK, RANDOMIZED, ACTIVE-CONTROLLED SAFETY STUDY OF DOUBLE-BLIND FORMOTEROL FUMARATE IN FREE COMBINATION WITH AN INHALED CORTICOSTEROID VERSUS AN INHALED CORTICOSTEROID IN ADOLESCENT AND ADULT PATIENTS WITH PERSISTENT ASTHMA / CFOR258D2416","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26649,"protocol_no":"212082BCA2004","submission_no":"163359","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-04-17","protocol_title":"PRE-OPERATIVE ASSESSMENT OF THE ANTI-PROLIFERATIVE EFFECTS AND GENOMIC ALTERATIONS OF 2 WEEKS OF ABIRATERONE ACETATE COMPARED TO 2 WEEKS OF AN AROMATASE INHIBITOR IN POST-MENOPAUSAL HORMONE RECEPTOR POSITIVE OPERABLE BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37890,"protocol_no":"REP0112","submission_no":"179985","status_id":1,"start_date":"2013-12-13","end_date":null,"nol_date":"2014-12-22","protocol_title":"A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL ASSIGNMENT STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPARIXIN IN PANCREATIC ISLET AUTO-TRANSPLANTATION,","medConditionList":[{"med_condition_id":135,"med_condition":"ISLET TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44376,"protocol_no":"CINC424A2411","submission_no":"201099","status_id":1,"start_date":"2017-04-27","end_date":null,"nol_date":"2017-01-10","protocol_title":"A MULTICENTER PHASE II, OPEN LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RUXOLITINIB IN THE TREATMENT OF ANEMIC MYELOFIBROSIS PATIENTS.","medConditionList":[{"med_condition_id":211,"med_condition":"PRIMARY MYELOFIBROSIS (PMF)"},{"med_condition_id":514,"med_condition":"POST-POLYCYTHEMIA VERA MYELOFIBROSIS"},{"med_condition_id":513,"med_condition":"POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44126,"protocol_no":"D081DC00007","submission_no":"200194","status_id":1,"start_date":"2017-02-03","end_date":null,"nol_date":"2016-12-16","protocol_title":"A PHASE III, OPEN LABEL, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF OLAPARIB (LYNPARZA¬ø) VERSUS ENZALUTAMIDE OR ABIRATERONE ACETATE IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE FAILED PRIOR TREATMENT WITH A NEW HORMONAL AGENT AND HAVE HOMOLOGOUS RECOMBINATION REPAIR GENE MUTATIONS (PROFOUND)","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26622,"protocol_no":"CAT-8015-1036","submission_no":"163266","status_id":1,"start_date":"2015-03-10","end_date":null,"nol_date":"2013-04-17","protocol_title":"\"A PHASE 2, MULTICENTER, SINGLE-ARM STUDY OF MOXETUMOMAB PASUDOTOX IN PEDIATRIC SUBJECTS WITH RELAPSED OR REFRACTORY PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (PALL) OR LYMPHOBLASTIC LYMPHOMA OF B-CELL ORIGIN.\"","medConditionList":[{"med_condition_id":148,"med_condition":"LYMPHOBLASTIC LEUKEMIA"},{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28994,"protocol_no":"HLC001","submission_no":"170495","status_id":1,"start_date":"2017-07-21","end_date":null,"nol_date":"2013-12-23","protocol_title":"NEOADJUVANT FINASTERIDE FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37933,"protocol_no":"SLNB - 14-7441","submission_no":"180175","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-22","protocol_title":"SENTINEL LYMPH NODE MAPPING OF HEAD AND NECK CANCER USING NEAR-INFRARED FLUORESCENCE IMAGING","medConditionList":[{"med_condition_id":95,"med_condition":"HEAD AND NECK CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46401,"protocol_no":"SP-1011-002","submission_no":"207415","status_id":1,"start_date":"2018-01-16","end_date":null,"nol_date":"2017-08-08","protocol_title":"FLUTICASONE IN EOSINOPHILIC ESOPHAGITIS (FLUTE): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, AND MAINTENANCE STUDY OF APT-1011 IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS","medConditionList":[{"med_condition_id":550,"med_condition":"EOSINOPHILIC ESOPHAGITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37875,"protocol_no":"VX13-809-011","submission_no":"179938","status_id":2,"start_date":"2015-02-18","end_date":"2015-11-30","nol_date":"2014-12-15","protocol_title":"A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN SUBJECTS 6 THROUGH 11 YEARS OF AGE WITH CYSTIC FIBROSIS, HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION.","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39649,"protocol_no":"1002-01","submission_no":"185969","status_id":1,"start_date":"2016-04-20","end_date":null,"nol_date":"2015-07-31","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I/II STUDY OF THE SAFETY AND EFFICACY OF INTRACORONARY DELIVERY OF ALLOGENEIC CARDIOSPHERE-DERIVED CELLS IN PATIENTS WITH A MYOCARDIAL INFARCTION AND ISCHEMIC LEFT VENTRICULAR DYSFUNCTION (ALLOGENIC HEART STEM CELLS TO ACHIEVE MYOCARDIAL REGENERATION. ALLSTAR)","medConditionList":[{"med_condition_id":637,"med_condition":"ISCHEMIC LEFT VENTRICULAR DYSFUNCTION"},{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28458,"protocol_no":"GX29107","submission_no":"168634","status_id":2,"start_date":"2013-11-06","end_date":"2014-12-05","nol_date":"2013-10-31","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF QUILIZUMAB IN PATIENTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA (CSU)","medConditionList":[{"med_condition_id":399,"med_condition":"CHRONIC SPONTANEOUS URTICARIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42326,"protocol_no":"CLJN452A2202","submission_no":"194610","status_id":1,"start_date":"2017-04-26","end_date":null,"nol_date":"2016-05-27","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, 2- PART, ADAPTIVE DESIGN, MULTICENTER 12-WEEK STUDY TO ASSESS SAFETY, TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)","medConditionList":[{"med_condition_id":734,"med_condition":"NONALCOHOLIC STEATOHEPATITIS (NASH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46594,"protocol_no":"EFC14868","submission_no":"208041","status_id":1,"start_date":"2017-12-21","end_date":null,"nol_date":"2017-08-24","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SOTAGLIFLOZIN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL ON METFORMIN","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27904,"protocol_no":"PHL-087 / NCI 9407","submission_no":"167018","status_id":1,"start_date":"2013-11-29","end_date":null,"nol_date":"2013-08-29","protocol_title":"PHASE I STUDY OF THE WEE 1 KINASE (WEE 1) INHIBITOR MK-1775 IN COMBINATION WITH CISPLATIN AND RADIATION IN CERVICAL CANCER","medConditionList":[{"med_condition_id":356,"med_condition":"CERVICAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39043,"protocol_no":"CCTL019B2202","submission_no":"183551","status_id":1,"start_date":"2015-11-25","end_date":null,"nol_date":"2015-05-20","protocol_title":"A PHASE II, SINGLE ARM, MULTICENTER TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOMBLASTIC LEUKEMIA","medConditionList":[{"med_condition_id":148,"med_condition":"LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39429,"protocol_no":"A4091059","submission_no":"185218","status_id":1,"start_date":"2016-12-14","end_date":null,"nol_date":"2015-07-23","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN","medConditionList":[{"med_condition_id":626,"med_condition":"CHRONIC LOW BACK PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38455,"protocol_no":"CA209-040","submission_no":"182072","status_id":1,"start_date":"2016-02-01","end_date":null,"nol_date":"2015-03-13","protocol_title":"A PHASE I DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, IMMUNOREGULATORY ACTIVITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF ANTI-PROGRAMMED-DEATH-1 (PD-1) ANTIBODY (BMS-936558) IN ADVANCED HEPATOCELLULAR CARCINOMA IN SUBJECTS WITH OR WITHOUT CHRONIC VIRAL HEPATITIS","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38269,"protocol_no":"CA209-238","submission_no":"181446","status_id":1,"start_date":"2017-03-30","end_date":null,"nol_date":"2015-02-18","protocol_title":"\"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ADJUVANT IMMUNOTHERAPY WITH NIVOLUMAB VERSUS IPILIMUMAB AFTER COMPLETE RESECTION OF STAGE IIIB/C OR STAGE IV MELANOMA IN SUBJECTS WHO ARE AT HIGH RISK FOR RECURRENCE","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40318,"protocol_no":"VB-111-215","submission_no":"187682","status_id":1,"start_date":"2016-05-24","end_date":null,"nol_date":"2015-10-14","protocol_title":"A PHASE 3, RANDOMIZED, CONTROLLED, DOUBLE-ARM, OPEN-LABEL, MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44245,"protocol_no":"D169AC00001","submission_no":"200521","status_id":1,"start_date":"2017-09-11","end_date":null,"nol_date":"2016-12-23","protocol_title":"A STUDY TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN ON RENAL OUTCOMES AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE","medConditionList":[{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41914,"protocol_no":"CA018-001","submission_no":"193214","status_id":1,"start_date":"2017-09-26","end_date":null,"nol_date":"2016-04-08","protocol_title":"A PHASE 2, FAST REAL-TIME ASSESSMENT OF COMBINATION THERAPIES IN IMMUNO-ONCOLOGY STUDY IN SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (FRACTION-LUNG)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43082,"protocol_no":"COMB157G2301","submission_no":"197063","status_id":1,"start_date":"2017-04-25","end_date":null,"nol_date":"2016-08-31","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB VERSUS TERIFLUNOMIDE IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42886,"protocol_no":"1346.23","submission_no":"196533","status_id":1,"start_date":"2018-02-23","end_date":null,"nol_date":"2016-07-27","protocol_title":"A MULTI-CENTRE, DOUBLE-BLIND, PARALLEL-GROUP, RANDOMIZED CONTROLLED STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORALLY ADMINISTERED BI 425809 DURING A 12-WEEK TREATMENT PERIOD COMPARED TO PLACEBO IN PATIENTS WITH COGNITIVE IMPAIRMENT DUE TO ALZHEIMER¬øS DISEASE.","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42726,"protocol_no":"CA209-649","submission_no":"196038","status_id":1,"start_date":"2017-05-01","end_date":null,"nol_date":"2016-07-12","protocol_title":"A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER","medConditionList":[{"med_condition_id":619,"med_condition":"GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"},{"med_condition_id":337,"med_condition":"GASTRIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43983,"protocol_no":"WO39210","submission_no":"199781","status_id":1,"start_date":"2017-04-03","end_date":null,"nol_date":"2016-11-16","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37240,"protocol_no":"GA29102","submission_no":"177941","status_id":1,"start_date":"2015-02-17","end_date":null,"nol_date":"2014-10-07","protocol_title":"PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (MAINTENANCE OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE ACUTE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37410,"protocol_no":"RD.03.SPR.101682","submission_no":"178539","status_id":1,"start_date":"2014-10-14","end_date":null,"nol_date":"2014-10-14","protocol_title":"SAFETY AND EFFICACY OF CD09882 IN ADULTS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26403,"protocol_no":"13-0039-A","submission_no":"162669","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-04-09","protocol_title":"DOES A PERIOPERATIVE COURSE OF GABAPENTIN IMPROVE ANALGESIA AFTER CESAREAN DELIVERY? A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28749,"protocol_no":"063-012","submission_no":"169652","status_id":2,"start_date":"2014-10-06","end_date":"2015-04-30","nol_date":"2013-12-04","protocol_title":"A SIX-MONTH, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF PRC-063 IN ADULTS AND ADOLESCENTS WITH ADHD.","medConditionList":[{"med_condition_id":9,"med_condition":"ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36755,"protocol_no":"DRI13839","submission_no":"176479","status_id":2,"start_date":"2015-05-26","end_date":"2016-02-29","nol_date":"2014-08-14","protocol_title":"A PHASE 2A/2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY ASSESSING EFFICACY, SAFETY, AND DOSE-RESPONSE OF VATELIZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)","medConditionList":[{"med_condition_id":565,"med_condition":"RELAPSING-REMITTING MULTIPLE SCLEROSIS"},{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37465,"protocol_no":"00-049-578","submission_no":"178716","status_id":1,"start_date":"2014-11-05","end_date":null,"nol_date":"2014-10-31","protocol_title":"18F-SODIUM FLUORIDE (18F-NAF) PET-CT IMAGING TO IDENTIFY VULNERABLE PLAQUES IN PATIENTS WITH DIABETES MELLITUS","medConditionList":[{"med_condition_id":388,"med_condition":"DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44901,"protocol_no":"ALC.4/E1910","submission_no":"202785","status_id":1,"start_date":"2017-10-21","end_date":null,"nol_date":"2017-03-13","protocol_title":"A PHASE III RANDOMIZED TRIAL OF BLINATUMOMAB FOR NEWLY DIAGNOSED BCR-ABL-NEGATIVE B LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37778,"protocol_no":"CO-1686-022","submission_no":"179694","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-10","protocol_title":"TIGER 1: A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF CO-1686 OR ERLOTINIB AS FIRST LINE TREATMENT OF PATIENTS WITH EGFR-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40018,"protocol_no":"PRT-201-320","submission_no":"186855","status_id":1,"start_date":"2017-03-15","end_date":null,"nol_date":"2015-09-11","protocol_title":"MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF VONAPANITASE (PRT-201) ADMINISTERED IMMEDIATELY AFTER RADIOCEPHALIC ARTERIOVENOUS FISTULA CREATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE","medConditionList":[{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28309,"protocol_no":"CPKC412US23","submission_no":"168198","status_id":1,"start_date":"2014-10-26","end_date":null,"nol_date":"2013-10-15","protocol_title":"A PHASE II, RANDOMIZED, COMPARATIVE TRIAL OF STANDARD OF CARE, WITH OR WITHOUT MIDOSTAURIN TO PREVENT RELAPSE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42818,"protocol_no":"AG-221-AML-005","submission_no":"196310","status_id":1,"start_date":"2016-10-28","end_date":null,"nol_date":"2016-07-25","protocol_title":"A PHASE 1B/2 OPEN-LABEL, RANDOMIZED STUDY OF 2 COMBINATIONS OF ISOCITRATE DEHYDROGENASE (IDH) MUTANT TARGETED THERAPIES PLUS AZACITIDINE: ORAL AG-120 PLUS SUBCUTANEOUS  AZACITIDINE AND ORAL AG-221 PLUS SC AZACITIDINE IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA HARBORING AN IDH1 OR AN IDH2 MUTATION, RESPECTIVELY, WHO ARE NOT CANDIDATES TO RECEIVE INTENSIVE INDUCTION CHEMOTHERAPY","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44018,"protocol_no":"DRI13926","submission_no":"199893","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-11-25","protocol_title":"AN OPEN-LABEL, SEQUENTIAL, ASCENDING, REPEATED DOSE-FINDING STUDY OF SARILUMAB, ADMINISTERED WITH SUBCUTANEOUS (SC) INJECTION, IN CHILDREN AND ADOLESCENTS, AGED 1 TO 17 YEARS, WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA), FOLLOWED BY AN EXTENSION PHASE","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44317,"protocol_no":"PYL-2301","submission_no":"200764","status_id":1,"start_date":"2017-02-02","end_date":null,"nol_date":"2016-12-20","protocol_title":"A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF 18F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER: EXAMINATION OF DIAGNOSTICS ACCURACY (OSPREY)","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41121,"protocol_no":"EMR 100070-007","submission_no":"190386","status_id":1,"start_date":"2016-11-10","end_date":null,"nol_date":"2016-01-20","protocol_title":"A PHASE III OPEN-LABEL, MULTICENTER TRIAL OF MAINTENANCE THERAPY WITH AVELUMAB (MSB0010718C) VERSUS CONTINUATION OF FIRST-LINE CHEMOTHERAPY IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, ADENOCARCINOMA OF THE STOMACH, OR OF THE GASTRO-ESOPHAGEAL JUNCTION","medConditionList":[{"med_condition_id":619,"med_condition":"GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"},{"med_condition_id":666,"med_condition":"ADENOCARCINOMA OF THE STOMACH"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43013,"protocol_no":"427","submission_no":"196886","status_id":1,"start_date":"2016-11-04","end_date":null,"nol_date":"2016-08-16","protocol_title":"A PHASE II SINGLE-ARM, OPEN-LABEL MONOTHERAPY CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) IN LOCALLY ADVANCED/METASTATIC RENAL CELL CARCINOMA (MRCC) (KEYNOTE-427)","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45599,"protocol_no":"CSJ117X2201","submission_no":"204907","status_id":1,"start_date":"2017-10-03","end_date":null,"nol_date":"2017-05-18","protocol_title":"A RANDOMIZED, SUBJECT- AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED, PARALLEL-DESIGN, BRONCHOPROVOCATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE DOSES OF INHALED CSJ117 IN ADULT SUBJECTS WITH MILD ATOPIC ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26946,"protocol_no":"AB04030","submission_no":"164298","status_id":1,"start_date":"2014-03-05","end_date":null,"nol_date":"2013-05-21","protocol_title":"A PROSPECTIVE, MULTICENTRE, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, 2-PARALLEL GROUP, PHASE III STUDY TO COMPARE EFFICACY AND SAFETY OF MASITINIB (AB1010) AT 7.5 MG/KG/DAY TO IMATINIB AT 400 OR 600 MG IN TREATMENT OF PATIENTS WITH GASTRO-INTESTINAL STROMAL TUMOUR IN FIRST LINE MEDICAL TREATMENT.","medConditionList":[{"med_condition_id":86,"med_condition":"GASTROINTESTINAL STROMAL TUMOR (GIST)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35910,"protocol_no":"CLGX818X2109","submission_no":"173897","status_id":1,"start_date":"2016-10-11","end_date":null,"nol_date":"2014-05-15","protocol_title":"A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF SEQUENTIAL LGX818/MEK162 COMBINATION FOLLOWED BY A RATIONAL COMBINATION WITH TARGETED AGENTS AFTER PROGRESSION, TO OVERCOME RESISTANCE IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BRAF V600 MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47660,"protocol_no":"RLM-MD-02","submission_no":"211508","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-15","protocol_title":"A 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"},{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"},{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":432,"med_condition":"DIABETIC GASTROPARESIS"},{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38508,"protocol_no":"TEMPO-2","submission_no":"181962","status_id":1,"start_date":"2015-04-20","end_date":null,"nol_date":"2015-03-18","protocol_title":"A RANDOMIZED CONTROLLED TRIAL OF TNK-TPA VERSUS STANDARD OF CARE FOR MINOR ISCHEMIC STROKE WITH PROVEN OCCLUSION","medConditionList":[{"med_condition_id":134,"med_condition":"ISCHEMIC ATTACK AND MINOR STROKE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48326,"protocol_no":"YO40245","submission_no":"213620","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-13","protocol_title":"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37464,"protocol_no":"ONC-DPX-SURVIVAC-05","submission_no":"178710","status_id":1,"start_date":"2017-01-16","end_date":null,"nol_date":"2014-11-06","protocol_title":"PHASE 2 STUDY OF AN IMMUNOTHERAPEUTIC VACCINE, DPX-SURVIVAC WITH LOW DOSE CYCLOPHOSPHAMID IN PATIENTS WITH RECURRENT, SURVIVIN-EXPRESSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)","medConditionList":[{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29110,"protocol_no":"CLEE011A2301","submission_no":"170899","status_id":1,"start_date":"2015-02-13","end_date":null,"nol_date":"2014-01-14","protocol_title":"A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER WHO RECEIVED NO PRIOR THERAPY FOR ADVANCED DISEASE","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43772,"protocol_no":"PS0016","submission_no":"199114","status_id":1,"start_date":"2016-12-29","end_date":null,"nol_date":"2016-11-09","protocol_title":"A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND STUDY TO EVALUATE THE TIME COURSE OF PHARMACODYNAMIC RESPONSE, SAFETY AND PHARMACOKINETICS OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: PHASE 2A","medConditionList":[{"med_condition_id":689,"med_condition":"CHRONIC PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39681,"protocol_no":"16244","submission_no":"186028","status_id":1,"start_date":"2015-09-15","end_date":null,"nol_date":"2015-07-31","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EVENT-DRIVEN PHASE III STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FINERENONE, IN ADDITION TO STANDARD OF CARE, ON THE PROGRESSION OF KIDNEY DISEASE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND THE CLINICAL DIAGNOSIS OF DIABETIC KIDNEY DISEASE","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39223,"protocol_no":"WO29636","submission_no":"184535","status_id":1,"start_date":"2016-10-17","end_date":null,"nol_date":"2015-06-11","protocol_title":"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED, HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER AFTER CYSTECTOMY","medConditionList":[{"med_condition_id":625,"med_condition":"BLADDER CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42255,"protocol_no":"240","submission_no":"194412","status_id":1,"start_date":"2017-01-19","end_date":null,"nol_date":"2016-05-20","protocol_title":"A PHASE III STUDY OF PEMBROLIZUMAB (MK-3475) VS. BEST SUPPORTIVE CARE AS SECOND-LINE THERAPY IN SUBJECTS WITH PREVIOUSLY SYSTEMICALLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (KEYNOTE-240)","medConditionList":[{"med_condition_id":519,"med_condition":"ADVANCED HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35431,"protocol_no":"ALDOXORUBICIN-P3-STS-01","submission_no":"172346","status_id":1,"start_date":"2015-04-30","end_date":null,"nol_date":"2014-03-21","protocol_title":"A MULTICENTER, RANDOMIZED, OPEN-LABEL PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ALDOXORUBICIN COMPARED TO INVESTIGATOR'S CHOICE IN SUBJECTS WITH METASTATIC, LOCALLY ADVANCED, OR UNRESECTABLE SOFT TISSUE SARCOMAS WHO EITHER RELAPSED OR WERE REFRACTORY TO PRIOR NON-ADJUVANT CHEMOTHERAPY","medConditionList":[{"med_condition_id":334,"med_condition":"SARCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27999,"protocol_no":"9785-CL-0403","submission_no":"167297","status_id":2,"start_date":"2013-12-06","end_date":"2016-11-24","nol_date":"2013-09-11","protocol_title":"A MULTICENTER, SINGLE-ARM, OPEN-LABEL, POST-MARKETING SAFETY STUDY TO EVALUATE THE RISK OF SEIZURE AMONG SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH ENZALUTAMIDE WHO ARE AT POTENTIAL INCREASED RISK OF SEIZURE PROTOCOL FOR PHASE 4 STUDY OF ENZALUTAMIDE.","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45374,"protocol_no":"VC02-102","submission_no":"204242","status_id":1,"start_date":"2017-06-30","end_date":null,"nol_date":"2017-04-26","protocol_title":"AN OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF VC-02 COMBINATION PRODUCT IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27864,"protocol_no":"FP187-301","submission_no":"166905","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-08-29","protocol_title":"A RANDOMISED, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE COMPARATOR AND PLACEBO CONTROLLED CONFIRMATIVE NON-INFERIORITY TRIAL OF FP187 COMPARED TO FUMADERM¬Æ IN MODERATE TO SEVERE PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40115,"protocol_no":"AXS02-301","submission_no":"187128","status_id":1,"start_date":"2016-05-13","end_date":null,"nol_date":"2015-09-14","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF AXS-02 (DISODIUM ZOLEDRONATE TETRAHYDRATE) ADMINISTERED ORALLY TO SUBJECTS WITH COMPLEX REGIONAL PAIN SYNDROME TYPE I","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40305,"protocol_no":"IN-CA-337-1960","submission_no":"187634","status_id":1,"start_date":"2016-01-08","end_date":null,"nol_date":"2015-09-29","protocol_title":"THE EFFECTS OF ANTI-VIRAL THERAPY ON THE CLINICAL STATUS, QUALITY OF LIFE, AND SURVIVAL OF PATIENTS WITH DECOMPENSATED CIRRHOSIS DUE TO HEPATITIS C GENOTYPE 1 INFECTION","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"},{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44196,"protocol_no":"039/2015","submission_no":"200364","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-12","protocol_title":"PERSONALIZED DOSING OF NICOTINE REPLACEMENT FOR SMOKING CESSATION: AN EFFECTIVENESS RANDOMIZED PLACEBO-CONTROLLED TRIAL.","medConditionList":[{"med_condition_id":236,"med_condition":"SMOKING CESSATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27380,"protocol_no":"TOK-200-10","submission_no":"165589","status_id":1,"start_date":"2014-02-10","end_date":null,"nol_date":"2013-07-11","protocol_title":"ARMOR2:  A 2-PART, PHASE 2 TRIAL OF GALETERONE IN THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42324,"protocol_no":"CGWN323X2101","submission_no":"194608","status_id":1,"start_date":"2017-08-11","end_date":null,"nol_date":"2016-06-10","protocol_title":"A PHASE I/IB OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION STUDY OF GWN323 (ANTI-GITR) AS A SINGLE AGENT AND IN COMBINATION WITH PDR001 (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS","medConditionList":[{"med_condition_id":691,"med_condition":"LYMPHOMA"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26501,"protocol_no":"20130105-01H","submission_no":"162950","status_id":1,"start_date":"2013-05-13","end_date":null,"nol_date":"2013-05-10","protocol_title":"COMPARISON OF THE EFFECT OF TICAGRELOR VERSUS CLOPIDOGREL ON MYOCARDIAL BLOOD FLOW (MBF) AND RESERVE (MBFR) MEASURED WITH POSITRON EMISSION TOMOGRAPHY (PET) IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD): THE PATH STUDY","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28764,"protocol_no":"TV7820-CNS-20002","submission_no":"169707","status_id":2,"start_date":"2016-06-14","end_date":"2016-08-12","nol_date":"2013-12-23","protocol_title":"A PHASE 2, DOSE-FINDING, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, EVALUATING THE SAFETY AND EFFICACY OF PRIDOPIDINE 45 MG, 67.5 MG, 90 MG, AND 112.5 MG TWICE-DAILY VERSUS PLACEBO FOR SYMPTOMATIC TREATMENT IN PATIENTS WITH HUNTINGTON'S DISEASE.","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27569,"protocol_no":"1160.106","submission_no":"166166","status_id":1,"start_date":"2014-03-06","end_date":null,"nol_date":"2013-07-31","protocol_title":"OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP, ACTIVE-CONTROLLED, MULTI-CENTRE, NON-INFERIORITY STUDY OF DABIGATRAN ETEXILATE VERSUS STANDARD OF CARE FOR VENOUS THROMBOEMBOLISM TREATMENT IN CHILDREN FROM BIRTH TO LESS THAN 18 YEARS OF AGE: THE DIVERSITY STUDY","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39898,"protocol_no":"B5201003","submission_no":"186590","status_id":1,"start_date":"2016-08-29","end_date":null,"nol_date":"2015-08-20","protocol_title":"AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL (GMI-1070) IN THE TREATMENT OF ONE OR MORE VASO-OCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE","medConditionList":[{"med_condition_id":232,"med_condition":"SICKLE CELL DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40848,"protocol_no":"63623872FLZ2002","submission_no":"189437","status_id":2,"start_date":"2016-12-13","end_date":"2017-05-31","nol_date":"2015-12-10","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF JNJ-63623872 IN COMBINATION WITH OSELTAMIVIR IN ADOLESCENT, ADULT, AND ELDERLY HOSPITALIZED PATIENTS WITH INFLUENZA A INFECTION","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42677,"protocol_no":"EFC14028","submission_no":"195825","status_id":1,"start_date":"2017-05-03","end_date":null,"nol_date":"2016-07-08","protocol_title":"A PHASE 3 RANDOMIZED, MULTICENTER, MULTINATIONAL, DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF REPEATED BIWEEKLY INFUSION OF NEOGAA (GZ402666) AND ALGLUCOSIDASE ALFA IN TREATMENT-NAIVE PATIENTS WITH LATE-ONSET POMPE DISEASE","medConditionList":[{"med_condition_id":201,"med_condition":"POMPE DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41502,"protocol_no":"1311.5","submission_no":"191675","status_id":2,"start_date":"2016-04-05","end_date":"2017-11-07","nol_date":"2016-02-26","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF CONCEPT, DOSE-RANGING STUDY OF BI 655066 IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48055,"protocol_no":"MER-XMT-1522-1","submission_no":"211705","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-15","protocol_title":"A PHASE 1B, FIRST-IN-HUMAN, DOSE ESCALATION AND EXANSION STUDY OF XMT-1522 IN PATIENTS WITH ADVANCED BREAST CANCER AND OTHER ADVANCED TUMORS EXPRESSING HER2","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47136,"protocol_no":"B7981007","submission_no":"209877","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-03","protocol_title":"A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN¬øS DISEASE.","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44277,"protocol_no":"KCP-330-023","submission_no":"200626","status_id":1,"start_date":"2017-05-04","end_date":null,"nol_date":"2016-12-20","protocol_title":"A PHASE 3 RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY OF SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE (SVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43500,"protocol_no":"64041575RSV2003","submission_no":"198261","status_id":1,"start_date":"2016-12-08","end_date":null,"nol_date":"2016-10-07","protocol_title":"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE ANTIVIRAL ACTIVITY, CLINICAL OUTCOMES, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORALLY ADMINISTERED ALS-008176 REGIMENS IN ADULT SUBJECTS HOSPITALIZED WITH RESPIRATORY SYNCYTIAL VIRUS","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46419,"protocol_no":"OOC-ACM-303","submission_no":"207465","status_id":1,"start_date":"2017-08-23","end_date":null,"nol_date":"2017-08-08","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OCTREOTIDE CAPSULES IN PATIENTS WHO PREVIOUSLY TOLERATED AND DEMONSTRATED BIOCHEMICAL CONTROL ON INJECTABLE SOMATOSTATIN RECEPTOR LIGANDS (SRL) TREATMENT","medConditionList":[{"med_condition_id":554,"med_condition":"ACROMEGALY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48045,"protocol_no":"SNA-125-102","submission_no":"212806","status_id":1,"start_date":"2018-02-06","end_date":null,"nol_date":"2018-02-05","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, INTRAINDIVIDUAL, VEHICLE-CONTROLLED, PHASE 1 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICALLY APPLIED SNA-125 GEL IN HEALTHY VOLUNTEERS AND SUBJECTS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27389,"protocol_no":"EMR 200066 012","submission_no":"165602","status_id":2,"start_date":"2014-02-14","end_date":"2017-12-08","nol_date":"2013-07-10","protocol_title":"PHASE II RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF COMBINATION OF PIMASERTIB WITH SAR245409 OR OF PIMASERTIB WITH SAR245409 PLACEBO IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOW GRADE OVARIAN CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46706,"protocol_no":"AALL1631","submission_no":"208440","status_id":1,"start_date":"2018-03-21","end_date":null,"nol_date":"2017-09-06","protocol_title":"INTERNATIONAL PHASE 3 TRIAL IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) TESTING IMATINIB IN COMBINATION WITH TWO DIFFERENT CYTOTOXIC CHEMOTHERAPY BACKBONES.","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48030,"protocol_no":"204862","submission_no":"212756","status_id":1,"start_date":"2018-02-23","end_date":null,"nol_date":"2018-02-02","protocol_title":"A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON- INFERIORITY STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF SWITCHING TO DOLUTEGRAVIR PLUS LAMIVUDINE IN HIV 1 INFECTED ADULTS WHO ARE VIROLOGICALLY SUPPRESSED","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47056,"protocol_no":"CQAW039A2317","submission_no":"209493","status_id":1,"start_date":"2018-02-27","end_date":null,"nol_date":"2017-10-19","protocol_title":"A 12 WEEK, MULTIICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD-OF-CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46088,"protocol_no":"CMIW815X2102J","submission_no":"206360","status_id":1,"start_date":"2018-03-14","end_date":null,"nol_date":"2017-06-29","protocol_title":"A PHASE IB, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MIW815 (ADU-S100) ADMINISTERED BY INTRATUMORAL INJECTION WITH PDR001 TO PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS OR LYMPHOMAS","medConditionList":[{"med_condition_id":691,"med_condition":"LYMPHOMA"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28179,"protocol_no":"AMSRF-01","submission_no":"167896","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-20","protocol_title":"AN OPEN LABEL STUDY TO ASSESS FATIGUE, MEDICAL RESOURCE UTILIZATION, AND NEUROPSYCHOLOGICAL STATUS OF SUBJECTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS RECEIVING DIRUCOTIDE (MBP8298)","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42469,"protocol_no":"1.1","submission_no":"195087","status_id":1,"start_date":"2016-06-06","end_date":null,"nol_date":"2016-07-05","protocol_title":"EFFECTIVENESS OF LITHIUM AS AN ADJUNCT TO COGNITIVE TRAINING IN AMNESTIC MILD COGNITIVE IMPAIRMENT: A FEASIBILITY STUDY","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44789,"protocol_no":"OZM-080","submission_no":"202456","status_id":1,"start_date":"2017-06-02","end_date":null,"nol_date":"2017-02-28","protocol_title":"A PHASE II, MULTI-CENTRE STUDY, OF COMBINING RADIOSURGERY AND NIVOLUMAB IN THE TREATMENT OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER AND RENAL CELL CANCER","medConditionList":[{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"},{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"},{"med_condition_id":27,"med_condition":"BRAIN METASTASES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40447,"protocol_no":"PUMA-NER-6201","submission_no":"188135","status_id":1,"start_date":"2017-10-31","end_date":null,"nol_date":"2015-10-29","protocol_title":"AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA IN PATIENTS WITH EARLY-STAGE HER2+ BREAST CANCER TREATED WITH NERATINIB AND INTENSIVE LOPERAMIDE PROPHYLAXIS","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"},{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40224,"protocol_no":"M13-583","submission_no":"187415","status_id":2,"start_date":"2015-11-18","end_date":"2016-12-13","nol_date":"2015-09-28","protocol_title":"A SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABT-493/ABT-530 IN ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 4, 5, OR 6 INFECTION (ENDURANCE-4)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27039,"protocol_no":"CL-N02-SC","submission_no":"164566","status_id":3,"start_date":"2013-11-14","end_date":null,"nol_date":"2013-05-30","protocol_title":"\"A PHASE I/II STUDY OF THE SAFETY AND PRELIMINARY EFFICACY OF INTRAMEDULLARY SPINAL CORD TRANSPLANTATION OF HUMAN CNS STEM CELLS (HUCNS-SC) IN SUBJECTS WITH THORAIC (T2-T11) SPINAL CORD TRAUMA.\"","medConditionList":[{"med_condition_id":238,"med_condition":"SPINAL CORD LESION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41688,"protocol_no":"I3Y-MC-JPBZ(A)","submission_no":"192319","status_id":1,"start_date":"2016-09-14","end_date":null,"nol_date":"2016-03-30","protocol_title":"MONARCHER: A PHASE 2, RANDOMIZED, MULTICENTER, 3-ARM, OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS TRASTUZUMAB WITH OR WITHOUT FULVESTRANT TO STANDARD-OF-CARE CHEMOTHERAPY OF PHYSICIAN'S CHOICE PLUS TRASTUZUMAB IN WOMEN WITH HR+, HER2+ LOCALLY ADVANCED OR METASTATIC BREAST CANCER.","medConditionList":[{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"},{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36031,"protocol_no":"AMG110","submission_no":"174241","status_id":1,"start_date":"2014-06-11","end_date":null,"nol_date":"2014-05-29","protocol_title":"A SINGLE CENTER, RANDOMIZED, 4-PERIOD STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF SINGLE OR REPEATED 3 MG DOSES OF INTRANASALLY ADMINISTERED GLUCAGON IN ADULTS WITH TYPE 1 OR TYPE 2 DIABETES","medConditionList":[{"med_condition_id":388,"med_condition":"DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40816,"protocol_no":"NA-1-007","submission_no":"189317","status_id":1,"start_date":"2017-02-23","end_date":null,"nol_date":"2015-12-03","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL GROUP, SINGLE-DOSE DESIGN TO DETERMINE THE EFFICACY AND SAFETY OF INTRAVENOUS NA-1 IN SUBJECTS WITH ACUTE ISCHEMIC STROKE UNDERGOING ENDOVASCULAR THROMBECTOMY.","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37101,"protocol_no":"PO-AMYL-PI-0022","submission_no":"177515","status_id":1,"start_date":"2014-10-27","end_date":null,"nol_date":"2014-10-02","protocol_title":"PHASE I STUDY OF POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE (PVD) AS FIRST-LINE TREATMENT OF AL AMYLOIDOSIS OR LIGHT CHAIN DEPOSITION DISEASE","medConditionList":[{"med_condition_id":574,"med_condition":"AMYLOIDOSIS"},{"med_condition_id":575,"med_condition":"LIGHT CHAIN DEPOSITION DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39141,"protocol_no":"CNTO136MDD2001","submission_no":"184279","status_id":1,"start_date":"2016-04-06","end_date":null,"nol_date":"2015-06-02","protocol_title":"\"A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF SIRUKUMAB AS ADJUNCTIVE TREATMENT TO A MONOAMINERGIC ANTIDEPRESSANT IN ADULTS WITH MAJOR DEPRESSIVE DISORDER.\"","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37729,"protocol_no":"ACCL1034","submission_no":"179582","status_id":1,"start_date":"2015-05-04","end_date":null,"nol_date":"2014-11-17","protocol_title":"IMPACT OF CLEANSING WITH CHLORHEXIDINE GLUCONATE (CHG) ON REDUCING CENTRAL LINE ASSOCIATED BLOODSTREAM INFECTION (CLABSI) AND ACQUISITION OF MULTI-DRUG RESISTANT ORGANISMS (MDRO) IN CHILDREN WITH CANCER OR THOSE RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"},{"med_condition_id":662,"med_condition":"ARTICULAR CARTILAGE INJURY"},{"med_condition_id":552,"med_condition":"PROPHYLAXIS OF INFECTIONS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29229,"protocol_no":"TV5600-IMM-30009","submission_no":"171267","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-04","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY OF LAQUINIMOD IN ACTIVE MODERATE TO SEVERE CROHN'S DISEASE PATIENTS","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37197,"protocol_no":"N/A","submission_no":"177810","status_id":1,"start_date":"2014-12-15","end_date":null,"nol_date":"2014-10-09","protocol_title":"BOTULIUNUM TOXIN TYPE A FOR COLD SENSITIVITY AFTER HAND TRAUMA","medConditionList":[{"med_condition_id":543,"med_condition":"TRAUMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36523,"protocol_no":"156-13-210","submission_no":"175680","status_id":2,"start_date":"2015-01-20","end_date":"2017-04-12","nol_date":"2014-07-15","protocol_title":"A PHASE 3B, MULTI-CENTER, RANDOMIZED-WITHDRAWAL, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP TRIAL TO COMPARE THE EFFICACY AND SAFETY OF TOLVAPTAN (45 TO 120 MG/DAY, SPLIT-DOSE) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE BETWEEN LATE STAGE 2 TO EARLY STAGE 4 DUE TO AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE","medConditionList":[{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46295,"protocol_no":"037-00","submission_no":"207047","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-20","protocol_title":"A PHASE 3 CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-3682B (GRAZOPREVIR/RUZASVIR/UPRIFOSBUVIR) IN PARTICIPANTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 3 INFECTION.","medConditionList":[{"med_condition_id":108,"med_condition":"HEPATITIS C VIRUS GENOTYPE 3"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43333,"protocol_no":"201585","submission_no":"197810","status_id":1,"start_date":"2016-11-14","end_date":null,"nol_date":"2016-09-30","protocol_title":"A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY, OPEN-LABEL STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF SWITCHING TO LONG-ACTING CABOTEGRAVIR PLUS LONG-ACTING RILPIVIRINE FROM CURRENT INI- NNRTI-, OR PI-BASED ANTIRETROVIRAL REGIMEN IN HIV-1-INFECTED ADULTS WHO ARE VIROLOGICALLY SUPPRESSED","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42009,"protocol_no":"LA-II-02","submission_no":"193594","status_id":1,"start_date":"2016-09-15","end_date":null,"nol_date":"2016-04-27","protocol_title":"BIOREST LIPOSOMAL ALENDRONATE ADMINISTRATION FOR DIABETIC PATIENTS UNDERGOING DRUG-ELUTING STENT PERCUTANEOUS CORONARY INTERVENTION THE BLADE-PCI TRIAL","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45361,"protocol_no":"CAMHPET-CTA-106","submission_no":"204188","status_id":1,"start_date":"2017-05-10","end_date":null,"nol_date":"2017-04-21","protocol_title":"FOUR REPEAT TAUOPATHY NEUROIMAGING INITIATIVE","medConditionList":[{"med_condition_id":768,"med_condition":"PROGRESSIVE SUPRANUCLEAR PALSY"},{"med_condition_id":786,"med_condition":"CARTICOBASAL DEGENERATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47537,"protocol_no":"GO39733","submission_no":"211203","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-11","protocol_title":"A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS","medConditionList":[{"med_condition_id":796,"med_condition":"METASTATIC SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38788,"protocol_no":"103A-301","submission_no":"183173","status_id":1,"start_date":"2016-12-14","end_date":null,"nol_date":"2015-04-24","protocol_title":"A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, ADAPTIVE PHASE 3 TRIAL OF POL-103A POLYVALENT MELANOMA VACCINE IN POST-RESECTION MELANOMA PATIENTS WITH A HIGH RISK OF RECURRENCE.","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38577,"protocol_no":"CV185-325","submission_no":"182477","status_id":1,"start_date":"2015-10-14","end_date":null,"nol_date":"2015-03-31","protocol_title":"A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND EXTRAPOLATED EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT.","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28452,"protocol_no":"LYC.1 (E1411)","submission_no":"168610","status_id":1,"start_date":"2016-07-28","end_date":null,"nol_date":"2013-11-06","protocol_title":"INTERGROUP RANDOMIZED PHASE II FOUR ARM STUDY IN PATIENTS 60 WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA OF THERAPY WITH: ARM A = RITUXIMAB+ BENDAMUSTINE FOLLOWED BY RITUXIMAB CONSOLIDATION; ARM B = RITUXIMAB + BENDAMUSTINE + BORTEZOMIB FOLLOWED BY RITUXIMAB CONSOLIDATION, ARM C = RITUXIMAB + BENDAMUSTINE FOLLOWED BY LENALIDOMIDE + RITUXIMAB CONSOLIDATION OR ARM D = RITUXIMAB + BENDAMUSTINE + BORTEZOMIB FOLLOWED BY LENALIDOMIDE + RITUXIMAB CONSOLIDATION","medConditionList":[{"med_condition_id":424,"med_condition":"MANTLE CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27901,"protocol_no":"CAMN107A2203","submission_no":"167004","status_id":1,"start_date":"2016-09-01","end_date":null,"nol_date":"2013-08-28","protocol_title":"A MULTI-CENTER, OPEN LABEL, NON-CONTROLLED PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF ORAL NILOTINIB IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) IN CHRONIC PHASE (CP) OR WITH PH+ CML IN CP OR ACCELERATED PHASE (AP) RESISTANT OR INTOLERANT TO EITHER IMATINIB OR DASATINIB","medConditionList":[{"med_condition_id":46,"med_condition":"CHRONIC MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43753,"protocol_no":"2179","submission_no":"199062","status_id":1,"start_date":"2016-12-01","end_date":null,"nol_date":"2016-11-08","protocol_title":"STRESS ULCER PROPHYLAXIS IN CRITICALLY ILL CHILDREN: A PILOT TRIAL","medConditionList":[{"med_condition_id":829,"med_condition":"CRITICALLY ILL"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37768,"protocol_no":"LP0053-1030","submission_no":"179677","status_id":1,"start_date":"2015-02-06","end_date":null,"nol_date":"2014-12-11","protocol_title":"PATIENT INSIGHTS FOLLOWING USE OF LEO 90100 AEROSOL FOAM AND DOVOBET GEL IN SUBJECTS WITH PSORIASIS VULGARIS.","medConditionList":[{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37212,"protocol_no":"IM140-103","submission_no":"177874","status_id":1,"start_date":"2017-02-08","end_date":null,"nol_date":"2014-10-10","protocol_title":"OPEN LABEL, ADAPTIVE DESIGN, ASCENDING, MULTIPLE-DOSE STUDY TO EVALUATE SAFETY AND EFFICACY OF BMS-986004 (ANTI-CD40L DAB) IN ADULT SUBJECTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)","medConditionList":[{"med_condition_id":128,"med_condition":"IMMUNE THROMBOCYTOPENIA (ITP)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28216,"protocol_no":"GS-US-292-0117","submission_no":"167971","status_id":1,"start_date":"2014-02-04","end_date":null,"nol_date":"2013-09-20","protocol_title":"A PHASE 3, TWO-PART STUDY TO EVALUATE THE EFFICACY OF TENOFOVIR ALAFENAMIDE VERSUS PLACEBO ADDED TO A FAILING REGIMEN FOLLOWED BY TREATMENT WITH ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN HIV-1 POSITIVE, ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28290,"protocol_no":"DRM02-ADM02","submission_no":"168166","status_id":2,"start_date":"2013-10-18","end_date":"2014-03-25","nol_date":"2013-10-08","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF TOPICAL DRM02 IN SUBJECTS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28282,"protocol_no":"VX13-135-105","submission_no":"168150","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-10-25","protocol_title":"A PHASE 2, MULTICENTER, PARTIALLY RANDOMIZED, PARTIALLY BLIND, DOSE  RANGING STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF VX 135 AND DACLATASVIR IN TREATMENT NA√èVE ADULT SUBJECTS WITH GENOTYPES 1 AND 3 CHRONIC HEPATITIS C.","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27337,"protocol_no":"GIC13-01","submission_no":"165477","status_id":1,"start_date":"2013-11-12","end_date":null,"nol_date":"2013-07-03","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIA PROOF-OF-CONCEPT STUDY OF GIC-1001 IN THE MANAGEMENT OF VISCERAL PAIN IN SUBJECTS UNDERGOING SEDATION-FREE FULL COLONOSCOPY","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40382,"protocol_no":"AI444-377","submission_no":"187907","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-10-20","protocol_title":"A RANDOMIZED, OPEN-LABEL STUDY OF DACLATASVIR AND SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR 8 WEEKS IN TREATMENT-NAIVE, NON-CIRRHOTIC SUBJECTS INFECTED WITH CHRONIC HCV GENOTYPE 3.","medConditionList":[{"med_condition_id":108,"med_condition":"HEPATITIS C VIRUS GENOTYPE 3"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47697,"protocol_no":"1289.49","submission_no":"211591","status_id":1,"start_date":"2018-01-03","end_date":null,"nol_date":"2017-12-20","protocol_title":"A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306 DURING A 28-WEEK TREATMENT PERIOD AS ADJUNCTIVE THERAPY TO ANTIPSYCHOTIC TREATMENT FOR THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA.","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43608,"protocol_no":"1620302","submission_no":"198628","status_id":1,"start_date":"2016-12-14","end_date":null,"nol_date":"2016-10-27","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DAXIBOTULINUMTOXINA FOR INJECTION TO TREAT MODERATE TO SEVERE GLABELLAR LINES (SAKURA 2)","medConditionList":[{"med_condition_id":380,"med_condition":"GLABELLAR LINES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38732,"protocol_no":"AI468038","submission_no":"183002","status_id":2,"start_date":"2015-08-28","end_date":"2017-08-21","nol_date":"2015-04-15","protocol_title":"A PHASE 2B RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND TRIAL TO INVESTIGATE SAFETY, EFFICACY AND DOSE-RESPONSE OF BMS-955176, GIVEN ON A BACKBONE OF TENOFOVIR/EMTRICITABINE, IN TREATMENT-NAIVE HIV-1 INFECTED ADULTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36177,"protocol_no":"1199.52","submission_no":"174728","status_id":2,"start_date":"2015-03-05","end_date":"2016-06-14","nol_date":"2014-06-09","protocol_title":"A DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED PHASE III STUDY OF NINTEDANIB PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD THERAPIES","medConditionList":[{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35935,"protocol_no":"280114","submission_no":"174006","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-05-14","protocol_title":"RISEDRONATE IN CHRONIC KIDNEY DISEASE (RICK): A RANDOMIZED CONTROLLED PILOT STUDY","medConditionList":[{"med_condition_id":181,"med_condition":"OSTEROPOROSIS"},{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41804,"protocol_no":"04-30","submission_no":"192804","status_id":1,"start_date":"2016-06-01","end_date":null,"nol_date":"2016-04-01","protocol_title":"A PHASE III, INTERNATIONAL, RANDOMIZED, CONTROLLED STUDY OF RIGOSERTIB VERSUS PHYSICIAN'S CHOICE OF TREATMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AFTER FAILURE OF A HYPOMETHYLATING AGENT","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36775,"protocol_no":"A8241021","submission_no":"176537","status_id":2,"start_date":"2015-01-29","end_date":"2016-12-14","nol_date":"2014-08-15","protocol_title":"A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON'S DISEASE","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41989,"protocol_no":"APOE2","submission_no":"193520","status_id":2,"start_date":"2016-06-01","end_date":"2017-04-18","nol_date":"2016-04-21","protocol_title":"PROOF-OF-CONCEPT EVALUATION OF PROBUCOL FOR PREVENTION OF ALZHEIMER'S DEMENTIA","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44874,"protocol_no":"DU-176B-C-U4001","submission_no":"202676","status_id":1,"start_date":"2017-05-04","end_date":null,"nol_date":"2017-03-01","protocol_title":"EDOXABAN VERSUS STANDARD OF CARE AND THEIR EFFECTS ON CLINICAL OUTCOMES IN PATIENTS HAVING UNDERGONE TRANSCATHETER AORTIC VALVE IMPLANTATION ¬ø IN ATRIAL FIBRILLATION (ENVISAGE-TAVI-AF)","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46640,"protocol_no":"ISIS 443 139-CS2","submission_no":"208212","status_id":1,"start_date":"2017-11-06","end_date":null,"nol_date":"2017-09-12","protocol_title":"AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY,","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45844,"protocol_no":"SCI-B-VAC-002","submission_no":"205637","status_id":1,"start_date":"2017-12-06","end_date":null,"nol_date":"2017-06-14","protocol_title":"A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL TO ASSESS THE LOT-TO-LOT CONSISTENCY OF SCI-B-VAC IN ADULTS","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47839,"protocol_no":"STRIVE.2017","submission_no":"212135","status_id":1,"start_date":"2018-04-06","end_date":null,"nol_date":"2018-01-17","protocol_title":"ADJUNCTIVE, LOW-DOSE INTRACORONARY RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) VERSUS PLACEBO FOR PRIMARY PCI IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION","medConditionList":[{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37111,"protocol_no":"20140128","submission_no":"177553","status_id":1,"start_date":"2015-04-13","end_date":null,"nol_date":"2014-09-26","protocol_title":"A MULTICENTER, OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF EVOLOCUMAB","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46179,"protocol_no":"16-214-02","submission_no":"206658","status_id":1,"start_date":"2017-12-13","end_date":null,"nol_date":"2017-07-14","protocol_title":"A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-214 AND NIVOLUMAB IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39219,"protocol_no":"CAMHPET-CTA-96","submission_no":"184524","status_id":1,"start_date":"2015-06-24","end_date":null,"nol_date":"2015-06-12","protocol_title":"MULTIMODAL ASSESSMENT FOR PREDICTING SPECIFIC PATHOLOGICAL SUBSTRATE IN FRONTOTEMPORAL LOBAR DEGENERATION","medConditionList":[{"med_condition_id":624,"med_condition":"FRONTOTEMPORAL LOBAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28778,"protocol_no":"BO28407","submission_no":"169800","status_id":1,"start_date":"2014-04-22","end_date":null,"nol_date":"2013-12-06","protocol_title":"A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES  AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27290,"protocol_no":"B1871040","submission_no":"165296","status_id":1,"start_date":"2014-01-14","end_date":null,"nol_date":"2013-06-27","protocol_title":"AN OPEN LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008","medConditionList":[{"med_condition_id":46,"med_condition":"CHRONIC MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35743,"protocol_no":"GA28950","submission_no":"173305","status_id":1,"start_date":"2014-09-29","end_date":null,"nol_date":"2014-05-02","protocol_title":"PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE REFRACTORY TO OR INTOLERANT OF TNF INHIBITORS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38379,"protocol_no":"KCP-330-017","submission_no":"181897","status_id":1,"start_date":"2016-02-15","end_date":null,"nol_date":"2015-02-24","protocol_title":"A PHASE 1B/2 STUDY OF SELINEXOR (KPT-330) IN COMBINATION WITH BACKBONE TREATMENTS FOR RESISTANT/REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42675,"protocol_no":"M15-574","submission_no":"195817","status_id":1,"start_date":"2017-05-08","end_date":null,"nol_date":"2016-07-07","protocol_title":"A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF ADALIMUMAB USED IN CONJUNCTION WITH SUGERY IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA","medConditionList":[{"med_condition_id":112,"med_condition":"HIDRADENITIS SUPPURATIVA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43682,"protocol_no":"SGI-110-06","submission_no":"198884","status_id":1,"start_date":"2017-02-27","end_date":null,"nol_date":"2016-10-27","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF GUADECITABINE (SGI-110) VERSUS TREATMENT CHOICE IN ADULTS WITH PREVIOUSLY TREATED ACUTE MYELOID LEUKEMIA","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41967,"protocol_no":"C31004","submission_no":"193443","status_id":1,"start_date":"2017-11-17","end_date":null,"nol_date":"2016-04-13","protocol_title":"A PHASE 2, RANDOMIZED STUDY OF MLN0128 (A DUAL TORC1/2 INHIBITOR), MLN0128+MLN1117 (A PI3K? INHIBITOR), WEEKLY PACLITAXEL, OR THE COMBINATION OF WEEKLY PACLITAXEL AND MLN0128 IN WOMEN WITH ADVANCED, RECURRENT, OR PERSISTENT ENDOMETRIAL CANCER","medConditionList":[{"med_condition_id":73,"med_condition":"ENDOMETRIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41404,"protocol_no":"V01-120A-201","submission_no":"191408","status_id":2,"start_date":"2016-02-22","end_date":"2016-12-13","nol_date":"2016-02-11","protocol_title":"A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-120 GEL IN THE TREATMENT OF ACNE VULGARIS.","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36787,"protocol_no":"PRO 48233","submission_no":"176567","status_id":1,"start_date":"2014-09-18","end_date":null,"nol_date":"2014-08-20","protocol_title":"A PROSPECTIVE, MULTI-CENTER, RANDOMIZED TRIAL OF FECAL MICROBIOTA TRANSPLANTATION (FMT) DELIVERED BY CAPSULE VS. COLONOSCOPY IN THE MANAGEMENT OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (CDI)","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27961,"protocol_no":"ASM-024/II/STA-04","submission_no":"167166","status_id":1,"start_date":"2013-10-07","end_date":null,"nol_date":"2013-09-04","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-WAY CROSSOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND CLINICAL ACTIVITY OF ASM-024 ADMINISTERED BY DRY POWDER INHALATION TO PATIENTS WITH GOLD 2 (MODERATE) OR GOLD 3 (SEVERE) CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44873,"protocol_no":"VX16-809-116","submission_no":"202674","status_id":1,"start_date":"2017-05-25","end_date":null,"nol_date":"2017-02-22","protocol_title":"A PHASE 3, ROLLOVER STUDY TO EVALUATE THE SAFETY OF LONG-TERM TREATMENT WITH LUMACAFTOR/IVACAFTOR COMBINATION THERAPY IN SUBJECTS AGED 2 YEARS AND OLDER WITH CYSTIC FIBROSIS, HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39192,"protocol_no":"201755","submission_no":"184426","status_id":1,"start_date":"2016-03-03","end_date":null,"nol_date":"2015-06-11","protocol_title":"A PHASE IIB, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-ADAPTIVE, STUDY OF THE EFFICACY AND SAFETY OF GSK3196165 IN COMBINATION WITH METHOTREXATE THERAPY, IN SUBJECTS WITH ACTIVE MODERATE-SEVERE RHEUMATOID ARTHRITIS DESPITE TREATMENT WITH METHOTREXATE","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38236,"protocol_no":"CAIN457 F2336","submission_no":"181352","status_id":1,"start_date":"2015-07-28","end_date":null,"nol_date":"2015-02-13","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB (150MG) IN PRE-FILLED SYRINGE, WITH OR WITHOUT LOADING REGIMEN TO DEMONSTRATE EFFICACY, SAFETY AND TOLERABILITY UP TO 2 YEARS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (FUTURE4)","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43843,"protocol_no":"ZX008-1504","submission_no":"199355","status_id":1,"start_date":"2017-04-12","end_date":null,"nol_date":"2016-11-16","protocol_title":"A MULTICENTER, 2-COHORT TRIAL TO FIRST ASSESS THE PHARMACOKINETIC AND SAFETY PROFILE OF A SINGLE DOSE OF ZX008 (FENFLURAMINE HYDROCHLORIDE) ORAL SOLUTION WHEN ADDED TO STANDARD OF CARE (COHORT 1), FOLLOWED BY A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ZX008 AS ADJUNCTIVE ANTIEPILEPTIC THERAPY TO STIRIPENTOL TREATMENT IN CHILDREN AND YOUNG ADULTS WITH DRAVET SYNDROME (COHORT 2)","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36746,"protocol_no":"ISIS 396443-CS3B","submission_no":"176460","status_id":1,"start_date":"2014-11-03","end_date":null,"nol_date":"2014-08-12","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, SHAM-PROCEDURE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY AND SAFETY OF ISIS 396443 ADMINISTERED INTRATHECALLY IN PATIENTS WITH INFANTILE-ONSET SPINAL MUSCULAR ATROPHY","medConditionList":[{"med_condition_id":321,"med_condition":"SPINAL MUSCULAR ATROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42613,"protocol_no":"SHP626-201","submission_no":"195571","status_id":1,"start_date":"2017-07-07","end_date":null,"nol_date":"2016-06-30","protocol_title":"A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF VOLIXIBAT POTASSIUM, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)","medConditionList":[{"med_condition_id":734,"med_condition":"NONALCOHOLIC STEATOHEPATITIS (NASH)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47273,"protocol_no":"CCT38473","submission_no":"210404","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-02","protocol_title":"RE-EVALUATING THE INHIBITION OF STRESS EROSIONS AND PROPHYLAXIS AGAINST GASTROINTESTINAL BLEEDING IN THE CRITICALLY ILL (REVISE) TRIAL - THE REVISE TRIAL","medConditionList":[{"med_condition_id":594,"med_condition":"ULCERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39544,"protocol_no":"15-8820","submission_no":"185661","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-08-07","protocol_title":"IN VIVO LUNG PERFUSION (IVLP) AS AN ADJUVANT TREATMENT FOR PATIENTS UNDERGOING SURGICAL RESECTION OF PULMONARY METASTASES OF BONE AND SOFT TISSUES SARCOMAS","medConditionList":[{"med_condition_id":237,"med_condition":"SOFT TISSUE SARCOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36838,"protocol_no":"ANBL1232","submission_no":"176714","status_id":1,"start_date":"2015-05-22","end_date":null,"nol_date":"2014-08-21","protocol_title":"UTILIZING RESPONSE AND BIOLOGY-BASED RISK FACTORS TO GUIDE THERAPY IN PATIENTS WITH NON-HIGH-RISK NEUROBLASTOMA","medConditionList":[{"med_condition_id":172,"med_condition":"NEUROBLASTOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37139,"protocol_no":"M14-423","submission_no":"177665","status_id":1,"start_date":"2015-01-27","end_date":null,"nol_date":"2014-09-24","protocol_title":"AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE LONG-TERM OUTCOMES WITH ABT-450/RITONAVIR/ABT-267 (ABT-450/R/ABT-267) AND ABT-333 WITH OR WITHOUT RIBAVIRIN (RBV) IN ADULTS WITH GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION (TOPAZ-I).","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28805,"protocol_no":"ICH02","submission_no":"169902","status_id":1,"start_date":"2014-05-23","end_date":null,"nol_date":"2014-01-09","protocol_title":"MINIMALLY INVASIVE SURGERY PLUS RT-PA FOR ICH EVACUATION MISTIE","medConditionList":[{"med_condition_id":404,"med_condition":"INTRACEREBAL HEMORRAGE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39622,"protocol_no":"NBI-98854-1402","submission_no":"185882","status_id":2,"start_date":"2015-10-01","end_date":"2017-03-01","nol_date":"2015-07-28","protocol_title":"A PHASE 3, OPEN-LABEL, SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF TARDIVE DYSKINESIA","medConditionList":[{"med_condition_id":604,"med_condition":"TARDIVE DYSKINESIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42527,"protocol_no":"FKB238-002","submission_no":"195267","status_id":2,"start_date":"2017-02-09","end_date":"2018-01-17","nol_date":"2016-06-28","protocol_title":"A RANDOMISED, PARALLEL, DOUBLE BLINDED STUDY TO COMPARE THE EFFICACY AND SAFETY OF FKB238 TO AVASTIN IN 1ST LINE TREATMENT FOR PATIENTS WITH ADVANCED/RECURRENT NON SQUAMOUS NON-SMALL CELL LUNG CANCER IN COMBINATION OF PACLITAXEL AND CARBOPLATIN","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45970,"protocol_no":"000233","submission_no":"205969","status_id":1,"start_date":"2018-01-26","end_date":null,"nol_date":"2017-06-16","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, RESPONSE-ADAPTIVE DOSE-FINDING TRIAL","medConditionList":[{"med_condition_id":175,"med_condition":"NOCTURIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46222,"protocol_no":"D3250C00045","submission_no":"206778","status_id":1,"start_date":"2017-09-05","end_date":null,"nol_date":"2017-07-26","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, PHASE 3B STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BENRALIZUMAB 30 MG SC IN PATIENTS WITH SEVERE ASTHMA UNCONTROLLED ON STANDARD OF CARE TREATMENT","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41358,"protocol_no":"20120124","submission_no":"191265","status_id":1,"start_date":"2016-12-12","end_date":null,"nol_date":"2016-02-03","protocol_title":"OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF EVOLOCUMAB FOR LDL-C REDUCTION, AS ADD-ON TO DIET AND LIPID-LOWERING THERAPY, IN PEDIATRIC SUBJECTS FROM 10 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)","medConditionList":[{"med_condition_id":116,"med_condition":"HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"},{"med_condition_id":111,"med_condition":"HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43674,"protocol_no":"PN041","submission_no":"198870","status_id":2,"start_date":"2017-02-24","end_date":"2017-12-22","nol_date":"2016-10-31","protocol_title":"A PHASE 2, OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF 12 WEEKS OF THE COMBINATION REGIMEN OF MK-3682 + MK-8408 IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45538,"protocol_no":"M15-554","submission_no":"204733","status_id":1,"start_date":"2017-10-06","end_date":null,"nol_date":"2017-05-03","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING ABT-494 TO PLACEBO IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE A HISTORY OF INADEQUATE RESPONSE TO AT LEAST ONE BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUG (BDMARD) ¬ø SELECT ¬ø PSA 2","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39350,"protocol_no":"022","submission_no":"184905","status_id":1,"start_date":"2017-01-05","end_date":null,"nol_date":"2015-07-03","protocol_title":"A PHASE I/II STUDY TO ASSESS THE SAFETY AND EFFICACY OF MK-3475 IN COMBINATION WITH TRAMETINIB AND DABRAFENIB IN SUBJECTS WITH ADVANCED MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36653,"protocol_no":"MMRC-043 (IRB # 12-1725)","submission_no":"176125","status_id":1,"start_date":"2017-07-27","end_date":null,"nol_date":"2014-07-29","protocol_title":"OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY OF THE INITIAL AND POST-TRANSPLANT TREATMENT WITH CARFILZOMIB, LENALIDOMIDE AND LOW DOSE DEXAMETHASONE (CRD) IN TRANSPLANT CANDIDATES WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) REQUIRING SYSTEMIC CHEMOTHERAPY","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47034,"protocol_no":"NLRC4/XIAP.2016.001","submission_no":"209542","status_id":1,"start_date":"2017-12-12","end_date":null,"nol_date":"2017-10-20","protocol_title":"MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WITH TADEKINIG ALFA (R-IL-18BP) IN PATIENTS WITH IL-18 DRIVEN MONOGENIC AUTOINFLAMMATORY CONDITIONS: NLRC4 MUTATION AND XIAP DEFICIENCY","medConditionList":[{"med_condition_id":811,"med_condition":"IL-18 DRIVEN MONOGENIC AUTOINFLAMMATORY CONDITIONS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27417,"protocol_no":"TRC117146","submission_no":"165674","status_id":1,"start_date":"2014-05-08","end_date":null,"nol_date":"2013-07-04","protocol_title":"A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE ORAL THROMBOPOIETIN RECEPTOR AGONIST, ELTROMBOPAG, ADMINISTERED TO SUBJECTS WITH ACUTE MYELOGENOUS LEUKAEMIA (AML) RECEIVING INDUCTION CHEMOTHERAPY","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43137,"protocol_no":"GS-US-417-0301","submission_no":"197283","status_id":1,"start_date":"2016-11-14","end_date":null,"nol_date":"2016-08-25","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, MULTICENTER, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF FILGOTINIB ADMINISTERED FOR 52 WEEKS IN COMBINATION WITH METHOTREXATE TO SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE AN INADEQUATE RESPONSE TO METHOTREXATE","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38501,"protocol_no":"20120123","submission_no":"182247","status_id":1,"start_date":"2016-05-13","end_date":null,"nol_date":"2015-03-19","protocol_title":"DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO CHARACTERIZE THE EFFICACY, SAFETY AND TOLERABLITY OF 24 WEEKS OF EVOLOCUMAB FOR LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LSL-C) REDUCTION, AS ADD-ON TO DIET AND LIPID-LOWERING THERAPY, IN PEDIATRIC SUBJECTS 10 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)","medConditionList":[{"med_condition_id":111,"med_condition":"HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45773,"protocol_no":"SPY LNM 01","submission_no":"205451","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-14","protocol_title":"A RANDOMIZED, PROSPECTIVE, OPEN LABEL, MULTICENTER STUDY ASSESSING THE SAFETY AND UTILITY OF IC2000 AND SPY FLUORESCENCE IMAGING SYSTEMS IN THE IDENTIFICATION OF LYMPH NODES DURING LYMPHATIC MAPPING IN SUBJECTS WITH BREAST CANCER.","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27222,"protocol_no":"170676","submission_no":"165179","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-06-21","protocol_title":"PILOT STUDY OF TENOFOVIR AND EMTRICITABINE FOR PRIMARY BILIARY CIRRHOSIS","medConditionList":[{"med_condition_id":209,"med_condition":"PRIMARY BILIARY CIRRHOSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26695,"protocol_no":"CDHA-RS/2013-110","submission_no":"163511","status_id":3,"start_date":"2013-05-01","end_date":null,"nol_date":"2013-04-24","protocol_title":"\"THE USE OF FIBRINOGEN CONCENTRATE IN HIGH-RISK CARDIAC SURGERY: A PROSPECTIVE, DOUBLE-BLINDED, RANDOMIZED, CONTROLLED STUDY.\"","medConditionList":[{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45334,"protocol_no":"M15-656","submission_no":"204137","status_id":1,"start_date":"2017-10-31","end_date":null,"nol_date":"2017-04-12","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE VERSUS AZACITIDINE IN TREATMENT NA√èVE SUBJECTS WITH ACUTE MYELOID LEUKEMIA WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47708,"protocol_no":"BP39055","submission_no":"211590","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-20","protocol_title":"A TWO-PART SEAMLESS, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS.","medConditionList":[{"med_condition_id":321,"med_condition":"SPINAL MUSCULAR ATROPHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47589,"protocol_no":"679","submission_no":"211311","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-14","protocol_title":"A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) PLUS EPACADOSTAT VS STANDARD OF CARE (SUNITINIB OR PAZOPANIB) AS FIRST-LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA (MRCC) (KEYNOTE-679/ECHO-302)","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36332,"protocol_no":"GS-US-312-0133","submission_no":"175088","status_id":1,"start_date":"2015-06-24","end_date":null,"nol_date":"2014-06-25","protocol_title":"A PHASE 2, SINGLE ARM STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27219,"protocol_no":"5945-OIC-12-04","submission_no":"165170","status_id":1,"start_date":"2013-08-06","end_date":null,"nol_date":"2013-06-21","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CB-5945 FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN ADULTS TAKING OPIOID THERAPY FOR CHRONIC NON-CANCER PAIN","medConditionList":[{"med_condition_id":276,"med_condition":"OPIOID-INDUCED CONSTIPATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45741,"protocol_no":"B7451002","submission_no":"205359","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-06","protocol_title":"A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF 04965842 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)","medConditionList":[{"med_condition_id":311,"med_condition":"SYSTEMIC LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48304,"protocol_no":"COMB157G1301","submission_no":"213555","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-09","protocol_title":"A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF OFATUMUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS FOLLOWED BY AN EXTENDED TREATMENT OF AT LEAST 24 WEEKS WITH OPEN-LABEL OFATUMUMAB","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45546,"protocol_no":"R727-CL-1628","submission_no":"204763","status_id":1,"start_date":"2017-09-27","end_date":null,"nol_date":"2017-05-24","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","medConditionList":[{"med_condition_id":116,"med_condition":"HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35587,"protocol_no":"12-325-BMA","submission_no":"172845","status_id":2,"start_date":"2015-11-02","end_date":"2016-03-09","nol_date":"2014-04-04","protocol_title":"PHYSIOLOGICAL MECHANISMS OF DYSPNEA RELIEF AND IMPROVED EXERCISE TOLERANCE AFTER TREATMENT WITH ORAL MORPHINE IN PATIENTS WITH ADVANCED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28817,"protocol_no":"GS-US-315-0102","submission_no":"169932","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-12","protocol_title":"A PHASE 1B STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF GS 9820 MONOTHERAPY AND COMBINATION THERAPY IN SUBJECTS WITH LYMPHOID MALIGNANCIES","medConditionList":[{"med_condition_id":440,"med_condition":"LYMPHOID MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39895,"protocol_no":"15KMHI","submission_no":"186567","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-09-02","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PARALLEL STUDY TO INVESTIGATE THE EFFECT OF 7-KETO ON RESTING METABOLIC RATE IN OVERWEIGHT ADULTS","medConditionList":[{"med_condition_id":415,"med_condition":"OVERWEIGHT/OBESITY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28156,"protocol_no":"POST 5","submission_no":"167463","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-11-07","protocol_title":"ASSESSMENT OF METOPROLOL IN THE PREVENTION OF VASOVAGAL SYNCOPE IN AGING SUBJECTS","medConditionList":[{"med_condition_id":413,"med_condition":"VASOVAGAL SYNCOPE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40765,"protocol_no":"BCX7353-201","submission_no":"189058","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-02","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, 4 WEEK, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF BCX7353 AS A PREVENTATIVE TREATMENT TO REDUCE THE FREQUENCY OF ATTACKS IN SUBJECTS WITH HEREDITARY ANGIOEDEMA","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41100,"protocol_no":"ZA8DEC2015","submission_no":"190283","status_id":1,"start_date":"2016-08-23","end_date":null,"nol_date":"2016-01-05","protocol_title":"INTRAVENOUS ZOLEDRONIC ACID FOR THE TREATMENT OF OSTEOPOROSIS AND OSTEONECROSIS IN CHILDREN WITH LEUKEMIA: A PILOT STUDY","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39425,"protocol_no":"D2210C00014","submission_no":"185197","status_id":1,"start_date":"2016-03-22","end_date":null,"nol_date":"2015-07-08","protocol_title":"A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED, 12-WEEK, PHASE 2 STUDY TO EVALUATE THE EFFECT OF TRALOKINUMAB ON AIRWAY INFLAMMATION IN ADULTS WITH ASTHMA INADEQUATELY CONTROLLED ON INHALED CORTICOSTROID (MESOS).","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47377,"protocol_no":"18F-AV-1451-A23","submission_no":"210762","status_id":1,"start_date":"2018-01-08","end_date":null,"nol_date":"2017-11-28","protocol_title":"A MULTICENTER SCREENING STUDY WITH FLORTAUCIPIR F 18 IN PATIENTS WITH EARLY SYMPTOMATIC AD","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28732,"protocol_no":"191622-130","submission_no":"169580","status_id":1,"start_date":"2014-05-07","end_date":null,"nol_date":"2013-12-18","protocol_title":"BOTOX TREATMENT OF MASSETER MUSCLE HYPERTROPHY","medConditionList":[{"med_condition_id":403,"med_condition":"MASSETER MUSCLE HYPERTROPHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42374,"protocol_no":"AP26113-13-301","submission_no":"194748","status_id":1,"start_date":"2017-03-16","end_date":null,"nol_date":"2016-05-31","protocol_title":"A PHASE 3 MULTICENTER OPEN-LABEL STUDY OF BRIGATINIB (AP26113) VERSUS CRIZOTINIB IN PATIENTS WITH ALK-POSITIVE ADVANCED LUNG CANCER AP26113-13-301","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43637,"protocol_no":"EFC14833","submission_no":"198727","status_id":1,"start_date":"2017-09-08","end_date":null,"nol_date":"2016-10-24","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SOTAGLIFLOZIN AS MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL","medConditionList":[{"med_condition_id":388,"med_condition":"DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45084,"protocol_no":"A083-02","submission_no":"203262","status_id":1,"start_date":"2017-04-28","end_date":null,"nol_date":"2017-03-28","protocol_title":"A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ACE-083 IN PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY","medConditionList":[{"med_condition_id":774,"med_condition":"MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41237,"protocol_no":"3HP-IQ-OT-01","submission_no":"190784","status_id":1,"start_date":"2016-05-30","end_date":null,"nol_date":"2016-01-21","protocol_title":"TAIMA TB 3HP STUDY: ACCEPTABILITY AND COMPLETION RATES OF A NEW 12 DOSE TREATMENT (3 MONTH) COMPARED TO THE STANDARD TREATMENT FOR LATENT TB INFECTION TREATMENT","medConditionList":[{"med_condition_id":790,"med_condition":"LATENT TUBERCULOSIS (TB) INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44781,"protocol_no":"I1F-MC-RHCD","submission_no":"202392","status_id":1,"start_date":"2017-04-24","end_date":null,"nol_date":"2017-03-01","protocol_title":"MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42026,"protocol_no":"RVT-101-2001","submission_no":"193696","status_id":2,"start_date":"2016-09-13","end_date":"2018-04-24","nol_date":"2016-04-21","protocol_title":"A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF RVT-101 IN SUBJECTS WITH DEMENTIA WITH LEWY BODIES (DLB)","medConditionList":[{"med_condition_id":361,"med_condition":"DEMENTIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39006,"protocol_no":"ALN-TTRSC-004","submission_no":"183863","status_id":2,"start_date":"2016-12-02","end_date":"2017-07-12","nol_date":"2015-05-19","protocol_title":"A PHASE 3 MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALN-TTRSC IN PATIENTS WITH TRANSTHYRETIN (TTR) MEDIATED FAMILIAL AMYLOIDOTIC CARDIOMYOPATHY (FAC)","medConditionList":[{"med_condition_id":657,"med_condition":"FAMILIAL AMYLOIDOTIC CARDIOMYOPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46978,"protocol_no":"TAK-653-2001","submission_no":"209349","status_id":1,"start_date":"2017-12-13","end_date":null,"nol_date":"2017-10-12","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-653 IN THE TREATMENT OF SUBJECTS WITH TREATMENT-RESISTANT DEPRESSION","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37898,"protocol_no":"AB08026","submission_no":"180021","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-17","protocol_title":"A PROSPECTIVE, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, TWO-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF MASITINIB AT 7.5 MG/KG/DAY TO DACARBAZINE IN THE TREATMENT OF PATIENTS WITH NON-RESECTABLE OR METASTATIC STAGE 3 OR STAGE 4 MELANOMA CARRYING A MUTATION IN THE JUXTA MEMBRANE DOMAIN OF C-KIT.","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38073,"protocol_no":"R668-AD-1412","submission_no":"180645","status_id":1,"start_date":"2015-02-19","end_date":null,"nol_date":"2015-01-16","protocol_title":"A PHASE 2A STUDY INVESTIGATING THE SAFETY, PHARMACOKINETICS, IMMUNOGENOCITY AND EXPLORATORY EFFICACY OF DUPILUMAB IN PATIENTS AGED 6 TO 12 YEARS WITH ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27865,"protocol_no":"CAT-2003-201","submission_no":"166907","status_id":1,"start_date":"2013-08-28","end_date":null,"nol_date":"2013-08-28","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY TO ASSESS THE SAFETY, EFFICACY AND PHARMACODYNAMICS OF CAT-2003 ALONE AND IN COMBINATION WITH A STATIN IN PATIENTS WITH HYPERLIPIDEMIA (PATHWAYS I)","medConditionList":[{"med_condition_id":349,"med_condition":"HYPERTRIGLYCERIDEMIA"},{"med_condition_id":348,"med_condition":"HYPERLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36323,"protocol_no":"1160.108","submission_no":"175068","status_id":1,"start_date":"2017-04-03","end_date":null,"nol_date":"2014-06-25","protocol_title":"OPEN LABEL, SINGLE ARM SAFETY PROSPECTIVE COHORT STUDY OF DABIGATRAN  ETEXILATE FOR SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM IN CHILDREN FROM 0 TO LESS THAN 18 YEARS","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36675,"protocol_no":"PED-301","submission_no":"176223","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-21","protocol_title":"A MULTICENTER TRIAL OF THE EFFICACY AND SAFETY OF DICLEGIS¬Æ FOR NAUSEA AND VOMITING OF PREGNANCY IN PREGNANT ADOLESCENTS","medConditionList":[{"med_condition_id":302,"med_condition":"NAUSEA AND VOMITING"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27902,"protocol_no":"PHL-088 / NCI 9416","submission_no":"167010","status_id":2,"start_date":"2014-09-11","end_date":"2017-01-31","nol_date":"2013-08-29","protocol_title":"A RANDOMIZED PHASE II TRIAL OF CISPLATIN WITH OR WITHOUT WEE1 KINASE INHIBITOR MK-1775 FOR FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC SQUAMOUS CELL CANCER OF THE HEAD AND NECK (RM-SCCHN)","medConditionList":[{"med_condition_id":34,"med_condition":"CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41882,"protocol_no":"156-11-294","submission_no":"193106","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-04-05","protocol_title":"A PHASE 3B, MULTICENTER, EXTENSION FOLLOW-UP TRIAL TO EVALUATE THE LONG-TERM SAFETY OF CHILDREN AND ADOLESCENT SUBJECTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA WHO HAVE PREVIOUSLY PARTICIPATED IN A TRIAL OF TITRATED ORAL SAMSCA  (TOLVAPTAN)","medConditionList":[{"med_condition_id":730,"med_condition":"EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35985,"protocol_no":"PRO00026356","submission_no":"174101","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-05-13","protocol_title":"CONTRAST ENHANCED THREE-DIMENSIONAL ULTRASOUND (3D CEUS) IN VOLUMETRIC VISUALIZATION OF CAROTID ARTERY PLAQUE: COMPARISON VS. CONVENTIONAL ULTRASOUND AND VALIDATION WITH HISTOPATHOLOGIC ANALYSIS DATA: A PILOT STUDY","medConditionList":[{"med_condition_id":522,"med_condition":"CAROTID ARTERY PLAQUE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27251,"protocol_no":"MDV3100-11","submission_no":"165225","status_id":1,"start_date":"2014-02-03","end_date":null,"nol_date":"2013-06-21","protocol_title":"A PHASE 2, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ENZALUTAMIDE IN PATIENTS WITH ADVANCED, ANDROGEN RECEPTOR POSITIVE, TRIPLE NEGATIVE BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28635,"protocol_no":"BRF117277","submission_no":"169253","status_id":1,"start_date":"2014-11-03","end_date":null,"nol_date":"2013-11-15","protocol_title":"A PHASE II, OPEN-LABEL, MULTICENTRE STUDY OF DABRAFENIB PLUS TRAMETINIB IN SUBJECTS WITH BRAF MUTATION-POSITIVE MELANOMA THAT HAS METASTASIZED TO THE BRAIN","medConditionList":[{"med_condition_id":342,"med_condition":"MELANOMA WITH BRAF MUTATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36766,"protocol_no":"GS-US-342-1138","submission_no":"176511","status_id":2,"start_date":"2014-10-07","end_date":"2015-11-12","nol_date":"2014-08-12","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SOFOSBUVIR/GS-5816 FIXED DOSE COMBINATION FOR 12 WEEKS IN SUBJECTS WITH CHRONIC HCV","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36635,"protocol_no":"CTSN POAF","submission_no":"176059","status_id":1,"start_date":"2014-05-23","end_date":null,"nol_date":"2014-07-18","protocol_title":"RATE CONTROL VERSUS RHYTHM CONTROL FOR POSTOPERATIVE ATRIAL FIBRILLATION","medConditionList":[{"med_condition_id":416,"med_condition":"ATRIAL FLUTTER"},{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36427,"protocol_no":"20130484","submission_no":"175379","status_id":1,"start_date":"2014-11-24","end_date":null,"nol_date":"2014-07-04","protocol_title":"A PHASE 2, OPEN LABEL, PILOT STUDY TO EXAMINE THE USE OF RIVAROXABAN PLUS ASPIRIN  VS. CLOPIDOGREL PLUS ASPIRIN FOR THE PREVENTION OF RESTENOSIS AFTER INFRAINGUINAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY FOR CRITICAL LIMB ISCHEMIA; THE RIFLE STUDY","medConditionList":[{"med_condition_id":536,"med_condition":"INFRAINGUINAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36326,"protocol_no":"1160.186","submission_no":"175073","status_id":2,"start_date":"2016-01-07","end_date":"2017-10-17","nol_date":"2014-06-25","protocol_title":"A PROSPECTIVE RANDOMISED, OPEN LABEL, BLINDED ENDPOINT (PROBE) STUDY TO EVALUATE DUAL ANTITHROMBOTIC THERAPY WITH DABIGATRAN ETEXILATE (110MG AND 150MG B.I.D.) PLUS CLOPIDOGREL OR TICAGRELOR VS. TRIPLE THERAPY STRATEGY WITH WARFARIN (INR 2.0 - 3.0) PLUS CLOPIDOGREL OR TICAGRELOR AND ASPIRIN IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION (NVAF) THAT HAVE UNDERGONE A PERCUTANEOUS CORONARY INTERVENTION (PCI) WITH STENTING. (RE-DUAL PCI)","medConditionList":[{"med_condition_id":56,"med_condition":"CORONARY HEART DISEASE OR HIGH RISK OF CORONONARY HEART DISEASE"},{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44586,"protocol_no":"IXA-CSP-001","submission_no":"201780","status_id":1,"start_date":"2017-03-24","end_date":null,"nol_date":"2017-01-27","protocol_title":"A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE II, DOSE-RANGING TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL LITOXETINE 10 MG, 20 MG AND 40 MG TWICE DAILY (BID) VERSUS PLACEBO IN WOMEN WITH MIXED URINARY INCONTINENCE","medConditionList":[{"med_condition_id":405,"med_condition":"URINARY INCONTINENCE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28556,"protocol_no":"U01NS062091","submission_no":"168963","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-01-17","protocol_title":"ANTIHYPERTENSIVE TREATMENT OF ACUTE CEREBRAL HEMORRHAGE (ATACH)-II","medConditionList":[{"med_condition_id":124,"med_condition":"HYPERTENSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43735,"protocol_no":"MO29983","submission_no":"199032","status_id":1,"start_date":"2017-03-10","end_date":null,"nol_date":"2016-11-04","protocol_title":"AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"},{"med_condition_id":760,"med_condition":"URINARY TRACT CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45532,"protocol_no":"15834","submission_no":"204566","status_id":1,"start_date":"2017-08-11","end_date":null,"nol_date":"2017-05-12","protocol_title":"PHASE 1B MULTI-INDICATION STUDY OF ANETUMAB RAVTANSINE (BAY 94-9343) IN PATIENTS WITH MESOTHELIN EXPRESSING ADVANCED OR RECURRENT MALIGNANCIES","medConditionList":[{"med_condition_id":474,"med_condition":"MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44720,"protocol_no":"802NP301","submission_no":"202196","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-02-17","protocol_title":"A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB074 IN SUBJECTS WITH TRIGEMINAL NEURALGIA","medConditionList":[{"med_condition_id":174,"med_condition":"NEUROPATHIC PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35791,"protocol_no":"BO28408/TRIO021","submission_no":"173473","status_id":1,"start_date":"2014-10-31","end_date":null,"nol_date":"2014-04-30","protocol_title":"A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE III NEOADJUVANT STUDY EVALUATING TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB COMPARED WITH CHEMOTHERAPY PLUS TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH HER-2 POSITIVE BREAST CANCER","medConditionList":[{"med_condition_id":29,"med_condition":"BREAST CANCER HER2-POSITIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35460,"protocol_no":"001-01","submission_no":"172446","status_id":2,"start_date":"2015-03-26","end_date":"2016-09-29","nol_date":"2014-03-21","protocol_title":"A PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF MK-8228 (LETERMOVIR) FOR THE PREVENTION OF CLINICALLY SIGNIFICANT HUMAN CYTOMEGALOVIRUS (CMV) INFECTION IN ADULT, CMV-SEROPOSITIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS","medConditionList":[{"med_condition_id":62,"med_condition":"CYTOMEGALOVIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43941,"protocol_no":"AS0008","submission_no":"199627","status_id":1,"start_date":"2016-11-23","end_date":null,"nol_date":"2016-11-23","protocol_title":"A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS","medConditionList":[{"med_condition_id":3,"med_condition":"ACTIVE ANKYLOSING SPONDYLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42104,"protocol_no":"I1F-MC-RHBX","submission_no":"193912","status_id":1,"start_date":"2016-07-25","end_date":null,"nol_date":"2016-05-02","protocol_title":"A 52-WEEK MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB (LY2439821) IN BDMARD NAIVE PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS","medConditionList":[{"med_condition_id":673,"med_condition":"AXIAL SPONDYLARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41874,"protocol_no":"I1F-MC-RHBQ","submission_no":"193086","status_id":1,"start_date":"2016-04-12","end_date":null,"nol_date":"2016-04-06","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS PLACEBO IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS","medConditionList":[{"med_condition_id":682,"med_condition":"GENITAL PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40705,"protocol_no":"DCC-2618-01-001","submission_no":"188902","status_id":1,"start_date":"2015-12-15","end_date":null,"nol_date":"2015-12-03","protocol_title":"A MULTICENTER PHASE 1, OPEN-LABEL STUDY OF DCC-2618 TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS IN PATIENTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46477,"protocol_no":"ALN-AT3SC-009","submission_no":"207705","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-14","protocol_title":"ATLAS-PPX: AN OPEN-LABEL, MULTINATIONAL, SWITCHING STUDY TO DESCRIBE THE EFFICACY AND SAFETY OF FITUSIRAN PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A AND B PREVIOUSLY RECEIVING FACTOR OR BYPASSING AGENT PROPHYLAXIS.","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"},{"med_condition_id":100,"med_condition":"HEMOPHILIA B"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":43879,"protocol_no":"M15-997","submission_no":"199219","status_id":1,"start_date":"2017-07-13","end_date":null,"nol_date":"2016-11-14","protocol_title":"A MULTICENTER, OPEN LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF RISANKIZUMAB FOR MAINTENANCE IN MODERATE TO SEVERE PLAQUE TYPE PSORIASIS (LIMMITLESS)","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46553,"protocol_no":"BP29435","submission_no":"207948","status_id":1,"start_date":"2017-12-12","end_date":null,"nol_date":"2017-08-25","protocol_title":"A PHASE IB, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF CERGUTUZUMAB AMUNALEUKIN. AN IMMUNOCYTOKINE, WHICH CONSISTS OF A VARIANT OF INTERLEUKIN 2 (IL2V), THAT TARGETS CARCINOEMBROYONIC ANTIGEN (CEA), AND ATEZOLIZUMAB, AN ANTIBODY THAT TARGETS PROGRAMMED DEATH-LIGAND 1 (PD-L1), ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORS","medConditionList":[{"med_condition_id":796,"med_condition":"METASTATIC SOLID TUMOURS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40067,"protocol_no":"XPF-005-101","submission_no":"187000","status_id":2,"start_date":"2016-02-19","end_date":"2017-04-27","nol_date":"2015-09-15","protocol_title":"A PHASE 1 AND 2 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, AND EXPOSURE OF UP TO 12 WEEKS OF XPF-005 TREATMENT IN HEALTHY VOLUNTEERS AND SUBJECTS WITH ACNE VULGARIS","medConditionList":[{"med_condition_id":1,"med_condition":"ACNE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38374,"protocol_no":"2013-14","submission_no":"181873","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-03-03","protocol_title":"A PHASE II TRIAL ON THE EFFECT OF LOW-DOSE VERSUS HIGH-DOSE VITAMIN D SUPPLEMENTATION ON BONE MASS IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)","medConditionList":[{"med_condition_id":430,"med_condition":"NEUROFIBROMATOSIS TYPE I"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27138,"protocol_no":"12-252","submission_no":"164907","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-06-14","protocol_title":"\"PILOT TRIAL OF BOTOX BLADDER NECK INJECTION FOR TREATMENT OF PRIMARY BLADDER NECK OBSTRUCTION.\"","medConditionList":[{"med_condition_id":283,"med_condition":"PRIMARY BLADDER OBSTRUCTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35800,"protocol_no":"201312","submission_no":"173514","status_id":1,"start_date":"2015-09-15","end_date":null,"nol_date":"2014-04-30","protocol_title":"STUDY 201312: A MULTI-CENTRE, OPEN-LABEL, STUDY OF MEPOLIZUMAB IN A SUBSET OF SUBJECTS WITH A HISTORY OF LIFE THREATENING/SERIOUSLY DEBILITATING ASTHMA WHO PARTICIPATED IN THE MEA115661 TRIAL","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45888,"protocol_no":"629","submission_no":"205767","status_id":1,"start_date":"2017-11-10","end_date":null,"nol_date":"2017-06-15","protocol_title":"A PHASE 2, OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEMBROLIZUMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (R/M CSCC)","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47666,"protocol_no":"SAN-LE-002","submission_no":"210222","status_id":1,"start_date":"2018-04-24","end_date":null,"nol_date":"2017-12-21","protocol_title":"A RANDOMIZED, SINGLE-BLIND, CROSS-OVER STUDY OF LOTEPREDNOL ETABONATE IN ADULTS UNDERGOING BILATERAL CATARACT SURGERY","medConditionList":[{"med_condition_id":727,"med_condition":"CATARACT SURGERY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36836,"protocol_no":"TULANDI1234","submission_no":"176712","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-17","protocol_title":"PREEMPTIVE USE OF GABAPENTIN BEFORE LAPAROSCOPIC TOTAL HYSTERECTOMY","medConditionList":[{"med_condition_id":569,"med_condition":"HYSTERECTOMY ASSOCIATED PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45063,"protocol_no":"B2016:027","submission_no":"203176","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-24","protocol_title":"TREATMENT OF TEMPORO-MYOFASCIAL DISORDER OF MUSCULAR ORIGIN USING BOTULINUM TOXIN: A PROSPECTIVE STUDY","medConditionList":[{"med_condition_id":777,"med_condition":"TEMPOROMANDIBULAR DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38725,"protocol_no":"NCIC CTG: IND.221","submission_no":"182983","status_id":1,"start_date":"2015-01-01","end_date":null,"nol_date":"2015-04-21","protocol_title":"A DOSE-RANGING STUDY OF IPH2201 IN PATIENTS WITH HIGH GRADE SEROUS CARCINOMA OF OVARIAN, FALLOPIAN TUBE OR PERITONEAL ORIGIN","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"},{"med_condition_id":194,"med_condition":"PERITONEAL CARCINOMATOSIS"},{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27069,"protocol_no":"026-00","submission_no":"164679","status_id":1,"start_date":"2013-09-17","end_date":null,"nol_date":"2013-05-30","protocol_title":"A PHASE III, MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF MK-3102 COMPARED WITH THE ADDITION OF SITAGLIPTIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS WITH INADEQUATE GLYCEMIC CONTROL ON METFORMIN","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29002,"protocol_no":"OMS824-HTD-002","submission_no":"170540","status_id":2,"start_date":"2014-09-04","end_date":"2015-07-20","nol_date":"2014-01-03","protocol_title":"PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL COHORT STUDY TO EVALUATE SAFETY AND EFFICACY OF OMS643762 IN SUBJECTS WITH HUNTINGTON'S DISEASE","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39873,"protocol_no":"ALK5461-207","submission_no":"186501","status_id":2,"start_date":"2015-09-25","end_date":"2016-05-20","nol_date":"2015-08-26","protocol_title":"A PHASE 3 EFFICACY AND SAFETY STUDY OF ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (THE FORWARD-5 STUDY)","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37186,"protocol_no":"035-2014","submission_no":"177794","status_id":1,"start_date":"2015-04-11","end_date":null,"nol_date":"2014-10-07","protocol_title":"INCOMPLETE RESPONSE IN LATE-LIFE DEPRESSION: GETTING TO REMISSION WITH BUPRENORPHINE","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36747,"protocol_no":"D3561C00004","submission_no":"176461","status_id":1,"start_date":"2015-09-17","end_date":null,"nol_date":"2014-08-01","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, CROSS-OVER STUDY OF ROSUVASTATIN IN CHILDREN AND ADOLESCENTS (AGED 6 TO <18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","medConditionList":[{"med_condition_id":111,"med_condition":"HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26718,"protocol_no":"TIPS-3","submission_no":"163582","status_id":1,"start_date":"2013-07-24","end_date":null,"nol_date":"2013-05-10","protocol_title":"A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL FOR THE EVALUATION OF A POLYCAP, LOW DOSE ASPIRIN AND VITAMIN D SUPPLEMENTATION IN PRIMARY PREVENTION - THE INTERNATIONAL POLYCAP STUDY 3 (TIPS 3),","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27035,"protocol_no":"VX11-770-108","submission_no":"164556","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-06-07","protocol_title":"A PHASE 3, 2 PART, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF IVACAFTOR IN SUBJECTS WITH CYSTIC FIBROSIS WHO ARE 2 THROUGH 5 YEARS OF AGE AND HAVE A CFTR GATING MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27019,"protocol_no":"I5S-MC-EFJE(B)","submission_no":"164503","status_id":3,"start_date":"2013-07-04","end_date":null,"nol_date":"2013-05-31","protocol_title":"\"A PHASE 2 EFFICACY AND SAFETY DOSE-RANGING STUDY OF LY3015014 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA.\"","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27012,"protocol_no":"1","submission_no":"164477","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-06-03","protocol_title":"CYCLOSERINE IN THE TREATMENT OF SLEEP APNEA.","medConditionList":[{"med_condition_id":310,"med_condition":"SLEEP APNEA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45033,"protocol_no":"355-2016 (CHC_LACC_0001)","submission_no":"203103","status_id":1,"start_date":"2017-11-13","end_date":null,"nol_date":"2017-03-29","protocol_title":"HYPERPOLARIZED 13C MR IMAGING OF LACTATE IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER FOR TREATMENT WITH DEFINITIVE CHEMORADIATION THERAPY","medConditionList":[{"med_condition_id":356,"med_condition":"CERVICAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41278,"protocol_no":"A14-11-2181","submission_no":"191081","status_id":1,"start_date":"2016-05-18","end_date":null,"nol_date":"2016-02-18","protocol_title":"PHASE II PERSONNALIZED RADIOACTIVE THERAPY FOR NEUROENDOCRINE TUMORS","medConditionList":[{"med_condition_id":633,"med_condition":"NEUROENDOCRINE TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38159,"protocol_no":"14-213","submission_no":"180576","status_id":1,"start_date":"2015-02-01","end_date":null,"nol_date":"2015-02-10","protocol_title":"L'ACIDE TRANEXAMIQUE COMME TRAITEMENT M√âDICAL DES H√âMATOMES SOUS-DURAUX CHRONIQUES","medConditionList":[{"med_condition_id":606,"med_condition":"CHRONIC SUBDURAL HEMATOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35498,"protocol_no":"54767414MMY3003","submission_no":"172581","status_id":1,"start_date":"2015-05-08","end_date":null,"nol_date":"2014-03-27","protocol_title":"PHASE 3 STUDY COMPARING DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37213,"protocol_no":"14-0909","submission_no":"177875","status_id":1,"start_date":"2014-10-15","end_date":null,"nol_date":"2014-10-16","protocol_title":"RANDOMIZED CONTROLLED TRIAL OF HIGH VERSUS STANDARD DOSE TRIVALENT INACTIVATED INFLUENZA VACCINE FOR HEALTHCARE WORKERS: RECTOGENICITY AND TOLERABILITY.","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28917,"protocol_no":"1000039383","submission_no":"170242","status_id":1,"start_date":"2017-09-22","end_date":null,"nol_date":"2013-12-20","protocol_title":"PLACEBO CONTROLLED DOUBLE BLIND CROSSOVER TRIAL OF METFORMIN FOR BRAIN REPAIR IN CHILDREN TREATED WITH CRANIAL-SPINAL RADIATION FOR MEDULLOBLASTOMA","medConditionList":[{"med_condition_id":460,"med_condition":"MEDULLOBLASTOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42545,"protocol_no":"H16-00390","submission_no":"195322","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-07-14","protocol_title":"DEXAMETHASONE IN POPLITEAL SCIATIC NERVE BLOCKS: AN UP-AND-DOWN DOSE-FINDING STUDY","medConditionList":[{"med_condition_id":827,"med_condition":"SURGERY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39458,"protocol_no":"MB102230","submission_no":"185351","status_id":2,"start_date":"2015-11-03","end_date":"2018-03-02","nol_date":"2015-06-29","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPAGLIFLOZIN AS AN ADD-ON TO INSULIN THERAPY IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS - STUDY TWO","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28426,"protocol_no":"CBKM120E2102","submission_no":"168528","status_id":2,"start_date":"2014-02-14","end_date":"2016-07-07","nol_date":"2013-10-18","protocol_title":"PHASE IB/II STUDY OF BUPARLISIB PLUS CARBOPLATIN OR LOMUSTINE IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM)","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38293,"protocol_no":"M14-867","submission_no":"181531","status_id":2,"start_date":"2015-05-04","end_date":"2016-05-30","nol_date":"2015-02-20","protocol_title":"AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CO-ADMINISTRATION OF ABT-493 AND ABT-530 WITH AND WITHOUT RIBAVIRIN IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, AND 6 INFECTION (SURVEYOR-I)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28528,"protocol_no":"CBAF312X2206","submission_no":"168866","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-11-08","protocol_title":"A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, EFFICACY AND PRELIMINARY DOSE-RESPONSE OF BAF312 IN PATIENTS WITH ACTIVE DERMATOMYOSITIS.","medConditionList":[{"med_condition_id":427,"med_condition":"DERMATOMYOSITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41757,"protocol_no":"205165","submission_no":"192597","status_id":1,"start_date":"2016-05-13","end_date":null,"nol_date":"2016-03-23","protocol_title":"A PHASE III, 4-WEEK, RANDOMISED, DOUBLE-BLIND STUDY TO COMPARE 'CLOSED' TRIPLE THERAPY (FF/UMEC/VI), 'OPEN' TRIPLE THERAPY (FF/VI + UMEC) AND DUAL THERAPY (FF/VI) IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45916,"protocol_no":"414-2016","submission_no":"205831","status_id":1,"start_date":"2017-11-15","end_date":null,"nol_date":"2017-06-19","protocol_title":"A PHASE II STUDY OF AVELUMAB IN UNRESECTABLE/METASTATIC, PROGRESSIVE GRADE 2-3 NEUROENDOCRINE TUMORS","medConditionList":[{"med_condition_id":633,"med_condition":"NEUROENDOCRINE TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41732,"protocol_no":"CINC280X2108","submission_no":"192493","status_id":1,"start_date":"2016-11-01","end_date":null,"nol_date":"2016-03-22","protocol_title":"A PHASE IB/II, OPEN-LABEL, MULTI-CENTER STUDY OF INC280 IN COMBINATION WITH PDR001 OR PDR001 SINGLE AGENT IN ADVANCED HEPATOCELLULAR CARCINOMA","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37182,"protocol_no":"127-2014","submission_no":"177789","status_id":1,"start_date":"2016-01-06","end_date":null,"nol_date":"2014-10-09","protocol_title":"QUANTITATIVE BLOOD OXYGENATION LEVEL DEPENDENT (QBOLD) MR IMAGING OF GLIOBLASTOMA MULTIFORME FOR ASSESSMENT OF TUMOR HYPOXIA.","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43883,"protocol_no":"GS-US-428-4025","submission_no":"199486","status_id":1,"start_date":"2017-01-20","end_date":null,"nol_date":"2016-11-18","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF GS 9674 IN SUBJECTS WITH PRIMARY SCLEROSING CHOLANGITIS WITHOUT CIRRHOSIS","medConditionList":[{"med_condition_id":601,"med_condition":"PRIMARY SCLEROSING CHOLANGITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27172,"protocol_no":"20120356","submission_no":"165016","status_id":1,"start_date":"2013-06-24","end_date":null,"nol_date":"2013-06-20","protocol_title":"\"A MULTI-CENTER, RANDOMIZED STUDY IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPDEMIA TO ASSESS SUBJECTS' ABILITY TO ADMINISTER A FULL DOSE OF AMG 145 IN HOME-USE, USING EITHER A 3.5ML PERSONAL INJECTOR OR A PREFILLED AUTOINJECTOR/PEN.\"","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27414,"protocol_no":"20120263","submission_no":"165668","status_id":2,"start_date":"2014-01-09","end_date":"2015-03-18","nol_date":"2013-07-18","protocol_title":"\"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 501 COMPARED WITH ADALIMUMAB IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.\"","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41902,"protocol_no":"20160014","submission_no":"193172","status_id":1,"start_date":"2016-05-10","end_date":null,"nol_date":"2016-04-15","protocol_title":"99MTC-RHANNEXIN V-128 SPECT IMAGING OF APOPTOSIS IN ASYMPTOMATIC PATIENTS WITH CAROTID ATHEROSCLEROTIC PLAQUE","medConditionList":[{"med_condition_id":684,"med_condition":"CAROTID ATHEROSCLEROTIC PLAQUE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27767,"protocol_no":"ICLS-06-2013","submission_no":"166671","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-08-29","protocol_title":"\"A SINGLE BLIND, SPLIT-FACE, RANDOMIZED, PILOT STUDY TO COMPARE THE EFFECTS OF INTRADERMAL & INTRAMUSCULAR TREATMENTS WITH TWO COMMERCIALLY AVAILABLE BOTULINUM TOXIN A FORMULAS TO REDUCE THE SIGNS OF FACIAL AGING.\"","medConditionList":[{"med_condition_id":381,"med_condition":"FACIAL AGING"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36606,"protocol_no":"C41443/2057","submission_no":"175980","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-25","protocol_title":"AN OPEN-LABEL, SINGLE-GROUP CLINICAL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF OMACETAXINE MEPESUCCINATE GIVEN SUBCUTANEOUSLY AS A FIXED DOSE IN PATIENTS WITH CHRONIC PHASE OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA WHO HAVE FAILED 2 OR MORE TYROSINE KINASE INHIBITOR THERAPIES.","medConditionList":[{"med_condition_id":46,"med_condition":"CHRONIC MYELOID LEUKEMIA"},{"med_condition_id":544,"med_condition":"CHRONIC PHASE OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47935,"protocol_no":"GBT440-034","submission_no":"212513","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-23","protocol_title":"AN OPEN LABEL EXTENSION STUDY OF GBT440 ADMINISTERED ORALLY TO PATIENTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN GBT440 CLINICAL TRIALS","medConditionList":[{"med_condition_id":232,"med_condition":"SICKLE CELL DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36192,"protocol_no":"28431754DIA2004","submission_no":"174761","status_id":1,"start_date":"2014-09-24","end_date":null,"nol_date":"2014-06-06","protocol_title":"A RANDOMIZED PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-TO-TARGET, PARALLEL-GROUP, 3-ARM, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF CANAGLIFLOZIN AS ADD-ON THERAPY TO INSULIN","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40367,"protocol_no":"202093","submission_no":"187847","status_id":2,"start_date":"2015-11-19","end_date":"2016-02-25","nol_date":"2015-10-20","protocol_title":"A PHASE 2A STUDY TO EVALUATE THE PHARMACOKINETIC, SAFETY, TOLERABILITY AND CLINICAL EFFECT OF TOPICALLY APPLIED UMECLIDINIUM/GSK573719 IN SUBJECTS WITH PRIMARY AXILLARY HYPERHIDROSIS","medConditionList":[{"med_condition_id":511,"med_condition":"AXILLARY HYPERHIDROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38403,"protocol_no":"A5481034","submission_no":"181921","status_id":2,"start_date":"2015-10-28","end_date":"2017-12-18","nol_date":"2015-02-20","protocol_title":"AN EXPANDED ACCESS STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE.","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37549,"protocol_no":"BP29387","submission_no":"178969","status_id":2,"start_date":"2015-05-11","end_date":"2015-12-01","nol_date":"2014-11-14","protocol_title":"PHASE IA/IB, OPEN-LABEL, MULTICENTER, MULTIPLE ASCENDING DOSE STUDY FOLLOWED BY AN EXTENSION PHASE TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ACTIVITY OF RO6927005, AN ANTI-MESOTHELIN (MSLN) RECOMBINANT CYTOLYTIC FUSION PROTEIN (CFP), ADMINISTERED EITHER ALONE (PART A) OR IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL (PART B) IN PATIENTS WITH MESOTHELIN-POSITIVE METASTATIC AND/OR LOCALLY ADVANCED MALIGNANT SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39824,"protocol_no":"2215-CL-0301","submission_no":"186362","status_id":1,"start_date":"2016-04-20","end_date":null,"nol_date":"2015-08-28","protocol_title":"A PHASE 3 OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ASP2215 VERSUS SALVAGE CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH FLT3 MUTATION","medConditionList":[{"med_condition_id":506,"med_condition":"RELAPSED OR REFRACTORY ACUTE MYELOID  LEUKEMIA (AML)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39319,"protocol_no":"VITDAL-PICU-01","submission_no":"184825","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-07-03","protocol_title":"RAPID NORMALIZATION OF VITAMIN D IN CRITICALLY ILL CHILDREN: A PHASE II DOSE EVALUATION RANDOMIZED CONTROLLED TRIAL (VITDAL-PICU PILOT)","medConditionList":[{"med_condition_id":267,"med_condition":"VITAMIN DEFICIENCY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39721,"protocol_no":"CP-Q14VLP-009","submission_no":"186153","status_id":1,"start_date":"2016-09-16","end_date":null,"nol_date":"2015-08-12","protocol_title":"A RANDOMIZED, OBSERVER-BLIND, MULTICENTER, PHASE 2B STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A PLANT-DERIVED QUADRIVALENT VLP INFLUENZA VACCINE IN ADULTS 18-64 YEARS OF AGE","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"},{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43961,"protocol_no":"DX-CTC-003","submission_no":"199687","status_id":1,"start_date":"2017-02-01","end_date":null,"nol_date":"2016-11-22","protocol_title":"A PIVITOL PHASE III STUDY OF CYCLOTRON-PRODUCED TC-99M PERTECHNETATE (CTC) COMPARED TO GENERATOR-PRODUCED TC-99M PERTECHNETATE (G-PERT) IN SUBJECTS WITH THYROID DISORDERS","medConditionList":[{"med_condition_id":763,"med_condition":"THYROID DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47730,"protocol_no":"PTI-801-01","submission_no":"211675","status_id":1,"start_date":"2018-03-05","end_date":null,"nol_date":"2017-12-22","protocol_title":"A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 1, TWO-PART STUDY DESIGNED TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, FOOD EFFECT, AND DRUG-DRUG INTERACTIONS OF PTI-801 IN HEALTHY VOLUNTEERS, AND SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PTI-801 IN SUBJECTS WITH CYSTIC FIBROSIS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48451,"protocol_no":"EP0093","submission_no":"212871","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-23","protocol_title":"AN OPEN LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28120,"protocol_no":"000004 (ESTHER-1)","submission_no":"167664","status_id":2,"start_date":"2014-02-01","end_date":"2016-10-12","nol_date":"2013-09-20","protocol_title":"\"A RANDOMISED, CONTROLLED, ASSESSOR-BLIND, PARALLEL GROUPS, MULTICENTRE, MULTINATIONAL TRIAL COMPARING THE EFFICACY AND SAFETY OF FE 999049 WITH FOLLITROPIN ALFA (GONAL-F) IN CONTROLLED OVARIAN STIMULATION IN WOMEN UNDERGOING AN ASSISTED REPRODUCTIVE TECHNOLOGY PROGRAMME. ESTHER-1 (EVIDENCE-BASED STIMULATION TRIAL WITH HUMAN RFSH IN EUROPE AND REST OF WORLD).\"","medConditionList":[{"med_condition_id":374,"med_condition":"ASSISTED REPRODUCTIVE TECHNOLOGY PROGRAMME"},{"med_condition_id":373,"med_condition":"OVARIAN STIMULATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42720,"protocol_no":"MNK19013058","submission_no":"196027","status_id":1,"start_date":"2016-10-04","end_date":null,"nol_date":"2016-07-11","protocol_title":"A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 (THE CONFIRM STUDY)","medConditionList":[{"med_condition_id":755,"med_condition":"HEPATORENAL SYNDROME TYPE 1"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43185,"protocol_no":"64091742PCR2001","submission_no":"197437","status_id":1,"start_date":"2017-04-24","end_date":null,"nol_date":"2016-08-30","protocol_title":"A PHASE 2 EFFICACY AND SAFETY STUDY OF NIRAPARIB IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND DNA-REPAIR ANOMALIES.","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42722,"protocol_no":"1321.7","submission_no":"196030","status_id":1,"start_date":"2017-01-05","end_date":null,"nol_date":"2016-07-15","protocol_title":"SINGLE DOSE, OPEN LABEL, UNCONTROLLED, SAFETY TRIAL OF INTRAVENOUS ADMINISTRATION OF IDARUCIZUMAB TO PAEDIATRIC PATIENTS ENROLLED FROM ONGOING PHASE IIB/III CLINICAL TRIALS WITH DABIGATRAN ETEXILATE FOR THE TREATMENT AND SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38789,"protocol_no":"119858","submission_no":"183176","status_id":1,"start_date":"2015-04-30","end_date":null,"nol_date":"2015-04-23","protocol_title":"PREHOSPITAL TRANEXAMIC ACID USE FOR TRAUMATIC BRAIN INJURY","medConditionList":[{"med_condition_id":437,"med_condition":"TRAUMATIC BRAIN INJURY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43720,"protocol_no":"FHGT002","submission_no":"199002","status_id":1,"start_date":"2017-09-01","end_date":null,"nol_date":"2016-11-04","protocol_title":"AAV8-MEDIATED LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR) GENE REPLACEMENT IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)","medConditionList":[{"med_condition_id":116,"med_condition":"HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39881,"protocol_no":"GS-US-339-1559","submission_no":"186520","status_id":1,"start_date":"2017-07-17","end_date":null,"nol_date":"2015-08-25","protocol_title":"A PHASE 1B/2 STUDY OF ENTOSPLETINIB (GS-9973) MONOTHERAPY AND IN COMBINATION WITH CHEMOTHERAPY IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA (AML)","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40022,"protocol_no":"I5B-MC-JGDJ(A)","submission_no":"186869","status_id":1,"start_date":"2016-02-12","end_date":null,"nol_date":"2015-09-09","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF DOXORUBICIN PLUS OLARATUMAB VERSUS DOXORUBICIN PLUS PLACEBO IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA,","medConditionList":[{"med_condition_id":237,"med_condition":"SOFT TISSUE SARCOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38574,"protocol_no":"CV185-324 (ARTESIA)","submission_no":"182470","status_id":1,"start_date":"2015-03-16","end_date":null,"nol_date":"2015-03-27","protocol_title":"APIXABAN FOR THE REDUCTION OF THROMBO-EMBOLISM IN PATIENTS WITH DEVICE-DETECTED SUB-CLINICAL ATRIAL FIBRILLATION","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42109,"protocol_no":"15-402","submission_no":"193933","status_id":1,"start_date":"2017-01-25","end_date":null,"nol_date":"2016-05-04","protocol_title":"EFFECTS OF EMPAGLIFLOZIN ON CARDIAC STRUCTURE, FUNCTION, AND CIRCULATING BIOMARKERS IN PATIENTS WITH TYPE 2 DIABETES: EMPA-HEART TRIAL","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43744,"protocol_no":"MA29957","submission_no":"199047","status_id":1,"start_date":"2017-02-09","end_date":null,"nol_date":"2016-11-04","protocol_title":"A PHASE IIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND INTERMEDIATE OR HIGH PROBABILITY OF GROUP 3 PULMONARY HYPERTENSION","medConditionList":[{"med_condition_id":127,"med_condition":"IDIOPATHIC PULMONARY FIBROSIS (IPF)"},{"med_condition_id":483,"med_condition":"PULMONARY HYPERTENSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45735,"protocol_no":"MO29872","submission_no":"205342","status_id":1,"start_date":"2017-09-19","end_date":null,"nol_date":"2017-06-02","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAIVE ADVANCED OR RECURRENT (STAGE IIIB NOT AMENABLE FOR MULTIMODALITY TREATMENT) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER WHO ARE DEEMED UNSUITABLE FOR PLATINUM-CONTAINING THERAPY","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42549,"protocol_no":"M14-496","submission_no":"195336","status_id":1,"start_date":"2016-08-19","end_date":null,"nol_date":"2016-06-23","protocol_title":"A PHASE 4 OPEN-LABEL RANDOMIZED CONTROLLED STUDY COMPARING THE EFFECTIVENESS OF ADALIMUMAB INTRODUCTION AND METHOTREXATE DOSE ESCALATION IN SUBJECTS WITH PSORIATIC ARTHRITIS (CONTROL)","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41359,"protocol_no":"PEVONEDISTAT-2001","submission_no":"191263","status_id":1,"start_date":"2016-08-05","end_date":null,"nol_date":"2016-02-08","protocol_title":"A PHASE 2, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF THE EFFICACY AND SAFETY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, AND LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"},{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"},{"med_condition_id":747,"med_condition":"CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39841,"protocol_no":"POE14-01","submission_no":"186412","status_id":1,"start_date":"2016-08-31","end_date":null,"nol_date":"2015-09-09","protocol_title":"PHASE I STUDY OF CARFILZOMIB IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE FOR CHILDREN WITH RELAPSED AND REFRACTORY SOLID TUMORS AND LEUKEMIA.","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"},{"med_condition_id":308,"med_condition":"LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41939,"protocol_no":"VX15-770-124","submission_no":"193333","status_id":1,"start_date":"2017-02-16","end_date":null,"nol_date":"2016-04-07","protocol_title":"A PHASE 3, 2-PART, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF IVACAFTOR IN SUBJECTS WITH CYSTIC FIBROSIS WHO ARE LESS THAN 24 MONTHS OF AGE AT TREATMENT INITIATION AND HAVE A CFTR GATING MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44029,"protocol_no":"CPKC412A2001X","submission_no":"199922","status_id":1,"start_date":"2017-02-24","end_date":null,"nol_date":"2016-12-02","protocol_title":"AN OPEN-LABELED, MULTI¬øCENTER, EXPANDED TREATMENT PROTOCOL (ETP) OF MIDOSTAURIN (PKC412) IN PATIENTS 18 YEARS OF AGE OR OLDER WITH NEWLY-DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) WHO ARE ELIGIBLE FOR STANDARD INDUCTION AND CONSOLIDATION CHEMOTHERAPY","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26833,"protocol_no":"PEJ-688","submission_no":"163961","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-17","protocol_title":"EFFECTS OF PSYCHO-STIMULATING MEDICATION ON AWAKENING AND COGNITIVE FUNCTIONS FOLLOWING CRANIOCEREBRAL TRAUMA","medConditionList":[{"med_condition_id":436,"med_condition":"CRANIOCEREBRAL TRAUMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42208,"protocol_no":"PS-G202","submission_no":"194275","status_id":1,"start_date":"2016-11-30","end_date":null,"nol_date":"2016-05-26","protocol_title":"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INCOMPLETE BLOCK CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VX-371 SOLUTION FOR INHALATION IN SUBJECTS WITH PRIMARY CILIARY DYSKINESIA","medConditionList":[{"med_condition_id":733,"med_condition":"PRIMARY CILIARY DYSKINESIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43738,"protocol_no":"M15-942","submission_no":"199034","status_id":2,"start_date":"2017-01-25","end_date":"2017-12-19","nol_date":"2016-11-02","protocol_title":"AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABT 493/ABT-530 IN COMBINATION WITH SOFOSBUVIR AND RIBAVIRIN IN CHRONIC HEPATITIS C (HCV) INFECTED SUBJECTS WHO HAVE EXPERIENCED VIROLOGIC FAILURE IN ABBVIE HCV CLINICAL STUDIES (MAGELLAN-3)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28515,"protocol_no":"MITNEC-C6","submission_no":"168835","status_id":1,"start_date":"2015-09-25","end_date":null,"nol_date":"2013-11-07","protocol_title":"AMYLOID AND GLUCOSE PET IMAGING IN ALZHEIMER AND VASCULAR COGNITIVE IMPAIRMENT PATIENTS WITH SIGNIFICANT WHITE MATTER DISEASE","medConditionList":[{"med_condition_id":285,"med_condition":"COGNITIVE IMPAIRMENT"},{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41274,"protocol_no":"EMR 200647-001","submission_no":"191068","status_id":1,"start_date":"2017-01-25","end_date":null,"nol_date":"2016-01-27","protocol_title":"A PHASE I, OPEN-LABEL, MULTIPLE-ASCENDING DOSE TRIAL TO INVESTIGATE THE SAFETY AND TOLERABILITY, PHARMACOKINETICS, BIOLOGICAL AND CLINICAL ACTIVITY OF MSB0011359C IN SUBJECTS WITH METASTATIC OR LOCALLY ADVANCED SOLID TUMORS AND EXPANSION TO SELECT INDICATIONS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28518,"protocol_no":"OCR002-HE209","submission_no":"168843","status_id":1,"start_date":"2014-07-01","end_date":null,"nol_date":"2013-12-19","protocol_title":"MULTICENTER, RANDOMIZED PHASE 2B STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF OCR-002 (ORNITHINE PHENYLACETATE) IN HOSPITALIZED PATIENTS WITH CIRRHOSIS AND ASSOCIATED HYPERAMMONEMIA WITH AN EPISODE OF HEPATIC ENCEPHALOPATHY (STOP-HE STUDY)","medConditionList":[{"med_condition_id":282,"med_condition":"HEPATIC ENCEPHALOPATHY"},{"med_condition_id":426,"med_condition":"HYPERAMMONEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27664,"protocol_no":"190-03122013","submission_no":"166373","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-06","protocol_title":"COMPARISON OF THE EFFECTS OF A SMALL PARTICLE CORTICOSTEROID, ALVESCO¬Æ, TO A LARGER PARTICLE CORTICOSTEROID ON THE SMALL AIRWAY PHYSIOLOGY OF ASTHMATIC SUBJECTS BY HYPERPOLARIZED HELIUM-3 MRI","medConditionList":[{"med_condition_id":304,"med_condition":"MRI IMAGING"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26700,"protocol_no":"H7T-MC-TADO","submission_no":"163519","status_id":1,"start_date":"2014-09-04","end_date":null,"nol_date":"2013-04-24","protocol_title":"A PHASE 3, DOUBLE-BLIND, RANDOMIZED, EFFICACY AND SAFETY COMPARISON OF PRASUGREL AND PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE","medConditionList":[{"med_condition_id":233,"med_condition":"SICKLE CELL ANEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41257,"protocol_no":"2015-01-001","submission_no":"190922","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-01-13","protocol_title":"PROSPECTIVE EVALUATION OF XEOMIN COSMETIC IN THE MANAGEMENT OF THE MASSETER USING TWO DIFFERENT INJECTION TECHNIQUES","medConditionList":[{"med_condition_id":670,"med_condition":"MANAGEMENT OF THE MASSETER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43974,"protocol_no":"CINC424C2301","submission_no":"199639","status_id":1,"start_date":"2017-07-17","end_date":null,"nol_date":"2016-12-01","protocol_title":"A PHASE III RANDOMIZED OPEN-LABEL MULTI-CENTER STUDY OF RUXOLITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH CORTICOSTEROID-REFRACTORY ACUTE GRAFT VS. HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION","medConditionList":[{"med_condition_id":370,"med_condition":"GRAFT VS HOST DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42928,"protocol_no":"205715","submission_no":"196669","status_id":1,"start_date":"2016-11-29","end_date":null,"nol_date":"2016-08-11","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY, COMPARING THE EFFICACY, SAFETY AND TOLERABILITY OF THE FIXED DOSE COMBINATION FF/UMEC/VI WITH THE FIXED DOSE DUAL COMBINATION OF FF/VI, ADMINISTERED ONCE-DAILY VIA A DRY POWDER INHALER IN SUBJECTS WITH INADEQUATELY CONTROLLED ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39131,"protocol_no":"MOBILITY-003","submission_no":"184257","status_id":1,"start_date":"2016-01-14","end_date":null,"nol_date":"2015-06-02","protocol_title":"MOLECULAR BASKET TRIAL IN MULTIPLE MALIGNANCIES WITH COMMON TARGET PATHWAY ABERRANCIES","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36389,"protocol_no":"140009","submission_no":"175254","status_id":2,"start_date":"2014-08-11","end_date":"2014-10-17","nol_date":"2014-07-02","protocol_title":"OPEN-LABEL, 3-PART, MULTIPLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETIC PROFILE, DOSE-RESPONSE, SAFETY, AND TOLERABILITY OF DIFFERENT DOSES OF TESTOSTERONE UNDECANOATE TRANSMUCOSAL SOLUBLE FILMS IN HYPOGONADAL SUBJECTS","medConditionList":[{"med_condition_id":247,"med_condition":"TESTOSTERONE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38901,"protocol_no":"5527","submission_no":"183549","status_id":1,"start_date":"2015-05-30","end_date":null,"nol_date":"2015-05-07","protocol_title":"\"ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF RELAPSING, NON-SEVERE, GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) (ABROGATE).\"","medConditionList":[{"med_condition_id":618,"med_condition":"GRANULOMATOSIS"},{"med_condition_id":579,"med_condition":"POLYANGITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42660,"protocol_no":"COG AOST1321","submission_no":"195762","status_id":1,"start_date":"2016-08-17","end_date":null,"nol_date":"2016-06-29","protocol_title":"PHASE 2 STUDY OF DENOSUMAB (IND# 127430, NSC# 744010), A RANK LIGAND ANTIBODY, FOR RECURRENT REFRACTORY OSTEOSARCOMA","medConditionList":[{"med_condition_id":586,"med_condition":"OSTEOSARCOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28506,"protocol_no":"EVP-6124-024","submission_no":"168801","status_id":1,"start_date":"2014-04-14","end_date":null,"nol_date":"2013-11-04","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 26-WEEK, PHASE 3 STUDY OF TWO DOSES OF EVP-6124 OR PLACEBO IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE CURRENTLY OR PREVIOUSLY RECEIVING AN ACETYLCHOLINESTERASE INHIBITOR MEDICATION","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35573,"protocol_no":"TRC112121","submission_no":"172814","status_id":2,"start_date":"2015-04-02","end_date":"2016-04-28","nol_date":"2014-04-01","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III, MULTI-CENTRE STUDY OF ELTROMBOPAG OR PLACEBO IN COMBINATION WITH AZACITIDINE IN SUBJECTS WITH IPSS INTERMEDIATE-1, INTERMEDIATE 2 AND HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28608,"protocol_no":"MOR-008","submission_no":"169147","status_id":3,"start_date":"2014-01-13","end_date":null,"nol_date":"2013-11-20","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PILOT STUDY OF THE SAFETY AND PHYSIOLOGICAL EFFECTS OF TWO DOSES OF BMN 110 IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS IVA (MORQUIO A SYNDROME)","medConditionList":[{"med_condition_id":160,"med_condition":"MUCOPOLYSACCHARIDOSIS IVA (MORQUIO  SYNDROME)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29025,"protocol_no":"CIGE025A2445T","submission_no":"170627","status_id":1,"start_date":"2014-04-01","end_date":null,"nol_date":"2014-01-08","protocol_title":"RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF THE PREDNISONE SPARING EFFECT OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH PREDNISONE-DEPENDENT ASTHMA WITH EOSINOPHILIC BROCHITIS","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41440,"protocol_no":"CLBH589D2222","submission_no":"191521","status_id":1,"start_date":"2016-11-22","end_date":null,"nol_date":"2016-02-19","protocol_title":"A MULTICENTER, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF THREE DIFFERENT REGIMENS OF ORAL PANOBINOSTAT IN COMBINATION WITH SUBCUTANEOUS BORTEZOMIB AND ORAL DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE BEEN PREVIOUSLY EXPOSED TO IMMUNOMODULATORY AGENTS","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29157,"protocol_no":"LUM001-302","submission_no":"171046","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PAEDIATRIC PATIENTS WITH ALAGILLE SYNDROME","medConditionList":[{"med_condition_id":453,"med_condition":"ALAGILLE SYNDROME"},{"med_condition_id":452,"med_condition":"CHOLESTATIC LIVER DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":29147,"protocol_no":"LUM001-501","submission_no":"171037","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-06","protocol_title":"OPEN LABEL STUDY OF THE EFFICACY AND LONG TERM SAFETY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS","medConditionList":[{"med_condition_id":452,"med_condition":"CHOLESTATIC LIVER DISEASE"},{"med_condition_id":454,"med_condition":"PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42645,"protocol_no":"DRI13925","submission_no":"195685","status_id":1,"start_date":"2016-11-17","end_date":null,"nol_date":"2016-07-06","protocol_title":"AN OPEN-LABEL, SEQUENTIAL, ACENDING, REPEATED DOSE-FINDING STUDY OF SARILUMAB, ADMINISTERED WITH SUBCUTANEOUS (SC) INJECTION, IN CHILDREN AND ADOLESCENTS, AGED 2 TO 17 YEARS, WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA) FOLLOWED BY AN EXTENSION PHASE","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42685,"protocol_no":"CRFB002D2404","submission_no":"195850","status_id":1,"start_date":"2016-09-23","end_date":null,"nol_date":"2016-07-05","protocol_title":"A 24-WEEK, RANDOMIZED, SINGLE-MASKED, MULTICENTER, PHASE IV STUDY TO COMPARE SYSTEMIC VEGF LEVELS FOLLOWING MONTHLY INTRAVITREAL INJECTIONS OF 0.5 MG RANIBIZUMAB VERSUS 2 MG AFLIBERCEPT UNTIL WEEK 24 IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA (TIDE DME)","medConditionList":[{"med_condition_id":64,"med_condition":"DIABETIC MACULAR EDEMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36490,"protocol_no":"D5082C00002","submission_no":"175591","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-16","protocol_title":"A PHASE II TRIAL TO EVALUATE THE EFFICACY OF AZD6094 (HMPL-504) IN PATIENTS WITH PAPILLARY RENAL CELL CARCINOMA (PRCC).","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39520,"protocol_no":"021-02","submission_no":"185606","status_id":1,"start_date":"2017-03-21","end_date":null,"nol_date":"2015-07-31","protocol_title":"A PHASE III MULTICENTER, DOUBLE-BLIND, RANDOMIZED, ACTIVE COMPARATOR-CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF MK-1439A ONCE-DAILY VERSUS ATRIPLA¬ø ONCE-DAILY IN TREATMENT-NA√èVE HIV-1 INFECTED SUBJECTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45482,"protocol_no":"CN002012","submission_no":"204518","status_id":1,"start_date":"2017-11-22","end_date":null,"nol_date":"2017-05-04","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUSLY ADMINISTERED BMS-986168 IN PARTCIPANTS WITH PROGRESSIVE SUPRANUCLEAR PALSY","medConditionList":[{"med_condition_id":768,"med_condition":"PROGRESSIVE SUPRANUCLEAR PALSY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36454,"protocol_no":"1000043023","submission_no":"175474","status_id":1,"start_date":"2015-07-28","end_date":null,"nol_date":"2014-08-08","protocol_title":"PHASE II RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND CLINICAL TRIAL OF VALSARTAN FOR ATTENUATING DISEASE EVOLUTION IN EARLY SARCOMERIC HCM.","medConditionList":[{"med_condition_id":540,"med_condition":"SARCOMERIC HYPERTROPHIC CARDIOMYOPATHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38341,"protocol_no":"CLBH589D2001X","submission_no":"181719","status_id":2,"start_date":"2015-11-02","end_date":"2017-05-15","nol_date":"2015-02-24","protocol_title":"AN OPEN-LABEL, MULTI-CENTER, EXPANDED TREATMENT PROTOCOL OF ORAL PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENT WITH RELAPSED, AND RELAPSED AND REFRACTORY (RR) MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38892,"protocol_no":"1423M0634","submission_no":"183520","status_id":2,"start_date":"2015-07-24","end_date":"2016-12-22","nol_date":"2015-05-06","protocol_title":"A PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF S-888711 (LUSUTROMBOPAG) FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING ELECTIVE INVASIVE PROCEDURES (L-PLUS 2)/PROTOCOL NUMBER","medConditionList":[{"med_condition_id":515,"med_condition":"THROMBOCYTOPENIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43007,"protocol_no":"EG-01-1962-03","submission_no":"196862","status_id":1,"start_date":"2016-11-28","end_date":null,"nol_date":"2016-08-08","protocol_title":"PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY COMPARING EG-1962 TO STANDARD OF CARE ORAL NIMODIPINE IN ADULTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE","medConditionList":[{"med_condition_id":336,"med_condition":"ANEURYSMAL SUBARACHNOID HEMORRHAGE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37910,"protocol_no":"140371","submission_no":"179989","status_id":1,"start_date":"2014-03-30","end_date":null,"nol_date":"2014-12-29","protocol_title":"OPEN-LABEL, RANDOMIZED, FOUR PERIOD, FOUR TREATMENT, CROSS-OVER, SINGLE DOSE STUDY TO EVALUATE BIOAVAILABILITY AND PHARMACOKINETICS OF ORAL TESTOSTERONE UNDECANOATE (TU) CAPSULE AS A FUNCTION OF FOOD FAT CONTENT IN HYPOGONADAL MALES","medConditionList":[{"med_condition_id":125,"med_condition":"HYPOGONADAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40403,"protocol_no":"GTI1502","submission_no":"187988","status_id":1,"start_date":"2016-09-12","end_date":null,"nol_date":"2015-10-23","protocol_title":"AN OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF IGSC 20% ADMINISTERED FOR 6 MONTHS IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY","medConditionList":[{"med_condition_id":210,"med_condition":"PRIMARY IMMUNODEFICIENCY DISEASES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41741,"protocol_no":"204836","submission_no":"192517","status_id":2,"start_date":"2016-07-08","end_date":"2017-01-21","nol_date":"2016-03-24","protocol_title":"A 29-DAY, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF THREE-TIMES WEEKLY DOSING OF GSK1278863 IN HEMODIALYSIS-DEPENDENT SUBJECTS WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE WHO ARE SWITCHED FROM A STABLE DOSE OF AN ERYTHROPOIESIS-STIMULATING AGENT","medConditionList":[{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28819,"protocol_no":"14862A","submission_no":"169954","status_id":2,"start_date":"2015-03-10","end_date":"2016-11-23","nol_date":"2013-12-16","protocol_title":"\"RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF LU AE58054 IN PATIENTS WITH MILD-MODERATE ALZHEIMER'S DISEASE TREATED WITH DONEPEZIL; STUDY 2\"","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39540,"protocol_no":"I1F-MC-RHBS","submission_no":"185664","status_id":1,"start_date":"2016-05-27","end_date":null,"nol_date":"2015-08-05","protocol_title":"A 52-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO USTEKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS,","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36491,"protocol_no":"STEADY-PD III","submission_no":"175594","status_id":1,"start_date":"2014-12-15","end_date":null,"nol_date":"2014-07-10","protocol_title":"A PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF ISRADIPINE AS A DISEASE MODIFYING AGENT IN SUBJECTS WITH EARLY PARKINSON DISEASE","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43995,"protocol_no":"NP001-10-003","submission_no":"199813","status_id":1,"start_date":"2017-02-01","end_date":null,"nol_date":"2016-12-07","protocol_title":"A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NP001 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND EVIDENCE OF ELEVATED SYSTEMIC INFLAMMATION","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41438,"protocol_no":"CLCZ696B2401","submission_no":"191517","status_id":2,"start_date":"2016-11-11","end_date":"2018-03-29","nol_date":"2016-02-19","protocol_title":"A MULTICENTER, RANDOMIZED, OPEN LABEL, PARALLEL GROUP STUDY COMPARING PRE-DISCHARGE AND POST-DISCHARGE TREATMENT INITIATION WITH LCZ696 IN HEART FAILURE PATIENTS WITH REDUCED EJECTION-FRACTION HOSPITALIZED FOR AN ACUTE DECOMPENSATION EVENT (ADHF)","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39453,"protocol_no":"TRIO-BD 100","submission_no":"185320","status_id":1,"start_date":"2015-08-01","end_date":null,"nol_date":"2015-07-27","protocol_title":"TREATING INSULIN RESISTANCE AS A STRATEGY TO IMPROVE OUTCOME IN REFRACTORY BIPOLAR DISORDER: A  RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROL STUDY OF THE EFFICACY OF METFORMIN IN PATIENTS WITH INSULIN RESISTANCE AND NON-REMITTING BIPOLAR ILLNESS","medConditionList":[{"med_condition_id":501,"med_condition":"BIPOLAR DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36864,"protocol_no":"KCP-330-006","submission_no":"176791","status_id":1,"start_date":"2015-01-29","end_date":null,"nol_date":"2014-08-25","protocol_title":"A PHASE 2, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF HEAD AND NECK, LUNG, OR ESOPHAGUS [STARRS STUDY: SELINEXOR TREATMENT OF ADVANCED RELAPSED/REFRACTORY SQUAMOUS CELL CARCINOMAS]","medConditionList":[{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26896,"protocol_no":"ANBL12P1","submission_no":"164164","status_id":1,"start_date":"2013-09-18","end_date":null,"nol_date":"2013-05-16","protocol_title":"PILOT STUDY USING MYELOABLATIVE BUSULFAN/MELPHALAN (BUMEL) CONSOLIDATION FOLLOWING INDUCTION CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA","medConditionList":[{"med_condition_id":172,"med_condition":"NEUROBLASTOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36455,"protocol_no":"CCI-USMANI-01","submission_no":"175478","status_id":1,"start_date":"2017-09-12","end_date":null,"nol_date":"2014-07-02","protocol_title":"PREMIUM - PREVENTION OF METABOLIC SYNDROME AND INCREASED WEIGHT USING METFORMIN CONCURRENT TO ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR HIGH RISK, ADENOCARCINOMA OF THE PROSTATE","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"},{"med_condition_id":213,"med_condition":"PROSTATE ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26775,"protocol_no":"CA209-067","submission_no":"163799","status_id":1,"start_date":"2014-10-15","end_date":null,"nol_date":"2013-05-08","protocol_title":"\"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF NIVOLUMAB MONOTHERAPY OR NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERUS IPILIMUMAB MONOTHERAPY IN PREVIOUSLY UNTREATED, UNRESECTABLE OR METASTATIC MELANOMA (CHECKMATE 067: CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 067).\"","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27685,"protocol_no":"905-EC-012","submission_no":"166445","status_id":2,"start_date":"2013-08-27","end_date":"2014-11-21","nol_date":"2013-08-07","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADDING MIRABEGRON TO SOLIFENACIN IN INCONTINENT OAB SUBJECTS WHO HAVE RECEIVED SOLIFENACIN FOR 4 WEEKS AND WARRANT ADDITIONAL RELIEF FOR THEIR OAB SYMPTOMS.","medConditionList":[{"med_condition_id":185,"med_condition":"OVERACTIVE BLADDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38418,"protocol_no":"059","submission_no":"181998","status_id":1,"start_date":"2015-12-24","end_date":null,"nol_date":"2015-03-04","protocol_title":"A PHASE II CLINICAL TRIAL OF PEMBROLIZUMAB AS MONOTHERAPY AND IN COMBINATION WITH CISPLATIN+5-FLUOROURACIL IN SUBJECTS WITH RECURRENT OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (KEYNOTE-059)","medConditionList":[{"med_condition_id":619,"med_condition":"GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"},{"med_condition_id":337,"med_condition":"GASTRIC CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42409,"protocol_no":"MC1582","submission_no":"194857","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-05-27","protocol_title":"PHASE 1 / 2 TRIAL OF IDASANUTLIN IN COMBINATION WITH IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH 17P DELETED, RELAPSED MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28663,"protocol_no":"13-01","submission_no":"169351","status_id":1,"start_date":"2013-12-19","end_date":null,"nol_date":"2014-01-10","protocol_title":"A SINGLE CENTRE CONTROLLED COMPARISON STUDY TO EVALUATE THE SAFETY OF LIDOCAINE 30% IN PLASTICIZED BASE USED AS LOCAL ANAESTHESIA FOR INTENSE PULSED LIGHT TREATMENTS.","medConditionList":[{"med_condition_id":467,"med_condition":"ANALGESIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38705,"protocol_no":"109MS308","submission_no":"182886","status_id":1,"start_date":"2015-09-24","end_date":null,"nol_date":"2015-04-08","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF BG00012 IN DELAYING DISABILITY PROGRESSION IN SUBJECTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46022,"protocol_no":"20170005","submission_no":"206101","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-20","protocol_title":"FEASIBILITY AND SAFETY OF IMMUNOGLOBULIN (IG) TREATMENT IN COPD OUTPATIENTS WITH FREQUENT EXACERBATIONS: A PILOT STUDY","medConditionList":[{"med_condition_id":793,"med_condition":"ACUTE PULMONARY EMBOLISM"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47282,"protocol_no":"NSABP B-59/GBG 96-GEPARDOUZE","submission_no":"210443","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-01","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PHASE III CLINICAL TRIAL OF NEOADJUVANT CHEMOTHERAPY WITH ATEZOLIZUMAB OR PLACEBO IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER FOLLOWED BY ADJUVANT CONTINUATION OF ATEZOLIZUMAB OR PLACEBO","medConditionList":[{"med_condition_id":702,"med_condition":"BREAST CANCER TRIPLE NEGATIVE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28718,"protocol_no":"20090406","submission_no":"169534","status_id":2,"start_date":"2014-07-02","end_date":"2016-02-26","nol_date":"2013-11-28","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY AND EFFECT ON RADIOGRAPHIC PROGRESSION OF BRODALUMAB IN SUBJECTS WITH PSORIATIC ARTHRITIS: AMVISION-1","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43123,"protocol_no":"355","submission_no":"197241","status_id":1,"start_date":"2017-03-30","end_date":null,"nol_date":"2016-09-01","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF PEMBROLIZUMAB (MK-3475) PLUS CHEMOTHERAPY VS PLACEBO PLUS CHEMOTHERAPY FOR PREVIOUSLY UNTREATED LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER - (KEYNOTE-355)","medConditionList":[{"med_condition_id":702,"med_condition":"BREAST CANCER TRIPLE NEGATIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43303,"protocol_no":"MDV3800-06","submission_no":"197772","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-09-20","protocol_title":"A PHASE 2, OPEN LABEL, 2 ARM, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE).","medConditionList":[{"med_condition_id":215,"med_condition":"PROSTATE CANCER METASTATIC CASTRATION RESISTANT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45178,"protocol_no":"VHCRP1401","submission_no":"203582","status_id":1,"start_date":"2017-06-08","end_date":null,"nol_date":"2017-04-11","protocol_title":"A RANDOMISED STUDY OF INTERFERON-FREE TREATMENT FOR RECENTLY ACQUIRED HEPATITIS C IN PEOPLE WHO INJECT DRUGS AND PEOPLE WITH HIV COINFECTION (REACT)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"},{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44763,"protocol_no":"522","submission_no":"202323","status_id":1,"start_date":"2017-04-26","end_date":null,"nol_date":"2017-02-24","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE PEMBROLIZUMAB PLUS CHEMOTHERAPY VS PLACEBO PLUS CHEMOTHERAPY AS NEOADJUVANT THERAPY AND PEMBROLIZUMAB VS PLACEBO AS ADJUVANT THERAPY FOR TRIPLE NEGATIVE BREAST CANCER (TNBC)","medConditionList":[{"med_condition_id":702,"med_condition":"BREAST CANCER TRIPLE NEGATIVE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39907,"protocol_no":"2015-01","submission_no":"186601","status_id":1,"start_date":"2016-07-25","end_date":null,"nol_date":"2015-08-27","protocol_title":"AN OPEN-LABEL SAFETY ASSESSMENT OF REBIOTIX RBX2660 (MICROBIOTA SUSPENSION) FOR THE TREATMENT OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40721,"protocol_no":"MIP-1404-3301","submission_no":"188948","status_id":1,"start_date":"2017-03-29","end_date":null,"nol_date":"2015-11-27","protocol_title":"A PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 99MTC-MIP-1404 SPECT/CT IMAGING TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH BIOPSY PROVEN LOW-GRADE PROSTATE CANCER WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE (PROSPECT-AS)","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28470,"protocol_no":"M14-097","submission_no":"168678","status_id":2,"start_date":null,"end_date":"2013-12-20","nol_date":"2013-10-28","protocol_title":"AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE CO-ADMINISTRATION OF ABT-450/R/ABT-267 WITH RBV IN TREATMENT-NA√èVE AND TREATMENT-EXPERIENCED SUBJECTS WITH GENOTYPE 2 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46946,"protocol_no":"MP17","submission_no":"209266","status_id":1,"start_date":"2017-11-01","end_date":null,"nol_date":"2017-10-04","protocol_title":"AN OPEN-LABEL, MULTI-SITE PHASE 2 STUDY OF THE SAFETY AND EFFECT OF MANUALIZED MDMA-ASSISTED PSYCHOTHERAPY FOR THE TREATMENT OF SEVERE POSTTRAUMATIC STRESS DISORDER","medConditionList":[{"med_condition_id":207,"med_condition":"POST-TRAUMATIC STRESS DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42856,"protocol_no":"CCTG: REC.3/S1500","submission_no":"196409","status_id":1,"start_date":"2016-10-17","end_date":null,"nol_date":"2016-07-27","protocol_title":"A RANDOMIZED, PHASE II EFFICACY ASSESSMENT OF MULTIPLE MET KINASE INHIBITORS (CABOZANTINIB [NSC #761968], CRIZOTINIB [NSC #749005], SAVOLITINIB [NSC #785348], AND SUNITINIB [NSC #736511]) IN METASTATIC PAPILLARY RENAL CARCINOMA (PAPMET)","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43692,"protocol_no":"ADP-0022-003","submission_no":"198923","status_id":1,"start_date":"2017-05-12","end_date":null,"nol_date":"2016-11-04","protocol_title":"A PHASE 1 DOSE ESCALATION, OPEN-LABEL CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF MAGE-A10C796T IN SUBJECTS WITH STAGE IIIB OR STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44328,"protocol_no":"CLCZ696B2319","submission_no":"200879","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-28","protocol_title":"MULTICENTER, OPEN-LABEL, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND, PHARMACODYNAMICS OF LCZ696 FOLLOWED BY A 52-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ696 COMPARED WITH ENALAPRIL IN PEDIATRIC PATIENTS FROM1 MONTH TO < 18 YEARS OF AGE WITH HEART FAILURE DUE TO SYSTEMIC LEFT VENTRICLE SYSTOLIC DYSFUNCTION","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38585,"protocol_no":"1000047454","submission_no":"182502","status_id":1,"start_date":"2015-07-16","end_date":null,"nol_date":"2015-03-25","protocol_title":"HOD08 - REDUCED DURATION STANFORD V CHEMOTHERAPY WITH OR WITHOUT LOW-DOSE TAILORED-FIELD RADIATION THERAPY FOR FAVORABLE RISK PEDIATRIC HODGKIN LYMPHOMA","medConditionList":[{"med_condition_id":481,"med_condition":"HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39259,"protocol_no":"CL-SCI-201","submission_no":"184628","status_id":1,"start_date":"2015-10-06","end_date":null,"nol_date":"2015-06-18","protocol_title":"\"A SINGLE-BLIND, RANDOMIZED, PARALLEL ARM, PHASE II PROOF-OF-CONCEPTS STUDY OF THE SAFETY AND EFFICACY OF HUCNS-SC TRANSPLANTATION IN CERVICAL SPINAL CORD INJURY.\"","medConditionList":[{"med_condition_id":238,"med_condition":"SPINAL CORD LESION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46170,"protocol_no":"TCD14906","submission_no":"206616","status_id":1,"start_date":"2018-02-15","end_date":null,"nol_date":"2017-07-21","protocol_title":"A PHASE 1/2 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND EFFICACY OF ISATUXIMAB IN COMBINATION WITH REGN2810 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27338,"protocol_no":"14727","submission_no":"165482","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-07-10","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, MONOTHERAPY-CONTROLLED STUDY OF NIFEDIPINE GASTROINTESTINAL THERAPEUTIC SYSTEM AND CANDESARTAN CILEXETIL IN COMBINATION TAKEN ORALLY FOR 8 WEEKS IN ADULT SUBJECTS WITH ESSENTIAL HYPERTENSION WHO ARE INADEQUATELY CONTROLLED ON 16 MG CANDESARTAN CILEXETIL MONOTHERAPY","medConditionList":[{"med_condition_id":124,"med_condition":"HYPERTENSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29153,"protocol_no":"EMR 63325-021","submission_no":"171057","status_id":1,"start_date":"2014-06-12","end_date":null,"nol_date":"2014-01-31","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL OF TECEMOTIDE VERSUS PLACEBO IN SUBJECTS WIHT COMPLETED CONCURRENT CHEMO-RADIOTHERAPY FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47860,"protocol_no":"2102-HEM-101","submission_no":"212198","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-12","protocol_title":"A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF FT 2102 AS A SINGLE AGENT AND IN COMBINATION WITH AZACITIDINE OR CYTARABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH AN IDH1 MUTATION","medConditionList":[{"med_condition_id":719,"med_condition":"ACUTE MYELOID LEUKEMIA"},{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27647,"protocol_no":"PRO 38873","submission_no":"166339","status_id":1,"start_date":"2014-01-20","end_date":null,"nol_date":"2013-08-15","protocol_title":"\"HUMAN BIOTHERAPY IN THE MANAGEMENT OF HEPATIC ENCEPHALOPATHY\"","medConditionList":[{"med_condition_id":282,"med_condition":"HEPATIC ENCEPHALOPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27000,"protocol_no":"1199.93","submission_no":"164450","status_id":1,"start_date":"2013-08-19","end_date":null,"nol_date":"2013-05-24","protocol_title":"DOUBLE BLIND, RANDOMISED, MULTICENTRE, PHASE II STUDY OF NINTEDANIB IN COMBINATION WITH PEMETREXED / CISPLATIN FOLLOWED BY CONTINUING NINTEDANIB MONOTHERAPY VERSUS PLACEBO IN COMBINATION WITH PEMETREXED / CISPLATIN FOLLOWED BY CONTINUING PLACEBO MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA","medConditionList":[{"med_condition_id":153,"med_condition":"MALIGNANT PLEURAL MESOTHELIOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43265,"protocol_no":"DX-2930-04","submission_no":"197666","status_id":1,"start_date":"2017-08-08","end_date":null,"nol_date":"2016-09-09","protocol_title":"HELP STUDY EXTENSIONTM: AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF DX-2930 FOR PREVENTION AGAINST ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28850,"protocol_no":"M13-538","submission_no":"170076","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-17","protocol_title":"PHASE 2 STUDY, MULTICENTER, OPEN-LABEL EXTENSION (OLE) STUDY IN RHEUMATOID ARTHRITIS SUBJECTS WHO HAVE COMPLETED A PRECEDING PHASE 2 RANDOMIZED CONTROLLED TRIAL (RCT) WITH ABT-494","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42041,"protocol_no":"CLC-102","submission_no":"193725","status_id":1,"start_date":"2016-09-15","end_date":null,"nol_date":"2016-04-29","protocol_title":"A PHASE 1, DOSE-ESCALATION/DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF ORALLY ADMINISTERED CB-5083 IN SUBJECTS WITH LYMPHOID HEMATOLOGICAL MALIGNANCIES","medConditionList":[{"med_condition_id":440,"med_condition":"LYMPHOID MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46517,"protocol_no":"INSLIL08174 (LIXILAN-INSIGHT)","submission_no":"207830","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-03","protocol_title":"A RANDOMIZED, 30-WEEK, ACTIVE-CONTROLLED, OPEN-LABEL, 2-TREATMENT ARM, PARALLEL GROUP, MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF INSULIN GLARGINE/LIXISENATIDE FIXED RATIO COMBINATION TITRATED USING THE INSIGHT ALGORITHM COMPARE WITH PHYSICIAN ADJUSTMENT OF ORAL GLUCOSE LOWERING AGENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)¬ø","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37196,"protocol_no":"D5160C00007","submission_no":"177809","status_id":1,"start_date":"2015-08-05","end_date":null,"nol_date":"2014-10-03","protocol_title":"A PHASE III, DOUBLE-BLIND, RANDOMISED STUDY TO ASSESS THE EFFICACY AND SAFETY OF AZD9291 VERSUS A STANDARD OF CARE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR AS FIRST-LINE TREATMENT IN PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37394,"protocol_no":"IMMU-107-04","submission_no":"178468","status_id":2,"start_date":"2016-02-12","end_date":"2017-08-25","nol_date":"2014-10-30","protocol_title":"AN INTERNATIONAL, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PHASE III TRIAL OF 90Y-CLIVATUZUMAB TETRAXETAN PLUS LOW-DOSE GEMCITABINE VERSUS PLACEBO PLUS LOW-DOSE GEMCITABINE IN PATIENTS WITH METASTATIC (STAGE IV) PANCREATIC ADENCARCINOMA WHO RECIEVED AT LEAST TWO PRIOR TREATMENTS (PANCRIT-1)","medConditionList":[{"med_condition_id":401,"med_condition":"PANCREATIC ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41410,"protocol_no":"097/2015","submission_no":"191415","status_id":1,"start_date":"2016-03-21","end_date":null,"nol_date":"2016-02-17","protocol_title":"TOPIRAMATE IN TREATMENT REFRACTORY PSYCHOTIC ILLNESS: EFFECTS ON WEIGHT GAIN AND PSYCHOPATHOLOGY","medConditionList":[{"med_condition_id":341,"med_condition":"WEIGHT GAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38498,"protocol_no":"I4T-MC-JVCU","submission_no":"181968","status_id":1,"start_date":"2015-05-22","end_date":null,"nol_date":"2015-03-09","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF CAPECITABINE AND CISPLATIN WITH OR WITHOUT RAMUCIRUMAB AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (RAINFALL)","medConditionList":[{"med_condition_id":619,"med_condition":"GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"},{"med_condition_id":337,"med_condition":"GASTRIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44512,"protocol_no":"MDCO-PCS-16-01","submission_no":"201606","status_id":1,"start_date":"2017-04-15","end_date":null,"nol_date":"2017-01-26","protocol_title":"AN OPEN LABEL, ACTIVE COMPARATOR EXTENSION TRIAL TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN AND EVOLOCUMAB GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C (ORION-3)","medConditionList":[{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"},{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40123,"protocol_no":"104-201505","submission_no":"187141","status_id":1,"start_date":"2016-07-20","end_date":null,"nol_date":"2015-09-30","protocol_title":"A 1-YEAR, MULTICENTER, PHASE 2, OPEN-LABEL SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE¬øS DISEASE","medConditionList":[{"med_condition_id":155,"med_condition":"MENIERE'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42470,"protocol_no":"PM1183-C-003-14","submission_no":"195088","status_id":1,"start_date":"2017-01-03","end_date":null,"nol_date":"2016-06-15","protocol_title":"PHASE III RANDOMIZED CLINICAL TRIAL OF LURBINECTEDIN (PM01183)/DOXORUBICIN (DOX) VERSUS CYCLOPHOSPHAMIDE (CTX), DOXORUBICIN (DOX) AND VINCRISTINE (VCR) (CAV) OR TOPOTECAN AS TREATMENT IN PATIENTS WITH SMALL-CELL LUNG CANCER (SCLC) WHO FAILED ONE PRIOR PLATINUM CONTAINING LINE (ATLANTIS TRIAL)","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41018,"protocol_no":"STRIP-001","submission_no":"189972","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-22","protocol_title":"STUDY OF THE BIOACCUMULATION OF TINZAPARIN IN RENALLY IMPAIRED PATIENTS WHEN GIVEN AT PROPHYLACTIC DOSES","medConditionList":[{"med_condition_id":221,"med_condition":"RENAL INSUFFICIENCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43434,"protocol_no":"SHP633-304","submission_no":"198117","status_id":1,"start_date":"2017-06-23","end_date":null,"nol_date":"2016-09-30","protocol_title":"A PROSPECTIVE, OPEN-LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTSWITH SHORT BOWEL SYNDROME WHO COMPLETED TED-C14-006","medConditionList":[{"med_condition_id":697,"med_condition":"SHORT BOWEL SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36591,"protocol_no":"PTC124-GD-021-CF","submission_no":"175879","status_id":2,"start_date":"2015-03-03","end_date":"2016-09-19","nol_date":"2014-07-22","protocol_title":"A PHASE 3 EFFICACY AND SAFETY STUDY OF ATALUREN (PTC124 ¬Æ) IN PATIENTS WITH NONSENSE MUTATION CYSTIC FIBROSIS.","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35839,"protocol_no":"13605","submission_no":"173617","status_id":2,"start_date":"2015-10-28","end_date":"2016-09-14","nol_date":"2014-05-01","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RIOCIGUAT (0.5 MG, 1.0 MG, 1.5 MG, 2.0 MG AND 2.5 MG TID) IN PATIENTS WITH SYMPTOMATIC PULMONARY HYPERTENSION ASSOCIATED WITH IDIOPATHIC INTERSTITIAL PNEUMONIAS (IIP)","medConditionList":[{"med_condition_id":260,"med_condition":"PULMONARY DISORDERS"},{"med_condition_id":510,"med_condition":"SYMPTOMATIC PULMONARY HYPERTENSION ASSOCIATED WITH IDIOPATHIC INTERSTITIAL PNEUMONIAS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37797,"protocol_no":"059-03","submission_no":"179751","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-11","protocol_title":"A PHASE II/III CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172 AND MK-8742 IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS INFECTION WITH ADVANCED CIRRHOSIS AND CHILD-PUGH (CP)-B HEPATIC INSUFFICIENCY.","medConditionList":[{"med_condition_id":602,"med_condition":"HEPATIC INSUFFICIENCY"},{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35745,"protocol_no":"PB-02","submission_no":"173310","status_id":3,"start_date":"2014-06-25","end_date":null,"nol_date":"2014-04-24","protocol_title":"PHASE II STUDY OF THE USE OF PULMOBIND FOR MOLECULAR IMAGING OF PULMONARY HYPERTENSION","medConditionList":[{"med_condition_id":483,"med_condition":"PULMONARY HYPERTENSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37594,"protocol_no":"TMC114IFD3013","submission_no":"179100","status_id":1,"start_date":"2015-05-05","end_date":null,"nol_date":"2014-11-18","protocol_title":"A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE SWITCHING TO A DARUNAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (D/C/F/TAF) ONCE-DAILY SINGLE-TABLET REGIMEN VERSUS CONTINUING THE CURRENT REGIMEN CONSISTING OF A BOOSTED PROTEASE INHIBITOR (BPI) COMBINED WITH EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (FTC/TDF) IN VIROLOGICALLY-SUPPRESSED, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTED SUBJECTS","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43588,"protocol_no":"LP0053-1004","submission_no":"198542","status_id":1,"start_date":"2017-07-26","end_date":null,"nol_date":"2016-10-19","protocol_title":"LEO 90100 TWICE WEEKLY MAINTENANCE REGIMEN FOR PSORIASIS VULGARIS","medConditionList":[{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46758,"protocol_no":"2017-01","submission_no":"208593","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-08","protocol_title":"A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REBIOTIX RBX2660 (MICROBIOTA SUSPENSION) FOR THE PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46316,"protocol_no":"M16-133","submission_no":"207121","status_id":1,"start_date":"2017-11-08","end_date":null,"nol_date":"2017-07-17","protocol_title":"A SINGLE ARM, OPEN LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GLECAPREVIR(GLE)/PIBRENTASVIR(PIB) IN TREATMENT NA√èVE ADULTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPES 1- 6 INFECTION AND ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX (APRI) ¬ø 1","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28149,"protocol_no":"1000038584","submission_no":"167757","status_id":3,"start_date":"2013-10-03","end_date":null,"nol_date":"2013-09-24","protocol_title":"\"A PHASE I/IIA TRIAL OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) THERAPY FOLLOWING PORTOENTEROSTOMY IN INFANTS WITH BILIARY ATRESIA (PRIME).\"","medConditionList":[{"med_condition_id":369,"med_condition":"BILIARY ATRESIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42314,"protocol_no":"CCHIK-01","submission_no":"194592","status_id":1,"start_date":"2017-07-27","end_date":null,"nol_date":"2016-05-25","protocol_title":"STRICT IGF-1 CONTROL IN ACROMEGALY","medConditionList":[{"med_condition_id":554,"med_condition":"ACROMEGALY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43850,"protocol_no":"GO29438","submission_no":"199400","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-11-15","protocol_title":"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN + PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN + PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND HAVE STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45335,"protocol_no":"M15-925","submission_no":"204140","status_id":1,"start_date":"2017-07-27","end_date":null,"nol_date":"2017-04-10","protocol_title":"A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND STUDY COMPARING ABT-494 TO ABATACEPT IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS (BDMARDS) ON STABLE CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS)","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28539,"protocol_no":"R668-AD-1307","submission_no":"168913","status_id":1,"start_date":"2013-11-08","end_date":null,"nol_date":"2013-11-08","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, STUDY INVESTIGATING THE EFFICACY, SERUM CONCENTRATION, AND BIOMARKER PROFILE OF DUPILUMAB ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28559,"protocol_no":"GREENGENE F_E_P3","submission_no":"168971","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-11-07","protocol_title":"\"AN OPEN LABEL SAFETY AND EFFICACY EXTENSION STUDY OF GREENGENE F IN PREVIOUSLY TREATED PATIENTS DIAGNOSED WITH SEVERE HEMOPHILIA A.\"","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38009,"protocol_no":"CVT-301-004","submission_no":"180538","status_id":2,"start_date":"2015-03-26","end_date":"2016-12-06","nol_date":"2015-01-08","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF CVT-301 (LEVODOPA INHALATION  POWDER)  IN  PARKINSON'S  DISEASE  PATIENTS  WITH  MOTOR RESPONSE FLUCTUATIONS (OFF PHENOMENA)","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42284,"protocol_no":"IND.227","submission_no":"194481","status_id":1,"start_date":"2017-01-23","end_date":null,"nol_date":"2016-05-20","protocol_title":"A PHASE II RANDOMIZED STUDY OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA","medConditionList":[{"med_condition_id":198,"med_condition":"PLEURAL MESOTHELIOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38701,"protocol_no":"I4T-MC-JVDC","submission_no":"182891","status_id":1,"start_date":"2016-04-08","end_date":null,"nol_date":"2015-04-10","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA WHO PROGRESSED ON OR AFTER PLATINUM-BASED THERAPY","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29104,"protocol_no":"VGTPH 001","submission_no":"170869","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-06","protocol_title":"A CONTROLLED N-OF-1 BEFORE-AND-AFTER STUDY TO DETERMINE SAFETY AND EFFICACY TRIHEPTANOIN IN PATIENTS WITH GLUCOSE TRANSPORTER 1 DEFICIENCY SYNDROME, VGTPH001","medConditionList":[{"med_condition_id":463,"med_condition":"GLUCOSE TRANSPORTER 1 DEFICIENCY SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28008,"protocol_no":"MOT113445","submission_no":"167317","status_id":2,"start_date":"2015-03-11","end_date":"2016-05-28","nol_date":"2013-09-11","protocol_title":"NUTRITIONAL ADEQUACY THERAPEUTIC ENHANCEMENT IN THE CRITICALLY ILL: A RANDOMIZED DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF THE MOTILIN RECEPTOR AGONIST GSK962040.  THE NUTRIATE STUDY","medConditionList":[{"med_condition_id":359,"med_condition":"GASTROPARESIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44258,"protocol_no":"00-055-342","submission_no":"200562","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-22","protocol_title":"18F-DOPA PET IMAGING: AN EVALUATION OF BIODISTRIBUTION AND SAFETY","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"},{"med_condition_id":765,"med_condition":"PRIMARY BRAIN TUMOUR"},{"med_condition_id":172,"med_condition":"NEUROBLASTOMA"},{"med_condition_id":766,"med_condition":"CONGENITAL HYPERINSULINEMIA"},{"med_condition_id":633,"med_condition":"NEUROENDOCRINE TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27268,"protocol_no":"CRFB002G2301","submission_no":"165262","status_id":1,"start_date":"2014-01-07","end_date":null,"nol_date":"2013-06-26","protocol_title":"A 12-MONTH, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 0.5MG RANIBIZUMAB INTRAVITREAL INJECTIONS IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) DRIVEN CHOROIDAL NEOVASCULARIZATION (CNV).","medConditionList":[{"med_condition_id":325,"med_condition":"CHOROIDAL NEOVASCULARIZATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41561,"protocol_no":"ATB-346-P2A","submission_no":"191898","status_id":1,"start_date":"2016-03-24","end_date":null,"nol_date":"2016-03-04","protocol_title":"AN OPEN LABEL, PILOT PHASE IIA STUDY OF A TEN DAY DOSING REGIMEN OF ATB-346 ORALLY ADMINISTRATED TO MALE AND FEMALE PATIENTS DIAGNOSED WITH OSTEOARTHRITIS OF THE KNEE","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42609,"protocol_no":"16-5225","submission_no":"195552","status_id":1,"start_date":"2017-10-01","end_date":null,"nol_date":"2016-06-27","protocol_title":"A PILOT STUDY OF CYSTIC VOLUME REDUCTION BY FOAM SCLEROTHERAPY IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE","medConditionList":[{"med_condition_id":743,"med_condition":"AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE"},{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42124,"protocol_no":"CFI-402257-CL-001","submission_no":"193990","status_id":1,"start_date":"2016-10-25","end_date":null,"nol_date":"2016-05-03","protocol_title":"AN OPEN LABEL, DOSE ESCALATION, SAFETY, AND PHARMACOKINETIC STUDY OF CFI-402257 ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29510,"protocol_no":"CAIN457 A2317","submission_no":"172035","status_id":2,"start_date":"2015-04-14","end_date":"2016-06-28","nol_date":"2014-03-07","protocol_title":"A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE EFFICACY AS ASSESSED BY PSORIASIS AREA AND SEVERITY INDEX AT 16 WEEKS OF TREATMENT COMPARED TO USTEKINUMAB AND TO ASSESS LONG-TERM SAFETY, TOLERABILITY AND EFFICACY IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43709,"protocol_no":"ARGX-113-1602","submission_no":"198966","status_id":1,"start_date":"2017-04-19","end_date":null,"nol_date":"2016-11-04","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ARGX-113 IN PATIENTS WITH MYASTHENIA GRAVIS WHO HAVE GENERALIZED MUSCLE WEAKNESS","medConditionList":[{"med_condition_id":163,"med_condition":"MYASTHENIA GRAVIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47162,"protocol_no":"SYM021-01","submission_no":"209993","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-02","protocol_title":"A PHASE 1, OPEN-LABEL, MULTICENTER TRIAL INVESTIGATING THE SAFETY, TOLERABILITY, AND PRELIMINARY ANTINEOPLASTIC ACTIVITY OF SYM021 (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES OR LYMPHOMAS","medConditionList":[{"med_condition_id":691,"med_condition":"LYMPHOMA"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37236,"protocol_no":"CAMHPET-CTA-88","submission_no":"177932","status_id":1,"start_date":"2014-10-01","end_date":null,"nol_date":"2014-10-16","protocol_title":"PREVENTION OF ALZHEIMER'S DEMENTIA WITH COGNITIVE REMEDIATION PLUS TRANSCRANIAL DIRECT CURRENT STIMULATION IN MILD COGNITIVE IMPAIRMENT AND DEPRESSION: ROLE OF B-AMYLOID (PACT-MDB)","medConditionList":[{"med_condition_id":361,"med_condition":"DEMENTIA"},{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47622,"protocol_no":"42756493BLC3001","submission_no":"211386","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-10","protocol_title":"A PHASE 3 STUDY OF ERDAFITINIB COMPARED WITH VINFLUNINE OR DOCETAXEL OR PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED UROTHELIAL CANCER AND SELECTED FGFR GENE ABERRATIONS","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27525,"protocol_no":"CC-10004-PSA-006","submission_no":"165983","status_id":2,"start_date":"2014-05-15","end_date":"2017-02-28","nol_date":"2013-07-22","protocol_title":"A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) MONOTHERAPY IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43261,"protocol_no":"METFORMIN 001","submission_no":"197650","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-09-13","protocol_title":"THE EFFECTS OF NEOADJUVANT METFORMIN ON TUMOUR CELL PROLIFERATION AND TUMOUR PROGRESSION IN PANCREATIC DUCTAL ADENOCARCINOMA","medConditionList":[{"med_condition_id":678,"med_condition":"PANCREATIC DUCTAL ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27393,"protocol_no":"TAK-875_310","submission_no":"165614","status_id":1,"start_date":"2013-08-19","end_date":null,"nol_date":"2013-07-09","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, 24-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAILY ORAL TAK-875 50 MG COMPARED WITH SITAGLIPTIN","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41643,"protocol_no":"M14-327","submission_no":"192180","status_id":1,"start_date":"2016-08-02","end_date":null,"nol_date":"2016-03-04","protocol_title":"A PHASE 2, MULTICENTER, OPEN-LABEL EXTENSION (OLE) STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF REPEATED ADMINISTRATION OF ABT 494 IN SUBJECTS WITH CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26815,"protocol_no":"TRX-237-015","submission_no":"163899","status_id":2,"start_date":"2013-05-22","end_date":"2015-11-30","nol_date":"2013-05-10","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 12 MONTH TRIAL OF LEUCO-METHYLTHIONINUM BIS(HYDROMETHANESULFONATE) IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41909,"protocol_no":"M13-542","submission_no":"193196","status_id":2,"start_date":"2016-04-21","end_date":"2017-03-02","nol_date":"2016-03-30","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING ABT-494 TO PLACEBO ON STABLE CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI RHEUMATIC DRUGS (CSDMARDS) IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS (BDMARDS)","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45286,"protocol_no":"AAG-G-H-1220","submission_no":"203912","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-28","protocol_title":"A PHASE 3 PROSPECTIVE, RANDOMIZED, PARTIALLY BLINDED MULTI-CENTER STUDY TO MEASURE THE SAFETY AND EFFICACY OF NOVOCART 3D, COMPARED TO MICROFRACTURE IN THE TREATMENT OF ARTICULAR CARTILAGE DEFECTS","medConditionList":[{"med_condition_id":782,"med_condition":"ARTICULAR CARTILAGE DEFECT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46903,"protocol_no":"SERES-013","submission_no":"209072","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-04","protocol_title":"ECOSPOR IV: AN OPEN-LABEL EXTENSION OF STUDY SERES-012 EVALUATING SER-109 IN ADULT SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI)","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38406,"protocol_no":"MEA116841","submission_no":"181982","status_id":1,"start_date":"2015-11-13","end_date":null,"nol_date":"2015-03-09","protocol_title":"MEPOLIZUMAB LONG-TERM ACCESS PROGRAMME FOR SUBJECTS WHO PARTICIPATED IN STUDY MEA115921 (PLACEBO-CONTROLLED STUDY OF MEPOLIZUMAB IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS IN SUBJECTS RECEIVING STANDARD-OF-CARE THERAPY)","medConditionList":[{"med_condition_id":579,"med_condition":"POLYANGITIS"},{"med_condition_id":402,"med_condition":"EOSINOPHILIC GRANULOMATOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43799,"protocol_no":"D6000C00003","submission_no":"199206","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-11-10","protocol_title":"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, SINGLE-DOSE, ACTIVE-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEDI8852 IN ADULTS WHO ARE HOSPITALIZED WITH INFLUENZA CAUSED BY TYPE A STRAINS","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38649,"protocol_no":"NPH-002-101","submission_no":"182745","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-08","protocol_title":"A RANDOMIZED, SINGLE-CENTER, DOUBLE-MASKED, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NPH-002 OPHTHALMIC SOLUTION IN SUBJECTS WITH ALLERGIC CONJUNCTIVITIS.","medConditionList":[{"med_condition_id":631,"med_condition":"ALLERGIC CONJUNCTIVITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26777,"protocol_no":"CNTO148UCO1001","submission_no":"163801","status_id":3,"start_date":"2013-12-17","end_date":null,"nol_date":"2013-05-08","protocol_title":"\"A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF SUBCUTANEOUSLY ADMINISTERED GOLIMUMAB, A HUMAN ANTI-TNFA ANTIBODY, IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS.\"","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47912,"protocol_no":"H17-02157","submission_no":"212359","status_id":1,"start_date":"2018-02-13","end_date":null,"nol_date":"2018-01-29","protocol_title":"ANESTHETIC SPARING EFFECT OF DEXMEDETOMIDINE DURING TIVA WITH PROPOFOL AND REMIFENTANIL FOR CHILDREN UNDERGOING DENTAL PROCEDURES","medConditionList":[{"med_condition_id":553,"med_condition":"ANASTHESIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38540,"protocol_no":"M12-927","submission_no":"182361","status_id":1,"start_date":"2015-12-03","end_date":null,"nol_date":"2015-03-24","protocol_title":"AN OPEN-LABEL, RANDOMIZED 26-WEEK STUDY COMPARING LEVODOPA-CARBIDOPA INTESTINAL GEL (LCIG) THERAPY TO OPTIMIZED MEDICAL TREATMENT (OMT) ON NON-MOTOR SYMPTOMS (NMS) IN SUBJECTS WITH ADVANCED PARKINSON'S DISEASE - INSIGHTS STUDY","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35714,"protocol_no":"GO27878","submission_no":"173206","status_id":1,"start_date":"2015-08-10","end_date":null,"nol_date":"2014-04-25","protocol_title":"A PHASE IB/II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF GDC-0199 (ABT-199) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA (NHL) AND DLBCL","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"},{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42842,"protocol_no":"H3B-6527-G000-101","submission_no":"196380","status_id":1,"start_date":"2017-08-03","end_date":null,"nol_date":"2016-07-25","protocol_title":"AN OPEN-LABEL MULTICENTER PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF H3B-6527 IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA OR INTRAHEPATIC CHOLANGIOCARCINOMA","medConditionList":[{"med_condition_id":587,"med_condition":"CHOLANGIOCARCINOMA"},{"med_condition_id":753,"med_condition":"INTRAHEPATIC CHOLANGIOCARCINOMA"},{"med_condition_id":519,"med_condition":"ADVANCED HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26441,"protocol_no":"SARB-123","submission_no":"162777","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-04-10","protocol_title":"\"A PROSPECTIVE RANDOMIZED CONTROL TRIAL COMPARING THE USE OF SUB-CONJUNCTIVAL AVASTIN (BEVACIZUMAB) VERSUS 5-FU (FLUOROURACIL) IN CONJUNCTION WITH BLEB NEEDLING FOR THE RESCUE OF FAILING BLEBS.\"","medConditionList":[{"med_condition_id":286,"med_condition":"BLEB"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42605,"protocol_no":"CPDR001X2103","submission_no":"195545","status_id":1,"start_date":"2017-08-10","end_date":null,"nol_date":"2016-06-30","protocol_title":"PHASE 1B, OPEN-LABEL, MULTI-CENTER STUDY TO CHARACTERIZE THE SAFETY, TOLERABILITY AND PHARMACODYNAMICS (PD) OF PDR001 IN COMBINATION WITH CJM112, EGF816, ILARIS (CANAKINUMAB) OR MEKINIST (TRAMETINIB)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"},{"med_condition_id":702,"med_condition":"BREAST CANCER TRIPLE NEGATIVE"},{"med_condition_id":50,"med_condition":"COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46330,"protocol_no":"HCA2017","submission_no":"207151","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-03","protocol_title":"HEPARIN ANTICOAGULATION TO IMPROVE OUTCOMES IN SEPTIC SHOCK: THE HALO INTERNATIONAL PHASE II RCT","medConditionList":[{"med_condition_id":583,"med_condition":"SEPTIC SHOCK"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29455,"protocol_no":"12-1387","submission_no":"171859","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-28","protocol_title":"ASSESSMENT OF MYOCARDIAL ISCHEMIA USING OXYGENATION-SENSITIVE CMR (AMIOS): BLOOD-OXYGEN LEVEL DEPENDENT CARDIOVASCULAR MR AT 3.0T IN DETECTION OF HEMODYNAMICALLY SIGNIFICANT CORONARY ARTERY STENOSIS - VALIDATION AGAINST FRACTIONAL FLOW RESERVE","medConditionList":[{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35699,"protocol_no":"ADVL1312","submission_no":"173153","status_id":2,"start_date":"2014-11-20","end_date":"2017-01-03","nol_date":"2014-04-23","protocol_title":"A PHASE 1/2 STUDY OF MK-1775 (AZD1775, IND# 121422) IN COMBINATION WITH ORAL","medConditionList":[{"med_condition_id":507,"med_condition":"RELAPSED OR REFRACTORY SOLID TUMORS"},{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37905,"protocol_no":"MOM-M402-103","submission_no":"180043","status_id":1,"start_date":"2015-07-29","end_date":null,"nol_date":"2014-12-19","protocol_title":"A PHASE I/II, TWO-PART, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF M402 IN COMBINATION WITH NAB-PACLITAXEL AND GEMCITABINE IN PATIENTS WITH METASTATIC PANCREATIC CANCER","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28227,"protocol_no":"CAMPHET-CTA-80","submission_no":"167989","status_id":3,"start_date":"2013-10-01","end_date":null,"nol_date":"2013-10-04","protocol_title":"FURTHER VALIDATION OF [C-11]CURB -  A NEW PET LIGAND FOR THE FATTY ACID AMIDE HYDROLASE (FAAH) - IN NEUTROPSYCHIATRIC CONDITIONS","medConditionList":[{"med_condition_id":398,"med_condition":"NEUTROPSYCHIATRIC CONDITIONS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39905,"protocol_no":"CTH-301","submission_no":"186583","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-08-31","protocol_title":"AN OPEN-LABEL, PHASE 3 STUDY EXAMINING THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF APL-130277 IN LEVODOPA RESPONSIVE PATIENTS WITH PARKINSON¬øS DISEASE COMPLICATED BY MOTOR FLUCTUATIONS (¬øOFF¬ø EPISODES)","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39637,"protocol_no":"547-SSE-301","submission_no":"185922","status_id":1,"start_date":"2016-01-26","end_date":null,"nol_date":"2015-08-14","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-547 INJECTION IN THE TREATMENT OF SUBJECTS WITH SUPER-REFRACTORY STATUS EPILEPTICUS","medConditionList":[{"med_condition_id":392,"med_condition":"EPILEPSY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27188,"protocol_no":"C16015","submission_no":"165055","status_id":2,"start_date":"2014-03-13","end_date":"2017-05-24","nol_date":"2013-06-07","protocol_title":"PHASE 1/1B PHARMACOKINETICS STUDY OF ORAL MLN9708 PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH NORMAL RENAL FUNCTION OR SEVERE RENAL IMPAIRMENT","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35969,"protocol_no":"SAG/0211PFC-11S1","submission_no":"174079","status_id":2,"start_date":"2015-11-19","end_date":"2017-05-01","nol_date":"2014-05-14","protocol_title":"A MULTICENTRE, LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS STUDY OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >=6 TO <18 YEARS WITH FUNCTIONAL CONSTIPATION","medConditionList":[{"med_condition_id":468,"med_condition":"CONSTIPATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40052,"protocol_no":"CAMHPET-CTA-94","submission_no":"186950","status_id":1,"start_date":"2015-09-17","end_date":null,"nol_date":"2015-09-11","protocol_title":"INVESTIGATING THE ENDOCANNABINOID SYSTEM IN BORDERLINE PERSONALITY DISORDER AND ANTISOCIAL PERSONALITY DISORDER","medConditionList":[{"med_condition_id":642,"med_condition":"PERSONALITY DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39882,"protocol_no":"NCIC CTG: IND.226","submission_no":"186522","status_id":1,"start_date":"2016-05-27","end_date":null,"nol_date":"2015-08-27","protocol_title":"A PHASE IB STUDY OF DUVALUMAB (MEDI-4736) WITH OR WITHOUT TREMELIMUMAB IN PATIENTS WITH ADVANCED INCURABLE SOLID MALIGNANCIES RECEIVING STANDARD CHEMOTHERAPY REGIMENS","medConditionList":[{"med_condition_id":499,"med_condition":"ACUTE CORONARY SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37488,"protocol_no":"PRO147960","submission_no":"178427","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-11-04","protocol_title":"EARLY TREATMENT WITH SOFOSBUVIR (SOF) AND RIBAVIRIN (RBV) TO PREVENT HCV RECURRENCE AFTER LIVER TRANSPLANTATION (OLT)","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39989,"protocol_no":"CAMHPET-CTA-100","submission_no":"186793","status_id":1,"start_date":"2015-09-03","end_date":null,"nol_date":"2015-09-01","protocol_title":"POST-CONCUSSION SYNDROME IN PROFESSIONAL ATHLETES: A MULTIDISCIPLINARY STUDY","medConditionList":[{"med_condition_id":644,"med_condition":"POST-CONCUSSION SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28826,"protocol_no":"MHIPS-002","submission_no":"170005","status_id":1,"start_date":"2014-07-28","end_date":null,"nol_date":"2013-12-30","protocol_title":"A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF COLCHICINE ON VASCULAR INFLAMMATION AS ASSESSED WITH POSITRON EMISSION TOMOGRAPHY (PET) IMAGING IN PATIENTS WITH ATHEROSCLEROTIC VASCULAR DISEASE","medConditionList":[{"med_condition_id":444,"med_condition":"VASCULAR INFLAMMATION"},{"med_condition_id":445,"med_condition":"ATHEROSCLEROTIC VASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37924,"protocol_no":"TXV14-01","submission_no":"180120","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-22","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TX-004HR IN POSTMENOPAUSAL WOMEN WITH MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY","medConditionList":[{"med_condition_id":443,"med_condition":"VULVOVAGINAL ATROPHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37701,"protocol_no":"TOAD2015","submission_no":"179480","status_id":1,"start_date":"2014-12-01","end_date":null,"nol_date":"2014-12-12","protocol_title":"COMBINED USE OF INTRANASAL OXYTOCIN AND INTERPERSONAL PSYCHOTHERAPY FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD): A RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27548,"protocol_no":"D4880C00003","submission_no":"166051","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-08-07","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING TREMELIMUMAB TO PLACEBO IN SECOND OR THIRD-LINE TREATMENT OF SUBJECTS WITH UNRESECTABLE PLEURAL OR PERITONEAL MALIGNANT MESOTHELIOMA","medConditionList":[{"med_condition_id":153,"med_condition":"MALIGNANT PLEURAL MESOTHELIOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26764,"protocol_no":"CES05PONV","submission_no":"163759","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-06-27","protocol_title":"A RANDOMIZED CONTROLLED TRIAL OF CESAMET FOR THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN ELECTIVE OUTPATIENT SURGERY","medConditionList":[{"med_condition_id":302,"med_condition":"NAUSEA AND VOMITING"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45104,"protocol_no":"IMCGP100-202","submission_no":"203323","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-30","protocol_title":"A PHASE II RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 COMPARED WITH INVESTIGATOR'S CHOICE IN HLA-A*0201 POSITIVE PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED UVEAL MELANOMA","medConditionList":[{"med_condition_id":489,"med_condition":"UVEAL MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36384,"protocol_no":"CANALI-HC","submission_no":"175244","status_id":1,"start_date":"2014-09-01","end_date":null,"nol_date":"2014-07-03","protocol_title":"THE USE OF THE CALCIUM CHANNEL BLOCKER AMLODIPINE AS AN ADJUVANT TREATMENT TO IRON CHELATION FOR THE PREVENTION OF IRON OVERLOAD CARDIOMYOPATHY IN PATIENTS WITH THALASSEMIA","medConditionList":[{"med_condition_id":535,"med_condition":"TRANSFUSION DEPENDENT THALASSEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39615,"protocol_no":"CC-5013-AML-002","submission_no":"185861","status_id":1,"start_date":"2016-05-05","end_date":null,"nol_date":"2015-07-10","protocol_title":"A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE ACTIVITY, SAFETY AND PHARMACOKINETICS OF LENALIDOMIDE (REVLIMID¬Æ) IN PEDIATRIC SUBJECTS FROM 1 TO <= 18 YEARS OF AGE WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA","medConditionList":[{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39527,"protocol_no":"GX29176","submission_no":"185626","status_id":1,"start_date":"2015-11-11","end_date":null,"nol_date":"2015-07-03","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION","medConditionList":[{"med_condition_id":568,"med_condition":"MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28077,"protocol_no":"CD-ON-MEDI4736-1108","submission_no":"167518","status_id":1,"start_date":"2015-12-22","end_date":null,"nol_date":"2013-09-18","protocol_title":"\"A PHASE I STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MDI4736 IN SUBJECTS WITH ADVANCED SOLID TUMORS.\"","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27091,"protocol_no":"ZS-003","submission_no":"164768","status_id":2,"start_date":"2013-07-25","end_date":"2013-12-20","nol_date":"2013-06-07","protocol_title":"A PHASE 3 MULTICENTER, TWO-PHASE, MULTI-DOSE, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ZS (MICROPOROUS, FRACTIONATED, PROTONATED ZIRCONIUM SILICATE), AN ORAL SORBENT, IN SUBJECTS WITH MILD TO MODERATE HYPERKALEMIA","medConditionList":[{"med_condition_id":271,"med_condition":"HYPERKALEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36784,"protocol_no":"GS-US-342-1140","submission_no":"176516","status_id":2,"start_date":"2015-05-01","end_date":"2015-08-31","nol_date":"2014-08-12","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF SOFOSBUVIR/GS-5816 FIXED DOSE COMBINATION FOR 12 WEEKS WITH SOFOSBUVIR AND RIBAVIRIN FOR 24 WEEKS IN SUBJECTS WITH CHRONIC GENOTYPE 3 HCV INFECTION","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40348,"protocol_no":"MK-3475-054","submission_no":"187770","status_id":1,"start_date":"2015-12-10","end_date":null,"nol_date":"2015-10-14","protocol_title":"ADJUVANT IMMUNOTHERAPY WITH ANTI-PD-1 MONOCLONAL ANTIBODY PEMBROLIZUMAB (MK-3475) VERSUS PLACEBO AFTER COMPLETE RESECTION OF HIGH-RISK STAGE III MELANOMA: A RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL OF THE EORTC MELANOMA GROUP","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44779,"protocol_no":"64304500CRD2001","submission_no":"202387","status_id":1,"start_date":"2017-10-03","end_date":null,"nol_date":"2017-03-06","protocol_title":"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER PROTOCOL TO EVALUATE THE SAFETY AND EFFICACY OF JNJ-64304500 IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37929,"protocol_no":"DALF-PS-1016","submission_no":"180137","status_id":1,"start_date":"2015-09-17","end_date":null,"nol_date":"2014-12-22","protocol_title":"A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE STRENGTHS OF DALFAMPRIDINE EXTENDED RELEASE TABLETS FOR TREATMENT OF STABLE WALKING DEFICITS IN POST-ISCHEMIC STROKE (MILESTONE)","medConditionList":[{"med_condition_id":243,"med_condition":"STROKE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42625,"protocol_no":"OCOG-2016-MISTER","submission_no":"195596","status_id":1,"start_date":"2016-12-20","end_date":null,"nol_date":"2016-06-30","protocol_title":"ASSESSMENT OF NEW MOLECULAR IMAGING STRATEGIES FOR PROSTATE CANCER: PREDICTIVE VALUE OF ESTABLISHED AND NOVEL PET RADIOTRACERS IN CASTRATION-RESISTANT PROSTATE CANCER (MISTER)","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37911,"protocol_no":"NICHD-2013-ABS01","submission_no":"180060","status_id":1,"start_date":"2016-02-02","end_date":null,"nol_date":"2014-12-18","protocol_title":"ANTIBIOTIC SAFETY IN INFANTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS   (SCAMP TRIAL)","medConditionList":[{"med_condition_id":133,"med_condition":"INTRA-ABDOMINAL INFECTION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42541,"protocol_no":"16758A","submission_no":"195291","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-06-16","protocol_title":"INTERVENTIONAL, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-COMPARATOR, FLEXIBLE-DOSE STUDY TO COMPARE THE EFFECTIVENESS OF BREXPIPRAZOLE TO THAT OF RISPERIDONE IN ADULT PATIENTS WITH SCHIZOPHRENIA","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46381,"protocol_no":"029","submission_no":"207320","status_id":1,"start_date":"2017-10-27","end_date":null,"nol_date":"2017-08-08","protocol_title":"A PHASE 1/2 CLINICAL TRIAL TO STUDY THE SAFETY AND TOLERABILITY OF MK-3475 + PEGYLATED INTERFERON ALFA-2B (PEG-IFN) AND MK-3475 + IPILIMUMAB (IPI) IN SUBJECTS WITH ADVANCED MELANOMA (MEL) AND RENAL CELL CARCINOMA (RCC) (KEYNOTE 029)","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"},{"med_condition_id":722,"med_condition":"RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27630,"protocol_no":"CLEE011X2105","submission_no":"166297","status_id":1,"start_date":"2014-05-26","end_date":null,"nol_date":"2013-08-01","protocol_title":"A PHASE IB/II, MULTICENTER, STUDY OF LEE011 IN COMBINATION WITH LGX818 IN ADULT PATIENTS WITH BRAF MUTANT MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"},{"med_condition_id":342,"med_condition":"MELANOMA WITH BRAF MUTATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28350,"protocol_no":"54781532UCO2001","submission_no":"168294","status_id":2,"start_date":"2014-03-20","end_date":"2015-12-22","nol_date":"2013-10-17","protocol_title":"A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RESPONSE STUDY EVALUATING THE EFFICACY AND SAFETY OF JNJ-54781532 IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44477,"protocol_no":"GED-0301-CD-003","submission_no":"200406","status_id":1,"start_date":"2017-06-01","end_date":null,"nol_date":"2017-01-20","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MONGERSEN (GED-0301) FOR THE TREATMENT OF ADULT AND ADOLESCENT SUBJECTS WITH ACTIVE CROHN¬øS DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28716,"protocol_no":"20110144","submission_no":"169532","status_id":1,"start_date":"2014-07-02","end_date":null,"nol_date":"2013-11-29","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRODALUMAB IN SUBJECTS WITH PSORIATIC ARTHRITIS: AMVISION-2","medConditionList":[{"med_condition_id":217,"med_condition":"PSORIATIC ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26801,"protocol_no":"GO28396","submission_no":"163857","status_id":2,"start_date":"2014-08-05","end_date":"2015-01-08","nol_date":"2013-05-02","protocol_title":"A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE DOSE OF TIZANIDINE (A CYP1A2 SUBSTRATE) IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.","medConditionList":[{"med_condition_id":314,"med_condition":"METASTATIC MALIGNANCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28134,"protocol_no":"200170","submission_no":"167693","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-18","protocol_title":"A ROLLOVER STUDY TO PROVIDE CONTINUED TREATMENT WITH ELTROMBOPAG","medConditionList":[{"med_condition_id":128,"med_condition":"IMMUNE THROMBOCYTOPENIA (ITP)"},{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47563,"protocol_no":"AE051-G-16-007","submission_no":"211260","status_id":1,"start_date":"2017-12-20","end_date":null,"nol_date":"2017-12-08","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF JTE-051 ADMINISTERED FOR 12 WEEKS IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (CLEAR-PS),","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36556,"protocol_no":"RD.06.SPR.18132","submission_no":"175788","status_id":1,"start_date":"2014-10-16","end_date":null,"nol_date":"2014-07-21","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, VEHICLE CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF CALCITRIOL 3 MCG/G OINTMENT APPLIED TWICE DAILY FOR 8 WEEKS IN PEDIATRIC SUBJECTS (2 TO 12 YEARS OF AGE) WITH MILD TO MODERATE PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35461,"protocol_no":"CNVA237B2301","submission_no":"172453","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-03-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 52-WEEK STUDY EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF NVA237 IN PATIENTS WITH POORLY CONTROLLED ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37908,"protocol_no":"ALXN1007-APS-201","submission_no":"179913","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-12-17","protocol_title":"AN OPEN-LABEL PROOF OF CONCEPT PHASE IIA TRIAL OF ALXN1007 FOR THE TREATMENT OF NON-CRITERIA MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME","medConditionList":[{"med_condition_id":584,"med_condition":"ANTIPHOSPHOLIPID SYNDROME"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26505,"protocol_no":"E-203B","submission_no":"162965","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-04-12","protocol_title":"A SINGLE-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO ASSESS THE TOLERABILITY AND SAFETY OF THE ADDITION OF USTEKINUMAB TO INGAP PEPTIDE TREATMENT IN ADULTS WITH ESTABLISHED TYPE 1 DIABETES MELLITUS","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29396,"protocol_no":"NN7999-3895 (PARADIGM 6)","submission_no":"171707","status_id":1,"start_date":"2015-11-10","end_date":null,"nol_date":"2014-02-19","protocol_title":"AN OPEN-LABEL SINGLE-ARM MULTICENTRE NON-CONTROLLED PHASE 3A TRIAL INVESTIGATING SAFETY AND NONACOG BETA PEGOL (N9-GP) IN PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY UNTREATED PATIENTS WITH HAEMOPHILIA B","medConditionList":[{"med_condition_id":100,"med_condition":"HEMOPHILIA B"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38712,"protocol_no":"15984","submission_no":"182924","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-16","protocol_title":"A COMBINED PHASE IIA / IIB STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF REPEATED TOPICAL DOSES OF REGORAFENIB EYE DROPS, IN TREATMENT NA√èVE SUBJECTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION","medConditionList":[{"med_condition_id":288,"med_condition":"NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46279,"protocol_no":"20150267","submission_no":"206992","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-24","protocol_title":"A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36468,"protocol_no":"RRC/2013/1340 (B2014:032)","submission_no":"175516","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-07-11","protocol_title":"CASE SERIES OF CONTINUOUSLY-INFUSED AMPHOTERICIN-B AND FOLLOW-UP VORICONAZOLE THERAPY FOR SEVERE BLASTOMYCOSIS PULMONARY INFECTIONS","medConditionList":[{"med_condition_id":541,"med_condition":"PAPILLARY RENAL CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46657,"protocol_no":"CIFLOT3-16IA01","submission_no":"208260","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-07","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CIPROFLOXACIN 0.3% PLUS FLUOCINOLONE ACETONIDE 0.025% AURICULAR SOLUTION COMPARED TO CIPROFLOXACIN 0.3% AURICULAR SOLUTION AND TO FLUOCINOLONE ACETONIDE 0.025% AURICULAR SOLUTION IN THE TREATMENT OF ACUTE OTITIS EXTERNA (AOE). ¬øCIFLOTEX STUDY¬ø","medConditionList":[{"med_condition_id":182,"med_condition":"OTITIS EXTERNA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36794,"protocol_no":"13-027","submission_no":"176576","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-08-14","protocol_title":"SENTINEL LYMPH NODE DETECTION IN PATIENTS WITH ENDOMETRIAL CANCER FOLLOWING INTRA-OPERATIVE CERVICAL INJECTION: A COMPARISON BETWEEN PATENT BLUE AND INDOCYANINE GREEN FLUORESCENT DYE","medConditionList":[{"med_condition_id":73,"med_condition":"ENDOMETRIAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37282,"protocol_no":"D3250C00021","submission_no":"178139","status_id":1,"start_date":"2016-01-04","end_date":null,"nol_date":"2014-10-15","protocol_title":"A MULTICENTRE, RANDOMIZED, PARALLEL GROUP, PHASE 3 SAFETY EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BENRALIZUMAB (MEDI-563) IN ASTHMATIC ADULTS AND ADOLESCENTS ON INHALED CORTICOSTEROID PLUS LONG-ACTING B2 AGONIST (BORA)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38533,"protocol_no":"048","submission_no":"182348","status_id":1,"start_date":"2016-12-21","end_date":null,"nol_date":"2015-04-01","protocol_title":"A PHASE 3 CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) IN FIRST LINE TREATMENT OF RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA","medConditionList":[{"med_condition_id":34,"med_condition":"CARCINOMA OF THE HEAD AND NECK"},{"med_condition_id":240,"med_condition":"SQUAMOUS CELL CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43845,"protocol_no":"1000053649","submission_no":"199371","status_id":1,"start_date":"2017-03-13","end_date":null,"nol_date":"2016-11-17","protocol_title":"PILOT STUDY OF NIVOLUMAB IN PEDIATRIC PATIENTS WITH HYPERMUTANT CANCERS","medConditionList":[{"med_condition_id":764,"med_condition":"HYPERMUTANT CANCER"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":28193,"protocol_no":"HGT-FIR-096","submission_no":"167919","status_id":1,"start_date":"2014-01-03","end_date":null,"nol_date":"2013-10-02","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO ¬ñCONTROLLED, MULTICENTER CLINICAL STUDY EVALUATING THE SAFETY AND EFFICACY OF ICATIBANT AS A TREATMENT FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITOR (ACE-I)-INDUCED ANGIOEDEMA IN ADULTS.","medConditionList":[{"med_condition_id":391,"med_condition":"ACE INHIBITOR INDUCED ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35836,"protocol_no":"RD.06.SPR.18131","submission_no":"173613","status_id":1,"start_date":"2014-01-05","end_date":null,"nol_date":"2014-05-01","protocol_title":"A MULTICENTER OPEN LABEL UNCONTROLLED STUDY OF THE LONG TERM SAFETY AND EFFICACY OF CALCITRIOL","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36252,"protocol_no":"JP20140701","submission_no":"174888","status_id":1,"start_date":"2015-05-15","end_date":null,"nol_date":"2014-07-11","protocol_title":"ESSAI RANDOMIS√â CONTROL√â CONCERNANT L'EFFICACIT√â DE LA VITAMINE D COMME TRAITEMENT ADJUVANT DE LA MALADIE DE CROHN P√âDIATRIQUE.","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35368,"protocol_no":"GS-US-352-1154","submission_no":"172112","status_id":1,"start_date":"2015-10-31","end_date":null,"nol_date":"2014-03-10","protocol_title":"OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF MOMELOTINIB IN SUBJECTS WITH PRIMARY MYELOFIBROSIS, POST POLYCYTHEMIA VERA MYELOFIBROSIS, POST ESSENTIAL THROMBOCYTHEMIA  MYELOFIBROSIS, POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA","medConditionList":[{"med_condition_id":199,"med_condition":"POLYCYTHEMIA VERA (PV)"},{"med_condition_id":353,"med_condition":"MYELOFIBROSIS"},{"med_condition_id":249,"med_condition":"THROMBOCYTHEMIA MYELOFIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29129,"protocol_no":"RIVAROXHFA3001 (IMPACT 16302)","submission_no":"171004","status_id":1,"start_date":"2015-05-01","end_date":null,"nol_date":"2014-01-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, EVENT-DRIVEN, MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF ORAL RIVAROXABAN WITH PLACEBO FOR REDUCING THE RISK OF DEATH, MYOCARDIAL INFARCTION OR STROKE IN SUBJECTS WITH CHRONIC HEART FAILURE AND SIGNIFICANT CORONARY ARTERY DISEASE FOLLOWING A HOSPITALIZATION FOR EXACERBATION OF HEART FAILURE.","medConditionList":[{"med_condition_id":319,"med_condition":"CHRONIC HEART FAILURE"},{"med_condition_id":243,"med_condition":"STROKE"},{"med_condition_id":169,"med_condition":"MYOCARDIAL INFARCTION"},{"med_condition_id":56,"med_condition":"CORONARY HEART DISEASE OR HIGH RISK OF CORONONARY HEART DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41478,"protocol_no":"0202EA","submission_no":"191611","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-02-18","protocol_title":"AN EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME IN PATIENTS WITH ALREADY MANUFACTURED DCVAX¬Æ-L, AUTOLOGOUS DENDRITIC  CELLS PULSED WTIH TUMOR LYSATE ANTIGEN WHO HAVE SCREEN-FAILED PROTOCOL 020221","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41796,"protocol_no":"17613","submission_no":"192729","status_id":1,"start_date":"2016-05-20","end_date":null,"nol_date":"2016-03-31","protocol_title":"AN OPEN-LABEL, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE-3B STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF THREE DIFFERENT TREATMENT REGIMENS OF 2 MG AFLIBERCEPT ADMINISTERED BY INTRAVITREAL INJECTIONS TO SUBJECTS WITH DIABETIC MACULAR EDEMA (DME)","medConditionList":[{"med_condition_id":64,"med_condition":"DIABETIC MACULAR EDEMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43282,"protocol_no":"NCT02726659","submission_no":"197701","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-09-22","protocol_title":"ADJUNCTIVE USE OF CELECOXIB IN THE TREATMENT OF BIPOLAR POSTPARTUM DEPRESSION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"},{"med_condition_id":744,"med_condition":"BIPOLAR POSTPARTUM DEPRESSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38622,"protocol_no":"H14-02920","submission_no":"182643","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-10-06","protocol_title":"A PHASE 2A MULTI-CENTER STUDY OF 18F-FDG PET, SAFETY, AND TOLERABILITY OF AZD0530 IN MILD ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38974,"protocol_no":"WA29330","submission_no":"183770","status_id":1,"start_date":"2015-05-21","end_date":null,"nol_date":"2015-05-14","protocol_title":"\"A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-COMPARATOR, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RITUXIMAB VERSUS MMF IN PATIENTS WITH PEMPHIGUS VULGARIS.\"","medConditionList":[{"med_condition_id":585,"med_condition":"PEMPHIGUS VULGARIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40563,"protocol_no":"AC-080A201","submission_no":"188491","status_id":2,"start_date":"2016-07-06","end_date":"2017-04-07","nol_date":"2015-11-12","protocol_title":"MULTI-CENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO- AND ACTIVE-REFERENCE, PARALLEL GROUP, PHASE 2 DOSE-FINDING STUDY WITH ACT-132577 IN SUBJECTS WITH ESSENTIAL HYPERTENSION (GRADE 1 AND 2).","medConditionList":[{"med_condition_id":124,"med_condition":"HYPERTENSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46177,"protocol_no":"C16029","submission_no":"206649","status_id":1,"start_date":"2018-01-25","end_date":null,"nol_date":"2017-07-10","protocol_title":"A PHASE 2/3, RANDOMIZED, OPEN-LABEL STUDY COMPARING ORAL IXAZOMIB/DEXAMETHASONE AND ORAL POMALIDOMIDE/DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39228,"protocol_no":"VX14-809-109","submission_no":"184543","status_id":2,"start_date":"2015-11-30","end_date":"2016-09-02","nol_date":"2015-06-02","protocol_title":"A PHASE 3, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 6 THROUGH 11 YEARS WITH CYSTIC FIBROSIS, HOMOZYGOUS FOR THE F508DEL CFTR MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38483,"protocol_no":"MEA117113","submission_no":"182187","status_id":1,"start_date":"2015-03-20","end_date":null,"nol_date":"2015-03-13","protocol_title":"MEPOLIZUMAB VS. PLACEBO AS ADD-ON TREATMENT FOR FREQUENTLY EXACERBATING COPD PATIENTS CHARACTERIZED BY EOSINOPHIL LEVEL","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40431,"protocol_no":"M14-748","submission_no":"188082","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-10-22","protocol_title":"AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF OMBITASVIR (OBV), PARITAPREVIR (PTV), RITONAVIR (RTV) WITH OR WITHOUT DASABUVIR (DSV) AND WITH OR WITHOUT RIBAVIRIN (RBV) IN PEDIATRIC SUBJECTS WITH GENOTYPE 1 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION (ZIRCON)","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"},{"med_condition_id":577,"med_condition":"HEPATITIS C VIRUS GENOTYPE 4"},{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"},{"med_condition_id":105,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1 OR 4"},{"med_condition_id":106,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1A OR 1B"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42595,"protocol_no":"EFC13794","submission_no":"195498","status_id":1,"start_date":"2016-07-21","end_date":null,"nol_date":"2016-07-05","protocol_title":"AS PER CTA-A CTRL # 199456, TITLE CHANGED TO READ:  A 26-WEEK RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, PARALLEL-GROUP, STUDY ASSESSING THE EFFICACY AND SAFETY OF THE INSULIN GLARGINE/LIXISENATIDE FIXED RATIO COMBINATION IN ADULTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON GLP-1 RECEPTOR AGONIST AND METFORMIN ¬± PIOGLITAZONE, FOLLOWED BY A FIXED RATIO COMBINATION SINGLE-ARM 26-WEEK EXTENSION PERIOD","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47719,"protocol_no":"SNA-120-202","submission_no":"211642","status_id":1,"start_date":"2018-01-17","end_date":null,"nol_date":"2017-12-22","protocol_title":"AN EXPLORATORY, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF SNA-120 (PEGCANTRATINIB) OINTMENT FOR THE SYMPTOMATIC TREATMENT OF PERSISTENT PRURITUS AND PSORIASIS IN SUBJECTS BEING TREATED WITH CALCIPOTRIENE OINTMENT","medConditionList":[{"med_condition_id":792,"med_condition":"PRURITIS"},{"med_condition_id":371,"med_condition":"PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42015,"protocol_no":"D1680C00016","submission_no":"193677","status_id":1,"start_date":"2016-12-21","end_date":null,"nol_date":"2016-04-27","protocol_title":"A 24-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECTS OF SAXAGLIPTIN, SAXAGLIPTIN COMBINED WITH DAPAGLIFLOZIN, AND SITAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HEART FAILURE","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"},{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44034,"protocol_no":"NN9535-4269 / SUSTAIN 9","submission_no":"199334","status_id":1,"start_date":"2017-03-15","end_date":null,"nol_date":"2016-12-07","protocol_title":"EFFICACY AND SAFETY OF SEMAGLUTIDE ONCE-WEEKLY VERSUS PLACEBO AS ADD-ON TO SGLT-2I IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44825,"protocol_no":"SI02","submission_no":"202561","status_id":1,"start_date":"2015-07-21","end_date":null,"nol_date":"2017-03-01","protocol_title":"VACCINATING CHILDREN AFTER CHEMOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"},{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40740,"protocol_no":"A4091064","submission_no":"188979","status_id":1,"start_date":"2016-04-08","end_date":null,"nol_date":"2015-11-26","protocol_title":"A PHASE 3, MULTI-CENTER, LONG-TERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A TOTAL KNEE, HIP, OR SHOULDER REPLACEMENT","medConditionList":[{"med_condition_id":466,"med_condition":"KNEE ARTHROPLASTY"},{"med_condition_id":465,"med_condition":"HIP ARTHROPLASTY"},{"med_condition_id":707,"med_condition":"SHOULDER REPLACEMENT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26792,"protocol_no":"A6301091","submission_no":"163843","status_id":1,"start_date":"2014-06-23","end_date":null,"nol_date":"2013-05-08","protocol_title":"\"A PHASE IIIB OPEN LABEL STUDY TO OPTIMIZE THE SINGLE BOLUS DOSE OF DALTEPARIN SODIUM FOR THE PREVENTION OF CLOTTING WITHIN THE EXTRACORPOREAL SYSTEM DURING HEMODIALYSIS PROCEDURES FOR PATIETS WITH CHRONIC RENAL INSUFFICIENCY: THE PARROT STUDY.\"","medConditionList":[{"med_condition_id":221,"med_condition":"RENAL INSUFFICIENCY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37527,"protocol_no":"U19-MMU-02","submission_no":"178887","status_id":1,"start_date":"2014-12-16","end_date":null,"nol_date":"2014-11-13","protocol_title":"THE EFFECT OF PEPTIDE IMMUNOTHERAPY ON FREQUENCY, MEMORY PHENOTYPE, CHEMOKINE RECEPTOR EXPRESSION AND MARKERS OF REGULATORY T CELL FUNCTION ALLERGAN-SPECIFIC T CELLS.  A RANDOMIZED PROSPECTIVE CLINICAL TRIAL OF FEL D 1 PEPTIDE IMMUNOTHERAPY","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27923,"protocol_no":"SJS-CT-001","submission_no":"167082","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-05","protocol_title":"A PHASE I OPEN-LABELLED, SINGLE-ARM, SINGLE-CENTERED STUDY TO TEST THE SAFETY OF ADSC-SVF-002 IN SUBJECTS WITH SOFT TISSUE DEFECTS OR ABNORMAL WOUND HEALING","medConditionList":[{"med_condition_id":384,"med_condition":"ABNORMAL WOUND HEALING"},{"med_condition_id":383,"med_condition":"SOFT TISSUE DEFECTS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45278,"protocol_no":"OSE2101C301","submission_no":"203866","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-18","protocol_title":"A RANDOMIZED PARALLEL GROUP PHASE III TRIAL OF OSE2101 AS 2ND OR 3RD LINE COMPARED WITH STANDARD TREATMENT (DOCETAXEL OR PEMETREXED) IN HLA-A2 POSITIVE PATIENTS WITH LOCALLY ADVANCED (IIIB) UNSUITABLE FOR RADIOTHERAPY OR METASTATIC (IV) NON-SMALL-CELL LUNG CANCER.","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47047,"protocol_no":"HOPE-09-2017","submission_no":"209574","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-19","protocol_title":"A RANDOMIZED DOUBLE-BLINDED PHASE II STUDY TO DETERMINE TREATMENT PROTOCOL FOR HEMOGLOBIN OPTIMIZATION TO PREVENT TRANSFUSION AND ADVERSE EVENTS IN PERIOPERATIVE PATIENTS WITH IRON RESTRICTED ANEMIA ¬ø HOPE-HB STUDY","medConditionList":[{"med_condition_id":329,"med_condition":"ANEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29472,"protocol_no":"1237.16","submission_no":"171910","status_id":2,"start_date":"2014-08-01","end_date":"2016-04-04","nol_date":"2014-03-03","protocol_title":"AN EXPLORATORY, 12 WEEK, RANDOMISED, PARTIALLY DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL TO EXPLORE THE EFFECTS OF ONCE DAILY TREATMENTS OF ORALLY INHALED TIOTROPIUM + OLODATEROL FIXED DOSE COMBINATION OR TIOTROPIUM (BOTH DELIVERED BY THE RESPIMAT¬Æ INHALER), SUPERVISED EXERCISE TRAINING AND BEHAVIOUR MODIFICATION ON EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27595,"protocol_no":"VS-6063-202","submission_no":"166217","status_id":1,"start_date":"2013-07-01","end_date":null,"nol_date":"2013-08-01","protocol_title":"A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF VS 6063 IN SUBJECTS WITH MALIGNANT PLEURAL MESOTHELIOMA","medConditionList":[{"med_condition_id":153,"med_condition":"MALIGNANT PLEURAL MESOTHELIOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35937,"protocol_no":"B1481021","submission_no":"174018","status_id":1,"start_date":"2014-06-23","end_date":null,"nol_date":"2014-05-16","protocol_title":"A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","medConditionList":[{"med_condition_id":111,"med_condition":"HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42240,"protocol_no":"PCYC-1119-CA","submission_no":"194385","status_id":1,"start_date":"2016-11-14","end_date":null,"nol_date":"2016-06-23","protocol_title":"A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON¬øS TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS¬ø) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29146,"protocol_no":"CBKM120F2202","submission_no":"171042","status_id":1,"start_date":"2014-04-17","end_date":null,"nol_date":"2014-01-17","protocol_title":"A RANDOMIZED DOUBLE-BLIND, PLACEBO CONTROLLED, PHASE II/III STUDY OF BKM120 PLUS PACLITAXEL IN PATIENTS WITH HER2 NEGATIVE INOPERABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER, WITH OR WITHOUT PI3K PATHWAY ACTIVATION","medConditionList":[{"med_condition_id":31,"med_condition":"BREAST CANCER METASTATIC"},{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26687,"protocol_no":"ROB0037","submission_no":"163498","status_id":1,"start_date":"2014-04-08","end_date":null,"nol_date":"2013-05-24","protocol_title":"STRUCTURE AND FUNCTION MRI OF ASTHMA","medConditionList":[{"med_condition_id":304,"med_condition":"MRI IMAGING"},{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28266,"protocol_no":"00103311","submission_no":"168103","status_id":1,"start_date":"2015-11-17","end_date":null,"nol_date":"2013-10-08","protocol_title":"A PHASE 3, RANDOMIZED, OPEN LABEL STUDY INVESTIGATING THE EFFICACY OF THE BITE ANTIBODY BLINATUMOMAB VERSUS STANDARD OF CARE CHEMOTHERAPY IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)","medConditionList":[{"med_condition_id":394,"med_condition":"ACUTE LYMPHOBLASTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43380,"protocol_no":"ONS-3010-002","submission_no":"197937","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-09-23","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, EQUIVALENCE STUDY OF ONS-3010 AND HUMIRA FOR THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39724,"protocol_no":"MLN0002-3026","submission_no":"186158","status_id":1,"start_date":"2017-05-16","end_date":null,"nol_date":"2015-08-12","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB IV COMPARED TO ADALIMUMAB SC IN SUBJECTS WITH ULCERATIVE COLITIS,","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41924,"protocol_no":"IND.225","submission_no":"193249","status_id":1,"start_date":"2017-08-15","end_date":null,"nol_date":"2016-04-13","protocol_title":"A PHASE II STUDY OF THE ASSESSMENT OF RESPONSE TO PEMBROLIZUMAB IN METASTATIC MELANOMA: CT TEXTURE ANALAYSIS AS A PREDICTIVE BIOMARKER","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37815,"protocol_no":"178-MA-1005","submission_no":"179787","status_id":1,"start_date":"2015-03-23","end_date":null,"nol_date":"2014-12-17","protocol_title":"A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN OLDER ADULT SUBJECTS WITH OVERACTIVE BLADDER (OAB)","medConditionList":[{"med_condition_id":185,"med_condition":"OVERACTIVE BLADDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40206,"protocol_no":"N/A","submission_no":"187375","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-10-01","protocol_title":"A RANDOMIZED CONTROLLED TRIAL COMPARING ADJUVANTED VS. NONADJUVANTED INFLUENZA VACCINE IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"},{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46048,"protocol_no":"CAEB1102-102A","submission_no":"206192","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-30","protocol_title":"AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFECTS OF INTRAVENOUS AEB1102 IN PATIENTS WITH ARGINASE I DEFECIENCY WHO PREVIOUSLY RECEIVED TREATMENT IN STUDY CAEB1102-101A","medConditionList":[{"med_condition_id":775,"med_condition":"ARGINASE-1 DEFICIENCY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26584,"protocol_no":"V1 28-01-13","submission_no":"163182","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-04-24","protocol_title":"\"REGULATION OF INTESTINAL AND HEPATIC LIPOPROTEIN PARTICLE PRODUCTION BY INTRAVENOUS GLUCOSE IN HUMANS.\"","medConditionList":[{"med_condition_id":290,"med_condition":"LIPOPROTEIN PARTICLE PRODUCTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39138,"protocol_no":"D3461C00004","submission_no":"184269","status_id":1,"start_date":"2015-11-13","end_date":null,"nol_date":"2015-06-12","protocol_title":"\"A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ANIFROLUMAB IN ADULT SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS.\"","medConditionList":[{"med_condition_id":311,"med_condition":"SYSTEMIC LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41699,"protocol_no":"2009-012575-10","submission_no":"192362","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-05-20","protocol_title":"TORPEDO-CF - TRIAL OF OPTIMAL THERAPY FOR PSEUDOMONAS ERADICATION IN CYSTIC FIBROSIS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26604,"protocol_no":"A-003","submission_no":"163227","status_id":2,"start_date":"2014-02-21","end_date":"2015-09-23","nol_date":"2013-04-12","protocol_title":"A PHASE II MULTI-CENTER, PARALLEL-GROUP, RANDOMIZED, DOUBLE BLIND, PROOF-OF-CONCEPT, ADAPTIVE STUDY INVESTIGATING THE SAFETY AND EFFICACY OF THR-184 ADMINISTERED VIA INTRAVENOUS INFUSION IN PATIENTS AT INCREASED RISK OF DEVELOPING CARDIAC SURGERY ASSOCIATED-ACUTE KIDNEY INJURY (CSA-AKI)","medConditionList":[{"med_condition_id":220,"med_condition":"RENAL FAILURE"},{"med_condition_id":221,"med_condition":"RENAL INSUFFICIENCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36581,"protocol_no":"WA29231","submission_no":"175857","status_id":1,"start_date":"2016-05-03","end_date":null,"nol_date":"2014-07-23","protocol_title":"LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS","medConditionList":[{"med_condition_id":136,"med_condition":"JUVENILE IDIOPATHIC ARTHRITIS (SJIA)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42484,"protocol_no":"8-01","submission_no":"195146","status_id":1,"start_date":"2017-02-20","end_date":null,"nol_date":"2016-07-15","protocol_title":"A RANDOMIZED COMPARISON OF NEOCART TO MICROFRACTURE FOR THE REPAIR OF ARTICULAR CARTILAGE INJURIES IN THE KNEE","medConditionList":[{"med_condition_id":662,"med_condition":"ARTICULAR CARTILAGE INJURY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28609,"protocol_no":"1000037723","submission_no":"169148","status_id":1,"start_date":"2013-12-09","end_date":null,"nol_date":"2013-11-19","protocol_title":"REGISTRY OF SODIUM 18F-FLUORIDE (NA18F) POSITRON EMISSION TOMOGRAPHY (PET) SCANS PERFORMED TO EVALUATE SKELETAL PATHOLOGY IN CHILDREN","medConditionList":[{"med_condition_id":708,"med_condition":"SKELETAL PATHOLOGY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26619,"protocol_no":"EVP-6124-015","submission_no":"163263","status_id":2,"start_date":"2013-08-28","end_date":"2016-01-08","nol_date":"2013-04-12","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, 26 WEEK, PHASE 3 STUDY OF 2 DOSES OF AN ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST (EVP 6124) OR PLACEBO AS AN ADJUNCTIVE PRO-COGNITIVE TREATMENT IN SCHIZOPHRENIA SUBJECTS ON CHRONIC STABLE ATYPICAL ANTIPSYCHOTIC THERAPY","medConditionList":[{"med_condition_id":227,"med_condition":"SCHIZOPHRENIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40825,"protocol_no":"GED-0301-CD-004","submission_no":"189355","status_id":1,"start_date":"2016-05-21","end_date":null,"nol_date":"2015-12-07","protocol_title":"A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHN¬øS DISEASE.","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29098,"protocol_no":"QTP MS 01","submission_no":"170878","status_id":1,"start_date":"2014-08-13","end_date":null,"nol_date":"2014-02-04","protocol_title":"A DOSE-FINDING, SAFETY AND TOLERABILITY TRIAL OF EXTENDED-RELEASE QUETIAPINE IN RELAPSING-REMITTING AND PROGRESSIVE MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39243,"protocol_no":"VRI-001","submission_no":"184584","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-06-04","protocol_title":"CLINICAL EFFICACY OF ADDING A SCLEROSING AGENT TO LOCAL ANESTHETIC FOR THE PURPOSES OF NERVE BLOCKS IN CHRONIC PAIN SETTING.","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38517,"protocol_no":"STP-001","submission_no":"182270","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-03-17","protocol_title":"A PILOT STUDY OF SUBCUTANEOUS VS. INTRAMUSCULAR TESTOSTERONE FOR GENDER AFFIRMING THERAPY","medConditionList":[{"med_condition_id":613,"med_condition":"GENDER AFFIRMING THERAPY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35695,"protocol_no":"ISIS 494372-CS3","submission_no":"173146","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-17","protocol_title":"A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, PHASE 2 STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ISIS 494372 ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HIGH LIPOPROTEIN(A)","medConditionList":[{"med_condition_id":348,"med_condition":"HYPERLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28391,"protocol_no":"DIAN-TU-001","submission_no":"168399","status_id":1,"start_date":"2017-05-16","end_date":null,"nol_date":"2013-11-22","protocol_title":"A PHASE II/III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-CENTER STUDY OF 2 POTENTIAL DISEASE MODIFYING THERAPIES IN INDIVIDUALS AT RISK FOR AND WITH DOMINANTLY INHERITED ALZHEIMER'S DISEASE (ADAD)","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38373,"protocol_no":"17616","submission_no":"181856","status_id":1,"start_date":"2015-06-30","end_date":null,"nol_date":"2015-03-05","protocol_title":"AN OPEN-LABEL, NON-RANDOMIZED, PHASE I STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF RONICICLIB IN PATIENTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46037,"protocol_no":"AC-058B303","submission_no":"206162","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-29","protocol_title":"MULTICENTER, NON-COMPARATIVE EXTENSION OF STUDY AC-058B301, TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND CONTROL OF DISEASE OF PONESIMOD 20 MG IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":39303,"protocol_no":"TOVPD-100","submission_no":"184763","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-10-20","protocol_title":"RANDOMIZED CROSS-OVER STUDY OF FESOTERODINE ON URGENCY EPISODES IN PARKINSON¬øS DISEASE POPULATION.","medConditionList":[{"med_condition_id":185,"med_condition":"OVERACTIVE BLADDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38652,"protocol_no":"NPH-002-102","submission_no":"182750","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-04-08","protocol_title":"A RANDOMIZED, SINGLE-CENTER, DOUBLE-MASKED, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NPH-002 OPHTHALMIC SOLUTION IN SUBJECTS WITH ALLERGIC CONJUNCTIVITIS","medConditionList":[{"med_condition_id":631,"med_condition":"ALLERGIC CONJUNCTIVITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28737,"protocol_no":"MK-8835-004-00 (B1521021)","submission_no":"169599","status_id":1,"start_date":"2014-04-07","end_date":null,"nol_date":"2013-11-29","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE","medConditionList":[{"med_condition_id":265,"med_condition":"VASCULAR DISEASE"},{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47216,"protocol_no":"0139","submission_no":"210252","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-08","protocol_title":"CAN PENTOXIFYLLINE IMPROVE LONG-TERM OUTCOMES IN PRETERM INFANTS WITH LATE-ONSET SEPSIS OR NECROTIZING ENTEROCOLITIS?  A PRAGMATIC, RANDOMISED, PLACEBO CONTROLLED TRIAL","medConditionList":[{"med_condition_id":230,"med_condition":"SEPSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":35551,"protocol_no":"CMEK162X2203","submission_no":"172736","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-09","protocol_title":"A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF AEB071 AND MEK162 IN ADULT PATIENTS WITH METASTATIC UVEAL MELANOMA","medConditionList":[{"med_condition_id":489,"med_condition":"UVEAL MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35506,"protocol_no":"HGT-HIT-094","submission_no":"172601","status_id":1,"start_date":"2017-06-16","end_date":null,"nol_date":"2014-03-25","protocol_title":"A CONTROLLED, RANDOMIZED, TWO-ARM, OPEN-LABEL, ASSESSOR-BLINDED, MULTICENTER STUDY OF INTRATHECAL IDURSULFASE-OT ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PEDIATRIC PATIENTS WITH HUNTER SYNDROME AND EARLY COGNITIVE IMPAIRMENT","medConditionList":[{"med_condition_id":479,"med_condition":"HUNTER SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41346,"protocol_no":"OZM-057","submission_no":"191237","status_id":1,"start_date":"2017-12-15","end_date":null,"nol_date":"2016-01-25","protocol_title":"AN OPEN LABEL, SINGLE-CENTRE, PILOT STUDY FOR RADIOSENSITIZATION OF EVEROLIMUS WITH EXTERNAL BEAM RADIOTHERAPY FOR THE TREATMENT OF METASTATIC NEUROENDOCRINE LIVER METASTASIS","medConditionList":[{"med_condition_id":633,"med_condition":"NEUROENDOCRINE TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48022,"protocol_no":"R475-PN-1612","submission_no":"212748","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-05","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE","medConditionList":[{"med_condition_id":626,"med_condition":"CHRONIC LOW BACK PAIN"},{"med_condition_id":482,"med_condition":"OSTEOARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44229,"protocol_no":"1620303","submission_no":"200475","status_id":1,"start_date":"2017-06-29","end_date":null,"nol_date":"2016-12-08","protocol_title":"AN OPEN-LABEL, MULTI-CENTER TRIAL TO ASSESS THE SAFETY OF SINGLE AND REPEAT DAXIBOTULINUMTOXINA FOR INJECTION FOR TREATMENT OF MODERATE TO SEVERE GLABELLAR LINES (SAKURA OPEN-LABEL SAFETY)","medConditionList":[{"med_condition_id":380,"med_condition":"GLABELLAR LINES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36306,"protocol_no":"ADS-AMT-PD301","submission_no":"175019","status_id":1,"start_date":"2014-12-11","end_date":null,"nol_date":"2014-06-25","protocol_title":"EFFICACY AND SAFETY STUDY OF ADS-5102 (AMANTADINE HCL) EXTENDED RELEASE (ER) CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA IN PARKINSON'S DISEASE PATIENTS (EASE LID STUDY)","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39302,"protocol_no":"BBI503-201","submission_no":"184754","status_id":1,"start_date":"2015-09-23","end_date":null,"nol_date":"2015-07-17","protocol_title":"A PHASE IB/II CLINICAL STUDY OF BBI503 IN COMBINATION WITH SELECTED ANTI-CANCER THERAPEUTICS IN ADULT PATIENTS WITH ADVANCED CANCER","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35649,"protocol_no":"ACETYL-L-CARNITINE-CHAN-001","submission_no":"173005","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-09","protocol_title":"ACETYL-L-CARNITINE TO ENHANCE NERVE REGENERATION IN PATIENTS WITH CARPAL TUNNEL SYNDROME: A RANDOMIZED CONTROL TRIAL","medConditionList":[{"med_condition_id":503,"med_condition":"CARPAL TUNNEL SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45722,"protocol_no":"CCNP520A2202J","submission_no":"205311","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-24","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF ALZHEIMER'S DISEASE (AD)","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47528,"protocol_no":"CEGF816X2102","submission_no":"211094","status_id":1,"start_date":"2018-03-16","end_date":null,"nol_date":"2017-12-22","protocol_title":"A PHASE IB, OPEN LABEL, MULTI-CENTER STUDY TO CHARACTERIZE THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF EGF816 IN COMBINATION WITH SELECTED TARGETED AGENTS IN EGFR MUTANT NSCLC","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39050,"protocol_no":"D1690C00024","submission_no":"183965","status_id":2,"start_date":"2016-03-17","end_date":"2017-11-07","nol_date":"2015-05-14","protocol_title":"A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, RANDOMIZED, PHASE III STUDY TO EVALUATE THE GLYCEMIC EFFICACY AND RENAL SAFETY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND MODERATE RENAL IMPAIRMENT (CKD 3A) WHO HAVE INADEQUATE GLYCEMIC CONTROL","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40569,"protocol_no":"STML-401-0314","submission_no":"188511","status_id":1,"start_date":"2017-05-30","end_date":null,"nol_date":"2015-11-13","protocol_title":"SL-401 IN PATIENTS WITH ADVANCED, HIGH RISK MYELOPROLIFERATIVE NEOPLASMS","medConditionList":[{"med_condition_id":654,"med_condition":"MYELOPROLIFERATIVE NEOPLASMS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28400,"protocol_no":"PJC-013 / NCI 9343","submission_no":"168448","status_id":1,"start_date":"2013-11-04","end_date":null,"nol_date":"2013-10-23","protocol_title":"A PHASE 1 AND PHARMACOKINETIC STUDY OF DABRAFENIB (GSK2118436B) IN PATIENTS WITH BRAFV600X MUTATIONS AND RENAL OR HEPATIC DYSFUNCTION.","medConditionList":[{"med_condition_id":220,"med_condition":"RENAL FAILURE"},{"med_condition_id":26,"med_condition":"BRAF MUTATION-POSITIVE TUMORS"},{"med_condition_id":143,"med_condition":"LIVER / HEPATIC DYSFUNCTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42780,"protocol_no":"D2615C00001","submission_no":"196202","status_id":1,"start_date":"2017-02-20","end_date":null,"nol_date":"2016-07-22","protocol_title":"AN OPEN-LABEL, RANDOMISED, MULTI-DRUG, BIOMARKER-DIRECTED, MULTI-CENTRE, MULTI-ARM PHASE 1B STUDY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC WHO HAVE PROGRESSED ON PRIOR TREATMENT (BISCAY)","medConditionList":[{"med_condition_id":625,"med_condition":"BLADDER CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37358,"protocol_no":"GS-US-218-1227","submission_no":"178369","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-24","protocol_title":"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-CENTER STUDY EVALUATING ANTIVIRAL EFFECTS, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF GS-5806 IN HOSPITALIZED ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41230,"protocol_no":"TBA","submission_no":"190754","status_id":1,"start_date":"2016-05-10","end_date":null,"nol_date":"2016-01-20","protocol_title":"18F-FLUOROAZOMYCIN ARABINOSIDE (FAZA) POSITRON EMISSION TOMOGRAPHY / MAGNETIC RESONANCE IMAGING (PET/MR) AS A BIOMARKER OF HYPOXIA IN RECTAL CANCER: A PILOT STUDY","medConditionList":[{"med_condition_id":671,"med_condition":"RECTAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42433,"protocol_no":"AGS62P1-16-1","submission_no":"194942","status_id":1,"start_date":"2017-01-12","end_date":null,"nol_date":"2016-06-09","protocol_title":"A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS62P1 GIVEN AS MONOTHERAPY IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA (AML)","medConditionList":[{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43576,"protocol_no":"KTE-C19-101","submission_no":"198501","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-11-09","protocol_title":"A PHASE 1-2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF KTE-C19 IN SUBJECTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA (NHL)","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42375,"protocol_no":"TV48125-CNS-30049","submission_no":"194751","status_id":1,"start_date":"2016-06-09","end_date":null,"nol_date":"2016-06-03","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF 2 DOSE REGIMENS OF SUBCUTANEOUS ADMINISTRATION OF TEV-48125 VERSUS PLACEBO FOR THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE","medConditionList":[{"med_condition_id":158,"med_condition":"CHRONIC MIGRAINE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45588,"protocol_no":"M16-006","submission_no":"203524","status_id":1,"start_date":"2018-01-03","end_date":null,"nol_date":"2017-05-19","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY OF THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46747,"protocol_no":"SERES-012","submission_no":"208558","status_id":1,"start_date":"2017-11-30","end_date":null,"nol_date":"2017-09-27","protocol_title":"A PHASE 3 MULTICENTER, RANDOMIZEED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF SER-109 VS. PLACEBO TO REDUCE RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN ADULTS WHO HAVE RECEIVED ANTIBACTERIAL DRUG TREATMENT FOR RECURRENT CDI (RCDI)","medConditionList":[{"med_condition_id":33,"med_condition":"CLOSTRIDIUM DIFFICILE INFECTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41152,"protocol_no":"ALS-8176-510","submission_no":"190472","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-01-08","protocol_title":"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF ORALLY ADMINISTERED ALS-008176 IN ADULTS HOSPITALIZED WITH A RESPIRATORY SYNCYTIAL VIRUS-RELATED ILLNESS","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41903,"protocol_no":"20160082","submission_no":"193173","status_id":1,"start_date":"2016-05-16","end_date":null,"nol_date":"2016-04-15","protocol_title":"99M TC-RHANNEXIN V-128 IMAGING OF APOPTOSIS AND CARDIOTOXICITY IN RELATIONSHIP TO VENTRICULAR FUNCTION IN PATIENTS WITH EARLY STAGE BREAST CANCER RECEIVING DOXORUBICIN-BASED CHEMOTHERAPY","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45513,"protocol_no":"062","submission_no":"204640","status_id":1,"start_date":"2017-07-28","end_date":null,"nol_date":"2017-05-10","protocol_title":"A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PRELADENANT AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27799,"protocol_no":"MPD-RC 114","submission_no":"166732","status_id":1,"start_date":"2014-07-30","end_date":null,"nol_date":"2013-08-21","protocol_title":"EXPLORING THE POTENTIAL OF DUAL KINASE JAK 1/2 INHIBITOR RUXOLITINIB (INC424) WITH REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS","medConditionList":[{"med_condition_id":353,"med_condition":"MYELOFIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48507,"protocol_no":"RPC01-3203","submission_no":"214105","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-26","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN¬øS DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27323,"protocol_no":"M11-352","submission_no":"165406","status_id":2,"start_date":"2013-08-20","end_date":"2018-02-19","nol_date":"2013-06-27","protocol_title":"A RANDOMIZED, MULTICOUNTRY, MULTICENTER, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF ATRASENTAN ON RENAL OUTCOMES IN SUBJECTS WITH TYPE 2 DIABETES AND NEPHROPATHY - SONAR:  STUDY OF DIABETIC NEPHROPATHY WITH ATRASENTAN","medConditionList":[{"med_condition_id":65,"med_condition":"DIABETIC NEPHROPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40696,"protocol_no":"WB28182","submission_no":"188863","status_id":2,"start_date":"2015-12-17","end_date":"2016-04-19","nol_date":"2015-11-26","protocol_title":"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER TRIAL TO ASSESS THE ORAL CORTICOSTEROID-SPARING EFFECT OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE CORTICOSTEROID DEPENDENT ASTHMA","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26813,"protocol_no":"TRX-237-005","submission_no":"163897","status_id":2,"start_date":"2013-10-03","end_date":"2016-05-27","nol_date":"2013-05-10","protocol_title":"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 18 MONTH SAFETY AND EFFICACY STUDY OF LEUCO-METHYLTHIONINIUM BIS(HYDROMETHANESULFONATE) IN SUBJECTS WITH MILD ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41479,"protocol_no":"URCOH-PMS-001","submission_no":"191621","status_id":1,"start_date":"2017-03-13","end_date":null,"nol_date":"2016-02-25","protocol_title":"A PHASE I/II STUDY OF PEMBROLIZUMAB IN COMBINAISON WITH NAB-PACLITAXEL IN PATIENTS WITH UNRESECTABLE STAGE III OR STAGE IV NON-SMALL CELL LUNG CARCINOMA","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37626,"protocol_no":"117177 (ZOSTER 007)","submission_no":"179194","status_id":1,"start_date":"2014-12-01","end_date":null,"nol_date":"2014-11-27","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE BLIND MULTICENTER STUDY, TO EVALUATE CONSISTENCY, IMMUNOGENICITY, SAFETY AND REACTOGENICITY OF 3 LOTS OF GSK BIOLOGICALS' HERPES ZOSTER HZ/SU CANDIDATE VACCINE WHEN ADMINISTERED INTRAMUSCULARLY ON A 0 AND 2 MONTH SCHEDULE TO ADULTS >50 YEARS OF AGE","medConditionList":[{"med_condition_id":289,"med_condition":"HERPES ZOSTER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35490,"protocol_no":"TX-LUT-LONDON-001","submission_no":"172567","status_id":1,"start_date":"2015-07-21","end_date":null,"nol_date":"2014-03-17","protocol_title":"AN OPEN LABEL PHASE II REGISTRY STUDY OF LUTETIUM-177 DOTA-TATE TREATMENT IN PATIENTS WITH SOMATOSTATIN POSITIVE TUMOURS","medConditionList":[{"med_condition_id":291,"med_condition":"SOMATOSTATIN RECEPTOR POSITIVE TUMOURS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46639,"protocol_no":"2017-1639","submission_no":"208185","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-08-30","protocol_title":"A CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFECTIVENESS OF AN ANTIMICROBIAL PROPHYLAXIS FOR A TREATMENT VIA EXTRACORPOREAL LITHOTRIPSY TO REDUCE URINARY TRACT INFECTIONS","medConditionList":[{"med_condition_id":552,"med_condition":"PROPHYLAXIS OF INFECTIONS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40756,"protocol_no":"NN8640-4172","submission_no":"189032","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-02","protocol_title":"A RANDOMISED, MULTINATIONAL, ACTIVE-CONTROLLED, (OPEN-LABELLED), DOSE FINDING, (DOUBLE-BLINDED), PARALLEL GROUP TRIAL INVESTIGATING EFFICACY AND SAFETY OF ONCE-WEEKLY NNC0195-0092 TREATMENT COMPARED TO DAILY GROWTH HORMONE TREATMENT (NORDITROPIN FLEXPRO) IN GROWTH HORMONE TREATMENT NA√èVE PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENCY","medConditionList":[{"med_condition_id":94,"med_condition":"GROWTH HORMONE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":46100,"protocol_no":"CY 5022","submission_no":"206384","status_id":1,"start_date":"2017-09-19","end_date":null,"nol_date":"2017-06-23","protocol_title":"A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK 2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42064,"protocol_no":"VEDOLIZUMAB-4004","submission_no":"193789","status_id":1,"start_date":"2017-01-18","end_date":null,"nol_date":"2016-05-05","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENTYVIO (VEDOLIZUMAB IV) IN THE TREATMENT OF CHRONIC POUCHITIS (EARNEST)","medConditionList":[{"med_condition_id":695,"med_condition":"POUCHITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42120,"protocol_no":"005-00","submission_no":"193976","status_id":2,"start_date":"2016-10-21","end_date":"2017-01-11","nol_date":"2016-05-06","protocol_title":"A PHASE IB TRIAL WITH MK-8628, A SMALL MOLECULE INHIBITOR OF THE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEINS, IN SUBJECTS WITH SELECTED HEMATOLOGIC MALIGNANCIES","medConditionList":[{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"},{"med_condition_id":150,"med_condition":"DIFFUSE LARGE B-CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41086,"protocol_no":"RVT-101-3001","submission_no":"190230","status_id":2,"start_date":"2016-05-06","end_date":"2017-08-08","nol_date":"2016-01-05","protocol_title":"A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF RVT-101 VERSUS PLACEBO WHEN ADDED TO EXISTING STABLE DONEPEZIL TREATMENT IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER¬øS DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27842,"protocol_no":"006","submission_no":"166859","status_id":1,"start_date":"2014-09-12","end_date":null,"nol_date":"2013-08-29","protocol_title":"\"A MULTICENTER, RANDOMIZED, CONTROLLED, THREE-ARM, PHASE III STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO DOSING SCHEDULES OF MK-3475 COMPARED TO IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA.\"","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42029,"protocol_no":"OZM-074","submission_no":"193704","status_id":1,"start_date":"2017-03-27","end_date":null,"nol_date":"2016-04-29","protocol_title":"CLINICAL PILOT STUDY OF AUTOLOGOUS STEM CELL TRANSPLANTATION OF CD34+ CELLS ENGINEERED TO EXPRESS ALPHA-GALACTOSIDASE A IN PATIENTS WITH FABRY DISEASE","medConditionList":[{"med_condition_id":79,"med_condition":"FABRY DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26855,"protocol_no":"RPC01-201","submission_no":"164055","status_id":2,"start_date":"2014-06-05","end_date":"2017-07-19","nol_date":"2013-05-17","protocol_title":"A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED (PART A) AND DOUBLE BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RPC1063 ADMINISTERED ORALLY TO RELAPSING MULTIPLE SCLEROSIS PATIENTS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39942,"protocol_no":"VB4-845-02-IIIA","submission_no":"186677","status_id":1,"start_date":"2015-11-27","end_date":null,"nol_date":"2015-09-03","protocol_title":"AN OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF INTRAVESICAL VICINIUM IN SUBJECTS WITH NON MUSCLE-INVASIVE CARCINOMA IN SITU (CIS) AND/OR HIGH-GRADE PAPILLARY DISEASE OF THE BLADDER PREVIOUSLY TREATED WITH BCG","medConditionList":[{"med_condition_id":625,"med_condition":"BLADDER CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41419,"protocol_no":"M12-815","submission_no":"191451","status_id":2,"start_date":"2016-07-06","end_date":"2017-06-21","nol_date":"2016-02-16","protocol_title":"A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELAGOLIX IN COMBINATION WITH ESTRADIOL/NORETHINDRONE ACETATE FOR THE MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS IN PREMENOPAUSAL WOMEN","medConditionList":[{"med_condition_id":333,"med_condition":"UTERINE FIBROIDS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27284,"protocol_no":"CICL670A2421","submission_no":"165264","status_id":2,"start_date":"2015-11-02","end_date":"2017-03-22","nol_date":"2013-06-26","protocol_title":"AN OPEN-LABEL, PHASE II, RANDOMIZED, PILOT STUDY TO ASSESS THE EFFECT IN TERM OF ERYTHROID IMPROVEMENT OF DEFERASIROX COMBINED WITH ERYTHROPOIETIN COMPARED TO ERYTHROPOIETIN ALONE IN PATIENTS WITH LOW- AND INT-1-RISK MYELODYSPLASTIC SYNDROME.","medConditionList":[{"med_condition_id":317,"med_condition":"MYELODYSPLASTIC SYNDROME"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28885,"protocol_no":"CC-4047-MM-014","submission_no":"170176","status_id":1,"start_date":"2016-09-20","end_date":null,"nol_date":"2013-12-20","protocol_title":"A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA FOLLOWING LENALIDOMIDE PLUS DEXAMETHASONE IN THE SECOND-LINE SETTING","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44576,"protocol_no":"K-877-302","submission_no":"201763","status_id":1,"start_date":"2017-03-27","end_date":null,"nol_date":"2017-02-02","protocol_title":"PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES (PROMINENT)","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"},{"med_condition_id":37,"med_condition":"CARDIOVASCULAR DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40923,"protocol_no":"GTI1201-OLE","submission_no":"189705","status_id":1,"start_date":"2017-05-09","end_date":null,"nol_date":"2015-11-30","protocol_title":"AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY OF WEEKLY INTRAVENOUS ALPHA1-PROTEINASE INHIBITOR (HUMAN), MODIFIED PROCESS 60 MG/KG IN SUBJECTS WITH PULMONARY EMPHYSEMA DUE TO ALPHA1-ANTITRYPSIN DEFICIENCY","medConditionList":[{"med_condition_id":72,"med_condition":"PULMONARY EMPHYSEMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40034,"protocol_no":"NN9828-4150","submission_no":"186909","status_id":1,"start_date":"2017-01-25","end_date":null,"nol_date":"2015-09-18","protocol_title":"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTRE, CLINICAL PROOF-OF-PRINCIPLE TRIAL IN ADULT SUBJECTS WITH NEWLY DIAGNOSED TYPE 1 DIABETES MELLITUS INVESTIGATING THE EFFECT OF NNC01114-0006 AND LIRAGLUTIDE ON PRESERVATION OF BETA-CELL FUNCTION","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36774,"protocol_no":"CL2-066913-002","submission_no":"176539","status_id":1,"start_date":"2015-05-06","end_date":null,"nol_date":"2014-08-15","protocol_title":"A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL, INTERNATIONAL MULTICENTER STUDY ASSESSING THE EFFICACY OF S 066913 IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION. DOUBLE-BLIND, INTERNATIONAL STUDY ASSESSING EFFICACY OF S 066913 IN PAROXYSMAL ATRIAL FIBRILLATION - IKUR INHIBITOR","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38804,"protocol_no":"TT-03","submission_no":"183252","status_id":1,"start_date":"2015-07-01","end_date":null,"nol_date":"2015-04-17","protocol_title":"\"A DOSE-RESPONSE EVALUATION OF THE SQ TREE SLIT-TABLET IN SUBJECTS WITH MODERATE TO SEVERE ALLERGIC RHINOCONJUNCTIVITIS INDUCED BY POLLENS FROM THE BIRCH GROUP DURING CONTROLLED EXPOSURE IN AN ENVIRONMENTAL EXPOSURE CHAMBER.\"","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29427,"protocol_no":"CA209-026","submission_no":"171785","status_id":1,"start_date":"2015-07-21","end_date":null,"nol_date":"2014-02-28","protocol_title":"AN OPEN-LABEL, RANDOMIZED, PHASE 3 TRIAL OF NIVOLUMAB VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY AS FIRST-LINE THERAPY FOR STAGE IV OR RECURRENT PD-L1+NON-SMALL CELL LUNG CNACER (NSCLC) (CHECKMATE 026: CHECKPOINT PATHWAY AND NIVOLUMMAB CLINICAL TRIAL EVALUATION 026)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29039,"protocol_no":"AL1304AV","submission_no":"170654","status_id":1,"start_date":"2014-01-29","end_date":null,"nol_date":"2014-01-09","protocol_title":"EVALUATION OF THE UTILITY OF AN ENVIRONMENTAL EXPOSURE CHAMBER (EEC) FOR ASSESSING EFFICACY OF SPECIFIC IMMUNOTHERAPY (SIT) IN PIVOTAL CLINICAL TRIALS","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35589,"protocol_no":"TMC435HPC3017","submission_no":"172847","status_id":1,"start_date":"2014-05-27","end_date":null,"nol_date":"2014-04-03","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A 12- OR 8-WEEK TREATMENT REGIMEN OF SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR IN TREATMENT-NA√èVE AND -EXPERIENCED SUBJECTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS INFECTION WITHOUT CIRRHOSIS","medConditionList":[{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39866,"protocol_no":"ACE-CL-007","submission_no":"186480","status_id":1,"start_date":"2016-05-23","end_date":null,"nol_date":"2015-09-16","protocol_title":"A RANDOMIZED, MULTICENTER, OPEN-LABEL, 3 ARM PHASE 3 STUDY OF OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL, ACP-196 IN COMBINATION WITH OBINUTUZUMAB, AND ACP-196 MONOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40110,"protocol_no":"NN1218-4131","submission_no":"187115","status_id":1,"start_date":"2016-05-04","end_date":null,"nol_date":"2015-10-06","protocol_title":"EFFICACY AND SAFETY OF FASTER-ACTING INSULIN ASPART COMPARED TO NOVORAPID BOTH IN COMBINATION WITH INSULIN DEGLUDEC IN ADULTS WITH TYPE 1 DIABETES","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35451,"protocol_no":"FAITH2-13807","submission_no":"172430","status_id":1,"start_date":"2015-01-16","end_date":null,"nol_date":"2014-04-15","protocol_title":"FIXATION USING ALTERNATIVE IMPLANTS FOR THE TREATMENT OF HIP FRACTURES (FAITH-2): A MULTI-CENTRE 2X2 FACTORIAL RANDOMIZED TRIAL COMPARING SLIDING HIP SCREWS VERSUS CANCELLOUS SCREWS AND VITAMIN D VERSUS PLACEBO ON PATIENT IMPORTANT OUTCOMES AND QUALITY OF LIFE IN THE TREATMENT OF YOUNG ADULT (18-60) FEMORAL NECK FRACTURES","medConditionList":[{"med_condition_id":469,"med_condition":"BONE FRACTURES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36483,"protocol_no":"CSL627_3001","submission_no":"175579","status_id":2,"start_date":null,"end_date":"2017-05-17","nol_date":"2014-07-08","protocol_title":"A PHASE III OPEN LABEL, MULTICENTER, EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF RECOMBINANT COAGULATION FACTOR VIII (RVIII-SINGLE CHAIN, CSL627) IN SUBJECTS WITH SEVERE HEMOPHILIA A","medConditionList":[{"med_condition_id":99,"med_condition":"HEMOPHILIA A"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41774,"protocol_no":"1000051364","submission_no":"192671","status_id":1,"start_date":"2016-07-28","end_date":null,"nol_date":"2016-03-23","protocol_title":"ONRELTEA (BRIMONIDINE 0.33%) GEL IN PEDIATRIC PATIENTS WITH CAPILLARY MALFORMATIONS: A PROSPECTIVE, OPEN-LABEL, COHORT STUDY","medConditionList":[{"med_condition_id":728,"med_condition":"FACIAL CAPILLARY MALFORMATIONS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45623,"protocol_no":"CN001016","submission_no":"204959","status_id":1,"start_date":"2017-06-09","end_date":null,"nol_date":"2017-05-24","protocol_title":"A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF BMS-986089 IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY, PHASE 2/3","medConditionList":[{"med_condition_id":70,"med_condition":"DUCHENNE MUSCULAR DYSTROPHY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":37891,"protocol_no":"LOEX 014","submission_no":"179988","status_id":1,"start_date":"2014-12-23","end_date":null,"nol_date":"2014-12-23","protocol_title":"SASS 2: RECONSTITUTED BILAMELLAR AUTOLOGOUS SKIN FOR PERMANENET COVERING OF ACUTE PHASE CUTANEOUS WOUNDS ON MAJOR BURN VICTIMS","medConditionList":[{"med_condition_id":589,"med_condition":"BURN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35572,"protocol_no":"18F-AV-45-A14","submission_no":"172813","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-04-04","protocol_title":"CLINICAL EVALUATION OF FLORBETAPIR F 18","medConditionList":[{"med_condition_id":700,"med_condition":"UNSPECIFIED"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42634,"protocol_no":"GV29893","submission_no":"195664","status_id":2,"start_date":"2016-08-26","end_date":"2018-01-19","nol_date":"2016-06-30","protocol_title":"A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION IN OTHERWISE HEALTHY ADULTS","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26559,"protocol_no":"PHL-089 / NCI 8993","submission_no":"163116","status_id":1,"start_date":"2016-03-11","end_date":null,"nol_date":"2013-04-09","protocol_title":"A RANDOMIZED PHASE II STUDY OF GEMCITABINE, CISPLATIN +/- VELIPARIB IN PATIENTS WITH PANCREAS ADENOCARCINOMA AND A KNOWN BRCA/ PALB2 MUTATION (PART I) AND A PHASE II SINGLE ARM STUDY OF SINGLE-AGENT VELIPARIB IN PREVIOUSLY TREATED PANCREAS ADENOCARCINOMA (PART II)","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41316,"protocol_no":"GA29469","submission_no":"191162","status_id":1,"start_date":"2017-05-22","end_date":null,"nol_date":"2016-02-05","protocol_title":"\"AN OBSERVER-BLINDED, PLACEBO-CONTROLLED, MULTIPLE-ASCENDING DOSE ESCALATION STUDY TO EXPLORE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF REPEAT INTRAVENOUS ADMINISTRATIONS OF UTTR1147A IN HEALTHY VOLUNTEERS AND PATIENTS WITH ULCERATIVE COLITIS,\"","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28371,"protocol_no":"LAS-MD-45","submission_no":"168357","status_id":2,"start_date":"2013-05-31","end_date":"2017-09-29","nol_date":"2013-10-18","protocol_title":"DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO EVALUATE THE EFFECT OF ACLIDINIUM BROMIDE ON LONG-TERM CARDIOVASCULAR SAFETY AND COPD EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD (ASCENT COPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43249,"protocol_no":"MDV3800-13","submission_no":"197614","status_id":1,"start_date":"2017-01-05","end_date":null,"nol_date":"2016-09-14","protocol_title":"A SINGLE ARM, OPEN LABEL, MULTICENTER, EXTENDED TREATMENT, SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB","medConditionList":[{"med_condition_id":665,"med_condition":"ADVANCED MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39157,"protocol_no":"CV185-316","submission_no":"184318","status_id":1,"start_date":"2016-03-22","end_date":null,"nol_date":"2015-05-29","protocol_title":"AN OPEN-LABEL, 2 X 2 FACTORIAL, RANDOMIZED CONTROLLED, CLINICAL TRIAL TO EVALUATE THE SAFETY OF APIXABAN VS. VITAMIN K ANTAGONIST AND ASPIRIN VS. ASPIRIN PLACEBO IN PATIENTS WITH ATRIAL FIBRILLATION AND ACUTE CORONARY SYNDROME OR PERCUTANEOUS CORONARY INTERVENTION","medConditionList":[{"med_condition_id":499,"med_condition":"ACUTE CORONARY SYNDROME"},{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43255,"protocol_no":"D6020C00001","submission_no":"197624","status_id":1,"start_date":"2017-09-08","end_date":null,"nol_date":"2016-09-12","protocol_title":"A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF MEDI0680 (AMP-514) IN COMBINATION WITH MEDI4736 AND MEDI0680 MONOTHERAPY IN SUBJECTS WITH SELECT ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47718,"protocol_no":"M16-383","submission_no":"211640","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-28","protocol_title":"A STUDY TO EVALUATE SAFETY AND EFFICACY OF ELAGOLIX ALONE OR ELAGOLIX WITH HORMONAL ADD-BACK IN SUBJECTS WITH ENDOMETRIOSIS WITH ASSOCIATED MODERATE TO SEVERE PAIN","medConditionList":[{"med_condition_id":74,"med_condition":"ENDOMETRIOSIS"},{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46440,"protocol_no":"BBI-DSP7888-201G","submission_no":"207581","status_id":1,"start_date":"2017-11-29","end_date":null,"nol_date":"2017-08-15","protocol_title":"A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF DSP-7888 DOSING EMULSION IN COMBINATION WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN PATIENTS WITH RECURRENT OR PROGRESSIVE GLIOBLASTOMA FOLLOWING INTIAL THERAPY","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40194,"protocol_no":"2401BT-002","submission_no":"187339","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-09-30","protocol_title":"A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF A CONDITIONALLY REPLICATIVE ADENOVIRUS DNX-2401 FOR RECURRENT GLIOBLASTOMA OR GLIOSARCOMA (TARGET II),","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36714,"protocol_no":"BUC-CLIN-303","submission_no":"176334","status_id":2,"start_date":"2015-07-29","end_date":"2018-03-30","nol_date":"2014-08-12","protocol_title":"GENETIC-AF - A GENOTYPE-DIRECTED COMPARATIVE EFFECTIVENESS TRIAL OF BUCINDOLOL AND AND TOPROL-XL FOR PREVENTION OF SYMPTOMATIC ATRIAL FIBRILLATION/ATRIAL FLUTTER IN PATIENTS WITH HEART FAILURE","medConditionList":[{"med_condition_id":416,"med_condition":"ATRIAL FLUTTER"},{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42701,"protocol_no":"201619","submission_no":"195918","status_id":1,"start_date":"2016-07-04","end_date":null,"nol_date":"2016-07-12","protocol_title":"SYNCHRONIZING EXERCISES, REMEDIES IN GAIT AND COGNITION (SYNERGIC).  A RANDOMIZED DOUBLE BLIND TRIAL.","medConditionList":[{"med_condition_id":285,"med_condition":"COGNITIVE IMPAIRMENT"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26948,"protocol_no":"MB001-001","submission_no":"164300","status_id":1,"start_date":"2015-11-04","end_date":null,"nol_date":"2013-05-24","protocol_title":"EXENATIDE FOR MYOCARDIAL PROTECTION DURING REPERFUSION STUDY A DOUBLE BLIND, PLACEBO CONTROLLED TRIAL (EMPRES)","medConditionList":[{"med_condition_id":170,"med_condition":"MYOCARDIAL PERFUSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29204,"protocol_no":"CTO-201","submission_no":"171209","status_id":2,"start_date":"2014-12-24","end_date":"2016-02-03","nol_date":"2014-02-12","protocol_title":"A 2-STAGE STUDY TO EVALUATE SINGLE DOSES OF MZ-004 AT DIFFERENT DOSE LEVELS IN PATIENTS WITH CHRONIC TOTAL OCCLUSIONS","medConditionList":[{"med_condition_id":410,"med_condition":"OCCLUSIONS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41608,"protocol_no":"107283","submission_no":"192037","status_id":1,"start_date":"2017-01-31","end_date":null,"nol_date":"2016-03-03","protocol_title":"A NEW ANTICOAGULATION METHOD USING DALTEPARIN IN QUOTIDIAN AND NOCTURNAL HOME HEMODIALYSIS PATIENTS: A PROSPECTIVE STUDY","medConditionList":[{"med_condition_id":668,"med_condition":"THROMBOSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38823,"protocol_no":"BCX4161-301","submission_no":"183309","status_id":2,"start_date":"2015-05-20","end_date":"2016-02-09","nol_date":"2015-04-24","protocol_title":"OPUS-2: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE LEVELS OF BCX4161 FOR 12 WEEKS AS AN ORAL PROPHYLAXIS TREATMENT FOR ATTACKS OF HEREDITARY ANGIOEDEMA","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35749,"protocol_no":"SPD476-319","submission_no":"173306","status_id":1,"start_date":"2015-08-14","end_date":null,"nol_date":"2014-04-24","protocol_title":"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO DETERMINE THE SAFETY AND EFFICACY OF MMX MESALAMINE/MESALAZINE IN PEDIATRIC SUBJECTS WITH MILD TO MODERATE ULCERATIVE COLITIS, IN BOTH ACUTE AND MAINTENANCE PHASES","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36434,"protocol_no":"CIMS-2014-01","submission_no":"175419","status_id":1,"start_date":"2015-07-09","end_date":null,"nol_date":"2014-07-09","protocol_title":"A PHASE I STUDY OF 99M TC PERTECHNETATE PRODUCED IN HIGH ENERY CYCLOTRON (CYCLOTEC) IN PATIENTS WITH THYROID SCAN INDICATION","medConditionList":[{"med_condition_id":629,"med_condition":"THYROID SCAN INDICATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37131,"protocol_no":"D081FC00001","submission_no":"177620","status_id":1,"start_date":"2015-07-24","end_date":null,"nol_date":"2014-09-25","protocol_title":"A PHASE III, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE STUDY OF MAINTENANCE OLAPARIB MONOTHERAPY IN PATIENTS WITH GBRCA MUTATED METASTATIC PANCREATIC CANCER WHOSE DISEASE HAS NOT PROGRESSED ON FIRST LINE PLATINUM BASED CHEMOTHERAPY","medConditionList":[{"med_condition_id":187,"med_condition":"PANCREATIC CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41800,"protocol_no":"NA 99MO 001","submission_no":"192746","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-03-31","protocol_title":"A CROSS-OVER COMPARISON OF THE DIAGNOSTIC ACCURACY OF TECHNETIUM (99MTC) MEDRONATE INJECTION PREPARED WITH 99MTC DERIVED FROM NEUTRON-ACTIVATION-PRODUCED 99MO AND 99MTC DERIVED FROM FISSION-PRODUCED 99MO","medConditionList":[{"med_condition_id":712,"med_condition":"BONE METASTASES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37035,"protocol_no":"BO25323","submission_no":"177309","status_id":1,"start_date":"2016-06-20","end_date":null,"nol_date":"2014-09-17","protocol_title":"A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND GDC-0199 (ABT-199) VERSUS OBINUTUZUMAB AND CHLORAMBUCIL IN PREVIOUSLY UNTREATED PATIENTS WITH CLL AND COEXISITING MEDICAL CONDITIONS.","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39295,"protocol_no":"911401","submission_no":"184746","status_id":1,"start_date":"2015-10-09","end_date":null,"nol_date":"2015-06-19","protocol_title":"\"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY, AND IMMUNOGENICITY OF AN ADALIMUMAB BIOSIMILAR (M923) AND HUMIRA IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASIS.\"","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44374,"protocol_no":"ADXS001-02","submission_no":"201097","status_id":1,"start_date":"2017-06-27","end_date":null,"nol_date":"2017-01-11","protocol_title":"PHASE 3 STUDY OF ADXS11-001 ADMINISTERED FOLLOWING CHEMORADIATION AS ADJUVANT TREATMENT FOR HIGH RISK LOCALLY ADVANCED CERVICAL  CANCER: AIM2CERV","medConditionList":[{"med_condition_id":356,"med_condition":"CERVICAL CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27447,"protocol_no":"VX11-770-109","submission_no":"165779","status_id":2,"start_date":"2014-05-28","end_date":"2016-01-19","nol_date":"2013-07-19","protocol_title":"PHASE 3, 2-ARM, ROLL-OVER STUDY TO EVALUATE THE LONG-TERM SAFETY AND PHARMACODYNAMICS OF IVACAFTOR TREATMENT IN PEDIATRIC SUBJECTS WITH CYSTIC FIBROSIS AND A CFTR GATING MUTATION","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27094,"protocol_no":"082/2012","submission_no":"164786","status_id":2,"start_date":"2014-02-11","end_date":"2016-02-02","nol_date":"2013-06-07","protocol_title":"TESTING THE PPAR HYPOTHESIS OF NICOTINE DEPENDENCE IN HUMANS: GEMFIBROZIL AS A NOVEL TREATMENT FOR TOBACCO ADDICTION","medConditionList":[{"med_condition_id":420,"med_condition":"ADDICTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39763,"protocol_no":"1000049033","submission_no":"186231","status_id":1,"start_date":"2015-11-18","end_date":null,"nol_date":"2015-08-10","protocol_title":"HYPERPOLARIZED XENON MRI IN CYSTIC FIBROSIS PULMONARY EXACERBATIONS (PEX MRI)","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40945,"protocol_no":"17618","submission_no":"189761","status_id":1,"start_date":"2017-02-02","end_date":null,"nol_date":"2015-12-18","protocol_title":"7-DAY STUDY OF THE SAFETY, EFFICACY AND THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF ORAL RIVAROXABAN IN CHILDREN FROM BIRTH TO LESS THAN 6 MONTHS WITH CATHETER-RELATED ARTERIAL OR VENOUS THROMBOSIS","medConditionList":[{"med_condition_id":530,"med_condition":"VENOUS THROMBOSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":38871,"protocol_no":"MLN1117-1501","submission_no":"183484","status_id":2,"start_date":"2016-04-27","end_date":"2017-01-20","nol_date":"2015-05-01","protocol_title":"A PHASE 1B/ADAPTIVE PHASE 2 STUDY OF DOCETAXEL WITH OR WITHOUT MLN1117 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27704,"protocol_no":"LCH-IV","submission_no":"166498","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-09-12","protocol_title":"LCH-IV INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR CHILDREN AND ADOLESCENTS WITH LANGERHANS CELL HISTIOCYTOSIS","medConditionList":[{"med_condition_id":139,"med_condition":"LANGERHANS CELL HISTIOCYTOSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42423,"protocol_no":"TV48125-CNS-30051","submission_no":"194885","status_id":1,"start_date":"2016-08-10","end_date":null,"nol_date":"2016-06-23","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY EVALUATING THE LONG TERM SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TEV 48125 FOR THE PREVENTATIVE TREATMENT OF MIGRAINE","medConditionList":[{"med_condition_id":157,"med_condition":"MIGRAINE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46807,"protocol_no":"ATG2017","submission_no":"208752","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-25","protocol_title":"GRAFT-VS-HOST DISEASE PROPHYLAXIS WITH HIGH DOSE ANTITHYMOCYTE GLOBULIN (THYMOGLOBULIN) AND NO CYCLOSPORINE","medConditionList":[{"med_condition_id":370,"med_condition":"GRAFT VS HOST DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38071,"protocol_no":"RPC01-301","submission_no":"180766","status_id":2,"start_date":"2015-09-04","end_date":"2016-12-22","nol_date":"2015-01-15","protocol_title":"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RPC1063 ADMINISTERED ORALLY TO RELAPSING MULTIPLE SCLEROSIS PATIENTS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47824,"protocol_no":"M15-563","submission_no":"211731","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-03","protocol_title":"AN EXTENSION STUDY OF ABBV-8E12 IN PROGRESSIVE SUPRANUCLEAR PALSY (PSP)","medConditionList":[{"med_condition_id":768,"med_condition":"PROGRESSIVE SUPRANUCLEAR PALSY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47030,"protocol_no":"INKED-PC","submission_no":"209536","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-10-10","protocol_title":"A PHASE II, OPEN-LABEL CLINICAL TRIAL OF INTRANASAL KETAMINE FOR DEPRESSION IN PATIENTS WITH CANCER RECEIVING PALLIATIVE CARE (INKED-PC STUDY)","medConditionList":[{"med_condition_id":323,"med_condition":"DEPRESSION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36963,"protocol_no":"M14-359","submission_no":"177098","status_id":1,"start_date":"2015-09-09","end_date":null,"nol_date":"2014-09-09","protocol_title":"A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 2 TRIAL COMPARING VELIPARIB PLUS CARBOPLATIN AND PACLITAXEL VERSUS INVESTIGATOR'S CHOICE OF STANDARD CHEMOTHERAPY IN SUBJECTS RECEIVING FIRST CYTOTOXIC CHEMOTHERAPY FOR METASTATIC OR ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) AND WHO ARE CURRENT OR FORMER SMOKERS.","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"},{"med_condition_id":505,"med_condition":"LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40480,"protocol_no":"EPI-506-CS-0001","submission_no":"188274","status_id":1,"start_date":"2017-09-01","end_date":null,"nol_date":"2015-11-03","protocol_title":"A PHASE 1/2 OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF ORAL EPI-506 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"},{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42286,"protocol_no":"VEDOLIZUMAB-4006","submission_no":"194484","status_id":1,"start_date":"2017-03-30","end_date":null,"nol_date":"2016-05-24","protocol_title":"AN OPEN-LABEL, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRIPLE COMBINATION THERAPY WITH VEDOLIZUMAB IV, ADALIMUMAB SC, AND ORAL METHOTREXATE IN EARLY TREATMENT OF SUBJECTS WITH CROHN'S DISEASE STRATIFIED AT HIGHER RISK FOR DEVELOPING COMPLICATIONS","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45596,"protocol_no":"M16-135","submission_no":"204900","status_id":1,"start_date":"2017-08-09","end_date":null,"nol_date":"2017-05-09","protocol_title":"A SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GLECAPREVIR (GLE)/PIBRENTASVIR (PIB) IN TREATMENT NA√èVE ADULTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 4, 5 OR 6 INFECTION AND COMPENSATED CIRRHOSIS","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44214,"protocol_no":"205667","submission_no":"199410","status_id":1,"start_date":"2017-02-21","end_date":null,"nol_date":"2016-12-20","protocol_title":"AN OPEN-LABEL, SINGLE ARM, REPEAT DOSE, MULTI-CENTRE STUDY TO EVALUATE THE USE OF A SAFETY SYRINGE FOR THE SUBCUTANEOUS ADMINISTRATION OF MEPOLIZUMAB IN SUBJECTS WITH SEVERE EOSINOPHILIC ASTHMA (STUDY 205667)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43656,"protocol_no":"M12-816","submission_no":"198782","status_id":1,"start_date":"2018-02-09","end_date":null,"nol_date":"2016-10-27","protocol_title":"EXTENSION STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELAGOLIX IN PREMENOPAUSAL WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS","medConditionList":[{"med_condition_id":333,"med_condition":"UTERINE FIBROIDS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42007,"protocol_no":"15-155-MUHC","submission_no":"193639","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-05-05","protocol_title":"ENHANCING THE ANABOLIC EFFECT OF NUTRITION IN CRITICALLY ILL PATIENTS BY ADMINISTERING EXOGENOUS AMINO ACIDS","medConditionList":[{"med_condition_id":563,"med_condition":"CRITICAL LIMB ISCHEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29096,"protocol_no":"D1344C00001","submission_no":"170864","status_id":2,"start_date":"2014-10-29","end_date":"2016-01-22","nol_date":"2014-01-16","protocol_title":"A RANDOMISED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY OF SELUMETINIB (AZD6244, HYD-SULFATE) IN COMBINATION WITH DACARBAZINE COMPARED WITH PLACEBO IN COMBINATION WITH DACARBAZINE AS FIRST SYSTEMIC THERAPY IN PATIENTS WITH METASTATIC UVEAL MELANOMA (SUMIT)","medConditionList":[{"med_condition_id":489,"med_condition":"UVEAL MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37156,"protocol_no":"NN9068-4056","submission_no":"177736","status_id":1,"start_date":"2014-11-12","end_date":null,"nol_date":"2014-10-03","protocol_title":"DUAL-IV-EASY TITRATION: A CLINICAL TRIAL COMPARING EFFICACY OF INSULIN DEGLUDEC/LIRAGLUTIDE (IDEGLIRA) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS USING TWO DIFFERENT TITRATION ALGORITHMS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40513,"protocol_no":"B3451002","submission_no":"188361","status_id":1,"start_date":"2016-06-21","end_date":null,"nol_date":"2015-11-06","protocol_title":"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4-ANTIGEN VACCINE (SA4AG) IN ADULTS UNDERGOING ELECTIVE POSTERIOR INSTRUMENTED LUMBAR SPINAL FUSION PROCEDURES","medConditionList":[{"med_condition_id":653,"med_condition":"POSTERIOR INSTRUMENTED LUMBAR SPINAL FUSION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38256,"protocol_no":"GA29144","submission_no":"181428","status_id":1,"start_date":"2015-09-01","end_date":null,"nol_date":"2015-02-18","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29001,"protocol_no":"ERC-238","submission_no":"170539","status_id":1,"start_date":"2014-02-07","end_date":null,"nol_date":"2013-12-30","protocol_title":"INTRAVAGINAL PRASTERONE (DHEA) AGAINST VULVOVAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE (PLACEBO CONTROLLED, DOUBLE BLIND AND RANDOMIZED PHASE III STUDY)","medConditionList":[{"med_condition_id":443,"med_condition":"VULVOVAGINAL ATROPHY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39347,"protocol_no":"WO29522","submission_no":"184902","status_id":1,"start_date":"2015-08-05","end_date":null,"nol_date":"2015-06-26","protocol_title":"A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35382,"protocol_no":"434-2013","submission_no":"172174","status_id":1,"start_date":"2015-04-16","end_date":null,"nol_date":"2014-03-04","protocol_title":"PROSPECTIVE STUDY OF PALONOSETRON IN THE PROPHYLAXIS/RESCUE OF RADIATION INDUCED NAUSEA AND VOMITING (RINV) - A PHASE II STUDY","medConditionList":[{"med_condition_id":302,"med_condition":"NAUSEA AND VOMITING"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37316,"protocol_no":"E6011-A001-102","submission_no":"178266","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-10-23","protocol_title":"A MULTICENTER, PHASE 1B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL-COHORT, MULTIPLE-ASCENDING-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF 3 SUBCUTANEOUS AND 1 INTRAVENOUS DOSE OF E6011 IN SUBJECTS WIHT ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47163,"protocol_no":"B9991023","submission_no":"210006","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-01","protocol_title":"A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":665,"med_condition":"ADVANCED MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37744,"protocol_no":"14-8200","submission_no":"179610","status_id":1,"start_date":"2015-01-13","end_date":null,"nol_date":"2014-12-18","protocol_title":"VITAMIN K SUPPLEMENTATION TO IMPROVE INR STABILITY IN PATIENTS ON HEMODIALYSIS TAKING WARFARIN FOR ATRIAL FIBRILLATION","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38927,"protocol_no":"116945 [DTPA(BOOSTRIX)-047]","submission_no":"183631","status_id":1,"start_date":"2015-10-29","end_date":null,"nol_date":"2015-05-06","protocol_title":"A PHASE IV, OBSERVER-BLIND, RANDOMISED, CROSS-OVER, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A SINGLE DOSE OF BOOSTRIX IN PREGNANT WOMEN.","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27830,"protocol_no":"VEG116731","submission_no":"166824","status_id":1,"start_date":"2017-09-11","end_date":null,"nol_date":"2013-08-22","protocol_title":"A PHASE II STUDY OF PAZOPANIB GW786034, NSC# 737754 IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH REFRACTORY SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40001,"protocol_no":"GS-US-313-1580","submission_no":"186825","status_id":1,"start_date":"2016-11-09","end_date":null,"nol_date":"2015-09-16","protocol_title":"DOSE OPTIMIZATION STUDY OF IDELALISIB IN FOLLICULAR LYMPHOMA AND SMALL LYMPHOCYTIC LYMPHOMA","medConditionList":[{"med_condition_id":315,"med_condition":"FOLLICULAR LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35622,"protocol_no":"YAT-LUR-01","submission_no":"172932","status_id":2,"start_date":"2014-06-16","end_date":"2015-10-19","nol_date":"2014-04-16","protocol_title":"CHANGES IN COGNITIVE FUNCTIONING IN EUTHYMIC BIPOLAR PATIENTS TREATED WITH LURASIDONE VERSUS TREATMENT AS USUAL; A RANDOMIZED, OPEN-LABEL STUDY","medConditionList":[{"med_condition_id":501,"med_condition":"BIPOLAR DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29131,"protocol_no":"CC2014","submission_no":"170996","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-01-15","protocol_title":"CHRONIC COUGH TREATMENT: THE MCGILL EXPERIENCE","medConditionList":[{"med_condition_id":42,"med_condition":"CHRONIC COUGH"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29068,"protocol_no":"POST 6","submission_no":"170774","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-02-18","protocol_title":"A PROOF OF PRINCIPLE STUDY OF ATOMOXETINE FOR THE PREVENTION OF VASOVAGAL SYNCOPE","medConditionList":[{"med_condition_id":413,"med_condition":"VASOVAGAL SYNCOPE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27328,"protocol_no":"BAN2401-G000-201","submission_no":"165432","status_id":1,"start_date":"2013-10-31","end_date":null,"nol_date":"2013-07-03","protocol_title":"A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, BAYESIAN ADAPTIVE RANDOMIZATION DESIGN AND DOSE REGIMEN-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY AND EFFICACY OF BAN2401 IN SUBJECTS WITH EARLY ALZHEIMER'S DISEASE","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39378,"protocol_no":"D5165C00001","submission_no":"184986","status_id":1,"start_date":"2015-08-21","end_date":null,"nol_date":"2015-07-02","protocol_title":"A PHASE III, MULTI-CENTRE, OPEN LABEL, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF AZD9291 IN COMBINATION WITH MEDI4736 VERSUS AZD9291 MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER WHO HAVE RECEIVED PRIOR EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR THERAPY (CAURAL)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46409,"protocol_no":"ALSFUS001","submission_no":"207434","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-26","protocol_title":"SAFETY AND FEASIBILITY OF PRIMARY MOTOR CORTEX BLOOD-BRAIN BARRIER OPENING USING TRANSCRANIAL MR-GUIDED FOCUSED ULTRASOUND WITH INTRAVENOUS ULTRASOUND CONTRAST AGENT IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44252,"protocol_no":"ADP-0011-001","submission_no":"200539","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-12-28","protocol_title":"A PHASE I/IIA, OPEN LABEL CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF AUTOLOGOUS T CELLS EXPRESSING ENHANCED TCRS SPECIFIC FOR NY ESO 1 IN PATIENTS WITH RECURRENT OR TREATMENT REFRACTORY OVARIAN CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43756,"protocol_no":"VX15-440-101","submission_no":"199067","status_id":1,"start_date":"2017-02-09","end_date":null,"nol_date":"2016-11-10","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE BLIND, CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VX-440 COMBINATION THERAPY IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43599,"protocol_no":"15-005","submission_no":"198566","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-10-14","protocol_title":"PHASE II STUDY OF CLOFARABINE IN PATIENTS WITH RECURRENT OR REFRACTORY LANGERHANS CELL HISTIOCYTOSIS","medConditionList":[{"med_condition_id":139,"med_condition":"LANGERHANS CELL HISTIOCYTOSIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43587,"protocol_no":"D5290C00003","submission_no":"198539","status_id":1,"start_date":"2016-11-29","end_date":null,"nol_date":"2016-10-20","protocol_title":"A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MEDI8897, A MONOCLONAL ANTIBODY WITH AN EXTENDED HALF-LIFE AGAINST RESPIRATORY SYNCYTIAL VIRUS, IN HEALTH PRETERM INFANTS","medConditionList":[{"med_condition_id":280,"med_condition":"RESPIRATORY SYNCYTIAL VIRUS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41964,"protocol_no":"006-00","submission_no":"193439","status_id":2,"start_date":"2016-06-09","end_date":"2017-01-24","nol_date":"2016-04-15","protocol_title":"A PHASE IB DOSE EXPLORATION TRIAL WITH MK-8628, A SMALL MOLECULE INHIBITOR OF THE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEINS, IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36627,"protocol_no":"TV5600-CNS-20007 (LEGATO-HD)","submission_no":"176036","status_id":1,"start_date":"2016-03-24","end_date":null,"nol_date":"2014-07-29","protocol_title":"A MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LAQUINIMOD (0.5, 1.0 AND 1.5 MG/DAY) AS TREATMENT IN PATIENTS WITH HUNTINGTON'S DISEASE.","medConditionList":[{"med_condition_id":120,"med_condition":"HUNTINGTON DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45039,"protocol_no":"TV48125-CNS-30058","submission_no":"203111","status_id":1,"start_date":"2017-04-12","end_date":null,"nol_date":"2017-03-23","protocol_title":"A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EXPLORE THE LONG-TERM SAFETY OF TEV-48125 FOR THE PREVENTION OF CLUSTER HEADACHE","medConditionList":[{"med_condition_id":628,"med_condition":"CHRONIC CLUSTER HEADACHE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40012,"protocol_no":"1000039945","submission_no":"186844","status_id":1,"start_date":"2017-04-13","end_date":null,"nol_date":"2015-08-26","protocol_title":"FETAL ATRIAL FLUTTER & SUPRAVENTRICULAR TACHYCARDIA (FAST) THERAPY TRIAL","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"},{"med_condition_id":418,"med_condition":"SUPRAVENTRICULAR TACHYARRHYTHMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37026,"protocol_no":"186-03","submission_no":"177283","status_id":1,"start_date":"2014-12-08","end_date":null,"nol_date":"2014-09-17","protocol_title":"A 4 WEEK STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF SHK-186 IN ACTIVE PLAQUE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47610,"protocol_no":"CA2099NC / INCB 24360-309","submission_no":"211373","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-28","protocol_title":"A PHASE 3, RANDOMIZED, GLOBAL TRIAL OF NIVOLUMAB AND EPACADOSTAT WITH PLATINUM DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":235,"med_condition":"SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46573,"protocol_no":"207489","submission_no":"208000","status_id":1,"start_date":"2017-12-13","end_date":null,"nol_date":"2017-08-24","protocol_title":"A PHASE IIB, RANDOMISED, OBSERVER-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THE GSK BIOLOGICALS' INVESTIGATIONAL VACCINE GSK3277511A WHEN ADMINISTERED INTRAMUSCULARLY ACCORDING TO A 0,2 MONTH SCHEDULE IN COPD PATIENTS AGED 40 TO 80 YEARS WITH A PREVIOUS HISTORY OF ACUTE EXACERBATION (AECOPD)","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35522,"protocol_no":"13-0290-A","submission_no":"172654","status_id":1,"start_date":"2014-03-21","end_date":null,"nol_date":"2014-04-02","protocol_title":"A MULTICENTER TRIAL OF ALLOPURINOL TO PREVENT GFR LOSS IN TYPE 1 DIABETES","medConditionList":[{"med_condition_id":65,"med_condition":"DIABETIC NEPHROPATHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39195,"protocol_no":"AHE-1","submission_no":"184431","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-06-30","protocol_title":"A RANDOMIZED CONTROLLED STUDY OF ZOPICLONE FOR THE TREATMENT OF PATIENTS WITH COGNITIVE-BEHAVIORAL DYSFUNCTION DUE TO VARIOUS AETIOLOGIES AND ASSOCIATED WITH EEG DYSRHYTHMIA","medConditionList":[{"med_condition_id":285,"med_condition":"COGNITIVE IMPAIRMENT"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47334,"protocol_no":"VC02-101","submission_no":"210585","status_id":1,"start_date":"2017-04-12","end_date":null,"nol_date":"2017-12-01","protocol_title":"AN OPEN-LABEL, FIRST-IN-HUMAN, STUDY EVALUATING THE SAFETY,TOLERABILITY, AND EFFICACY OF VC-02 COMBINATION PRODUCT IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS AND HYPOGLYCEMIA UNAWARENESS","medConditionList":[{"med_condition_id":771,"med_condition":"HYPOGLYCEMIA UNAWARENESS"},{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28621,"protocol_no":"ECAD001","submission_no":"169189","status_id":1,"start_date":"2014-08-18","end_date":null,"nol_date":"2013-11-15","protocol_title":"ELIMINATE CORONARY HEART DISEASE","medConditionList":[{"med_condition_id":56,"med_condition":"CORONARY HEART DISEASE OR HIGH RISK OF CORONONARY HEART DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47544,"protocol_no":"205646","submission_no":"211215","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-01-15","protocol_title":"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 104-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELIMUMAB ADMINISTERED IN COMBINATION WITH RITUXIMAB TO ADULT SUBJECTS WITH LUPUS ERYTHEMATOSUS (SLE)","medConditionList":[{"med_condition_id":473,"med_condition":"LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46777,"protocol_no":"071301","submission_no":"208637","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-09-13","protocol_title":"A PROSPECTIVE PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH RVWF IN SEVERE VON WILLEBRAND DISEASE","medConditionList":[{"med_condition_id":268,"med_condition":"VON WILLEBRAND DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42995,"protocol_no":"CA015-003","submission_no":"196856","status_id":1,"start_date":"2016-08-23","end_date":null,"nol_date":"2016-08-17","protocol_title":"A PHASE 1/2 STUDY OF BMS-986183 IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA","medConditionList":[{"med_condition_id":110,"med_condition":"HEPATOCELLULAR CARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27629,"protocol_no":"CFZ001","submission_no":"166296","status_id":2,"start_date":"2014-03-24","end_date":"2017-01-16","nol_date":"2013-08-01","protocol_title":"AN OPEN-LABEL, SINGLE ARM, PHASE 1 STUDY OF THE PHARMACOKINETICS AND SAFETY OF CARFILZOMIB IN SUBJECTS WITH RELAPSED MULTIPLE MYELOMA AND END-STAGE RENAL DISEASE","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46145,"protocol_no":"ATRI-001","submission_no":"206500","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-07-05","protocol_title":"ALZHEIMER'S DISEASE NEUROIMAGING INITATIVE3 (ADN13)","medConditionList":[{"med_condition_id":14,"med_condition":"ALZHEIMER'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35865,"protocol_no":"062-00","submission_no":"173665","status_id":1,"start_date":"2015-06-29","end_date":null,"nol_date":"2014-05-06","protocol_title":"A PHASE III OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172/MK-8742 IN TREATMENT-NA√èVE SUBJECTS WITH CHRONIC HCV GT1, GT4, GT5, AND GT6 INFECTION WHO ARE ON OPIATE SUBSTITUTION THERAPY","medConditionList":[{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36984,"protocol_no":"TH005","submission_no":"177148","status_id":1,"start_date":"2014-11-27","end_date":null,"nol_date":"2014-09-11","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTRE FIELD STUDY TO ASSESS THE EFFICACY AND SAFETY OF HDM-SPIRE IN SUBJECTS WITH A HISTORY OF HOUSE DUST MITE-INDUCED RHINOCONJUNCTIVITIS","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28535,"protocol_no":"M13-550","submission_no":"168897","status_id":2,"start_date":null,"end_date":"2016-04-04","nol_date":"2013-11-08","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ABT-494 GIVEN WITH METHOTREXATE (MTX) IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ANTI-TNF BIOLOGIC THERAPY","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42021,"protocol_no":"CO 1686-020","submission_no":"193686","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-04-22","protocol_title":"TIGER-3: A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ORAL ROCILETINIB (CO 1686) MONOTHERAPY VERSUS SINGLE-AGENT CYTOTOXIC CHEMOTHERAPY IN PATIENTS WITH MUTANT EGFR NON-SMALL CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST 1 PREVIOUS EGFR-DIRECTED TYROSINE KINASE INHIBITOR (TKI) AND PLATINUM-DOUBLET CHEMOTHERAPY","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29103,"protocol_no":"082/2013","submission_no":"170885","status_id":1,"start_date":"2014-03-17","end_date":null,"nol_date":"2014-01-17","protocol_title":"ORAL NALOXONE FOR TREATMENT OF OPIOID-INDUCED CONSTIPATION IN PATIENTS RECEIVING METHADONE MAINTENANCE TREATMENT.","medConditionList":[{"med_condition_id":68,"med_condition":"DRUG ADDICTION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27713,"protocol_no":"GI-R-01-2011","submission_no":"166520","status_id":1,"start_date":"2017-01-25","end_date":null,"nol_date":"2013-08-07","protocol_title":"THERAPEUTIC EVALUATION OF STEROIDS IN IGA NEPHROPATHY GLOBAL (TESTING) STUDY - CANADIAN NETWORK","medConditionList":[{"med_condition_id":360,"med_condition":"NEPHROPATHY"},{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27145,"protocol_no":"CAMHPET-CTA 78","submission_no":"164936","status_id":1,"start_date":"2015-11-01","end_date":null,"nol_date":"2013-06-13","protocol_title":"\"IMAGING NEUROINFLAMMATION IN MILD COGNITIVE IMPAIRMENT USING A NOVEL TRANSLOCATOR PROTEIN 18KDA (TSPO) PET RADIOLIGAND: [18F] FEPPA.\"","medConditionList":[{"med_condition_id":285,"med_condition":"COGNITIVE IMPAIRMENT"},{"med_condition_id":284,"med_condition":"NEUROINFLAMMATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42459,"protocol_no":"201334","submission_no":"195045","status_id":1,"start_date":"2017-07-05","end_date":null,"nol_date":"2016-06-09","protocol_title":"A PHASE IV, OPEN-LABEL, NON-RANDOMISED, MULTI-CENTRE STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A BOOSTER DOSE OF INFANRIX HEXA IN HEALTHY INFANTS BORN TO MOTHERS VACCINATED WITH BOOSTRIX DURING PREGNANCY OR IMMEDIATELY POST-DELIVERY","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":45412,"protocol_no":"1001","submission_no":"204344","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-04-20","protocol_title":"PROSPECTIVE, OPEN-LABEL, PHASE IIIB STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF PANZYGA IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY ADMINISTERED AT STANDARD AND HIGH INFUSION RATES","medConditionList":[{"med_condition_id":44,"med_condition":"CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35673,"protocol_no":"M14-011","submission_no":"173074","status_id":1,"start_date":"2015-11-15","end_date":null,"nol_date":"2014-04-14","protocol_title":"A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING SAFETY AND EFFICACY OF THE ADDITION OF VELIPARIB PLUS CARBOPLATIN VERSUS THE ADDITION OF CARBOPLATIN TO STANDARD NEOADJUVANT CHEMOTHERAPY VERSUS STANDARD NEOADJUVANT CHEMOTHERAPY IN SUBJECTS WITH EARLY STAGE TRIPLE NEGATIVE BREAST CANCER (TNBC)","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40713,"protocol_no":"CMBG453X2101","submission_no":"188924","status_id":1,"start_date":"2016-10-17","end_date":null,"nol_date":"2015-11-27","protocol_title":"A PHASE I-IB/II, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":665,"med_condition":"ADVANCED MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43418,"protocol_no":"CY 5021","submission_no":"198044","status_id":1,"start_date":"2017-04-05","end_date":null,"nol_date":"2016-09-29","protocol_title":"A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY OF CK 2127107 IN TWO ASCENDING DOSE COHORTS OF PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)","medConditionList":[{"med_condition_id":321,"med_condition":"SPINAL MUSCULAR ATROPHY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39007,"protocol_no":"1245.69","submission_no":"183864","status_id":2,"start_date":"2015-08-21","end_date":"2017-11-08","nol_date":"2015-05-19","protocol_title":"A PHASE III, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, EFFICACY, SAFETY AND TOLERABILITY TRIAL OF ONCE DAILY, ORAL DOSES OF EMPAGLIFLOZIN AS ADJUNCTIVE TO INSULIN THERAPY OVER 52 WEEKS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS (EASE-2)","medConditionList":[{"med_condition_id":388,"med_condition":"DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45003,"protocol_no":"ACT14820","submission_no":"203043","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-14","protocol_title":"MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GZ/SAR402671 IN PATIENTS WITH EARLY-STAGE PARKINSON¬øS DISEASE CARRYING A GBA MUTATION OR OTHER PRESPECIFIED VARIANT.","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40586,"protocol_no":"0232","submission_no":"188540","status_id":1,"start_date":"2016-03-01","end_date":null,"nol_date":"2015-11-12","protocol_title":"ASSESSING THE EFFECTIVENESS OF IBUPROFEN COMPARED TO MORPHINE AS A PEDIATRIC POSTOPERATIVE PAIN MANAGEMENT TOOL FOLLOWING INGUINAL SURGERY.","medConditionList":[{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47036,"protocol_no":"I4V-MC-JAHM","submission_no":"209538","status_id":2,"start_date":null,"end_date":"2018-02-27","nol_date":"2017-10-20","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44594,"protocol_no":"AC-061A303","submission_no":"201813","status_id":1,"start_date":"2017-08-15","end_date":null,"nol_date":"2017-02-02","protocol_title":"A PROSPECTIVE, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF CADAZOLID VERSUS VANCOMYCIN IN PEDIATRIC SUBJECTS WITH CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA","medConditionList":[{"med_condition_id":531,"med_condition":"CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHOEA (CDAD)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41126,"protocol_no":"192024-093","submission_no":"190409","status_id":1,"start_date":"2016-04-28","end_date":null,"nol_date":"2016-01-07","protocol_title":"A  COMPARISON OF BIMATOPROST SR TO SELECTIVE LASER TRABECULOPLASTY IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION","medConditionList":[{"med_condition_id":89,"med_condition":"GLAUCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41822,"protocol_no":"9785-MA-1010","submission_no":"192846","status_id":1,"start_date":"2017-05-11","end_date":null,"nol_date":"2016-03-24","protocol_title":"A RANDOMIZED STUDY OF ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE (ENACT).","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37211,"protocol_no":"GV29216","submission_no":"177867","status_id":1,"start_date":"2015-01-15","end_date":null,"nol_date":"2014-10-10","protocol_title":"\"A PHASE 2 RANDOMIZED, DOUBLE-BLINE PLACEBO-CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION.","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40626,"protocol_no":"E7438-G000-101","submission_no":"188649","status_id":1,"start_date":"2016-11-07","end_date":null,"nol_date":"2015-12-04","protocol_title":"AN OPEN-LABEL, MULTICENTER, PHASE 1/2 STUDY OF E7438 (EZH2 HISTONE METHYL TRANSFERASE [HMT] INHIBITOR) AS A SINGLE AGENT IN SUBJECTS WITH ADVANCED SOLID TUMORS OR WITH B CELL LYMPHOMAS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29022,"protocol_no":"RH01997","submission_no":"170616","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-01-03","protocol_title":"A PROOF-OF-PRINCIPLE AND DOSE-RANGING SINGLE-DOSE STUDY OF A CARBON DIOXIDE NASAL SPRAY IN RAGWEED ALLERGIC SUBJECTS WITH NASAL CONGESTION","medConditionList":[{"med_condition_id":448,"med_condition":"RAGWEED ALLERGY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28966,"protocol_no":"201-201302","submission_no":"170372","status_id":1,"start_date":"2014-02-26","end_date":null,"nol_date":"2013-12-24","protocol_title":"A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED, MULTICENTER, PHASE 3 STUDY OF OTO-201 GIVEN AS A SINGLE INTRATYMPANIC INJECTION FOR INTRA-OPERATIVE TREATMENT OF MIDDLE EAR EFFUSION IN PEDIATRIC SUBJECTS REQUIRING TYMPANOSTOMY TUBE PLACEMENT","medConditionList":[{"med_condition_id":455,"med_condition":"MIDDLE EAR EFFUSION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":47531,"protocol_no":"SPI POZ 202","submission_no":"211191","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-01","protocol_title":"A PHASE 2 STUDY OF POZIOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER, LOCALLY ADVANCED OR METASTATIC, WITH EGFR OR HER2 EXON 20 INSERTION MUTATION (POZITIVE20-1)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42598,"protocol_no":"DOUGLAS 16/01","submission_no":"195521","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-02-20","protocol_title":"ATORVASTATIN FOR THE TREATMENT OF LITHIUM-INDUCED NEPHROGENIC DIABETES INSIPIDUS: A RANDOMIZED CONTROLLED TRIAL","medConditionList":[{"med_condition_id":388,"med_condition":"DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38197,"protocol_no":"C1 3201","submission_no":"181242","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-02-20","protocol_title":"A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-PERIOD CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RECOMBINANT HUMAN C1 INHIBITOR IN THE PROPHYLAXIX OF ANGIOEDEMA ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA","medConditionList":[{"med_condition_id":395,"med_condition":"HEREDITARY ANGIOEDEMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39367,"protocol_no":"18445","submission_no":"184952","status_id":1,"start_date":"2011-11-08","end_date":null,"nol_date":"2015-06-26","protocol_title":"USE OF KINEMATIC ASSESSMENT OF HAND TREMOR PRE- AND POST-TREATMENT WITH BOTULINUM TOXIN TYPE A IN ESSENTIAL TREMOR AND PARKINSON DISEASE","medConditionList":[{"med_condition_id":597,"med_condition":"ESSENTIAL TREMOR"},{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28930,"protocol_no":"112-2013","submission_no":"170266","status_id":2,"start_date":"2015-05-26","end_date":"2016-03-01","nol_date":"2014-02-07","protocol_title":"DEVELOPMENT OF A DIETARY SUPPLEMENTS FOR MOOD SYMPTOMS IN POSTPARTUM","medConditionList":[{"med_condition_id":491,"med_condition":"POST PARTUM MOOD SYMPTOMS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27048,"protocol_no":"MAST_01","submission_no":"164605","status_id":1,"start_date":"2013-10-23","end_date":null,"nol_date":"2013-05-21","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF METFORMIN IN REDUCING PROGRESSION AMONG MEN ON EXPECTANT MANAGEMENT FOR LOW RISK PROSTATE CANCER: THE MAST (METFORMIN ACTIVE SURVEILLANCE TRIAL) STUDY","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44393,"protocol_no":"ART-I02-001","submission_no":"201148","status_id":1,"start_date":"2017-11-15","end_date":null,"nol_date":"2017-01-09","protocol_title":"A SINGLE DOSE CLINICAL TRIAL TO STUDY THE SAFETY OF ART-I02 IN PATIENTS WITH RHEUMATOID ARTHRITIS","medConditionList":[{"med_condition_id":224,"med_condition":"RHEUMATOID ARTHRITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42033,"protocol_no":"1407-004","submission_no":"193711","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-04-22","protocol_title":"CLINICAL EVALUATION OF USE OF PRISMOCITRATE 18 IN PATIENTS UNDERGOING ACUTE CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)","medConditionList":[{"med_condition_id":731,"med_condition":"ACUTE RENAL INJURY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43566,"protocol_no":"NN9924-4280","submission_no":"198482","status_id":1,"start_date":"2017-02-02","end_date":null,"nol_date":"2016-10-12","protocol_title":"PIONEER 8-INSULIN ADD-ON EFFICACY AND SAFETY OF ORAL SEMAGLUTIDE VERSUS PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH INSULIN","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37202,"protocol_no":"B1481030","submission_no":"177841","status_id":1,"start_date":"2014-12-29","end_date":null,"nol_date":"2014-10-08","protocol_title":"A PHASE-3, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO AND ACTIVE CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH DYSLIPIDEMIA WHO ARE INTOLERANT TO STATINS","medConditionList":[{"med_condition_id":387,"med_condition":"DYSLIPIDEAMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":26532,"protocol_no":"CRFB002A2405","submission_no":"163044","status_id":1,"start_date":"2011-12-08","end_date":null,"nol_date":"2013-04-03","protocol_title":"\"A 24-MONTH, PHASE IIIB, RANDOMIZED, DOUBLE-MASKED, MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF TWO TREATMENT REGIMENS OF 0.5MG RANIBIZUMAB INTRAVITREAL INJECTIONS GUIDED BY FUNCTIONAL AND/OR ANATOMICAL CRITERIA, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (OCTAVE).\"","medConditionList":[{"med_condition_id":288,"med_condition":"NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36007,"protocol_no":"2014-1673","submission_no":"174178","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-05-23","protocol_title":"OS-BHEEF - BREATHING MANEUVERS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: AN OXYGENATION-SENSITIVE CMR STUDY.","medConditionList":[{"med_condition_id":421,"med_condition":"HEART FAILURE"},{"med_condition_id":523,"med_condition":"HEART FAILURE WITH PRESERVED EJECTION FRACTION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":35848,"protocol_no":"061-00","submission_no":"173639","status_id":1,"start_date":"2014-10-20","end_date":null,"nol_date":"2014-05-06","protocol_title":"A PHASE III OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMEN OF MK-5172/MK-8742  IN TREATMENT-NA√èVE SUBJECTS WITH CHRONIC HCV GT1, GT4, GT5, AND GT6 INFECTION WHO ARE CO-INFECTED WITH HIV","medConditionList":[{"med_condition_id":117,"med_condition":"HUMAN IMMUNODEFICIENCY VIRUS (HIV)"},{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47192,"protocol_no":"SHP647-302","submission_no":"209527","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-24","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (FIGARO UC 302)","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":29464,"protocol_no":"M11-089","submission_no":"171878","status_id":1,"start_date":"2014-11-24","end_date":null,"nol_date":"2014-03-03","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY COMPARING VELIPARIB PLUS CARBOPLATIN AND PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN AND PACLITAXEL IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40321,"protocol_no":"M15-684","submission_no":"187689","status_id":2,"start_date":"2015-11-17","end_date":"2016-12-20","nol_date":"2015-09-30","protocol_title":"AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN TREATMENT-NA√èVE ADULTS WITH GENOTYPE 1B HEPATITIS C VIRUS (HCV) WITHOUT CIRRHOSIS (GARNET)","medConditionList":[{"med_condition_id":106,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1A OR 1B"},{"med_condition_id":275,"med_condition":"HEPATITIS C VIRUS"},{"med_condition_id":104,"med_condition":"HEPATITIS C VIRUS GENOTYPE 1"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47051,"protocol_no":"I3Y-MC-JPCF","submission_no":"209578","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-03","protocol_title":"MONARCHE: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41926,"protocol_no":"NN1218-3854","submission_no":"193257","status_id":1,"start_date":"2016-07-06","end_date":null,"nol_date":"2016-04-13","protocol_title":"EFFICACY AND SAFETY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION OF FASTER-ACTING INSULIN ASPART COMPARED TO NOVORAPID IN ADULTS WITH TYPE 1 DIABETES","medConditionList":[{"med_condition_id":256,"med_condition":"TYPE 1 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":28215,"protocol_no":"PHL-091 / NCI 9460","submission_no":"167965","status_id":1,"start_date":"2015-08-11","end_date":null,"nol_date":"2013-10-08","protocol_title":"PHASE 2 STUDY OF SEQUENTIAL TRAMETINIB AND GSK2141795 IN RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA","medConditionList":[{"med_condition_id":386,"med_condition":"RELAPSED OR REFRACTORY MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43749,"protocol_no":"LYC-30937-2001","submission_no":"199049","status_id":1,"start_date":"2017-10-11","end_date":null,"nol_date":"2016-10-27","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION THERAPY WITH LYC-30937-EC IN SUBJECTS WITH ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41872,"protocol_no":"ALK8700-A301","submission_no":"193012","status_id":1,"start_date":"2016-12-09","end_date":null,"nol_date":"2016-03-30","protocol_title":"A PHASE 3 OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ALKS 8700 IN ADULTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS","medConditionList":[{"med_condition_id":565,"med_condition":"RELAPSING-REMITTING MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39632,"protocol_no":"CTOT-19","submission_no":"185918","status_id":1,"start_date":"2017-06-30","end_date":null,"nol_date":"2015-07-29","protocol_title":"RANDOMIZED CONTROLLED TRIAL OF INFLIXIMAB INDUCTION THERAPY FOR DECEASED DONOR KIDNEY TRANSPLANT RECIPIENTS","medConditionList":[{"med_condition_id":255,"med_condition":"TRANSPLANTATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45486,"protocol_no":"CA209-039","submission_no":"204560","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-05-05","protocol_title":"MULTIPLE PHASE 1 SAFETY COHORTS OF NIVOLUMAB MONOTHERAPY OR NIVOLUMAB COMBINATION REGIMENS ACROSS RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44347,"protocol_no":"PRPL-007","submission_no":"200955","status_id":1,"start_date":"2017-12-18","end_date":null,"nol_date":"2017-01-17","protocol_title":"D√âSORDRES POST-TRAUMATIQUES CHEZ LES POLICIERS ET LES PR√âPOS√âS DU 9-1-1 : UNE COMPARAISON DE L¬øEFFICACIT√â ET DES CO√õTS ENTRE L¬øINTERVENTION HABITUELLE ET UNE INTERVENTION NOVATRICE","medConditionList":[{"med_condition_id":207,"med_condition":"POST-TRAUMATIC STRESS DISORDER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45574,"protocol_no":"LHRI AN 2017","submission_no":"204833","status_id":1,"start_date":"2017-10-20","end_date":null,"nol_date":"2017-05-18","protocol_title":"A WINDOW OF OPPORTUNITY STUDY TO ASSESS THE MODULATION OF BIOMARKERS IN HEAD AND NECK SQUAMOUS CELL CANCER (HNSCC) BY PREOPERATIVE TREATMENT WITH BYL719","medConditionList":[{"med_condition_id":95,"med_condition":"HEAD AND NECK CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44819,"protocol_no":"CANSTEM43L","submission_no":"202542","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-02-20","protocol_title":"A PHASE III RANDOMIZED, OPEN-LABEL CLINICAL TRIAL OF BBI-608 PLUS WEEKLY PACLITAXEL VERSUS WEEKLY PACLITAXEL ALONE IN PATIENTS WITH ADVANCED, PREVIOUSLY TREATED, NON-SQUAMOUS NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39967,"protocol_no":"AP24534-15-303","submission_no":"186745","status_id":1,"start_date":"2016-11-28","end_date":null,"nol_date":"2015-09-03","protocol_title":"A RANDOMIZED, OPEN-LABEL STUDY OF PONATINIB VERSUS NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE FOLLOWING RESISTANCE TO IMATINIB","medConditionList":[{"med_condition_id":46,"med_condition":"CHRONIC MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43239,"protocol_no":"9785-CL-0123","submission_no":"197568","status_id":1,"start_date":"2016-10-19","end_date":null,"nol_date":"2016-09-08","protocol_title":"A PHASE 2 OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WITH PROSTATE CANCER WHO PREVIOUSLY PARTICIPATED IN AN ENZALUTAMIDE CLINICAL STUDY.","medConditionList":[{"med_condition_id":214,"med_condition":"PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38637,"protocol_no":"GA29145","submission_no":"182705","status_id":1,"start_date":"2015-09-22","end_date":null,"nol_date":"2015-03-27","protocol_title":"AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42764,"protocol_no":"ONFH-ASA2016","submission_no":"196155","status_id":1,"start_date":"2017-07-24","end_date":null,"nol_date":"2016-07-20","protocol_title":"ASPIRIN (ACETYLSALICYLIC ACID) IN THE PREVENTION OF COLLAPSE OF THE FEMORAL HEAD IN NONTRAUMATIC OSTEONECROSIS: A TWO-YEAR MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY","medConditionList":[{"med_condition_id":754,"med_condition":"OSTEONECROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47458,"protocol_no":"2017-1066","submission_no":"210997","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-12","protocol_title":"IMPACT OF INTRAOPERATIVE INTRAVENOUS LIDOCAINE ADMINISTERED DURING LAPAROSCOPIC COLORECTAL SURGERY ON REMIFENTANIL CONSUMPTION, POSTOPERATIVE PAIN AND IMMUNE CELL ACTIVITY: A PILOT STUDY.","medConditionList":[{"med_condition_id":553,"med_condition":"ANASTHESIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42716,"protocol_no":"RTOG-3505","submission_no":"196014","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-07-15","protocol_title":"RANDOMIZED, DOUBLE BLINDED PHASE III TRIAL OF CISPLATIN AND ETOPOSIDE PLUS THORACIC RADIATION THERAPY FOLLOWED BY NIVOLUMAB/PLACEBO FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38002,"protocol_no":"1000045997","submission_no":"180476","status_id":1,"start_date":"2015-03-25","end_date":null,"nol_date":"2015-01-07","protocol_title":"PROPHYLACTIC ANTIBIOTICS OR PLACEBO AFTER HYPOSPADIAS REPAIR","medConditionList":[{"med_condition_id":608,"med_condition":"HYPOSPADIAS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26602,"protocol_no":"TAR-100-202","submission_no":"163224","status_id":2,"start_date":"2013-10-15","end_date":"2015-03-31","nol_date":"2013-04-10","protocol_title":"A PHASE 2A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY EVALUATING SAFETY, TOLERABILITY AND EFFICACY OF LIRIS¬Æ 400 MG IN WOMEN WITH INTERSTITIAL CYSTITIS FOLLOWED BY AN OPEN LABEL EXTENSION","medConditionList":[{"med_condition_id":132,"med_condition":"INTERSTITIAL CYSTITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40121,"protocol_no":"V72_75","submission_no":"187139","status_id":1,"start_date":"2015-11-05","end_date":null,"nol_date":"2015-09-17","protocol_title":"A PHASE 3B, OPEN LABEL, CONTROLLED, MULTI CENTER, EXTENSION STUDY TO ASSESS THE PERSISTENCE OF BACTERICIDAL ACTIVITY AT 4 TO 7.5 YEARS AFTER TWO DOSE PRIMARY SERIES OF NOVARTIS MENINGOCOCCAL B RECOMBINANT VACCINE AND THE RESPONSE TO A THIRD DOSE IN ADOLESCENTS AND YOUNG ADULT SUBJECTS WHO PREVIOUSLY PARTICIPATED IN PARENT STUDIES V72_41 AND V72PI0, COMPARED TO NAIVE HEALTHY CONTROLS","medConditionList":[{"med_condition_id":632,"med_condition":"IMMUNIZATION"},{"med_condition_id":156,"med_condition":"MENINGITIS B"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":44321,"protocol_no":"BIO 16-255","submission_no":"200771","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-01-11","protocol_title":"EFFICACY OF OPIOID-FREE ANESTHESIA IN REDUCING POSTOPERATIVE RESPIRATORY DEPRESSION IN CHILDREN UNDERGOING TONSILLECTOMY: A PILOT STUDY.","medConditionList":[{"med_condition_id":553,"med_condition":"ANASTHESIA"},{"med_condition_id":833,"med_condition":"TONSILLECTOMY"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":27375,"protocol_no":"CAIN457B2203","submission_no":"165583","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-07-05","protocol_title":"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, ADAPTIVE DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AIN457 (SECUKINUMAB) IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS.","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38979,"protocol_no":"14-0188-A","submission_no":"181774","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-05-13","protocol_title":"A RANDOMIZED DOUBLE-BLINDED TRIAL COMPARING DESMOPRESSIN TO FESOTERODINE IN THE TREATMENT OF SEVERE NOCTURIA IN WOMEN AGED 65 AND OLDER:  THE DEFEND TRIAL","medConditionList":[{"med_condition_id":175,"med_condition":"NOCTURIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37511,"protocol_no":"B7451005","submission_no":"178836","status_id":1,"start_date":"2015-01-12","end_date":null,"nol_date":"2014-11-12","protocol_title":"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE PSORIASIS","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37677,"protocol_no":"E-VOLVE","submission_no":"179379","status_id":1,"start_date":"2015-01-07","end_date":null,"nol_date":"2014-11-25","protocol_title":"A PROOF OF CONCEPT CLINICAL TRIAL OF THE COMBINATION CEDIRANIB-OLAPARIB AT THE TIME OF DISEASE PROGRESSION ON OLAPARIB IN OVARIAN CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43260,"protocol_no":"NAT-2016-01","submission_no":"197645","status_id":2,"start_date":"2016-10-18","end_date":"2017-11-23","nol_date":"2016-09-15","protocol_title":"A 150-DAY, PROSPECTIVE, PHASE 4, OPEN-LABEL STUDY, EVALUATING PATIENT SATISFACTION AND SYMPTOM IMPROVEMENT WHEN TREATING MALE HYPOGONADISM WITH TESTOSTERONE NASAL GEL (NATESTO) (MY-T STUDY).","medConditionList":[{"med_condition_id":125,"med_condition":"HYPOGONADAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36686,"protocol_no":"GO27802","submission_no":"176259","status_id":1,"start_date":"2014-12-22","end_date":null,"nol_date":"2014-08-05","protocol_title":"A PHASE 1B OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF GDC-0032 IN COMBINATION WITH EITHER DOCETAXEL OR PACLITAXEL IN PATIENTS WITH HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER OR NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"},{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45052,"protocol_no":"EMR200095-006","submission_no":"203148","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-03-30","protocol_title":"A PHASE IB/II MULTICENTER, RANDOMIZED, OPEN LABEL TRIAL TO COMPARE TEPOTINIB (MSC2156119J) COMBINED WITH GEFITINIB VERSUS CHEMOTHERAPY AS SECOND-LINE TREATMENT IN SUBJECTS WITH MET POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EGFR MUTATION AND HAVING ACQUIRED RESISTANCE TO PRIOR EGFR-TYROSINE KINASE INHIBITOR (EGFR-TKI) THERAPY","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40881,"protocol_no":"B1641001","submission_no":"189583","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-12-16","protocol_title":"A PHASE 1 STUDY OF PF-05082566 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED CANCER, AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"},{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37293,"protocol_no":"M11-665","submission_no":"178193","status_id":2,"start_date":"2015-03-18","end_date":"2017-02-10","nol_date":"2014-10-09","protocol_title":"A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OMBITASVIR/ABT-450/RITONAVIR CO-ADMINISTERED WITH RIBAVIRIN (RBV) IN ADULTS WITH GENOTYPE 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AND CIRRHOSIS.","medConditionList":[{"med_condition_id":577,"med_condition":"HEPATITIS C VIRUS GENOTYPE 4"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42653,"protocol_no":"X396-CLI-301","submission_no":"195727","status_id":1,"start_date":"2017-05-09","end_date":null,"nol_date":"2016-07-04","protocol_title":"PHASE 3 RANDOMIZED STUDY COMPARING X-396 TO CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43053,"protocol_no":"IND.223","submission_no":"196997","status_id":1,"start_date":"2016-12-19","end_date":null,"nol_date":"2016-08-18","protocol_title":"A PHASE II STUDY OF PALBOCICLIB, A CDK4/6 INHIBITOR, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":44707,"protocol_no":"VERSION 1","submission_no":"202140","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-01-27","protocol_title":"AVELUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME","medConditionList":[{"med_condition_id":90,"med_condition":"GLIOBLASTOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":46270,"protocol_no":"M14-702","submission_no":"206967","status_id":1,"start_date":"2017-11-03","end_date":null,"nol_date":"2017-07-24","protocol_title":"A PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ELAGOLIX IN COMBINATION WITH ESTRADIOL/NORETHINDRONE ACETATE IN SUBJECTS WITH MODERATE TO SEVERE ENDOMETRIOSIS-ASSOCIATED PAIN","medConditionList":[{"med_condition_id":74,"med_condition":"ENDOMETRIOSIS"},{"med_condition_id":186,"med_condition":"PAIN"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44320,"protocol_no":"15-007","submission_no":"200770","status_id":1,"start_date":"2017-10-30","end_date":null,"nol_date":"2017-01-12","protocol_title":"A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PREVENTION OF HEPATIC VENO-OCCLUSIVE DISEASE IN ADULT AND PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT","medConditionList":[{"med_condition_id":770,"med_condition":"HEPATIC VENO-OCCLUSIVE DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39802,"protocol_no":"20110265","submission_no":"186314","status_id":1,"start_date":"2017-08-14","end_date":null,"nol_date":"2015-08-24","protocol_title":"\"A PHASE IB/3, MULTICENTER, OPEN-LABEL TRIAL OF TALIMOGENE LAHERPAREPVEC IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) FOR TREATMENT OF UNRESECTED, STAGE IIIB TO IVM1C MELANOMA (MASTERKEY-265).\"","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27419,"protocol_no":"XL184-308","submission_no":"165681","status_id":1,"start_date":"2014-07-29","end_date":null,"nol_date":"2013-07-09","protocol_title":"A PHASE 3, RANDOMIZED, CONTROLLED STUDY OF CABOZANTINIB (XL184) VS EVEROLIMUS IN SUBJECTS WITH METASTATIC RENAL CELL CARCINOMA THAT HAS PROGRESSED AFTER PRIOR VEGFR TYROSINE KINASE INHIBITOR THERAPY","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48295,"protocol_no":"CA209-9TM","submission_no":"213525","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-09","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF NIVOLUMAB OR NIVOLUMAB PLUS CISPLATIN, IN COMBINATION WITH RADIOTHERAPY IN PARTICIPANTS WITH CISPLATIN INELIGIBLE AND CISPLATIN ELIGIBLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)","medConditionList":[{"med_condition_id":724,"med_condition":"SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36026,"protocol_no":"17020","submission_no":"174236","status_id":1,"start_date":"2015-07-10","end_date":null,"nol_date":"2014-05-27","protocol_title":"MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EARLY SIGNS OF EFFICACY OF TID ORALLY ADMINISTERED BAY63-2521 IN ADULT  F508 HOMOZYGOUS CYSTIC FIBROSIS PATIENTS","medConditionList":[{"med_condition_id":61,"med_condition":"CYSTIC FIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47590,"protocol_no":"698","submission_no":"211313","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-14","protocol_title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY OF PEMBROLIZUMAB + EPACADOSTAT VS PEMBROLIZUMAB + PLACEBO AS A TREATMENT FOR RECURRENT OR PROGRESSIVE METASTATIC UROTHELIAL CARCINOMA IN PATIENTS WHO HAVE FAILED A FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN FOR ADVANCED/METASTATIC DISEASE (KEYNOTE-698/ECHO-303)","medConditionList":[{"med_condition_id":393,"med_condition":"UROTHELIAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28881,"protocol_no":"NP28903","submission_no":"170159","status_id":1,"start_date":"2014-10-14","end_date":null,"nol_date":"2013-12-20","protocol_title":"A MULTI-CENTER, OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML)","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27918,"protocol_no":"GS-US-339-0103","submission_no":"167066","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-08-30","protocol_title":"A PHASE 2, OPEN-LABEL STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF GS-9973 IN COMBINATION WITH IDELALISIB IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":38494,"protocol_no":"201187","submission_no":"182223","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-03-18","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF PAZOPANIB VERSUS PLACEBO AS MAINTENANCE THERAPY FOR PATIENTS WHO HAVE NOT PROGRESSED AFTER FIRST-LINE CHEMOTHERAPY FOR ADVANCED SOFT TISSUE SARCOMA (STS)","medConditionList":[{"med_condition_id":237,"med_condition":"SOFT TISSUE SARCOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39495,"protocol_no":"R668-AD-1434","submission_no":"185537","status_id":1,"start_date":"2018-01-05","end_date":null,"nol_date":"2015-07-24","protocol_title":"AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >6 TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS.","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28415,"protocol_no":"GO28609","submission_no":"168490","status_id":2,"start_date":"2014-07-10","end_date":"2017-01-25","nol_date":"2013-10-25","protocol_title":"A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DNIB0600A COMPARED TO PEGYLATE LIPOSOMAL DOXORUBICIN ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38221,"protocol_no":"1160.204","submission_no":"181314","status_id":2,"start_date":"2015-04-28","end_date":"2017-04-12","nol_date":"2015-02-13","protocol_title":"RANDOMISED EVALUATION OF DABIGATRAN ETEXILATE COMPARED TO WARFARIN IN PULMONARY VEIN ABLATION: ASSESSMENT OF AN UNINTERRUPTED PERIPROCEDURAL ANTICOAGULATION STRATEGY (THE RE-CIRCUIT TRIAL)","medConditionList":[{"med_condition_id":433,"med_condition":"ATRIAL FIBRILLATION"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46250,"protocol_no":"585-00","submission_no":"206882","status_id":1,"start_date":"2017-10-27","end_date":null,"nol_date":"2017-07-21","protocol_title":"A PHASE III, RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) PLUS CHEMOTHERAPY (XP OR FP) VERSUS PLACEBO PLUS CHEMOTHERAPY (XP OR FP) AS NEOADJUVANT/ADJUVANT TREATMENT FOR SUBJECTS WITH GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA (KEYNOTE-585)","medConditionList":[{"med_condition_id":619,"med_condition":"GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27210,"protocol_no":"CBKM120D2204","submission_no":"165125","status_id":1,"start_date":"2014-05-07","end_date":null,"nol_date":"2013-06-27","protocol_title":"A DOSE-FINDING PHASE IB STUDY FOLLOWED BY A RANDOMIZED, DOUBLE-BLIND PHASE II STUDY OF CARBOPLATIN AND PACLITAXEL WITH OR WITHOUT BUPARLISIB IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HISTOLOGY","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27047,"protocol_no":"ARRAY-162-311","submission_no":"164596","status_id":1,"start_date":"2014-02-03","end_date":null,"nol_date":"2013-05-30","protocol_title":"THE MILO STUDY (MEK INHIBITOR IN LOW-GRADE SEROUS OVARIAN CANCER): A MULTINATIONAL, RANDOMIZED, OPEN-LABEL PHASE 3 STUDY OF MEK162 VS. PHYSICIAN'S CHOICE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PERSISTENT LOW-GRADE SEROUS CARCINOMAS OF THE OVARY, FALLOPIAN TUBE OR PRIMARY PERITONEUM","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40392,"protocol_no":"MEDI4736-MM-001","submission_no":"187923","status_id":1,"start_date":"2016-02-25","end_date":null,"nol_date":"2015-10-23","protocol_title":"\"A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOW DOSE-DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM),\"","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26869,"protocol_no":"TP0503","submission_no":"164083","status_id":2,"start_date":"2013-09-30","end_date":"2016-05-17","nol_date":"2013-05-14","protocol_title":"A RANDOMISED ACTIVE-CONTROLLED DOUBLE-BLIND AND OPEN LABEL EXTENSION STUDY TO EVALUATE THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF TP05 3.2 G/DAY FOR THE TREATMENT OF ACTIVE ULCERATIVE COLITIS (UC)","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45002,"protocol_no":"GS-US-320-4018","submission_no":"203032","status_id":1,"start_date":"2017-04-10","end_date":null,"nol_date":"2017-03-15","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) 300 MG QD TO TENOFOVIR ALAFENAMIDE (TAF) 25MG QD IN SUBJECTS WITH CHRONIC HEPATITIS B WHO ARE VIROLOGICALLY SUPPRESSED","medConditionList":[{"med_condition_id":345,"med_condition":"CHRONIC HEPATITIS B"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45330,"protocol_no":"301OTC01","submission_no":"204130","status_id":1,"start_date":"2017-07-14","end_date":null,"nol_date":"2017-04-25","protocol_title":"A PHASE 1/2, OPEN-LABEL SAFETY AND DOSE-FINDING STUDY OF ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 (AAV8)-MEDIATED GENE TRANSFER OF HUMAN ORNITHINE TRANSCARBAMYLASE (OTC) IN ADULTS WITH LATE-ONSET OTC DEFICIENCY","medConditionList":[{"med_condition_id":785,"med_condition":"ORNITHINE TRANSCARBAMYLASE DEFICIENCY"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":40745,"protocol_no":"CHS-1420-02","submission_no":"188991","status_id":1,"start_date":"2015-12-15","end_date":null,"nol_date":"2015-12-11","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP, ACTIVE-CONTROL STUDY TO COMPARE THE EFFICACY AND SAFETY OF CHS-1420 VERSUS HUMIRA IN SUBJECTS WITH CHRONIC PLAQUE PSORIASIS (PSOSIM),","medConditionList":[{"med_condition_id":196,"med_condition":"PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41973,"protocol_no":"C31005","submission_no":"193442","status_id":1,"start_date":"2016-10-28","end_date":null,"nol_date":"2016-04-13","protocol_title":"A PHASE 2, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SINGLE-AGENT MLN0128 AND THE COMBINATION OF MLN0128+MLN1117 COMPARED WITH EVEROLIMUS IN THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC CLEAR-CELL RENAL CELL CARCINOMA THAT HAS PROGRESSED ON VASCULAR ENDOTHELIAL GROWTH FACTOR-TARGETED THERAPY","medConditionList":[{"med_condition_id":219,"med_condition":"RENAL CELL CARCINOMA METASTATIC"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38088,"protocol_no":"CLDK378A2205","submission_no":"180822","status_id":1,"start_date":"2017-08-09","end_date":null,"nol_date":"2015-01-09","protocol_title":"A PHASE II, MULTI-CENTER, OPEN-LABEL, FIVE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL CERITINIB TREATMENT FOR PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER METASTATIC TO THE BRAIN AND/OR TO LEPTOMENINGES.","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39579,"protocol_no":"17992","submission_no":"185756","status_id":1,"start_date":"2016-02-10","end_date":null,"nol_date":"2015-07-17","protocol_title":"SINGLE-DOSE STUDY TESTING A RIVAROXABAN DRY POWDER FORMULATION FOR ORAL SUSPENSION IN CHILDREN FROM 6 MONTHS TO 12 YEARS WITH PREVIOUS THROMBOSIS.","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":26675,"protocol_no":"NCT00991029","submission_no":"163468","status_id":1,"start_date":"2013-08-02","end_date":null,"nol_date":"2013-04-10","protocol_title":"PLATELET-ORIENTED INHIBITION IN NEW TIA AND MINOR ISCHEMIC STROKE (POINT) TRIAL, A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER CLINICAL TRIAL","medConditionList":[{"med_condition_id":134,"med_condition":"ISCHEMIC ATTACK AND MINOR STROKE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41483,"protocol_no":"5026","submission_no":"191627","status_id":1,"start_date":"2016-09-08","end_date":null,"nol_date":"2016-01-29","protocol_title":"FEASIBILITY AND SAFETY OF IMMUNOGLOBULIN (IG) TREATMENT IN COPD PATIENTS WITH  FREQUENT EXACERBATIONS: A PILOT STUDY 2B","medConditionList":[{"med_condition_id":47,"med_condition":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47630,"protocol_no":"C34008","submission_no":"211415","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-15","protocol_title":"A PHASE 1B STUDY OF TAK-659 IN COMBINATION WITH VENETOCLAX FOR ADULT PATIENTS WITH PREVIOUSLY TREATED NON-HODGKIN LYMPHOMA.","medConditionList":[{"med_condition_id":177,"med_condition":"NON-HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40545,"protocol_no":"BAY59-7939/390390 (SEE NOTES)","submission_no":"188439","status_id":1,"start_date":"2016-01-26","end_date":null,"nol_date":"2015-11-09","protocol_title":"EFFICACY AND SAFETY OF RIVAROXABAN PROPHYLAXIS COMPARED WITH PLACEBO IN AMBULATORY CANCER PATIENTS INITIATING SYSTEMIC CANCER THERAPY AND AT HIGH RISK FOR VENOUS THROMBOEMBOLISM","medConditionList":[{"med_condition_id":338,"med_condition":"VENOUS THROMBOEMBOLISM"},{"med_condition_id":662,"med_condition":"ARTICULAR CARTILAGE INJURY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":27879,"protocol_no":"20120249","submission_no":"166947","status_id":1,"start_date":"2014-03-19","end_date":null,"nol_date":"2013-08-29","protocol_title":"\"A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER PHASE 2 TRIAL OF DENOSUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER.\"","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42880,"protocol_no":"AQX-1125-301","submission_no":"196524","status_id":1,"start_date":"2016-12-23","end_date":null,"nol_date":"2016-07-29","protocol_title":"THE LEADERSHIP 301 TRIAL: A 12-WEEK, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL-GROUP, PHASE 3 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 2 DOSES OF AQX-1125 TARGETING THE SHIP1 PATHWAY IN SUBJECTS WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME FOLLOWED BY 14 OR 40-WEEK EXTENSION PERIODS","medConditionList":[{"med_condition_id":132,"med_condition":"INTERSTITIAL CYSTITIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":36547,"protocol_no":"D081DC00008","submission_no":"175751","status_id":1,"start_date":"2016-02-19","end_date":null,"nol_date":"2014-07-23","protocol_title":"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE II STUDY TO COMPARE THE EFFICACY, SAFETY AND TOLERABILITY OF OLAPARIB VERSUS PLACEBO WHEN GIVEN IN ADDITION TO ABIRATERONE TREATMENT IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL","medConditionList":[{"med_condition_id":343,"med_condition":"CASTRATION RESISTANT PROSTATE CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37842,"protocol_no":"D0816C00010","submission_no":"179853","status_id":1,"start_date":"2016-11-11","end_date":null,"nol_date":"2014-12-22","protocol_title":"A PHASE III, OPEN LABEL, RANDOMISED, CONTROLLED, MULTI-CENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF OLAPARIB MONOTHERAPY VERSUS PHYSICIAN'S CHOICE SINGLE AGENT CHEMOTHERAPY IN THE TREATMENT OF PLATINUM SENSITIVE RELAPSED OVARIAN CANCER IN PATIENTS CARRYING GERMLINE BRCA1/2 MUTATIONS","medConditionList":[{"med_condition_id":183,"med_condition":"OVARIAN CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29075,"protocol_no":"TR007","submission_no":"170806","status_id":3,"start_date":"2014-01-17","end_date":null,"nol_date":"2014-01-15","protocol_title":"A MULTI-CENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF RAGWEED-SPIRE IN SUBJETS WITH ASTHMA AND RAGWEED-INDUCED RHINOCONJUNCTIVITIS","medConditionList":[{"med_condition_id":11,"med_condition":"ALLERGIES ENVIRONMENTAL"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46220,"protocol_no":"IMCGP100-102","submission_no":"206776","status_id":1,"start_date":"2017-09-20","end_date":null,"nol_date":"2017-07-14","protocol_title":"A PHASE I, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 USING THE INTRA-PATIENT ESCALATION DOSING REGIMEN PATIENTS WITH ADVANCED UVEAL MELANOMA","medConditionList":[{"med_condition_id":489,"med_condition":"UVEAL MELANOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":43758,"protocol_no":"0403","submission_no":"199074","status_id":1,"start_date":"2017-05-12","end_date":null,"nol_date":"2016-11-09","protocol_title":"A RANDOMIZED, OPEN LABEL PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MIRVETUXIMAB SORAVTANSINE (IMGN853) VERSUS INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN WOMEN WITH FOLATE RECEPTOR A-POSITIVE ADVANCED EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CANCER OR FALLOPIAN TUBE CANCER","medConditionList":[{"med_condition_id":692,"med_condition":"PRIMARY PERITONEAL CANCER"},{"med_condition_id":680,"med_condition":"EPITHELIAL OVARIAN CANCER"},{"med_condition_id":81,"med_condition":"FALLOPIAN TUBE CANCER"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29007,"protocol_no":"1672013","submission_no":"170563","status_id":3,"start_date":"2014-01-20","end_date":null,"nol_date":"2014-01-07","protocol_title":"VALUATION OF THE EFFICACY OF INTRADERMAL ONABOTULINUMTOXINA FOR THE TREATMENT OF ACCORDION WRINKLES: A 2-CENTRE RANDOMIZED DOUBLE-BLINDED SPLIT-FACE CLINICAL TRIAL","medConditionList":[{"med_condition_id":406,"med_condition":"ACCORDION WRINKLES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":37473,"protocol_no":"ADVL1315","submission_no":"178731","status_id":3,"start_date":null,"end_date":null,"nol_date":"2014-11-06","protocol_title":"A PHASE 1 STUDY OF THE VEGF RECEPTOR TYROSINE KINASE INHIBITOR AXITINIB (INLYTA, IND# 123101) IN CHILDREN WITH RECURRENT OR REFRACTORY SOLID TUMORS","medConditionList":[{"med_condition_id":507,"med_condition":"RELAPSED OR REFRACTORY SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":36979,"protocol_no":"20140368","submission_no":"177131","status_id":1,"start_date":"2015-11-12","end_date":null,"nol_date":"2014-09-10","protocol_title":"MESENCHYMAL STEM CELL THERAPY FOR CANADIAN MS PATIENTS - MESCAMS","medConditionList":[{"med_condition_id":161,"med_condition":"MULTIPLE SCLEROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35365,"protocol_no":"GS-US-352-1214","submission_no":"172107","status_id":1,"start_date":"2014-09-15","end_date":null,"nol_date":"2014-03-10","protocol_title":"A PHASE 3, RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN ANEMIC OR THROMBOCYTOPENIC SUBJECTS WITH PRIMARY MYELOFIBROSIS, POST POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS WHO WERE TREATED WITH RUXOLITINIB","medConditionList":[{"med_condition_id":353,"med_condition":"MYELOFIBROSIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28870,"protocol_no":"JAK115919","submission_no":"170143","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-12-12","protocol_title":"AN ADAPTIVE PHASE II STUDY TO EVALUATE THE EFFICACY, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF GSK2586184 IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS.","medConditionList":[{"med_condition_id":473,"med_condition":"LUPUS ERYTHEMATOSUS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48204,"protocol_no":"SRF231-101","submission_no":"213284","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-01","protocol_title":"A PHASE 1 STUDY OF SRF231 IN PATIENTS WITH ADVANCED SOLID AND HEMATOLOGIC CANCERS","medConditionList":[{"med_condition_id":292,"med_condition":"HEMATOLOGICAL MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42986,"protocol_no":"1230.37","submission_no":"196815","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-08-16","protocol_title":"A PHASE I STUDY OF VOLASERTIB COMBINED WITH STANDARD INDUCTION CHEMOTHERAPY FOR PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA (VIAC)","medConditionList":[{"med_condition_id":6,"med_condition":"ACUTE MYELOGENOUS LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48387,"protocol_no":"3119002","submission_no":"213787","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-14","protocol_title":"EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS","medConditionList":[{"med_condition_id":15,"med_condition":"AMYOTROPHIC LATERAL SCLEROSIS (ALS)"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40761,"protocol_no":"15-9426","submission_no":"189050","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-20","protocol_title":"A RANDOMIZED CONTROLLED TRIAL OF THE ANALGESIC EFFECT OF DEXMEDETOMIDINE AS AN ADJUNCT TO LOCAL INFILTRATION ANALGESIA IN TOTAL KNEE ARTHROPLASTY","medConditionList":[{"med_condition_id":466,"med_condition":"KNEE ARTHROPLASTY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":48206,"protocol_no":"027","submission_no":"213287","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-02-26","protocol_title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-7264 IN ADULT PARTICIPANTS WITH CHRONIC COUGH","medConditionList":[{"med_condition_id":42,"med_condition":"CHRONIC COUGH"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28626,"protocol_no":"CIC-AIC-02","submission_no":"169225","status_id":3,"start_date":"2013-01-22","end_date":null,"nol_date":"2013-11-22","protocol_title":"SEGMENTAL ALLERGEN CHALLENGE","medConditionList":[{"med_condition_id":13,"med_condition":"ALLERGIES RESPITATORY"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41927,"protocol_no":"107433","submission_no":"193261","status_id":3,"start_date":null,"end_date":null,"nol_date":"2016-04-12","protocol_title":"KINEMATIC BIOMECHANICAL CHARACTERIZATION OF UPPER LIMB PARKINSON'S DISEASE TREMOR FOR OPTIMIZATION OF BOTULINUM TOXIN TYPE A INJECTION PARAMETERS","medConditionList":[{"med_condition_id":191,"med_condition":"PARKINSON'S DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":42536,"protocol_no":"UX023-CL301","submission_no":"195283","status_id":1,"start_date":"2016-12-05","end_date":null,"nol_date":"2016-06-17","protocol_title":"A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF KRN23 VERSUS ORAL PHOSPHATE AND ACTIVE VITAMIN D TREATMENT IN PEDIATRIC PATIENTS WITH X LINKED HYPOPHOSPHATEMIA (XLH)","medConditionList":[{"med_condition_id":643,"med_condition":"X-LINKED HYPOPHOSPHATEMIA"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":42055,"protocol_no":"20130287","submission_no":"193769","status_id":2,"start_date":"2016-06-02","end_date":"2017-11-29","nol_date":"2016-04-29","protocol_title":"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF EVOLOCUMAB (AMG 145) ON LDL-C IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA/MIXED DYSLIPIDEMIA","medConditionList":[{"med_condition_id":296,"med_condition":"MIXED DYSLIPIDEMIA"},{"med_condition_id":122,"med_condition":"HYPERCHOLESTEROLEMIA"},{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44233,"protocol_no":"NN1250-4252","submission_no":"199333","status_id":1,"start_date":"2017-03-13","end_date":null,"nol_date":"2016-12-22","protocol_title":"A TRIAL COMPARING THE EFFICACY AND SAFETY OF INSULIN DEGLUDEC AND INSULIN GLARGINE 300 UNITS/ML IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY TREATED WITH BASAL INSULIN WITH OR WITHOUT ORAL ANTIDIABETIC DRUGS","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42838,"protocol_no":"PB-102-F20","submission_no":"196365","status_id":1,"start_date":"2016-12-29","end_date":null,"nol_date":"2016-07-29","protocol_title":"A RANDOMIZED, DOUBLE BLIND, ACTIVE CONTROL STUDY OF THE SAFETY AND EFFICACY OF PRX-102 COMPARED TO AGALSIDASE BETA ON RENAL FUNCTION IN PATIENTS WITH FABRY DISEASE PREVIOUSLY TREATED WITH AGALSIDASE BETA","medConditionList":[{"med_condition_id":79,"med_condition":"FABRY DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46052,"protocol_no":"C3291001","submission_no":"206214","status_id":1,"start_date":"2017-07-26","end_date":null,"nol_date":"2017-06-26","protocol_title":"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY, TO CHARACTERIZE THE MECHANISM OF ACTION OF CRISABOROLE OINTMENT 2%, BY EVALUATION OF EFFICACY AND CHANGES IN SKIN BIOMARKERS, IN ADULT SUBJECTS WITH MILD TO MODERATE ATOPIC DERMATITIS, WITH A 4 WEEK OPEN-LABEL EXTENSION.","medConditionList":[{"med_condition_id":279,"med_condition":"ATOPIC DERMATITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":42241,"protocol_no":"GFT505-315-1","submission_no":"194387","status_id":1,"start_date":"2017-03-29","end_date":null,"nol_date":"2016-05-19","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELAFIBRANOR IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS","medConditionList":[{"med_condition_id":734,"med_condition":"NONALCOHOLIC STEATOHEPATITIS (NASH)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41929,"protocol_no":"1002-040","submission_no":"193260","status_id":2,"start_date":"2016-12-15","end_date":"2018-02-13","nol_date":"2016-04-06","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER LONG-TERM SAFETY AND TOLERABILITY STUDY OF ETC-1002 IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY CONTROLLED BY THEIR LIPID-MODIFYING THERAPY","medConditionList":[{"med_condition_id":348,"med_condition":"HYPERLIPIDEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41651,"protocol_no":"QRK209","submission_no":"192238","status_id":2,"start_date":"2016-07-04","end_date":"2018-02-09","nol_date":"2016-03-10","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QPI-1002 FOR THE PREVENTION OF ACUTE KIDNEY INJURY IN SUBJECTS AT HIGH RISK FOR AKI FOLLOWING CARDIAC SURGERY","medConditionList":[{"med_condition_id":294,"med_condition":"CARDIAC SURGERY"},{"med_condition_id":137,"med_condition":"KIDNEY DISEASE"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40489,"protocol_no":"UC.FMT.2","submission_no":"188300","status_id":3,"start_date":null,"end_date":null,"nol_date":"2015-11-05","protocol_title":"RANDOMIZED TRIAL OF ANTIMICROBIALS VERSUS PLACEBO IN ADDITION TO FECAL MICROBIOTA TRANSPLANTATION FOR THE INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS","medConditionList":[{"med_condition_id":258,"med_condition":"ULCERATIVE COLITIS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":47269,"protocol_no":"CNIS793X2101","submission_no":"210392","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-11-17","protocol_title":"A PHASE I/IB, OPEN-LABEL, MULTI-CENTER DOSE ESCALATION STUDY OF NIS793 IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES","medConditionList":[{"med_condition_id":665,"med_condition":"ADVANCED MALIGNANCIES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37037,"protocol_no":"200200","submission_no":"177314","status_id":2,"start_date":"2017-06-09","end_date":"2018-01-01","nol_date":"2014-09-11","protocol_title":"A PHASE I OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF GSK2879552 GIVEN ORALLY IN SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA.","medConditionList":[{"med_condition_id":165,"med_condition":"MYELOID LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39885,"protocol_no":"D1690C00023","submission_no":"186537","status_id":1,"start_date":"2015-09-18","end_date":null,"nol_date":"2015-08-26","protocol_title":"AN EXPLORATORY PHASE II/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL DESIGN STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF DAPAGLIFLOZIN AND DAPAGLIFLOZIN IN COMBINATION WITH SAXAGLIPTIN IN CKD3 PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ALBUMINURIA TREATED WITH ACEI OR ARB.","medConditionList":[{"med_condition_id":63,"med_condition":"DIABETES MELLITUS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":48129,"protocol_no":"M14-064","submission_no":"212304","status_id":3,"start_date":null,"end_date":null,"nol_date":"2018-03-01","protocol_title":"PHASE 2 STUDY COMPARING EFFICACY AND SAFETY OF ABT-165 PLUS FOLFIRI VS BEVACIZUMAB PLUS FOLFIRI IN METASTATIC COLORECTAL CANCER PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE/OXALIPLATIN AND BEVACIZUMAB","medConditionList":[{"med_condition_id":400,"med_condition":"METASTATIC COLORECTAL CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":37170,"protocol_no":"NCIC CTG: BR.31","submission_no":"177762","status_id":1,"start_date":"2015-05-07","end_date":null,"nol_date":"2014-10-08","protocol_title":"A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":27503,"protocol_no":"14570A","submission_no":"165941","status_id":2,"start_date":"2014-07-17","end_date":"2016-04-22","nol_date":"2013-07-19","protocol_title":"INTERVENTIONAL, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, FLEXIBLE-DOSE LONG-TERM STUDY TO EVALUATE THE MAINTENANCE OF EFFICACY AND SAFETY OF 1 TO 3 MG/DAY OF BREXPIPRAZOLE AS ADJUNCTIVE TREATMENT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER WITH AN INADEQUATE RESPONSE TO ANTIDEPRESSANT TREATMENT","medConditionList":[{"med_condition_id":152,"med_condition":"MAJOR DEPRESSIVE DISORDER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":38668,"protocol_no":"D3250C00029","submission_no":"182786","status_id":1,"start_date":"2015-06-25","end_date":null,"nol_date":"2015-04-02","protocol_title":"A MULTICENTER, OPEN-LABEL, FUNCTIONALITY, RELIABILITY AND PERFORMANCE STUDY OF AN ACCESSORIZED PRE-FILLED SYRINGE WITH HOME-ADMINISTERED SUBCUTANEOUS BENRALIZUMAB IN ADULT PATIENTS WITH SEVERE ASTHMA (GREGALE)","medConditionList":[{"med_condition_id":19,"med_condition":"ASTHMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":26837,"protocol_no":"CAIN457 A2312","submission_no":"163987","status_id":1,"start_date":"2015-04-01","end_date":null,"nol_date":"2013-05-09","protocol_title":"\"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO DEMONSTRATE THE EFFICACY AT 16 WEEKS OF SECUKINUMAB 150 AND 300 MG SC AND TO ASSESS SAFETY, TOLERABILITY AND LONG-TERM EFFICACY UP TO 80 WEEKS IN SUBJECTS WITH MODERATE TO SEVERE PALMOPLATER PSORIASIS.\"","medConditionList":[{"med_condition_id":297,"med_condition":"PALMOPLATER PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47721,"protocol_no":"201410","submission_no":"211663","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-12-14","protocol_title":"A 52-WEEK OPEN LABEL (SPONSOR-BLIND), RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPRODUSTAT COMPARED TO RECOMBINANT HUMAN ERYTHROPOIETIN IN SUBJECTS WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE WHO ARE INITIATING DIALYSIS","medConditionList":[{"med_condition_id":329,"med_condition":"ANEMIA"},{"med_condition_id":456,"med_condition":"CHRONIC KIDNEY DISEASE (CKD)"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36549,"protocol_no":"1199.128","submission_no":"175762","status_id":1,"start_date":"2015-05-29","end_date":null,"nol_date":"2014-07-14","protocol_title":"MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE III TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORAL NINTEDANIB PLUS DOCETAXEL THERAPY COMPARED TO PLACEBO PLUS DOCETAXEL THERAPY IN PATIENTS WITH STAGE IIIB/IV OR RECURRENT, ADENOCARCINOMA SUBTYPE NON-SMALL CELL LUNG CANCER AFTER FAILURE OF FIRST LINE CHEMOTHERAPY","medConditionList":[{"med_condition_id":179,"med_condition":"NON-SMALL CELL LUNG CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36829,"protocol_no":"NIH R01","submission_no":"176686","status_id":1,"start_date":"2014-10-22","end_date":null,"nol_date":"2014-08-21","protocol_title":"IMMUNE RESPONSE TO HIGH-DOSE VS. STANDARD DOSE INFLUENZA VACCINE","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":35788,"protocol_no":"MB130002","submission_no":"173431","status_id":1,"start_date":"2015-12-21","end_date":null,"nol_date":"2014-04-25","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMIC EFFECTS OF BMS-986036 IN OBESE ADULTS WITH TYPE-2 DIABETES","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":28589,"protocol_no":"CR6261CR8020FLZ2001","submission_no":"169073","status_id":3,"start_date":null,"end_date":null,"nol_date":"2013-11-13","protocol_title":"MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF CR8020 AND CR6261 IN HOSPITALIZED PATIENTS WITH INFLUENZA A INFECTION","medConditionList":[{"med_condition_id":131,"med_condition":"INFLUENZA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29457,"protocol_no":"SP304203-01","submission_no":"171865","status_id":1,"start_date":"2014-09-29","end_date":null,"nol_date":"2014-03-07","protocol_title":"AN OPEN-LABEL EXTENSION (OLE), LONG-TERM SAFETY AND TOLERABILITY STUDY OF PLECANATIDE IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION (CIC)","medConditionList":[{"med_condition_id":322,"med_condition":"IDIOPATHIC CONSTIPATION"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":39205,"protocol_no":"I3Y-MC-JPBY","submission_no":"184467","status_id":1,"start_date":"2016-05-03","end_date":null,"nol_date":"2015-05-29","protocol_title":"NEOMONARCH:  A PHASE 2 NEOADJUVANT TRIAL COMPARING THE BIOLOGICAL EFFECTS OF 2 WEEKS OF ABEMACICLIB (LY2835219) IN COMBINATION WITH ANASTROZOLE TO THOSE OF ABEMACICLIB MONOTHERAPY AND ANASTROZOLE MONOTHERAPY AND EVALUATING THE CLINICAL ACTIVITY AND SAFETY OF A SUBSEQUENT 14 WEEKS OF THERAPY WITH ABEMACICLIB IN COMBINATION WITH ANASTROZOLE IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER","medConditionList":[{"med_condition_id":527,"med_condition":"BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45917,"protocol_no":"HMR-MM-003","submission_no":"205827","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-08","protocol_title":"A PHASE II, OPEN-LABEL STUDY OF LENALIDOMIDE AND DEXAMETHASONE FOLLOWED BY DONOR LYMPHOCYTE INFUSIONS IN RELAPSED MULTIPLE MYELOMA FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT","medConditionList":[{"med_condition_id":167,"med_condition":"MULTIPLE MYELOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":29458,"protocol_no":"28431754DIA4004","submission_no":"171867","status_id":2,"start_date":"2014-04-24","end_date":"2015-11-19","nol_date":"2014-02-26","protocol_title":"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM, PARALLEL-GROUP, 26-WEEK, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CANAGLIFLOZIN IN THE TREATMENT OF SUBJECTS WITH TYPE 2 DIABETES MELLITUS WITH INADEQUATE GLYCEMIC CONTROL ON METFORMIN AND SITAGLIPTIN THERAPY","medConditionList":[{"med_condition_id":257,"med_condition":"TYPE 2 DIABETES"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40156,"protocol_no":"14372","submission_no":"187240","status_id":1,"start_date":"2017-05-11","end_date":null,"nol_date":"2015-10-02","protocol_title":"MULTICENTER, OPEN-LABEL, ACTIVE-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN AGE-AND BODY WEIGHT-ADJUSTED RIVAROXABAN REGIMEN COMPARED TO STANDARD OF CARE IN CHILDREN WITH ACUTE VENOUS THROMBOEMBOLISM - EINSTEIN JUNIOR PHASE III: ORAL RIVAROXABAN IN CHILDREN WITH VENOUS THROMBOSIS","medConditionList":[{"med_condition_id":529,"med_condition":"ACUTE VENOUS THROMBOEMBOLISM"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40158,"protocol_no":"CA009-002","submission_no":"187264","status_id":1,"start_date":"2017-05-01","end_date":null,"nol_date":"2015-09-25","protocol_title":"A PHASE 1/2A DOSE ESCALATION AND COHORT EXPANSION STUDY FOR SAFETY, TOLERABILITY, AND EFFICACY OF BMS-986156 ADMINISTERED ALONE AND IN COMBINATION WITH NIVOLUMAB (BMS-936558, ANTI PD-1 MONOCLONAL ANTIBODY) IN ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":36235,"protocol_no":"TED13751","submission_no":"174844","status_id":1,"start_date":"2014-07-15","end_date":null,"nol_date":"2014-06-18","protocol_title":"A FIRST-IN-HUMAN STUDY FOR THE EVALUATION OF THE SAFETY, PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF SAR408701 IN PATIENTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":278,"med_condition":"SOLID TUMOR"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45576,"protocol_no":"CLCI699C2302","submission_no":"204846","status_id":1,"start_date":"2017-10-11","end_date":null,"nol_date":"2017-05-02","protocol_title":"A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, 48 WEEK STUDY WITH AN INITIAL 12 WEEK PLACEBO-CONTROLLED PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF OSILODROSTAT IN PATIENTS WITH CUSHING¬øS DISEASE","medConditionList":[{"med_condition_id":58,"med_condition":"CUSHING'S DISEASE"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":43388,"protocol_no":"PS0010","submission_no":"197959","status_id":1,"start_date":"2016-10-06","end_date":null,"nol_date":"2016-09-27","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BINEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: PHASE 2B","medConditionList":[{"med_condition_id":689,"med_condition":"CHRONIC PLAQUE PSORIASIS"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":45068,"protocol_no":"ALXN1210-AHUS-312","submission_no":"203219","status_id":1,"start_date":"2018-01-19","end_date":null,"nol_date":"2017-03-21","protocol_title":"A PHASE 3, OPEN-LABEL MULTICENTER STUDY OF ALXN1210 IN CHILDREN AND ADOLESCENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)","medConditionList":[{"med_condition_id":21,"med_condition":"ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":41556,"protocol_no":"CER-001-CLIN-009","submission_no":"191855","status_id":1,"start_date":"2017-02-28","end_date":null,"nol_date":"2016-03-30","protocol_title":"PHASE III, MULTI-CENTER, RANDOMIZED, 48 WEEKS, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF CER-001 ON VESSEL WALL AREA IN PATIENTS WITH GENETICALLY DEFINED FAMILIAL PRIMARY HYPOALPHALIPOPROTEINEMIA RECEIVING BACKGROUND OPTIMIZED LIPID THERAPY","medConditionList":[{"med_condition_id":675,"med_condition":"FAMILIAL PRIMARY HYPOALPHALIPOPROTEINEMIA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":40677,"protocol_no":"KCP-330-020","submission_no":"188796","status_id":1,"start_date":"2017-11-16","end_date":null,"nol_date":"2015-11-20","protocol_title":"A PHASE 2-3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)","medConditionList":[{"med_condition_id":600,"med_condition":"LIPOSARCOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":3,"study_population":"PEDIATRIC"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":47299,"protocol_no":"002-00","submission_no":"210467","status_id":1,"start_date":"2018-01-10","end_date":null,"nol_date":"2017-11-24","protocol_title":"PHASE 1B OPEN-LABEL STUDY OF MK-7162 IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) +/- OTHER THERAPIES IN PARTICIPANTS WITH ADVANCED SOLID TUMORS","medConditionList":[{"med_condition_id":571,"med_condition":"ADVANCED SOLID TUMORS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45705,"protocol_no":"CTO 0807","submission_no":"205245","status_id":1,"start_date":"2017-11-06","end_date":null,"nol_date":"2017-06-21","protocol_title":"A PILOT STUDY ASSESSING THE FEASIBILITY OF A RANDOMIZED CONTROLLED TRIAL EVALUATING ASPIRIN VERSUS LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) AND ASPIRIN IN WOMEN WITH ANTIPHOSPHOLIPID SYNDROME AND PREGNANCY LOSS.","medConditionList":[{"med_condition_id":584,"med_condition":"ANTIPHOSPHOLIPID SYNDROME"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":39308,"protocol_no":"087","submission_no":"184780","status_id":1,"start_date":"2017-07-12","end_date":null,"nol_date":"2015-07-02","protocol_title":"\"A PHASE II CLINICAL TRIAL OF MK-3475 (PEMBROLIZUMAB) IN SUBJECTS WITH RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA.\"","medConditionList":[{"med_condition_id":481,"med_condition":"HODGKIN LYMPHOMA"}],"studyPopulationList":[{"study_population_id":2,"study_population":"ADULT FEMALE"},{"study_population_id":1,"study_population":"ADULT MALE"}]},{"protocol_id":41511,"protocol_no":"CA209-511","submission_no":"191714","status_id":1,"start_date":"2017-01-27","end_date":null,"nol_date":"2016-02-23","protocol_title":"PHASE IIIB/IV, RANDOMIZED, DOUBLE BLINDED, STUDY OF NIVOLUMAB 3 MG/KG IN COMBINATION WITH IPILIMUMAB 1 MG/KG VS NIVOLUMAB 1 MG/KG IN COMBINATION WITH IPILIMUMAB 3 MG/KG IN SUBJECTS WITH PREVIOUSLY UNTREATED, UNRESECTABLE OR METASTATIC MELANOMA","medConditionList":[{"med_condition_id":154,"med_condition":"MELANOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41993,"protocol_no":"M15-550","submission_no":"193570","status_id":1,"start_date":"2017-08-21","end_date":null,"nol_date":"2016-04-14","protocol_title":"OPEN-LABEL, SINGLE ARM, PHASE 3B, MULTI-CENTER STUDY EVALUATING THE EFFICACY OF VENETOCLAX (ABT-199) IN RELAPSED/REFRACTORY SUBJECTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) INCLUDING THOSE WITH THE 17P DELETION OR TP53 MUTATION OR THOSE WHO ARE REFRACTORY OR INTOLERANT TO B-CELL RECEPTOR INHIBITORS.","medConditionList":[{"med_condition_id":362,"med_condition":"CHRONIC LYMPHOCYTIC LEUKEMIA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":45752,"protocol_no":"PCYC-1143-CA","submission_no":"205405","status_id":3,"start_date":null,"end_date":null,"nol_date":"2017-06-22","protocol_title":"PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN SUBJECTS WITH MANTLE CELL LYMPHOMA","medConditionList":[{"med_condition_id":424,"med_condition":"MANTLE CELL LYMPHOMA"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":41566,"protocol_no":"ESPS-001","submission_no":"191858","status_id":1,"start_date":"2017-09-07","end_date":null,"nol_date":"2016-03-03","protocol_title":"A PHASE 1B/2A TWO-PART OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LY2880070 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH ADVANCED OR METASTATIC CANCER","medConditionList":[{"med_condition_id":314,"med_condition":"METASTATIC MALIGNANCY"},{"med_condition_id":10,"med_condition":"ADVANCED CANCERS"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":46206,"protocol_no":"SPI-GCF-302","submission_no":"206746","status_id":1,"start_date":"2017-11-22","end_date":null,"nol_date":"2017-07-14","protocol_title":"RANDOMIZED, OPEN-LABEL, ACTIVE CONTROL TRIAL OF SPI-2012 (EFLAPEGRASTIM) VERSUS PEGFILGRASTIM IN THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NEUTROPENIA IN EARLY-STAGE BREAST CANCER PATIENTS RECEIVING DOCETAXEL AND CYCLOPHOSPHAMIDE (TC) (RECOVER)","medConditionList":[{"med_condition_id":28,"med_condition":"BREAST CANCER"}],"studyPopulationList":[{"study_population_id":1,"study_population":"ADULT MALE"},{"study_population_id":2,"study_population":"ADULT FEMALE"}]},{"protocol_id":44171,"protocol_no":"CNTO1275CRD1001","submission_no":"200302","status_id":1,"start_date":"2017-08-21","end_date":null,"nol_date":"2016-12-15","protocol_title":"A RANDOMIZED DOUBLE-BLIND PHARMACOKINETIC STUDY OF USTEKINUMAB IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE","medConditionList":[{"med_condition_id":57,"med_condition":"CROHN'S DISEASE"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]},{"protocol_id":40874,"protocol_no":"LIN-MD-63","submission_no":"189544","status_id":1,"start_date":"2017-08-03","end_date":null,"nol_date":"2015-12-08","protocol_title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, SAFETY AND EFFICACY STUDY OF A RANGE OF LINACLOTIDE DOSES ADMINISTERED ORALLY TO CHILDREN, AGES 7 TO 17 YEARS, WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) (IE, FULFILL ROME III CRITERIA FOR CHILD/ADOLESCENT IBS AND FULFILL MODIFIED ROME III CRITERIA FOR CHILD/ADOLESCENT FUNCTIONAL CONSTIPATION)","medConditionList":[{"med_condition_id":468,"med_condition":"CONSTIPATION"}],"studyPopulationList":[{"study_population_id":3,"study_population":"PEDIATRIC"}]}]